PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Krogstad, U; Hofoss, D; Hjortdahl, P				Krogstad, U; Hofoss, D; Hjortdahl, P			Continuity of hospital care: beyond the question of personal contact	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ORGANIZATION; OUTCOMES; TEAMWORK; ISSUES		Cent Hosp Akershus, HELTEF Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway; Univ Oslo, Dept Gen Practice & Community Med, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Krogstad, U (corresponding author), Cent Hosp Akershus, HELTEF Fdn Hlth Serv Res, N-1474 Nordbyhagen, Norway.							AIKEN LH, 1994, MED CARE, V32, P771, DOI 10.1097/00005650-199408000-00002; Aiken LH, 1999, MED CARE, V37, P760, DOI 10.1097/00005650-199908000-00006; Aiken LH, 1998, QUAL HEALTH CARE, V7, P222, DOI 10.1136/qshc.7.4.222; [Anonymous], 1949, AM J SOCIOL; BRENNER P, 1984, NOVICE EXPERT EXCELL; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; De Maeseneer J, 2000, BRIT MED J, V320, P1616, DOI 10.1136/bmj.320.7250.1616; Flood A B, 1994, Med Care Rev, V51, P381, DOI 10.1177/107755879405100402; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1985, J ROY COLL GEN PRACT, V35, P423; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Freer SD, 1999, NEW ENGL J MED, V341, P850; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; Krogstad Unni, 1997, Tidsskrift for den Norske Laegeforening, V117, P4439; Manian FA, 1999, NEW ENGL J MED, V340, P1362, DOI 10.1056/NEJM199904293401712; MINZBERG H, 1971, STRUCTURING ORG; Risser DT, 1999, ANN EMERG MED, V34, P373, DOI 10.1016/S0196-0644(99)70134-4; Schon D.A, 2017, REFLECTIVE PRACTITIO; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; SHERN DL, 1986, COMMUNITY MENT HLT J, V22, P190, DOI 10.1007/BF00756981; Smith L, 2000, J ADV NURS, V31, P812, DOI 10.1046/j.1365-2648.2000.01339.x; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P17, DOI 10.1111/j.1547-5069.2000.00017.x; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P131, DOI 10.1111/j.1547-5069.2000.00131.x; Sturmberg JP, 2000, FAM PRACT, V17, P16, DOI 10.1093/fampra/17.1.16; TRESCH DD, 1985, J AM GERIATR SOC, V33, P819, DOI 10.1111/j.1532-5415.1985.tb05433.x; VEENSTRA M, 2000, PATIENTS EXPERIENCES	29	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					36	38		10.1136/bmj.324.7328.36	http://dx.doi.org/10.1136/bmj.324.7328.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777807	Green Published			2022-12-28	WOS:000173205700025
J	Freedman, SB; Isner, JM				Freedman, SB; Isner, JM			Therapeutic angiogenesis for coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; CHRONIC MYOCARDIAL-ISCHEMIA; TRANSMYOCARDIAL LASER REVASCULARIZATION; INTRAMUSCULAR GENE-TRANSFER; REFRACTORY ANGINA-PECTORIS; COLLATERAL VESSEL DEVELOPMENT; CRITICAL LIMB ISCHEMIA; LABEL DOSE-ESCALATION; PROGENITOR CELLS; IN-VIVO	A large body of evidence in animal models of ischemia shows that administration of angiogenic growth factors, either as recombinant protein or by gene transfer, can augment nutrient perfusion through neovascularization. Many cytokines have angiogenic activity; those that have been best studied in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Clinical trials of therapeutic angiogenesis in patients with end-stage coronary artery disease have shown increases in exercise time and reductions in anginal symptoms and have provided objective evidence of improved perfusion and left ventricular function. Larger-scale placebo-controlled trials have been limited to intracoronary and intravenous administration of recombinant protein and have not yet shown significant improvement in exercise time or angina compared with placebo. Larger-scale placebo-controlled studies of gene transfer are in progress. Clinical studies are required to determine the optimal dose, formulation, route of administration, and combinations of growth factors and the utility of adjunctive endothelial progenitor-cell or stem-cell supplementation, to provide safe and effective therapeutic myocardial angiogenesis. Determination of which growth factors or cells are required to optimize therapeutic neovascularization in an individual patient should be a goal of future research.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Boston, MA 02135 USA; Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW 2006, Australia	St. Elizabeth's Medical Center; Tufts University; Concord Repatriation General Hospital; University of Sydney	Freedman, SB (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, 736 Cambridge St, Boston, MA 02135 USA.							Aaberge L, 2000, J AM COLL CARDIOL, V35, P1170, DOI 10.1016/S0735-1097(00)00519-2; Al-Sheikh T, 1999, CIRCULATION, V100, P135, DOI 10.1161/01.CIR.100.2.135; Allen KB, 1999, NEW ENGL J MED, V341, P1029, DOI 10.1056/NEJM199909303411403; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Asahara T, 2000, GENE THER, V7, P451, DOI 10.1038/sj.gt.3301142; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Asahara T, 1996, CIRCULATION, V94, P3291, DOI 10.1161/01.CIR.94.12.3291; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BenHaim SA, 1996, NAT MED, V2, P1393, DOI 10.1038/nm1296-1393; Burkhoff D, 1999, LANCET, V354, P885, DOI 10.1016/S0140-6736(99)08113-1; Burkhoff D, 1996, ANN THORAC SURG, V61, P1532, DOI 10.1016/0003-4975(96)00090-2; Carmeliet P, 1997, AM J PHYSIOL-HEART C, V273, pH2091, DOI 10.1152/ajpheart.1997.273.5.H2091; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cooper LT, 2000, CIRCULATION, V102, P373; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; Deutsch E, 2000, J AM COLL CARDIOL, V35, p6A; DILSIZIAN V, 1993, CIRCULATION, V87, P1; Esakof DD, 1999, HUM GENE THER, V10, P2307, DOI 10.1089/10430349950016951; Ferguson JJ, 1999, CIRCULATION, V100, P570, DOI 10.1161/01.CIR.100.6.570; Fisher PE, 1997, ANN THORAC SURG, V64, P466, DOI 10.1016/S0003-4975(97)00519-5; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frazier OH, 1999, NEW ENGL J MED, V341, P1021, DOI 10.1056/NEJM199909303411402; Gepstein L, 1998, CIRCULATION, V98, P2055, DOI 10.1161/01.CIR.98.19.2055; GILBERT SF, 1997, DEV BIOL, P342; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRINES CL, 2001, ADENOVIRUS FGF ANGIO; Hamawy AH, 1999, CURR OPIN CARDIOL, V14, P515, DOI 10.1097/00001573-199911000-00012; Harada K, 1996, AM J PHYSIOL-HEART C, V270, pH1791, DOI 10.1152/ajpheart.1996.270.5.H1791; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; Hariawala MD, 1996, J SURG RES, V63, P77, DOI 10.1006/jsre.1996.0226; Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118; Hendel RC, 2000, CIRCULATION, V102, P769; Henry, 2000, Curr Interv Cardiol Rep, V2, P228; Henry TD, 1999, BMJ-BRIT MED J, V318, P1536, DOI 10.1136/bmj.318.7197.1536; Henry TD, 1999, CIRCULATION, V100, P476; Henry TD, 2001, AM HEART J, V142, P872, DOI 10.1067/mhj.2001.118471; Henry TD, 2000, CIRCULATION, V102, P309; Henry Timothy D., 1999, Journal of the American College of Cardiology, V33, p384A; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Horowitz JR, 1997, ARTERIOSCL THROM VAS, V17, P2793, DOI 10.1161/01.ATV.17.11.2793; Huggins GS, 1998, CIRCULATION, V98, P1291, DOI 10.1161/01.CIR.98.13.1291; Hughes CG, 1999, CIRCULATION, V100, P476; Hughes GC, 1998, ANN THORAC SURG, V66, P2029, DOI 10.1016/S0003-4975(98)01095-9; Hughes GC, 1999, AM HEART J, V137, P1163, DOI 10.1016/S0002-8703(99)70377-7; Isner JM, 1998, ADV DRUG DELIVER REV, V30, P185, DOI 10.1016/S0169-409X(97)00115-4; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Isner JM, 2000, J CLIN INVEST, V106, P615, DOI 10.1172/JCI10961; ISNER JM, 1998, TXB CARDIOVASCULAR M, P2491; ISNER JM, 1989, CARDIOVASCULAR LASER, P63; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Kerwin TC, 2001, CIRCULATION, V104, P456; Kleiman NS, 2000, J AM COLL CARDIOL, V36, P310, DOI 10.1016/S0735-1097(00)00805-6; Kloner RA, 2000, J THROMB THROMBOLYS, V10, P285, DOI 10.1023/A:1026507627097; Kornowski R, 2000, J AM COLL CARDIOL, V35, p73A; Kwong KF, 1997, J THORAC CARDIOV SUR, V114, P883, DOI 10.1016/S0022-5223(97)70001-1; Kwong KF, 1998, CIRCULATION, V98, pII67; Laham RJ, 2000, J AM COLL CARDIOL, V36, P2132, DOI 10.1016/S0735-1097(00)00988-8; Laham RJ, 2000, J AM COLL CARDIOL, V35, p73A; Laham RJ, 2000, J AM COLL CARDIOL, V35, p10A; Laham RJ, 2000, J PHARMACOL EXP THER, V292, P795; Laham RJ, 1999, CIRCULATION, V100, P1865, DOI 10.1161/01.CIR.100.18.1865; Laitinen M, 2000, HUM GENE THER, V11, P263, DOI 10.1089/10430340050016003; Lauer B, 1999, J AM COLL CARDIOL, V34, P1663, DOI 10.1016/S0735-1097(99)00419-2; Lazarous DF, 1999, CARDIOVASC RES, V44, P294, DOI 10.1016/S0008-6363(99)00203-5; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Lazarous DF, 1997, CARDIOVASC RES, V36, P78, DOI 10.1016/S0008-6363(97)00142-9; LAZAROUS DF, 1995, CIRCULATION, V91, P145, DOI 10.1161/01.CIR.91.1.145; Lee LY, 2000, ANN THORAC SURG, V69, P14, DOI 10.1016/S0003-4975(99)01102-9; Lee RJ, 2000, CIRCULATION, V102, P898; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; Leon MB, 2000, CIRCULATION, V102, P565; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Lopez JJ, 1998, AM J PHYSIOL-HEART C, V274, pH930, DOI 10.1152/ajpheart.1998.274.3.H930; Lopez JJ, 1997, J PHARMACOL EXP THER, V282, P385; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; LUSCHER TF, 1994, J CARDIOVASC PHARM, V24, pS16; Mack C A, 1997, J Clin Laser Med Surg, V15, P275; Mack CA, 1998, J THORAC CARDIOV SUR, V115, P168, DOI 10.1016/S0022-5223(98)70455-6; Malekan R, 1998, CIRCULATION, V98, pII62; MAZUE G, 1991, ANN NY ACAD SCI, V638, P329, DOI 10.1111/j.1749-6632.1991.tb49043.x; MCKIRNAN MD, 2000, CARDIAC VASCULAR REG, V1, P11; MIRHOSEINI M, 1982, Lasers in Surgery and Medicine, V2, P187, DOI 10.1002/lsm.1900020209; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Mukherjee D, 1999, AM J CARDIOL, V84, P598, DOI 10.1016/S0002-9149(99)00387-2; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Pearlman JD, 2000, RADIOLOGY, V214, P801, DOI 10.1148/radiology.214.3.r00mr39801; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; Rajanayagam MAS, 2000, J AM COLL CARDIOL, V35, P519, DOI 10.1016/S0735-1097(99)00550-1; Rimoldi O, 1999, CIRCULATION, V100, P134; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Rosengart TK, 1999, CIRCULATION, V100, P770; Schainfeld RM, 1999, ANN INTERN MED, V130, P442, DOI 10.7326/0003-4819-130-5-199903020-00017; Schaper W, 1999, ANGIOGENESIS AND CARDIOVASCULAR DISEASE, P159; Schofield PM, 1999, LANCET, V353, P519, DOI 10.1016/S0140-6736(98)11478-2; Schultz A, 1999, CIRCULATION, V100, P547, DOI 10.1161/01.CIR.100.5.547; Schumacher B, 1998, J CARDIOVASC SURG, V39, P783; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Sellke FW, 1998, ANN THORAC SURG, V65, P1540, DOI 10.1016/S0003-4975(98)00340-3; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN YT, 1995, CIRC RES, V76, P479, DOI 10.1161/01.RES.76.3.479; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; Shou M, 1997, J AM COLL CARDIOL, V29, P1102, DOI 10.1016/S0735-1097(97)00014-4; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Stegmann TJ, 2000, HERZ, V25, P589, DOI 10.1007/PL00001972; STEGMANN TJ, 2000, CARDIAC VASCULAR REG, V1, P5; Symes JF, 1999, ANN THORAC SURG, V68, P830, DOI 10.1016/S0003-4975(99)00807-3; Tabata H, 1997, CARDIOVASC RES, V35, P470, DOI 10.1016/S0008-6363(97)00152-1; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takeshita S, 1997, CIRCULATION, V95, P805; Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Takeshita S, 1996, LAB INVEST, V74, P1061; Tio RA, 1999, HUM GENE THER, V10, P2953, DOI 10.1089/10430349950016366; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Udelson JE, 2000, CIRCULATION, V102, P1605, DOI 10.1161/01.CIR.102.14.1605; Unger EF, 2000, AM J CARDIOL, V85, P1414, DOI 10.1016/S0002-9149(00)00787-6; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; UNGER EF, 1993, AM J PHYSIOL, V264, pH1567, DOI 10.1152/ajpheart.1993.264.5.H1567; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Vale PR, 1998, CIRCULATION, V98, P66; Vale PR, 1999, J AM COLL CARDIOL, V34, P246, DOI 10.1016/S0735-1097(99)00143-6; Vale PR, 2001, CIRCULATION, V103, P2138; Vale PR, 2001, CIRCULATION, V104, P253; Vale PR, 1999, CIRCULATION, V100, P22; Vale PR, 2000, CIRCULATION, V102, P689; Vale PR, 2000, CIRCULATION, V102, P563; Vale PR, 1999, CIRCULATION, V100, P512; Vale PR, 1998, CIRCULATION, V98, P353; Vale PR, 1999, CIRCULATION, V100, P477; VanBelle E, 1997, J AM COLL CARDIOL, V29, P1371, DOI 10.1016/S0735-1097(97)00049-1; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; VanBelle E, 1997, CIRCULATION, V95, P438; vanderZee R, 1997, CIRCULATION, V95, P1030; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; WHITE FC, 1992, CIRC RES, V71, P1490, DOI 10.1161/01.RES.71.6.1490; WHITTAKER P, 1993, J AM COLL CARDIOL, V22, P302, DOI 10.1016/0735-1097(93)90848-U; Wijns W, 1998, NEW ENGL J MED, V339, P173, DOI 10.1056/NEJM199807163390307; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Yamamoto N, 1998, J AM COLL CARDIOL, V31, P1426, DOI 10.1016/S0735-1097(98)00086-2	165	190	233	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					54	71		10.7326/0003-4819-136-1-200201010-00011	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00011			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777364				2022-12-28	WOS:000173188300006
J	Iglehart, JK				Iglehart, JK			The centers for Medicare and Medicaid services	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REFORM											Bernstein J, 1999, HEALTH AFFAIR, V18, P180, DOI 10.1377/hlthaff.18.1.180; Brett AS, 1998, NEW ENGL J MED, V339, P1705, DOI 10.1056/NEJM199812033392312; BROWN LD, 1985, J HEALTH POLIT POLIC, V10, P579, DOI 10.1215/03616878-10-3-579; Butler SM, 1999, HEALTH AFFAIR, V18, P8, DOI 10.1377/hlthaff.18.1.8; EPSTEIN, 2001, SPECIAL ALERT    OCT; FINGER AL, 2001, MED EC          0507, P114; *GEN ACC OFF, 2000, GAOHEHS00161; *GEN ACC OFF, 2001, GAO01817; *GEN ACC OFF, 1999, GAOHEHS99115; GINSBURG P, 2001, HLTH CARE SPENDING U; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; Iglehart JK, 1999, NEW ENGL J MED, V340, P403, DOI 10.1056/NEJM199902043400525; Iglehart JK, 1999, NEW ENGL J MED, V341, P299, DOI 10.1056/NEJM199907223410424; Jost TS, 1999, ADMIN LAW REV, V51, P39; Kassirer JP, 1998, NEW ENGL J MED, V339, P1697, DOI 10.1056/NEJM199812033392308; LASTER L, 2001, WASHINGTON POST 0112, pB3; MANGANO MF, 2001, COMMUNICATION   0606; MEYER JA, 2001, REDUCING HLTH CARE F; PEAR R, 2001, NY TIMES        0206, pA17; Pollitz K, 2000, HEALTH AFFAIR, V19, P7, DOI 10.1377/hlthaff.19.4.7; RUNDLE RL, 2001, WALL STREET J   0924, pB4; SMITH V, 2001, MEDICAID BUDGETS STR; Sparrow M., 2000, LICENSE STEAL FRAUD; Stanton TH, 2001, HEALTH AFFAIR, V20, P28, DOI 10.1377/hlthaff.20.4.28; Vladeck BC, 2001, NEW ENGL J MED, V345, P456, DOI 10.1056/NEJM200108093450611; Wilensky GR, 2001, NEW ENGL J MED, V345, P458, DOI 10.1056/NEJM200108093450612	26	14	14	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1920	1924		10.1056/NEJM200112273452617	http://dx.doi.org/10.1056/NEJM200112273452617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505TY	11756589				2022-12-28	WOS:000172932700022
J	Kim, WY; Danias, PG; Stuber, M; Flamm, SD; Plein, S; Nagel, E; Langerak, SE; Weber, OM; Pedersen, EM; Schmidt, M; Botnar, RM; Manning, WJ				Kim, WY; Danias, PG; Stuber, M; Flamm, SD; Plein, S; Nagel, E; Langerak, SE; Weber, OM; Pedersen, EM; Schmidt, M; Botnar, RM; Manning, WJ			Coronary magnetic resonance angiography for the detection of coronary stenoses	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAM COMPUTED-TOMOGRAPHY; MR-ANGIOGRAPHY; ARTERY STENOSIS; NONINVASIVE DETECTION; GOLD STANDARD; HEART; RECOMMENDATIONS; DEFINITION; DISEASE; SAFETY	Background An accurate, noninvasive technique for the diagnosis of coronary disease would be an important advance. We investigated the accuracy of coronary magnetic resonance angiography among patients with suspected coronary disease in a prospective, multicenter study. Methods Coronary magnetic resonance angiography was performed during free breathing in 109 patients before elective x-ray coronary angiography, and the results of the two diagnostic procedures were compared. Results A total of 636 of 759 proximal and middle segments of coronary arteries (84 percent) were interpretable on magnetic resonance angiography. In these segments, 78 (83 percent) of 94 clinically significant lesions (those with a greater than or equal to 50 percent reduction in diameter on x-ray angiography) were also detected by magnetic resonance angiography. Overall, coronary magnetic resonance angiography had an accuracy of 72 percent (95 percent confidence interval, 63 to 81 percent) in diagnosing coronary artery disease. The sensitivity, specificity, and accuracy for patients with disease of the left main coronary artery or three-vessel disease were 100 percent (95 percent confidence interval, 97 to 100 percent), 85 percent (95 percent confidence interval, 78 to 92 percent), and 87 percent (95 percent confidence interval, 81 to 93 percent), respectively. The negative predictive values for any coronary artery disease and for left main artery or three-vessel disease were 81 percent (95 percent confidence interval, 73 to 89 percent) and 100 percent (95 percent confidence interval, 97 to 100 percent), respectively. Conclusions Among patients referred for their first x-ray coronary angiogram, three-dimensional coronary magnetic resonance angiography allows for the accurate detection of coronary artery disease of the proximal and middle segments. This noninvasive approach reliably identifies (or rules out) left main coronary artery or three-vessel disease. (N EngI J Med 2001;345:1863-9.) Copyright (C) 2001 Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Aarhus Univ Hosp, Skejby Hosp, Magnet Resonance Ctr, Dept Cardiol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Skejby Hosp, Inst Expt Clin Res, DK-8000 Aarhus, Denmark; Philips Med Syst, Best, Netherlands; Leeds Gen Infirm, Yorkshire Heart Ctr, Leeds, W Yorkshire, England; St Lukes Episcopal Hosp, Houston, TX 77030 USA; Texas Heart Inst, Houston, TX 77025 USA; German Heart Inst, Berlin, Germany; Leiden Univ, Med Ctr, Dept Radiol & Cardiol, Leiden, Netherlands; Univ Zurich, Inst Biomed Engn, Zurich, Switzerland; Swiss Fed Inst Technol, Zurich, Switzerland; Univ Cologne, Nukl Med Klin & Poliklin, Cologne, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Aarhus University; Aarhus University; Philips; Philips Healthcare; Leeds General Infirmary; University of Leeds; Saint Lukes Episcopal Hospital; Texas Heart Institute; German Heart Center Berlin; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne	Manning, WJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, 330 Brookline Ave, Boston, MA 02215 USA.	wmanning@caregroup.harvard.edu	Nagel, Eike/C-6903-2008; Botnar, Rene M/E-6875-2012; Botnar, Rene Michael/AAZ-2112-2020; Pedersen, Erik Morre/G-4459-2012; Flamm, Scott/K-9034-2019; Stuber, Matthias/B-2949-2010	Nagel, Eike/0000-0002-6044-950X; Botnar, Rene M/0000-0003-2811-2509; Pedersen, Erik Morre/0000-0001-6798-3644; Stuber, Matthias/0000-0001-9843-2028; Plein, Sven/0000-0002-0997-4384; Botnar, Rene/0000-0002-9447-4367				Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; American Heart Association, 2000, 2001 HEART STROK STA; Baim D. S., 1996, CARDIAC CATHETERIZAT; Botnar RM, 1999, CIRCULATION, V99, P3139, DOI 10.1161/01.CIR.99.24.3139; Budinger TF, 1998, RADIOLOGY, V208, P573, DOI 10.1148/radiology.208.3.9722831; Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898; DUERINCKX AJ, 1994, RADIOLOGY, V193, P731, DOI 10.1148/radiology.193.3.7972815; Eagle KA, 1999, CIRCULATION, V100, P1464, DOI 10.1161/01.CIR.100.13.1464; EDELMAN RR, 1991, RADIOLOGY, V181, P641, DOI 10.1148/radiology.181.3.1947074; EHMAN RL, 1989, RADIOLOGY, V173, P255, DOI 10.1148/radiology.173.1.2781017; Fischer SE, 1999, MAGN RESON MED, V42, P361, DOI 10.1002/(SICI)1522-2594(199908)42:2<361::AID-MRM18>3.0.CO;2-9; HILLIS LD, 1987, AM J CARDIOL, V59, P358, DOI 10.1016/0002-9149(87)90814-9; Hug J, 2000, RADIOLOGY, V216, P781, DOI 10.1148/radiology.216.3.r00se03781; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MANNING WJ, 1994, NEW ENGL J MED, V330, P152; MCCONNELL MV, 1995, CIRCULATION, V92, P3158, DOI 10.1161/01.CIR.92.11.3158; McConnell MV, 1997, AM J ROENTGENOL, V168, P1369, DOI 10.2214/ajr.168.5.9129447; Moustapha AI, 2001, J AM COLL CARDIOL, V37, p380A; Muller MF, 1997, J MAGN RESON IMAGING, V7, P644, DOI 10.1002/jmri.1880070406; Neubauer S, 1998, EUR HEART J, V19, P19; Nieman K, 2001, LANCET, V357, P599, DOI 10.1016/S0140-6736(00)04058-7; Oshinski JN, 1996, RADIOLOGY, V201, P737, DOI 10.1148/radiology.201.3.8939224; PAULIN S, 1987, AM J ROENTGENOL, V148, P665, DOI 10.2214/ajr.148.4.665; Pennell DJ, 1996, HEART, V75, P127, DOI 10.1136/hrt.75.2.127; POST JC, 1995, CIRCULATION, V92, P3163, DOI 10.1161/01.CIR.92.11.3163; Post JC, 1997, EUR HEART J, V18, P426; Razmi RM, 2001, J AM COLL CARDIOL, V37, p380A; Regenfus M, 2000, J AM COLL CARDIOL, V36, P44, DOI 10.1016/S0735-1097(00)00672-0; Rensing BJ, 1998, CIRCULATION, V98, P2509, DOI 10.1161/01.CIR.98.23.2509; Sawyer-Glover AM, 2000, J MAGN RESON IMAGING, V12, P92, DOI 10.1002/1522-2586(200007)12:1<92::AID-JMRI11>3.0.CO;2-7; Stuber M, 1999, J AM COLL CARDIOL, V34, P524, DOI 10.1016/S0735-1097(99)00223-5; Stuber M, 1999, RADIOLOGY, V212, P579, DOI 10.1148/radiology.212.2.r99au50579; Taylor AM, 2000, CIRCULATION, V101, P1670; van Geuns RJM, 2000, RADIOLOGY, V217, P270, DOI 10.1148/radiology.217.1.r00oc01270; VANDERZWET PMJ, 1994, J AM COLL CARDIOL, V24, P216, DOI 10.1016/0735-1097(94)90566-5; Woodard PK, 1998, AM J ROENTGENOL, V170, P883, DOI 10.2214/ajr.170.4.9530027	36	630	660	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1863	1869		10.1056/NEJMoa010866	http://dx.doi.org/10.1056/NEJMoa010866			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756576				2022-12-28	WOS:000172932700001
J	McConnachie, A; Hunt, K; Emslie, C; Hart, C; Watt, G				McConnachie, A; Hunt, K; Emslie, C; Hart, C; Watt, G			"Unwarranted survivals" and "anomalous deaths" from coronary heart disease: prospective survey of general population	BRITISH MEDICAL JOURNAL			English	Article							LAY EPIDEMIOLOGY; HEALTH-EDUCATION; LIFE-STYLE; RISK; PREVENTION; RENFREW; WOMEN; MEN	Objectives To assess survival in people who are at apparent high risk who do not develop coronary heart disease ("unwarranted survivals") and mortality in people at low risk who die from the disease ("anomalous deaths") and the extent to which these outcomes are explained by other, less visible, risk factors. Design Prospective general population survey. Setting Renfrew and Paisley, Scotland. Participants 6068 men aged 45-64 years at screening in 1972-6, allocated to "visible" risk groups on the basis of body mass index and smoking. Main outcome measures Survival and death from coronary heart disease by age 70 years. Results Visible risk was a good predictor of mortality: 13% (45) of men at low risk and 45% (86) of men at high risk had died by age 70 years. Of these deaths, 12 (4%) and 44 (23%), respectively, were from coronary heart disease. In the group at low visible risk other less visible risk factors accounted for increased risk in 83% (10/12) of men who died from coronary heart disease and 29% (84/292) of men who survived. In the high risk group 81/107 who survived (76%) and 19/44 (43%) who died from coronary heart disease had lower risk after other factors were considered. Different risk factors modified risk (beyond smoking and body mass index) in the two groups. Among men at low visible risk, poor respiratory function, diabetes, previous coronary heart disease, and socioeconomic deprivation modified risk. Among men at high visible risk, height and cholesterol concentration modified risk. Conclusions Differences in survival between these extreme risk groups are dramatic. Health promotion messages would be more credible if they discussed anomalies and the limits of prediction of coronary disease at an individual level.	Univ Glasgow, MRC, Social & Publ Hlth Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Hunt, K (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Unit, Glasgow G12 8RZ, Lanark, Scotland.			Emslie, Carol/0000-0003-2170-2039				Blaxter M., 1990, HLTH LIFESTYLES; Charlton J., 1997, HLTH ADULT BRITAIN 1, VVolume 2, P60; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DAVISON C, 1989, Health Education Research, V4, P329, DOI 10.1093/her/4.3.329; DAVISON C, 1992, SOC SCI MED, V34, P675, DOI 10.1016/0277-9536(92)90195-V; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; *DEP HLTH, 2000, NAT SERV FRAM COR HE; DONG W, 1997, SCOTLANDS HLTH SCOTT, V1; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; Emslie C, 2001, SOCIOL HEALTH ILL, V23, P203, DOI 10.1111/1467-9566.00248; EMSLIE C, 2001, CORONARY HLTH CARE, V4, P1; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; Hole DJ, 1996, BRIT MED J, V313, P711; Hunt K, 2001, INT J EPIDEMIOL, V30, P442, DOI 10.1093/ije/30.3.442; Hunt K, 2001, LANCET, V357, P1168, DOI 10.1016/S0140-6736(00)04334-8; MARTEAU TM, 1995, BRIT J GEN PRACT, V45, P5; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; The Scottish Office, 1999, HLTH SCOTL WHIT PAP; [No title captured]	21	13	13	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1487	1491		10.1136/bmj.323.7327.1487	http://dx.doi.org/10.1136/bmj.323.7327.1487			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751367	Green Accepted, Green Published			2022-12-28	WOS:000172979900028
J	Casale, TB; Condemi, J; LaForce, C; Nayak, A; Rowe, M; Watrous, M; McAlary, M; Fowler-Taylor, A; Racine, M; Gupta, N; Fick, R; Della Cioppa, G				Casale, TB; Condemi, J; LaForce, C; Nayak, A; Rowe, M; Watrous, M; McAlary, M; Fowler-Taylor, A; Racine, M; Gupta, N; Fick, R; Della Cioppa, G		Omalizumab Seasonal Allergic Rhin	Effect of omalizumab on symptoms of seasonal allergic rhinitis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-IGE ANTIBODY; MONOCLONAL-ANTIBODY; PROTECTIVE IMMUNITY; NASAL SPRAY; RHINOCONJUNCTIVITIS; ASTHMA; PREVALENCE; BRASILIENSIS; EOSINOPHILIA; MANAGEMENT	Context Seasonal allergic rhinitis is a common IgE-mediated disorder that produces troublesome symptoms, A recombinant humanized monoclonal anti-IgE antibody (omalizumab) forms complexes with free IgE, blocking its interaction with mast cells and basophils and lowering free IgE levels in the circulation. Objective To assess the efficacy and safety of omalizumab for prophylaxis of symptoms in patients with seasonal allergic rhinitis. Design Randomized, double-blind, dose-ranging, placebo-controlled trial conducted from July 25 through November 21, 1997. Setting Twenty-five outpatient centers throughout the United States. Patients Five hundred thirty-six patients aged 12 to 75 years with at least a 2-year history of moderate to severe ragweed-induced seasonal allergic rhinitis and a baseline IgE level between 30 and 700 IU/mL. Interventions Patients were randomly assigned to receive omalizumab, 50 mg (n=137), 150 mg (n=134), or 300 mg (n=129), or placebo (n=136) subcutaneously just prior to ragweed season and repeated during the pollen season every 3 weeks in patients with baseline IgE levels of 151 to 700 IU/mL (4 total treatments) and every 4 weeks in patients with baseline IgE levels of 30 to 150 IU/mL (3 total treatments). Main Outcome Measures Self-assessed daily nasal symptom severity scores (range, 0-3), rescue antihistamine use, and rhinitis-specific quality of life during the 12 weeks from the start of treatment. Results Nasal symptom severity scores were significantly lower in patients who received 300 mg of omalizumab than in those who received placebo (least squares means, 0.75 vs 0.98, respectively; P=.002). A significant association was observed between IgE reduction and nasal symptoms and rescue antihistamine use. Rhinitis-specific quality of life scores were consistently better in patients who received 300 mg of omalizumab than in those who received lower dosages or placebo and did not decline during peak season. The frequency of adverse events was not significantly different among the omalizumab and placebo groups. Conclusion Omalizumab decreased serum free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis.	Creighton Univ, Dept Med, Omaha, NE 68131 USA; Univ Rochester, Rochester, NY USA; N Carolina Clin Res, Raleigh, NC USA; Univ Illinois, Dept Pediat, Chicago, IL USA; Michigan Resp Hlth & Res Inst, Novi, MI USA; Genentech Inc, San Francisco, CA 94080 USA; Novartis Pharmaceut Corp, E Hanover, NJ USA; Novartis Pharma AG, Basel, Switzerland; Novartis Horsham Res Ctr, Horsham, W Sussex, England	Creighton University; University of Rochester; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Roche Holding; Genentech; Novartis; Novartis; Novartis	Casale, TB (corresponding author), Creighton Univ, Dept Med, 601 N 30th St,Suite 5850, Omaha, NE 68131 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; AMIRI P, 1994, J EXP MED, V180, P43, DOI 10.1084/jem.180.1.43; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BOUSQUET J, 1990, RESP MED, V84, P11, DOI 10.1016/S0954-6111(08)80002-9; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CASALE TB, 2000, ANN ALLERG ASTHMA IM, V84, P125; EVANS R, 1993, ALLERGY PRINCIPLES P, V2, P1109; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fox J. A., 1997, Pharmaceutical Research (New York), V14, pS217; FROEHLICH J, 1995, J ALLERGY CLIN IMMUN, V95, P356; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hadley JA, 1999, MED CLIN N AM, V83, P13, DOI 10.1016/S0025-7125(05)70084-5; Hurst DS, 1996, LARYNGOSCOPE, V106, P1128, DOI 10.1097/00005537-199609000-00017; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019, DOI 10.1017/S0022215100142380; Juniper EF, 1997, CAN MED ASSOC J, V156, P1123; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; LEDFORD DK, 1998, J RESP DIS, V19, P647; LEWIS WH, 1991, AM J OTOLARYNG, V12, P205, DOI 10.1016/0196-0709(91)90121-U; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; MARSHALL JS, 1987, IMMUNOLOGY, V60, P303; MEITZER EO, 1999, J ALLERGY CLIN IMMUN, V99, pS815; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 1998, CLIN EXP ALLERGY, V28, P27; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814, DOI 10.1164/ajrccm.159.6.9810016; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; ROSS RN, 1996, AM J MANAG CARE, V2, P285; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Spector S, 1999, J ALLERGY CLIN IMMUN, V103, pS386, DOI 10.1016/S0091-6749(99)70217-4; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; TERR AI, 1991, BASIC CLIN IMMUNOL, P375; *UPPS MON CTR, 1998, ADV REACT TERM; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VELGEROUSSEL F, 1991, J IMMUNOL, V147, P3967; WATANABE N, 1988, P NATL ACAD SCI USA, V85, P4460, DOI 10.1073/pnas.85.12.4460; White P, 1998, CLIN EXP ALLERGY, V28, P266; 1999, DRUGS THER PERSPECT, V14, P12	45	258	270	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2956	2967		10.1001/jama.286.23.2956	http://dx.doi.org/10.1001/jama.286.23.2956			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743836				2022-12-28	WOS:000172764500027
J	Sargent, JD; Beach, ML; Dalton, MA; Mott, LA; Tickle, J; Ahrens, MB; Heatherton, TF				Sargent, JD; Beach, ML; Dalton, MA; Mott, LA; Tickle, J; Ahrens, MB; Heatherton, TF			Effect of seeing tobacco use in films on trying smoking among adolescents: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							POPULAR FILMS; ALCOHOL-USE; HOLLYWOOD; CHILDREN; YOUTH	Objective To test the hypothesis that greater exposure to smoking in films is associated with trying smoking among adolescents. Design Cross sectional survey of 4919 schoolchildren aged 9-15 years, and assessment of occurrence of smoking in 601 films. Setting Randomly selected middle schools in Vermont and New Hampshire, USA. Main outcome measure Number of schoolchildren who had ever tried smoking a cigarette. Results The films contained a median of 5 (interquartile range 1-12) Occurrences of smoking. The typical adolescent had seen 17 of 50 films listed. Exposure to smoking in films varied widely: median 91 (49-152) occurrences. The prevalence of ever trying smoking increased with higher categories of exposure: 4.9% among students who saw 0-50 occurrences of smoking, 13.7% for 51-100 occurrences, 22.1% for 101-150, and 31.3% for > 150. The association remained significant after adjustment for age; sex; school performance; school; parents' education; smoking by friend, sibling, or parent; and receptivity to tobacco promotions. The adjusted odds ratios of ever trying smoking for students in the higher categories of exposure, compared with students exposed to 0-50 occurrences of smoking in films, were 1.7 (95% confidence interval 1.2 to 2.4),2.4 (1.7 to 3.4), and 2.7 (2.0 to 3.8). These odds ratios were not substantially affected by adjustment for parenting style or for personality traits of the adolescent. Conclusion In this sample of adolescents there was a strong, direct, and independent association between seeing tobacco use in films and trying cigarettes, a finding that supports the hypothesis that smoking in films has a role in the initiation of smoking in adolescents.	Dartmouth Coll Sch Med, Dept Pediat, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Anesthesia, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA; Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College	Sargent, JD (corresponding author), Dartmouth Coll Sch Med, Dept Pediat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Heatherton, Todd F/H-5478-2011; Sargent, James D/I-2773-2013		NATIONAL CANCER INSTITUTE [R01CA077026] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077026, CA-77026] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carvajal SC, 2000, J ADOLESCENT HEALTH, V27, P255, DOI 10.1016/S1054-139X(00)00124-5; Chapman S, 1997, Tob Control, V6, P269; CHRISTENSEN P. G., 2000, SUBSTANCE USE POPULA; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DALTON MA, IN PRESS PREV MED; Distefan JM, 1999, PREV MED, V28, P1, DOI 10.1006/pmed.1998.0409; Everett SA, 1998, J COMMUN HEALTH, V23, P317, DOI 10.1023/A:1018727606500; Goldstein AO, 1999, JAMA-J AM MED ASSOC, V281, P1131, DOI 10.1001/jama.281.12.1131; HAZAN AR, 1994, AM J PUBLIC HEALTH, V84, P998, DOI 10.2105/AJPH.84.6.998; Jackson C, 1998, HEALTH EDUC BEHAV, V25, P319, DOI 10.1177/109019819802500307; KRUGMAN DM, 1991, JOURNALISM QUART, V68, P1; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Lynch BS., 1994, GROWING TOBACCO FREE; McComb G, 2000, POPTRONICS, V1, P52; McIntosh WD, 1998, ADDICT BEHAV, V23, P395, DOI 10.1016/S0306-4603(97)00071-3; Pechmann C, 1999, J MARKETING, V63, P1, DOI 10.2307/1251772; Pierce J.P, 1993, TOBACCO USE CALIFORN; Pierce JP, 1998, JAMA-J AM MED ASSOC, V279, P511, DOI 10.1001/jama.279.7.511; RIDCOUT VJ, 1999, KIDS MEDIA NEW MILLE; ROBERTS D, 1999, SUBSTANCE USE POPULA; Roberts DF, 2000, J ADOLESCENT HEALTH, V27, P8, DOI 10.1016/S1054-139X(00)00128-2; RUSSO MF, 1993, J PSYCHOPATHOL BEHAV, V15, P69, DOI 10.1007/BF00960609; Sargent JD, 2001, LANCET, V357, P29, DOI 10.1016/S0140-6736(00)03568-6; Sargent JD, 2000, PREV MED, V30, P320, DOI 10.1006/pmed.1999.0629; Shields DLL, 1999, TOB CONTROL, V8, P378, DOI 10.1136/tc.8.4.378; Strasburger V C, 2000, Adolesc Med, V11, P51; Tickle JJ, 2001, TOB CONTROL, V10, P16, DOI 10.1136/tc.10.1.16; ZUCKERMAN M, 1972, J CONSULT CLIN PSYCH, V39, P308, DOI 10.1037/h0033398	28	155	159	2	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1394	1397		10.1136/bmj.323.7326.1394	http://dx.doi.org/10.1136/bmj.323.7326.1394			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505EX	11744562	Bronze, Green Published			2022-12-28	WOS:000172900400015
J	Wyrick, JJ; Aparicio, JG; Chen, T; Barnett, JD; Jennings, EG; Young, RA; Bell, SP; Aparicio, OM				Wyrick, JJ; Aparicio, JG; Chen, T; Barnett, JD; Jennings, EG; Young, RA; Bell, SP; Aparicio, OM			Genome-wide distribution of ORC and MCM proteins in S-cerevisiae: High-resolution mapping of replication origins	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME-VI; DNA-REPLICATION; ARS ELEMENTS; YEAST; IDENTIFICATION; RECOGNITION; INITIATION; EUKARYOTES; SEQUENCE	DNA replication origins are fundamental to chromosome organization and duplication, but understanding of these elements is limited because only a small fraction of these sites have been identified in eukaryotic genomes. Origin Recognition Complex (ORC) and minichromosome maintenance (MCM) proteins form prereplicative complexes at origins of replication. Using these proteins as molecular landmarks for origins, we identified ORC- and MCM-bound sites throughout the yeast genome. Four hundred twenty-nine sites in the yeast genome were predicted to contain replication origins, and similar to 80% of the loci identified on chromosome X demonstrated origin function. A substantial fraction of the predicted origins are associated with repetitive DNA sequences, including subtelomeric elements (X and Y') and transposable element-associated sequences (tong terminal repeats). These findings identify the global set of yeast replication origins and open avenues of investigation into the role(s) ORC and MCM proteins play in chromosomal architecture and dynamics.	Univ So Calif, Program Mol & Computat Biol, Los Angeles, CA 90089 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University of Southern California; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Aparicio, OM (corresponding author), Univ So Calif, Program Mol & Computat Biol, Los Angeles, CA 90089 USA.	oaparici@usc.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Bell, Stephen/0000-0002-2876-610X; Aparicio, Oscar/0000-0002-5591-0277; Aparicio, Jennifer/0000-0002-6442-3032	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52339, GM34365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1999, CURRENT PROTOCOLS MO, V4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Boeke J.D., 1991, MOL CELLULAR BIOL YE, V1, P193; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; Friedman KL, 1995, J CELL SCI, P51; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NEWLON CS, 1991, GENETICS, V129, P343; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	28	318	328	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2357	2360		10.1126/science.1066101	http://dx.doi.org/10.1126/science.1066101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743203				2022-12-28	WOS:000172817200048
J	Diekema, DJ; Jones, RN				Diekema, DJ; Jones, RN			Oxazolidinone antibiotics	LANCET			English	Review							IN-VITRO ACTIVITIES; ENTEROCOCCUS-FAECIUM BACTEREMIA; RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL SURVEILLANCE PROGRAM; UNITED-STATES; QUINUPRISTIN-DALFOPRISTIN; LINEZOLID PNU-100766; EPEREZOLID PNU-100592; ANTIBACTERIAL AGENTS; PROTEIN-SYNTHESIS	Many common gram-positive pathogens (eg, Staphylococcus aureus, Enterococcus spp, and Streptococcus pneumoniae) have become increasingly resistant to antimicrobial agents, and new drugs with activity against gram-positive bacteria are urgently needed. The oxazolidinones, a new chemical class of synthetic antimicrobial agent, have a unique mechanism of inhibiting bacterial protein synthesis. Linezolid, the first oxazolidinone to be approved for clinical use, displays in-vitro activity (generally bacteriostatic) against many important resistant pathogens, including meticillin-resistant Staph aureus, vancomycin-resistant enterococci, and penicillin-resistant Strep pneumoniae. Linezolid is a parenteral agent that also possesses near-complete oral bioavailability plus favourable pharmacokinetic and toxic effect profiles. Clinical trials confirm the activity of linezolid in the setting of pneumonia, skin and soft-tissue infections, and infections due to vancomycin-resistant enterococci. Linezolid shows promise as an alternative to glycopeptides and streptogramins to treat serious infections due to resistant gram-positive organisms. New agents with greater potency and new spectra of activity could arise from further modification of the oxazolidinone nucleus.	Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Div Infect Dis, Iowa City, IA 52242 USA; Jones Microbiol Inst, Jones Grp, N Liberty, IA USA	University of Iowa; University of Iowa	Diekema, DJ (corresponding author), Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, C606 GH, Iowa City, IA 52242 USA.	daniel-diekema@uiowa.edu		Diekema, Daniel/0000-0003-1273-0724				ALBORN WE, 1991, ANTIMICROB AGENTS CH, V35, P2282, DOI 10.1128/AAC.35.11.2282; ANDES D, 1998, 38 INT C ANT AG CHEM; ANDES D, 1996, 36 INT C ANT AG CHEM; Antal EJ, 2001, J CLIN PHARMACOL, V41, P552, DOI 10.1177/00912700122010294; Antony SJ, 1999, CLIN INFECT DIS, V29, P1341, DOI 10.1086/313492; ASHTEKAR DR, 1991, DIAGN MICR INFEC DIS, V14, P465, DOI 10.1016/0732-8893(91)90002-W; Babcock HM, 2001, CLIN INFECT DIS, V32, P1373, DOI 10.1086/319986; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; Barbachyn MR, 1996, J MED CHEM, V39, P680, DOI 10.1021/jm950956y; BASSETTI M, 2000, 40 INT C ANT AG CHEM; Betriu C, 2000, ANTIMICROB AGENTS CH, V44, P1838, DOI 10.1128/AAC.44.7.1838-1841.2000; BIRMINGHAM MC, 2000, 40 INT C ANT AG CHEM; BOCHUD PY, 1994, AM J MED, V97, P256, DOI 10.1016/0002-9343(94)90009-4; Bostic GD, 1998, DIAGN MICR INFEC DIS, V30, P109, DOI 10.1016/S0732-8893(97)00210-1; Bowersock TL, 2000, ANTIMICROB AGENTS CH, V44, P1367, DOI 10.1128/AAC.44.5.1367-1369.2000; Brickner SJ, 1996, CURR PHARM DESIGN, V2, P175; Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556; BRIER ME, 1998, 38 INT C ANT AG CHEM; Brown D, 2000, J INST BRIT TELECOMM, V1, P45; Brown-Elliot BA, 2001, CLIN INFECT DIS, V33, P1433, DOI 10.1086/322523; CAMMARATA SK, 2000, AM THOR SOC INT C TO; CAMMARATA SK, 2000, 40 INT C ANT AG CHEM; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P813; Chien JW, 2000, CLIN INFECT DIS, V30, P146, DOI 10.1086/313597; Cynamon MH, 1999, ANTIMICROB AGENTS CH, V43, P1189, DOI 10.1128/AAC.43.5.1189; Dailey CF, 2001, ANTIMICROB AGENTS CH, V45, P2304, DOI 10.1128/AAC.45.8.2304-2308.2001; DALY JS, 1988, J ANTIMICROB CHEMOTH, V21, P721, DOI 10.1093/jac/21.6.721; Di Pentima MC, 1998, CLIN INFECT DIS, V26, P1169, DOI 10.1086/520309; Diekema DJ, 2000, DRUGS, V59, P7, DOI 10.2165/00003495-200059010-00002; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Doern GV, 1998, CLIN INFECT DIS, V27, P764, DOI 10.1086/514953; DRESSERJD, 2000, 40 INT C ANT AG CHEM; DUVALL SE, 2000, 9 INT C INF DIS BUEN; Edlund Charlotta, 1999, Clin Microbiol Infect, V5, P51, DOI 10.1111/j.1469-0691.1999.tb00099.x; Eliopoulos GM, 1996, ANTIMICROB AGENTS CH, V40, P1745, DOI 10.1128/AAC.40.7.1745; ENDERMANN R, 1998, 38 INT C ANT AG CHEM; *EUR COMM ANT SUSC, 2001, CLIN MICROBIOL INFEC, V7, P283; EUSTICE DC, 1988, ANTIMICROB AGENTS CH, V32, P1218, DOI 10.1128/AAC.32.8.1218; Fines M, 2000, J ANTIMICROB CHEMOTH, V45, P797, DOI 10.1093/jac/45.6.797; Ford CW, 1996, ANTIMICROB AGENTS CH, V40, P1508, DOI 10.1128/AAC.40.6.1508; Ford CW, 1997, TRENDS MICROBIOL, V5, P196, DOI 10.1016/S0966-842X(97)01032-9; GADWOOD RC, 1998, 38 INT C ANT AG CHEM; GILLILAND KK, 2000, 40 INT C ANT AG CHEM; Goldstein EJC, 1999, ANTIMICROB AGENTS CH, V43, P1469, DOI 10.1128/AAC.43.6.1469; Gonzales RD, 2001, LANCET, V357, P1179, DOI 10.1016/S0140-6736(00)04376-2; Hirschl AM, 2000, ANTIMICROB AGENTS CH, V44, P1977, DOI 10.1128/AAC.44.7.1977-1979.2000; Hoppe JE, 1999, J CHEMOTHERAPY, V11, P220, DOI 10.1179/joc.1999.11.3.220; HYATT JM, 1998, 38 INT C ANT AG CHEM; JONES RN, 1995, DIAGN MICR INFEC DIS, V21, P85, DOI 10.1016/0732-8893(94)00147-O; Jones RN, 1997, ANTIMICROB AGENTS CH, V41, P488, DOI 10.1128/AAC.41.2.488; Jones RN, 1996, ANTIMICROB AGENTS CH, V40, P720, DOI 10.1128/AAC.40.3.720; Jorgensen JH, 1997, ANTIMICROB AGENTS CH, V41, P465, DOI 10.1128/AAC.41.2.465; Kaatz GW, 1996, ANTIMICROB AGENTS CH, V40, P799, DOI 10.1128/AAC.40.3.799; Kaplan SL, 2001, PEDIATR INFECT DIS J, V20, P488, DOI 10.1097/00006454-200105000-00004; Kenny GE, 2001, ANTIMICROB AGENTS CH, V45, P2604, DOI 10.1128/AAC.45.9.2604-2608.2001; Li ZM, 2001, PHARMACOTHERAPY, V21, P263, DOI 10.1592/phco.21.3.263.34198; Lin AH, 1997, ANTIMICROB AGENTS CH, V41, P2127, DOI 10.1128/AAC.41.10.2127; Linden PK, 1997, J ANTIMICROB CHEMOTH, V39, P145, DOI 10.1093/jac/39.suppl_1.145; Livermore DM, 2001, J ANTIMICROB CHEMOTH, V48, P452, DOI 10.1093/jac/48.3.452; Malathum K, 1999, ANTIMICROB AGENTS CH, V43, P930, DOI 10.1128/AAC.43.4.930; Martin JP, 1998, 38 INT C ANT AG CHEM; Mason EO, 1996, ANTIMICROB AGENTS CH, V40, P1039, DOI 10.1128/AAC.40.4.1039; McNeil SA, 2000, CLIN INFECT DIS, V30, P403, DOI 10.1086/313669; Melzer M, 2000, CLIN INFECT DIS, V31, P208, DOI 10.1086/313897; Mercier RC, 1997, ANTIMICROB AGENTS CH, V41, P2573, DOI 10.1128/AAC.41.11.2573; Moellering RC, 1999, ANN INTERN MED, V130, P155, DOI 10.7326/0003-4819-130-2-199901190-00012; Moellering RC, 1998, CLIN INFECT DIS, V26, P1196, DOI 10.1086/520283; MOISE PA, 2000, 40 INT C ANT AG CHEM; Mulazimoglu L, 1996, ANTIMICROB AGENTS CH, V40, P2428, DOI 10.1128/AAC.40.10.2428; Murray RW, 1998, ANTIMICROB AGENTS CH, V42, P947, DOI 10.1128/AAC.42.4.947; Noskin GA, 1999, ANTIMICROB AGENTS CH, V43, P2059, DOI 10.1128/AAC.43.8.2059; Noskin GA, 1999, CLIN INFECT DIS, V28, P689, DOI 10.1086/517221; Oramas-Shirey MP, 2001, J ANTIMICROB CHEMOTH, V47, P349, DOI 10.1093/jac/47.3.349; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; Patel R, 2001, ANTIMICROB AGENTS CH, V45, P621, DOI 10.1128/AAC.45.2.621-623.2001; Pelton SI, 2000, ANTIMICROB AGENTS CH, V44, P654, DOI 10.1128/AAC.44.3.654-657.2000; Perl TM, 1998, ANN PHARMACOTHER, V32, pS7, DOI 10.1177/106002809803200104; PETERS J, 1995, J ANTIMICROB CHEMOTH, V35, P675, DOI 10.1093/jac/35.5.675; Pfaller MA, 1998, ANTIMICROB AGENTS CH, V42, P1762, DOI 10.1128/AAC.42.7.1762; *PHARM UPJ, 1999, M12600051 PHARM UPJ; *PHARM UPJ, 1999, M12600054A PHARM UPJ; *PHARM UPJ, 1999, M12600033 PHARM UPJ; *PHARM UPJ CO, 2000, ZYV PACK INS; Plouffe JF, 2000, CLIN INFECT DIS, V31, pS144, DOI 10.1086/314080; ROOT JD, 2000, 40 INT C ANT AG CHEM; Rubinstein E, 2001, CLIN INFECT DIS, V32, P402, DOI 10.1086/318486; Rybak MJ, 1998, ANTIMICROB AGENTS CH, V42, P721, DOI 10.1128/AAC.42.3.721; Rybak MJ, 2000, ANTIMICROB AGENTS CH, V44, P1062, DOI 10.1128/AAC.44.4.1062-1066.2000; Schulin T, 1998, ANTIMICROB AGENTS CH, V42, P1520, DOI 10.1128/AAC.42.6.1520; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; Shinabarger DL, 1997, ANTIMICROB AGENTS CH, V41, P2132, DOI 10.1128/AAC.41.10.2132; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; Spangler SK, 1996, ANTIMICROB AGENTS CH, V40, P481, DOI 10.1128/AAC.40.2.481; STALKER DJ, 1998, 36 M INF DIS SOC AM; STALKER DJ, 1997, 37 INT C ANT AG CHEM; Stevens DL, 2000, ANTIMICROB AGENTS CH, V44, P3408, DOI 10.1128/AAC.44.12.3408-3413.2000; Swaney SM, 1998, ANTIMICROB AGENTS CH, V42, P3251, DOI 10.1128/AAC.42.12.3251; SWANEY SM, 1998, 38 INT C ANT AG CHEM; Tsiodras S, 2001, LANCET, V358, P207, DOI 10.1016/S0140-6736(01)05410-1; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Wallace RJ, 2001, ANTIMICROB AGENTS CH, V45, P764, DOI 10.1128/AAC.45.3.764-767.2001; WU M, 1998, 38 INT C ANT AG CHEM; Yagi BH, 1997, ANAEROBE, V3, P301, DOI 10.1006/anae.1997.0115; Zeana C, 2001, CLIN INFECT DIS, V33, P477, DOI 10.1086/321896; Zurenko GE, 1996, ANTIMICROB AGENTS CH, V40, P839, DOI 10.1128/AAC.40.4.839; ZURENKO GE, 1999, 39 INT C ANT AG CHEM	106	287	310	2	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1975	1982		10.1016/S0140-6736(01)06964-1	http://dx.doi.org/10.1016/S0140-6736(01)06964-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747939				2022-12-28	WOS:000172622200032
J	Loeffler, JM; Nelson, D; Fischetti, VA				Loeffler, JM; Nelson, D; Fischetti, VA			Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase	SCIENCE			English	Article							CONJUGATE VACCINE; CARRIAGE	Nasopharyngeal carriage is the major reservoir for Streptococcus pneumoniae in the community. Although eliminating this reservoir would greatly reduce disease occurrence, no suitable intervention has been available for this purpose. We show here that seconds after contact, a purified pneumococcal bacteriophage lytic enzyme (Pal) is able to kill 15 common serotypes of pneumococci, including highly penicillin-resistant strains. In vivo, previously colonized mice revealed undetectable pneumococcal titers 5 hours after a single enzyme treatment. Pal enzyme had little or no effect on microorganisms normally found in the human oropharynx, and Pal-resistant pneumococci could not be detected after extensive exposure to the enzyme.	Rockefeller Univ, Lab Bacterial Pathogenesis, New York, NY 10021 USA	Rockefeller University	Fischetti, VA (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis, 1230 York Ave, New York, NY 10021 USA.		Nelson, Daniel C./I-2198-2012; Loeffler, Jutta M/C-2747-2008	Nelson, Daniel C./0000-0003-3248-4831; 				Bernhardt TG, 2001, SCIENCE, V292, P2326, DOI 10.1126/science.1058289; Garcia P, 1997, MICROB DRUG RESIST, V3, P165, DOI 10.1089/mdr.1997.3.165; GILLESPIE SH, 1993, INFECT IMMUN, V61, P3076, DOI 10.1128/IAI.61.7.3076-3077.1993; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Lopez R, 1997, MICROB DRUG RESIST, V3, P199, DOI 10.1089/mdr.1997.3.199; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Merril CR, 1996, P NATL ACAD SCI USA, V93, P3188, DOI 10.1073/pnas.93.8.3188; Nelson D, 2001, P NATL ACAD SCI USA, V98, P4107, DOI 10.1073/pnas.061038398; Pelton SI, 2000, VACCINE, V19, pS96, DOI 10.1016/S0264-410X(00)00286-3; Putnam SD, 2000, CLIN MICROBIOL INFEC, V6, P2, DOI 10.1046/j.1469-0691.2000.00001.x; Roberts RB, 2001, MICROB DRUG RESIST, V7, P137, DOI 10.1089/10766290152045011; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Sa-Leao R, 2000, J INFECT DIS, V182, P1153, DOI 10.1086/315813; SANCHEZPUELLES JM, 1992, EUR J BIOCHEM, V203, P153, DOI 10.1111/j.1432-1033.1992.tb19840.x; Sheehan MM, 1997, MOL MICROBIOL, V25, P717, DOI 10.1046/j.1365-2958.1997.5101880.x; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; TUOMANEN E, 1991, SCAND J INFECT DIS, V74, P102; Wu HY, 1997, MICROB PATHOGENESIS, V23, P127, DOI 10.1006/mpat.1997.0142	18	357	409	4	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2170	2172		10.1126/science.1066869	http://dx.doi.org/10.1126/science.1066869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739958				2022-12-28	WOS:000172647700052
J	Kaufman, D; Boyle, R; Hazen, KC; Patrie, JT; Robinson, M; Donowitz, LG				Kaufman, D; Boyle, R; Hazen, KC; Patrie, JT; Robinson, M; Donowitz, LG			Fluconazole prophylaxis against fungal colonization and infection in preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MARROW TRANSPLANT RECIPIENTS; CANDIDA-ALBICANS; RANDOMIZED-TRIAL; AMPHOTERICIN-B; CHANGING FACE; DOUBLE-BLIND; BLOOD; PHARMACOKINETICS; PLACEBO; SUSCEPTIBILITY	Background: Invasive fungal infection is associated with substantial morbidity and mortality in preterm infants. We evaluated the efficacy of prophylactic fluconazole in preventing fungal colonization and invasive infection in extremely-low-birth-weight infants. Methods: We conducted a prospective, randomized, double-blind clinical trial over a 30-month period in 100 preterm infants with birth weights of less than 1000 g. The infants were randomly assigned during the first five days of life to receive either intravenous fluconazole or placebo for six weeks. We obtained weekly surveillance cultures from all patients. Results: The 50 infants randomly assigned to fluconazole and the 50 control infants were similar in terms of birth weight, gestational age at birth, and base-line risk factors for fungal infection. During the six-week treatment period, fungal colonization was documented in 30 infants in the placebo group (60 percent) and 11 infants in the fluconazole group (22 percent; difference in risk, 0.38; 95 percent confidence interval, 0.18 to 0.56; P=0.002). Invasive fungal infection with positive growth of fungal isolates from the blood, urine, or cerebrospinal fluid developed in 10 infants in the placebo group (20 percent) and none of the infants in the fluconazole group (difference in risk, 0.20; 95 percent confidence interval, 0.04 to 0.36; P=0.008). The sensitivities of the fungal isolates to fluconazole did not change during the study, and no adverse effects of the fluconazole therapy were documented. Conclusions: Prophylactic administration of fluconazole during the first six weeks of life is effective in preventing fungal colonization and invasive fungal infection in infants with birth weights of less than 1000 g. (N Engl J Med 2001;345:1660-6.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pathol & Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Kaufman, D (corresponding author), Univ Virginia Hlth Syst, Dept Pediat, Div Neonatol, Box 800386, Charlottesville, VA 22908 USA.	dak4r@virginia.edu						BALEY JE, 1986, PEDIATRICS, V78, P225; BALEY JE, 1991, CLIN PERINATOL, V18, P263, DOI 10.1016/S0095-5108(18)30523-2; BERGER RL, 1994, J AM STAT ASSOC, V89, P1012, DOI 10.2307/2290928; BRAMMER KW, 1994, EUR J CLIN MICROBIOL, V13, P325, DOI 10.1007/BF01974613; DIGGLE P, 1994, ANAL LONGITUDINAL DA, P143; GARCHA UK, 1995, J INFECT DIS, V172, P1620, DOI 10.1093/infdis/172.6.1620; GHANNOUM MA, 1992, ANTIMICROB AGENTS CH, V36, P2239, DOI 10.1128/AAC.36.10.2239; Gleason TG, 1997, ARCH SURG-CHICAGO, V132, P1197, DOI 10.1001/archsurg.1997.01430350047008; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; Gotzsche PC, 1997, BMJ-BRIT MED J, V314, P1238, DOI 10.1136/bmj.314.7089.1238; Hazen KC, 2000, FEMS MICROBIOL LETT, V183, P89, DOI 10.1111/j.1574-6968.2000.tb08938.x; HENNEKENS CH, 1994, EPIDEMIOLOGY MED, P87; Huang YC, 1999, INFECTION, V27, P97, DOI 10.1007/BF02560505; Kanda Y, 2000, CANCER, V89, P1611, DOI 10.1002/1097-0142(20001001)89:7&lt;1611::AID-CNCR27&gt;3.0.CO;2-B; Kern W, 1998, CANCER-AM CANCER SOC, V83, P291, DOI 10.1002/(SICI)1097-0142(19980715)83:2&lt;291::AID-CNCR13&gt;3.3.CO;2-C; Kicklighter SD, 2001, PEDIATRICS, V107, P293, DOI 10.1542/peds.107.2.293; Lewis RE, 1999, AM J HEALTH-SYST PH, V56, P525, DOI 10.1093/ajhp/56.6.525; Lumbreras C, 1996, J INFECT DIS, V174, P583, DOI 10.1093/infdis/174.3.583; Marr KA, 2000, BLOOD, V96, P2055; Marr KA, 2000, J INFECT DIS, V181, P309, DOI 10.1086/315193; MEHTA C, 1999, P STATX 4 SAS US, P257; MILLON L, 1994, J CLIN MICROBIOL, V32, P1115, DOI 10.1128/JCM.32.4.1115-1118.1994; Minguez FM, 1997, CHEMOTHERAPY, V43, P346, DOI 10.1159/000239588; Mucke R, 1998, MYCOSES, V41, P421, DOI 10.1111/j.1439-0507.1998.tb00364.x; MURRAY PR, 1999, MANUAL CLIN MICROBIO, P1191; *NAT COMM CLIN LAB, 1997, M27A NCCLS NAT COMM; Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V33, P217, DOI 10.1016/S0732-8893(98)00160-6; Pfaller MA, 1998, ANTIMICROB AGENTS CH, V42, P3242, DOI 10.1128/AAC.42.12.3242; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; SANTNER TJ, 1980, J AM STAT ASSOC, V75, P386, DOI 10.2307/2287464; SAXEN H, 1993, CLIN PHARMACOL THER, V54, P269, DOI 10.1038/clpt.1993.147; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; Spicer A. D., 1992, Medical Microbiology Letters, V1, P284; Stoll BJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e63; Stoll BJ, 1996, J PEDIATR-US, V129, P63, DOI 10.1016/S0022-3476(96)70191-9; TEEN KA, 1989, MYCOSES, V32, P551; Vaden SL, 1997, J VET PHARMACOL THER, V20, P181, DOI 10.1111/j.1365-2885.1997.tb00093.x; VANTWOUT JW, 1990, J ANTIMICROB CHEMOTH, V25, P803, DOI 10.1093/jac/25.5.803; WaggonerFountain LA, 1996, CLIN INFECT DIS, V22, P803, DOI 10.1093/clinids/22.5.803; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; XANTHOU M, 1975, ARCH DIS CHILD, V50, P72, DOI 10.1136/adc.50.1.72	43	331	352	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1660	1666		10.1056/NEJMoa010494	http://dx.doi.org/10.1056/NEJMoa010494			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759644	Bronze			2022-12-28	WOS:000172517200002
J	Salis, G; Kato, Y; Ensslin, K; Driscoll, DC; Gossard, AC; Awschalom, DD				Salis, G; Kato, Y; Ensslin, K; Driscoll, DC; Gossard, AC; Awschalom, DD			Electrical control of spin coherence in semiconductor nanostructures	NATURE			English	Article							QUANTUM; GAAS	The processing of quantum information based on the electron spin degree of freedom(1,2) requires fast and coherent manipulation of local spins. One approach is to provide spatially selective tuning of the spin splitting-which depends on the g-factor-by using magnetic fields(3), but this requires their precise control at reduced length scales. Alternative proposals employ electrical gating(1) and spin engineering in semiconductor heterostructures involving materials with different g-factors. Here we show that spin coherence can be controlled in a specially designed AlxGa1-xAs quantum well in which the Al concentration x is gradually varied across the structure. Application of an electric field leads to a displacement of the electron wavefunction within the quantum well, and because the electron g-factor varies strongly with x, the spin splitting is therefore also changed. Using time-resolved optical techniques, we demonstrate gate-voltage-mediated control of coherent spin precession over a 13-GHz frequency range in a fixed magnetic field of 6 T, including complete suppression of precession, reversal of the sign of g, and operation up to room temperature.	Univ Calif Santa Barbara, Ctr Spintron & Quantum Comp, Santa Barbara, CA 93106 USA; Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	University of California System; University of California Santa Barbara; Swiss Federal Institutes of Technology Domain; ETH Zurich	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Ctr Spintron & Quantum Comp, Santa Barbara, CA 93106 USA.	awsch@physics.ucsb.edu	Salis, Gian/B-5651-2018; Kato, Yuichiro K./B-5051-2008	Kato, Yuichiro K./0000-0002-9942-1459; Salis, Gian/0000-0001-6263-4517				Amand T, 1997, PHYS REV LETT, V78, P1355, DOI 10.1103/PhysRevLett.78.1355; BIR GL, 1976, ZH EKSP TEOR FIZ, V42, P705; Chu-Liang Y, 1988, PHYS REV B, V37, P1364; De Poortere EP, 2000, SCIENCE, V290, P1546, DOI 10.1126/science.290.5496.1546; DiVincenzo DP, 1999, J APPL PHYS, V85, P4785, DOI 10.1063/1.370481; GOSSARD AC, 1986, IEEE J QUANTUM ELECT, V22, P1649, DOI 10.1109/JQE.1986.1073165; Ivchenko EL, 1997, SOLID STATE COMMUN, V102, P375, DOI 10.1016/S0038-1098(97)00009-4; Jiang HW, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.041307; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; KOWALSKI B, 1994, PHYS REV B, V49, P14786, DOI 10.1103/PhysRevB.49.14786; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MARANOWSKI KD, 1995, APPL PHYS LETT, V66, P3459, DOI 10.1063/1.113387; MILLER DAB, 1984, PHYS REV LETT, V53, P2173, DOI 10.1103/PhysRevLett.53.2173; MILLER RC, 1985, PHYS REV B, V32, P5443, DOI 10.1103/PhysRevB.32.5443; OESTREICH M, 1995, PHYS REV LETT, V74, P2315, DOI 10.1103/PhysRevLett.74.2315; Paillard M, 2001, PHYS REV LETT, V86, P1634, DOI 10.1103/PhysRevLett.86.1634; Salis G, 1997, PHYS REV LETT, V79, P5106, DOI 10.1103/PhysRevLett.79.5106; SNELLING MJ, 1991, PHYS REV B, V44, P11345, DOI 10.1103/PhysRevB.44.11345; WEISBUCH C, 1977, PHYS REV B, V15, P816, DOI 10.1103/PhysRevB.15.816	20	273	275	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					619	622		10.1038/414619a	http://dx.doi.org/10.1038/414619a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740554				2022-12-28	WOS:000172535600042
J	Kobayashi, T; Saito, T; Ohtani, H				Kobayashi, T; Saito, T; Ohtani, H			Real-time spectroscopy of transition states in bacteriorhodopsin during retinal isomerization	NATURE			English	Article							OPTICAL PARAMETRIC AMPLIFICATION; RESONANCE RAMAN-SPECTROSCOPY; LIGHT-INDUCED EVENTS; PULSE GENERATION; PRIMARY STEP; DYNAMICS; PHOTOISOMERIZATION; PHOTOCYCLE; SPECTRA; MODEL	Real-time investigations of the rearrangement of bonds during chemical transformations require femtosecond temporal resolution, so that the atomic vibrations within the reacting molecules can be observed. Following the development of lasers capable of emitting ultrashort laser flashes on this timescale, chemical reactions involving relatively simple molecules have been monitored in detail, revealing the transient existence of intermediate species as reactants are transformed into products(1-3). Here we report the direct observation of nuclear motion in a complex biological system, the retinal chromophore of bacteriorhodopsin (bR(568))(4), as it undergoes the trans-cis photoisomerization that is fundamental to the vision process. By using visible-light pulses of less than 5 femtosecond in duration(5,6), we are able to monitor changes in the vibrational spectra of the transition state and thus show that despite photoexcitation of the anti-bonding molecular orbital involved, isomerization does not occur instantly, but involves transient formation of a so-called 'tumbling state'. Our observations thus agree with growing experimental(7-14) and ab initio evidence(15,16) for a three-state photoisomerization model(8-10,17) and firmly discount the initially suggested two-state model(18-20) for this process.	Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Yokohama, Kanagawa 2268501, Japan	University of Tokyo; Tokyo Institute of Technology	Kobayashi, T (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.							ATKINSON GH, 1989, CHEM PHYS, V131, P1, DOI 10.1016/0301-0104(89)87077-6; Atkinson GH, 2000, J PHYS CHEM A, V104, P4130, DOI 10.1021/jp9918306; Bardeen CJ, 1998, J PHYS CHEM A, V102, P2759, DOI 10.1021/jp980346k; DILLER R, 1995, CHEM PHYS LETT, V241, P109, DOI 10.1016/0009-2614(95)00598-X; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DU M, 1993, BIOPHYS CHEM, V48, P101, DOI 10.1016/0301-4622(93)85002-Y; EYRING G, 1982, BIOCHEMISTRY-US, V21, P384, DOI 10.1021/bi00531a028; Gai F, 1998, SCIENCE, V279, P1886, DOI 10.1126/science.279.5358.1886; Garavelli M, 1999, J AM CHEM SOC, V121, P1023, DOI 10.1021/ja981719y; Haran G, 1996, CHEM PHYS LETT, V261, P389, DOI 10.1016/0009-2614(96)01017-2; Hasson KC, 1996, P NATL ACAD SCI USA, V93, P15124, DOI 10.1073/pnas.93.26.15124; Humphrey W, 1998, BIOPHYS J, V75, P1689, DOI 10.1016/S0006-3495(98)77611-8; Kobayashi T, 2000, APPL PHYS B-LASERS O, V70, pS239, DOI 10.1007/s003400000325; Kobayashi T, 2000, CHEM PHYS LETT, V321, P385, DOI 10.1016/S0009-2614(00)00282-7; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; MYERS AB, 1983, J CHEM PHYS, V79, P603, DOI 10.1063/1.445807; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PETEANU LA, 1993, P NATL ACAD SCI USA, V90, P11762, DOI 10.1073/pnas.90.24.11762; POLANYI JC, 1995, ACCOUNTS CHEM RES, V28, P119, DOI 10.1021/ar00051a005; POLLARD WT, 1992, J PHYS CHEM-US, V96, P6147, DOI 10.1021/j100194a013; ROSE TS, 1989, J CHEM PHYS, V91, P7415, DOI 10.1063/1.457266; ROSE TS, 1988, J CHEM PHYS, V88, P6672, DOI 10.1063/1.454408; Shirakawa A, 1999, APPL PHYS LETT, V74, P2268, DOI 10.1063/1.123820; Shirakawa A, 1998, OPT LETT, V23, P1292, DOI 10.1364/OL.23.001292; SHOENLEIN RW, 1993, J PHYS CHEM-US, V97, P12087; Song L, 1998, J AM CHEM SOC, V120, P8889, DOI 10.1021/ja980390d; VANDENBERG R, 1990, BIOPHYS J, V58, P135, DOI 10.1016/S0006-3495(90)82359-6; Vreven T, 1997, J AM CHEM SOC, V119, P12687, DOI 10.1021/ja9725763; Ye T, 1999, J PHYS CHEM B, V103, P5122, DOI 10.1021/jp9846227; Zhong Q, 1996, J AM CHEM SOC, V118, P12828, DOI 10.1021/ja961058+	30	348	359	0	63	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					531	534		10.1038/35107042	http://dx.doi.org/10.1038/35107042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734850				2022-12-28	WOS:000172405900043
J	Ransohoff, DF; Sandler, RS				Ransohoff, DF; Sandler, RS			Screening for colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OCCULT BLOOD-TEST; SOCIETY GUIDELINES; COST-EFFECTIVENESS; COLONOSCOPY; SIGMOIDOSCOPY; MORTALITY; TRIAL; SURVEILLANCE; UPDATE; LUNG		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ransohoff, DF (corresponding author), Univ N Carolina, Dept Med, CB 7080,724 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	ransohof@med.unc.edu						Ashley OS, 2001, AM J MED, V111, P643, DOI 10.1016/S0002-9343(01)00959-7; Atkin WS, 2000, GASTROENTEROLOGY, V118, pA187, DOI 10.1016/S0016-5085(00)82822-X; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Fenlon HM, 1999, NEW ENGL J MED, V341, P1496, DOI 10.1056/NEJM199911113412003; FENLON HM, 2000, NEW ENGL J MED, V342, P524; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P144; HERRINTON LJ, 1995, AM J EPIDEMIOL, V142, P961, DOI 10.1093/oxfordjournals.aje.a117744; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Imperiale TF, 2001, GASTROENTEROLOGY, V120, pA15; KRAMER BS, 1993, CANCER, V71, P589; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Lang CA, 1998, EUR J GASTROEN HEPAT, V10, P199, DOI 10.1097/00042737-199803000-00002; Levin TR, 2001, GASTROENTEROLOGY, V120, pA65; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; LIEBERMAN T, 2001, LOS ANGELES TIM 0319, pS1; LIEBERMAN T, 2001, LOS ANGELES TIM 0319, pS7; Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; PIGNONE MP, IN PRESS AHRQ PUBLIC; Podolsky DK, 2000, NEW ENGL J MED, V343, P207, DOI 10.1056/NEJM200007203430309; Ransohoff DF, 1997, ANN INTERN MED, V126, P811, DOI 10.7326/0003-4819-126-10-199705150-00014; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Saitoh Y, 2001, GASTROENTEROLOGY, V120, P1657, DOI 10.1053/gast.2001.24886; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; Smith RA, 2001, CA-CANCER J CLIN, V51, P150; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; WAGNER JL, 1995, BPH146 OFF TECHN ASS; Willett WC, 2001, CANCER EPIDEM BIOMAR, V10, P3; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Winawer SJ, 1998, GASTROENTEROLOGY, V114, P625; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P1060; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Woolf SH, 2000, NEW ENGL J MED, V343, P1641, DOI 10.1056/NEJM200011303432211; 1999, MMWR MORB MORTAL WKL, V48, P116	41	139	149	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					40	44		10.1056/NEJMcp010886	http://dx.doi.org/10.1056/NEJMcp010886			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11778002				2022-12-28	WOS:000173033600008
J	Schwetz, BA				Schwetz, BA			Rheumatoid arthritis treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					33	33		10.1001/jama.287.1.33-b	http://dx.doi.org/10.1001/jama.287.1.33-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754690				2022-12-28	WOS:000172978500006
J	Ernst, E				Ernst, E			The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava	ANNALS OF INTERNAL MEDICINE			English	Article							BENIGN PROSTATIC HYPERPLASIA; RANDOMIZED CLINICAL-TRIALS; INTERMITTENT CLAUDICATION; CEREBRAL INSUFFICIENCY; COMPLEMENTARY MEDICINE; BILOBA EXTRACT; UNITED-STATES; DEPRESSION; METAANALYSIS; EFFICACY	Because use of herbal remedies is increasing, a risk-benefit profile of commonly used herbs is needed. This article provides a clinically oriented overview of the efficacy and safety of ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Wherever possible, assessments are based on systematic reviews of randomized clinical trials. Encouraging data support the efficacy of some of these popular herbal medicinal products, and the potential for doing good seems greater than that for doing harm. The published evidence suggests that ginkgo is of questionable use for memory loss and tinnitus but has some effect on dementia and intermittent claudication. St. John's wort is efficacious for mild to moderate depression, but serious concerns exist about its interactions with several conventional drugs. Well-conducted clinical trials do not support the efficacy of ginseng to treat any condition. Echinacea may be helpful in the treatment or prevention of upper respiratory tract infections, but trial data are not fully convincing. Saw palmetto has been shown in short-term trials to be efficacious in reducing the symptoms of benign prostatic hyperplasia. Kava is an efficacious short-term treatment for anxiety. None of these herbal medicines is free of adverse effects. Because the evidence is incomplete, risk-benefit assessments are not completely reliable, and much knowledge is still lacking.	Univ Exeter, Sch Sport & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Sport & Hlth Sci, Dept Complementary Med, 25 Victoria Pk Rd, Exeter EX2 4NT, Devon, England.	E.Ernst@exeter.ac.uk						Ackermann RT, 2001, ARCH INTERN MED, V161, P813, DOI 10.1001/archinte.161.6.813; Almeida JC, 1996, ANN INTERN MED, V125, P940, DOI 10.7326/0003-4819-125-11-199612010-00023; BAHRKE MS, 1994, SPORTS MED, V18, P229, DOI 10.2165/00007256-199418040-00003; Bauer R., 1991, EC MED PLANT RES, V5, P253; Blumenthal M, 1999, HERBALGRAM, V47, P64; BOHMER D, 1988, HERZ KREISLAUF, V20, P5; BOON H, 1999, BOT PHARM PHARM 47 C; Cupp MJ., 2000, TOXICOLOGY CLIN PHAR; DEFEUDIS FV, 1991, GINKGO BILOBA; DISILVERIO F, 1992, EUR UROL, V21, P309; DREWE J, 2000, PHYTOPHARMAKA 6 FORS; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, PERFUSION-GERMANY, V13, P60; Ernst E, 2000, PERFUSION, V13, P4; Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 2000, BRIT MED J, V321, P707; Ernst E, 1998, EUR J CLIN PHARMACOL, V54, P99, DOI 10.1007/s002280050428; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; ERNST E, 1994, BRIT MED J, V308, P1640, DOI 10.1136/bmj.308.6944.1640; Ernst E, 1999, CLIN DRUG INVEST, V17, P301, DOI 10.2165/00044011-199917040-00006; Ernst E, 1999, CLIN OTOLARYNGOL, V24, P164, DOI 10.1046/j.1365-2273.1999.00243.x; Ernst E, 1998, PERFUSION, V11, P209; ERNST E, 2000, MEYLERS SIDE EFFECTS, P1649; FETROW CW, 1999, PROFESSIONALS HDB CO; Gallo M, 2000, ARCH INTERN MED, V160, P3141, DOI 10.1001/archinte.160.20.3141; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; HOBBS C, 1994, HERBALGRAM S, V30, P1; HOFMANN R, 1996, PSYCHO S, V22, P51; HOPFENMULLER W, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1005; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Jappe U, 1998, J AM ACAD DERMATOL, V38, P104, DOI 10.1016/S0190-9622(98)70547-X; JUSSOFIE A, 1994, PSYCHOPHARMACOLOGY, V116, P469, DOI 10.1007/BF02247480; Kim HL, 1999, J NERV MENT DIS, V187, P532, DOI 10.1097/00005053-199909000-00002; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KOLTRINGER P, 1989, PERFUSION, V1, P28; Leng GC, 2000, COCHRANE DATABASE SY; LETZEL H, 1992, VASA-J VASCULAR DIS, V21, P403; LINDE K, 2000, COCHRANE DATABASE SY; Lindenberg D, 1990, Fortschr Med, V108, P49; Lowe FC, 1999, UROLOGY, V53, P671, DOI 10.1016/S0090-4295(98)00664-5; LUETTIG B, 1989, J NATL CANCER I, V81, P669, DOI 10.1093/jnci/81.9.669; Marks LS, 2000, J UROLOGY, V163, P1451, DOI 10.1016/S0022-5347(05)67641-0; Matthews HB, 1999, ENVIRON HEALTH PERSP, V107, P773, DOI 10.2307/3454572; MELCHART D, 2000, COCHRANE DATABASE SY; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mullins RJ, 1998, MED J AUSTRALIA, V168, P170, DOI 10.5694/j.1326-5377.1998.tb126773.x; NORTON SA, 1994, J AM ACAD DERMATOL, V31, P89, DOI 10.1016/S0190-9622(94)70142-3; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Pittler MH, 2000, AM J MED, V108, P276, DOI 10.1016/S0002-9343(99)00454-4; Pittler MH, 2000, J CLIN PSYCHOPHARM, V20, P84, DOI 10.1097/00004714-200002000-00014; Relman AS, 1999, ARCH INTERN MED, V159, P2122; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Schulz V, 2000, PERFUSION-GERMANY, V13, P486; SCHULZ V, 1999, RATIONALE PHYTOTHERA; Siegers C.P., 1992, ARZNEIMITTEL-FORSCH, V39, P7; Stevinson C, 1999, CNS DRUGS, V11, P125, DOI 10.2165/00023210-199911020-00004; Stevinson C, 1999, EUR NEUROPSYCHOPHARM, V9, P501, DOI 10.1016/S0924-977X(99)00032-2; Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009; STOLLER A, 2000, SCHWEIZERISCHE ARZTE, V133, P5; TYLER VE, 2000, HNR, V7, P279; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Vuksan V, 2000, ARCH INTERN MED, V160, P1009, DOI 10.1001/archinte.160.7.1009; Wagner PJ, 1999, J FAM PRACTICE, V48, P615; White A., 2001, DESKTOP GUIDE COMPLE; WILKS J, 1999, INT J ALTERNATIV SEP, P1; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011; WILT T, 2000, COCHRANE DATABASE SY; YOKOZAWA T, 1975, CHEM PHARM BULL, V23, P3095; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; Yun TK, 1998, INT J EPIDEMIOL, V27, P359, DOI 10.1093/ije/27.3.359	74	333	366	0	93	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					42	53		10.7326/0003-4819-136-1-200201010-00010	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777363				2022-12-28	WOS:000173188300005
J	Obernosterer, A; Aschauer, M; Schnedl, W; Lipp, RW				Obernosterer, A; Aschauer, M; Schnedl, W; Lipp, RW			Anomalies of the inferior vena cava in patients with iliac venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; LOWER-EXTREMITIES; PELVIC VEINS; APLASIA; ABSENCE	Background: Cases of deep venous thrombosis in the lower extremities triggered by abnormalities of the vena cava have been reported. Objective: To describe anomalies of the inferior vena cava in patients with deep venous thrombosis. Design: Prospective, consecutive case series. Setting: University Hospital, Graz, Austria. Patients: 97 patients with deep venous thrombosis. Intervention: Sonography, venography, or both to diagnose deep venous thrombosis; magnetic resonance angiography to image the inferior vena cava. Measurements: Anomalies of the inferior vena cava imaged by magnetic resonance angiography. Results: 31 of 97 patients showed thrombotic occlusion of iliac veins (common and external iliac vein [n = 29] or external iliac vein [n = 2]). Five of 31 patients (3 men, 2 women) had an anomaly of the inferior vena cava. Anomalies were missing inferior vena cava, hypoplastic hepatic segment, and missing renal or postrenal segments. Patients with anomalies were significantly younger than the 92 patients without (mean age +/- SD, 25 +/- 6 years vs. 53 +/- 19 years; P = 0.002). In 2 patients with anomalies, the thrombotic occlusion was recurrent. Conclusions: An anomaly of the inferior vena cava should be suspected if thrombosis involving the iliac veins is seen in patients 30 years of age or younger. Patients with both an anomaly and thrombosis may be at higher risk for thrombotic recurrence.	Graz Univ, Dept Internal Med, Div Angiol, A-8036 Graz, Austria	University of Graz	Obernosterer, A (corresponding author), Graz Univ, Dept Internal Med, Div Angiol, Auenbruggerpl 15, A-8036 Graz, Austria.	andrea.obernosterer@kfunigraz.ac.at		Schnedl, Wolfgang/0000-0002-5212-5230				BALDRIDGE ED, 1987, ARCH SURG-CHICAGO, V122, P1184; Bergqvist D, 1997, ANN INTERN MED, V126, P454, DOI 10.7326/0003-4819-126-6-199703150-00006; BORUCHOW IB, 1972, SURG GYNECOL OBSTETR, V134, P115; CHUANG VP, 1974, BRIT J RADIOL, V47, P206, DOI 10.1259/0007-1285-47-556-206; Dougherty MJ, 1996, J VASC SURG, V23, P141, DOI 10.1016/S0741-5214(05)80044-8; Hach W, 1985, PHLEBOGRAPHIE BEIN B, P56; HALBMAYER WM, 1993, DEUT MED WOCHENSCHR, V118, P1561, DOI 10.1055/s-2008-1059485; Kellman G M, 1988, Radiographics, V8, P533; Klessen C, 1999, DEUT MED WOCHENSCHR, V124, P523, DOI 10.1055/s-2007-1024354; Mirzaie M, 1999, VASA-J VASCULAR DIS, V28, P293, DOI 10.1024/0301-1526.28.4.293; MUELHEIMS GH, 1962, AM J CARDIOL, V9, P945, DOI 10.1016/0002-9149(62)90225-4; Ordonez FS, 1998, ANGIOLOGY, V49, P951, DOI 10.1177/000331979804901113; POLAK JF, 1992, PERIPHERAL VASCULAR, P155; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; SAITO H, 1995, CARDIOVASC INTER RAD, V18, P410, DOI 10.1007/BF00338312; Shah NL, 1996, SURGERY, V120, P891, DOI 10.1016/S0039-6060(96)80100-0; Thornton MJ, 1999, AM J ROENTGENOL, V173, P999, DOI 10.2214/ajr.173.4.10511166; Tiesenhausen K, 1999, VASA-J VASCULAR DIS, V28, P289, DOI 10.1024/0301-1526.28.4.289; Timmers GJ, 1999, INT J CLIN PRACT, V53, P75; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	20	129	140	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					37	41		10.7326/0003-4819-136-1-200201010-00009	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777362				2022-12-28	WOS:000173188300004
J	Liu, XH; Gross, RL; Suits, AG				Liu, XH; Gross, RL; Suits, AG			"Heavy electron" photoelectron spectroscopy: Rotationally resolved ion pair imaging of CH3+	SCIENCE			English	Article							PHOTODISSOCIATION; SPECTRUM; DISSOCIATION; MOLECULES	We applied the velocity map imaging technique under high-resolution conditions to study ion pair products of the vacuum ultraviolet photodissociation of methyl chloride. We obtained rotationally resolved kinetic energy release spectra that directly provide vibrational frequencies and rotational constants of the fundamental carbocation, CH3+. The technique is analogous to photoelectron spectroscopy, with the chloride anion playing the rote of a "heavy electron." The approach shows promise as a general probe of ionic species not amenable to study by traditional methods.	Brookhaven Natl Lab, Dept Chem, Gas Phase Mol Dynam Grp, Upton, NY 11973 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Suits, AG (corresponding author), Brookhaven Natl Lab, Dept Chem, Gas Phase Mol Dynam Grp, Upton, NY 11973 USA.							Ahmed M, 1997, J CHEM PHYS, V106, P7617, DOI 10.1063/1.473764; Ahmed M, 2001, CHEM PHYS LETT, V339, P203, DOI 10.1016/S0009-2614(01)00252-4; Berkowitz J., 1979, PHOTOABSORPTION PHOT; BLUSH JA, 1993, J CHEM PHYS, V98, P3557, DOI 10.1063/1.464077; Chang BY, 1998, REV SCI INSTRUM, V69, P1665, DOI 10.1063/1.1148824; CROFTON MW, 1988, J CHEM PHYS, V88, P666, DOI 10.1063/1.454194; CROFTON MW, 1985, J CHEM PHYS, V83, P3702, DOI 10.1063/1.449125; DYKE J, 1976, J CHEM SOC FARAD T 2, V72, P1385, DOI 10.1039/f29767201385; Eppink ATJB, 1997, REV SCI INSTRUM, V68, P3477, DOI 10.1063/1.1148310; FROHNE MV, 1994, THESIS KANSAS STATE; Gurvich, 1989, THERMODYNAMICS PROPE; Hikosaka Y, 2000, RAPID COMMUN MASS SP, V14, P2305; HIROTA E, 1992, CHEM REV, V92, P141, DOI 10.1021/cr00009a006; Hirota E., 2001, ANNU REP PROG CHEM C, V96, P95; JACKSON WM, 2000, IMAGING CHEM DYNAMIC, P103; Kawasaki M, 1996, J PHYS CHEM-US, V100, P19853, DOI 10.1021/jp9609343; KRAEMER WP, 1991, J MOL SPECTROSC, V149, P235, DOI 10.1016/0022-2852(91)90155-4; Litorja M, 1997, J CHEM PHYS, V107, P9852, DOI 10.1063/1.475282; Martin JDD, 1997, PHYS REV LETT, V79, P3154, DOI 10.1103/PhysRevLett.79.3154; Martin JDD, 1998, J CHEM PHYS, V109, P8139, DOI 10.1063/1.477476; Olkhov RV, 1998, J CHEM PHYS, V108, P10046, DOI 10.1063/1.476465; Vrakking MJJ, 2001, REV SCI INSTRUM, V72, P4084, DOI 10.1063/1.1406923; ZAHEDI M, 1994, J CHEM PHYS, V100, P4043, DOI 10.1063/1.466342	23	47	47	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2527	2529		10.1126/science.1066595	http://dx.doi.org/10.1126/science.1066595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752573				2022-12-28	WOS:000172927700052
J	Furberg, CD; Psaty, BM; Pahor, M; Alderman, MH				Furberg, CD; Psaty, BM; Pahor, M; Alderman, MH			Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SURROGATE END-POINTS; CALCIUM-ANTAGONISTS; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIAL; HEALTH OUTCOMES; ACE-INHIBITORS; DRUGS; MORBIDITY; MORTALITY; RAMIPRIL	Several recent comparative trials in hypertension have reported that similar blood pressure reductions may not necessarily translate into similar reductions in risk for cardiovascular complications. Thus, the method used to lower blood pressure may be important. In the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT), low-dose chlorthalidone as the first-line drug was superior to doxazosin. The 25% higher risk for major cardiovascular events associated with doxazosin was attributed primarily to a doubling in the risk for heart failure. A metaanalysis of patients with type 2 diabetes mellitus suggested that despite achieving similar blood pressure reductions, angiotensin-converting enzyme inhibitors are superior to other antihypertensive drugs in reducing the risk for acute myocardial infarction and cardiovascular events, but not stroke. Although individual comparative trials have failed to show conclusively that calcium-channel blockers differ from other antihypertensive drugs, a meta-analysis that included all published trials concluded that calcium-channel blockers are inferior to other classes of drugs in reducing the risk for acute myocardial infarction and heart failure. These observations suggest not only that anti hypertensive drugs may have important mechanisms of action apart from blood pressure lowering but also that effective treatment is not a matter of simply lowering blood pressure. These findings have potential implications for the regulatory approval of anti hypertensive agents, revisions of treatment guidelines, the design of future randomized trials comparing different antihypertensive drugs and, most important, the selection of drugs for the treatment of hypertensive patients.	Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Washington, Seattle, WA 98195 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Wake Forest University; University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine	Furberg, CD (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	cfurberg@wfubmc.edu						Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 1999, LANCET, V354, P1202, DOI 10.1016/S0140-6736(99)03190-6; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; LIPICKY RJ, 1993, J AM COLL CARDIOL, V22, pA179, DOI 10.1016/0735-1097(93)90487-L; MacMahon S, 2000, LANCET, V356, P352, DOI 10.1016/S0140-6736(00)02521-6; Neal B, 2000, LANCET, V356, P1955; Pahor M, 2000, DIABETES CARE, V23, P888, DOI 10.2337/diacare.23.7.888; Pahor M, 2001, LANCET, V358, P152, DOI 10.1016/S0140-6736(01)05362-4; Pahor M, 2000, LANCET, V356, P1949, DOI 10.1016/S0140-6736(00)03306-7; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Wheeldon Nigel M., 2001, American Journal of Hypertension, V14, p2A, DOI 10.1016/S0895-7061(01)01323-1; Yusuf S, 2000, NEW ENGL J MED, V342, P145	21	36	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1074	1078		10.7326/0003-4819-135-12-200112180-00011	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747386				2022-12-28	WOS:000172759700007
J	Grenfell, BT; Bjornstad, ON; Kappey, J				Grenfell, BT; Bjornstad, ON; Kappey, J			Travelling waves and spatial hierarchies in measles epidemics	NATURE			English	Article							PATTERN-FORMATION; DYNAMICS; PERSISTENCE; CHAOS; HETEROGENEITY; PERIODICITY; POPULATIONS; VACCINATION; SYNCHRONY; MODELS	Spatio-temporal travelling waves are striking manifestations of predator-prey and host-parasite dynamics. However, few systems are well enough documented both to detect repeated waves and to explain their interaction with spatio-temporal variations in population structure and demography. Here, we demonstrate recurrent epidemic travelling waves in an exhaustive spatio-temporal data set for measles in England and Wales. We use wavelet phase analysis, which allows for dynamical nonstationarity-a complication in interpreting spatio-temporal patterns in these and many other ecological time series. In the prevaccination era, conspicuous hierarchical waves of infection moved regionally from large cities to small towns; the introduction of measles vaccination restricted but did not eliminate this hierarchical contagion. A mechanistic stochastic model suggests a dynamical explanation for the waves-spread via infective 'sparks' from large 'core' cities to smaller 'satellite' towns. Thus, the spatial hierarchy of host population structure is a prerequisite for these infection waves.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Penn State Univ, Dept Entomol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Grenfell, BT (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	b.t.grenfell@zoo.cam.ac.uk	Bjornstad, Ottar N/I-4518-2012					ANDERSON R M, 1991; ANDERSON RM, 1984, J HYG-CAMBRIDGE, V93, P587, DOI 10.1017/S0022172400065177; [Anonymous], 2020, INFECT DIS POVERTY, DOI DOI 10.1186/s40249-020-00640-3; BAK P, 1977, NATURE WORKS SCI ORG; Bartlett M.S., 1956, P 3 BERK S MATH STAT, P81, DOI DOI 10.2307/2342553; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bjornstad ON, 2001, J ANIM ECOL, V70, P924, DOI 10.1046/j.0021-8790.2001.00560.x; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Bjornstad ON, 2001, ENVIRON ECOL STAT, V8, P53, DOI 10.1023/A:1009601932481; BJORNSTAD ON, IN PRESS ECOL MONOGR; Blasius B, 1999, NATURE, V399, P354, DOI 10.1038/20676; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; BRADSHAW GA, 1992, J ECOL, V80, P205, DOI 10.2307/2261007; Breiman L, 1992, PROBABILITY; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; Cliff A, 1993, MEASLES HIST GEOGRAP, P1840; CLIFF AD, 1992, STAT MED, V11, P1409, DOI 10.1002/sim.4780111102; Earn DJD, 2000, SCIENCE, V287, P667, DOI 10.1126/science.287.5453.667; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; Finkenstadt B, 1998, P ROY SOC B-BIOL SCI, V265, P211, DOI 10.1098/rspb.1998.0284; Finkenstadt BF, 2000, J R STAT SOC C-APPL, V49, P187, DOI 10.1111/1467-9876.00187; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; Grenfell BT, 1998, ECOL LETT, V1, P63; GRENFELL BT, IN PRESS ECOL MONOGR; HALL P, 1994, PROBAB THEORY REL, V99, P399, DOI 10.1007/BF01199899; HANSKI I, 1993, AM NAT, V142, P17, DOI 10.1086/285527; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; Jeltsch F, 1997, P ROY SOC B-BIOL SCI, V264, P495, DOI 10.1098/rspb.1997.0071; KENDALL BE, 1993, PHYS LETT A, V177, P13, DOI 10.1016/0375-9601(93)90366-8; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; Lloyd AL, 1996, J THEOR BIOL, V179, P1, DOI 10.1006/jtbi.1996.0042; MAY RM, 1984, MATH BIOSCI, V72, P83, DOI 10.1016/0025-5564(84)90063-4; MOLLISON D, 1986, PHILOS T R SOC B, V314, P675, DOI 10.1098/rstb.1986.0080; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; Nason GP, 1999, PHILOS T R SOC A, V357, P2511, DOI 10.1098/rsta.1999.0445; NEUBERT MG, 1995, THEOR POPUL BIOL, V48, P7, DOI 10.1006/tpbi.1995.1020; Office of Population Censuses and Surveys, 1944, REG GEN WEEKL RET EN; Percival D.B., 2000, CA ST PR MA, V4; Ranta E, 1997, NATURE, V390, P456, DOI 10.1038/37261; Rhodes CJ, 1996, NATURE, V381, P600, DOI 10.1038/381600a0; SCHAFFER WM, 1985, J THEOR BIOL, V112, P403, DOI 10.1016/S0022-5193(85)80294-0; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SCHWARTZ IB, 1989, BIOMEDICAL MODELLING, P201; Sherratt JA, 2001, ECOL LETT, V4, P30, DOI 10.1046/j.1461-0248.2001.00193.x; SOLE RV, 1992, PHYS LETT A, V166, P123, DOI 10.1016/0375-9601(92)90546-X; Stenseth NC, 1999, SCIENCE, V285, P1071, DOI 10.1126/science.285.5430.1071; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2	50	640	652	0	120	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					716	723		10.1038/414716a	http://dx.doi.org/10.1038/414716a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742391				2022-12-28	WOS:000172676200039
J	Rodewald, HR; Paul, S; Haller, C; Bluethmann, H; Blum, C				Rodewald, HR; Paul, S; Haller, C; Bluethmann, H; Blum, C			Thymus medulla consisting of epithelial islets each derived from a single progenitor	NATURE			English	Article							CELL DIFFERENTIATION; STEM-CELLS; C-KIT; MICE; EXPANSION	The thymus is organized into medullary and cortical zones that support distinct stages of T-cell development. The formation of medulla and cortex compartments is thought to occur through invagination of an endodermal epithelial sheet into an ectodermal one at the third pharyngeal pouch and cleft, respectively(1-5). Epithelial stem/progenitor cells have been proposed to be involved in thymus development(6,7), but evidence for their existence has been elusive. We have constructed chimaeric mice by injecting embryonic stem (ES) cells into blastocysts using ES cells and blastocysts differing in their major histocompatibility complex (MHC) type. Here we show that the MHC class-II-positive medullary epithelium in these chimaeras is composed of cell clusters, most of which derive from either embryonic stem cell or blastocyst, but not mixed, origin. Thus, the medulla comprises individual epithelial 'islets' each arising from a single progenitor. One thymic lobe has about 300 medullary areas that originate from as few as 900 progenitors. Islet formation can be recapitulated after implantation of 'reaggregated fetal thymic organs'(8) into mice, which shows that medullary 'stem' cells retain their potential until at least day 16.5 in fetal development. Thus, medulla- cortex compartmentalization is established by formation of medullary islets from single progenitors.	Univ Ulm, Dept Immunol, D-89081 Ulm, Germany; Basel Inst Immunol, CH-4005 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4070 Basel, Switzerland	Ulm University; Roche Holding	Rodewald, HR (corresponding author), Univ Ulm, Dept Immunol, Albert Einstein Allee 11, D-89081 Ulm, Germany.							ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BESCHORNER WE, 1987, CELL IMMUNOL, V110, P350, DOI 10.1016/0008-8749(87)90128-6; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; CRISAN C., 1935, ZEITSCHR ANAT U ENTUNCKLUNGSGESCH, V104, P327, DOI 10.1007/BF02118610; GOSGROVE D, 1991, CELL, V66, P1051; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Lampert I. A., 1988, THYMUS UPDATE, P5; Manley NR, 2000, SEMIN IMMUNOL, V12, P421, DOI 10.1006/smim.2000.0263; NORRIS EH, 1938, CONTRIB EMBRYOL, V166, P191; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; Rodewald HR, 1997, IMMUNITY, V6, P265, DOI 10.1016/S1074-7613(00)80329-5; Rodewald HR, 1999, P NATL ACAD SCI USA, V96, P15068, DOI 10.1073/pnas.96.26.15068; Stewart JJ, 1998, IMMUNOL TODAY, V19, P352, DOI 10.1016/S0167-5699(98)01298-5; Suniara RK, 1999, EUR J IMMUNOL, V29, P75, DOI 10.1002/(SICI)1521-4141(199901)29:01<75::AID-IMMU75>3.3.CO;2-3; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1980, J HISTOCHEM CYTOCHEM, V28, P1089, DOI 10.1177/28.10.6999083; VONGAUDECKER B, 1991, ANAT EMBRYOL, V183, P1; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	21	159	163	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					763	768		10.1038/414763a	http://dx.doi.org/10.1038/414763a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742403				2022-12-28	WOS:000172676200051
J	Rupprecht, HD; Riess, R				Rupprecht, HD; Riess, R			Acute myoglobinuric renal failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Munich, D-80336 Munich, Germany; Klinikum Nurnberg, D-90340 Nurnberg, Germany	University of Munich; Klinikum Nurnberg Nord	Rupprecht, HD (corresponding author), Univ Munich, D-80336 Munich, Germany.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1747	1747		10.1056/NEJMicm990470	http://dx.doi.org/10.1056/NEJMicm990470			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742049				2022-12-28	WOS:000172656100005
J	[Anonymous]				[Anonymous]			Educating future scientists	NATURE			English	Editorial Material																			0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					673	673						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742350				2022-12-28	WOS:000172676200001
J	Di Bisceglie, AM				Di Bisceglie, AM			SEN and sensibility: interactions between newly discovered and other hepatitis viruses?	LANCET			English	Editorial Material									Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Bisceglie, AM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA.	DIBISCAM@SLU.EDU						HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; Ning Q, 1998, J IMMUNOL, V160, P3487; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503	4	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1925	1926		10.1016/S0140-6736(01)06976-8	http://dx.doi.org/10.1016/S0140-6736(01)06976-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747913				2022-12-28	WOS:000172622200006
J	Bullock, SL; Ish-Horowicz, D				Bullock, SL; Ish-Horowicz, D			Conserved signals and machinery for RNA transport in Drosophila oogenesis and embryogenesis	NATURE			English	Article							POSTERIOR DETERMINANT NANOS; PAIR-RULE TRANSCRIPTS; OSKAR MESSENGER-RNA; BICAUDAL-D PROTEIN; BICOID RNA; ANTERIOR POLE; EGG CHAMBER; LOCALIZATION; OOCYTE; GENE	Localization of cytoplasmic messenger RNA transcripts is widely used to target proteins within cells. For many transcripts, localization depends on cis-acting elements within the transcripts and on microtubule-based motors; however, little is known about other components of the transport machinery or how these components recognize specific RNA cargoes. Here, we show that in Drosophila the same machinery and RNA signals drive specific accumulation of maternal RNAs in the early oocyte and apical transcript localization in blastoderm embryos. We demonstrate in vivo that Egalitarian (Egl) and Bicaudal D (BicD), maternal proteins required for oocyte determination, are selectively recruited by, and co-transported with, localizing transcripts in blastoderm embryos, and that interfering with the activities of Egl and BicD blocks apical localization. We propose that Egl and BicD are core components of a selective dynein motor complex that drives transcript localization in a variety of tissues.	Imperial Canc Res Fund, Dev Genet Lab, London WC2A 3PX, England	Cancer Research UK	Ish-Horowicz, D (corresponding author), Imperial Canc Res Fund, Dev Genet Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.		Bullock, Simon/K-6885-2012	Bullock, Simon/0000-0001-9491-4548; Ish-Horowicz, David/0000-0001-5684-7129				Baens M, 1997, GENOMICS, V45, P601, DOI 10.1006/geno.1997.4971; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Lall S, 1999, CELL, V98, P171, DOI 10.1016/S0092-8674(00)81012-0; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LANTZ V, 1994, MOL CELL BIOL, V14, P2235, DOI 10.1128/MCB.14.4.2235; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; Macdonald PM, 1997, RNA, V3, P1413; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MOHLER J, 1986, GENETICS, V112, P803; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Oh J, 2000, GENETICS, V154, P713; Oh J, 2001, DEV BIOL, V232, P91, DOI 10.1006/dbio.2001.0170; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAN B, 1994, DEVELOPMENT, V120, P1233; Riedl A, 1996, MOL CELL BIOL, V16, P3047; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Saunders C, 1999, MOL CELL, V3, P43, DOI 10.1016/S1097-2765(00)80173-2; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; SCHUPBACH T, 1991, GENETICS, V129, P1119; SERANO T, 1995, DEVELOPMENT, V121, P3809; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Simmonds AJ, 2001, CELL, V105, P197, DOI 10.1016/S0092-8674(01)00311-7; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Swan A, 1999, NAT CELL BIOL, V1, P444, DOI 10.1038/15680; Swan A, 1996, DEVELOPMENT, V122, P3577; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1994, DEV BIOL, V165, P352, DOI 10.1006/dbio.1994.1258; Thio GL, 2000, DEV BIOL, V221, P435, DOI 10.1006/dbio.2000.9690; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; Wilkie GS, 2001, CELL, V105, P209, DOI 10.1016/S0092-8674(01)00312-9	45	199	206	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					611	616		10.1038/414611a	http://dx.doi.org/10.1038/414611a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740552				2022-12-28	WOS:000172535600040
J	Valencia, M; Bentele, M; Vaze, MB; Herrmann, G; Kraus, E; Lee, SE; Schar, P; Haber, JE				Valencia, M; Bentele, M; Vaze, MB; Herrmann, G; Kraus, E; Lee, SE; Schar, P; Haber, JE			NEJ1 controls non-homologous end joining in Saccharomyces cerevisiae	NATURE			English	Article							DOUBLE-STRAND BREAKS; DNA-LIGASE; MATING-TYPE; ILLEGITIMATE RECOMBINATION; GENE-EXPRESSION; REPAIR; YEAST; KU70; IDENTIFICATION; MUTATIONS	Broken DNA ends are rejoined by non-homologous end-joining (NHEJ) pathways requiring the Ku proteins (Ku70, Ku80), DNA ligase IV and its associated protein Lif1/Xrcc4 (ref. 1). In mammalian meiotic cells, Ku protein levels are much lower than in somatic cells, apparently reducing the capacity of meiotic cells to carry out NHEJ and thereby promoting homologous recombination(2). In Saccharomyces cerevisiae, NHEJ is also downregulated in meiosis-competent MATa/MAT alpha diploid cells in comparison with diploids or haploids expressing only MATa or MAT alpha (3,4). Diploids expressing both MATa and MAT alpha show enhanced mitotic homologous recombination(4). Here we report that mating-type-dependent regulation of NHEJ in budding yeast is caused in part by transcriptional repression of both LIF1 and the gene NEJ1 (YLR265C)-identified from microarray screening of messenger RNAs. Deleting NEJ1 reduces NHEJ 100-fold in MATa or MAT alpha haploids. Constitutive expression of NEJ1, but not expression of LIF1, restores NHEJ in MATa/MAT alpha cells. Nej1 regulates the subcellular distribution of Lif1. A green fluorescent protein (GFP)-Lif1 fusion protein accumulates in the nucleus in cells expressing NEJ1 but is largely cytoplasmic when NEJ1 is repressed.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland	Brandeis University; Brandeis University; University of Zurich	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.		Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147; Haber, James/0000-0002-1878-0610				Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OOI SL, 2001, SCIENCE         1108; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wu XH, 1996, CELL, V87, P277, DOI 10.1016/S0092-8674(00)81345-8; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	29	174	178	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					666	669		10.1038/414666a	http://dx.doi.org/10.1038/414666a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740566				2022-12-28	WOS:000172535600054
J	Irvine, D				Irvine, D			Doctors in the UK: their new professionalism and its regulatory framework	LANCET			English	Article							PERFORMANCE; MEDICINE; NHS	The new professionalism evolving in UK medicine is fundamentally different from the past. Founded on the General Medical Council's (GMC) Good Medical Practice, the new professionalism is an explicit statement of professional duties, responsibilities, values, and standards for doctors, developed and agreed on by the public and the profession. Compliance is being secured by embedding the culture of Good Medical Practice into medical education and by [inking it directly with medical registration (licensure). From 2004 doctors will have their abilities assessed regularly by peers and by members of the public to ensure that they remain up-to-date and fit to practise medicine. Disciplinary action will follow if they are not. To ensure patient safety, the new professionalism requires professional leadership with great public input to medical regulation, a modern GMC, and a closer fit between the licensure of doctors and the quality assurance of the organisations In which they work.			Irvine, D (corresponding author), 178 Great Portland St, London W1W 5JE, England.							[Anonymous], 2001, ROYAL LIVERPOOL CHIL; [Anonymous], 2001, BRISTOL ROYAL INFIRM; BOSELEY S, 1998, GUARDIAN        0625; *CHIEF MED OFF ENG, 1999, SUPP DOCT PROT PAT; *COMM HLTH IMPR, 2001, INV ISS AR CAS LOUGH; Cruess RL, 2000, LANCET, V356, P156, DOI 10.1016/S0140-6736(00)02458-2; Cruess SR, 2000, CAN MED ASSOC J, V162, P668; DONALDSON LJ, 1994, BRIT MED J, V308, P1277, DOI 10.1136/bmj.308.6939.1277; EVANS R, 2000, REPORT INDEPENDENT I; Freidson E., 1988, PROFESSIONAL POWERS; *GEN MED COUNC, 2000, STRUCT CONST GOV GMC; *GEN MED COUNC, 1998, DET PROF COND COMM C; *GEN MED COUNC, 1998, MAINT GOOD MED PRACT; *GEN MED COUNC, 1995, GOOD MED PRACT; General Medical Council, 2001, GOOD MED PRACT; General Medical Council, 2000, REV DOCT ENS STAND S; General Medical Council, 1993, TOM DOCT; Horton R, 2000, LANCET, V355, P2010, DOI 10.1016/S0140-6736(00)02343-6; Horton R, 1998, LANCET, V352, P1166, DOI 10.1016/S0140-6736(05)60528-4; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; Irvine D, 2001, J ROY SOC MED, V94, P162, DOI 10.1177/014107680109400403; Irvine D, 1999, LANCET, V353, P1174, DOI 10.1016/S0140-6736(99)91160-1; Kennedy I, 1983, UNMASKING MED; Klein R, 2001, Health Serv J, V111, P28; Klein R., 1998, REGULATING MED PROFE; RITCHIE J, 2000, REPORT INQUIRY QUALI; ROSENTHAL MM, 1995, INCOMPETENT DOCTOR C; *SECR STAT HLTH, 2000, ORG MEM; *SECR STAT HLTH, 1998, FIRST CLASS SERV QUA; *SECR STAT HLTH, 2000, NHS PLAN PLAN INV PL; *SECR STAT HLTH, 2001, ASS QUAL MED PRACT I; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917; SMITH R, 1989, BRIT MED J, V298, P1241, DOI 10.1136/bmj.298.6682.1241; STACEY M, 1992, REGULATING BRIT MED; 1998, GUARDIAN        1123, P17; 1998, INDEPENDENT SUN 0531; 2000, SUNDAY TIMES    0604, P18; 2001, STATEMENT BEHALF GOV; 2000, TIMES           0614, P23	40	38	39	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1807	1810		10.1016/S0140-6736(01)06800-3	http://dx.doi.org/10.1016/S0140-6736(01)06800-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734261				2022-12-28	WOS:000172385100037
J	Chang, D; Markman, BS				Chang, D; Markman, BS			Spontaneous resolution of a pubic-symphysis diastasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									San Francisco Orthopaed Residency Program, San Francisco, CA 94117 USA		Chang, D (corresponding author), San Francisco Orthopaed Residency Program, San Francisco, CA 94117 USA.								0	4	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					39	39		10.1056/NEJMicm980471	http://dx.doi.org/10.1056/NEJMicm980471			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11778001				2022-12-28	WOS:000173033600006
J	Csernansky, JG; Mahmoud, R; Brenner, R				Csernansky, JG; Mahmoud, R; Brenner, R		Risperidone-USA-79 Study Grp	A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO; NEUROLEPTICS; OLANZAPINE; MEDICATION; SCALE	Background: Prevention of relapse is a major goal of maintenance treatment in patients with psychotic disorders. We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder. Methods: In a double-blind, prospective study at 40 sites, we randomly assigned adult outpatients in stable condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexible doses of either risperidone or haloperidol for a minimum of one year. Results: Of the 397 patients who underwent randomization, data from 2 were excluded because they did not receive study medication; data from all 30 patients from one site were excluded by the sponsor, the Janssen Research Foundation, because of concern about the integrity of the data. The median duration of treatment was 364 days in the risperidone group and 238 days in the haloperidol group (P=0.02). Of the 177 patients assigned to risperidone and the 188 assigned to haloperidol who remained in the analysis, 44.1 percent and 52.7 percent, respectively, discontinued treatment for reasons other than relapse. The Kaplan-Meier estimate of the risk of relapse at the end of the study was 34 percent for the risperidone group and 60 percent for the haloperidol group (P<0.001); the risk ratio for relapse with haloperidol, from the Cox model, was 1.93 (95 percent confidence interval, 1.33 to 2.80; P<0.001). Early discontinuation of treatment for any reason was more frequent among haloperidol-treated patients (risk ratio, 1.52; 95 percent confidence interval, 1.18 to 1.96). Patients in the risperidone group had greater reductions in the mean severity of both psychotic symptoms and extrapyramidal side effects than those in the haloperidol group. Conclusions: Adult outpatients with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if they are treated with risperidone than if they are treated with haloperidol. (N Engl J Med 2002;346:16-22.) Copyright (C) 2002 Massachusetts Medical Society.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Metropolitan St Louis Psychiat Ctr, St Louis, MO USA; Janssen Res Fdn, Titusville, NJ USA; St Johns Episcopal Hosp, Far Rockaway, NY USA	Washington University (WUSTL); Johnson & Johnson; Johnson & Johnson USA	Csernansky, JG (corresponding author), Washington Univ, Sch Med, Dept Psychiat, Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NC, 1995, LANCET, V346, P477, DOI 10.1016/S0140-6736(95)91325-4; Arvanitis LA, 1997, BIOL PSYCHIAT, V42, P233, DOI 10.1016/S0006-3223(97)00190-X; Ayuso-Gutierrez JL, 1997, SCHIZOPHR RES, V28, P199, DOI 10.1016/S0920-9964(97)00131-X; Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P; Buckley PF, 1998, AM J MANAG CARE, V4, P611; CHOUINARD G, 1980, CAN J NEUROL SCI, V7, P233; Dellva MA, 1997, PSYCHIATR SERV, V48, P1571; Fenton WS, 1997, SCHIZOPHRENIA BULL, V23, P637, DOI 10.1093/schbul/23.4.637; GUY W, 1976, US DHEW PUBLICATION, V76, P338; Herz MI, 2000, ARCH GEN PSYCHIAT, V57, P277, DOI 10.1001/archpsyc.57.3.277; Hogarty GE, 1998, J PSYCHIATR RES, V32, P243, DOI 10.1016/S0022-3956(97)00013-7; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kane JM, 1999, BIOL PSYCHIAT, V46, P1396, DOI 10.1016/S0006-3223(99)00059-1; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kendler KS, 1996, ARCH GEN PSYCHIAT, V53, P1022; LANG TA, 1997, REPORT STAT MED ANNO, P249; Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205; MARDER SR, 1994, AM J PSYCHIAT, V151, P825; Marder SR, 1998, J CLIN PSYCHIAT, V59, P200; Marder SR, 1999, SCHIZOPHR RES, V35, pS87, DOI 10.1016/S0920-9964(98)00167-4; Mattes JA, 1998, AM J PSYCHIAT, V155, P153, DOI 10.1176/ajp.155.1.153; Mattes JA, 1997, SCHIZOPHRENIA BULL, V23, P155, DOI 10.1093/schbul/23.1.155; Moller HJ, 1998, INT CLIN PSYCHOPHARM, V13, P99; Rice DP, 1999, J CLIN PSYCHIAT, V60, P4; Richelson E, 1996, J CLIN PSYCHIAT, V57, P4; WEIDEN PJ, 1995, SCHIZOPHRENIA BULL, V21, P419, DOI 10.1093/schbul/21.3.419; WYATT RJ, 1991, SCHIZOPHRENIA BULL, V17, P325, DOI 10.1093/schbul/17.2.325	28	509	530	1	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					16	22		10.1056/NEJMoa002028	http://dx.doi.org/10.1056/NEJMoa002028			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11777998				2022-12-28	WOS:000173033600003
J	Zametkin, AJ; Alter, MR; Yemini, T				Zametkin, AJ; Alter, MR; Yemini, T			Suicide in teenagers - Assessment, management, and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRYPTOPHAN-HYDROXYLASE GENE; ADOLESCENT SUICIDE; DEPRESSED-PATIENTS; MAJOR DEPRESSION; POLYMORPHISM; BEHAVIOR; ATTEMPTERS; VICTIMS; FAMILY; AUGMENTATION	Adolescents who kill themselves invariably have an underlying psychiatric disorder. Biological markers are not yet clinically useful for identifying adolescents at risk, and there is a paucity of research data on the effectiveness of behavioral intervention for suicidal teenagers. A case of a 16-year-old scholar and athlete is presented to illustrate how multiple risk factors and a family diathesis often go undetected, resulting in tragic consequences. Psychiatric, familial, genetic, and social risk factors of adolescent suicide are reviewed, and the efficacy of lithium and antidepressant pharmacotherapy in reducing suicide rates is discussed. The importance of screening adolescent patients for depression is emphasized. Although teenage suicide is rare and hard to predict, identifying and treating adolescents at risk is essential to further reduce teenage suicide.	NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA; NIMH, Geriatr Psychiat Branch, Bethesda, MD 20892 USA; US PHS, Washington, DC 20201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); United States Public Health Service	Zametkin, AJ (corresponding author), NIMH, Mood & Anxiety Disorders Program, 3N238 Bldg 10,9000 Rockville Pike, Bethesda, MD 20892 USA.	zametkin@mail.nih.gov						ABBAR M, 1995, ARCH GEN PSYCHIAT, V52, P846; Abbar M, 2001, MOL PSYCHIATR, V6, P268, DOI 10.1038/sj.mp.4000846; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 2001, NAT STRAT SUIC PREV; [Anonymous], SURG GEN CALL ACT PR; Arango V, 1997, ANN NY ACAD SCI, V836, P269, DOI 10.1111/j.1749-6632.1997.tb52365.x; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; Brent DA, 1996, ARCH GEN PSYCHIAT, V53, P1145; Du LS, 2000, INT J NEUROPSYCHOPH, V3, P215, DOI 10.1017/S1461145700001954; EGELAND JA, 1985, JAMA-J AM MED ASSOC, V254, P915, DOI 10.1001/jama.254.7.915; Emslie GJ, 1999, J AM ACAD CHILD PSY, V38, P517, DOI 10.1097/00004583-199905000-00013; GOODWIN FK, 2000, INT J NEUROPSYCHO S1, V5, P12; Greenhill LL, 1997, PSYCHIAT CLIN N AM, V20, P641, DOI 10.1016/S0193-953X(05)70335-X; HRDINA PD, 1993, BRAIN RES, V614, P37, DOI 10.1016/0006-8993(93)91015-K; Mann JJ, 2000, ARCH GEN PSYCHIAT, V57, P729, DOI 10.1001/archpsyc.57.8.729; Mann JJ, 1997, AM J PSYCHIAT, V154, P1451; MCLEAVEY BC, 1994, SUICIDE LIFE-THREAT, V24, P382; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34; Olfson M, 1998, ARCH GEN PSYCHIAT, V55, P310, DOI 10.1001/archpsyc.55.4.310; Oquendo MA, 2000, PSYCHIAT CLIN N AM, V23, P11, DOI 10.1016/S0193-953X(05)70140-4; PAPADIMITRIOU GN, 1991, ACTA PSYCHIAT SCAND, V83, P417, DOI 10.1111/j.1600-0447.1991.tb05567.x; PIACENTINI J, 1995, J CONSULT CLIN PSYCH, V63, P469, DOI 10.1037/0022-006X.63.3.469; Roy A, 1997, ANN NY ACAD SCI, V836, P135, DOI 10.1111/j.1749-6632.1997.tb52358.x; Roy A, 2001, NEUROPSYCHOBIOLOGY, V43, P233, DOI 10.1159/000054895; Ryan ND, 1998, BIOL PSYCHIAT, V44, P336, DOI 10.1016/S0006-3223(98)00163-2; RYAN ND, 1988, J AM ACAD CHILD PSY, V27, P371, DOI 10.1097/00004583-198805000-00018; RYAN ND, 1987, ARCH GEN PSYCHIAT, V44, P854; Schulsinger F., 1979, ORIGIN PREVENTION TR, P277; SEGAL NL, 1995, PERS INDIV DIFFER, V19, P937, DOI 10.1016/S0191-8869(95)00132-8; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; Shaffer D, 2001, J AM ACAD CHILD PSY, V40, p24S, DOI 10.1097/00004583-200107001-00003; SHAFFER D, 1994, CHILD ADOLESCENT PSY, P407; SPIRITO A, 1994, PEDIATR EMERG CARE, V10, P6, DOI 10.1097/00006565-199402000-00003; Statham DJ, 1998, PSYCHOL MED, V28, P839, DOI 10.1017/S0033291798006916; STROBER M, 1992, J AM ACAD CHILD PSY, V31, P16, DOI 10.1097/00004583-199201000-00004; TISHLER CL, 1981, SUICIDE LIFE-THREAT, V11, P86; TONDO L, 2000, INT J NEUROPSYCHO S1, V5, P6; TRAUTMAN PD, 1993, J AM ACAD CHILD PSY, V32, P89, DOI 10.1097/00004583-199301000-00013; Turecki G, 1999, AM J PSYCHIAT, V156, P1456; Turecki G, 2001, MOL PSYCHIATR, V6, P98, DOI 10.1038/sj.mp.4000816; WATERHOUSE J, 1990, BRIT J PSYCHIAT, V156, P236, DOI 10.1192/bjp.156.2.236	42	31	32	3	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3120	3125		10.1001/jama.286.24.3120	http://dx.doi.org/10.1001/jama.286.24.3120			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505QM	11754678				2022-12-28	WOS:000172927100030
J	Clarfield, AM				Clarfield, AM			In grandfather's room	BRITISH MEDICAL JOURNAL			English	Article									Soroka Hosp Ctr, Beer Sheva, Israel; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center; Ben Gurion University	Clarfield, AM (corresponding author), Soroka Hosp Ctr, Beer Sheva, Israel.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1496	1497		10.1136/bmj.323.7327.1496	http://dx.doi.org/10.1136/bmj.323.7327.1496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751369	Green Published			2022-12-28	WOS:000172979900030
J	Halliday, S				Halliday, S			Death and miasma in Victorian London: an obstinate belief	BRITISH MEDICAL JOURNAL			English	Article									Buckinghamshire Chilterns Univ Coll, Giles HP8 4AD, Bucks, England	Buckinghamshire New University	Halliday, S (corresponding author), Buckinghamshire Chilterns Univ Coll, Chalfont St, Giles HP8 4AD, Bucks, England.							[Anonymous], 1846, PARLIAMENTARY PAP, V10, P651; BAZALGETTE J, 1864, P I CIVIL ENG, V24, P285; BOOTH H, 1844, BUILDER         0716, P350; Chadwick Edwin, 1965, REPORT SANITARY COND; *COMM SCI ENQ, 1854, PARLIAMENTARY PAP, V21, P49; *GEN BOARD HLTH EP, 1850, PARLIAMENTARY PAP, V21, P543; Halliday S, 2000, J Med Biogr, V8, P220; HEAD F, 1842, Q REV, V71, P422; *ROYAL COMM ENQ ST, 1844, PARLIAMENTARY PAP, V17, P50; *ROYAL COMM ENQ ST, 1844, PARLIAMENTARY PAP, V17, P122; SNOW J, 1857, BMJ-BRIT MED J, V2, P864; SNOW J, 1858, MED TIMES GAZ, P191; 1867, PARLIAMENTARY PAPERS, V37, pR56; 1858, TIMES           0618, P9; 1849, TIMES           1004, P8; 1859, NOTES NURSING, P16; 1890, BUILDER         0201, P78	17	60	62	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1469	1471		10.1136/bmj.323.7327.1469	http://dx.doi.org/10.1136/bmj.323.7327.1469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751359	Green Published			2022-12-28	WOS:000172979900019
J	Redelmeier, DA; Singh, SM				Redelmeier, DA; Singh, SM			Longevity of screenwriters who win an academy award: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC-STATUS; HEALTH; MORTALITY; STRESS	Objective To determine whether the link between high success and longevity extends to academy award winning screenwriters. Design Retrospective cohort analysis. Participants All screenwriters ever nominated for an academy award. Main outcome measures Life expectancy and all cause mortality Results A total of 850 writers were nominated; the median duration of follow up from birth was 68 years; and 428 writers died. On average, winners were more successful than nominees, as indicated by a 14% longer career (27.7 v 24.2, P = 0.004), 34% more total films (23.2 v 17.3, P < 0.001), 58% more four star films (4.8 v 3.1, P < 0.001), and 62% more nominations (2.1 v, 1.3, P < 0.001). However, life expectancy was 3.6 years shot-ter for winners than for nominees (74.1 v, 77.7 years. P = 0.004), equivalent to a 37% relative increase in death rates (95% confidence interval 10 to 70). After adjustment for year of birth, sex, and other factors, a 35% relative increase in death rates was found (7%, to 70%). Additional wins were associated with a 22% relative increase in death rates (31% to 44%). Additional nominations and additional other films in a career otherwise caused no significant increase in death rates. Conclusion The link between occupational achievement and longevity is reversed in screenwriters who win academy awards. Doubt is cast on simple biological theories for the survival gradients found for other members of society.	Sunnybrook & Womens Hosp, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Redelmeier, DA (corresponding author), Sunnybrook & Womens Hosp, Toronto, ON M4N 3M5, Canada.							Adler NE, 1999, ANN NY ACAD SCI, V896, P3, DOI 10.1111/j.1749-6632.1999.tb08101.x; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Detsky AS, 1998, NEW ENGL J MED, V339, P402, DOI 10.1056/NEJM199808063390611; Evans R. G., 1994, WHY ARE SOME PEOPLE; GAIL MH, 1972, ANN INTERN MED, V76, P815, DOI 10.7326/0003-4819-76-5-815; GARBER AM, 1989, PATHWAYS HLTH ROLE S, P271; Katz Ephraim, 1998, FILM ENCY; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1984, LANCET, V1, P1003; MYERS J, 1968, DECADE LATER FOLLOW; SAPOLSKY RM, 1990, SCI AM, V262, P116, DOI 10.1038/scientificamerican0190-116; STEWART WT, 1981, INT FILM NECROLOGY; Syme SL, 1998, MILBANK Q, V76, P493, DOI 10.1111/1468-0009.00100; Thomas Nicholas, 1990, INT DICT FILMS FILMM; Vincendeau G., 1995, ENCY EUROPEAN CINEMA; WALKER J, 1997, HALLIWELLS FILMGOERS	20	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1491	1496		10.1136/bmj.323.7327.1491	http://dx.doi.org/10.1136/bmj.323.7327.1491			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751368	Green Published			2022-12-28	WOS:000172979900029
J	Mathis, D; Vence, L; Benoist, C				Mathis, D; Vence, L; Benoist, C			beta-cell death during progression to diabetes	NATURE			English	Review							CD8 T-CELL; HUMAN PANCREATIC-ISLETS; NITRIC-OXIDE; FAS LIGAND; NOD MICE; PSAMMOMYS-OBESUS; TRANSGENIC MICE; CYTOTOXIC PATHWAYS; GENE-EXPRESSION; DENDRITIC CELLS	The hallmark of type 1 diabetes is specific destruction of pancreatic islet beta -cells. Apoptosis of beta -cells may be crucial at several points during disease progression, initiating leukocyte invasion of the islets and terminating the production of insulin in islet cells. beta -Cell apoptosis may also be involved in the occasional evolution of type 2 into type 1 diabetes.	Brigham & Womens Hosp, Joslin Diabet Ctr, Dept Med, Sect Immunol & Innumogenet, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Mathis, D (corresponding author), Brigham & Womens Hosp, Joslin Diabet Ctr, Dept Med, Sect Immunol & Innumogenet, 1 Joslin Pl, Boston, MA 02215 USA.	cbdm@joslin.harvard.edu						Allison J, 2000, INT IMMUNOL, V12, P9, DOI 10.1093/intimm/12.1.9; Allison J, 1998, P NATL ACAD SCI USA, V95, P13818, DOI 10.1073/pnas.95.23.13818; Amrani A, 1999, J CLIN INVEST, V103, P1201, DOI 10.1172/JCI6266; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Bach JF, 1997, RES IMMUNOL, V148, P285, DOI 10.1016/S0923-2494(97)87235-5; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Bar-On H, 1999, PANCREAS, V18, P259, DOI 10.1097/00006676-199904000-00007; Bellone M, 1997, J IMMUNOL, V159, P5391; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Beutler BA, 1999, J RHEUMATOL, V26, P16; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; COLES HSR, 1993, DEVELOPMENT, V118, P777; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P8992, DOI 10.1073/pnas.90.19.8992; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; Delaney CA, 1996, FEBS LETT, V394, P300, DOI 10.1016/0014-5793(96)00977-5; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EIZIRIK DL, 1994, P NATL ACAD SCI USA, V91, P9253, DOI 10.1073/pnas.91.20.9253; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Gonzalez A, 1997, IMMUNITY, V7, P873, DOI 10.1016/S1074-7613(00)80405-7; Graser RT, 2000, J IMMUNOL, V164, P3913, DOI 10.4049/jimmunol.164.7.3913; Green EA, 1998, IMMUNITY, V9, P733, DOI 10.1016/S1074-7613(00)80670-6; Guerder S, 1998, J IMMUNOL, V161, P2128; Guiot Y, 2001, DIABETES, V50, pS188, DOI 10.2337/diabetes.50.2007.S188; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Herrera PL, 2000, P NATL ACAD SCI USA, V97, P279, DOI 10.1073/pnas.97.1.279; Hoglund P, 1999, J EXP MED, V189, P331, DOI 10.1084/jem.189.2.331; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Hotta M, 1998, J EXP MED, V188, P1445, DOI 10.1084/jem.188.8.1445; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Itoh N, 1997, J EXP MED, V186, P613, DOI 10.1084/jem.186.4.613; ITOH N, 1993, J CLIN INVEST, V92, P2313, DOI 10.1172/JCI116835; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kagi D, 1999, J IMMUNOL, V162, P4598; Kagi D, 1997, J EXP MED, V186, P989, DOI 10.1084/jem.186.7.989; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Kassem SA, 2000, DIABETES, V49, P1325, DOI 10.2337/diabetes.49.8.1325; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; Kim S, 2000, J IMMUNOL, V164, P2931, DOI 10.4049/jimmunol.164.6.2931; Kim YH, 1999, EUR J IMMUNOL, V29, P455, DOI 10.1002/(SICI)1521-4141(199902)29:02<455::AID-IMMU455>3.0.CO;2-A; KLAUS GGB, 1979, IMMUNOLOGY, V38, P687; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuwel HTC, 1999, J IMMUNOL, V163, P4335; KRONCKE KD, 1991, DIABETOLOGIA, V34, P232, DOI 10.1007/BF00405081; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kurrer MO, 1997, P NATL ACAD SCI USA, V94, P213, DOI 10.1073/pnas.94.1.213; Leibowitz G, 2001, DIABETES, V50, pS113, DOI 10.2337/diabetes.50.2007.S113; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lortz S, 2000, DIABETES, V49, P1123, DOI 10.2337/diabetes.49.7.1123; Loweth AC, 1998, DIABETES, V47, P727, DOI 10.2337/diabetes.47.5.727; MANDAKOVIC T, 1987, PRODUCTIVITY MANAGEM, V1, P139; Mathews CE, 2001, P NATL ACAD SCI USA, V98, P235, DOI 10.1073/pnas.98.1.235; MAYOR F, 1985, BIOL NEONATE, V48, P185, DOI 10.1159/000242171; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MUELLER C, 1995, DIABETES, V44, P112, DOI 10.2337/diabetes.44.1.112; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; OBrien BA, 1997, DIABETES, V46, P750, DOI 10.2337/diabetes.46.5.750; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Pakala SV, 1999, J EXP MED, V189, P1053, DOI 10.1084/jem.189.7.1053; PARHAM P, 1988, NATURE, V333, P500, DOI 10.1038/333500a0; Petrik J, 1998, ENDOCRINOLOGY, V139, P2994, DOI 10.1210/en.139.6.2994; Pittoni V, 1998, SEMIN ARTHRITIS RHEU, V28, P163, DOI 10.1016/S0049-0172(98)80033-4; RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; RAO RV, IN PRESS J BIOL CHEM; Rothe H, 1996, DIABETOLOGIA, V39, P119; Sarukhan A, 1999, EUR J IMMUNOL, V29, P3410, DOI 10.1002/(SICI)1521-4141(199910)29:10<3410::AID-IMMU3410>3.0.CO;2-K; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Seewaldt S, 2000, DIABETES, V49, P1801, DOI 10.2337/diabetes.49.11.1801; Sempoux C, 2001, DIABETES, V50, pS172, DOI 10.2337/diabetes.50.2007.S172; Serreze DV, 1997, J IMMUNOL, V158, P3978; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; SHIMABUKURO M, 1988, DIABETES RES, V9, P151; Stassi G, 1997, J EXP MED, V186, P1193, DOI 10.1084/jem.186.8.1193; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Su X, 2000, J IMMUNOL, V164, P2523, DOI 10.4049/jimmunol.164.5.2523; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Thomas HE, 1999, J IMMUNOL, V163, P1562; Thomas HE, 2000, DIABETES-METAB RES, V16, P251, DOI 10.1002/1520-7560(200007/08)16:4<251::AID-DMRR126>3.3.CO;2-3; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Trudeau JD, 2000, DIABETES, V49, P1, DOI 10.2337/diabetes.49.1.1; Walter U, 2000, EUR J IMMUNOL, V30, P1224, DOI 10.1002/1521-4141(200004)30:4<1224::AID-IMMU1224>3.0.CO;2-B; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; Wegmann DR, 1996, CURR OPIN IMMUNOL, V8, P860, DOI 10.1016/S0952-7915(96)80016-1; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; YANG XD, 1994, J EXP MED, V180, P995, DOI 10.1084/jem.180.3.995; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	100	700	780	2	72	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					792	798		10.1038/414792a	http://dx.doi.org/10.1038/414792a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742411				2022-12-28	WOS:000172676200059
J	Weijers, D; Geldner, N; Offringa, R; Jurgens, G				Weijers, D; Geldner, N; Offringa, R; Jurgens, G			Seed development - Early paternal gene activity in Arabidopsis	NATURE			English	Article							PATTERN-FORMATION; EMBRYO; PROTEIN		Leiden Univ, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands; Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany	Leiden University; Leiden University - Excl LUMC; Eberhard Karls University of Tubingen	Weijers, D (corresponding author), Leiden Univ, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands.		Geldner, Niko/Y-2481-2019; Weijers, Dolf/ABI-1332-2020; Weijers, Dolf/A-2076-2010	Weijers, Dolf/0000-0003-4378-141X; Weijers, Dolf/0000-0003-4378-141X; Offringa, Remko/0000-0002-3293-5295				Hamann T, 1999, DEVELOPMENT, V126, P1387; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; Lu PZ, 1996, PLANT CELL, V8, P2155, DOI 10.1105/tpc.8.12.2155; MAYER U, 1993, DEVELOPMENT, V117, P149; Springer PS, 2000, DEVELOPMENT, V127, P1815; SURANI MA, 1990, DEVELOPMENT, P89; THOMA S, 1994, PLANT PHYSIOL, V105, P35, DOI 10.1104/pp.105.1.35; Vielle-Calzada JP, 2000, NATURE, V404, P91, DOI 10.1038/35003595; Waizenegger I, 2000, CURR BIOL, V10, P1371, DOI 10.1016/S0960-9822(00)00775-2	9	93	98	2	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					709	710		10.1038/414709a	http://dx.doi.org/10.1038/414709a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742384				2022-12-28	WOS:000172676200032
J	Zimmet, P; Alberti, KGMM; Shaw, J				Zimmet, P; Alberti, KGMM; Shaw, J			Global and societal implications of the diabetes epidemic	NATURE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; CARDIOVASCULAR RISK-FACTORS; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; MICROVASCULAR COMPLICATIONS; THRIFTY GENOTYPE; FASTING GLUCOSE; PUBLIC-HEALTH; MELLITUS; PREVALENCE	Changes in human behaviour and lifestyle over the last century have resulted in a dramatic increase in the incidence of diabetes worldwide. The epidemic is chiefly of type 2 diabetes and also the associated conditions known as 'diabesity' and 'metabolic syndrome'. In conjunction with genetic susceptibility, particularly in certain ethnic groups, type 2 diabetes is brought on by environmental and behavioural factors such as a sedentary lifestyle, overly rich nutrition and obesity. The prevention of diabetes and control of its micro- and macrovascular complications will require an integrated, international approach if we are to see significant reduction in the huge premature morbidity and mortality it causes.	Int Diabet Inst, Caulfield, Vic 3162, Australia; Royal Coll Physicians, London NW1 4LE, England	Royal College of Physicians	Zimmet, P (corresponding author), Int Diabet Inst, 260 Kooyong Rd, Caulfield, Vic 3162, Australia.	pzimmet@idi.org.au	Zimmet, Paul/O-8486-2019; Adiels, Martin/C-9278-2011; Shaw, Jonathan/E-7388-2010	Zimmet, Paul/0000-0003-0627-0776; Shaw, Jonathan/0000-0002-6187-2203				ALBERTI K, 1996, DIABETIC MED, V13, P6; Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; [Anonymous], 2000, Pediatrics, V105, P671; [Anonymous], 1995, Diabetes, V44, P1249; Astrup A, 2000, Obes Rev, V1, P57, DOI 10.1046/j.1467-789x.2000.00013.x; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Bloom BR, 2000, LANCET, V356, pS50, DOI 10.1016/S0140-6736(00)92036-1; Bonetta L, 2001, NAT MED, V7, P387, DOI 10.1038/86405; Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; Bray GA, 1999, DIABETES CARE, V22, P623; CHOU P, 1992, DIABETES CARE, V15, P81, DOI 10.2337/diacare.15.1.81; Collier GR, 2000, DIABETES, V49, P1766, DOI 10.2337/diabetes.49.11.1766; de Courten M, 1997, INT TXB DIABETES MEL, P143; DOWSE G, 1993, BRIT MED J, V306, P532, DOI 10.1136/bmj.306.6877.532; DOWSE GK, 1991, AM J EPIDEMIOL, V133, P1093, DOI 10.1093/oxfordjournals.aje.a115822; Eastman Richard C., 1996, P621; Ehtisham S, 2000, DIABETIC MED, V17, P867, DOI 10.1046/j.1464-5491.2000.00409.x; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; Fagot-Campagna A, 2001, BMJ-BRIT MED J, V322, P377, DOI 10.1136/bmj.322.7283.377; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 2000, LANCET, V355, P253; Groop LC, 1997, J INTERN MED, V241, P95, DOI 10.1046/j.1365-2796.1997.99897000.x; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15; Harris M, 1997, INT TXB DIABETES MEL, P9; Harrison LC, 1999, DIABETES NEW MILLENN, P85; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; HENNEKENS G, 1987, EPIDEMIOLOGY MED; HEROLD KC, 1995, DIABETES, V44, P354, DOI 10.2337/diabetes.44.3.354; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208; Larkin M, 2001, LANCET, V358, P565, DOI 10.1016/S0140-6736(01)05751-8; Mann J, 2000, LANCET, V356, P1454, DOI 10.1016/S0140-6736(00)02862-2; McKinlay J, 2000, LANCET, V356, P757, DOI 10.1016/S0140-6736(00)02641-6; Myers MA, 2001, DIABETOLOGIA, V44, P1199; NEEL JV, 1962, AM J HUM GENET, V14, P353; ODEA K, 1991, MED J AUSTRALIA, V155, P258, DOI 10.5694/j.1326-5377.1991.tb142236.x; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pan XR, 1997, DIABETES CARE, V20, P1664, DOI 10.2337/diacare.20.11.1664; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Perry RC, 1999, DIABETES CARE, V22, P883, DOI 10.2337/diacare.22.6.883; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ramachandran A, 1997, DIABETOLOGIA, V40, P232, DOI 10.1007/s001250050668; Ray NF, 1998, DIABETES CARE, V21, P296; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Rosenfeld M, 1999, ECOL LETT, V2, P345; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shaw JA, 1999, DIABETES CARE, V22, P399, DOI 10.2337/diacare.22.3.399; Shaw JE, 1999, DIABETOLOGIA, V42, P1050, DOI 10.1007/s001250051269; Shaw JE, 2000, DIABETES CARE, V23, pB5; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; SONGER TJ, 1992, DIABETES METAB REV, V8, P389, DOI 10.1002/dmr.5610080406; Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; TUOMILEHTO J, 1992, INT J EPIDEMIOL, V21, P518, DOI 10.1093/ije/21.3.518; TUOMILEHTO J, 1991, DIABETES CARE, V14, P982, DOI 10.2337/diacare.14.11.982; Tuomilehto J, 1997, INT TXB DIABETES MEL, P1799; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; World Health Organization, 1985, DIAB MELL REP WHO ST; ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203; Zimmet P, 2000, J INTERN MED, V247, P301, DOI 10.1046/j.1365-2796.2000.00625.x; Zimmet P, 1999, ANN NY ACAD SCI, V892, P25, DOI 10.1111/j.1749-6632.1999.tb07783.x; Zimmet P, 1996, DIABETOLOGIA, V39, P1247; ZIMMET P, 2000, HLTH COMMONWEALTH, P74; ZIMMET PZ, 1995, DIABETES CARE, V18, P1050, DOI 10.2337/diacare.18.7.1050; Zimmet PZ, 1999, DIABETOLOGIA, V42, P499, DOI 10.1007/s001250051188; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232; ZIMMET PZ, 1997, LANCET S1, V350, P1; Ziv E, 1997, DIABETES METAB, V23, P331	77	3989	4243	31	849	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					782	787		10.1038/414782a	http://dx.doi.org/10.1038/414782a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742409	Green Accepted			2022-12-28	WOS:000172676200057
J	Zhen, CL; Sangl, J; Bierman, AS; Miller, MR; Friedman, B; Wickizer, SW; Meyer, GS				Zhen, CL; Sangl, J; Bierman, AS; Miller, MR; Friedman, B; Wickizer, SW; Meyer, GS			Potentially inappropriate medication use in the community-dwelling elderly - Findings from the 1996 Medical Expenditure Panel Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Gerontological-Society-of-America	NOV, 2000	WASHINGTON, D.C.	Gerontol Soc Amer			EXPLICIT CRITERIA; NURSING-HOMES; FACILITIES; RESIDENTS	Context Inappropriate medication use is a major patient safety concerr, especially for the elderly population. Using explicit criteria, prior studies have found that 23.5% and 17.5% of the US community-dwelling elderly population used at least 1 of 20 potentially inappropriate medications in 1987 and 1992, respectively. Objectives To determine the prevalence of potentially inappropriate medication use in community-dwelling elderly persons in 1996, to assess trends over 10 years, categorize inappropriate medication use according to explicit criteria, and to examine risk factors for inappropriate medication use. Design, Setting, and Participants Respondents aged 65 years or older (n=2455) to the 1996 Medical Expenditure Panel Survey, a nationally representative survey of the US noninstitutionalized population were included. A 7-member expert panel was convened to categorize inappropriate medications. Main Outcome Measure Prevalence of use of 33 potentially inappropriate medications. Results In 1996, 21.3% (95% confidence interval [CI], 19.5%-23.1%)of community-dwelling elderly patients in the United States received at least 1 of 33 potentially inappropriate medications. Using the expert panel's classifications, about 2.6% of elderly patients (95% Cl, 2.0%-3.2%) used at least 1 of the 11 medications that should always be avoided by elderly patients; 9.1% (95% Cl, 7.9%-10.3%) used at least 1 cf the 8 that would rarely be appropriate; and 13.3% (95% Cl, 11.7%-14.9%) used at least 1 of the 14 medications that have some indications but are often misused. Use of some inappropriate medications declined between 1987 and 1996. Persons with poor health and more prescriptions had a significantly higher risk of inappropriate medication use. Conclusions Overall inappropriate medication use in elderly patients remains a serious problem. Despite challenges in using explicit criteria for assessing inappropriate medications for elderly patients, such criteria can be applied to population-based surveys to identify opportunities to improve quality of care and patient safety. Enhancements of existing data sources to include dosage, duration, and indication may augment national improvement and monitoring efforts.	Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD 20852 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Univ Rochester, Dept Community & Prevent Med, Rochester, NY USA	Agency for Healthcare Research & Quality; Johns Hopkins University; University of Rochester	Zhen, CL (corresponding author), Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, 6011 Execut Blvd,Suite 200, Rockville, MD 20852 USA.							Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Aparasu RR, 1997, ANN PHARMACOTHER, V31, P823, DOI 10.1177/106002809703100702; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; Blazer D, 2000, J AM GERIATR SOC, V48, P1073, DOI 10.1111/j.1532-5415.2000.tb04782.x; Cantrill JA, 2011, INT J PHARM PRACT, V4, P67, DOI DOI 10.1111/J.2042-7174.1996.TB00844.X; COBBS E, 1999, GERIATRICS REV SYLLA, P120; COHEN SB, 1997, 2 MEPS AG HEALTHC RE; Golden AG, 1999, J AM GERIATR SOC, V47, P948, DOI 10.1111/j.1532-5415.1999.tb01289.x; GOSNEY M, 1984, LANCET, V2, P564; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P316, DOI 10.1001/jama.272.4.316; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; *I MED, 1999, ERR IS HUM BUILD SAF; LEDERLE FA, 1993, ARCH INTERN MED, V153, P705, DOI 10.1001/archinte.153.6.705; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; MOELLER JF, 2001, HC010A AG HEALTHC RE; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; Mort JR, 2000, ARCH INTERN MED, V160, P2825, DOI 10.1001/archinte.160.18.2825; Nash DB., 2000, WHY ELDERLY NEED IND; Newcomer LN, 2000, HEALTH AFFAIR, V19, P59, DOI 10.1377/hlthaff.19.2.59; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; Spore DL, 1997, AM J PUBLIC HEALTH, V87, P404, DOI 10.2105/AJPH.87.3.404; *US GAO, 1995, PRESCR DRUGS ELD MAN; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; WILLIAMS B, 1995, J AM GERIATR SOC, V43, P513, DOI 10.1111/j.1532-5415.1995.tb06098.x	29	150	155	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2823	2829		10.1001/jama.286.22.2823	http://dx.doi.org/10.1001/jama.286.22.2823			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500YC	11735757				2022-12-28	WOS:000172655400030
J	Kornack, DR; Rakic, P				Kornack, DR; Rakic, P			Cell proliferation without neurogenesis in adult primate neocortex	SCIENCE			English	Article							OLIGODENDROCYTE PROGENITOR CELLS; CEREBRAL-CORTEX; VISUAL-CORTEX; DENTATE GYRUS; DNA-SYNTHESIS; STEM-CELLS; RAT; MIGRATION; NEURONS; TELENCEPHALON	A recent assertion that new neurons are continually added to the neocortex of adult macaque monkeys has profound implications for understanding the cellular mechanisms of higher cognitive functions. Here we searched for neurogenesis in adult macaques by using immunofluorescent triple labeling for the DNA-replication indicator, bromodeoxyuridine (BrdU), and neuronal and glial cell markers. Although numerous BrdU-labeled cells were distributed throughout the cerebral wall, including the neocortex, these were identified as non-neuronal cells; evidence for newly generated neurons was limited to the hippocampus and olfactory bulb. Thus, our results do not substantiate the claim of neurogenesis in normal adult primate neocortex.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA; Univ Rochester, Med Ctr, Ctr Aging & Dev Biol, Dept Neurobiol & Anat, Rochester, NY 14642 USA	Yale University; University of Rochester	Rakic, P (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St, New Haven, CT 06510 USA.	pasko.rakic@yale.edu			NEI NIH HHS [EY02593] Funding Source: Medline; NINDS NIH HHS [NS14841] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014841] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; BRUCKNER G, 1976, J COMP NEUROL, V166, P245, DOI 10.1002/cne.901660208; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Coskun V, 2001, J NEUROSCI, V21, P3092, DOI 10.1523/JNEUROSCI.21-09-03092.2001; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAZZANIGA MS, 1999, COGNITIVE NEUROSCIEN; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gould E, 2000, SCIENCE, V288, p771a; HICKS SP, 1968, ANAT REC, V160, P619, DOI 10.1002/ar.1091600311; JACKSON CA, 1989, J NEUROSCI, V9, P1242; Jessel T. M., 1991, PRINCIPLES NEUROSCIE; Kakita A, 1999, NEURON, V23, P461, DOI 10.1016/S0896-6273(00)80800-4; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; KORR H, 1973, J COMP NEUROL, V150, P169, DOI 10.1002/cne.901500205; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Levison SW, 1999, J NEUROSCI RES, V57, P435, DOI 10.1002/(SICI)1097-4547(19990815)57:4<435::AID-JNR3>3.0.CO;2-L; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARES V, 1978, J COMP NEUROL, V177, P519, DOI 10.1002/cne.901770310; Markakis EA, 1999, J COMP NEUROL, V406, P449; MCDERMOTT KWG, 1990, DEV BRAIN RES, V57, P269, DOI 10.1016/0165-3806(90)90053-2; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Nacher J, 2000, J COMP NEUROL, V424, P628, DOI 10.1002/1096-9861(20000904)424:4<628::AID-CNE5>3.0.CO;2-4; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nowakowski R, 2000, SCIENCE, V288, p771a, DOI DOI 10.1126/SCIENCE.288.5467.771A; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PRIVAT A, 1975, INT REV CYTOL, V40, P281, DOI 10.1016/S0074-7696(08)60955-9; RAKIC P, 1985, ANN NY ACAD SCI, V457, P193, DOI 10.1111/j.1749-6632.1985.tb20806.x; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Rakic P, 1998, NAT NEUROSCI, V1, P645, DOI 10.1038/3643; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1993, RESTORATIVE NEUROLOG, V6, P257; RAKIC P, IN PRESS NATURE REV; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Seress L, 2001, NEUROSCIENCE, V105, P831, DOI 10.1016/S0306-4522(01)00156-7; SMART IHM, 1982, J ANAT, V134, P273; Thomas LB, 1996, GLIA, V17, P1; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001	53	468	492	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2127	2130		10.1126/science.1065467	http://dx.doi.org/10.1126/science.1065467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739948				2022-12-28	WOS:000172647700040
J	Yang, Q; Bermingham, NA; Finegold, MJ; Zoghbi, HY				Yang, Q; Bermingham, NA; Finegold, MJ; Zoghbi, HY			Requirement of Math1 for secretory cell lineage commitment in the mouse intestine	SCIENCE			English	Article							TRANSCRIPTION FACTOR; TRANSGENIC MICE; STEM-CELLS; DIFFERENTIATION; PROGENITORS; REGULATOR; REVEALS	The mouse small intestinal epithelium consists of four principal cell types deriving from one multipotent stem cell: enterocytes, goblet, enteroendocrine, and Paneth cells. Previous studies showed that Math1, a basic helix-loop-helix (bHLH) transcription factor, is expressed in the gut. We find that toss of Math1 leads to depletion of goblet, enteroendocrine, and Paneth cells without affecting enterocytes. Colocalization of Math1 with Ki-67 in some proliferating cells suggests that secretory cells (goblet, enteroendocrine, and Paneth cells) arise from a common progenitor that expresses Math1, whereas absorptive cells (enterocytes) arise from a progenitor that is Math1-independent. The continuous rapid renewal of these cells makes the intestinal epithelium a model system for the study of stem cell regeneration and lineage commitment.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.			Zoghbi, Huda/0000-0002-0700-3349				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; Ben-Arie N, 2000, DEVELOPMENT, V127, P1039; Bermingham NA, 2001, NEURON, V30, P411, DOI 10.1016/S0896-6273(01)00305-1; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Blaugrund E, 1996, DEVELOPMENT, V122, P309; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; Darmoul D, 1997, AM J PHYSIOL-GASTR L, V272, pG197, DOI 10.1152/ajpgi.1997.272.1.G197; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; Ito T, 2000, DEVELOPMENT, V127, P3913; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Pabst O, 1999, DEVELOPMENT, V126, P2215; Rindi G, 1999, DEVELOPMENT, V126, P4149; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; YANG Q, UNPUB; Zheng JL, 2000, DEVELOPMENT, V127, P4551	24	674	706	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2155	2158		10.1126/science.1065718	http://dx.doi.org/10.1126/science.1065718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739954				2022-12-28	WOS:000172647700048
J	Dean, C; Leakey, MG; Reid, D; Schrenk, F; Schwartz, GT; Stringer, C; Walker, A				Dean, C; Leakey, MG; Reid, D; Schrenk, F; Schwartz, GT; Stringer, C; Walker, A			Growth processes in teeth distinguish modern humans from Homo erectus and earlier hominins	NATURE			English	Article							DENTAL DEVELOPMENT; ENAMEL THICKNESS; FOSSIL HOMINIDS; LIFE-HISTORY; MICROSTRUCTURE; PATTERNS; DEATH; TOOTH; TIME; AGE	A modern human-like sequence of dental development, as a proxy for the pace of life history, is regarded as one of the diagnostic hallmarks of our own genus Homo(1-3). Brain size, age at first reproduction, lifespan and other life-history traits correlate tightly with dental development(4-6). Here we report differences in enamel growth that show the earliest fossils attributed to Homo do not resemble modern humans in their development. We used daily incremental markings in enamel to calculate rates of enamel formation in 13 fossil hominins and identified differences in this key determinant of tooth formation time. Neither australopiths nor fossils currently attributed to early Homo shared the slow trajectory of enamel growth typical of modern humans; rather, both resembled modern and fossil African apes. We then reconstructed tooth formation times in australopiths, in the similar to1.5-Myr-old Homo erectus skeleton from Nariokotome, Kenya(7), and in another Homo erectus specimen, Sangiran S7-37 from Java(8). These times were shorter than those in modern humans. It therefore seems likely that truly modern dental development emerged relatively late in human evolution.	UCL, Dept Anat & Dev Biol, Evolutionary Anat Unit, London WC1E 6BT, England; Natl Museums Kenya, Dept Palaeontol, Nairobi, Kenya; Sch Dent, Newcastle Upon Tyne NE2 4BW, Tyne & Wear, England; Forschungsinst Senckenberg, D-60325 Frankfurt, Germany; George Washington Univ, Dept Anthropol, Washington, DC 20052 USA; Nat Hist Museum, London SW7 5BD, England; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA	University of London; University College London; Senckenberg Gesellschaft fur Naturforschung (SGN); George Washington University; Natural History Museum London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Dean, C (corresponding author), UCL, Dept Anat & Dev Biol, Evolutionary Anat Unit, Gower St, London WC1E 6BT, England.	ucgacrd@ucl.ac.uk						Allman J, 1999, NEUROBIOL AGING, V20, P447, DOI 10.1016/S0197-4580(99)00076-7; Antoine D., 1999, DENT MORPHOLOGY 1998, P48; BEYNON AD, 1987, ARCH ORAL BIOL, V32, P773, DOI 10.1016/0003-9969(87)90002-1; BEYNON AD, 1986, AM J PHYS ANTHROPOL, V70, P177, DOI 10.1002/ajpa.1330700205; BEYNON AD, 1988, NATURE, V335, P509, DOI 10.1038/335509a0; Beynon AD, 1998, J HUM EVOL, V35, P163, DOI 10.1006/jhev.1998.0230; BOYDE A, 1990, MG PRIMATOL, V14, P229; BROMAGE TG, 1985, NATURE, V317, P525, DOI 10.1038/317525a0; BROMAGE TG, 1991, AM J PHYS ANTHROPOL, V86, P205, DOI 10.1002/ajpa.1330860209; de Castro JMB, 1999, P NATL ACAD SCI USA, V96, P4210, DOI 10.1073/pnas.96.7.4210; Dean C, 2000, J ANAT, V197, P77, DOI 10.1046/j.1469-7580.2000.19710077.x; DEAN MC, 1993, AM J PHYS ANTHROPOL, V91, P401, DOI 10.1002/ajpa.1330910402; FitzGerald CM, 1998, J HUM EVOL, V35, P371, DOI 10.1006/jhev.1998.0232; Grine F.E., 1988, P3; Grine Frederick Edward, 1994, Courier Forschungsinstitut Senckenberg, V171, P75; Jernvall J, 2000, YEARB PHYS ANTHROPOL, V43, P171; KELLEY J, HUMAN EVOLUTION DEV; Lovejoy CO, 1999, P NATL ACAD SCI USA, V96, P13247, DOI 10.1073/pnas.96.23.13247; MOGGICECCHI J, 2000, ORIGIN HUMANKIND, P35; Reid DJ, 2000, AM J PHYS ANTHROPOL, V113, P135; Risnes S, 1998, J HUM EVOL, V35, P331, DOI 10.1006/jhev.1998.0229; Rozzi FR, 1998, J HUM EVOL, V35, P543, DOI 10.1006/jhev.1998.0250; Schwartz GT, 2001, INT J PRIMATOL, V22, P837, DOI 10.1023/A:1012073601808; Schwartz GT, 2000, AM J PHYS ANTHROPOL, V111, P221, DOI 10.1002/(SICI)1096-8644(200002)111:2<221::AID-AJPA8>3.0.CO;2-G; SMITH BH, 1995, ANNU REV ANTHROPOL, V24, P257, DOI 10.1146/annurev.an.24.100195.001353; SMITH BH, 1994, AM J PHYS ANTHROPOL, V94, P307, DOI 10.1002/ajpa.1330940303; SMITH BH, 1989, EVOLUTION, V43, P683, DOI 10.1111/j.1558-5646.1989.tb04266.x; WALKER A, 1993, NARIOKOTOME HORNO ER; Wood B, 1999, SCIENCE, V284, P65, DOI 10.1126/science.284.5411.65; Wood B. A., 1991, HOMINID CRANIAL REMA, V4	30	350	361	4	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					628	631		10.1038/414628a	http://dx.doi.org/10.1038/414628a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	498WB	11740557				2022-12-28	WOS:000172535600045
J	Meadow, R				Meadow, R			Personal paper - A case of murder and the BMJ	BRITISH MEDICAL JOURNAL			English	Article																		FLEMING PJ, 2000, SUDDEN UNEXPECTED DE; Watkins SJ, 2000, BRIT MED J, V320, P2, DOI 10.1136/bmj.320.7226.2	2	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					41	43		10.1136/bmj.324.7328.41	http://dx.doi.org/10.1136/bmj.324.7328.41			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777809	Green Published			2022-12-28	WOS:000173205700027
J	Skene, L; Smallwood, R				Skene, L; Smallwood, R			Informed consent: lessons from Australia	BRITISH MEDICAL JOURNAL			English	Article									Univ Melbourne, Fac Law, Parkville, Vic 3010, Australia; Dept Hlth & Aged Care, Woden, ACT 2606, Australia	University of Melbourne	Skene, L (corresponding author), Univ Melbourne, Fac Law, Parkville, Vic 3010, Australia.							*AUSTR NAT HLTH ME, 1993, GEN GUID MED PRACT P; *COMPTR AUD GEN, 2001, HANDL CLIN NEGL CLAI; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; *ROYAL COLL SURG E, 2000, GOOD SURG PRACT; *SEN SURG, 1997, SURG DUT CAR GUID SU; Skene Loane, 1997, HLTH LAW ETHICS, P69	6	73	73	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					39	41		10.1136/bmj.324.7328.39	http://dx.doi.org/10.1136/bmj.324.7328.39			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777808	Green Submitted, Green Published			2022-12-28	WOS:000173205700026
J	Schwetz, BA				Schwetz, BA			Drug for severe adult sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fushers Ln, Rockville, MD 20857 USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					33	33		10.1001/jama.287.1.33-b	http://dx.doi.org/10.1001/jama.287.1.33-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754690				2022-12-28	WOS:000172978500004
J	Tulina, N; Matunis, E				Tulina, N; Matunis, E			Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT signaling	SCIENCE			English	Article							GENE-EXPRESSION; GERMLINE; PROTEIN; DIFFERENTIATION; PROLIFERATION; ENCODES; PATHWAY; KINASE	Stem cells, which regenerate tissue by producing differentiating cells, also produce cells that renew the stem cell population. Signals from regulatory microenvironments (niches) are thought to cause stem cells to retain self-renewing potential. However, the molecular characterization of niches remains an important goat. In Drosophila testes, germ tine and somatic stem cells attach to a cluster of support cells called the hub. The hub specifically expresses Unpaired, a ligand activating the JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling cascade. Without JAK-STAT signaling, germ line stem cells differentiate but do not self-renew. Conversely, ectopic JAK-STAT signaling greatly expands both stem cell populations. We conclude that the support cells of the hub signal to adjacent stem cells by activation of the JAK-STAT pathway, thereby defining a niche for stem cell self-renewal.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Matunis, E (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				NICHD NIH HHS [R01HD40307, R01 HD040307] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040307] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Boyle M, 1997, DEVELOPMENT, V124, P971; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; FULLER MT, 1993, DEV DROSOPHILA MELAN, V1, P71; GONCZY P, 1992, DEVELOPMENT, V114, P89; GONCZY P, 1995, THESIS ROCKEFELLER U; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hime GR, 1996, J CELL SCI, V109, P2779; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; LIN HF, 1994, DEVELOPMENT, V120, P947; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Matunis E, 1997, DEVELOPMENT, V124, P4383; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Smith AG, 2001, DEV BIOL, V235, P289; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; TSAI YC, 2001, A DROS RES C, V42, pC585; Van Doren M, 1998, CURR BIOL, V8, P243; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482	24	479	498	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2546	2549		10.1126/science.1066700	http://dx.doi.org/10.1126/science.1066700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752575				2022-12-28	WOS:000172927700058
J	Smith, GS; Keyl, PM; Hadley, JA; Bartley, CL; Foss, RD; Tolbert, WG; McKnight, J				Smith, GS; Keyl, PM; Hadley, JA; Bartley, CL; Foss, RD; Tolbert, WG; McKnight, J			Drinking and recreational boating fatalities - A population-based case-control study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; INJURIES; OPERATION; ETHANOL; RISK	Context Alcohol is increasingly recognized as a factor in many boating fatalities, but the association between alcohol consumption and mortality among boaters has not been well quantified. Objectives To determine the association of alcohol use with passengers' and operators' estimated relative risk (RR) of dying while boating. Design, Setting, and Participants Case-control study of recreational boating deaths among persons aged 18 years or older from 1990-1998 in Maryland and North Carolina (n=221), compared with control interviews obtained from a multistage probability sample of boaters in each state from 1997-1999 (n=3943). Main Outcome Measure Estimated RR of fatality associated with different levels of blood alcohol concentration (BAC) among boaters. Results Compared with the referent of a BAC of 0, the estimated RR of death increased even with a BAC of 10 mg/dL (odds ratio [OR], 1.3; 95% confidence interval [CI], 1.2-1.4). The OR was 52.4 (95% CI, 25.9-106.1) at a BAC of 250 mg/dL. The estimated RR associated with alcohol use was similar for passengers and operators and did not vary by boat type or whether the boat was moving or stationary. Conclusions Drinking increases the RR of dying while boating, wh ich becomes apparent at low levels of BAC and increases as BAC increases. Prevention efforts targeted only at those operating a boat are ignoring many boaters at high risk. Countermeasures that reduce drinking by all boat occupants are therefore more likely to effectively reduce boating fatalities.	Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD USA; Univ N Carolina, Highway Safety Res Ctr, Chapel Hill, NC USA; Pacific Inst Res & Evaluat, Rockville, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of North Carolina; University of North Carolina Chapel Hill; Pacific Institute for Research & Evaluation (PIRE)	Smith, GS (corresponding author), Liberty Mutual Res Ctr Safety & Hlth, Ctr Safety Res, 71 Franklin Rd, Hopkinton, MA 01746 USA.		Foss, Robert/W-1750-2019	Foss, Robert/0000-0002-1150-5763; Smith, Gordon/0000-0002-2911-3071	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007700] Funding Source: NIH RePORTER; NIAAA NIH HHS [R29AA07700] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		*AM RED CROSS, 1991, AM RED CROSS NAT BOA; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; Borkenstein R.F., 1974, BLUTALKOHOL, V11, P1; Branche CM, 1997, JAMA-J AM MED ASSOC, V278, P663, DOI 10.1001/jama.278.8.663; *CAN RED CROSS SOC, 1999, NAT DROWN REP AN DRO; CARLSON WL, 1979, ACCIDENT ANAL PREV, V11, P35, DOI 10.1016/0001-4575(79)90037-X; Ciraulo DL, 2000, AM SURGEON, V66, P604; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; HOWLAND J, 1993, JAMA-J AM MED ASSOC, V270, P91, DOI 10.1001/jama.270.1.91; Howland J, 1996, PUBLIC HEALTH REP, V111, P372; HOWLAND J, 1990, PUBLIC HEALTH REP, V105, P415; Howland J., 1993, Morbidity and Mortality Weekly Report, V42, P675; Howland J, 2000, ADDICTION, V95, P719, DOI 10.1046/j.1360-0443.2000.9557197.x; HOWLAND J, 1995, ALCOHOL COCAINE ACCI, P85; HOXIE P, 1988, US COAST GUARD PUBLI; Jones CS, 2000, ACCIDENT ANAL PREV, V32, P373, DOI 10.1016/S0001-4575(99)00091-3; LEVINE B, 1993, J FORENSIC SCI, V38, P663; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Logan P, 1999, AM J PREV MED, V16, P278, DOI 10.1016/S0749-3797(99)00022-7; Lunetta P, 1998, INT J EPIDEMIOL, V27, P1038, DOI 10.1093/ije/27.6.1038; MANDER A, 2001, WHOTDECK ADO WHOTDEC; MCKNIGHT AJ, 1994, EFFECTS ALCOHOL HUMA; MENGERT P, 1992, US COAST GUARD PUBLI; Moskowitz H, 1999, ACCIDENT ANAL PREV, V31, P175, DOI 10.1016/S0001-4575(98)00060-8; MOSKOWITZ H, 2000, NATL HIGHWAY TRAFFIC; *NAT TRANSP SAF BO, 1993, NATL TRANSP SAF BOAR; ONeal CL, 1996, AM J FOREN MED PATH, V17, P8, DOI 10.1097/00000433-199603000-00002; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2; STIEHL C, 1975, US COAST GUARD PUBLI; Wells JK, 1997, J STUD ALCOHOL, V58, P513, DOI 10.15288/jsa.1997.58.513; WINTEMUTE GJ, 1990, ACCIDENT ANAL PREV, V22, P291, DOI 10.1016/0001-4575(90)90020-L; WRIGHT SJ, 1985, ALCOHOL HEALTH RES W, V9, P28; Zador PL, 2000, J STUD ALCOHOL, V61, P387, DOI 10.15288/jsa.2000.61.387	35	61	62	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2974	2980		10.1001/jama.286.23.2974	http://dx.doi.org/10.1001/jama.286.23.2974			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	502VY	11743838				2022-12-28	WOS:000172764500029
J	Stoltzfus, RJ; Kvalsvig, JD; Chwaya, HM; Montresor, A; Albonico, M; Tielsch, JM; Savioli, L; Pollitt, E				Stoltzfus, RJ; Kvalsvig, JD; Chwaya, HM; Montresor, A; Albonico, M; Tielsch, JM; Savioli, L; Pollitt, E			Effects of iron supplementation and anthelmintic treatment on motor and language development of preschool children in Zanzibar: double blind, placebo controlled study	BRITISH MEDICAL JOURNAL			English	Article							SCHOOL-CHILDREN; COGNITIVE FUNCTION; LONGITUDINAL DATA; INFECTION; PERFORMANCE; INFANTS; ANEMIA; THERAPY; FORMULA; GROWTH	Objective To measure the effects of iron supplementation and anthelmintic treatment on iron status, anaemia, growth, morbidity, mid development of children aged 6-59 months. Design Double blind, placebo controlled randomised factorial trial of iron supplementation and anthelmintic treatment. Setting Community in Pemba Wand, Zanzibar. Participants 614 preschool children aged 6-59 months. Main outcome measures Development of language and motor skills assessed by parental interview before and after treatment in age appropriate Subgroups. Results Before intervention, anaemia was prevalent and severe, and geohelminth infections were prevalent and light-Plasmodium falciparum infection was nearly universal. Iron supplementation significantly improved iron status, but not haemoglobin status. Iron supplementation improved language development by 0.8 (95% confidence interval 0.2 to 1.4) points on the 20 point scale. Iron supplementation also improved motor development, but this effect was modified by baseline haemoglobin concentrations (P = 0.015 for interaction term) and was apparent only in children with baseline haemoglobin concentrations < 90 g/l. In children with a baseline haemoglobin concentration of 68 g/l (one standard deviation below the mean value), iron treatment increased scores by 1.1 (0.1 to 2.1) points on the 18 point motor scale. Mebendazole significantly reduced the number and severity of infections caused by Ascaris lumbricoides and Trichuris trichiura, but not by hookworms. Mebendazole increased development scores by 0.4 (-0.3 to 1.1) points on the motor scale and 0.3 (-0.3 to 0.9) points on the language scale. Conclusions Iron Supplementation improved motor and language development of preschool children in rural Africa. The effects of iron on motor development were limited to children with more severe anaemia (baseline haemoglobin concentration < 90 g/l). Mebendazole had a positive effect on motor and language development. but this was not statistically significant.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA; Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; Univ Natal, Child Dev Programme, ZA-4013 Congella, South Africa; Minist Hlth, Zanzibar, Tanzania; WHO, Parasit Dis & Vector Control, CH-1211 Geneva, Switzerland; Ivo de Carneri Fdn, I-20129 Milan, Italy	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Davis; University of Kwazulu Natal; World Health Organization	Stoltzfus, RJ (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA.		Montresor, Antonio/J-3137-2019	Montresor, Antonio/0000-0003-3103-8872; ALBONICO, Marco/0000-0002-7805-2391; Tielsch, James/0000-0002-1151-060X				Ash LR., 1994, BENCH AIDS DIAGNOSIS; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; COWEN EL, 1994, J AM ACAD CHILD PSY, V33, P400, DOI 10.1097/00004583-199403000-00015; Dickson R, 2000, BMJ-BRIT MED J, V320, P1697, DOI 10.1136/bmj.320.7251.1697; GLASCOE FP, 1995, J PEDIATR-US, V127, P831, DOI 10.1016/S0022-3476(95)70184-2; Hutchinson SE, 1997, EUR J CLIN NUTR, V51, P729, DOI 10.1038/sj.ejcn.1600473; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; IRETON H, 1995, CLIN PEDIATR, V34, P248, DOI 10.1177/000992289503400504; KNOBLOCH H, 1979, PEDIATRICS, V63, P872; KVALSVIG JD, 1991, ANN TROP MED PARASIT, V85, P551, DOI 10.1080/00034983.1991.11812608; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOZOFF B, 1987, PEDIATRICS, V79, P981; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; LOZOFF B, 1988, PEDIATRICS, V81, P683; LOZOFF B, 1997, NUTR HLTH CHILD DEV, P162; Morley R, 1999, ARCH DIS CHILD, V81, P247, DOI 10.1136/adc.81.3.247; NOKES C, 1992, PARASITOLOGY, V104, P539, DOI 10.1017/S0031182000063800; OSKI FA, 1983, PEDIATRICS, V71, P877; Sakti H, 1999, TROP MED INT HEALTH, V4, P322, DOI 10.1046/j.1365-3156.1999.00410.x; Sherriff A, 2001, ARCH DIS CHILD, V84, P480, DOI 10.1136/adc.84.6.480; SIMEON DT, 1995, PARASITOLOGY, V110, P457, DOI 10.1017/S0031182000064799; Stoltzfus RJ, 2000, J NUTR, V130, P1724, DOI 10.1093/jn/130.7.1724; WALTER T, 1989, AM J CLIN NUTR, V50, P655, DOI 10.1093/ajcn/50.3.655; WATKINS WE, 1997, NUTR HLTH CHILD DEV, P179; Williams J, 1999, BRIT MED J, V318, P693, DOI 10.1136/bmj.318.7185.693; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	26	170	181	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1389	1393		10.1136/bmj.323.7326.1389	http://dx.doi.org/10.1136/bmj.323.7326.1389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744561	Bronze, Green Published			2022-12-28	WOS:000172900400014
J	Broecker, WS; Clark, E				Broecker, WS; Clark, E			Glacial-to-Holocene redistribution of carbonate ion in the deep sea	SCIENCE			English	Article							IN-SITU MEASUREMENTS; ONTONG-JAVA PLATEAU; EQUATORIAL PACIFIC; CALCITE DISSOLUTION; CACO3 PRESERVATION; NORTH-ATLANTIC; CEARA RISE; SEDIMENTS; OCEAN; O-2	We have reconstructed the glacial-age distribution of carbonate ion concentration in the deep waters of the equatorial ocean on the basis of differences in weight between glacial and Holocene foraminifera shells picked from a series of cores spanning a range of water depth on the western Atlantic's Ceara Rise and the western Pacific's Ontong Java Plateau. The results suggest that unlike today's ocean, sizable vertical gradients in the carbonate ion concentration existed in the glacial-age deep ocean. In the equatorial Pacific, the concentration increased with depth, and in the Atlantic, it decreased with depth. In addition, the contrast between the carbonate ion concentration in deep waters produced in the northern Atlantic and deep water in the Pacific appears to have been larger than in today's ocean.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Broecker, WS (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	broecker@ldeo.columbia.edu						ARCHER D, 1989, GEOCHIM COSMOCHIM AC, V53, P2831, DOI 10.1016/0016-7037(89)90161-0; Boyle EA, 1988, PALEOCEANOGRAPHY, V3, P471, DOI 10.1029/PA003i004p00471; Broecker W, 2001, PALEOCEANOGRAPHY, V16, P531, DOI 10.1029/2000PA000600; BROECKER W S, 1971, Quaternary Research (Orlando), V1, P188, DOI 10.1016/0033-5894(71)90041-X; Broecker WS, 1990, GLOBAL BIOGEOCHEM CY, V4, P103, DOI 10.1029/GB004i001p00103; BROECKER WS, 1992, NATURE, V356, P587, DOI 10.1038/356587a0; BROECKER WS, 2001, G3 GC000177; BROECKER WS, 2001, G3 GC000151; BROECKER WS, 2000, G3 1 GC000039; BROECKER WS, 1971, LATE CENOZOIC GLACIA; CROWLEY TJ, 1983, MAR GEOL, V51, P1, DOI 10.1016/0025-3227(83)90085-3; Curry WB, 1988, PALEOCEANOGRAPHY, V3, P317, DOI 10.1029/PA003i003p00317; CURRY WB, 1985, AM GEOPHYS UNION MON, V32, P285; EMERSON SR, 1990, PHILOS T R SOC A, V331, P29, DOI 10.1098/rsta.1990.0054; Farrell JW, 1991, PALEOCEANOGRAPHY, V6, P485, DOI 10.1029/91PA00877; Farrell JW, 1989, PALEOCEANOGRAPHY, V4, P447, DOI 10.1029/PA004i004p00447; Hales B, 1996, GLOBAL BIOGEOCHEM CY, V10, P527, DOI 10.1029/96GB01522; HALES B, 1994, DEEP-SEA RES PT I, V41, P695, DOI 10.1016/0967-0637(94)90050-7; Hales B, 1997, GEOCHIM COSMOCHIM AC, V61, P501, DOI 10.1016/S0016-7037(96)00366-3; HEATH GR, 1970, GEOL SOC AM BULL, V81, P3157, DOI 10.1130/0016-7606(1970)81[3157:CDOSRO]2.0.CO;2; HOWARD WR, 1994, PALEOCEANOGRAPHY, V9, P453, DOI 10.1029/93PA03524; Karlin R, 1992, PALEOCEANOGRAPHY, V7, P43, DOI 10.1029/91PA03077; Le JN, 1992, PALEOCEANOGRAPHY, V7, P21, DOI 10.1029/91PA02854; Lea DW, 1990, PALEOCEANOGRAPHY, V5, P719, DOI 10.1029/PA005i005p00719; LEA DW, 1990, NATURE, V347, P269, DOI 10.1038/347269a0; LOHMANN GP, 1995, PALEOCEANOGRAPHY, V10, P445, DOI 10.1029/95PA00059; Martin WR, 1996, GEOCHIM COSMOCHIM AC, V60, P243, DOI 10.1016/0016-7037(95)00383-5; Matsumoto K, 2001, EARTH PLANET SC LETT, V192, P319, DOI 10.1016/S0012-821X(01)00412-5; MILLERO FJ, 1972, GEOCHIM COSMOCHIM AC, V36, P92, DOI 10.1016/0016-7037(72)90123-8; Peng TH, 1987, GLOBAL BIOGEOCHEM CY, V1, P155, DOI 10.1029/GB001i002p00155; Peterson LC., 1985, GEOPHYS MONOGR SER, P251; PYTKOWICZ RM, 1967, GEOCHEM J, V6, P169; SAYLES FL, 1980, MAR CHEM, V9, P223, DOI 10.1016/0304-4203(80)90026-2; Stephens MP, 1997, PALEOCEANOGRAPHY, V12, P797, DOI 10.1029/97PA02271; WU GP, 1991, MAR GEOL, V99, P135, DOI 10.1016/0025-3227(91)90087-K	35	97	100	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2152	2155		10.1126/science.1064171	http://dx.doi.org/10.1126/science.1064171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739953				2022-12-28	WOS:000172647700047
J	Heeley, E; Riley, J; Layton, D; Wilton, LV; Shakir, SAW				Heeley, E; Riley, J; Layton, D; Wilton, LV; Shakir, SAW			Prescription-event monitoring and reporting of adverse drug reactions	LANCET			English	Article								Newly marketed drugs in the UK are marked with a black triangle, indicating that doctors should report all adverse drug reactions associated with them to the Committee on Safety of Medicines (GSM). However, under-reporting of adverse reactions is frequent. Our aim was to establish what types of adverse reactions are under-reported to the CSM by family doctors who work in England. We used prescription-event monitoring data obtained for 15 newly marketed drugs. Only 9% (376) of 4211 events found on prescription-event monitoring were reported to the CSM, However, 53% (27) of 51 events classified as serious adverse drug reactions were reported, Overall, serious events were five times more likely to be reported to the CSM than non-serious events. Our results should not be extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports.	Drug Safety Res Unit, Southampton SO31 1AA, Hants, England		Heeley, E (corresponding author), Drug Safety Res Unit, Bursledon Hall, Southampton SO31 1AA, Hants, England.			Heeley, Emma/0000-0001-9190-2832				Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x; Martin RM, 1998, BRIT MED J, V317, P119, DOI 10.1136/bmj.317.7151.119; *MCA CSM, 2000, CURRENT PROB PHARMAC, V26, P9; 2001, ICH GUIDELINE GOOD C	5	97	101	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1872	1873		10.1016/S0140-6736(01)06898-2	http://dx.doi.org/10.1016/S0140-6736(01)06898-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741629				2022-12-28	WOS:000172463000015
J	Wellings, F; Nanchahal, K; Macdowall, W; McManus, S; Erens, B; Mercer, CH; Johnson, AM; Copas, AJ; Korovessis, C; Fenton, FA; Field, J				Wellings, F; Nanchahal, K; Macdowall, W; McManus, S; Erens, B; Mercer, CH; Johnson, AM; Copas, AJ; Korovessis, C; Fenton, FA; Field, J			Sexual behaviour in Britain: early heterosexual experience	LANCET			English	Article							INTERCOURSE; AGE	Background Relatively high rates of teenage conception and sexually transmitted infection among young people in Britain have focused attention on early sexual behaviour and its determinants. We report the results of the second National Survey of Sexual Attitudes and Lifestyles (Natsal 2000). Methods We did a probability sample survey between 1999 and 2001, of men and women aged 16-44 years in Britain. Participants were interviewed using a combination of computer-assisted face-to-face and self-completion questionnaires, and asked questions regarding first heterosexual intercourse, communication about sex, pregnancy, and sexually transmitted infections (STIs). Findings We recruited 11 161 men and women to the survey (4762 men, 6399 women). The proportion of those aged 16-19 years at interview reporting first heterosexual intercourse at younger than 16 years was 30% for men and 26% for women; median age was 16 years. The proportion of women reporting first intercourse before 16 years increased up to, but not after, the mid-1990s. There has been a sustained increase in condom use and a decline in the proportion of men and women reporting no contraceptive use at first intercourse with decreasing age at interview. Among 16-24 year olds, non-use of contraception increased with declining age at first intercourse; reported by 18% of men and 22% of women aged 13-14 years at occurrence. Early age at first intercourse was significantly associated with pregnancy under 18 years, but not with occurrence of STIs. Low educational attainment was associated with motherhood before 18 years, but not abortion. Interpretation The increase in the proportion of women reporting first intercourse before age 16 years does not appear to have continued throughout the past decade. Only a small minority of teenagers have unprotected first intercourse, and early motherhood is more strongly associated with educational level than with family background. Factors mast strongly associated with risk behaviour and adverse outcomes have considerable potential for preventive intervention.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Ctr Sexual Hlth Res, London WC1E 7HT, England; Natl Ctr Social Res, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat SCi, Ctr Infect Dis Epidemiol, London, England; Publ Hlth Lab Serv, HIV STI Div, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Public Health England	Wellings, F (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Ctr Sexual Hlth Res, Keppel St, London WC1E 7HT, England.	kaye.wellings@lshtm.ac.uk	McManus, Sally/HGD-4860-2022; McManus, Sally/S-4697-2019	McManus, Sally/0000-0003-2711-0819; Erens, Bob/0000-0002-4430-954X; Nanchahal, Kiran/0000-0001-8812-7628; Copas, Andrew/0000-0001-8968-5963; Mercer, Catherine/0000-0002-4220-5034; Erens, Robert/0000-0002-3054-504X; Macdowall, Wendy/0000-0001-5868-8336; Johnson, Anne/0000-0003-1330-7100				Bozon M, 1998, SOC AS AIDS, P37; COPAS AJ, 1990, IN PRESS ACCURACY RE; Department of Health, 2001, NAT STRAT SEX HLTH H; Dickson N, 1998, BRIT MED J, V316, P29, DOI 10.1136/bmj.316.7124.29; Edgardh K, 2000, SEX TRANSM INFECT, V76, P98, DOI 10.1136/sti.76.2.98; GIESECKE J, 1992, INT J STD AIDS, V3, P255, DOI 10.1177/095646249200300405; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KANE R, 1999, REDUCING RATE TEENAG; MICHAEL RT, 2001, SEX LOVE HLTH AM; NICOLL A, 1999, BRIT MED J, V38, P1322; Paul C, 2000, J ADOLESCENT HEALTH, V27, P136, DOI 10.1016/S1054-139X(99)00095-6; Singh S, 1999, FAM PLANN PERSPECT, V31, P212, DOI 10.2307/2991568; *SOC EXCL UN, 1999, TEEN PREGN; StuartSmith S, 1996, BRIT MED J, V312, P390; WELLINGS K, 1994, SEXUAL BEHAV BRIT; WEST P, 1993, J ADOLESCENCE, V16, P367, DOI 10.1006/jado.1993.1031; Wight D, 2000, BRIT MED J, V320, P1243, DOI 10.1136/bmj.320.7244.1243	18	426	431	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1843	1850		10.1016/S0140-6736(01)06885-4	http://dx.doi.org/10.1016/S0140-6736(01)06885-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	497NU	11741623				2022-12-28	WOS:000172463000009
J	Quist, D; Chapela, IH				Quist, D; Chapela, IH			Transgenic DNA introgressed into traditional maize landraces in Oaxaca, Mexico	NATURE			English	Article							GENE FLOW; PLANTS	Concerns have been raised about the potential effects of transgenic introductions on the genetic diversity of crop landraces and wild relatives in areas of crop origin and diversification, as this diversity is considered essential for global food security. Direct effects on non-target species(1,2), and the possibility of unintentionally transferring traits of ecological relevance onto landraces and wild relatives have also been sources of concern(3,4). The degree of genetic connectivity between industrial crops and their progenitors in landraces and wild relatives is a principal determinant of the evolutionary history of crops and agroecosystems throughout the world(5,6). Recent introductions of transgenic DNA constructs into agricultural fields provide unique markers to measure such connectivity. For these reasons, the detection of transgenic DNA in crop landraces is of critical importance. Here we report the presence of introgressed transgenic DNA constructs in native maize landraces grown in remote mountains in Oaxaca, Mexico, part of the Mesoamerican centre of origin and diversification of this crop(7-9).	Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Chapela, IH (corresponding author), Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA.	ichapela@nature.berkeley.edu						DOEBLEY J, 1990, BIOSCIENCE, V40, P443, DOI 10.2307/1311391; Ellstrand NC, 1999, ANNU REV ECOL SYST, V30, P539, DOI 10.1146/annurev.ecolsys.30.1.539; Ellstrand NC, 2001, PLANT PHYSIOL, V125, P1543, DOI 10.1104/pp.125.4.1543; Gachet E, 1998, TRENDS FOOD SCI TECH, V9, P380, DOI 10.1016/S0924-2244(99)00002-3; Hartl Daniel L., 1996, V58, P293; ILTIS HH, 1983, SCIENCE, V222, P886, DOI 10.1126/science.222.4626.886; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Matsuoka T, 2000, J FOOD HYG SOC JPN, V41, P137, DOI 10.3358/shokueishi.41.137; Pawlowski WP, 1998, P NATL ACAD SCI USA, V95, P12106, DOI 10.1073/pnas.95.21.12106; Piperno DR, 2001, P NATL ACAD SCI USA, V98, P2101, DOI 10.1073/pnas.98.4.2101; Saxena D, 1999, NATURE, V402, P480, DOI 10.1038/44997; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; White S, 1998, TRENDS GENET, V14, P327, DOI 10.1016/S0168-9525(98)01524-8; Zimmermann A, 2000, LEBENSM-WISS TECHNOL, V33, P210, DOI 10.1006/fstl.2000.0637; 1999, SMT4CT962072 EU BUND	15	358	435	0	138	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 29	2001	414	6863					541	543		10.1038/35107068	http://dx.doi.org/10.1038/35107068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734853				2022-12-28	WOS:000172405900046
J	Higashi, H; Tsutsumi, R; Muto, S; Sugiyama, T; Azuma, T; Asaka, M; Hatakeyama, M				Higashi, H; Tsutsumi, R; Muto, S; Sugiyama, T; Azuma, T; Asaka, M; Hatakeyama, M			SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein	SCIENCE			English	Article							GASTRIC EPITHELIAL-CELLS; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SH2 DOMAINS; FOCAL ADHESION; IV SECRETION; TRANSLOCATION; SH-PTP2; INVOLVEMENT; ANTIGEN	Helicobacter pylori CagA protein is associated with severe gastritis and gastric carcinoma. CagA is injected from the attached Helicobacter pylori into host cells and undergoes tyrosine phosphorylation. Wild-type but not phosphorylation-resistant CagA induced a growth factor-like response in gastric epithelial cells. Furthermore, CagA formed a physical complex with the SRC homology 2 domain (SH2)-containing tyrosine phosphatase SHP-2 in a phosphorylation-dependent manner and stimulated the phosphatase activity. Disruption of the CagA-SHP-2 complex abolished the CagA-dependent cellular response. Conversely, the CagA effect on cells was reproduced by constitutively active SHP-2. Thus, upon translocation, CagA perturbs cellular functions by deregulating SHP-2.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido 0600815, Japan; Fukui Med Univ, Dept Internal Med 2, Fukui 9101193, Japan	Hokkaido University; Hokkaido University; Hokkaido University; University of Fukui	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Sapporo, Hokkaido 0600815, Japan.	mhata@imm.hokudai.ac.jp	Asaka, Masahiro/A-5948-2012; Higashi, Hideaki/F-6872-2012	Tsutsumi, Ryouhei/0000-0002-1704-0362				AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BLASER MJ, 1995, CANCER RES, V55, P2111; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; DECHERT U, 1994, J BIOL CHEM, V269, P5602; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HIGASHI H, UNPUB; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Manes S, 1999, MOL CELL BIOL, V19, P3125; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	770	808	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 25	2002	295	5555					683	686		10.1126/science.1067147	http://dx.doi.org/10.1126/science.1067147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	516PD	11743164				2022-12-28	WOS:000173560900047
J	Dalakas, MC; Fujii, M; Li, M; Lutfi, B; Kyhos, J; McElroy, B				Dalakas, MC; Fujii, M; Li, M; Lutfi, B; Kyhos, J; McElroy, B			High-dose intravenous immune globulin for stiff-person syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; DIABETES-MELLITUS; AUTOANTIBODIES; IMMUNOGLOBULIN; DISEASES; THERAPY	Background Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that is characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutamic acid decarboxylase (GAD65), and a frequent association with autoimmune disorders. Because stiff-person syndrome is most likely immune-mediated, we evaluated the efficacy of intravenous immune globulin. Methods We assigned 16 patients who had stiff-person syndrome and anti-GAD65 antibodies, in random order, to receive intravenous immune globulin or placebo for three months, followed by a one-month washout period and then by three months of therapy with the alternative agent. Efficacy was judged by improvements in scores on the distribution-of-stiffness index and heightened-sensitivity scale from base line (month 1) to the second and third month of each treatment phase. Direct and carryover effects of treatment were compared in the two groups. Results Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02) and heightened-sensitivity scores decreased substantially during immune globulin therapy but rebounded during placebo administration. In contrast, the scores in the group that received placebo first remained constant during placebo administration but dropped significantly during immune globulin therapy (P=0.01). When the data were analyzed for a direct and a first-order carryover effect, there was a significant difference in stiffness scores (P=0.01 and P<0.001, respectively) between the immune globulin and placebo groups, and immune globulin therapy had a significant direct treatment effect on sensitivity scores (P=0.03). Eleven patients who received immune globulin became able to walk more easily or without assistance, their frequency of falls decreased, and they were able to perform work-related or household tasks. The duration of the beneficial effects of immune globulin varied from six weeks to one year. Anti-GAD65 antibody titers declined after immune globulin therapy but not after placebo administration. Conclusions Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies. (N Engl J Med 2001;345:1870-6.) Copyright (C) 2001 Massachusetts Medical Society.	NINCDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Dalakas, MC (corresponding author), NINCDS, Neuromuscular Dis Sect, NIH, Bldg 10,Rm 4N248,10 Ctr Dr MSC 1382, Bethesda, MD 20892 USA.	dalakasm@ninds.nih.gov						AMATO AA, 1994, NEUROLOGY, V44, P1652, DOI 10.1212/WNL.44.9.1652; Barker RA, 1998, J NEUROL NEUROSUR PS, V65, P633, DOI 10.1136/jnnp.65.5.633; Barker RA, 1997, J NEUROL NEUROSUR PS, V62, P426, DOI 10.1136/jnnp.62.4.426; Dalakas MC, 2000, NEUROLOGY, V55, P1531, DOI 10.1212/WNL.55.10.1531; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 2001, NEUROLOGY, V57, P780, DOI 10.1212/WNL.57.5.780; Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008; Dalakas MC, 1999, ANN INTERN MED, V131, P522; DALAKAS MC, 1999, ANN INTERN MED, V131, P529; DALAKAS MC, 1999, ANN INTERN MED, V131, P524; Daw K, 1996, J IMMUNOL, V156, P818; Dinkel K, 1998, ANN NEUROL, V44, P194, DOI 10.1002/ana.410440209; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; FLOETER MK, 1999, ANN INTERN MED, V131, P523; HARDING AE, 1989, LANCET, V2, P915; Ishida K, 1999, ANN NEUROL, V46, P263, DOI 10.1002/1531-8249(199908)46:2<263::AID-ANA19>3.0.CO;2-0; KARLSON HW, 1994, ARTHRITIS RHEUM-US, V37, P915, DOI 10.1002/art.1780370621; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; KENWARD MG, 1987, STAT MED, V6, P911, DOI 10.1002/sim.4780060806; Levy Lucien M., 1999, Annals of Internal Medicine, V131, P522; MEINCK HM, 1995, J NEUROL, V242, P134, DOI 10.1007/BF00936885; MITSUMOTO H, 1991, J NEUROL, V238, P91, DOI 10.1007/BF00315688; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TORO C, 1994, SEMIN NEUROL, V14, P154, DOI 10.1055/s-2008-1041073; VICARI AM, 1989, NEW ENGL J MED, V320, P1498; Weinberger DR, 2001, NEW ENGL J MED, V345, P304; Weinberger DR, 2001, NEW ENGL J MED, V344, P1247, DOI 10.1056/NEJM200104193441612; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311	30	248	261	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1870	1876		10.1056/NEJMoa01167	http://dx.doi.org/10.1056/NEJMoa01167			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756577				2022-12-28	WOS:000172932700002
J	Forastiere, A; Koch, W; Trotti, A; Sidransky, D				Forastiere, A; Koch, W; Trotti, A; Sidransky, D			Medical progress - Head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; BARR-VIRUS DNA; POSTOPERATIVE RADIATION-THERAPY; POSITRON-EMISSION-TOMOGRAPHY; PROSPECTIVE RANDOMIZED TRIAL; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; PHASE-III TRIAL; CONVENTIONAL FRACTIONATION		Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA	Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012588] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE12588] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADELSTEIN DJ, 2000, P AN M AM SOC CLIN, V19, pA411; AHSEE KW, 1994, CANCER RES, V54, P1617; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Alex JC, 2000, LARYNGOSCOPE, V110, P198, DOI 10.1097/00005537-200002010-00003; AlSarraf M, 1997, INT J RADIAT ONCOL, V37, P777, DOI 10.1016/S0360-3016(96)00614-1; Ang KK, 1999, FRONT RADIAT THER ON, V32, P145; ANG KK, 1996, P 4 INT C HEAD NECK, P231; Arbuck SG, 1999, CANC THERAPY EVALUAT; AWWAD HK, 1992, RADIOTHER ONCOL, V25, P261, DOI 10.1016/0167-8140(92)90245-P; Bachaud JM, 1996, INT J RADIAT ONCOL, V36, P999, DOI 10.1016/S0360-3016(96)00430-0; Bedi GC, 1996, CANCER RES, V56, P2484; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Brentani RR, 1999, HEAD NECK-J SCI SPEC, V21, P694; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339; BROWMAN GP, 1994, SEMIN ONCOL, V21, P311; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Califano J, 1999, J NATL CANCER I, V91, P599, DOI 10.1093/jnci/91.7.599; Califano J, 1999, CLIN CANCER RES, V5, P1862; Califano J, 1996, CANCER RES, V56, P2488; CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K; CANTO MT, 1975, IN PRESS ORAL ONCOL; Capone RB, 2000, CLIN CANCER RES, V6, P4171; Chan Anthony T. C., 1998, Current Opinion in Oncology, V10, P219, DOI 10.1097/00001622-199805000-00008; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Cooper JS, 1998, HEAD NECK-J SCI SPEC, V20, P588, DOI 10.1002/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.3.CO;2-6; DASSONVILLE O, 1993, J CLIN ONCOL, V11, P1873, DOI 10.1200/JCO.1993.11.10.1873; DATTA N R, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P132; Deleyiannis FWB, 1997, HEAD NECK-J SCI SPEC, V19, P466, DOI 10.1002/(SICI)1097-0347(199709)19:6<466::AID-HED2>3.0.CO;2-X; Dische S, 1997, RADIOTHER ONCOL, V44, P123, DOI 10.1016/S0167-8140(97)00094-7; EZEKIEL MP, 1999, P AN M AM SOC CLIN, V18, pA388; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245, DOI 10.1200/JCO.1992.10.8.1245; FORASTIERE AA, 2001, P AN M AM SOC CLIN, V20, pA2; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; HAFFTY BG, 1993, INT J RADIAT ONCOL, V27, P241, DOI 10.1016/0360-3016(93)90234-M; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise CC, 1999, CANCER RES, V59, P2623; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hong WK, 2000, J CLIN ONCOL, V18, p9S; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; Jackson SM, 1997, RADIOTHER ONCOL, V43, P39, DOI 10.1016/S0167-8140(97)01944-0; JARES P, 1994, CANCER RES, V54, P4813; JOHNSON JT, 1993, NEW ENGL J MED, V329, P390, DOI 10.1056/NEJM199308053290603; JOHNSON JT, 1985, ARCH OTOLARYNGOL, V111, P534; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Koch WM, 1998, ARCH OTOLARYNGOL, V124, P455, DOI 10.1001/archotol.124.4.455; Koch WM, 1999, LARYNGOSCOPE, V109, P1544, DOI 10.1097/00005537-199910000-00002; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; LACCOURREYE H, 1990, LARYNGOSCOPE, V100, P735; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lazarus CL, 1996, LARYNGOSCOPE, V106, P1157, DOI 10.1097/00005537-199609000-00021; LEE DJ, 1995, INT J RADIAT ONCOL, V32, P567, DOI 10.1016/0360-3016(95)00150-W; LEE DJ, 1989, INT J RADIAT ONCOL, V16, P465, DOI 10.1016/0360-3016(89)90343-X; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Leong PP, 1998, JNCI-J NATL CANCER I, V90, P972, DOI 10.1093/jnci/90.13.972; List MA, 1997, QUAL LIFE RES, V6, P274; Lo YMD, 1999, CANCER RES, V59, P1188; Lo YMD, 1999, CANCER RES, V59, P5452; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lowe VJ, 2000, J CLIN ONCOL, V18, P651, DOI 10.1200/JCO.2000.18.3.651; Lyos AT, 1999, PLAST RECONSTR SURG, V103, P442, DOI 10.1097/00006534-199902000-00011; Maciejewski B, 1996, RADIOTHER ONCOL, V40, P137, DOI 10.1016/0167-8140(96)01776-8; Mao L, 1998, J NATL CANCER I, V90, P1545, DOI 10.1093/jnci/90.20.1545; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MENDELSOHN J, 1999, PROG P AM SOC CLIN O, V18, pS389; Merlano M, 1996, J NATL CANCER I, V88, P583, DOI 10.1093/jnci/88.9.583; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Munro J, 1999, CANCER RES, V59, P2516; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NAWROZ H, 1994, CANCER RES, V54, P1152; Overgaard J, 1998, RADIOTHER ONCOL, V46, P135, DOI 10.1016/S0167-8140(97)00220-X; Papadimitrakopoulou V, 1997, ONCOGENE, V14, P1799, DOI 10.1038/sj.onc.1201010; Partridge M, 2000, CLIN CANCER RES, V6, P2718; Partridge M, 2000, CANCER RES, V60, P3893; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Peters L. J., 1999, International Journal of Radiation Oncology Biology Physics, V45, P148, DOI 10.1016/S0360-3016(99)90026-3; PETERS LJ, 1993, INT J RADIAT ONCOL, V26, P3, DOI 10.1016/0360-3016(93)90167-T; PINTO LHJ, 1991, INT J RADIAT ONCOL, V21, P557, DOI 10.1016/0360-3016(91)90670-Y; Reed AL, 1996, CANCER RES, V56, P3630; Ribeiro KDC, 2000, ARCH OTOLARYNGOL, V126, P1079; ROONEY M, 1985, CANCER, V55, P1123, DOI 10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8; Rosas SLB, 2001, CANCER RES, V61, P939; Rosin MP, 2000, CLIN CANCER RES, V6, P357; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Shotelersuk K, 2000, CLIN CANCER RES, V6, P1046; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SOMERS KD, 1992, CANCER RES, V52, P5997; Spafford MF, 2001, CLIN CANCER RES, V7, P607; STEVENS KR, 1994, INT J RADIAT ONCOL, V29, P687, DOI 10.1016/0360-3016(94)90555-X; Stokkel MPM, 2000, ANN SURG, V231, P229, DOI 10.1097/00000658-200002000-00012; Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702; Trotti A, 1998, SEMIN RADIAT ONCOL, V8, P282, DOI 10.1016/S1053-4296(98)80026-X; Trotti A, 1998, HEAD NECK-J SCI SPEC, V20, P119, DOI 10.1002/(SICI)1097-0347(199803)20:2<119::AID-HED4>3.3.CO;2-V; Trotti A, 2000, INT J RADIAT ONCOL, V47, P1, DOI 10.1016/S0360-3016(99)00558-1; Urken ML, 1998, ARCH OTOLARYNGOL, V124, P46, DOI 10.1001/archotol.124.1.46; VANDENBOGAERT W, 1986, INT J RADIAT ONCOL, V12, P587, DOI 10.1016/0360-3016(86)90067-2; VANDERRIET P, 1994, CANCER RES, V54, P1156; Vokes EE, 1999, SEMIN RADIAT ONCOL, V9, P70; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wan HS, 1999, CANCER RES, V59, P3518; Wendt TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318; WEPPELMANN B, 1992, INT J RADIAT ONCOL, V22, P1051, DOI 10.1016/0360-3016(92)90807-T; Westra WH, 1998, J NATL CANCER I, V90, P1500, DOI 10.1093/jnci/90.20.1500; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; [No title captured]	117	1031	1064	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1890	1900		10.1056/NEJMra001375	http://dx.doi.org/10.1056/NEJMra001375			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756581				2022-12-28	WOS:000172932700006
J	Dube, SR; Anda, RF; Felitti, VJ; Chapman, DP; Williamson, DF; Giles, WH				Dube, SR; Anda, RF; Felitti, VJ; Chapman, DP; Williamson, DF; Giles, WH			Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span - Findings from the adverse childhood experiences study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUAL-ABUSE; SUBSTANCE USE; WOMEN; ADOLESCENT; BEHAVIOR; PREVALENCE; DEPRESSION; IDEATION; ALCOHOL; DETERMINANTS	Context Suicide is a leading cause of death in the United States, but identifying persons at risk is difficult. Thus, the US surgeon general has made suicide prevention a national priority. An expanding body of research suggests that childhood trauma and adverse experiences can lead to a variety of negative health outcomes, including attempted suicide among adolescents and adults. Objective To examine the relationship between the risk of suicide attempts and adverse childhood experiences and the number of such experiences (adverse childhood experiences [ACE] score). Design, Setting, and Participants A retrospective cohort study of 17337 adult health maintenance organization members (54% female; mean [SD] age, 57 [15.3] years) who attended a primary care clinic in San Diego, Calif, within a 3-year period (1995-1997) and completed a survey about childhood abuse and household dysfunction, suicide attempts (including age at first attempt), and multiple other health-related issues. Main Outcome Measure Self-reported suicide attempts, compared by number of adverse childhood experiences, including emotional, physical, and sexual abuse; household substance abuse, mental illness, and incarcerations and parental domestic violence, separation, or divorce. Results The lifetime prevalence of having at least 1 suicide attempt was 3.8%. Adverse childhood experiences in any category increased the risk of attempted suicide 2- to 5-fold. The ACE score had a strong, graded relationship to attempted suicide during child hood/adolescence and adulthood (P<.001). Compared with persons with no such experiences (prevalence of attempted suicide, 1.1%), the adjusted odds ratio of ever attempting suicide among persons with 7 or more experiences (35.2 %) was 31.1 (95% confidence interval, 20.6-47.1). Adjustment for illicit drug use, depressed affect, and self-reported alcoholism reduced the strength of the relationship between the ACE score and suicide attempts, suggesting partial mediation of the adverse childhood experience-suicide attempt relationship by these factors. The population-attributable risk fractions for 1 or more experiences were 67%, 64%, and 80% for lifetime, adult, and childhood/ adolescent suicide attempts, respectively. Conclusions A powerful graded relationship exists between adverse childhood experiences and risk of attempted suicide throughout the life span, Alcoholism, depressed affect, and illicit drug use, which are strongly associated with such experiences, appear to partially mediate this relationship. Because estimates of the attributable risk fraction caused by these experiences were large, prevention of these experiences and the treatment of persons affected by them may lead to progress in suicide prevention.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA; Kaiser Permanente, So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA USA	Centers for Disease Control & Prevention - USA; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Dube, SR (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, 4770 Buford Hwy NE,MS K-45, Atlanta, GA 30341 USA.	skd7@cdc.gov						Alexopoulos GS, 1999, ARCH GEN PSYCHIAT, V56, P1048, DOI 10.1001/archpsyc.56.11.1048; Anda RF, 1999, JAMA-J AM MED ASSOC, V282, P1652, DOI 10.1001/jama.282.17.1652; Anda RF, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.2.e19; [Anonymous], SURG GEN CALL ACT PR; Beautrais AL, 1996, J AM ACAD CHILD PSY, V35, P1174, DOI 10.1097/00004583-199609000-00015; Bharucha AJ, 1997, HARVARD REV PSYCHIAT, V5, P55, DOI 10.3109/10673229709034728; Blair-West GW, 1999, J AFFECT DISORDERS, V55, P171, DOI 10.1016/S0165-0327(99)00004-X; BlairWest GW, 1997, ACTA PSYCHIAT SCAND, V95, P259, DOI 10.1111/j.1600-0447.1997.tb09629.x; Borges G, 2000, AM J EPIDEMIOL, V151, P781; BOXER PA, 1995, J OCCUP ENVIRON MED, V37, P442, DOI 10.1097/00043764-199504000-00016; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; Brodsky BS, 1997, AM J PSYCHIAT, V154, P1715, DOI 10.1176/ajp.154.12.1715; Brown J, 1999, J AM ACAD CHILD PSY, V38, P1490, DOI 10.1097/00004583-199912000-00009; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; Callahan CM, 1996, J AM GERIATR SOC, V44, P1205, DOI 10.1111/j.1532-5415.1996.tb01370.x; CLARK W, 1991, ALCOHOL AM DRINKING, P19; Dietz PH, 1999, JAMA-J AM MED ASSOC, V282, P1359, DOI 10.1001/jama.282.14.1359; Dinwiddie S, 2000, PSYCHOL MED, V30, P41, DOI 10.1017/S0033291799001373; DUBE SR, IN PRESS ADDICT BEHA; Edwards VJ, 2001, CHILD ABUSE NEGLECT, V25, P307, DOI 10.1016/S0145-2134(00)00238-6; Farber EW, 1996, GEN HOSP PSYCHIAT, V18, P56, DOI 10.1016/0163-8343(95)00098-4; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Femina D, 1990, CHILD ABUSE NEGLECT, V14, P227, DOI DOI 10.1016/0145-2134(90)90033-P; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Finkelhor D, 1998, JAMA-J AM MED ASSOC, V280, P1855; Fombonne E, 1998, BRIT J PSYCHIAT, V173, P154, DOI 10.1192/bjp.173.2.154; GARRISON CZ, 1993, AM J PUBLIC HEALTH, V83, P179, DOI 10.2105/AJPH.83.2.179; Grant BF, 1999, J STUD ALCOHOL, V60, P422, DOI 10.15288/jsa.1999.60.422; Haddix A, 1996, PREVENTION EFFECTIVE; Harwitz D, 2000, EMERG MED CLIN N AM, V18, P263, DOI 10.1016/S0733-8627(05)70123-1; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; Hillis SD, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.1.e11; Hollis C, 1996, J AM ACAD CHILD PSY, V35, P622, DOI 10.1097/00004583-199605000-00017; Hughes DH, 1996, GEN HOSP PSYCHIAT, V18, P416, DOI 10.1016/S0163-8343(96)00037-0; Kaplan DW, 2000, PEDIATRICS, V105, P871; KAPLAN HI, 1996, CONCISE TXB CLIN PSY, P361; Kaplan SJ, 1999, J INTERPERS VIOLENCE, V14, P976, DOI 10.1177/088626099014009005; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kingree JB, 1999, ADDICT BEHAV, V24, P583, DOI 10.1016/S0306-4603(98)00109-9; KLEIN RJ, 2001, PUBLICATION PHS; Lipschitz DS, 1999, J NERV MENT DIS, V187, P32, DOI 10.1097/00005053-199901000-00006; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; Moscicki Eve K., 1994, Annals of Epidemiology, V4, P152; Nagel R, 1998, Fam Med, V30, P362; Neeleman J, 1997, PSYCHOL MED, V27, P1165, DOI 10.1017/S0033291797005357; Ohberg A, 1996, J AM ACAD CHILD PSY, V35, P144, DOI 10.1097/00004583-199602000-00006; Oyefeso A, 1999, BRIT J PSYCHIAT, V175, P277, DOI 10.1192/bjp.175.3.277; Pages KP, 1997, J CLIN PSYCHIAT, V58, P510, DOI 10.4088/JCP.v58n1109; Perry BD, 1998, CHILD ADOL PSYCH CL, V7, P33, DOI 10.1016/S1056-4993(18)30258-X; RAO U, 1993, J AM ACAD CHILD PSY, V32, P21, DOI 10.1097/00004583-199301000-00004; Renaud J, 1999, J AM ACAD CHILD PSY, V38, P846, DOI 10.1097/00004583-199907000-00014; Rivara FP, 1997, JAMA-J AM MED ASSOC, V278, P569, DOI 10.1001/jama.278.7.569; ROCKETT IRH, 1989, AM J PUBLIC HEALTH, V79, P1396, DOI 10.2105/AJPH.79.10.1396; Rossow I, 2001, ADDICTION, V96, P227, DOI 10.1046/j.1360-0443.2001.9622275.x; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROY A, 1991, ARCH GEN PSYCHIAT, V48, P29; SCHOENBORN CA, 1995, NATL CTR HLTH STAT P; Sentell JW, 1997, MIL MED, V162, P168, DOI 10.1093/milmed/162.3.168; Statham DJ, 1998, PSYCHOL MED, V28, P839, DOI 10.1017/S0033291798006916; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; SUNDQVISTSTENSMAN UB, 1987, ACTA PSYCHIAT SCAND, V76, P15, DOI 10.1111/j.1600-0447.1987.tb02856.x; Turecki G, 1999, AM J PSYCHIAT, V156, P1456; *US DEP HHS, 1997, 9 US DEP HLTH HUM SE; *US DEP HLTH HUM S, 1991, HLTH PEOPL 2010; VANDERKOLK BA, 1991, AM J PSYCHIAT, V148, P1665; Wagner BM, 1997, PSYCHOL BULL, V121, P246, DOI 10.1037/0033-2909.121.2.246; WILLIAMS LM, 1995, J TRAUMA STRESS, V8, P649, DOI 10.1007/BF02102893; WYATT GE, 1985, CHILD ABUSE NEGLECT, V9, P507, DOI 10.1016/0145-2134(85)90060-2; Yoder KA, 1999, SUICIDE LIFE-THREAT, V29, P25; ZUNG WWK, 1993, J FAM PRACTICE, V37, P337	71	1379	1412	17	284	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3089	3096		10.1001/jama.286.24.3089	http://dx.doi.org/10.1001/jama.286.24.3089			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505QM	11754674				2022-12-28	WOS:000172927100026
J	Eskandar, EN; Cosgrove, GR; Shinobu, L				Eskandar, EN; Cosgrove, GR; Shinobu, L			Surgical treatment of Parkinson disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEEP BRAIN-STIMULATION; HIGH-FREQUENCY STIMULATION; TERM FOLLOW-UP; SUBTHALAMIC NUCLEUS; POSTEROVENTRAL PALLIDOTOMY; GLOBUS-PALLIDUS; STEREOTAXIC PALLIDOTOMY; UNILATERAL PALLIDOTOMY; ELECTRICAL-STIMULATION; THALAMIC-STIMULATION		Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Cosgrove, GR (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St,ACC 331, Boston, MA 02114 USA.	cosgrove@helix.mgh.harvard.edu						ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Alkhani A, 2001, J NEUROSURG, V94, P43, DOI 10.3171/jns.2001.94.1.0043; Alterman RL, 1998, NEUROSURG CLIN N AM, V9, P337; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Bejjani BP, 2000, J NEUROL NEUROSUR PS, V68, P595, DOI 10.1136/jnnp.68.5.595; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; Burchiel KJ, 1999, NEUROSURGERY, V45, P1375, DOI 10.1097/00006123-199912000-00024; Counihan TJ, 2001, NEUROLOGY, V56, P799, DOI 10.1212/WNL.56.6.799; Dalvi A, 1999, MOVEMENT DISORD, V14, P256, DOI 10.1002/1531-8257(199903)14:2<256::AID-MDS1010>3.0.CO;2-8; Dogali M, 1996, ADV NEUROL, V69, P585; Dostrovsky JO, 2000, J NEUROPHYSIOL, V84, P570, DOI 10.1152/jn.2000.84.1.570; Eskandar EN, 2000, J NEUROSURG, V92, P375, DOI 10.3171/jns.2000.92.3.0375; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gross C, 1997, J NEUROSURG, V87, P491, DOI 10.3171/jns.1997.87.4.0491; Guridi J, 2001, BRAIN, V124, P5, DOI 10.1093/brain/124.1.5; Haberler C, 2000, ANN NEUROL, V48, P372, DOI 10.1002/1531-8249(200009)48:3<372::AID-ANA12>3.0.CO;2-0; Hassler R, 1954, NERVENARZT, V25, P441; Houeto JL, 2000, ARCH NEUROL-CHICAGO, V57, P461, DOI 10.1001/archneur.57.4.461; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; JANKOVIC J, 1989, NEUROLOGY, V39, P1227, DOI 10.1212/WNL.39.9.1227; Johansson F, 1997, J NEUROL NEUROSUR PS, V62, P125, DOI 10.1136/jnnp.62.2.125; KELLY PJ, 1980, J NEUROSURG, V53, P332, DOI 10.3171/jns.1980.53.3.0332; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Kondziolka D, 1999, J NEUROSURG, V90, P197, DOI 10.3171/jns.1999.90.2.0197; Kopyov O, 1997, J NEUROSURG, V87, P52, DOI 10.3171/jns.1997.87.1.0052; Kumar R, 2000, NEUROLOGY, V55, pS34; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Lai EC, 2000, NEUROLOGY, V55, P1218, DOI 10.1212/WNL.55.8.1218; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang AE, 2000, ARCH NEUROL-CHICAGO, V57, P1118, DOI 10.1001/archneur.57.8.1118; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; Moro E, 1999, NEUROLOGY, V53, P85, DOI 10.1212/WNL.53.1.85; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Ondo WG, 1998, NEUROLOGY, V50, P266, DOI 10.1212/WNL.50.1.266; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Rodriguez Lopez J, 2000, REV DIALECT TRAD POP, V55, P45, DOI 10.3989/rdtp.2000.v55.i1.427; Rodriguez MC, 1998, ANN NEUROL, V44, pS175, DOI 10.1002/ana.410440726; Samii A, 1999, BRAIN, V122, P417, DOI 10.1093/brain/122.3.417; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Schumacher JM, 2000, NEUROLOGY, V54, P1042, DOI 10.1212/WNL.54.5.1042; Schuurman PR, 1997, ADV STER F, V12, P14; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434; Starr PA, 1999, NEUROSURGERY, V44, P303, DOI 10.1097/00006123-199902000-00031; Starr PA, 1998, NEUROSURG CLIN N AM, V9, P381; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; TOMLINSON FH, 1991, J NEUROSURG, V74, P579, DOI 10.3171/jns.1991.74.4.0579; Trepanier LL, 2000, BRAIN COGNITION, V42, P324, DOI 10.1006/brcg.1999.1108; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Vitek JL, 1997, ADV NEUROL, V74, P183; Volkmann J, 2001, NEUROLOGY, V56, P548, DOI 10.1212/WNL.56.4.548	61	13	13	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3056	3059		10.1001/jama.286.24.3056	http://dx.doi.org/10.1001/jama.286.24.3056			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754653				2022-12-28	WOS:000172927100002
J	Kramer, A; Yang, FC; Snodgrass, P; Li, XD; Scammell, TE; Davis, FC; Weitz, CJ				Kramer, A; Yang, FC; Snodgrass, P; Li, XD; Scammell, TE; Davis, FC; Weitz, CJ			Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling	SCIENCE			English	Article							GROWTH-FACTOR-ALPHA; SUPRACHIASMATIC NUCLEUS; CIRCADIAN PACEMAKERS; FUNCTIONAL-ANALYSIS; NOCTURNAL RODENTS; PROJECTIONS; EXPRESSION; MASKING; TEMPERATURE; HAMSTERS	The circadian clock in the suprachiasmatic nucleus (SCN) is thought to drive daily rhythms of behavior by secreting factors that act locally within the hypothalamus. in a systematic screen, we identified transforming growth factor-alpha (TGF-alpha) as a likely SCN inhibitor of locomotion. TGF-alpha is expressed rhythmically in the SCN, and when infused into the third ventricle it reversibly inhibited locomotor activity and disrupted circadian sleep-wake cycles. These actions are mediated by epidermal growth factor (EGF) receptors on neurons in the hypothalamic subparaventricular zone. Mice with a hypomorphic EGF receptor mutation exhibited excessive daytime locomotor activity and failed to suppress activity when exposed to light. These results implicate EGF receptor signaling in the daily control of locomotor activity, and identify a neural circuit in the hypothalamus that likely mediates the regulation of behavior both by the SCN and the retina.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Northeastern University; Harvard University; Beth Israel Deaconess Medical Center	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	cweitz@hms.harvard.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Kramer, Achim/0000-0001-9671-6078	NICHD NIH HHS [HD-18686] Funding Source: Medline; NIMH NIH HHS [MH62589] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD018686, R01HD018686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062589] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERS HE, 1991, J NEUROSCI, V11, P846; DAVIS FC, 1980, AM J PHYSIOL, V239, pR149, DOI 10.1152/ajpregu.1980.239.1.R149; Decoursey PJ, 1998, PHYSIOL BEHAV, V65, P457, DOI 10.1016/S0031-9384(98)00187-5; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Estabrooke IV, 2001, J NEUROSCI, V21, P1656, DOI 10.1523/JNEUROSCI.21-05-01656.2001; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KITA H, 1982, BRAIN RES BULL, V8, P249, DOI 10.1016/0361-9230(82)90055-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; KRAMER A, UNPUB; LEE DC, 1995, PHARMACOL REV, V47, P51; LeSauter J, 1998, CHRONOBIOL INT, V15, P535, DOI 10.3109/07420529808998706; Lu J, 2001, J NEUROSCI, V21, P4864, DOI 10.1523/JNEUROSCI.21-13-04864.2001; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MA YJ, 1992, NEURON, V9, P657; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Mrosovsky N, 1999, J COMP PHYSIOL A, V184, P423, DOI 10.1007/s003590050341; Mrosovsky N, 1999, CHRONOBIOL INT, V16, P415, DOI 10.3109/07420529908998717; Naylor E, 1998, SLEEP, V21, P687, DOI 10.1093/sleep/21.7.687; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; PATEL B, 1994, BRIT J OPHTHALMOL, V78, P714, DOI 10.1136/bjo.78.9.714; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P223, DOI 10.1007/BF01417856; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; Puopolo M, 2001, NEURON, V30, P211, DOI 10.1016/S0896-6273(01)00274-4; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Redlin U, 1999, J COMP PHYSIOL A, V184, P439, DOI 10.1007/s003590050343; ROKAL RR, 1995, BIOMETRY; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VANDENPOL AN, 1985, NEUROSCIENCE, V15, P1049, DOI 10.1016/0306-4522(85)90254-4; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOGELBAUM MA, 1992, J NEUROSCI, V12, P3619; WATTS AG, 1987, J COMP NEUROL, V258, P230, DOI 10.1002/cne.902580205; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440	40	388	399	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2511	2515		10.1126/science.1067716	http://dx.doi.org/10.1126/science.1067716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752569				2022-12-28	WOS:000172927700047
J	Narla, G; Heath, KE; Reeves, HL; Li, D; Giono, LE; Kimmelman, AC; Glucksman, MJ; Narla, J; Eng, FJ; Chan, AM; Ferrari, AC; Martignetti, JA; Friedman, SL				Narla, G; Heath, KE; Reeves, HL; Li, D; Giono, LE; Kimmelman, AC; Glucksman, MJ; Narla, J; Eng, FJ; Chan, AM; Ferrari, AC; Martignetti, JA; Friedman, SL			KLF6, a candidate tumor suppressor gene mutated in prostate cancer	SCIENCE			English	Article							ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; ALLELIC LOSS; DNA; PROMOTER	Kruppel-like factor 6 (KLF6) is a zinc finger transcription factor of unknown function. Here, we show that the KLF6 gene is mutated in a subset of human prostate cancer. Loss-of-heterozygosity analysis revealed that one KLF6 allele is deleted in 77% (17 of 22) of primary prostate tumors. Sequence analysis of the retained KLF6 allele revealed mutations in 71% of these tumors. Functional studies confirm that whereas wild-type KLF6 up-regulates p21 (WAF1/CIP1) in a p53-independent manner and significantly reduces cell proliferation, tumor-derived KLF6 mutants do not. Our data suggest that KLF6 is a tumor suppressor gene involved in human prostate cancer.	CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Med Oncol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Reg Med Ctr, San Jose, CA 95116 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, 1425 Madison Ave,Room 1170F,Box 1123, New York, NY 10029 USA.		Chan, Andrew Man-Lok/J-9497-2013; Heath, K. E./ABG-4658-2020; Narla, Goutham/AAZ-5710-2020; Heath, Karen Elise/K-7760-2014; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Heath, K. E./0000-0002-5816-7044; Narla, Goutham/0000-0003-4098-4203; Heath, Karen Elise/0000-0002-5816-7044; Chan, Andrew/0000-0001-9923-5464; Reeves, Helen/0000-0003-0359-9795; Giono, Luciana/0000-0001-6958-6044	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA079918, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [CA78207, CA79918] Funding Source: Medline; NICHD NIH HHS [5 P30 HD28822] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Gumerlock PH, 1997, J NATL CANCER I, V89, P66, DOI 10.1093/jnci/89.1.66; Ittmann M, 1996, CANCER RES, V56, P2143; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Latil A, 1998, VIRCHOWS ARCH, V432, P389, DOI 10.1007/s004280050183; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suzuki T, 1998, J BIOCHEM, V124, P389, DOI 10.1093/oxfordjournals.jbchem.a022124; Trybus TM, 1996, CANCER RES, V56, P2263	15	362	394	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2563	2566		10.1126/science.1066326	http://dx.doi.org/10.1126/science.1066326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752579				2022-12-28	WOS:000172927700063
J	Kaplan, NM				Kaplan, NM			Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CALCIUM-CHANNEL BLOCKER; BLOOD-PRESSURE; ACE-INHIBITORS; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR MORBIDITY; ANTIHYPERTENSIVE DRUGS; THERAPEUTIC BENEFITS; RANDOMIZED-TRIAL; RISK-FACTORS; MORTALITY	Hypertension and diabetes are becoming increasingly common. Most patients with both disorders have a markedly worsened risk for premature microvascular and macrovascular complications. The appropriate management of the hypertension seen in almost 70% of patients with type 2 diabetes mellitus remains controversial. However, over the past few years, many randomized, controlled trials have provided guidance for more effective therapy. These trials have established the need for a lower goal blood pressure (< 130/80 mm Hg) than has previously been recommended. in addition, they have proven the efficacy of drugs from three major classes of antihypertensive agents; however, comparative trials have failed to show definite superiority of any particular class in either lowering blood pressure or reducing cardiovascular morbidity and mortality. To achieve therapy goals, multiple anti hypertensive drugs are usually needed. On the basis of their apparent superiority in slowing diabetic nephropathy, angiotensin-converting enzyme inhibitors should probably be the first choice. Second and third choices should be a long-acting diuretic and a calcium-channel blocker or a beta -blocker, respectively. Attention should also be directed toward nonpharmacologic and pharmacologic control of hyperglycemia and dyslipidemia.	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kaplan, NM (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Chalmers J, 1999, J HYPERTENS, V17, P151; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Deedwania PC, 2000, ARCH INTERN MED, V160, P1585, DOI 10.1001/archinte.160.11.1585; Estacio RO, 2000, DIABETES CARE, V23, pB54; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Furberg CD, 1999, AM HEART J, V138, pS400; Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1; Gerstein HC, 2000, LANCET, V355, P253; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kizer JR, 2001, ARCH INTERN MED, V161, P1145, DOI 10.1001/archinte.161.9.1145; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Neal B, 2000, LANCET, V356, P1955; Pahor M, 2000, DIABETES CARE, V23, P888, DOI 10.2337/diacare.23.7.888; Parving HH, 2001, DIABETES CARE, V24, P177, DOI 10.2337/diacare.24.1.177-a; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Psaty BM, 2000, ARCH INTERN MED, V160, P2577, DOI 10.1001/archinte.160.17.2577; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902	35	51	54	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1079	1083		10.7326/0003-4819-135-12-200112180-00012	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747387				2022-12-28	WOS:000172759700008
J	Wald, HL; Aronson, MD				Wald, HL; Aronson, MD			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							RESISTANT ENTEROCOCCUS-FAECIUM; INFECTIONS; HEART; QUINUPRISTIN/DALFOPRISTIN; CATHETERIZATION; THERAPY; LUNG		Univ Penn, Philadelphia, PA 19104 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center	Wald, HL (corresponding author), Hosp Univ Penn, 3400 Spruce St,3 Silverstein, Philadelphia, PA 19104 USA.	heidi.wald@uphs.upenn.edu						Bernard GR, 2000, JAMA-J AM MED ASSOC, V283, P2568, DOI 10.1001/jama.283.19.2568; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Drew RH, 2000, J ANTIMICROB CHEMOTH, V46, P775, DOI 10.1093/jac/46.5.775; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Jones Ronald N., 1996, American Journal of Medicine, V100, p3S, DOI 10.1016/S0002-9343(96)00102-7; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P251, DOI 10.1093/jac/44.2.251; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; Winston DJ, 2000, CLIN INFECT DIS, V30, P790, DOI 10.1086/313766	11	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1052	1060		10.7326/0003-4819-135-12-200112180-00009	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747384				2022-12-28	WOS:000172759700005
J	Bansal, A				Bansal, A			Trends in reporting of SNP associations	LANCET			English	Editorial Material							CALPAIN-10		Gemini Genom UK Ltd, Dept Stat, Cambridge CB4 0GH, England		Bansal, A (corresponding author), Gemini Genom UK Ltd, Dept Stat, Cambridge CB4 0GH, England.	Aruna.Bansal@gemini-genomics.com						Greenberg DA, 1998, AM J HUM GENET, V62, P202, DOI 10.1086/301690; HOLM S, 1979, SCAND J STAT, V6, P65; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RYAN TA, 1960, PSYCHOL BULL, V57, P318, DOI 10.1037/h0044320; Tsai HJ, 2001, AM J HUM GENET, V69, P1236, DOI 10.1086/324646; Uhl GR, 2001, AM J HUM GENET, V69, P1290, DOI 10.1086/324467	8	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2016	2016		10.1016/S0140-6736(01)07139-2	http://dx.doi.org/10.1016/S0140-6736(01)07139-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755606				2022-12-28	WOS:000172722800008
J	Bowles, MJ; Benjamin, IS				Bowles, MJ; Benjamin, IS			ABC of the upper gastrointestinal tract - Cancer of the stomach and pancreas	BRITISH MEDICAL JOURNAL			English	Review									Kings Coll London Hosp, London, England; Kings Coll London, Guys Kings & St Thomass Sch Med, Acad Dept Surg, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Bowles, MJ (corresponding author), Kings Coll London Hosp, London, England.							Calam J, 2001, BRIT MED J, V323, P980, DOI 10.1136/bmj.323.7319.980	1	27	28	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1413	1416		10.1136/bmj.323.7326.1413	http://dx.doi.org/10.1136/bmj.323.7326.1413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744568	Green Published			2022-12-28	WOS:000172900400021
J	Walldius, G; Jungner, I; Holme, I; Aastveit, AH; Kolar, W; Steiner, E				Walldius, G; Jungner, I; Holme, I; Aastveit, AH; Kolar, W; Steiner, E			High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study	LANCET			English	Article							CHEMISTRY STANDARDIZATION PROJECT; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; INTERNATIONAL-FEDERATION; PLASMA APOLIPOPROTEINS; REFERENCE INTERVALS; SWEDISH MALES; RISK; CHOLESTEROL; VALUES	Background Apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I) are thought to be better predictors of acute myocardial infarction than total cholesterol and LDL-cholesterol. We investigated whether apoB and apoA-I are predictors of risk of fatal myocardial infarction. We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol. Methods We recruited 175 553 individuals mainly from screening programmes. We measured concentrations of apoB, apoA-I, total cholesterol, and triglycerides, and calculated apoB/apoA-I ratio and concentrations of LDL-cholesterol and HDL-cholesterol. The relation between death from acute myocardial infarction and initial values for apoB, apoA-I, and the other lipids was examined. Findings Mean follow-up was 66.8 months (SD 41.3) for 98 722 men and 64.4 months (41.4) for 76 831 women. 864 men and 359 women had fatal myocardial infarction. In univariate analyses adjusted for age and in multivariate analyses adjusted for age, total cholesterol, and triglycerides, the values for apoB and apoB/apoA-I ratio were strongly and positively related to increased risk of fatal myocardial infarction in men and in women. ApoA-I was noted to be protective. In multivariate analysis, apoB was a stronger predictor of risk than LDL-cholesterol in both sexes. Interpretation Although LDL-cholesterol and HDL-cholesterol are known risk factors, we suggest that apoB, apoB/apoA-I, and apoA-I should also be regarded as highly predictive in evaluation of cardiac risk. Although increased throughout the range of values of LDL-cholesterol, apoB and apoA-I might be of greatest value in diagnosis and treatment in men and women who have common lipid abnormalities, but have normal or low concentrations of LDL-cho le sterol.	AstraZeneca, S-43183 Molndal, Sweden; Karolinska Inst, King Gustaf V Res Inst, Stockholm, Sweden; St Gorans Univ Hosp, CALAB Res, Stockholm, Sweden; Ulleval Hosp, Ctr Prevent Med, Oslo, Norway; Agr Univ Norway, Dept Math Sci, As, Norway	AstraZeneca; Karolinska Institutet; Saint Goran's Hospital; University of Oslo; Norwegian University of Life Sciences	Walldius, G (corresponding author), AstraZeneca, S-43183 Molndal, Sweden.	goran.walldius@astrazeneca.com						Bachorik PS, 1997, CLIN CHEM, V43, P2364; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Connelly PW, 1999, CAN J CARDIOL, V15, P409; Contois JH, 1996, CLIN CHEM, V42, P515; Contois JH, 1996, CLIN CHEM, V42, P507; Crouse JR, 2000, ARTERIOSCL THROM VAS, V20, P2333, DOI 10.1161/01.ATV.20.11.2333; Francis MC, 2001, ATHEROSCLEROSIS, V155, P165, DOI 10.1016/S0021-9150(00)00528-1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARFAGNINI A, 1995, EUR HEART J, V16, P465, DOI 10.1093/oxfordjournals.eurheartj.a060937; GOTTO A, 2000, ILIB LIPID HDB CLIN; Gotto AM, 2000, CIRCULATION, V101, P477, DOI 10.1161/01.CIR.101.5.477; Graziani MS, 1998, CLIN CHEM, V44, P134; JUNGNER I, 1992, INT J CLIN LAB RES, V21, P247, DOI 10.1007/BF02591655; Jungner I, 1998, CLIN CHEM, V44, P1641; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; LEINO A, 1995, CLIN CHEM, V41, P1633; MARCOVINA SM, 1993, CLIN CHEM, V39, P773; MARCOVINA SM, 1994, CLIN CHEM, V40, P586; Moss AJ, 1999, CIRCULATION, V99, P2517, DOI 10.1161/01.CIR.99.19.2517; Mykkanen L, 1999, ARTERIOSCL THROM VAS, V19, P2742, DOI 10.1161/01.ATV.19.11.2742; OBRIEN T, 1995, ARTERIOSCL THROM VAS, V15, P228, DOI 10.1161/01.ATV.15.2.228; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; Sacks FM, 2000, CIRCULATION, V102, P1886, DOI 10.1161/01.CIR.102.16.1886; SCHAEFER EJ, 1994, J LIPID RES, V35, P779; Sniderman AD, 1996, CLIN CHEM, V42, P489; Sniderman AD, 2001, CAN MED ASSOC J, V164, P44; Sniderman AD, 1997, CLIN CHEM, V43, P1310; van Lennep JER, 2000, ARTERIOSCL THROM VAS, V20, P2408, DOI 10.1161/01.ATV.20.11.2408; WALLDIUS G, 1992, BLOOD PRESS S4, V1, P35; Warnick GR, 2000, CLIN CHEM LAB MED, V38, P287, DOI 10.1515/CCLM.2000.041; Westedt ML, 1998, RHEUMATOL INT, V18, P1, DOI 10.1007/s002960050045; Wood D, 1998, EUR HEART J, V19, P1434	35	924	975	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2026	2033		10.1016/S0140-6736(01)07098-2	http://dx.doi.org/10.1016/S0140-6736(01)07098-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755609				2022-12-28	WOS:000172722800011
J	Blewitt, G; Lavallee, D; Clarke, P; Nurutdinov, K				Blewitt, G; Lavallee, D; Clarke, P; Nurutdinov, K			A new global mode of Earth deformation: Seasonal cycle detected	SCIENCE			English	Article							GRAVITATIONAL-FIELD; ROTATION; PRESSURE	We have detected a global mode of Earth deformation that is predicted by theory. Precise positioning of Global Positioning System sites distributed worldwide reveals that during February to March, the Northern Hemisphere compresses (and the Southern Hemisphere expands), such that sites near the North Pole move downward by 3.0 millimeters, and sites near the equator are putted northward by 1.5 millimeters. The opposite pattern of deformation occurs during August to September. We identify this pattern as the degree-one spherical, harmonic response of an elastic Earth to increased winter loading of soil moisture, snow cover, and atmosphere. Data inversion shows the load moment's trajectory as a great circle traversing the continents, peaking at 6.9 x 10(22) kilogram meters near the North Pole in winter, indicating interhemispheric mass exchange of 1.0 x 10(16) +/- 0.2 x 10(16) kilograms.	Nevada Bur Mines & Geol, Reno, NV 89557 USA; Univ Nevada, Seismol Lab, Reno, NV 89557 USA; Univ Newcastle Upon Tyne, Dept Geomat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Nevada System of Higher Education (NSHE); University of Nevada Reno; Newcastle University - UK	Blewitt, G (corresponding author), Nevada Bur Mines & Geol, Reno, NV 89557 USA.	gblewitt@unr.edu	Clarke, Peter John/B-1783-2008	Clarke, Peter John/0000-0003-1276-8300				BLEWITT G, IN PRESS J GEOPHYS R; CHANG ATC, 1990, INT J REMOTE SENS, V11, P167, DOI 10.1080/01431169008955009; CHAO BF, 1987, J GEOPHYS RES-SOLID, V92, P9415, DOI 10.1029/JB092iB09p09415; Chen JL, 1999, J GEOPHYS RES-SOL EA, V104, P2683, DOI 10.1029/1998JB900019; Cohen J, 2001, GEOPHYS RES LETT, V28, P299, DOI 10.1029/2000GL011927; Davies P, 2000, J GEOPHYS RES-SOL EA, V105, P11083, DOI 10.1029/2000JB900004; FARRELL WE, 1972, REV GEOPHYS SPACE GE, V10, P761, DOI 10.1029/RG010i003p00761; FEKETE BM, 1999, 22 WMO GLOB RUN DAT; Grafarend EW, 1997, J GEODESY, V72, P11, DOI 10.1007/s001900050144; Greff-Lefftz M, 1997, GEOPHYS J INT, V131, P699, DOI 10.1111/j.1365-246X.1997.tb06607.x; Guan ZY, 2001, GEOPHYS RES LETT, V28, P263, DOI 10.1029/2000GL011563; TRENBERTH KE, 1981, J GEOPHYS RES-OCEANS, V86, P5238, DOI 10.1029/JC086iC06p05238; TRUPIN AS, 1992, GEOPHYS J INT, V108, P1, DOI 10.1111/j.1365-246X.1992.tb00835.x; van Dam T, 2001, GEOPHYS RES LETT, V28, P651, DOI 10.1029/2000GL012120; van Dam T., 1998, PHYS CHEM EARTH, V23, P1077, DOI DOI 10.1016/S0079-1946(98)00147-5; VANDAM TM, 1994, J GEOPHYS RES-SOL EA, V99, P23939, DOI 10.1029/94JB02122	16	250	258	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2342	2345		10.1126/science.1065328	http://dx.doi.org/10.1126/science.1065328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743198	Green Submitted			2022-12-28	WOS:000172817200043
J	Colman-Lerner, A; Chin, TE; Brent, R				Colman-Lerner, A; Chin, TE; Brent, R			Yeast Cbk1 and Mob2 activate daughter-specific genetic programs to induce asymmetric cell fates	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; HO GENE; TRANSCRIPTION FACTOR; CYCLE CONTROL; EXPRESSION; SWI5; IDENTIFICATION; REGULATORS; INHIBITOR	In Saccharomyces cerevisiae, mothers and daughters have distinct fates. We show that Cbk1 kinase and its interacting protein Mob2 regulate this asymmetry by inducing daughter-specific genetic programs. Daughter-specific expression is due to Cbk1/Mob2-dependent activation and localization of the Ace2 transcription factor to the daughter nucleus. Ectopic localization of active Ace2 to mother nuclei is sufficient to activate daughter-specific genes in mothers. Eight genes are daughter-specific under the tested conditions, while two are daughter-specific only in saturated cultures. Some daughter-specific gene products contribute to cell separation by degrading the cell wall. These experiments define programs of gene expression specific to daughters and describe how those programs are controlled.	Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Colman-Lerner, A (corresponding author), Inst Mol Sci, 2168 Shattuck Ave, Berkeley, CA 94704 USA.	colman-lerner@molsci.org	Colman-Lerner, Alejandro/ABC-3808-2020	Colman-Lerner, Alejandro/0000-0002-2557-8883				Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Doolin MT, 2001, MOL MICROBIOL, V40, P422, DOI 10.1046/j.1365-2958.2001.02388.x; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Futcher Bruce, 1999, Methods in Cell Science, V21, P79, DOI 10.1023/A:1009872403440; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Guthrie C., 1991, METHODS ENZYMOLOGY G; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jacobs C, 1998, CURR OPIN GENET DEV, V8, P386, DOI 10.1016/S0959-437X(98)80107-X; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kovacech B, 1996, MOL CELL BIOL, V16, P3264; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; O'Conallain C, 1999, MOL GEN GENET, V262, P275, DOI 10.1007/s004380051084; OSHIMA Y, 1971, GENETICS, V67, P327; Ouspenski II, 1999, NUCLEIC ACIDS RES, V27, P3001, DOI 10.1093/nar/27.15.3001; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; SIKORSKI RS, 1989, GENETICS, V122, P19; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; Toyn JH, 1997, GENETICS, V145, P85; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	50	261	268	2	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					739	750		10.1016/S0092-8674(01)00596-7	http://dx.doi.org/10.1016/S0092-8674(01)00596-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747810	Bronze			2022-12-28	WOS:000172771800007
J	Stemmann, O; Zou, H; Gerber, SA; Gygi, SP; Kirschner, MW				Stemmann, O; Zou, H; Gerber, SA; Gygi, SP; Kirschner, MW			Dual inhibition of sister chromatid separation at metaphase	CELL			English	Article							SPINDLE ASSEMBLY CHECKPOINT; XENOPUS EGG EXTRACTS; CELL-CYCLE EXTRACTS; MAP KINASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME ALIGNMENT; ANAPHASE TRANSITION; CENP-E; YEAST; DESTRUCTION	Separation of sister chromatids in anaphase is mediated by separase, an endopeptidase that cleaves the chromosomal cohesin SCC1. Separase is inhibited by securin, which is degraded at the metaphase-anaphase transition. Using Xenopus egg extracts, we demonstrate that high CDC2 activity inhibits anaphase but not securin degradation. We show that separase is kept inactive under these conditions by a mechanism independent of binding to securin. Mutation of a single phosphorylation site on separase relieves the inhibition and rescues chromatid separation in extracts with high CDC2 activity. Using quantitative mass spectrometry, we show that, in intact cells, there is complete phosphorylation of this site in metaphase and significant dephosphorylation in anaphase. We propose that separase activation at the metaphase-anaphase transition requires the removal of both securin and an inhibitory phosphate.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Stemmann, Olaf/0000-0003-3044-2515; Gerber, Scott/0000-0002-2964-5051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039023, R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00041] Funding Source: Medline; NIGMS NIH HHS [GM26875-17, GM39023-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; ENG J, 1994, J AM SOC MASS SPECTR, V5, P1579; Fang CH, 1998, INT J MOL MED, V1, P163; Foley E, 2001, CURR BIOL, V11, P151, DOI 10.1016/S0960-9822(01)00050-1; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KUMAGAI A, 1991, COLD SPRING HARB SYM, V56, P585; Leismann O, 2000, GENE DEV, V14, P2192, DOI 10.1101/gad.176700; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; Meyn MA, 2000, CURR BIOL, V10, P1599, DOI 10.1016/S0960-9822(00)00863-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	46	372	394	0	13	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 14	2001	107	6					715	726		10.1016/S0092-8674(01)00603-1	http://dx.doi.org/10.1016/S0092-8674(01)00603-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747808	Bronze			2022-12-28	WOS:000172771800005
J	Velikov, V; Borick, S; Angell, CA				Velikov, V; Borick, S; Angell, CA			The glass transition of water, based on hyperquenching experiments	SCIENCE			English	Article							AMORPHOUS SOLID WATER; LIQUID TRANSITION; POLY(2-HYDROXYETHYL METHACRYLATE); AQUEOUS-SOLUTIONS; ICE; RELAXATION; PRESSURE; FIBERS; VITRIFICATION; HEMOGLOBIN	The glass transition temperature (T-g) in water is still uncertain, with conflicting values reported in the literature. As with other hyperquenched glasses, water exhibits a large relaxation exotherm on reheating at the normal rate of 10 kelvin (K) per minute. This release of heat indicates the transformation of a high enthalpy state to a tower one found in slow-cooled glasses. When the exotherm temperature is scaled by T-g, the good glass-formers show a common pattern. However, for hyperquenched water, when this analysis is performed using the commonly accepted T-g = 136 K, its behavior appears completely different, but this should not be the case because enthalpy relaxation is fundamental to the calorimetric glass transition. With T-g = 165 5 K, normal behavior is restored in comparison with other hyperquenched glasses and with the binary solution behavior of network-former systems (H2O, ZnCl2, or BeF2 plus a second component). This revised value has relevance to the understanding of water-biomolecule interactions.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Angell, CA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.							ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ANGELL CA, 1980, J PHYS CHEM-US, V84, P268, DOI 10.1021/j100440a009; BOHMER R, 1993, J CHEM PHYS, V99, P4201, DOI 10.1063/1.466117; Burton E. F., 1935, P ROY SOC LOND A MAT, V153, P166, DOI 10.1098/rspa.1935.0229; Burton EF, 1935, NATURE, V135, P505, DOI 10.1038/135505b0; CHEN HS, 1976, APPL PHYS LETT, V28, P245, DOI 10.1063/1.88725; DEBOLT MA, 1976, J AM CERAM SOC, V59, P16, DOI 10.1111/j.1151-2916.1976.tb09377.x; Dobrokhotova ZV, 2000, INORG MATER+, V36, P191, DOI 10.1007/BF02758027; DOSHI J, 1995, J ELECTROSTAT, V35, P151, DOI 10.1016/0304-3886(95)00041-8; FISHER M, 1995, J PHYS CHEM-US, V99, P11584, DOI 10.1021/j100029a041; GHORMLEY JA, 1968, J CHEM PHYS, V48, P503, DOI 10.1063/1.1667954; GHORMLEY JA, 1957, J AM CHEM SOC, V79, P1862, DOI 10.1021/ja01565a025; GREEN JL, 1994, J PHYS CHEM-US, V98, P13780, DOI 10.1021/j100102a052; HALLBRUCKER A, 1989, J PHYS CHEM-US, V93, P4986, DOI 10.1021/j100349a061; HALLBRUCKER A, 1989, J PHYS CHEM-US, V93, P7751, DOI 10.1021/j100360a003; HALLBRUCKER A, 1987, J PHYS CHEM-US, V91, P503, DOI 10.1021/j100287a002; HANDA YP, 1988, J PHYS CHEM-US, V92, P3323, DOI 10.1021/j100323a005; HODGE IM, 1994, J NON-CRYST SOLIDS, V169, P211, DOI 10.1016/0022-3093(94)90321-2; HOFER K, 1991, J PHYS CHEM-US, V95, P7100, DOI 10.1021/j100171a071; HOFER K, 1990, J PHYS CHEM-US, V94, P2689, DOI 10.1021/j100369a083; HUANG J, 1992, J NON-CRYST SOLIDS, V151, P175, DOI 10.1016/0022-3093(92)90026-G; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; Jenniskens P, 1997, J CHEM PHYS, V107, P1232, DOI 10.1063/1.474468; Johari GP, 1998, J PHYS CHEM B, V102, P4711, DOI 10.1021/jp980765h; Johari GP, 1996, SCIENCE, V273, P90, DOI 10.1126/science.273.5271.90; JOHARI GP, 1987, NATURE, V330, P552, DOI 10.1038/330552a0; Kivelson D, 2001, J PHYS CHEM B, V105, P6620, DOI 10.1021/jp010104b; LAUGHLIN WT, 1972, J PHYS CHEM-US, V76, P2317, DOI 10.1021/j100660a023; MACFARLANE DR, 1984, J PHYS CHEM-US, V88, P759, DOI 10.1021/j150648a029; MACMILLAN JA, 1965, J CHEM PHYS, V42, P829; MAYER E, 1985, J MICROSC-OXFORD, V140, P3, DOI 10.1111/j.1365-2818.1985.tb02656.x; MAYER E, 1985, J APPL PHYS, V58, P663, DOI 10.1063/1.336179; MAYER E, COMMUNICATION; Meingast C., 1993, Modern Physics Letters B, V7, P1703, DOI 10.1142/S0217984993001740; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; MOYNIHAN CT, 1976, J AM CERAM SOC, V59, P12, DOI 10.1111/j.1151-2916.1976.tb09376.x; MOYNIHAN CT, 1971, J PHYS CHEM-US, V75, P3379, DOI 10.1021/j100690a033; NARTEN AH, 1976, J CHEM PHYS, V64, P1106, DOI 10.1063/1.432298; NEMILOV SV, 1968, INORG MATER, V4, P1453; PRYDE JA, 1952, NATURE, V170, P635; Reneker DH, 1996, NANOTECHNOLOGY, V7, P216, DOI 10.1088/0957-4484/7/3/009; Sartor G, 1995, BIOPHYS J, V69, P2679, DOI 10.1016/S0006-3495(95)80139-6; SARTOR G, 1994, BIOPHYS J, V66, P249, DOI 10.1016/S0006-3495(94)80774-X; Sceats M.G., 1982, WATER COMPREHENSIVE, V7, P83; Scherer G. W., 1986, RELAXATION GLASS COM; Smith RS, 1999, NATURE, V398, P788, DOI 10.1038/19725; SPEEDY RJ, UNPUB; STARR FW, UNPUB; SUGISAKI M, 1968, B CHEM SOC JPN, V41, P2591, DOI 10.1246/bcsj.41.2591; Tsekouras AA, 1998, PHYS REV LETT, V80, P5798, DOI 10.1103/PhysRevLett.80.5798; TSEKOURAS AA, UNPUB; VELIKOV V, IN PRESS J PHYS CHEM; Yue Y. Z., UNPUB	55	305	309	4	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2335	2338		10.1126/science.1061757	http://dx.doi.org/10.1126/science.1061757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743196				2022-12-28	WOS:000172817200041
J	Grigorenko, A; Bending, S; Tamegai, T; Ooi, S; Henini, M				Grigorenko, A; Bending, S; Tamegai, T; Ooi, S; Henini, M			A one-dimensional chain state of vortex matter	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; LAYERED SUPERCONDUCTORS; LATTICE; IRREVERSIBILITY; BI2SR2CACU2O8; ANISOTROPY; SURFACE; ORDER; LINE	Magnetic flux penetrates isotropic type II superconductors in flux-quantized vortices, which arrange themselves into a lattice structure that is independent of the direction of the applied field(1). In extremely anisotropic high-transition-temperature (high-T-c) superconductors, a lattice of stacks of circular 'pancake' vortices forms when a magnetic field is applied perpendicular to the copper oxide layers, while an orthogonal elongated lattice of elliptical Josephson vortices forms when the applied field is parallel to the layers(2-5). Here we report that when a tilted magnetic field is applied to single crystals of Bi2Sr2CaCu2O8+delta, these lattices can interact to form a new state of vortex matter in which all stacks of pancake vortices intersect the Josephson vortices. The sublattice of Josephson vortices can therefore be used to manipulate the sublattice of pancake vortices. This result explains the suppression of irreversible magnetization by in-plane fields as seen in Bi2Sr2CaCu2O8+delta crystals, a hitherto mysterious observation(6). The ability to manipulate sublattices could be important for flux-logic devices, where a 'bit' might be represented by a pancake vortex stack, and the problem of vortex positioning is overcome through sublattice interactions. This also enables the development of flux transducers and amplifiers, considerably broadening the scope for applications of anisotropic high-T-c superconductors.	Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England; Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138627, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Univ Nottingham, Dept Phys, Nottingham NG7 2RD, England	University of Bath; University of Tokyo; Japan Science & Technology Agency (JST); University of Nottingham	Bending, S (corresponding author), Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England.		OOI, Shuuichi/H-2781-2011; Bending, Simon J/D-3719-2018; Tamegai, Tsuyoshi/C-6656-2011; Henini, Mohamed/O-3341-2019	Bending, Simon J/0000-0002-4474-2554; Henini, Mohamed/0000-0001-9414-8492				Avraham N, 2001, NATURE, V411, P451, DOI 10.1038/35078021; BOLLE CA, 1991, PHYS REV LETT, V66, P112, DOI 10.1103/PhysRevLett.66.112; BULAEVSKII LN, 1992, PHYS REV B, V46, P366, DOI 10.1103/PhysRevB.46.366; BURLACHKOV L, 1994, PHYS REV B, V50, P16770, DOI 10.1103/PhysRevB.50.16770; Clem JR, 1998, SUPERCOND SCI TECH, V11, P909, DOI 10.1088/0953-2048/11/10/002; Farrell DE, 1996, PHYS REV B, V53, P11807, DOI 10.1103/PhysRevB.53.11807; GRIER DG, 1991, PHYS REV LETT, V66, P2270, DOI 10.1103/PhysRevLett.66.2270; GRIGORIEVA IV, 1995, PHYS REV B, V51, P3765, DOI 10.1103/PhysRevB.51.3765; HUSE DA, 1992, PHYS REV B, V46, P8621, DOI 10.1103/PhysRevB.46.8621; KLEINER WH, 1964, PHYS REV A-GEN PHYS, V133, P1226; Koshelev AE, 1999, PHYS REV LETT, V83, P187, DOI 10.1103/PhysRevLett.83.187; MARTINEZ JC, 1992, PHYS REV LETT, V69, P2276, DOI 10.1103/PhysRevLett.69.2276; NELSON DR, 1988, PHYS REV LETT, V60, P1973, DOI 10.1103/PhysRevLett.60.1973; Oral A, 1996, APPL PHYS LETT, V69, P1324, DOI 10.1063/1.117582; Soibel A, 2000, NATURE, V406, P282, DOI 10.1038/35018532; ZELDOV E, 1995, NATURE, V375, P373, DOI 10.1038/375373a0	16	168	171	3	38	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					728	731		10.1038/414728a	http://dx.doi.org/10.1038/414728a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742393				2022-12-28	WOS:000172676200041
J	Hill, RW; Proust, C; Taillefer, L; Fournier, P; Greene, RL				Hill, RW; Proust, C; Taillefer, L; Fournier, P; Greene, RL			Breakdown of Fermi-liquid theory in a copper-oxide superconductor	NATURE			English	Article							QUASI-PARTICLE TRANSPORT; UPPER CRITICAL-FIELD; VALENCE-BOND STATE; THERMAL-CONDUCTIVITY; LOW-TEMPERATURE; METAL CROSSOVER; LOCALIZATION; WIEDEMANN; GROWTH	The behaviour of electrons in solids is well described by Landau's Fermi-liquid theory, which predicts that although electrons in a metal interact, they can still be treated as well defined fermions, which are called 'quasiparticles'. At low temperatures, the ability of quasiparticles to transport heat is given strictly by their ability to transport charge, as described by a universal relation known as the Wiedemann-Franz law, which hitherto no material has been known to violate. High-temperature superconductors have long been thought to fall outside the realm of Fermi-liquid theory, as suggested by several anomalous properties, but this has yet to be shown conclusively. Here we report an experimental test of the Wiedemann-Franz law in the normal state of a copper-oxide superconductor, (Pr,Ce)(2)CuO4, which reveals that the elementary excitations that carry heat in this material are not fermions. This is compelling evidence for the breakdown of Fermi-liquid theory in high-temperature superconductors.	Univ Toronto, Dept Phys, Canadian Inst Adv Res, Toronto, ON M5S 1A7, Canada; Univ Maryland, Dept Phys, Ctr Superconduct Res, College Pk, MD 20742 USA	Canadian Institute for Advanced Research (CIFAR); University of Toronto; University System of Maryland; University of Maryland College Park	Taillefer, L (corresponding author), Univ Toronto, Dept Phys, Canadian Inst Adv Res, 60 St George St, Toronto, ON M5S 1A7, Canada.	Louis.Taillefer@utoronto.ca		Fournier, Patrick/0000-0002-2620-6272				AMATO A, 1987, J MAGN MAGN MATER, V63-4, P300, DOI 10.1016/0304-8853(87)90591-9; ANDERSON AC, 1968, PHYS REV LETT, V20, P459, DOI 10.1103/PhysRevLett.20.459; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Ashcroft N. W., 1976, SOLID STATE PHYS, P322; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; BAYOT V, 1990, PHYS REV LETT, V65, P2579, DOI 10.1103/PhysRevLett.65.2579; Behnia K, 1999, J LOW TEMP PHYS, V117, P1089, DOI 10.1023/A:1022534625754; Belin S, 1997, PHYS REV LETT, V79, P2125, DOI 10.1103/PhysRevLett.79.2125; Belin S, 1999, J SUPERCOND, V12, P497, DOI 10.1023/A:1007771815553; BERMAN R, 1976, THERMAL CONDUCTION S, P145; BOAKNIN E, 2001, IN PRESS PHYS REV LE; Boebinger GS, 1996, PHYS REV LETT, V77, P5417, DOI 10.1103/PhysRevLett.77.5417; Brinkmann M, 1996, J CRYST GROWTH, V163, P369, DOI 10.1016/0022-0248(95)00991-4; CASTELLANI C, 1987, PHYS REV LETT, V59, P477, DOI 10.1103/PhysRevLett.59.477; CHESTER GV, 1961, P PHYS SOC LOND, V77, P1005, DOI 10.1088/0370-1328/77/5/309; Chiao M, 2000, PHYS REV B, V62, P3554, DOI 10.1103/PhysRevB.62.3554; Chiao M, 1999, PHYS REV LETT, V82, P2943, DOI 10.1103/PhysRevLett.82.2943; Durst AC, 2000, PHYS REV B, V62, P1270, DOI 10.1103/PhysRevB.62.1270; Fournier P, 2000, PHYS REV B, V62, P11993, DOI 10.1103/PhysRevB.62.R11993; Fournier P, 1998, PHYS REV LETT, V81, P4720, DOI 10.1103/PhysRevLett.81.4720; Franz R., 1853, ANN PHYS-NEW YORK, V165, P497, DOI 10.1002/andp.18531650802; GLOOS K, 1990, CRYOGENICS, V30, P14, DOI 10.1016/0011-2275(90)90107-N; Granath M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.167011; GUTSMIEDL P, 1991, CRYOGENICS, V31, P54, DOI 10.1016/0011-2275(91)90191-X; HARUS GI, 1999, SOV JETP, V116, P1; Hussey NE, 2000, PHYS REV LETT, V85, P4140, DOI 10.1103/PhysRevLett.85.4140; Kambe S, 1999, J LOW TEMP PHYS, V117, P101, DOI 10.1023/A:1021865906745; KEARNEY MJ, 1988, J PHYS C SOLID STATE, V21, pL265, DOI 10.1088/0022-3719/21/9/004; KIVELSON SA, 1987, PHYS REV B, V35, P8865, DOI 10.1103/PhysRevB.35.8865; Kleefisch S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.100507; Kokales JD, 2000, PHYS REV LETT, V85, P3696, DOI 10.1103/PhysRevLett.85.3696; LANDAU LD, 1957, ZH EKSP TEOR FIZ, V3, P920; MACKENZIE AP, 1993, PHYS REV LETT, V71, P1238, DOI 10.1103/PhysRevLett.71.1238; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Osofsky M. S., 1996, Proceedings of the 10th Anniversary HTS Workshop on Physics, Materials and Applications, P284; OTT HR, 1984, SOLID STATE COMMUN, V49, P1129, DOI 10.1016/0038-1098(84)91046-9; PENG JL, 1991, PHYSICA C, V177, P79, DOI 10.1016/0921-4534(91)90300-N; Prozorov R, 2000, PHYS REV LETT, V85, P3700, DOI 10.1103/PhysRevLett.85.3700; RUMBO ER, 1976, J PHYS F MET PHYS, V6, P85, DOI 10.1088/0305-4608/6/1/012; Senthil T, 1998, PHYS REV LETT, V81, P4704, DOI 10.1103/PhysRevLett.81.4704; Senthil T, 2000, PHYS REV B, V62, P7850, DOI 10.1103/PhysRevB.62.7850; Suderow H, 1997, J LOW TEMP PHYS, V108, P11, DOI 10.1007/BF02396814; SYME RT, 1989, J PHYS-CONDENS MAT, V1, P3375, DOI 10.1088/0953-8984/1/21/009; Taillefer L, 1997, PHYS REV LETT, V79, P483, DOI 10.1103/PhysRevLett.79.483; TAILLEFER L, 2000, PHYS CAN, V56, P237; Tanatar MR, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.064505; THACHER PD, 1967, PHYS REV, V156, P975, DOI 10.1103/PhysRev.156.975; Tsuei CC, 2000, PHYS REV LETT, V85, P182, DOI 10.1103/PhysRevLett.85.182; Vojta M, 2000, PHYS REV LETT, V85, P4940, DOI 10.1103/PhysRevLett.85.4940	50	147	152	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					711	715		10.1038/414711a	http://dx.doi.org/10.1038/414711a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742390	Green Submitted			2022-12-28	WOS:000172676200038
J	[Anonymous]				[Anonymous]			Europe must unite to preserve its heritage	NATURE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					673	673						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742349				2022-12-28	WOS:000172676200002
J	Patel, SC; Levine, SR; Tilley, BC; Grotta, JC; Lu, M; Frankel, M; Haley, EC; Brott, TG; Broderick, JP; Horowitz, S; Lyden, PD; Lewandowski, CA; Marler, JR; Welch, KMA				Patel, SC; Levine, SR; Tilley, BC; Grotta, JC; Lu, M; Frankel, M; Haley, EC; Brott, TG; Broderick, JP; Horowitz, S; Lyden, PD; Lewandowski, CA; Marler, JR; Welch, KMA		Natl Inst Neurological Disorders	Lack of clinical significance of early ischemic changes on computed tomography in acute stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CT FINDINGS; PLASMINOGEN-ACTIVATOR; CEREBRAL INFARCTION; RT-PA; ALTEPLASE; VARIABILITY; RELIABILITY; AGREEMENT	Context The prevalence and clinical significance of early ischemic changes (EICs) on baseline computed tomography (CT) scan of the head obtained within 3 hours of ischemic stroke are not established. Objective To determine the frequency and significance of EIC on baseline head CT scans in the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA (recombinant tissue plasminogen activator) Stroke Trial. Design and Setting The original study, a randomized controlled trial, took place from January 1991 through October 1994 at 43 sites, during which CT images were obtained within 3 hours of symptom onset and prior to the initiation of rt-PA or placebo. For the current analysis, detailed reevaluation was undertaken after October 1994 of all baseline head CT scans with clinical data available pretreatment (blinded to treatment arm). Patients Of 624 patients enrolled in the trial, baseline CT scans were retrieved and reviewed for 616 (99%). Main Outcome Measures Frequency of EICs on baseline CT scans; association of EIC With other baseline variables; effect of EICs on deterioration at 24 hours (greater than or equal to4 points increase from the baseline National Institutes of Health Stroke Scale [NIHSS] score); clinical outcome (measured by 4 clinical scales) at 3 months, CT lesion volume at 3 months, death at 90 days; and symptomatic intracranial hemorrhage (ICH) within 36 hours of treatment. Results The prevalence of EIC on baseline CT in the combined rt-PA and placebo groups was 31% (n = 194). The EIC was significantly associated with baseline NIHSS score (p=0.23; P<.001) and time from stroke onset to baseline CT scan (p=0.11; P=.007). After adjusting for baseline variables, there was no EIC X treatment interaction detected for any clinical outcome, including deterioration at 24 hours, 4 clinical scales, lesion volume, and death at 90 days (P<greater than or equal to>.25), implying that EIC is unlikely to affect response to rt-PA treatment. After adjusting for NIHSS score (an independent predictor of ICH), no EIC association with symptomatic ICH at 36 hours was detected in the group treated with rt-PA (P greater than or equal to .22). Conclusions Our analysis suggests that EICs are prevalent within 3 hours of stroke onset and correlate with stroke severity. However, EICs are not independently associated with increased risk of adverse outcome after rt-PA treatment. Patients treated with rt-PA did better whether or not they had EICs, suggesting that EICs on CT scan are not critical to the decision to treat otherwise eligible patients with rt-PA within 3 hours of stroke onset.	Henry Ford Hosp & Hlth Sci Ctr, Div Neuroradiol, Detroit, MI 48202 USA; Mt Sinai Sch Med, New York, NY USA; Med Univ S Carolina, Charleston, SC 29425 USA; Univ Texas, Med Ctr, Houston, TX USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Virginia Hlth Syst, Charlottesville, VA USA; Mayo Clin, Jacksonville, FL 32224 USA; Univ Cincinnati, Cincinnati, OH USA; Univ Missouri, Columbia, MO USA; Univ Calif San Diego, Stroke Ctr, San Diego, CA 92103 USA; NINCDS, NIH, Bethesda, MD 20892 USA; Univ Kansas, Sch Med, Kansas City, KS USA	Henry Ford Health System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina; University of Texas System; Emory University; University of Virginia; Mayo Clinic; University System of Ohio; University of Cincinnati; University of Missouri System; University of Missouri Columbia; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Kansas; University of Kansas Medical Center	Patel, SC (corresponding author), Henry Ford Hosp & Hlth Sci Ctr, Div Neuroradiol, 2799 W Grand Blvd,K-3, Detroit, MI 48202 USA.	spatel@rad.hfh.edu	Grotta, James/AAH-7423-2021					Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Bornstein N, 2000, STROKE, V31, P309; BOZZAO L, 1989, AM J NEURORADIOL, V10, P1215; BOZZAO L, 1991, AM J NEURORADIOL, V12, P1115; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Grotta JC, 1999, STROKE, V30, P1528, DOI 10.1161/01.STR.30.8.1528; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HOROWITZ SH, 1991, STROKE, V22, P1245, DOI 10.1161/01.STR.22.10.1245; HOSMER DW, 1989, APPL LOGISTIC REGRES; HSIEH FY, 1989, STAT MED, V8, P795, DOI 10.1002/sim.4780080704; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Levine SR, 2000, STROKE, V31, P2912; Luire DN, 2000, STROKE, V31, P276; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks MP, 1999, STROKE, V30, P389, DOI 10.1161/01.STR.30.2.389; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; MOHR JP, 1995, STROKE, V26, P807, DOI 10.1161/01.STR.26.5.807; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Rothman K, 1986, MODERN EPIDEMIOLOGY; Schriger DL, 1998, JAMA-J AM MED ASSOC, V279, P1293, DOI 10.1001/jama.279.16.1293; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; TOMURA N, 1988, RADIOLOGY, V168, P463, DOI 10.1148/radiology.168.2.3393665; TRUWIT CL, 1990, RADIOLOGY, V176, P801, DOI 10.1148/radiology.176.3.2389039; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; von Kummer R, 1999, STROKE, V30, P250; von Kummer R, 2001, RADIOLOGY, V219, P95, DOI 10.1148/radiology.219.1.r01ap0695; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; vonKummer R, 1996, NEURORADIOLOGY, V38, P31, DOI 10.1007/BF00593212; VONKUMMER R, 1995, EARLY CT DIAGNOSIS H, P8; WALL SD, 1982, AM J ROENTGENOL, V138, P307, DOI 10.2214/ajr.138.2.307	39	256	267	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2830	2838		10.1001/jama.286.22.2830	http://dx.doi.org/10.1001/jama.286.22.2830			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735758				2022-12-28	WOS:000172655400031
J	Smith, DE; Zuber, MT; Neumann, GA				Smith, DE; Zuber, MT; Neumann, GA			Seasonal variations of snow depth on Mars	SCIENCE			English	Article							GENERAL-CIRCULATION MODEL; GLOBAL SURVEYOR; GRAVITY-FIELD; WATER-VAPOR; SUMMER TEMPERATURES; CARBON-DIOXIDE; POLAR; ICE; TOPOGRAPHY; EVOLUTION	Using topography collected over one martian year from the Mars Orbiter Laser Altimeter on the Mars Global Surveyor (MGS) spacecraft, we have measured temporal changes in the elevation of the martian surface that correlate with the seasonal cycle of carbon dioxide exchange between the surface and atmosphere. The greatest elevation change (1.5 to 2 meters) occurs at high latitudes ( above 80 degrees), whereas the bulk of the mass exchange occurs at tower latitudes (below 75 degrees N and below 73 degrees S). An unexpected period of sublimation was observed during northern hemisphere autumn, coincident with dust storms in the southern hemisphere. Analysis of MGS Doppler tracking residuals revealed temporal variations in the flattening of Mars that correlate with elevation changes. The combined changes in gravity and elevation constrain the average density of seasonally deposited carbon dioxide to be 910 +/- 230 kilograms per cubic meter, which is considerably denser than terrestrial snow.	NASA, Goddard Space Flight Ctr, Terr Phys Lab, Greenbelt, MD 20771 USA; MIT, Cambridge, MA 02139 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT)	Smith, DE (corresponding author), NASA, Goddard Space Flight Ctr, Terr Phys Lab, Greenbelt, MD 20771 USA.	dsmith@tharsis.gsfc.nasa.gov	Neumann, Gregory A/I-5591-2013	Neumann, Gregory A/0000-0003-0644-9944				Albee AL, 2001, J GEOPHYS RES-PLANET, V106, P23291, DOI 10.1029/2000JE001306; BARKER ES, 1970, SCIENCE, V170, P1308, DOI 10.1126/science.170.3964.1308; CHAO BF, 1990, J GEOPHYS RES-SOLID, V95, P14755, DOI 10.1029/JB095iB09p14755; FARMER CB, 1976, SCIENCE, V194, P1339, DOI 10.1126/science.194.4271.1339; Foster JL, 1998, J GEOPHYS RES-PLANET, V103, P25839, DOI 10.1029/98JE02493; HABERLE RM, 1993, J GEOPHYS RES-PLANET, V98, P3093, DOI 10.1029/92JE02946; HABERLE RM, UNPUB; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1359, DOI 10.1029/JB095iB02p01359; JAKOSKY BM, 1984, ICARUS, V57, P322, DOI 10.1016/0019-1035(84)90121-0; JAMES PB, 1992, MARS, P934; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; Kieffer HH, 2000, J GEOPHYS RES-PLANET, V105, P9653, DOI 10.1029/1999JE001136; KIEFFER HH, 1968, THESIS CATECH PASADE; LEIGHTON RB, 1966, SCIENCE, V153, P136, DOI 10.1126/science.153.3732.136; Lemoine FG, 2001, J GEOPHYS RES-PLANET, V106, P23359, DOI 10.1029/2000JE001426; Maass O, 1926, P R SOC LOND A-CONTA, V111, P224, DOI 10.1098/rspa.1926.0065; MCCARTHY JJ, 1994, GEODYN SYSTEMS DESCR; NAUMANN GA, UNPUB; PAIGE DA, 1992, ICARUS, V99, P15, DOI 10.1016/0019-1035(92)90167-6; PAVLIS DE, 2001, GEODYN OPERATIONS MA; Pettengill GH, 2000, GEOPHYS RES LETT, V27, P609, DOI 10.1029/1999GL010896; ROWLANDS DD, 1993, GEODYN 2 SYSTEM DESC; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; SMITH DE, 1995, GEOPHYS RES LETT, V22, P2171, DOI 10.1029/95GL01801; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; Smith DE, 1999, J GEOPHYS RES-PLANET, V104, P1885, DOI 10.1029/1998JE900024; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Smith DE, 1999, SCIENCE, V286, P94, DOI 10.1126/science.286.5437.94; Smith MD, 2001, J GEOPHYS RES-PLANET, V106, P23929, DOI 10.1029/2000JE001321; SUN X, 2001, EOS, V82; Titus TN, 2001, J GEOPHYS RES-PLANET, V106, P23181, DOI 10.1029/2000JE001284; Tyler GL, 2001, J GEOPHYS RES-PLANET, V106, P23327, DOI 10.1029/2000JE001348; Wilson RJ, 1997, GEOPHYS RES LETT, V24, P123, DOI 10.1029/96GL03814; Zuber MT, 2000, SCIENCE, V287, P1788, DOI 10.1126/science.287.5459.1788; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zurek R.W., 1992, MARS, P835	39	176	183	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2141	2146		10.1126/science.1066556	http://dx.doi.org/10.1126/science.1066556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739951				2022-12-28	WOS:000172647700044
J	Ayoubi, JM; Jouk, PS; Pons, JC				Ayoubi, JM; Jouk, PS; Pons, JC			Diastrophic dwarfism and pregnancy	LANCET			English	Editorial Material							DYSPLASIA		Univ Hosp, Dept Obstet Gynecol, Grenoble, France; Univ Hosp, Dept Genet, Grenoble, France	CHU Grenoble Alpes; CHU Grenoble Alpes	Ayoubi, JM (corresponding author), CHU, Dept Obstet Gynecol, BP 185, F-38042 Grenoble 09, France.		Jouk, Pierre-Simon/AAB-5262-2022; Jouk, Pierre-Simon/M-7367-2014	Jouk, Pierre-Simon/0000-0001-8301-320X; 				HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Jung C, 1998, PRENATAL DIAG, V18, P378; LAMY M, 1960, PRESSE MED, V68, P1977; MANTAGOS S, 1981, AM J OBSTET GYNECOL, V139, P111, DOI 10.1016/0002-9378(81)90423-3; Salle B, 1966, Pediatrie, V21, P311	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1778	1778		10.1016/S0140-6736(01)06806-4	http://dx.doi.org/10.1016/S0140-6736(01)06806-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734236				2022-12-28	WOS:000172385100014
J	Shibuya, K; Hashimoto, H; Yano, E				Shibuya, K; Hashimoto, H; Yano, E			Individual income, income distribution, and self rated health in Japan: cross sectional analysis of nationally representative sample	BRITISH MEDICAL JOURNAL			English	Editorial Material							UNITED-STATES; INEQUALITY; MORTALITY; TRANSITION; PATHWAYS; US	Objective To assess the effects on self rated health of individual income and income distribution in Japan. Design Cross sectional analysis. Data collected on household income, self rated health, and other sociodemographic characteristics at the individual level from comprehensive survey of the living conditions of people on health and welfare in a nationally representative sample from each prefecture, Setting Prefectures in Japan. Participants 80 899 people aged >15 years with full records in survey. Main outcome measures Dichotomous variable for self rated health of each respondent (0 if excellent very good or good; I if fair or poor). Results Inequality in income at die prefecture level measured by the Gini coefficient was comparable with that in other industrialised countries. Unadjusted odds ratios show a 14% increased risk (odds ratio 1.14, 95% confidence interval 1.02 to 1.27) in reporting poor or fair health for individuals living in prefectures with higher inequality in income. After adjustment, individual income was more strongly associated with self rated health than income inequality. Additional inclusion of regional effects showed that median income at the prefecture level was related to self rated health. Conclusions Individual income, probably relative to the median prefecture income, has a stronger association with self-rated health than income inequality at the prefecture level.	Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 173, Japan	Teikyo University	Hashimoto, H (corresponding author), Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 173, Japan.			Shibuya, Kenji/0000-0003-2528-7530				Atkinson AB, 1995, INCOME DISTRIBUTION; BenShlomo Y, 1996, BRIT MED J, V312, P1013; Blakely T, 2000, BRIT MED J, V321, P1532, DOI 10.1136/bmj.321.7275.1532; Blakely TA, 2000, J EPIDEMIOL COMMUN H, V54, P318, DOI 10.1136/jech.54.4.318; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; Brogan D. J., 1998, ENCY BIOSTATISTICS, V5, P4167; Chiang TL, 1999, BMJ-BRIT MED J, V319, P1162, DOI 10.1136/bmj.319.7218.1162; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; *INC STAT BRANCH H, 2001, MEAS HOUS INC IN 196; Kahn RS, 2000, BRIT MED J, V321, P1311, DOI 10.1136/bmj.321.7272.1311; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, SOC SCI MED, V45, P1121, DOI 10.1016/S0277-9536(97)00044-0; Kawachi I, 1999, HEALTH SERV RES, V34, P215; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; LeClere FB, 2000, AM J PUBLIC HEALTH, V90, P1892, DOI 10.2105/AJPH.90.12.1892; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; MELLOR JM, 2000, INCOME INEQUALITY HL; *MIN HLTH WELF, 1995, KOK SEIK KIS CHOS; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; Ross NA, 2000, BRIT MED J, V320, P898, DOI 10.1136/bmj.320.7239.898; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; TACHINABAKI T, 1998, EC DISPARITY JAPAN; Wagstaff A, 2000, ANNU REV PUBL HEALTH, V21, P543, DOI 10.1146/annurev.publhealth.21.1.543; WILKINSON RG, 1994, DAEDALUS, V123, P61; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165	30	159	165	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					16	19		10.1136/bmj.324.7328.16	http://dx.doi.org/10.1136/bmj.324.7328.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777798	Green Published, Bronze			2022-12-28	WOS:000173205700017
J	Sturm, R; Gresenz, CR				Sturm, R; Gresenz, CR			Relations of income inequality and family income to chronic medical conditions and mental health disorders: national survey in USA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CIVIL-SERVANTS; MORTALITY; DETERMINANTS; DESIGN; CARE	Objectives To analyse the relation between geographical inequalities in income and the prevalence of common chronic medical conditions and mental health disorders, and to compare it with the relation between family income mid these health problems. Design Nationally representative household telephone survey conducted in 1997-8. Setting 60 metropolitan areas or economic areas of the United States. Participants 9585 adults who participated in the community tracking study. Main outcome measures Self report of 17 common chronic medical conditions; current depressive disorder or anxiety disorder assessed by clinical screeners. Results A strong continuous association was seen between health and education or family income. No relation was found between income inequality and the prevalence of chronic medical problems or depressive disorders and anxiety disorders, either across the whole population or among poorer people. Only self reported overall health, the measure used in previous studies, was significantly correlated with inequality at the population level, but this correlation disappeared after adjustment for individual characteristics. Conclusions This study provides no evidence for the hypothesis that income inequality is a major risk factor for common disorders of physical or mental health.	RAND Corp, Santa Monica, CA 90401 USA; RAND Corp, Arlington, VA 22202 USA	RAND Corporation; RAND Corporation	Sturm, R (corresponding author), RAND Corp, 1700 Main St, Santa Monica, CA 90401 USA.	sturm@rand.org			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062124] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH062124, R01-MH62124] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cowell F.A., 1977, MEASURING INEQUALITY; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Fiscella K, 2000, HEALTH SERV RES, V35, P307; FLEGG AT, 1982, POP STUD-J DEMOG, V36, P441, DOI 10.2307/2174055; Jones A.F., 2000, CURRENT POPULATION R; Juster FT, 1997, J AM STAT ASSOC, V92, P1268, DOI 10.2307/2965397; Kahn RS, 2000, BRIT MED J, V321, P1311, DOI 10.1136/bmj.321.7272.1311; KAHN RS, 2000, BRIT MED J, V32, P1311; Kaplan GA, 1996, BRIT MED J, V312, P999; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; Kessler R.C., 1998, INT J METHODS PSYCHI, V7, P171, DOI [10.1002/mpr.47, DOI 10.1002/MPR.47]; LEGRAND J, 1987, EUR ECON REV, V31, P182, DOI 10.1016/0014-2921(87)90030-4; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; Marmot M, 2001, BMJ-BRIT MED J, V322, P1233, DOI 10.1136/bmj.322.7296.1233; Marmot MG, 1996, BRIT MED J, V313, P1177, DOI 10.1136/bmj.313.7066.1177; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; Mellor JM, 2001, J HEALTH POLIT POLIC, V26, P487, DOI 10.1215/03616878-26-3-487; MELLOR JM, IN PRESS J HUM RESOU; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; Sen A., 1973, EC INEQUALITY; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; Sturm R, 1999, INQUIRY-J HEALTH CAR, V36, P221; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weich S, 2001, BRIT J PSYCHIAT, V178, P222, DOI 10.1192/bjp.178.3.222; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; World Health Organization, 1995, COMP INT DIAGN INT V	31	148	151	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2002	324	7328					20	+		10.1136/bmj.324.7328.20	http://dx.doi.org/10.1136/bmj.324.7328.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777799	Bronze, Green Published			2022-12-28	WOS:000173205700018
J	Meden, T; St John-Larkin, C; Hermes, D; Sommerschield, S				Meden, T; St John-Larkin, C; Hermes, D; Sommerschield, S			Relationship between travel distance and utilization of breast cancer treatment in rural northern Michigan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSERVING SURGERY; PATIENT; WOMEN		Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Human Medicine	Meden, T (corresponding author), Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.							ABE O, 1995, NEW ENGL J MED, V333, P1444; Albain KS, 1996, J CLIN ONCOL, V14, P3009, DOI 10.1200/JCO.1996.14.11.3009; Bland KI, 1998, CANCER-AM CANCER SOC, V83, P1262, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1262::AID-CNCR28>3.0.CO;2-2; Kotwall CA, 1996, ANN SURG, V224, P419, DOI 10.1097/00000658-199610000-00001; Lazovich D, 1997, ARCH SURG-CHICAGO, V132, P418; SAMET JM, 1994, CANCER, V73, P2344, DOI 10.1002/1097-0142(19940501)73:9<2344::AID-CNCR2820730917>3.0.CO;2-V; Stafford D, 1998, AM J SURG, V176, P515, DOI 10.1016/S0002-9610(98)00257-8	7	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					111	111		10.1001/jama.287.1.111	http://dx.doi.org/10.1001/jama.287.1.111			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754721	hybrid			2022-12-28	WOS:000172978500037
J	Karol, KG; McCourt, RM; Cimino, MT; Delwiche, CF				Karol, KG; McCourt, RM; Cimino, MT; Delwiche, CF			The closest living relatives of land plants	SCIENCE			English	Article							GREEN-ALGAE; MESOSTIGMA VIRIDE; PHYLOGENY; ULTRASTRUCTURE; CHAROPHYCEAE; BRYOPHYTES; SEQUENCES; CHARA	The embryophytes (land plants) have long been thought to be related to the green algal group Charophyta, though the nature of this relationship and the origin of the land plants have remained unresolved. A four-gene phytogenetic analysis was conducted to investigate these relationships. This analysis supports the hypothesis that the land plants are placed phylogenetically within the Charophyta, identifies the Charales (stoneworts) as the closest living relatives of plants, and shows the Coleochaetales as sister to this Charales/land plant assemblage. The results also support the unicellular flagellate Mesostigma as the earliest branch of the charophyte lineage. These findings provide insight into the nature of the ancestor of plants, and have broad implications for understanding the transition from aquatic green algae to terrestrial plants.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Acad Nat Sci Philadelphia, Dept Bot, Philadelphia, PA 19103 USA	University System of Maryland; University of Maryland College Park; Drexel University	Karol, KG (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.		Delwiche, Charles F/C-6549-2008	Delwiche, Charles F/0000-0001-7854-8584				Bhattacharya D, 1998, J MOL EVOL, V47, P544, DOI 10.1007/PL00006410; Bower F. O., 1908, ORIGIN LAND FLORA TH; CHAPMAN RL, 1998, SYSTEMATICS PLANTS, V2, P508; Cook ME, 1997, AM J BOT, V84, P1169, DOI 10.2307/2446040; Doyle J. J., 1987, PHYTOCHEMISTRY B, V19, P11, DOI DOI 10.2307/4119796; Duncan TM, 1997, PLANT SYST EVOL, V204, P125, DOI 10.1007/BF00989201; Feist M, 1997, NATURE, V385, P401, DOI 10.1038/385401a0; Feist M., 1991, CALCAREOUS ALGAE STR, V11, P189, DOI [10.1007/978-3-642-52335-9, DOI 10.1007/978-3-642-52335-9]; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FRITSCH F.E., 1935, STRUCTURE REPROD ALG, V1; Graham L, 1993, ORIGIN LAND PLANTS; GRAHAM LE, 1991, ADV BRYOL, V4, P213; Graham LE, 2000, ALGAE; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; HUELSENBECK JP, 2001, HDB STAT GENETICS; Kenrick P., 1997, ORIGIN EARLY DIVERSI; Lemieux C, 2000, NATURE, V403, P649, DOI 10.1038/35001059; LEMIEUX C, IN PRESS; Marin B, 1999, PROTIST, V150, P399, DOI 10.1016/S1434-4610(99)70041-6; Mattox K. R., 1984, SYSTEMATICS GREEN AL, V27, P29; McCourt RM, 2000, J PHYCOL, V36, P747, DOI 10.1046/j.1529-8817.2000.99106.x; MISHLER B D, 1985, Cladistics, V1, P305, DOI 10.1111/j.1096-0031.1985.tb00431.x; MISHLER BD, 1984, BRITTONIA, V36, P406, DOI 10.2307/2806602; PICKETTHEAPS JD, 1972, CYTOBIOS, V6, P255; SLUIMAN HJ, 1985, PLANT SYST EVOL, V149, P217, DOI 10.1007/BF00983308; Sluiman HJ, 1999, J PHYCOL, V35, P395, DOI 10.1046/j.1529-8817.1999.3520395.x; Tappan H, 1980, PALEOBIOLOGY PLANT P	27	428	467	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2351	2353		10.1126/science.1065156	http://dx.doi.org/10.1126/science.1065156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743201				2022-12-28	WOS:000172817200046
J	Atkins, JF; Gesteland, RF				Atkins, JF; Gesteland, RF			mRNA readout at 40	NATURE			English	Editorial Material									Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Atkins, JF (corresponding author), Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA.			Atkins, John/0000-0001-7933-0165				Atkins J.F., 1999, RNA WORLD NATURE MOD, P637; Judson HF., 1979, 8 DAY CREATION; ORICK F, 1988, WHAT MAD PURSUIT PER, pCH12; ORICK FHC, 1961, NATURE, V192, P1227	4	3	3	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					693	693		10.1038/414693a	http://dx.doi.org/10.1038/414693a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742372	Bronze			2022-12-28	WOS:000172676200022
J	Rathore, SS; Chen, J; Wang, YF; Radford, MJ; Voccarino, V; Krumholz, HM				Rathore, SS; Chen, J; Wang, YF; Radford, MJ; Voccarino, V; Krumholz, HM			Sex differences in cardiac catheterization - The role of physician gender	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; HEART-DISEASE; CHEST PAIN; WOMEN; CARE; RACE; MANAGEMENT; BIAS; MEN	Context Many studies indicate that women are less likely than men to undergo cardiac procedures after an acute myocardial infarction (AMI), raising concerns of sexual bias in clinical care. However, no data exist regarding the relationship between patient sex, physician sex, and use of cardiac procedures. Objective To determine whether sex differences in cardiac catheterization after AM] were greater when patients were treated by male attending physicians compared with female attending physicians. Design, Setting, and Patients Analysis of data from the Cooperative Cardiovascular Project, a retrospective medical record-review. A total of 104231 Medicare fee-for-service beneficiaries who were hospitalized In US acute care hospitals for an AM] between January 1994 and February 1995. Main Outcome Measure Use of cardiac catheterization within 60 days of admission, compared between the 4 groups of patient sex-physician sex combinations. Results Women underwent fewer cardiac catheterizations than men when treated by either male physicians (38.6% vs 50.8%; P=.001) or female physicians (34.8% vs 45.8%; P=.001). Sex differences in procedure use were not greater when a patient and physician were of different sexes (P for interaction =.85). After potential confounders in multivariable analysis were accounted for, women were less likely to undergo cardiac catheterization (risk ratio, 0.90 [95% confidence interval {CI}, 0.88-0.92]), regardless of the treating physician's sex. Patients treated by male physicians were more likely to undergo cardiac catheterization (risk ratio, 1.06 [95% CI, 1.02-1.10]) than those treated by female physicians, regardless of patient sex. Conclusions Women who have had an AMI undergo a cardiac catheterization less often than men, whether treated by a male or female physician. These results suggest that factors other than sexual bias by male physicians toward women account for sex differences in cardiac procedure use.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA; Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA USA; Qualidigm, Middletown, CT USA	Yale University; Yale University; Yale University; University of Pennsylvania; Pennsylvania Medicine; Emory University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557	CIT NIH HHS [500-99-CT01] Funding Source: Medline	CIT NIH HHS		Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; *AM HOSP ASS, 1994, ANN SURV HOSP DAT DO; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BIRDWELL BG, 1993, ARCH INTERN MED, V153, P1991, DOI 10.1001/archinte.153.17.1991; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; CHERKIN D, 1977, MED CARE, V15, P767; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; COMSTOCK LM, 1982, J MED EDUC, V57, P105; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Dartmouth Medical School Center for the Evaluation of Clinical Sciences Maine Medical Center, 1999, DARTM ATL CARD HLTH; DHOORE W, 1994, AM J PUBLIC HEALTH, V84, P1013, DOI 10.2105/AJPH.84.6.1013; Douglas PS, 1996, NEW ENGL J MED, V334, P1311, DOI 10.1056/NEJM199605163342007; FENNEMA K, 1990, J FAM PRACTICE, V30, P441; FRANKS P, 1993, MED CARE, V31, P213, DOI 10.1097/00005650-199303000-00003; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; Goldberg RJ, 1998, AM HEART J, V136, P189, DOI 10.1053/hj.1998.v136.88874; HALL JA, 1990, MED CARE, V28, P489, DOI 10.1097/00005650-199006000-00002; HARRIS RB, 1991, J CLIN EPIDEMIOL, V44, P1071, DOI 10.1016/0895-4356(91)90009-X; JEZZONI LI, 1994, RISK ADJ MEAS HLTH C; Kenward K, 1996, AM J PUBLIC HEALTH, V86, P1481, DOI 10.2105/AJPH.86.10.1481; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; Levy S, 1992, Fam Med, V24, P58; LINK RN, 1991, J GEN INTERN MED, V6, P466; Lurie N, 1997, J GEN INTERN MED, V12, P34; LURIE N, 1993, NEW ENGL J MED, V329, P478, DOI 10.1056/NEJM199308123290707; MAHEUX B, 1990, MED CARE, V28, P87, DOI 10.1097/00005650-199001000-00009; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Maynard C, 1996, CIRCULATION, V94, P93; Milner KA, 1999, AM J CARDIOL, V84, P396, DOI 10.1016/S0002-9149(99)00322-7; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schwartz LM, 1997, ARCH INTERN MED, V157, P1545, DOI 10.1001/archinte.157.14.1545; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; SOFAER S, 1990, WOMEN HEALTH, V16, P47, DOI 10.1300/J013v16n03_04; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US BUR CENS, 1991, STAT METR AR DAT BOO; *US DEP HHS, 1988, INT CLASS DIS 9 REV; van Lennep JER, 2000, EUR HEART J, V21, P911, DOI 10.1053/euhj.1999.1941; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wong CC, 1998, AM HEART J, V135, P435, DOI 10.1016/S0002-8703(98)70319-9; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zucker DR, 1997, J GEN INTERN MED, V12, P79, DOI 10.1046/j.1525-1497.1997.00011.x	49	90	91	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2849	2856		10.1001/jama.286.22.2849	http://dx.doi.org/10.1001/jama.286.22.2849			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735761				2022-12-28	WOS:000172655400034
J	Eisman, JA				Eisman, JA			Good, good, good ... good vibrations: the best option for better bones?	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; RANDOMIZED TRIALS; PHYSICAL-ACTIVITY; PREMENOPAUSAL; EXERCISE; DENSITY; METAANALYSIS; MASS		Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research	Eisman, JA (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia.		Eisman, John A/C-2886-2014					Akhter MP, 2000, CALCIFIED TISSUE INT, V67, P337, DOI 10.1007/s002230001144; Berard A, 1997, OSTEOPOROSIS INT, V7, P331, DOI 10.1007/BF01623773; Chang YH, 2001, J BIOMECH, V34, P679, DOI 10.1016/S0021-9290(00)00196-2; Eisman JA, 2001, DRUG METAB DISPOS, V29, P505; Gregg EW, 2000, J AM GERIATR SOC, V48, P883, DOI 10.1111/j.1532-5415.2000.tb06884.x; Kelley GA, 1998, AM J PHYS MED REHAB, V77, P76, DOI 10.1097/00002060-199801000-00015; Lorentzon R, 2001, SCAND J MED SCI SPOR, V11, P131; Muehleman C, 1999, J ANAT, V195, P191, DOI 10.1046/j.1469-7580.1999.19520191.x; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Robling AG, 2001, BONE, V29, P105, DOI 10.1016/S8756-3282(01)00488-4; ROCKWELL JC, 1990, J CLIN ENDOCR METAB, V71, P988, DOI 10.1210/jcem-71-4-988; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; van der Meulen MCH, 2001, BONE, V29, P101, DOI 10.1016/S8756-3282(01)00491-4; Wallace BA, 2000, CALCIFIED TISSUE INT, V67, P10, DOI 10.1007/s00223001089; Ward KA, 2001, J BONE MINER RES, V16, pS173; Wolff I, 1999, OSTEOPOROSIS INT, V9, P1, DOI 10.1007/s001980050109; [No title captured]	19	32	33	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1924	1925		10.1016/S0140-6736(01)06975-6	http://dx.doi.org/10.1016/S0140-6736(01)06975-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747912				2022-12-28	WOS:000172622200005
J	Prough, DS				Prough, DS			Are enough explicit resuscitation directives obtained for critically ill patients?	LANCET			English	Editorial Material							PREFERENCES; PHYSICIANS		Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prough, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X				COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8	4	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1920	1921		10.1016/S0140-6736(01)06972-0	http://dx.doi.org/10.1016/S0140-6736(01)06972-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747909				2022-12-28	WOS:000172622200002
J	Westbrook, JI; Duggan, AE; McIntosh, JH				Westbrook, JI; Duggan, AE; McIntosh, JH			Prescriptions for antiulcer drugs in Australia: volume, trends, and costs	BRITISH MEDICAL JOURNAL			English	Article									Univ New S Wales, Ctr Hlth Informat, Kensington, NSW 2052, Australia; John Hunter Hosp, Dept Gastroenterol, New Lambton Hts, NSW 2305, Australia; Univ Sydney, Sch Hlth Informat Management, Lidcombe, NSW 1825, Australia	University of New South Wales Sydney; John Hunter Hospital; University of Sydney	Westbrook, JI (corresponding author), Univ New S Wales, Ctr Hlth Informat, Kensington, NSW 2052, Australia.		Westbrook, Johanna/J-9045-2018	Westbrook, Johanna/0000-0003-1083-8192				BRITT H, 1999, GEN PRACTICIE ACTIVI; LATNER A, 2000, PHARM TIMES; McManus P, 1998, BRIT J CLIN PHARMACO, V46, P409, DOI 10.1046/j.1365-2125.1998.00791.x; *NAT I CLIN EXC, 2000, GUID US PROT PUMP IN; Westbrook JI, 2000, ALIMENT PHARM THER, V14, P1581, DOI 10.1046/j.1365-2036.2000.00878.x	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1338	1339		10.1136/bmj.323.7325.1338	http://dx.doi.org/10.1136/bmj.323.7325.1338			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739219	Bronze, Green Published			2022-12-28	WOS:000172716900016
J	Krinos, CM; Coyne, MJ; Weinacht, KG; Tzianabos, AO; Kasper, DL; Comstock, LE				Krinos, CM; Coyne, MJ; Weinacht, KG; Tzianabos, AO; Kasper, DL; Comstock, LE			Extensive surface diversity of a commensal microorganism by multiple DNA inversions	NATURE			English	Article							BACTEROIDES-FRAGILIS; REVEALS; GENE	The dynamic interactions between a host and its intestinal microflora that lead to commensalism are unclear. Bacteria that colonize the intestinal tract do so despite the development of a specific immune response by the host(1). The mechanisms used by commensal organisms to circumvent this immune response have yet to be established. Here we demonstrate that the human colonic microorganism, Bacteroides fragilis, is able to modulate its surface antigenicity by producing at least eight distinct capsular polysaccharides-a number greater than any previously reported for a bacterium-and is able to regulate their expression in an on-off manner by the reversible inversion of DNA segments containing the promoters for their expression. This means of generating surface diversity allows the organism to exhibit a wide array of distinct surface polysaccharide combinations, and may have broad implications for how the predominant human colonic microorganisms, the Bacteroides species, maintain an ecological niche in the intestinal tract.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Comstock, LE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.				NIAID NIH HHS [R01 AI044193-04, R01 AI044193] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044193] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1985, P NATL ACAD SCI USA, V82, P5724, DOI 10.1073/pnas.82.17.5724; Bayley DP, 2000, FEMS MICROBIOL LETT, V193, P149, DOI 10.1111/j.1574-6968.2000.tb09417.x; Comstock LE, 1999, INFECT IMMUN, V67, P3525, DOI 10.1128/IAI.67.7.3525-3532.1999; Coyne MJ, 2000, INFECT IMMUN, V68, P6176, DOI 10.1128/IAI.68.11.6176-6181.2000; Coyne MJ, 2001, INFECT IMMUN, V69, P4342, DOI 10.1128/IAI.69.7.4342-4350.2001; KIM J, 1998, INFECT IMMUN, V66, P3303; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; OLSEN PB, 1994, FEMS MICROBIOL LETT, V116, P95; THOMPSON JS, 1990, J BACTERIOL, V172, P2584, DOI 10.1128/jb.172.5.2584-2593.1990	9	219	231	0	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					555	558		10.1038/35107092	http://dx.doi.org/10.1038/35107092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734857				2022-12-28	WOS:000172405900050
J	Ho, KKY				Ho, KKY			Place of pegvisomant in acromegaly	LANCET			English	Editorial Material							GROWTH-HORMONE SECRETION; DIAGNOSIS; RECEPTOR; THERAPY		St Vincents Hosp, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Ho, KKY (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Sydney, NSW 2010, Australia.		Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				CHEN WY, 1994, J BIOL CHEM, V269, P20806; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Giustina A, 2000, J CLIN ENDOCR METAB, V85, P526, DOI 10.1210/jc.85.2.526; HO KKY, 1994, CLIN ENDOCRINOL, V41, P75, DOI 10.1111/j.1365-2265.1994.tb03787.x; HO PJ, 1992, J CLIN ENDOCR METAB, V75, P812, DOI 10.1210/jc.75.3.812; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; RAJASOORYA C, 1994, CLIN ENDOCRINOL, V41, P95, DOI 10.1111/j.1365-2265.1994.tb03789.x; Ross RJM, 2001, J CLIN ENDOCR METAB, V86, P1716, DOI 10.1210/jc.86.4.1716; Swearingen B, 1998, J CLIN ENDOCR METAB, V83, P3419, DOI 10.1210/jc.83.10.3419; Trainer PJ, 2000, NEW ENGL J MED, V342, P1171, DOI 10.1056/NEJM200004203421604; van der Lely AJ, 2001, J CLIN ENDOCR METAB, V86, P478, DOI 10.1210/jc.86.2.478	12	12	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1743	1744		10.1016/S0140-6736(01)06839-8	http://dx.doi.org/10.1016/S0140-6736(01)06839-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734225				2022-12-28	WOS:000172385100003
J	Sagastegui-Rodriguez, JA; Cruz-Flores, S				Sagastegui-Rodriguez, JA; Cruz-Flores, S			Syringomyelia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Autonoma Nuevo Leon, Monterrey, Mexico; St Louis Univ, St Louis, MO 63110 USA	Universidad Autonoma de Nuevo Leon; Saint Louis University	Sagastegui-Rodriguez, JA (corresponding author), Univ Autonoma Nuevo Leon, Monterrey, Mexico.		Cruz-Flores, Salvador/AAR-1233-2020; Rusbridge, Clare/A-3794-2019	Cruz-Flores, Salvador/0000-0003-4998-1471; Rusbridge, Clare/0000-0002-3366-2110					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					E1	E1		10.1056/ENEJMicm960106	http://dx.doi.org/10.1056/ENEJMicm960106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11777995				2022-12-28	WOS:000173033600007
J	Peile, EB; Easton, GP; Olney, S				Peile, EB; Easton, GP; Olney, S			The Renaissance Shool of General Medicine	BRITISH MEDICAL JOURNAL			English	Article									Aston Clinton Surg, Alesury HP22 5LB, England; BBC, Dept Sci, Radio Sci Unit, London, England; The Surgery, London SW13 0DR, England		Peile, EB (corresponding author), Aston Clinton Surg, Alesury HP22 5LB, England.								0	2	2	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1454	1455		10.1136/bmj.323.7327.1454	http://dx.doi.org/10.1136/bmj.323.7327.1454			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751351	Green Published			2022-12-28	WOS:000172979900031
J	Frey, PA				Frey, PA			Enzymology - Coenzymes and radicals	SCIENCE			English	Editorial Material							INTERMEDIATE		Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.							BARLETTA G, 1990, J AM CHEM SOC, V112, P8144, DOI 10.1021/ja00178a044; CAMMACK R, 1980, FEBS LETT, V118, P271, DOI 10.1016/0014-5793(80)80236-5; Chabriere E, 2001, SCIENCE, V294, P2559, DOI 10.1126/science.1066198; FREY PA, 1990, CHEM REV, V90, P1343, DOI 10.1021/cr00105a014; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; HARTMANN C, 1995, METHOD ENZYMOL, V258, P69; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; REED GH, 1995, METHOD ENZYMOL, V258, P362; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Weil J. A., 2006, ELECT PARAMAGNETIC R	13	13	13	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2489	2490		10.1126/science.1067916	http://dx.doi.org/10.1126/science.1067916			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752561				2022-12-28	WOS:000172927700037
J	Disdier, P; Granel, B; Serratrice, J; Weiller, PJ				Disdier, P; Granel, B; Serratrice, J; Weiller, PJ			A teenager with rash and fever	LANCET			English	Editorial Material							MINOCYCLINE; LYMPHADENOPATHY; EOSINOPHILIA		CHU Timone, Serv Med Interne, F-13385 Marseille 5, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Disdier, P (corresponding author), CHU Timone, Serv Med Interne, F-13385 Marseille 5, France.		granel, brigitte/A-8000-2010					KAUFMANN D, 1994, ARCH INTERN MED, V154, P1983, DOI 10.1001/archinte.154.17.1983; MacNeil M, 1997, J AM ACAD DERMATOL, V36, P347, DOI 10.1016/S0190-9622(97)80414-8; Piette AM, 1999, REV MED INTERNE, V20, P869, DOI 10.1016/S0248-8663(00)80092-2	3	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2046	2046		10.1016/S0140-6736(01)07102-1	http://dx.doi.org/10.1016/S0140-6736(01)07102-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755613				2022-12-28	WOS:000172722800014
J	Klug, DD				Klug, DD			Thermodynamics - Glassy water	SCIENCE			English	Editorial Material							ICE-I; TRANSITION; LIQUID		Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Klug, DD (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.							ANGELL CA, 1995, P NATL ACAD SCI USA, V92, P6675, DOI 10.1073/pnas.92.15.6675; HANDA YP, 1988, J PHYS CHEM-US, V92, P3323, DOI 10.1021/j100323a005; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; Johari GP, 1998, J PHYS CHEM B, V102, P4711, DOI 10.1021/jp980765h; Johari GP, 1996, SCIENCE, V273, P90, DOI 10.1126/science.273.5271.90; MAYER E, 1985, J APPL PHYS, V58, P663, DOI 10.1063/1.336179; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; Sceats M.G., 1982, WATER COMPREHENSIVE, V7, P83; Tse JS, 1999, NATURE, V400, P647, DOI 10.1038/23216; Velikov V, 2001, SCIENCE, V294, P2335, DOI 10.1126/science.1061757	11	8	8	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2305	2306		10.1126/science.1066858	http://dx.doi.org/10.1126/science.1066858			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743189				2022-12-28	WOS:000172817200033
J	Langin, D				Langin, D			Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNCOUPLING PROTEIN-2; GENE		INSERM, U317, F-31403 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Langin, D (corresponding author), INSERM, U317, F-31403 Toulouse, France.			Langin, Dominique/0000-0002-2669-7825				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	5	31	35	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1772	1774		10.1056/NEJM200112133452412	http://dx.doi.org/10.1056/NEJM200112133452412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742055				2022-12-28	WOS:000172656100011
J	Malin, MC; Caplinger, MA; Davis, SD				Malin, MC; Caplinger, MA; Davis, SD			Observational evidence for an active surface reservoir of solid carbon dioxide on mars	SCIENCE			English	Article							RESIDUAL CO2 FROST; SOUTH POLAR-CAP; SUMMER TEMPERATURES; ASTRONOMICAL THEORY; CHAOTIC OBLIQUITY; WATER-VAPOR; INSOLATION	High-resolution images of the south polar residual cap of Mars acquired in 1999 and 2001 show changes in the configuration of pits, intervening ridges, and isolated mounds. Escarpments have retreated 1 to 3 meters in 1 martian year, changes that are an order of magnitude larger than can be explained by the sublimation of water ice, but close to what is expected for sublimation of carbon dioxide ice. These observations support a 35-year-old conjecture that Mars has a large surface reservoir of solid carbon dioxide. The erosion implies that this reservoir is not in equilibrium with the present environment and that global climate change is occurring on Mars.	Malin Space Sci Syst, San Diego, CA 92191 USA		Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.							BRIGGS GA, 1974, ICARUS, V23, P167, DOI 10.1016/0019-1035(74)90004-9; Clifford SM, 2000, ICARUS, V144, P210, DOI 10.1006/icar.1999.6290; DZURISIN D, 1975, J GEOPHYS RES, V80, P3286, DOI 10.1029/JB080i023p03286; FANALE FP, 1974, J GEOPHYS RES, V79, P3397, DOI 10.1029/JC079i024p03397; FANALE FP, 1976, ICARUS, V28, P172; FARMER CB, 1979, J GEOPHYS RES, V84, P2881, DOI 10.1029/JB084iB06p02881; Hess S. L., 1977, Journal of Geophysical Research, V82, P4559, DOI 10.1029/JS082i028p04559; HESS SL, 1976, SCIENCE, V194, P1352, DOI 10.1126/science.194.4271.1352; HESS SL, 1976, SCIENCE, V194, P78, DOI 10.1126/science.194.4260.78; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1359, DOI 10.1029/JB095iB02p01359; JAKOSKY BM, 1984, ICARUS, V57, P322, DOI 10.1016/0019-1035(84)90121-0; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; LEIGHTON RB, 1966, SCIENCE, V153, P136, DOI 10.1126/science.153.3732.136; Malin M. C., 1991, International Journal of Imaging Systems and Technology, V3, P76, DOI 10.1002/ima.1850030205; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; Malin MC, 2000, SCIENCE, V288, P2330, DOI 10.1126/science.288.5475.2330; MURRAY BC, 1973, SCIENCE, V182, P437, DOI 10.1126/science.182.4111.437; MURRAY BC, 1972, ICARUS, V17, P328, DOI 10.1016/0019-1035(72)90004-8; MURRAY BC, 1973, SCIENCE, V180, P638, DOI 10.1126/science.180.4086.638; NEUGEBAUER G, 1971, ASTRON J, V76, P719, DOI 10.1086/111189; PAIGE DA, 1985, SCIENCE, V228, P1160, DOI 10.1126/science.228.4704.1160; PAIGE DA, 1990, J GEOPHYS RES-SOLID, V95, P1319, DOI 10.1029/JB095iB02p01319; PAIGE DA, 1994, J GEOPHYS RES-PLANET, V99, P25993, DOI 10.1029/93JE03429; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; SODERBLOM LA, 1973, J GEOPHYS RES, V78, P4197, DOI 10.1029/JB078i020p04197; Thomas PC, 2000, NATURE, V404, P161, DOI 10.1038/35004528; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; WARD WR, 1974, J GEOPHYS RES, V79, P3387, DOI 10.1029/JC079i024p03387; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; WARD WR, 1973, SCIENCE, V181, P260, DOI 10.1126/science.181.4096.260; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	36	117	117	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2146	2148		10.1126/science.1066416	http://dx.doi.org/10.1126/science.1066416			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11768358				2022-12-28	WOS:000172647700045
J	Schumacher, MA; Miller, MC; Grkovic, S; Brown, MH; Skurray, RA; Brennan, RG				Schumacher, MA; Miller, MC; Grkovic, S; Brown, MH; Skurray, RA; Brennan, RG			Structural mechanisms of QacR induction and multidrug recognition	SCIENCE			English	Article							P-GLYCOPROTEIN; ANTIBIOTIC-RESISTANCE; CRYSTAL-STRUCTURE; BINDING; PROTEIN; GENE; TRANSPORTER; REGULATOR; IDENTIFICATION; EXPRESSION	The Staphylococcus aureus multidrug binding protein QacR represses transcription of the qacA multidrug transporter gene and is induced by structurally diverse cationic lipophilic drugs. Here, we report the crystal structures of six QacR-drug complexes. Compared to the DNA bound structure, drug binding elicits a coil-to-helix transition that causes induction and creates an expansive multidrug-binding pocket, containing four glutamates and multiple aromatic and polar residues. These structures indicate the presence of separate but linked drug-binding sites within a single protein. This muttisite drug-binding mechanism is consonant with studies on multidrug resistance transporters.	Oregon Hlth Sci & Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	Oregon Health & Science University; University of Sydney	Brennan, RG (corresponding author), Oregon Hlth Sci & Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	brennanr@ohsu.edu	Brown, Melissa/V-2296-2017	Brown, Melissa/0000-0001-6461-7550; Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 48593] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED M, 1994, J BIOL CHEM, V269, P28506; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; BEHR H, 1994, PATHOL BIOL, V42, P438; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; DOUBLIE S, 1999, METHOD ENZYMOL, V276, P523; GOLDSTEIN LJ, 1992, CRIT REV ONCOL HEMAT, V12, P243, DOI 10.1016/1040-8428(92)90057-W; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; GRKOVIC S, UNPUB; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Licht T, 1996, ANN HEMATOL, V72, P184, DOI 10.1007/s002770050159; Lovell S, 1999, J CHEM SOC PERK T 2, P2241, DOI 10.1039/a904367e; Mayer S, 2001, J ANTIMICROB CHEMOTH, V47, P896, DOI 10.1093/jac/47.6.896; Mitchell BA, 1999, J BIOL CHEM, V274, P3541, DOI 10.1074/jbc.274.6.3541; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; RAYMENT I, 1999, METHOD ENZYMOL, V276, P176; SCHUMACHER MA, UNPUB; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762	41	319	329	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2158	2163		10.1126/science.1066020	http://dx.doi.org/10.1126/science.1066020			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739955				2022-12-28	WOS:000172647700049
J	Fleisher, LA; Eagle, KA				Fleisher, LA; Eagle, KA			Lowering cardiac risk in noncardiac surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAOPERATIVE MYOCARDIAL-ISCHEMIA; TRANSLUMINAL CORONARY ANGIOPLASTY; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; VASCULAR-SURGERY; PULMONARY-ARTERY; RANDOMIZED TRIAL; CARDIOVASCULAR MORBIDITY; AORTIC-SURGERY; DISEASE		Univ Michigan, Sch Med, Dept Internal Med Cardiol, Div Cardiol, Ann Arbor, MI 48109 USA; Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Eagle, KA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med Cardiol, Div Cardiol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	keagle@umich.edu	Lee A, Fleisher/Q-9894-2019					ALLEN JR, 1991, SURG GYNECOL OBSTET, V173, P285; Bender JS, 1997, ANN SURG, V226, P229, DOI 10.1097/00000658-199709000-00002; BOERSMA E, 2001, JAMA-J AM MED ASSOC, V285, P1565; CORIAT P, 1984, ANESTHESIOLOGY, V61, P193, DOI 10.1097/00000542-198408000-00013; DODDS TM, 1993, ANESTH ANALG, V76, P705; Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; Eagle KA, 1996, CIRCULATION, V93, P1278; Eagle KA, 1999, J AM COLL CARDIOL, V34, P1262, DOI 10.1016/S0735-1097(99)00389-7; ELLIS JE, 1994, ANESTH ANALG, V79, P1133; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; Fleisher LA, 1999, ANESTH ANALG, V89, P849, DOI 10.1097/00000539-199910000-00007; GODET G, 1987, ANESTHESIOLOGY, V66, P241, DOI 10.1097/00000542-198702000-00027; Gottlieb A, 1998, J CARDIOTHOR VASC AN, V12, P501, DOI 10.1016/S1053-0770(98)90090-8; Hassan SA, 2001, AM J MED, V110, P260, DOI 10.1016/S0002-9343(00)00717-8; ISAACSON IJ, 1990, J VASC SURG, V12, P754, DOI 10.1067/mva.1990.24456; Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lee TH, 2001, NEW ENGL J MED, V344, P1840, DOI 10.1056/NEJM200106143442406; Mangano DT, 1997, NEW ENGL J MED, V336, P1039; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Oliver MF, 1999, ANESTHESIOLOGY, V91, P951, DOI 10.1097/00000542-199910000-00014; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Posner KL, 1999, ANESTH ANALG, V89, P553, DOI 10.1097/00000539-199909000-00003; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Reilly DF, 1999, ARCH INTERN MED, V159, P2185, DOI 10.1001/archinte.159.18.2185; Stuhmeier KD, 1996, ANESTHESIOLOGY, V85, P706, DOI 10.1097/00000542-199610000-00004; Valentine RJ, 1998, J VASC SURG, V27, P203, DOI 10.1016/S0741-5214(98)70351-9; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005	30	155	164	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1677	1682		10.1056/NEJMcp002842	http://dx.doi.org/10.1056/NEJMcp002842			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759647				2022-12-28	WOS:000172517200006
J	Stern, V				Stern, V			Gynaecological examinations post-Ledward - a private matter	LANCET			English	Editorial Material							CHAPERONES				Stern, V (corresponding author), 30 Goldhurst Terrace, London NW6 3HU, England.	vivien.stern@bushinternet.com						Bignell CJ, 1999, BMJ-BRIT MED J, V319, P137, DOI 10.1136/bmj.319.7203.137; JONES RH, 1983, J ROY COLL GEN PRACT, V33, P25; Morrow J, 1999, BMJ-BRIT MED J, V319, P1266; *ROYAL COLL OBST G, 1997, INT EX REP WORK PART; Torrance CJ, 1999, BRIT MED J, V319, P159, DOI 10.1136/bmj.319.7203.159; Webb R, 1996, CAN FAM PHYSICIAN, V42, P54; WRIGHT O, 2000, TIMES           1221, P5; 2000, REPORT INQUIRY QUALI	8	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1896	1898		10.1016/S0140-6736(01)06892-1	http://dx.doi.org/10.1016/S0140-6736(01)06892-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741649				2022-12-28	WOS:000172463000033
J	Watson, R; Pauly, D				Watson, R; Pauly, D			Systematic distortions in world fisheries catch trends	NATURE			English	Article							FISH	Over 75% of the world marine fisheries catch (over 80 million tonnes per year) is sold on international markets, in contrast to other food commodities (such as rice)(1,2). At present, only one institution, the Food and Agriculture Organization of the United Nations (FAO) maintains global fisheries statistics. As an intergovernmental organization, however, FAO must generally rely on the statistics provided by member countries, even if it is doubtful that these correspond to reality. Here we show that misreporting by countries with large fisheries, combined with the large and widely fluctuating catch of species such as the Peruvian anchoveta, can cause globally spurious trends. Such trends influence unwise investment decisions by firms in the fishing sector and by banks, and prevent the effective management of international fisheries.	Univ British Columbia, Fisheries Ctr, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Watson, R (corresponding author), Univ British Columbia, Fisheries Ctr, 2204 Main Mall, Vancouver, BC V6T 1Z4, Canada.		Pauly, Daniel Marc/AAY-2316-2021; Watson, Reg A/F-4850-2012	Watson, Reg A/0000-0001-7201-8865; Pauly, Daniel/0000-0003-3756-4793				ALVERSONS DL, 1994, 339 FAO, P1; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; CHEN W, 1999, 950 FAO, P1; *DAT AN PROD DIV M, 2000, S PLUS GUID STAT, V1; *FOOD AGR ORG, 2000, 961 FAO DAT STAT UN, P1; *FOOD AGR ORG, 2000, FISHSTAT PLUS U SOFT; FROESE R, 2000, FISHBASE 2000 CONCEP; *GLOB MAR BOUND DA, 2000, VER INF SOL 2000; Huang B., 1983, North American Journal of Fisheries Management, V3, P295, DOI 10.1577/1548-8659(1983)3<295:CAAPDO>2.0.CO;2; KWONG L, 1997, POLITICAL EC CORRUPT, P1; LONGHURST A, 1998, ECOLOGICAL GEOGRAPHY, P77; MACLEAN J, 1997, RICE ALMANAC, P31; Muck Peter, 1989, P386; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; PANG L, 2000, 9 U BRIT COL FISH, P1; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Pauly D, 1996, FISH RES, V25, P25, DOI 10.1016/0165-7836(95)00436-X; Tang Q., 1989, AAAS (American Association for the Advancement of Science) Selected Symposium, V111, P7; WATSON R, IN PRESS FISHERIES I	19	419	446	0	107	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					534	536		10.1038/35107050	http://dx.doi.org/10.1038/35107050			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734851				2022-12-28	WOS:000172405900044
J	Muller, A				Muller, A			Education, income inequality, and mortality: a multiple regression analysis	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; HEALTH	Objective To test whether the relation between income inequality and mortality found in US states is because of different levels of formal education. Design Cross sectional, multiple regression analysis. Setting All US states and the District of Columbia (n = 51). Data sources US census statistics and vital statistics for the years 1989 and 1990. Main outcome measure Multiple regression analysis with age adjusted mortality from all causes as the dependent variable and 3 independent variables-the Gini coefficient, per capita income, and percentage of people aged greater than or equal to18 years without a high school diploma. Results The income inequality effect disappeared when percentage of people without a high school diploma was added to the regression models. The fit of the regression significantly improved when education was added to the model. Conclusions Lack of high school education accounts for the income inequality effect and is a powerful predictor of mortality variation among US states.	Univ Arkansas, Dept Hlth Serv Adm, Little Rock, AR 72204 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Muller, A (corresponding author), Univ Arkansas, Dept Hlth Serv Adm, 207 Ross Hall,2801 S Univ Ave, Little Rock, AR 72204 USA.							Atkinson Anthony, 1983, SOCIAL JUSTICE PUBLI; Backlund E, 1999, SOC SCI MED, V49, P1373, DOI 10.1016/S0277-9536(99)00209-9; Fuchs V., 1974, WHO SHALL LIVE; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; Gregg P., 1999, RELATIONSHIP CHILDHO; GROSSMAN M, 1976, HOUSEHOLD PRODUCTION, P147; HADLEY J, 1982, MORE MED CARE BETTER; Jones A.F., 2000, CURRENT POPULATION R; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Lynch JW, 2000, BMJ-BRIT MED J, V320, P1200, DOI 10.1136/bmj.320.7243.1200; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; Maddala G.S., 1988, INTRO ECONOMETRICS; Marmot M, 2001, BMJ-BRIT MED J, V322, P1233, DOI 10.1136/bmj.322.7296.1233; McMurrer D. P., 1997, INTERGENERATIONAL MO; Ross NA, 2000, BRIT MED J, V320, P898, DOI 10.1136/bmj.320.7239.898; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; SOLON G, 1992, AM ECON REV, V82, P393; Statsoft, 1999, STATISTICA WIND; *US BUR CENS, AM FACT FIND TABL P1; *US BUR CENS, 1998, TABL B MED EARN FULL; *US BUR CENS, TABL S4 GIN RAT STAT; *US BUR CENS, AM FACT FIND TABL PO; *US CENS BUR, AM FACT FIND TABL PO; *US CENS BUR, AM FACT FIND TABL P1; *US PHS, CDC WONDER; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; Wilkinson RG, 1997, BRIT MED J, V314, P1727, DOI 10.1136/bmj.314.7096.1727; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953	30	163	166	2	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					23	+		10.1136/bmj.324.7328.23	http://dx.doi.org/10.1136/bmj.324.7328.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777800	Green Published, Bronze			2022-12-28	WOS:000173205700019
J	Hollman, A				Hollman, A			Postmortems on the kitchen table	BRITISH MEDICAL JOURNAL			English	Article									Sea Bank, Pett TN35 4EQ, E Sussex, England		Hollman, A (corresponding author), Sea Bank, Pett TN35 4EQ, E Sussex, England.							BAUER GE, 2000, BRIT CARDIOLOGY 20 C, P370; FORD JMT, 1987, MED HIST S, V7, P203; FRIEDLANDER R, 1969, BRIT MED J, V1, P127; HOCKING FDM, 1992, BODIES CRIMES PATHOL; Hollman A, 2000, HEART, V83, P586; HOLLMAN A, 1993, BRIT HEART J, V70, P587; HOLLMAN A, 2000, BRIT CARDIOLOGY 20 C, P363; WOODHEAD GS, 1888, PRACTICAL PATHOLOGY	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1472	1473		10.1136/bmj.323.7327.1472	http://dx.doi.org/10.1136/bmj.323.7327.1472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751360	Green Published			2022-12-28	WOS:000172979900020
J	Phillips, DP; Liu, GC; Kwok, K; Jarvinen, JR; Zhang, N; Abramson, IS				Phillips, DP; Liu, GC; Kwok, K; Jarvinen, JR; Zhang, N; Abramson, IS			The Hound of the Baskervilles effect: natural experiment on the influence of psychological stress on timing of death	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; MENTAL STRESS	Objective To determine whether cardiac mortality is abnormally high on days considered unlucky: Chinese and Japan se people consider the number 4 unlucky, white Americans do not. Design Examination of cardiac and non-cardiac mortality on and around the fourth of each month in Chinese and Japanese subjects and white controls. Setting United States. Subjects All Chinese and Japanese (n = 209 908) and white (n = 47 328 762) Americans whose computerised death certificates were recorded between the beginning of January 1973 and the end of December 1998. Main outcome measures Ratio of observed to expected numbers of deaths on the fourth day of the month (expected number was estimated from mortality on other days of the month). Results Cardiac mortality in Chinese and Japanese people peaked on the fourth of the month. The peak was particularly large for deaths from chronic heart disease (ratio of observed to expected deaths = 1.13, 95% confidence interval 1.06 to 1.21) and still larger for deaths from chronic heart disease in California (1.27,1.15 to 1.39). Within this group. inpatients showed a particularly large peak on the fourth day(1.45, 1.19 to 1.81). The peak was not followed by a compensatory drop in number of deaths. White controls, matched on age, sex, marital status, hospital status, location, and cause of death, showed no similar peak in cardiac mortality. Conclusions Our findings of excess cardiac mortality on "unlucky" days are consistent with the hypothesis that cardiac mortality increases on psychologically stressful occasions. The results are inconsistent with nine other possible explanations for the findings-for example, the fourth day peak does not seem to occur because of changes in the patient's diet, alcohol intake, exercise, or drug regimens.	Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Math, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Phillips, DP (corresponding author), Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA.							*CA DEP HLTH SERV, MORT FIL; DOYLE AC, 1964, HOUND BASKERVILLES; Gardner M. J., 1989, STAT CONFIDENCE; Krantz DS, 2000, JAMA-J AM MED ASSOC, V283, P1800, DOI 10.1001/jama.283.14.1800; *NAT CTR HLTH STAT, 1997, VIT STAT US 1994 A, V2; *NAT CTR HLTH STAT, 1976, VIT STAT US 1973 1 A, V2; Philips DP, 1999, NEW ENGL J MED, V341, P93, DOI 10.1056/NEJM199907083410206; PHILLIPS DF, 1995, JAMA-J AM MED ASSOC, V273, P1221, DOI 10.1001/jama.273.15.1221; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS DP, 1993, LANCET, V342, P1142, DOI 10.1016/0140-6736(93)92124-C; PHILLIPS DP, 2000, ENCY PSYCHOL; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; Soufer R, 1998, P NATL ACAD SCI USA, V95, P6454, DOI 10.1073/pnas.95.11.6454; STEPTOE A, 1991, CIRCULATION, V83, P14; *US NAT CTR HLTH S, MORT DET FIL; Witte DR, 2000, BMJ-BRIT MED J, V321, P1552, DOI 10.1136/bmj.321.7276.1552; 2000, W CALENDAR CALENDAR; 2000, SCHAUWECKERS GUIDE J	19	53	54	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1443	1446		10.1136/bmj.323.7327.1443	http://dx.doi.org/10.1136/bmj.323.7327.1443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506PA	11751347	Green Published			2022-12-28	WOS:000172979900006
J	Reimer, PJ				Reimer, PJ			Archaeology - A new twist in the radiocarbon tate	SCIENCE			English	Editorial Material							LOCATION-DEPENDENT DIFFERENCES; AGE CALIBRATION; C-14 CONTENT; WOOD		Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Reimer, PJ (corresponding author), Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA.		Reimer, Paula/I-5915-2015					BRAZIUNAS TF, 1995, GLOBAL BIOGEOCHEM CY, V9, P565, DOI 10.1029/95GB01725; Damon PE, 1995, RADIOCARBON, V37, P829, DOI 10.1017/S0033822200031441; Grove JM, 2001, CLIMATIC CHANGE, V48, P53, DOI 10.1023/A:1005662822136; Kromer B, 2001, SCIENCE, V294, P2529, DOI 10.1126/science.1066114; Manning S. W., 1999, TEST TIME VOLCANO TH; Manning SW, 2001, SCIENCE, V294, P2532, DOI 10.1126/science.1066112; McCormac FG, 1995, RADIOCARBON, V37, P395, DOI 10.1017/S0033822200030873; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; van Geel B, 1998, RADIOCARBON, V40, P1163	11	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2494	2495		10.1126/science.1068023	http://dx.doi.org/10.1126/science.1068023			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11743161				2022-12-28	WOS:000172927700040
J	Fored, CM; Ejerblad, E; Lindblad, P; Fryzek, JP; Dickman, PW; Signorello, LB; Lipworth, L; Elinder, C; Blot, WJ; McLaughlin, JK; Zack, MM; Nyren, O				Fored, CM; Ejerblad, E; Lindblad, P; Fryzek, JP; Dickman, PW; Signorello, LB; Lipworth, L; Elinder, C; Blot, WJ; McLaughlin, JK; Zack, MM; Nyren, O			Acetaminophen, aspirin, and chronic renal failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANALGESIC USE; DISEASE; NEPHROPATHY; KIDNEY; PARACETAMOL; RISK	Background: Several epidemiologic studies have demonstrated an association between heavy consumption of nonnarcotic analgesics and the occurrence of chronic renal failure, but it is unclear which is the cause and which is the effect. Methods: In a nationwide, population-based, case-control study of early-stage chronic renal failure in Sweden, face-to-face interviews were conducted with 926 patients with newly diagnosed renal failure and 998 control subjects, of whom 918 and 980, respectively, had complete data. We used logistic-regression models to estimate the relative risks of disease-specific types of chronic renal failure associated with the use of various analgesics. Results: Aspirin and acetaminophen were used regularly by 37 percent and 25 percent, respectively, of the patients with renal failure and by 19 percent and 12 percent, respectively, of the controls. Regular use of either drug in the absence of the other was associated with an increase by a factor of 2.5 in the risk of chronic renal failure from any cause. The relative risks rose with increasing cumulative lifetime doses, rose more consistently with acetaminophen use than with aspirin use, and were increased for most disease-specific types of chronic renal failure. When we disregarded the recent use of analgesics, which could have occurred in response to antecedents of renal disease, the associations were only slightly attenuated. Conclusions: Our results are consistent with the existence of exacerbating effects of acetaminophen and aspirin on chronic renal failure. However, we cannot rule out the possibility of bias due to the triggering of analgesic consumption by predisposing conditions. (N Engl J Med 2001;345:1801-8.) Copyright (C) 2001 Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Huddinge Univ Hosp, Dept Renal Med, S-14186 Huddinge, Sweden; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; Int Epidemiol Inst, Rockville, MD USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Karolinska Institutet; Karolinska Institutet; Vanderbilt University; Centers for Disease Control & Prevention - USA	Fored, CM (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, SE-17177 Stockholm, Sweden.		Dickman, Paul W/B-4572-2013	Dickman, Paul W/0000-0002-5788-3380				BUCKALEW VM, 1986, MEDICINE, V65, P291, DOI 10.1097/00005792-198609000-00002; Calltorp J, 1996, LANCET, V347, P587, DOI 10.1016/S0140-6736(96)91278-7; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Delzell E, 1998, MEDICINE, V77, P383; ELSEVIERS M, 1994, THESIS U ANTWERP DEP; Elseviers MM, 1999, DRUG SAFETY, V20, P15, DOI 10.2165/00002018-199920010-00003; Feinstein AR, 2000, KIDNEY INT, V58, P2259, DOI 10.1046/j.1523-1755.2000.00410.x; Goldfarb S, 1998, ANN INTERN MED, V129, P636, DOI 10.7326/0003-4819-129-8-199810150-00012; GRIMLUND K, 1963, ACTA MED SCAND, V405, P1; Henrich WL, 1996, AM J KIDNEY DIS, V27, P162, DOI 10.1016/S0272-6386(96)90046-3; *INT AG RES CANC, 1980, STAT METH CANC RES; MCCREDIE M, 1988, NEPHRON, V49, P296, DOI 10.1159/000185079; McLaughlin JK, 1998, KIDNEY INT, V54, P679, DOI 10.1046/j.1523-1755.1998.00043.x; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MOULTON LH, 1991, J CLIN EPIDEMIOL, V44, P915, DOI 10.1016/0895-4356(91)90054-D; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; NANRA RS, 1993, ANALGESIC NSAID INDU, P17; PERNEGER TV, 1995, AM J KIDNEY DIS, V25, P722, DOI 10.1016/0272-6386(95)90548-0; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; Rexrode KM, 2001, JAMA-J AM MED ASSOC, V286, P315, DOI 10.1001/jama.286.3.315; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sabatini S, 1996, AM J KIDNEY DIS, V28, pS34, DOI 10.1016/S0272-6386(96)90567-3; Salas M, 1999, AM J EPIDEMIOL, V149, P981; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SEGASOTHY M, 1988, NEPHRON, V50, P50, DOI 10.1159/000185116; SPUHLER O, 1953, Z KLIN MED, V151, P1; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; *USRDS COORD CTR, 2001, 2001 USRDS ADR REF T; WEST SL, 1994, PHARMACOEPIDEM DR S, P549; WING AJ, 1989, TOXICOL LETT, V46, P281, DOI 10.1016/0378-4274(89)90136-7	31	173	180	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1801	1808		10.1056/NEJMoa010323	http://dx.doi.org/10.1056/NEJMoa010323			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752356				2022-12-28	WOS:000172794800003
J	Lavie, P				Lavie, P			Current concepts: Sleep disturbances in the wake of traumatic events.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; PSYCHIATRIC-DISORDERS; BEHAVIOR DISORDER; SURVIVORS; SYMPTOMS; PTSD; NIGHTMARES; INSOMNIA; DISASTER		Technion Israel Inst Technol, Fac Med, Sleep Lab, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Lavie, P (corresponding author), Technion Israel Inst Technol, Fac Med, Sleep Lab, Gutwirth Bldg,Technion City, Haifa, Israel.		Lavie, Peretz/AAC-2736-2020					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BARTEMEIER LH, 1946, J NERV MENT DIS, V104, P358, DOI 10.1097/00005053-194610000-00002; Blake DD, 1998, PSYCHOL REP, V83, P1175, DOI 10.2466/PR0.83.7.1175-1178; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Brown TM, 1996, J TRAUMA STRESS, V9, P129, DOI 10.1002/jts.2490090111; CARTWRIGHT RD, 1983, ARCH GEN PSYCHIAT, V40, P197; Chesson AL, 1999, SLEEP, V22, P1128, DOI 10.1093/sleep/22.8.1128; Childress R. D., 1997, Journal of Travel Research, V36, P43; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Cluydts R, 1998, J INT MED RES, V26, P13, DOI 10.1177/030006059802600102; DAGAN Y, 1991, BIOL PSYCHIAT, V30, P618, DOI 10.1016/0006-3223(91)90031-G; Danjou P, 1999, BRIT J CLIN PHARMACO, V48, P367; DOLLINGER SJ, 1985, BRIT J MED PSYCHOL, V58, P375, DOI 10.1111/j.2044-8341.1985.tb02656.x; DOOLEY E, 1995, BRIT J PSYCHIAT, V167, P233, DOI 10.1192/bjp.167.2.233; Dow BM, 1996, BIOL PSYCHIAT, V39, P42, DOI 10.1016/0006-3223(95)00103-4; Engdahl BE, 2000, BIOL PSYCHIAT, V47, P520, DOI 10.1016/S0006-3223(99)00201-2; FAMULARO R, 1994, ARCH PEDIAT ADOL MED, V148, P1032, DOI 10.1001/archpedi.1994.02170100030007; GHAEMI SN, 1995, PSYCHOSOMATICS, V36, P416; Glaubman H., 1990, J TRAUMA STRESS, V3, P255, DOI DOI 10.1002/JTS.2490030207; Glod CA, 1997, J AM ACAD CHILD PSY, V36, P1236, DOI 10.1097/00004583-199709000-00016; GOLDSTEIN G, 1987, AM J PSYCHIAT, V144, P1210; GREENBERG R, 1972, BRIT J MED PSYCHOL, V45, P27, DOI 10.1111/j.2044-8341.1972.tb01416.x; Hall M, 1998, PSYCHOSOM MED, V60, P48, DOI 10.1097/00006842-199801000-00011; Harvey AG, 2001, CLIN PSYCHOL REV, V21, P1037, DOI 10.1016/S0272-7358(00)00083-0; HEFEZ A, 1987, AM J PSYCHIAT, V144, P344; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hurwitz TD, 1998, BIOL PSYCHIAT, V44, P1066, DOI 10.1016/S0006-3223(98)00089-4; Husain AM, 2001, J CLIN NEUROPHYSIOL, V18, P148, DOI 10.1097/00004691-200103000-00005; Ironson G, 1997, PSYCHOSOM MED, V59, P128, DOI 10.1097/00006842-199703000-00003; KAMINER H, 1991, J NERV MENT DIS, V179, P664, DOI 10.1097/00005053-199111000-00003; Kato H, 1996, ACTA PSYCHIAT SCAND, V93, P477, DOI 10.1111/j.1600-0447.1996.tb10680.x; KLEIN E, IN PRESS AM J PSYCHI; Koren D, 1999, AM J PSYCHIAT, V156, P367; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Krakow B, 2000, J PSYCHOSOM RES, V49, P291, DOI 10.1016/S0022-3999(00)00147-1; Krakow B, 2001, BIOL PSYCHIAT, V49, P948, DOI 10.1016/S0006-3223(00)01087-8; KRAMER M, 1984, PSYCHIAT J U OTTAWA, V9, P102; KRAMER M, 1987, J AM ACAD PSYCHOAN, V15, P67, DOI 10.1521/jaap.1.1987.15.1.67; KRAMER M, 1987, SLEEP RES, V16, P281; Kravitz Melva, 1993, Journal of Burn Care and Rehabilitation, V14, P83, DOI 10.1097/00004630-199301000-00018; KUCH K, 1992, AM J PSYCHIAT, V149, P337; Lavie P, 1998, BIOL PSYCHIAT, V44, P1060, DOI 10.1016/S0006-3223(98)00037-7; LAVIE P, 1979, AM J PSYCHIAT, V136, P175; LAVIE P, 1991, ISRAEL J MED SCI, V27, P681; LAVIE P, 1993, J SLEEP RES, V2, P34, DOI 10.1111/j.1365-2869.1993.tb00058.x; LAVIE P, 1979, BIOL PSYCHIAT, V14, P983; Lavie P., 1991, DREAMING, V1, P11, DOI [DOI 10.1037/H0094313, 10.1037/h0094313]; Mellman TA, 2001, J TRAUMA STRESS, V14, P241, DOI 10.1023/A:1007812321136; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P1659; Mellman TA, 1997, SLEEP, V20, P46, DOI 10.1093/sleep/20.1.46; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Mellman TA, 1997, ANN NY ACAD SCI, V821, P142, DOI 10.1111/j.1749-6632.1997.tb48275.x; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Neylan TC, 2001, J TRAUMA STRESS, V14, P461, DOI 10.1023/A:1011100420978; Nishith P, 2001, J TRAUMA STRESS, V14, P469, DOI 10.1023/A:1011152405048; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; Ohayon MM, 2000, COMPR PSYCHIAT, V41, P469, DOI 10.1053/comp.2000.16568; OLLENDICK DG, 1982, J COMMUNITY PSYCHOL, V10, P157, DOI 10.1002/1520-6629(198204)10:2<157::AID-JCOP2290100209>3.0.CO;2-8; PAI MN, 1969, SEARCHLIGHT SLEEP DI; Pfefferbaum B, 1999, AM J PSYCHIAT, V156, P1069; Pillar G, 2000, SLEEP MED REV, V4, P183, DOI 10.1053/smrv.1999.0095; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239; RAVIV A, 1983, STRESS ISRAEL, P138; REIST C, 1995, PROG NEURO-PSYCHOPH, V19, P433, DOI 10.1016/0278-5846(95)00024-P; REYNOLDS CF, 1993, BIOL PSYCHIAT, V34, P791, DOI 10.1016/0006-3223(93)90068-O; ROSEN J, 1991, AM J PSYCHIAT, V148, P62; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; ROSS RJ, 1994, SLEEP, V17, P723, DOI 10.1093/sleep/17.8.723; ROSS RJ, 1994, BIOL PSYCHIAT, V35, P195, DOI 10.1016/0006-3223(94)91152-5; Roth T, 2001, INT J CLIN PRACT, V55, P42; Sadavoy J, 1997, AM J GERIAT PSYCHIAT, V5, P287, DOI 10.1097/00019442-199700540-00004; Sadeh A, 1996, CHILD ADOL PSYCH CL, V5, P685, DOI 10.1016/S1056-4993(18)30356-0; Schenck CH, 1997, SLEEP, V20, P972, DOI 10.1093/sleep/20.11.972; SCHLOSBERG A, 1978, J CLIN PSYCHIAT, V39, P546; Schoen LKM, 1984, SLEEP RES, V13, P102; SHANNON MP, 1994, J AM ACAD CHILD PSY, V33, P80, DOI 10.1097/00004583-199401000-00012; Shochat T, 1998, ANN MED, V30, P109; Silva C, 1997, J WOMENS HEALTH, V6, P543, DOI 10.1089/jwh.1997.6.543; STERIADE M, 1994, J PSYCHIATR NEUROSCI, V19, P354; Stevinson C, 2000, SLEEP MED, V1, P91, DOI 10.1016/S1389-9457(99)00015-5; Stiasny K, 2001, NEUROLOGY, V56, P1399, DOI 10.1212/WNL.56.10.1399; Terr LC, 1996, AM J PSYCHIAT, V153, P618; Troy SM, 2000, J CLIN PSYCHOPHARM, V20, P328, DOI 10.1097/00004714-200006000-00007; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; VANDERKOLK B, 1984, AM J PSYCHIAT, V141, P187; VOGEL JM, 1993, J CLIN CHILD PSYCHOL, V22, P464, DOI 10.1207/s15374424jccp2204_7; Walsh JK, 2000, CLIN NEUROPHARMACOL, V23, P17, DOI 10.1097/00002826-200001000-00004; Weisaeth L, 2001, J CLIN PSYCHIAT, V62, P35; WOOD JM, 1992, J ABNORM PSYCHOL, V101, P219, DOI 10.1037/0021-843X.101.2.219; Woodward SH, 2000, PHYSIOL BEHAV, V70, P197, DOI 10.1016/S0031-9384(00)00271-7; Woodward SH, 1996, BIOL PSYCHIAT, V39, P182, DOI 10.1016/0006-3223(95)00104-2; Woodward SH, 2000, BIOL PSYCHIAT, V48, P1081, DOI 10.1016/S0006-3223(00)00917-3; Woodward SH, 1996, J TRAUMA STRESS, V9, P137, DOI 10.1002/jts.2490090112; Youakim JM, 1998, PSYCHOSOMATICS, V39, P168, DOI 10.1016/S0033-3182(98)71365-9; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	97	235	240	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1825	1832		10.1056/NEJMra012893	http://dx.doi.org/10.1056/NEJMra012893			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	503JF	11752360				2022-12-28	WOS:000172794800007
J	Nouira, S; Marghli, S; Belghith, M; Besbes, L; Elatrous, S; Abroug, F				Nouira, S; Marghli, S; Belghith, M; Besbes, L; Elatrous, S; Abroug, F			Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial	LANCET			English	Article							ACUTE BACTERIAL EXACERBATIONS; CHRONIC-BRONCHITIS; ANTIMICROBIAL RESISTANCE; CIPROFLOXACIN; COPD; EPIDEMIOLOGY; EFFICACY; SEVERITY	Background The role of antibiotics in treatment of patients with moderate exacerbations of chronic obstructive pulmonary disease (COPD) is uncertain, but such treatment might be useful in very severe episodes. Our objective was to assess the effects of ofloxacin in patients with exacerbations of COPD who required mechanical ventilation. Methods We did a prospective, randomised, double-blind, placebo-controlled trial in 93 patients with acute exacerbation of COPD who required mechanical ventilation. Patients were randomly assigned to receive oral ofloxacin 400 mg once daily (n=47) or placebo (46) for 10 days. Primary endpoints were death in hospital and need for an additional course of antibiotics, both separately and in combination. Analysis was by intention to treat. Findings Three patients dropped out of the study. Two (4%) patients receiving ofloxacin died in hospital and ten (22%) did so in the placebo group (absolute risk reduction 17.5%, 95% CI 4.3-30.7, p=0.01). Treatment with ofloxacin significantly reduced the need for additional courses of antibiotics (28.4%, 12.9-43-9, p=0.0006). The combined frequency of death in hospital and need for additional antibiotics was significantly lower in patients assigned to ofloxacin than in those receiving placebo (45.9%, 29.1-62.7, p<0.0001). The duration of mechanical ventilation and hospital stay was significantly shorter in the ofloxacin group than in the placebo group (absolute difference 4.2 days, 95% CI 2.5-5.9; and 9.6 days, 3.4-12.8, respectively). Interpretation New fluoroquinolones, such as ofloxacin, are beneficial in the treatment of COPD exacerbation requiring mechanical ventilation.	Bourguiba Univ, Med Intens Care Unit, Monastir 5000, Tunisia; Farhat Hached Univ Hosp, Med Intens Care Unit, Sousse, Tunisia	Universite de Monastir; Hopital Fattouma Bourguiba; Universite de Sousse; Hopital Farhat Hached	Nouira, S (corresponding author), Bourguiba Univ, Med Intens Care Unit, Monastir 5000, Tunisia.	semir.nouira@rns.tn	Abroug, Fekri/ADJ-0934-2022; Abroug, Fekri/ABI-6564-2022; Reid, David W/B-3263-2011	Abroug, Fekri/0000-0002-5626-5329; Besbes, Lamia/0000-0002-9905-5129; Nouira, Semir/0000-0002-0137-5491				ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; BALL P, 1995, CHEST, V108, pS43, DOI 10.1378/chest.108.2_Supplement.43S; Chodosh S, 1998, ANTIMICROB AGENTS CH, V42, P114, DOI 10.1128/AAC.42.1.114; Chodosh S, 1998, CLIN INFECT DIS, V27, P730, DOI 10.1086/514934; CHODOSH S, 1988, SCAND J INFECT DIS, P22; CHODOSH S, 1991, AM J MED, V91, pS93, DOI 10.1016/0002-9343(91)90318-R; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; DAMICO R, 1998, BRIT MED J, V16, P1275; Doern GV, 1995, AM J MED, V99, pS3, DOI 10.1016/S0002-9343(99)80303-9; GRAVES EJ, 1991, VITAL HLTH STAT, V12, P1; Grossman R, 1998, CHEST, V113, P131, DOI 10.1378/chest.113.1.131; HAGEDORN SD, 1992, POSTGRAD MED, V91, P105; Hirschmann JV, 2000, CHEST, V118, P193, DOI 10.1378/chest.118.1.193; Hooper DC, 1998, ANN INTERN MED, V129, P908, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00015; HUGHES DTD, 1969, BMJ-BRIT MED J, V4, P470, DOI 10.1136/bmj.4.5681.470; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Murphy TF, 2000, CHEST, V118, P204, DOI 10.1378/chest.118.1.204; O'Doherty B, 1998, EUR J CLIN MICROBIOL, V17, P441, DOI 10.1007/BF01691580; Obaji A, 2001, DRUG AGING, V18, P1, DOI 10.2165/00002512-200118010-00001; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; PUNAKIVI L, 1990, SCAND J INFECT DIS, P41; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766; Wilson R, 1996, J ANTIMICROB CHEMOTH, V37, P205, DOI 10.1093/jac/37.2.205; WOODBAKER R, 2000, COCHRANE DATABASE SY	27	172	194	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2020	2025		10.1016/S0140-6736(01)07097-0	http://dx.doi.org/10.1016/S0140-6736(01)07097-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755608				2022-12-28	WOS:000172722800010
J	Smeeth, L; Fletcher, AE; Stirling, S; Nunes, M; Breeze, E; Ng, E; Bulpitt, CJ; Jones, D				Smeeth, L; Fletcher, AE; Stirling, S; Nunes, M; Breeze, E; Ng, E; Bulpitt, CJ; Jones, D			Randomised comparison of three methods of administering a screening questionnaire to elderly people: findings from the MRC trial of the assessment and management of older people in the community	BRITISH MEDICAL JOURNAL			English	Article							GERIATRIC DEPRESSION SCALE; MINI-MENTAL-STATE; CHI-SQUARED TESTS; HEARING IMPAIRMENT; GENERAL-PRACTICE; POSTAL QUESTIONNAIRE; ALCOHOL-CONSUMPTION; WHISPERED VOICE; SHORT VERSIONS; INTERVIEW	Objective To compare three different methods of administering a brief screening questionnaire to elderly people: post. interview by lay interviewer, and interview by nurse. Design Randomised comparison of methods within a cluster randomised trial. Setting 106 general practices in the United Kingdom. Participants 32 990 people aged 75 years or over registered with participating practices. Main outcome measures Response rates, proportion of missing values, prevalence of self reported morbidity and sensitivity, and specificity of self reported measures by method of administration of questionnaire for four domains. Results The response rate was higher for the postal questionnaire than for the two interview methods combined (83.5% v 74.9%; difference 8.5%, 95% confidence interval 4.4% to 12.7%, P < 0.001). The proportion of missing or invalid responses was low overall (mean 2.1%) but was greater for the postal method than for the interview methods combined (4.1% v 0.9%; difference 3.2%. 2.7% to 3.6%, P < 0.001). With a few exceptions, levels of self reported morbidity were lower in the interview groups, particularly for interviews by nurses. The sensitivity of the self reported measures was lower in the nurse interview group for three Out Of four domains, but 95% confidence intervals for the estimates overlapped. Specificity of the self reported measures varied little by method of administration. Conclusions Postal questionnaires were associated with higher response rates but also higher proportions of missing values than were interview methods. Lower estimates of self reported morbidity were obtained with the nurse interview method and to a lesser extent with the lav interview method than with postal questionnaires.	Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1E 7HT, England; Fac Med, Imperial Coll, Sect Care Elderly, London W12 0NN, England; Univ Wales Coll Med, Dept Geriatr Med, Res Team Care Elderly People, Cardiff CF64 2XX, S Glam, Wales	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Cardiff University	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, Keppel St, London WC1E 7HT, England.		Breeze, Elizabeth/AAK-4927-2021; Ng, Edmond/L-5871-2019; Ng, Edmond/G-8788-2011; Smeeth, Liam/X-5862-2018	Smeeth, Liam/0000-0002-9168-6022				Addington-Hall J, 1998, J EPIDEMIOL COMMUN H, V52, P802, DOI 10.1136/jech.52.12.802; Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8; American Psychiatric Association, 1994, DIAGN STAT MENT DIS; ANDERSON WF, 1955, LANCET, V2, P239; Barber J H, 1980, J R Coll Gen Pract, V30, P49; Bowling A, 1997, RES METHODS HLTH, P228; BOWNS I, 1991, BRIT J GEN PRACT, V41, P100; BROWNING GG, 1989, J LARYNGOL OTOL, V103, P7, DOI 10.1017/S0022215100107923; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; CARTWRIGHT A, 1988, MILBANK Q, V66, P172, DOI 10.2307/3349989; Cochran W.G., 2007, SAMPLING TECHNIQUES; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; CUTLER SF, 1988, ALCOHOL ALCOHOLISM, V23, P441; DATH P, 1994, FAM PRACT, V11, P260, DOI 10.1093/fampra/11.3.260; *DEP HLTH, 2001, SINGL ASS PROC CONS; *DEP HLTH WELSH OF, 1989, GEN PRACT NAT HLTH S; Department of Health, 2001, NAT SERV FRAM OLD PE; DOLL H, 1991, SOC SCI MED, V33, P1303, DOI 10.1016/0277-9536(91)90079-R; *DRIV MED GROUP, 2000, GLANC GUID CURR MED; Eekhof JAH, 1996, BRIT J GEN PRACT, V46, P473; Fletcher A, 1998, BRIT MED BULL, V54, P945; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frost NA, 2000, BRIT J OPHTHALMOL, V84, P432, DOI 10.1136/bjo.84.4.432; HANGER HC, 1990, NEW ZEAL MED J, V103, P473; HAYES V, 1995, AGE AGEING, V24, P120, DOI 10.1093/ageing/24.2.120; Herrmann N, 1996, INT J GERIATR PSYCH, V11, P457, DOI 10.1002/(SICI)1099-1166(199605)11:5<457::AID-GPS325>3.0.CO;2-2; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Mallinson S, 1998, J EPIDEMIOL COMMUN H, V52, P324, DOI 10.1136/jech.52.5.324; MCDONNELL H, 1979, J EPIDEMIOL COMMUN H, V33, P203, DOI 10.1136/jech.33.3.203; MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; Picavet HSJ, 2001, J EPIDEMIOL COMMUN H, V55, P408, DOI 10.1136/jech.55.6.408; Pless I B, 1979, J Community Health, V5, P22, DOI 10.1007/BF01321567; RAO JNK, 1981, J AM STAT ASSOC, V76, P221, DOI 10.2307/2287815; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; Sheikh JI, 1986, CLIN GERONTOL, V37, P819, DOI DOI 10.1300/J018V05N01_; SIEMIATYCKI J, 1979, AM J PUBLIC HEALTH, V69, P238, DOI 10.2105/AJPH.69.3.238; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; VICTOR CR, 1988, ARCH GERONTOL GERIAT, V7, P163, DOI 10.1016/0167-4943(88)90028-3; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; WILCOCK GK, 1979, GERONTOLOGY, V25, P345, DOI 10.1159/000212363; WILLIAMSON J, 1964, LANCET, V1, P1117; Wiseman EJ, 1996, J ADDICT DIS, V15, P43, DOI 10.1300/J069v15n02_04; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	49	60	61	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1403	1407		10.1136/bmj.323.7326.1403	http://dx.doi.org/10.1136/bmj.323.7326.1403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505EX	11744565	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000172900400018
J	Drucker, E; Alcabes, PG; Marx, PA				Drucker, E; Alcabes, PG; Marx, PA			The injection century: massive unsterile injections and the emergence of human pathogens	LANCET			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; TYPE-2		Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; CUNY Hunter Coll, Sch Hlth Sci, New York, NY 10021 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; Tulane Univ, Hlth Sci Ctr, Sch Publ Hlth & Trop Med, Covington, LA USA; Tulane Univ, Hlth Sci Ctr, Tulane Reg Primate Res Ctr, Covington, LA USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Hunter College (CUNY); Rockefeller University; Tulane University; Tulane University	Drucker, E (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA.	drucker@aecom.yu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044596] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44596] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; [Anonymous], 1996, AIDS WORLD 2; *BECT DICK CORP, 1991, ECH, V11, P1; Birungi H., 1994, INJECTION USE PRACTI; Cayabyab M, 1999, J VIROL, V73, P976, DOI 10.1128/JVI.73.2.976-984.1999; Chen ZW, 1996, J VIROL, V70, P3617, DOI 10.1128/JVI.70.6.3617-3627.1996; CROFTS N, 2000, MANUAL REDUCING DRUG; Drucker E, 1998, AIDS, V12 Suppl A, pS217; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; *FROST SULL CORP, 1996, US DISP NEEDL SYR RE; GARRETT L, 1994, COMING PLAGUES NEWLY, P32; HAYWARD EG, 1949, 13 NAT FARM CHEM; HENDRICK R, 1994, COLONIALISM HLTH ILL; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Holterman L, 1999, J GEN VIROL, V80, P3089, DOI 10.1099/0022-1317-80-12-3089; HOPPER E, 1999, RIVER; HUYTIN Y, 2001, SAFE INJECTING GLOBA; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; NEWITT WL, 1967, ANN NY ACAD SCI, V145, P212; OLIVER R, 1977, AFRICA 1800; REELER AV, 1990, SOC SCI MED, V31, P1119, DOI 10.1016/0277-9536(90)90233-I; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; STIMSON VG, 1993, B NARCOTICS, V46, P3; *UN INT DRUG CONTR, 2000, WORLD DRUG REP; VANDERGEEST S, 1982, MED ANTHROPOL, V4, P197; *WHO, 1999, PROD INF SHEETS GLOB; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400; 1987, UNICEF HIST SERIES M, V6; IN PRESS P ROYAL SOC	31	152	155	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1989	1992		10.1016/S0140-6736(01)06967-7	http://dx.doi.org/10.1016/S0140-6736(01)06967-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747942				2022-12-28	WOS:000172622200035
J	Luo, ZC; Karlberg, J				Luo, ZC; Karlberg, J			Timing of birth and infant and early neonatal mortality in Sweden 1973-95: longitudinal birth register study	BRITISH MEDICAL JOURNAL			English	Article							DEATHS; ASPHYXIA	Objective To assess the impact of time of birth on infant mortality and early neonatal mortality in full term and preterm births. Design Analysis of data from the Swedish birth register, 1973-95. Participants 2 102 324 spontaneous live births of infants without congenital malformation. Outcome measurements Absolute and relative risk of infant mortality, early neonatal mortality, and early neonatal mortality related to asphyxia. Results Infant mortality, early neonatal morality, and early neonatal mortality related to asphyxia were higher in infants who were born during the night (9 pm to 9 am) compared with those born during the day for 1973-9, 1980-9, and 1990-5. The difference was more dramatic for preterm infants. The largest difference was observed during 1990-5, when there was a 30% increase in early neonatal morality (relative risk 1.31, 95% confidence interval 1.10 to 1.57) and a 70% increase in early neonatal mortality related to asphyxia (1.70, 1.22 to 2.38) in preterm infants born during the night compared with rates for preterm infants born during the day. A detailed analysis over 24 hours revealed two "high risk" periods: between 5 pm and 1 am and around 9 am. Conclusions Infants born during the night have a greater risk of infant and early neonatal mortality and early neonatal mortality related to asphyxia than those born during th day. There has been no improvement over the past two decades. The problem is more serious for preterm births and was even worse in the 1990s. Shift changes and the hours immediately after such changes are high risk periods for neonatal care.	Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Karlberg, J (corresponding author), Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China.		Luo, Zhong-Cheng/T-3882-2017; Karlberg, Johan Petter Einar/C-4290-2009; Karlberg, Johan/AAZ-7864-2020	Luo, Zhong-Cheng/0000-0002-1794-1312; 				Chalmers JWT, 1998, BRIT MED J, V317, P539; Cheung YB, 2000, AM J EPIDEMIOL, V152, P1107, DOI 10.1093/aje/152.12.1107; Cheung YB, 2001, STAT MED, V20, P2455, DOI 10.1002/sim.858; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Heller G, 2000, BRIT MED J, V321, P274, DOI 10.1136/bmj.321.7256.274; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; *PAN AM HLT ORG, 1998, HLTH AM; Stewart JH, 1998, BRIT MED J, V316, P657, DOI 10.1136/bmj.316.7132.657	8	54	55	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1327	1330		10.1136/bmj.323.7325.1327	http://dx.doi.org/10.1136/bmj.323.7325.1327			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739216	Bronze, Green Published			2022-12-28	WOS:000172716900013
J	Finkelstein, G				Finkelstein, G			Romanticism, race, and recapitulation	SCIENCE			English	Editorial Material									Univ Colorado, Dept Hist, Denver, CO 80217 USA	University of Colorado System; University of Colorado Denver	Finkelstein, G (corresponding author), Univ Colorado, Dept Hist, Denver, CO 80217 USA.		Finkelstein, Gabriel/A-1065-2013	Finkelstein, Gabriel/0000-0003-2447-0448				[Anonymous], 1994, RICHARD OWEN VICTORI; CARUS CG, 1849, DENKSCHRIFT HUNDERTJ, P95; DARWIN C, 1998, ORIGIN SPECIES FACSI, P61; ELIAS N, 1978, CIVILIZING PROCESS, V1, pR8; Gould S. J., 1977, ONTOGENY PHYLOGENY; KLEMM G, 1843, ALLGEMEINE CULTUR GE, V4, P229; KLEMM G, 1843, ALLGEMEINE CULTUR GE, V1, P195; Levi-Strauss Claude, 1992, TRISTES TROPIQUES	8	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2101	2102		10.1126/science.1066826	http://dx.doi.org/10.1126/science.1066826			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739938	Green Submitted, Bronze			2022-12-28	WOS:000172647700027
J	Sagarin, R				Sagarin, R			Phenology - False estimates of the advance of spring	NATURE			English	Article							CLIMATE-CHANGE; TRENDS		Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA	Stanford University	Sagarin, R (corresponding author), Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA.							BEEBEE TJC, 1995, NATURE, V374, P219, DOI 10.1038/374219a0; Both C, 2001, NATURE, V411, P296, DOI 10.1038/35077063; Bradley NL, 1999, P NATL ACAD SCI USA, V96, P9701, DOI 10.1073/pnas.96.17.9701; Crick HQP, 1997, NATURE, V388, P526, DOI 10.1038/41453; Dunn PO, 1999, P ROY SOC B-BIOL SCI, V266, P2487, DOI 10.1098/rspb.1999.0950; Inouye DW, 2000, P NATL ACAD SCI USA, V97, P1630, DOI 10.1073/pnas.97.4.1630; Magnuson JJ, 2000, SCIENCE, V289, P1743, DOI 10.1126/science.289.5485.1743; McCleery RH, 1998, NATURE, V391, P30, DOI 10.1038/34073; Sagarin R, 2001, SCIENCE, V294, P811, DOI 10.1126/science.1064218; Schwartz MD, 1999, INT J BIOMETEOROL, V42, P113, DOI 10.1007/s004840050093; Sparks TH, 1999, INT J BIOMETEOROL, V42, P134, DOI 10.1007/s004840050096; Steel Duncan, 2000, MARKING TIME	12	59	59	2	38	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					600	600		10.1038/414600a	http://dx.doi.org/10.1038/414600a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740547	Bronze			2022-12-28	WOS:000172535600035
J	Sampson, HA				Sampson, HA			Use of food-challenge tests in children	LANCET			English	Editorial Material							ADVERSE REACTIONS; ALLERGY		Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.							BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; LOVELESS MH, 1950, J ALLERGY, V21, P489, DOI 10.1016/0021-8707(50)90097-9; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SAMPSON HA, 1998, ALLERGY PRINCIPLES P, P1162; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x	13	24	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1832	1833		10.1016/S0140-6736(01)06881-7	http://dx.doi.org/10.1016/S0140-6736(01)06881-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741619				2022-12-28	WOS:000172463000005
J	Nash, P; Tang, XJ; Orlicky, S; Chen, QH; Gertler, FB; Mendenhall, MD; Sicheri, F; Pawson, T; Tyers, M				Nash, P; Tang, XJ; Orlicky, S; Chen, QH; Gertler, FB; Mendenhall, MD; Sicheri, F; Pawson, T; Tyers, M			Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication	NATURE			English	Article							UBIQUITIN-LIGASE COMPLEX; PROTEIN-PROTEIN INTERACTIONS; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; F-BOX; DEPENDENT DEGRADATION; S-PHASE; KAPPA-B; KINASE	SCF ubiquitin ligases target phosphorylated substrates for ubiquitin-dependent proteolysis by means of adapter subunits called F-box proteins. The F-box protein Cdc4 captures phosphorylated forms of the cyclin-dependent kinase inhibitor Sic1 for ubiquitination in late G1 phase, an event necessary for the onset of DNA replication. The WD40 repeat domain of Cdc4 binds with high affinity to a consensus phosphopeptide motif (the Cdc4 phospho-degron, CPD), yet Sic1 itself has many sub-optimal CPD motifs that act in concert to mediate Cdc4 binding. The weak CPD sites in Sic1 establish a phosphorylation threshold that delays degradation in vivo, and thereby establishes a minimal G1 phase period needed to ensure proper DNA replication. Multisite phosphorylation may be a more general mechanism to set thresholds in regulated protein-protein interactions.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Kentucky, Dept Biochem, LP Markey Canc Ctr, Lexington, KY 40536 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Kentucky; Massachusetts Institute of Technology (MIT); University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca; tyers@mshri.on.ca	Pawson, Tony J/E-4578-2013; Tyers, Michael/ABE-3194-2021; Sicheri, Frank/F-8856-2013	Orlicky, Stephen/0000-0002-8172-2042				Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; Cormack B, 1998, CURR OPIN MICROBIOL, V1, P406, DOI 10.1016/S1369-5274(98)80057-X; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Guthrie C, 1991, METHODS ENZYMOLOGY; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MCKINNEY JD, 1995, MOL CELL BIOL, V15, P2509; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pawson T, 2000, GENE DEV, V14, P1027; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schneider BL, 1998, NATURE, V395, P86, DOI 10.1038/25774; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPENCER F, 1990, GENETICS, V124, P237; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	48	631	639	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	2001	414	6863					514	521		10.1038/35107009	http://dx.doi.org/10.1038/35107009			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734846				2022-12-28	WOS:000172405900039
J	Huirne, JAF; Lambalk, CB				Huirne, JAF; Lambalk, CB			Gonadotropin-releasing-hormone-receptor antagonists	LANCET			English	Review							FOLLICLE-STIMULATING-HORMONE; IN-VITRO FERTILIZATION; LUTEINIZING-HORMONE; OVARIAN STIMULATION; GNRH ANTAGONIST; LH SURGE; EMBRYO IMPLANTATION; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; GENE-EXPRESSION	Pulsatile gonadotropin-releasing hormone (GnRH) stimulates the pituitary secretion of both luteinising hormone (LH) and follicle-stimulating hormone (FSH) and thus controls the hormonal and reproductive function of the gonads. Blockade of GnRH effects may be wanted for a variety of reasons-eg, to prevent untimely luteinisation during assisted reproduction or in the treatment of sex-hormone-dependent disorders. Selective blockade of LH/FSH secretion and subsequent chemical castration have previously been achieved by desensitising the pituitary to continuously administered GnRH or by giving long-acting GnRH agonists. Only recently have GnRH-receptor antagonists, that immediately block GnRH's effects, been developed for clinical use with acceptable pharmacokinetic, safety, and commercial profiles. In assisted reproduction, these compounds seem to be as effective as established therapy but with shorter treatment times, less use of gonadotropic hormones, improved patient acceptance, and fewer follicles and oocytes. All current indications for GnRH-agonist desensitisation may prove to be indications for a GnRH antagonist, including endometriosis, leiomyoma, and breast cancer in women, benign prostatic hypertrophy and prostatic carcinoma in men, and central precocious puberty in children. However, the best clinical evidence so far has been in assisted reproduction and prostate cancer.	Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynaecol, Div Reprod Med, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Lambalk, CB (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynaecol, Div Reprod Med, POB 7057, NL-1007 MB Amsterdam, Netherlands.	cb.lambalk@azvu.nl		Lambalk, Cornelis/0000-0003-3947-5129				Albano C, 2000, HUM REPROD, V15, P526, DOI 10.1093/humrep/15.3.526; Albano C, 1997, FERTIL STERIL, V67, P917, DOI 10.1016/S0015-0282(97)81407-0; ALINANY H, 2001, COCHRANE LIB; [Anonymous], 1998, Hum Reprod, V13, P3023; ASHTON WT, 1999, BIOORG MED CHEM LETT, V9, P2597; ATAYA K, 1995, BIOL REPROD, V52, P365, DOI 10.1095/biolreprod52.2.365; ATAYA K, 1995, J CLIN ENDOCR METAB, V80, P790, DOI 10.1210/jc.80.3.790; BAJUSZ S, 1988, P NATL ACAD SCI USA, V85, P1637, DOI 10.1073/pnas.85.5.1637; BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P241, DOI 10.1111/j.1365-2265.1994.tb02475.x; Ben-Josef E, 1999, J UROLOGY, V161, P970, DOI 10.1016/S0022-5347(01)61831-7; BONDUELLE M, 2001, 6 INT S GNRH AN CANC; Borm G, 2000, HUM REPROD, V15, P1490; Brus L, 1997, HUM REPROD, V12, P769, DOI 10.1093/humrep/12.4.769; CAMPEN CA, 1995, BIOCHEM PHARMACOL, V49, P1313, DOI 10.1016/0006-2952(95)00027-W; Carolsfeld J, 2000, ENDOCRINOLOGY, V141, P505, DOI 10.1210/en.141.2.505; CHANSON P, 1994, J ENDOCRINOL INVEST, V17, P91, DOI 10.1007/BF03347692; Chegini N, 1996, J CLIN ENDOCR METAB, V81, P3215, DOI 10.1210/jc.81.9.3215; Cheng KW, 2000, ENDOCRINOLOGY, V141, P2340, DOI 10.1210/en.141.7.2340; Christin-Maitre S, 2000, CLIN ENDOCRINOL, V52, P721, DOI 10.1046/j.1365-2265.2000.00992.x; Comaru-Schally AM, 1998, J CLIN ENDOCR METAB, V83, P3826, DOI 10.1210/jc.83.11.3826; CONN PM, 1994, ANNU REV MED, V45, P391, DOI 10.1146/annurev.med.45.1.391; Cook T, 2000, Oncologist, V5, P162, DOI 10.1634/theoncologist.5-2-162; COUZINET B, 1991, CLIN ENDOCRINOL, V34, P477, DOI 10.1111/j.1365-2265.1991.tb00328.x; DANESHDOOST L, 1990, J CLIN ENDOCR METAB, V71, P92, DOI 10.1210/jcem-71-1-92; de Jong D, 2000, FERTIL STERIL, V73, P1051, DOI 10.1016/S0015-0282(00)00414-3; de Jong D, 2001, FERTIL STERIL, V75, P688, DOI 10.1016/S0015-0282(00)01789-1; de Jong D, 1998, HUM REPROD, V13, P573, DOI 10.1093/humrep/13.3.573; DEGHENGHI R, 1993, BIOMED PHARMACOTHER, V47, P107, DOI 10.1016/0753-3322(93)90299-Z; Demirel LC, 2000, FERTIL STERIL, V74, P1001, DOI 10.1016/S0015-0282(00)01552-1; DUBOURDIEU S, 1993, HUM REPROD, V8, P2056, DOI 10.1093/oxfordjournals.humrep.a137981; Duijkers IJM, 1998, HUM REPROD, V13, P2392, DOI 10.1093/humrep/13.9.2392; Edwards RG, 1996, HUM REPROD, V11, P917; EIDNE KA, 1987, J CLIN ENDOCR METAB, V64, P425, DOI 10.1210/jcem-64-3-425; Emons G, 2000, RECENT RES CANCER, V153, P83; Emons G, 1998, J STEROID BIOCHEM, V65, P199, DOI 10.1016/S0960-0760(97)00189-1; Emons G, 2000, J CANCER RES CLIN, V126, P619, DOI 10.1007/PL00008473; Emons G, 2000, EUR J ENDOCRINOL, V142, P665, DOI 10.1530/eje.0.1420665; Erb K, 2001, FERTIL STERIL, V75, P316, DOI 10.1016/S0015-0282(00)01702-7; Fauser B C, 2000, Ned Tijdschr Geneeskd, V144, P370; Felberbaum R, 1999, HUM REPROD, V14, P207, DOI 10.1093/humrep/14.suppl_1.207; Felberbaum R E, 1999, Contracept Fertil Sex, V27, P701; FELBERBAUM RE, 1995, EUR J OBSTET GYN R B, V61, P151, DOI 10.1016/0301-2115(95)02138-W; Fluker M, 2001, FERTIL STERIL, V75, P38, DOI 10.1016/S0015-0282(00)01638-1; FLUKER MR, 1991, J CLIN ENDOCR METAB, V72, P912, DOI 10.1210/jcem-72-4-912; Fujimoto VY, 1997, FERTIL STERIL, V67, P469, DOI 10.1016/S0015-0282(97)80071-4; FUNSTON RN, 1995, BIOL REPROD, V53, P541, DOI 10.1095/biolreprod53.3.541; Garnick MB, 2000, MOL UROL, V4, P275; GARNICK MB, 1999, GYNECOL ENDOCRINO S1, V13; GARNICK MB, 1999, P AN M AM SOC CLIN, V18, pA321; Gittelman M, 2001, P ASCO, V20, P154; Giuliani A, 1998, FERTIL STERIL, V70, P831, DOI 10.1016/S0015-0282(98)00282-9; GonzalezBarcena D, 1997, HUM REPROD, V12, P2028, DOI 10.1093/humrep/12.9.2028; GONZALEZBARCENA D, 1994, EUR J ENDOCRINOL, V131, P286, DOI 10.1530/eje.0.1310286; GonzalezBarcena D, 1996, TREATMENT WITH GNRH ANALOGS: CONTROVERSIES AND PERSPECTIVES, P139; GORDON K, 1992, CURR OPIN OBSTET GYN, V4, P690; HALL JE, 1994, P NATL ACAD SCI USA, V91, P6894, DOI 10.1073/pnas.91.15.6894; Haviv F, 1998, Pharm Biotechnol, V11, P131; Hayes FJ, 1998, J CLIN ENDOCR METAB, V83, P2343, DOI 10.1210/jc.83.7.2343; Hernandez ER, 2000, HUM REPROD, V15, P1211, DOI 10.1093/humrep/15.6.1211; Itskovitz-Eldor J, 2000, HUM REPROD, V15, P1965, DOI 10.1093/humrep/15.9.1965; Janssens RMJ, 2000, HUM REPROD UPDATE, V6, P505, DOI 10.1093/humupd/6.5.505; Janssens RMJ, 2000, HUM REPROD, V15, P2333, DOI 10.1093/humrep/15.11.2333; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; KAKAR SS, 1994, MOL CELL ENDOCRINOL, V106, P145, DOI 10.1016/0303-7207(94)90196-1; Kamp GA, 2001, J CLIN ENDOCR METAB, V86, P2969, DOI 10.1210/jc.86.7.2969; Kang SK, 2001, ENDOCRINOLOGY, V142, P671, DOI 10.1210/en.142.2.671; Kang SK, 2000, ENDOCRINOLOGY, V141, P72, DOI 10.1210/en.141.1.72; KARTEN MJ, 1992, SERONO SYMP, P277; KETTEL LM, 1991, J CLIN ENDOCR METAB, V73, P644, DOI 10.1210/jcem-73-3-644; KOCH M, 2001, 96 ANN M AM UR ASS, P753; Kol S, 1999, HUM REPROD, V14, P2242, DOI 10.1093/humrep/14.9.2242; KOTTLER ML, 1995, HUM GENET, V96, P477; Krsmanovic LZ, 2000, ENDOCRINOLOGY, V141, P1187, DOI 10.1210/en.141.3.1187; LEROY I, 1994, FERTIL STERIL, V62, P461; LEUNG PCK, 1995, MAMM GENOME, V6, P309, DOI 10.1007/BF00352431; Levitsky AM, 1999, J AM GERIATR SOC, V47, P231, DOI 10.1111/j.1532-5415.1999.tb04583.x; LJUNGQVIST A, 1988, P NATL ACAD SCI USA, V85, P8236, DOI 10.1073/pnas.85.21.8236; Ludwig M, 2001, FERTIL STERIL, V75, P18, DOI 10.1016/S0015-0282(00)01632-0; Ludwig-Beymer P, 1999, J NURS CARE QUAL, V13, P1, DOI 10.1097/00001786-199908000-00002; Mannaerts B, 2000, HUM REPROD, V15, P1882, DOI 10.1093/humrep/15.9.1882; Martha PM, 1999, GYNECOL ENDOCRINOL, V13, P104; McLeod D, 2000, P AN M AM SOC CLIN, V19, p332a; Millar R, 2001, P NATL ACAD SCI USA, V98, P9636, DOI 10.1073/pnas.141048498; MILLER WR, 1985, NATURE, V313, P231, DOI 10.1038/313231a0; Morales P, 1999, HUM REPROD, V14, P2069, DOI 10.1093/humrep/14.8.2069; Neill JD, 2001, BIOCHEM BIOPH RES CO, V282, P1012, DOI 10.1006/bbrc.2001.4678; NESTOR JJ, 1992, J MED CHEM, V35, P3942, DOI 10.1021/jm00099a023; Noci I, 2000, CANCER LETT, V150, P71, DOI 10.1016/S0304-3835(99)00374-2; Oberye JJL, 1999, FERTIL STERIL, V72, P1001, DOI 10.1016/S0015-0282(99)00413-6; Olivennes F, 1998, HUM REPROD, V13, P2411, DOI 10.1093/humrep/13.9.2411; Olivennes F, 2000, FERTIL STERIL, V73, P314, DOI 10.1016/S0015-0282(99)00524-5; Olivennes F, 2000, HUM REPROD UPDATE, V6, P313, DOI 10.1093/humupd/6.4.313; Ortmann O, 2001, HUM REPROD, V16, P608, DOI 10.1093/humrep/16.4.608; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RABINOVICI J, 1992, J CLIN ENDOCR METAB, V75, P1220, DOI 10.1210/jc.75.5.1220; Raga F, 1999, ENDOCRINOLOGY, V140, P3705, DOI 10.1210/en.140.8.3705; REISSMANN T, 1995, HUM REPROD, V10, P1974, DOI 10.1093/oxfordjournals.humrep.a136219; RIVIER J, 1992, J MED CHEM, V35, P4270, DOI 10.1021/jm00101a003; Roth C, 2000, PEDIATR RES, V48, P468, DOI 10.1203/00006450-200010000-00009; Schally AV, 1999, PEPTIDES, V20, P1247, DOI 10.1016/S0196-9781(99)00130-8; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; SERONO, DOUBLE BLIND RANDOMI; Sharpless JL, 1999, J CLIN ENDOCR METAB, V84, P688, DOI 10.1210/jc.84.2.688; SOMMER L, 1994, EUR J ENDOCRINOL, V131, P280, DOI 10.1530/eje.0.1310280; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; Strickland P, 2000, J INST BRIT TELECOMM, V1, P24; Sun YM, 2001, J BIOL CHEM, V276, P7754, DOI 10.1074/jbc.M009020200; Swerdloff RS, 1998, J CLIN ENDOCR METAB, V83, P3527, DOI 10.1210/jc.83.10.3527; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; Tomera K, 2001, J UROLOGY, V165, P1585, DOI 10.1016/S0022-5347(05)66353-7; Trachtenberg J, 2001, P ASCO, V20, P152; van Hooren HG, 2001, HUM REPROD, V16, P644; VANLOENEN ACD, 2001, ESHRE, V16, P144; White RB, 1998, P NATL ACAD SCI USA, V95, P305, DOI 10.1073/pnas.95.1.305; WONG SL, 2000, FERTIL STERIL S1, V74, pP286; YANGFENG TL, 1986, SOMAT CELL MOLEC GEN, V12, P95, DOI 10.1007/BF01560732; 1994, DRUGS FUTURE, V19, P228; 2000, DRUGS FUTURE, V24, P393	119	231	259	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2001	358	9295					1793	1803		10.1016/S0140-6736(01)06797-6	http://dx.doi.org/10.1016/S0140-6736(01)06797-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734258				2022-12-28	WOS:000172385100034
J	Chandler, WL; Jelacic, S; Boster, DR; Ciol, MA; Williams, GD; Watkins, SL; Igarashi, T; Tarr, PI				Chandler, WL; Jelacic, S; Boster, DR; Ciol, MA; Williams, GD; Watkins, SL; Igarashi, T; Tarr, PI			Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XVIIIth Congress of the International-Society-on-Thrombosis-and-Haemostasis	JUL 06-12, 2001	PARIS, FRANCE	Int Soc Thrombosis & Haemostasis			TISSUE-PLASMINOGEN ACTIVATOR; ESCHERICHIA-COLI O157-H7; FIBRINOLYTIC THERAPY; INHIBITOR TYPE-1; FRAGMENT 1+2; D-DIMER; PLASMA; HISTOPATHOLOGY; IMMUNOASSAY; DEGRADATION	Background: The hemolytic-uremic syndrome is a thrombotic complication of Escherichia coli O157:H7 infection. It is not known whether the coagulation abnormalities precede, and potentially cause, this disorder. Methods: In 53 children infected with E. coli O157:H7, we measured a panel of markers indicating activation of the clotting cascade and renal function within four days after the onset of illness. These markers were measured again in as many as possible of the 16 children in whom the hemolytic-uremic syndrome developed. Results: The children in whom the hemolytic-uremic syndrome subsequently developed had significantly higher median plasma concentrations of prothrombin fragment 1+2, tissue plasminogen activator (t-PA) antigen, t-PA-plasminogen-activator inhibitor type 1 (PAI-1) complex, and d-dimer than children with uncomplicated infection. These abnormalities preceded the development of azotemia and thrombocytopenia. When the hemolytic-uremic syndrome developed, the urinary concentrations of beta(2)-microglobulin and N-acetyl-beta -glucosaminidase rose significantly (P=0.03 for both increases); the plasma concentrations of t-PA antigen, t-PA-PAI-1 complex, d-dimer, and plasmin-antiplasmin complex also increased significantly. The concentration of t-PA antigen correlated with that of the t-PA-PAI-1 complex in a linear regression model (squared correlation coefficient, 0.80; P<0.001). Conclusions: In the hemolytic-uremic syndrome, thrombin generation (probably due to accelerated thrombogenesis) and inhibition of fibrinolysis precede renal injury and may be the cause of such injury. (N Engl J Med 2002;346:23-32.) Copyright (C) 2002 Massachusetts Medical Society.	Childrens Hosp & Reg Med Ctr, Div Gastroenterol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Tokyo	Tarr, PI (corresponding author), Childrens Hosp & Reg Med Ctr, Div Gastroenterol, CH-24,4800 Sand Point Way NE, Seattle, WA 98105 USA.			Jelacic, Srdjan/0000-0002-6617-9870; Ciol, Marcia/0000-0001-6406-4706	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052081] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1DK52081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERMAN MH, 1983, NEW ENGL J MED, V309, P1213, DOI 10.1056/NEJM198311173092004; BELL BP, 1997, PEDIATRICS, V100, P127; BERGSTEIN JM, 1992, NEW ENGL J MED, V327, P755, DOI 10.1056/NEJM199209103271102; BRENNER B, 1990, CIRCULATION, V81, P1818, DOI 10.1161/01.CIR.81.6.1818; Chandler WL, 2000, CLIN CHEM, V46, P38; Chandler WL, 2000, HAEMOSTASIS, V30, P204; Chandler WL, 1997, CIRCULATION, V96, P761; CHART H, 1991, LANCET, V337, P437, DOI 10.1016/0140-6736(91)91222-G; COLDING H, 1992, APMIS, V100, P119, DOI 10.1111/j.1699-0463.1992.tb00849.x; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; EVRIN PE, 1972, SCAND J CLIN LAB INV, V29, P69, DOI 10.3109/00365517209081057; HABIB R, 1992, HEMOLYTIC UREMIC SYN, P315; Hayashi M, 1997, ACTA OBSTET GYN SCAN, V76, P590, DOI 10.3109/00016349709024590; HOLVOET P, 1986, THROMB HAEMOSTASIS, V56, P124; Inward CD, 1997, PEDIATR NEPHROL, V11, P556, DOI 10.1007/s004670050337; KATZ J, 1971, J PEDIATR-US, V78, P426, DOI 10.1016/S0022-3476(71)80222-6; KNECHT MF, 1992, THROMB RES, V67, P213, DOI 10.1016/0049-3848(92)90140-6; MONNENS L, 1982, CLIN NEPHROL, V17, P284; Nakao H, 2000, J NAT TOXINS, V9, P299; Nevard CHF, 1997, THROMB HAEMOSTASIS, V78, P1450; OKAMOTO K, 1992, HAEMOSTASIS, V22, P17; PELZER H, 1991, THROMB HAEMOSTASIS, V65, P153; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RIELLA MC, 1976, NEPHRON, V17, P188, DOI 10.1159/000180723; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; Tsai HM, 2001, PEDIATR RES, V49, P653, DOI 10.1203/00006450-200105000-00008; Van Geet C, 1998, KIDNEY INT, V54, P1324, DOI 10.1046/j.1523-1755.1998.00103.x; VANDEKAR NCAJ, 1994, PEDIATR RES, V36, P257, DOI 10.1203/00006450-199408000-00019; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601	29	157	166	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					23	32		10.1056/NEJMoa011033	http://dx.doi.org/10.1056/NEJMoa011033			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11777999				2022-12-28	WOS:000173033600004
J	van Everdingen, AA; Jacobs, JWG; van Reesema, DRS; Bijlsma, JWJ				van Everdingen, AA; Jacobs, JWG; van Reesema, DRS; Bijlsma, JWJ			Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects - A randomized, double-blind, placebo-controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							SINGLE COMPONENTS; JOINT DESTRUCTION; METHOTREXATE; SULFASALAZINE; VALIDITY; GLUCOCORTICOIDS; CORTICOSTEROIDS; RELIABILITY; COMBINATION; RADIOGRAPHS	Background: Oral glucocorticoids combined with disease-modifying antirheumatic drugs are beneficial and retard radiologic joint damage in rheumatoid arthritis. Objective: To investigate the clinical efficacy, disease-modifying properties, and side effects of low-dose glucocorticoids as monotherapy for previously untreated patients with early active rheumatoid arthritis. Design: 2-year randomized, double-blind, placebo-controlled clinical trial. Setting: 2 outpatient rheumatology clinics. Patients: 81 patients with early active rheumatoid arthritis who had not been treated with disease-modifying antirheumatic drugs. Intervention: 41 patients were assigned to 10 mg of oral prednisone per day, and 40 were assigned to placebo. Nonsteroidal anti-inflammatory drugs were allowed in both groups. After 6 months, sulfasalazine (2 g/d) could be prescribed as rescue medication. Measurements: Clinical variables were assessed at baseline and every 3 months; radiologic studies were performed every 6 months. Adverse effects were documented every 3 months. Results: In the first 6 months, the prednisone group showed more clinical improvement than the placebo group. This effect was not seen after 6 months except in grip strength and the 28-joint score for tenderness. Use of additional therapies was significantly less common in the prednisone group, particularly in the first 6 months. More than 65% of those who completed the study were not taking sulfasalazine. After month 6, radiologic scores showed significantly less progression in the prednisone group than in the placebo group. No clinically relevant adverse effects were observed, except for a higher incidence of osteoporotic fractures in the prednisone group. Conclusions: Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months, and substantially inhibits progression of radiologic joint damage in patients with early active rheumatoid arthritis and no previous treatment with disease-modifying antirheumatic drugs. Because of their limited disease-modifying effects, glucocorticoids should be combined with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.	Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Deventer Hosp, Deventer, Netherlands; Zutphen Hosp, Zutphen, Netherlands	Utrecht University; Deventer Hospital	Jacobs, JWG (corresponding author), Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, F02127,Box 85500, NL-3508 GA Utrecht, Netherlands.	j.w.g.jacobs@azu.nl						ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BIJLSMA JWJ, 1995, CLIN IMMUNOTHER, V3, P271, DOI 10.1007/BF03259279; BIJLSMA JWJ, 1998, RHEUMATOL EUROPE, V27, P67; BIJLSMA JWJ, 1990, J REHABIL SCI, V3, P71; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Dougados M, 1999, ANN RHEUM DIS, V58, P220, DOI 10.1136/ard.58.4.220; Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082; HENCH PS, 1950, ARCH INTERN MED, V85, P545, DOI 10.1001/archinte.1950.00230100002001; Hickling P, 1998, BRIT J RHEUMATOL, V37, P930; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Kirwan JR, 1999, J RHEUMATOL, V26, P720; KLEEREKOPER M, 1984, COP INT S OST, P103; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Pham B, 1999, J RHEUMATOL, V26, P712; PREVOO MLL, 1993, BRIT J RHEUMATOL, V32, P589; Saag KG, 1996, ARTHRITIS RHEUM-US, V39, P1818, DOI 10.1002/art.1780391107; SMOLEN JS, 1995, ARTHRITIS RHEUM, V38, P38, DOI 10.1002/art.1780380106; van der Heijde D, 1999, J RHEUMATOL, V26, P743; van der Heijde D, 1999, RHEUMATOLOGY, V38, P1213, DOI 10.1093/rheumatology/38.12.1213; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519	21	352	366	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					1	12		10.7326/0003-4819-136-1-200201010-00006	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777359				2022-12-28	WOS:000173188300001
J	David, AS				David, AS			Wanted-more answers than questions: literature review	BRITISH MEDICAL JOURNAL			English	Review									Inst Psychiat, London SE5 8AF, England; Guys Kings Coll, London SE5 8AF, England; St Thomass Sch Med, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	David, AS (corresponding author), Inst Psychiat, London SE5 8AF, England.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X				DAVID A, 1990, BRIT MED J, V300, P30, DOI 10.1136/bmj.300.6716.30; FISHER WA, 1991, INT J LAW PSYCHIAT, V14, P65, DOI 10.1016/0160-2527(91)90025-I; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; VANHEKKEN SMJ, 1982, J CHILD LANG, V9, P445, DOI 10.1017/S0305000900004803; Vickers A, 2000, BRIT J GEN PRACT, V50, P444	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1462	1463		10.1136/bmj.323.7327.1462	http://dx.doi.org/10.1136/bmj.323.7327.1462			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506PA	11751356	Green Published			2022-12-28	WOS:000172979900016
J	Rojstaczer, S; Sterling, SM; Moore, NJ				Rojstaczer, S; Sterling, SM; Moore, NJ			Human appropriation of photosynthesis products	SCIENCE			English	Article							GLOBAL CARBON-CYCLE; FORESTS; ECOSYSTEMS; STORAGE	Previous global estimates of the human impact on terrestrial photosynthesis products depended heavily on extrapolation from plot-scale measurements. Here, we estimated this impact with the use of recent data, many of which were collected at global and continental scales. Monte Carlo techniques that incorporate known and estimated error in our parameters provided estimates of uncertainty. We estimate that humans appropriate 10 to 55% of terrestrial photosynthesis products. This broad range reflects uncertainty in key parameters and makes it difficult to ascertain whether we are approaching crisis levels in our use of the planet's resources. Improved estimates will require high-resolution global measures within agricultural lands and tropical forests.	Duke Univ, Ctr Hydrol Sci, Durham, NC 27708 USA; Duke Univ, Div Earth & Ocean Sci, Durham, NC 27708 USA	Duke University; Duke University	Rojstaczer, S (corresponding author), Duke Univ, Ctr Hydrol Sci, Durham, NC 27708 USA.		Noojipady, Praveen/B-2511-2010					AJTAY GL, 1979, GLOBAL CARBON CYCLE, P129; ARMENTANO TV, 1980, CAN J FOREST RES, V10, P53, DOI 10.1139/x80-009; BROWN C, 1999, GFPOSWP03 FAO; BROWN S, 1992, INTERCIENCIA, V17, P8; BROWN S, 1982, BIOTROPICA, V14, P161, DOI 10.2307/2388024; FAO, 1995, FOR RES ASS 1990 GLO; *FAO, 1990, 1989 FAO PROD YB; *FAO, 1992, FOR RES TROP ZON MAI; Haberl H, 1997, AMBIO, V26, P143; LIETH H, 1973, HUM ECOL, V1, P303, DOI 10.1007/BF01536729; PANDEY D, 1997, GCPINT628UK FAO FOOD; Pandey D, 1995, 128 FAO; Pimentel D., 1996, FOOD ENERGY SOC; Postel SL, 1996, SCIENCE, V271, P785, DOI 10.1126/science.271.5250.785; POTTER CS, 1993, GLOBAL BIOGEOCHEM CY, V7, P811, DOI 10.1029/93GB02725; Scharpenberg R., 1998, GLOBAL FIBRE SUPPLY; Tilman D, 1999, P NATL ACAD SCI USA, V96, P5995, DOI 10.1073/pnas.96.11.5995; VITOUSEK PM, 1986, BIOSCIENCE, V36, P368, DOI 10.2307/1310258; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; WHITTAKER RH, 1973, HUM ECOL, V1, P357, DOI 10.1007/BF01536732; Winjum JK, 1997, AGR FOREST METEOROL, V84, P153, DOI 10.1016/S0168-1923(96)02383-0; WRIGHT DH, 1990, AMBIO, V19, P189; [No title captured]	23	174	197	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2549	2552		10.1126/science.1064375	http://dx.doi.org/10.1126/science.1064375			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752576				2022-12-28	WOS:000172927700059
J	Roth, JP; Yoder, JC; Won, TJ; Mayer, JM				Roth, JP; Yoder, JC; Won, TJ; Mayer, JM			Application of the Marcus cross relation to hydrogen atom transfer reactions	SCIENCE			English	Article							COUPLED ELECTRON-TRANSFER; PROTON; RADICALS; ABSTRACTION; COMPLEXES; RATES; DNA	The transfer of a hydrogen atom-a proton and an electron-is a fundamental process in chemistry and biology. A variety of hydrogen atom transfer reactions, involving iron complexes, phenols, hydroxylamines, (BuOOH)-Bu-t, toluene, and related radicals, are shown to follow the Marcus cross relation. Thus, the Marcus theory formalism based on ground-state energetics and self-exchange rates, originally developed for electron transfer processes, is also valuable for hydrogen atom transfer. Compounds that undergo slow proton transfer (C-H bonds) or slow electron transfer (cobalt complexes) also undergo slow hydrogen atom transfer. Limitations of this approach are also discussed.	Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Mayer, JM (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	mayer@chem.washington.edu	Roth, Justine/B-5488-2013		NIGMS NIH HHS [2 R01 GM50422-05, 1 F32 GM63383-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM063383, R01GM050422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERY WJ, 1980, ANNU REV PHYS CHEM, V31, P227, DOI 10.1146/annurev.pc.31.100180.001303; AVILA DV, 1995, J AM CHEM SOC, V117, P2929, DOI 10.1021/ja00115a029; Barbara PF, 1996, J PHYS CHEM-US, V100, P13148, DOI 10.1021/jp9605663; Baskin S., 1997, OXIDANTS ANTIOXIDANT; Bordwell FG, 1996, J AM CHEM SOC, V118, P10819, DOI 10.1021/ja961469q; Borgis D, 1996, J PHYS CHEM-US, V100, P1118, DOI 10.1021/jp9522324; Cabelli DE, 2001, ORGANOMETALLICS, V20, P3729, DOI 10.1021/om0102089; COHEN AO, 1968, J PHYS CHEM-US, V72, P4249, DOI 10.1021/j100858a052; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Donahue NM, 1998, J PHYS CHEM A, V102, P3923, DOI 10.1021/jp980372i; FISCHER H, 1984, LANDOLTBORNSTEIN, V13; FISCHER H, 1984, LANDOLTBORNSTEIN, V18; Iordanova N, 2001, J AM CHEM SOC, V123, P3723, DOI 10.1021/ja0100524; KOCHI JK, 1973, FREE RADICALS, V1, P69; KREILICK RW, 1966, J AM CHEM SOC, V88, P2645, DOI 10.1021/ja00964a004; KRISTJANSDOTTIR SS, 1991, J AM CHEM SOC, V113, P4366, DOI 10.1021/ja00011a070; Lee E, 2000, J PHYS CHEM B, V104, P6894, DOI 10.1021/jp000167e; Lee ISH, 2001, J AM CHEM SOC, V123, P7492, DOI 10.1021/ja004232+; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Marcus RA, 1997, J PHYS CHEM A, V101, P4072, DOI 10.1021/jp963722e; Mayer Jean Francois, UNPUB; Mayer JM, 1998, ACCOUNTS CHEM RES, V31, P441, DOI 10.1021/ar970171h; Mijs W.J., 1986, ORGANIC SYNTHESIS OX; Olah G.A., 1995, HYDROCARBON CHEM; Roth JP, 1999, INORG CHEM, V38, P2760, DOI 10.1021/ic990251c; Roth JP, 2000, J AM CHEM SOC, V122, P5486, DOI 10.1021/ja9941328; RUSSELL GA, 1973, FREE RADICALS, V1, P283; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; SUTIN N, 1983, PROG INORG CHEM, V30, P441, DOI 10.1002/9780470166314.ch9; Tanko JM, 2001, J AM CHEM SOC, V123, P5808, DOI 10.1021/ja005730l; Tommos C, 2000, BBA-BIOENERGETICS, V1458, P199, DOI 10.1016/S0005-2728(00)00069-4; Weatherly SC, 2001, J AM CHEM SOC, V123, P1236, DOI 10.1021/ja003788u; YODER JC, UNPUB; ZAVELOVICH EB, 1974, CHEM PHYS LETT, V29, P212, DOI 10.1016/0009-2614(74)85015-3	34	181	181	9	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2524	2526		10.1126/science.1066130	http://dx.doi.org/10.1126/science.1066130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752572				2022-12-28	WOS:000172927700051
J	de Groot, BL; Grubmuller, H				de Groot, BL; Grubmuller, H			Water permeation across biological membranes: Mechanism and dynamics of aquaporin-1 and GlpF	SCIENCE			English	Article							MOLECULAR-DYNAMICS; GLYCEROL FACILITATOR; CHANNEL; RECONSTITUTION; LIPOSOMES; VERSION; PORE	"Real time" molecular dynamics simulations of water permeation through human aquaporin-1 (AQP1) and the bacterial glycerol facilitator GlpF are presented. We obtained time-resolved, atomic-resolution models of the permeation mechanism across these highly selective membrane channels. Both proteins act as two-stage filters: Conserved fingerprint [asparagine-proline-alanine (NPA)] motifs form a selectivity-determining region; a second (aromatic/arginine) region is proposed to function as a proton filter. Hydrophobic regions near the NPA motifs are rate-limiting water barriers. In AQP1, a fine-tuned water dipole rotation during passage is essential for water selectivity. In GlpF, a glycerol-mediated "induced fit" gating motion is proposed to generate selectivity for glycerol over water.	Max Planck Inst Biophys Chem, Theoret Mol Biophys Grp, D-37077 Gottingen, Germany	Max Planck Society	Grubmuller, H (corresponding author), Max Planck Inst Biophys Chem, Theoret Mol Biophys Grp, Fassberg 11, D-37077 Gottingen, Germany.	hgrubmu@gwdg.de						Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BERENDSEN HJC, COMMUNICATION; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Borgnia MJ, 2001, P NATL ACAD SCI USA, V98, P2888, DOI 10.1073/pnas.051628098; Braun T, 2000, EMBO REP, V1, P183, DOI 10.1093/embo-reports/kvd022; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Groot BL, 2001, FEBS LETT, V504, P206, DOI 10.1016/S0014-5793(01)02743-0; Deen PMT, 1998, CURR OPIN CELL BIOL, V10, P435, DOI 10.1016/S0955-0674(98)80055-0; Engel A, 2000, EMBO J, V19, P800, DOI 10.1093/emboj/19.5.800; ENGEL A, IN PRESS INT REV CYT; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Espinosa E, 1998, CHEM PHYS LETT, V285, P170, DOI 10.1016/S0009-2614(98)00036-0; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Geissler PL, 2001, SCIENCE, V291, P2121, DOI 10.1126/science.1056991; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Heymann JB, 2000, J MOL BIOL, V295, P1039, DOI 10.1006/jmbi.1999.3413; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Pomes R, 1996, BIOPHYS J, V71, P19, DOI 10.1016/S0006-3495(96)79211-1; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; SHI LB, 1994, J BIOL CHEM, V269, P10417; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Stahlberg H, 2000, J STRUCT BIOL, V132, P133, DOI 10.1006/jsbi.2000.4317; Tieleman DP, 1998, BIOPHYS J, V74, P2786, DOI 10.1016/S0006-3495(98)77986-X; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zhu FQ, 2001, FEBS LETT, V504, P212, DOI 10.1016/S0014-5793(01)02749-1	39	776	794	6	281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2353	2357		10.1126/science.1062459	http://dx.doi.org/10.1126/science.1062459			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743202				2022-12-28	WOS:000172817200047
J	Thompson, JR; Gerald, PF; Willoughby, MLN; Armstrong, BK				Thompson, JR; Gerald, PF; Willoughby, MLN; Armstrong, BK			Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study	LANCET			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; NEURAL-TUBE DEFECTS; COLORECTAL-CANCER; COMMON MUTATION; RISK-FACTORS; LEUKEMIA; GENE; SUSCEPTIBILITY; DEFICIENCY; CHILDREN	Background Acute lymphoblastic leukaemia is the most common childhood cancer in more-developed countries but it has few recognised risk factors or preventive measures. We aimed to determine and assess the risk factors associated with this disease. Methods From 1984 to 1992, we investigated known and suspected risk factors for common acute lymphoblastic leukaemia diagnosed in a population-based case-control study of children aged 0-14 years in Western Australia. 83 children in the study group came from the sole referral centre for paediatric cancer in the state and 166 controls matched for age and sex were recruited through a postal survey of people randomly selected from the state electoral roll. We interviewed mothers of 83 study and 166 control children (82% and 74%, respectively, of those eligible). Fathers completed a self-administered questionnaire. Findings We recorded a protective association between iron or folate supplementation in pregnancy and risk of common acute lymphoblastic leukaemia in the child (odds ratio 0.37 [95% CI 0.21-0.65]; p=0.001). For iron alone, the odds ratio was 0.75 (0.37-1.51); only one mother took folate without iron. Further analyses of folate use with or without iron (0.40; 0.21-0.73) showed that the protective effect varies little by time of first use of supplements or for how long they were taken. The association was not weakened by adjustment for potentially confounding variables. Interpretation Our results, though unexpected, suggest that folate supplementation in pregnancy reduces the risk of common acute lymphoblastic leukaemia in the child.	Canc Fdn Western Australia, Perth, WA, Australia; Univ Newcastle, Royal Newcastle Hosp, Sch Populat Hlth Sci, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia; Princess Margaret Hosp, Dept Haematol & Oncol, Perth, WA, Australia; New S Wales Canc Council, Sydney, NSW, Australia	University of Newcastle; Cancer Council New South Wales	Thompson, JR (corresponding author), Canc Fdn Western Australia, Perth, WA, Australia.	rickthom@iinet.net.au	Armstrong, Bruce K/K-9464-2015	Armstrong, Bruce K/0000-0001-8940-7525				ARUNDEL SE, 1986, J EPIDEMIOL COMMUN H, V40, P30, DOI 10.1136/jech.40.1.30; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Bower C, 1997, AUST NZ J OBSTET GYN, V37, P267; BUCKLEY JD, 1994, LEUKEMIA, V8, P856; BUNIN GR, 1993, NEW ENGL J MED, V329, P536, DOI 10.1056/NEJM199308193290804; Chen J, 1996, CANCER RES, V56, P4862; CNATTINGIUS S, 1995, J NATL CANCER I, V87, P908, DOI 10.1093/jnci/87.12.908; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; Esteller M, 1997, CARCINOGENESIS, V18, P2307, DOI 10.1093/carcin/18.12.2307; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GREAVES MF, 1988, LEUKEMIA, V2, P120; Hobbs CA, 2000, AM J HUM GENET, V67, P623, DOI 10.1086/303055; KAYE SA, 1991, CANCER-AM CANCER SOC, V68, P1351, DOI 10.1002/1097-0142(19910915)68:6<1351::AID-CNCR2820680627>3.0.CO;2-J; Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6; KINLEN L, 1988, LANCET, V2, P1323; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; Ma J, 1997, CANCER RES, V57, P1098; MILLER RW, 1963, NEW ENGL J MED, V268, P393, DOI 10.1056/NEJM196302212680801; Parkin DM, 1998, IARC SCI PUBLICATION, V144; Petridou E, 1997, BRIT J CANCER, V76, P1241, DOI 10.1038/bjc.1997.541; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; Rozen R, 1999, AM J MED GENET, V83, P142, DOI 10.1002/(SICI)1096-8628(19990312)83:2<142::AID-AJMG12>3.0.CO;2-Y; Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810; Taylor GM, 1996, LEUKEMIA, P210; Ullen H, 1997, CANCER LETT, V114, P215, DOI 10.1016/S0304-3835(97)04666-1; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; VANSTEENSELMOLL HA, 1985, INT J EPIDEMIOL, V14, P555, DOI 10.1093/ije/14.4.555; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298	31	184	187	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1935	1940		10.1016/S0140-6736(01)06959-8	http://dx.doi.org/10.1016/S0140-6736(01)06959-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747917				2022-12-28	WOS:000172622200010
J	van den Brink, GR; Barbara, PD; Roberts, DJ				van den Brink, GR; Barbara, PD; Roberts, DJ			Development - Epithelial cell differentiation - a mather of Choice	SCIENCE			English	Editorial Material							HEDGEHOG; SIGNALS; GENES		Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	University of Amsterdam; Academic Medical Center Amsterdam; Harvard University; Massachusetts General Hospital	van den Brink, GR (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		de Santa Barbara, Pascal/N-6426-2015; de Santa Barbara, Pascal/AAO-5969-2021	de Santa Barbara, Pascal/0000-0001-9040-2481; de Santa Barbara, Pascal/0000-0001-9040-2481				Alexandre C, 1999, DEVELOPMENT, V126, P5689; Baker NE, 1997, CURR BIOL, V7, P122, DOI 10.1016/S0960-9822(06)00056-X; Bermingham NA, 2001, NEURON, V30, P411, DOI 10.1016/S0896-6273(01)00305-1; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; DESANTABARBARA P, IN PRESS SEMIN MED G; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Lee KJ, 1998, GENE DEV, V12, P3394, DOI 10.1101/gad.12.21.3394; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Skipper M, 2000, NAT GENET, V24, P3, DOI 10.1038/71653; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zhang J, 2001, DEV BIOL, V229, P188, DOI 10.1006/dbio.2000.9953	16	40	40	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2115	2116		10.1126/science.1067751	http://dx.doi.org/10.1126/science.1067751			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739944				2022-12-28	WOS:000172647700036
J	Johnson, AM; Mercer, CH; Erens, B; Copas, AJ; McManus, S; Wellings, K; Fenton, KA; Korovessis, C; Macdowall, W; Nanchahal, K; Purdon, S; Field, H				Johnson, AM; Mercer, CH; Erens, B; Copas, AJ; McManus, S; Wellings, K; Fenton, KA; Korovessis, C; Macdowall, W; Nanchahal, K; Purdon, S; Field, H			Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours	LANCET			English	Article							MEN	Background Sexual behaviour is a major determinant of sexual and reproductive health. We did a National Survey of Sexual Attitudes and Lifestyles (Natsal 2000) in 1999-2001 to provide population estimates of behaviour patterns and to compare them with estimates from 1990-91 (Natsal 1990). Methods We did a probability sample survey of men and women aged 16-44 years who were resident in Britain, using computer-assisted interviews. Results were compared with data from respondents in Natsal 1990. Findings We interviewed 11 161 respondents (4762 men, 6399 women). Patterns of heterosexual and homosexual partnership varied substantially by age, residence in Greater London, and marital status. In the past 5 years, mean numbers of heterosexual partners were 3.8 (SD 8.2) for men, and 2.4 (SD 4.6) for women; 2.6% (95% CI 2.2-3.1) of both men and women reported homosexual partnerships; and 4.3% (95% CI 3.7-5.0) of men reported paying for sex. In the past year, mean number of new partners varied from 2.04 (SD 8.4) for single men aged 25-34 years to 0.05 (SD 0.3) for married women aged 35-44 years. Prevalence of many reported behaviours had risen compared with data from Natsal 1990. Benefits of greater condom use were offset by increases in reported partners. Changes between surveys were generally greater for women than men and for respondents outside London. Interpretation Our study provides updated estimates of sexual behaviour patterns. The increased reporting of risky sexual behaviours is consistent with changing cohabitation patterns and rising incidence of sexually transmitted infections. Observed differences between Natsal 1990 and Natsal 2000 are likely to result from a combination of true change and greater willingness to report sensitive behaviours in Natsal 2000 due to Improved survey methodology and more tolerant social attitudes.	UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis Epidemiol, Dept Primary Care & Populat Sci, Mortimer Market Ctr, London WC1E 6AU, England; UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, London WC1E 6AU, England; Natl Ctr Social Res, London, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Ctr Sexual Hlth Res, London, England; Publ Hlth Lab Serv, HIV STI Div, London, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine; Public Health England	Johnson, AM (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis Epidemiol, Dept Primary Care & Populat Sci, Mortimer Market Ctr, London WC1E 6AU, England.	ajohnson@gum.ucl.ac.uk	McManus, Sally/HGD-4860-2022; McManus, Sally/S-4697-2019	McManus, Sally/0000-0003-2711-0819; Mercer, Catherine/0000-0002-4220-5034; Nanchahal, Kiran/0000-0001-8812-7628; Erens, Bob/0000-0002-4430-954X; Erens, Robert/0000-0002-3054-504X; Macdowall, Wendy/0000-0001-5868-8336; Johnson, Anne/0000-0003-1330-7100; Copas, Andrew/0000-0001-8968-5963				BROOK L, 2000, BRIT SOCIAL ATTITUDE; COPAS AJ, 1990, IN PRESS ACCURACY RE; Department of Health, 2001, NAT STRAT SEX HLTH H, P1; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; ERENS B, 1999, HLTH SURVEY ENGLAND; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Haskey J, 2001, Popul Trends, P4; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; Johnson AM, 2001, AIDS, V15, P111, DOI 10.1097/00002030-200101050-00016; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; *OFF NAT STAT, 2000, POP EST MID 1999; Petruckevitch A, 1997, GENITOURIN MED, V73, P348; PHLS DHSS & PS and the Scottish ISD (D)5 Collaborative Group, 2000, TRENDS SEX TRANSM IN; *REG GEN SCOTL, 2000, MID 1999 POP EST; SPIRA A, 1992, NATURE, V360, P407; TURNER CF, 1995, SEX TRANSM DIS, V22, P173, DOI 10.1097/00007435-199505000-00009; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; Wadsworth J, 1996, J R STAT SOC A STAT, V159, P111, DOI 10.2307/2983472; Wadsworth J, 1996, AIDS, V10, P193, DOI 10.1097/00002030-199602000-00010; Wellings F, 2001, LANCET, V358, P1843, DOI 10.1016/S0140-6736(01)06885-4; WELLINGS K, 1995, BRIT MED J, V311, P417, DOI 10.1136/bmj.311.7002.417; WELLINGS K, 1994, SEXUAL BEHAV BRIT; 1996, COMMUN DIS REP CDR R, V6, pR1; 1996, CONTRACEPTIVES	26	593	600	3	58	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1835	1842		10.1016/S0140-6736(01)06883-0	http://dx.doi.org/10.1016/S0140-6736(01)06883-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741621				2022-12-28	WOS:000172463000007
J	Vecchione, M; Young, RE; Guerra, A; Lindsay, DJ; Clague, DA; Bernhard, JM; Sager, WW; Gonzalez, AF; Rocha, FJ; Segonzac, M				Vecchione, M; Young, RE; Guerra, A; Lindsay, DJ; Clague, DA; Bernhard, JM; Sager, WW; Gonzalez, AF; Rocha, FJ; Segonzac, M			Worldwide observations of remarkable deep-sea squids	SCIENCE			English	Article									Natl Museum Nat Hist, Natl Marine Fisheries Serv, Systemat Lab, Washington, DC 20560 USA; Univ Hawaii, Dept Oceanog, Honolulu, HI 96822 USA; CSIC, Inst Invest Marinas, ECOBIOMAR, Vigo, Spain; Japan Marine Sci & Technol Ctr, Marine Ecosyst Res Dept, Yokosuka, Kanagawa, Japan; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ S Carolina, Dept Environm Hlth Sci, Columbia, SC 29208 USA; Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA; IFREMER, CENTOB, Plouzane, France	National Oceanic Atmospheric Admin (NOAA) - USA; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Hawaii System; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Marinas (IIM); Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Monterey Bay Aquarium Research Institute; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Texas A&M University System; Texas A&M University College Station; Ifremer	Vecchione, M (corresponding author), Natl Museum Nat Hist, Natl Marine Fisheries Serv, Systemat Lab, Washington, DC 20560 USA.	vecchione.michael@nmnh.si.edu	Bernhard, Joan/M-3260-2013	Bernhard, Joan/0000-0003-2121-625X				ASUBEL J, 1999, OCEANOGRAPHY, V12, P4; Smith CR, 1998, DEEP-SEA RES PT II, V45, P1, DOI 10.1016/S0967-0645(97)00088-X; Vecchione M, 1998, S AFR J MARINE SCI, V20, P429	3	31	35	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2505	2506		10.1126/science.294.5551.2505	http://dx.doi.org/10.1126/science.294.5551.2505			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752567	Green Submitted			2022-12-28	WOS:000172927700044
J	Hulbe, CL				Hulbe, CL			Glaciology - How ice sheets flow	SCIENCE			English	Editorial Material							WEST ANTARCTICA; GLACIER; WATER; BED		Portland State Univ, Dept Geol, Portland, OR 97207 USA	Portland State University	Hulbe, CL (corresponding author), Portland State Univ, Dept Geol, Portland, OR 97207 USA.	chulbe@pdx.edu		Hulbe, Christina/0000-0003-4765-7037				Ackert RP, 1999, SCIENCE, V286, P276, DOI 10.1126/science.286.5438.276; Anderson J.B., 2001, ANTARCT RES SER, V77, P45, DOI DOI 10.1029/AR077P0045; BINDSCHADLER R, 1983, J GLACIOL, V29, P3, DOI 10.3189/S0022143000005104; CLARKE GKC, 1988, J GLACIOL, V2; DESAUSSURE HB, 1779, VOYAGES ALPES PRECED, V1, P378; FAHNESTOCK M, 1993, SCIENCE, V262, P1530, DOI 10.1126/science.262.5139.1530; Fahnestock M, 2001, SCIENCE, V294, P2338, DOI 10.1126/science.1065370; Joughin I, 1999, SCIENCE, V286, P283, DOI 10.1126/science.286.5438.283; Kamb B., 2001, ANTARCT RES SER, V77, DOI DOI 10.1029/AR077P0157; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; Tulaczyk S, 2000, J GEOPHYS RES-SOL EA, V105, P483, DOI 10.1029/1999JB900328; WEERTMAN J, 1972, REV GEOPHYS SPACE GE, V10, P287, DOI 10.1029/RG010i001p00287; 2001, W ANT IC SHEET IN WO	13	2	2	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2300	2301		10.1126/science.1066730	http://dx.doi.org/10.1126/science.1066730			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743186				2022-12-28	WOS:000172817200030
J	Murphy, WJ; Eizirik, E; O'Brien, SJ; Madsen, O; Scally, M; Douady, CJ; Teeling, E; Ryder, OA; Stanhope, MJ; de Jong, WW; Springer, MS				Murphy, WJ; Eizirik, E; O'Brien, SJ; Madsen, O; Scally, M; Douady, CJ; Teeling, E; Ryder, OA; Stanhope, MJ; de Jong, WW; Springer, MS			Resolution of the early placental mammal radiation using Bayesian phylogenetics	SCIENCE			English	Article							MOLECULAR PHYLOGENETICS; SEQUENCES; ORIGINS	Molecular phylogenetic studies have resolved placental. mammals into four major groups, but have not established the full hierarchy of interordinal relationships, including the position of the root. The latter is critical for understanding the early biogeographic history of placentals. We investigated placental phylogeny using Bayesian and maximum-likelihood methods and a 16.4-kilobase molecular data set. Interordinal. relationships are almost entirely resolved. The basal split is between Afrotheria and other placentals, at about 103 million years, and may be accounted for by the separation of South America and Africa in the Cretaceous. Crown-group Eutheria may have their most recent common ancestry in the Southern Hemisphere (Gondwana).	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; NCI, Lab Genom Divers, Frederick, MD 21702 USA; Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Univ Nijmegen, Dept Biochem, Nijmegen, Netherlands; Queens Univ Belfast, Belfast, Antrim, North Ireland; Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA; Glaxo SmithKline, Collegeville, PA 19426 USA; Inst Systemat & Populat Biol, Amsterdam, Netherlands	University of California System; University of California Riverside; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Radboud University Nijmegen; Queens University Belfast; Zoological Society of San Diego; GlaxoSmithKline	O'Brien, SJ (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	obrien@ncifcr.gov; mark.springer@ucr.edu	Eizirik, Eduardo/K-8034-2012; Madsen, Ole/E-3730-2012; OBRIEN, STEPHEN/ABD-1346-2020; Douady, Christophe/N-3069-2019; Douady, Christophe J/N-1357-2014	Eizirik, Eduardo/0000-0002-9658-0999; Madsen, Ole/0000-0001-8082-7881; Douady, Christophe/0000-0002-4503-8040; Douady, Christophe J/0000-0002-4503-8040; OBRIEN, STEPHEN/0000-0001-7857-0757; Teeling, Emma/0000-0002-3309-1346				Eizirik E, 2001, J HERED, V92, P212, DOI 10.1093/jhered/92.2.212; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; Goldman N, 2000, SYST BIOL, V49, P652, DOI 10.1080/106351500750049752; Hay WW, 1999, GEOL S AM S, P1; Hillis David M., 1996, P515; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Liu FGR, 2001, SCIENCE, V291, P1786, DOI 10.1126/science.1056346; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; Matthew W. D., 1915, Annals of the New York Academy of Sciences, V24; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; O'Brien SJ, 2001, SCIENCE, V292, P2264, DOI 10.1126/science.1059393; Penny D, 1999, SYST BIOL, V48, P76, DOI 10.1080/106351599260454; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; RAINGER R, 1991, AGENDA ANTIQUITY HF; Rambaut A, 1998, MOL BIOL EVOL, V15, P442, DOI 10.1093/oxfordjournals.molbev.a025940; SIMPSON GG, 1945, B AM MUS NAT HIST, V85, P1; Smith AG, 1994, ATLAS CENOZOIC MESOZ; Springer MS, 2001, MOL BIOL EVOL, V18, P132, DOI 10.1093/oxfordjournals.molbev.a003787; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Wallace A. R, 1962, GEOGRAPHICAL DISTRIB; Whelan S, 2001, TRENDS GENET, V17, P262, DOI 10.1016/S0168-9525(01)02272-7; Wollenberg KR, 2000, P NATL ACAD SCI USA, V97, P3288, DOI 10.1073/pnas.070154797; [No title captured]	29	974	1020	3	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2348	2351		10.1126/science.1067179	http://dx.doi.org/10.1126/science.1067179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743200				2022-12-28	WOS:000172817200045
J	Kerstjens, HAM; Groen, HJ; van der Bij, W				Kerstjens, HAM; Groen, HJ; van der Bij, W			Recent advances - Respiratory medicine	BRITISH MEDICAL JOURNAL			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; VOLUME-REDUCTION SURGERY; CELL LUNG-CANCER; QUALITY-OF-LIFE; FLUTICASONE PROPIONATE; INHALED BUDESONIDE; CONTROLLED TRIAL; SEVERE EMPHYSEMA; ASTHMA; TRANSPLANTATION		Univ Groningen Hosp, Dept Pulm Med, NL-9700 RB Groningen, Netherlands	University of Groningen	Kerstjens, HAM (corresponding author), Univ Groningen Hosp, Dept Pulm Med, NL-9700 RB Groningen, Netherlands.		Kerstjens, Huib/N-4754-2017; Groen, Harry/AAP-2242-2021	Kerstjens, Huib/0000-0001-7705-7927; 				Altose MD, 2000, NEW ENGL J MED, V343, P1902; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; Criner GJ, 1999, AM J RESP CRIT CARE, V160, P2018, DOI 10.1164/ajrccm.160.6.9902117; Dahlen B, 2000, AM J RESP CRIT CARE, V161, pS137, DOI 10.1164/ajrccm.161.supplement_1.ltta-27; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Fishman A, 2001, NEW ENGL J MED, V345, P1075; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; GIBSON PG, 2001, COCHRANE DATABASE SY, V3; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leyenson N, 2000, CHEST, V118, P728, DOI 10.1378/chest.118.3.728; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Miller J D, 2000, Can Respir J, V7, P329; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Serna DL, 1998, AM SURGEON, V64, P1014; Steen S, 2001, LANCET, V357, P825, DOI 10.1016/S0140-6736(00)04195-7; Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165; SUNDARESAN S, 1995, J THORAC CARDIOV SUR, V109, P1075, DOI 10.1016/S0022-5223(95)70190-7; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; TenVergert EM, 1998, CHEST, V113, P358, DOI 10.1378/chest.113.2.358; Utz JP, 1998, MAYO CLIN PROC, V73, P552, DOI 10.4065/73.6.552; Valk PE, 1995, ANN THORAC SURG, V60, P1573, DOI 10.1016/0003-4975(95)00752-0; Vansteenkiste JF, 1998, J CLIN ONCOL, V16, P2142, DOI 10.1200/JCO.1998.16.6.2142; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Young J, 1999, THORAX, V54, P779, DOI 10.1136/thx.54.9.779	32	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1349	1353		10.1136/bmj.323.7325.1349	http://dx.doi.org/10.1136/bmj.323.7325.1349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739224	Green Published			2022-12-28	WOS:000172716900020
J	Zermansky, AG; Petty, DR; Raynor, DK; Freemantle, N; Vail, A; Lowe, CJ				Zermansky, AG; Petty, DR; Raynor, DK; Freemantle, N; Vail, A; Lowe, CJ			Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice	BRITISH MEDICAL JOURNAL			English	Article							CARE; OUTPATIENTS; QUALITY	Objective To determine whether a pharmacist can effectively review repeat prescriptions through consultations with elderly patients in general practice. Design Randomised controlled trial comparing clinical medication review by a pharmacist against normal general practice review. Setting Four general practices. Participants 1188 patients aged 65 or over who were receiving at least one repeat prescription and living in the community. Intervention Patients were invited to a consultation at which the pharmacist reviewed their medical conditions and current treatment. Main outcome measures Number of changes to repeat prescriptions over one year, drug costs, and use of healthcare services. Results 590 (97%) patients in the intervention group were reviewed compared with 233 (44%) in the control group. Patients seen by the pharmacist were more likely to have changes made to their repeat prescriptions (mean number of changes per patient 2.2 v 1.9; difference = 0.31, 95% confidence interval 0.06 to 0.57; P = 0.02). Monthly drug costs rose in both groups over the year, but the rise was less in the intervention group (mean difference pound4.72 per 28 days, -pound7.04 to -pound2.41); equivalent to pound 61 per patient a year. Intervention patients had a smaller rise in the number of drugs prescribed (0.2 v 0.4; mean difference -0.2, -0.4 to -0.1). there was no evidence that review of treatment by the pharmacist affected practice consultation rates, outpatient consultations, hospital admissions, or death rate. Conclusions A clinical pharmacist can conduct effective consultations with elderly patients in general practice to review their drugs. Such review results in significant changes in patients' drugs and saves more than the cost of the intervention without affecting the workload of general practitioners.	Univ Leeds, Sch Healthcare Studies, Div Acad Pharm Practice, Leeds LS2 9UT, W Yorkshire, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Manchester, Hope Hosp, Biostat Grp, Salford M6 8HD, Lancs, England	University of Leeds; University of Birmingham; University of Manchester	Zermansky, AG (corresponding author), Univ Leeds, Sch Healthcare Studies, Div Acad Pharm Practice, Leeds LS2 9UT, W Yorkshire, England.			Freemantle, Nick/0000-0001-5807-5740; Vail, Andy/0000-0001-8274-2726				*AUDT COMM, 1994, PRESCR IMPR MOR RAT; BORGSDORF LR, 1994, AM J HOSP PHARM, V51, P772, DOI 10.1093/ajhp/51.6.772; Cassidy IB, 1996, ANN PHARMACOTHER, V30, P745, DOI 10.1177/106002809603000707; Deady J E, 1991, Hosp Pharm, V26, P93; Department of Health, 2001, MED OLD PEOPL IMPL M; Goldstein R, 1998, INT J PHARM PRACT, V6, P60, DOI DOI 10.1111/J.2042-7174.1998.TB00917.X; Granas AG., 1999, INT J PHARM PRACT, DOI [10.1111/j.2042-7174.1999.tb00978.x, DOI 10.1111/J.2042-7174.1999.TB00978.X]; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Harris CM, 1996, BRIT J GEN PRACT, V46, P649; LOBAS NH, 1992, AM J HOSP PHARM, V49, P1681, DOI 10.1093/ajhp/49.7.1681; Lowe CJ, 2000, PHARM WORLD SCI, V22, P121, DOI 10.1023/A:1008758823788; Mackie CA., 1999, PHARM J, V263, pR7; MURRAY MD, 1993, ANN PHARMACOTHER, V27, P616; Petty DR, 2001, PHARM WORLD SCI, V23, P22, DOI 10.1023/A:1011276924820; PURVES I, 1994, QUALITY GEN PRACTICE; Royal College of Physicians, 1997, MED OLD PEOPL; Zermansky AG, 1996, BRIT J GEN PRACT, V46, P643	17	175	180	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1340	1343		10.1136/bmj.323.7325.1340	http://dx.doi.org/10.1136/bmj.323.7325.1340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739221	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000172716900017
J	Bird, A				Bird, A			Molecular biology - Methylation talk between histones and DNA	SCIENCE			English	Editorial Material							NEUROSPORA-CRASSA; DEACETYLASE; REPRESSION; CHROMATIN; MECP2		Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland.			Bird, Adrian/0000-0002-8600-0372				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Irelan JT, 1997, GENETICS, V146, P509; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508	12	130	159	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2113	2115		10.1126/science.1066726	http://dx.doi.org/10.1126/science.1066726			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739943				2022-12-28	WOS:000172647700035
J	Paige, DA				Paige, DA			Planetary science - Global change on Mars?	SCIENCE			English	Editorial Material							RESIDUAL CO2 FROST; SOUTH POLAR-CAP; SUMMER TEMPERATURES; VIKING; VARIABILITY; CYCLE		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Paige, DA (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.							JAKOSKY BM, 1984, ICARUS, V57, P322, DOI 10.1016/0019-1035(84)90121-0; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LEIGHTON RB, 1966, SCIENCE, V153, P136, DOI 10.1126/science.153.3732.136; Malin MC, 2001, SCIENCE, V294, P2146, DOI 10.1126/science.1066416; MURRAY BC, 1973, SCIENCE, V182, P437, DOI 10.1126/science.182.4111.437; PAIGE DA, 1985, SCIENCE, V228, P1160, DOI 10.1126/science.228.4704.1160; PAIGE DA, 1990, J GEOPHYS RES-SOLID, V95, P1319, DOI 10.1029/JB095iB02p01319; PAIGE DA, 1992, ICARUS, V99, P15, DOI 10.1016/0019-1035(92)90167-6; Smith DE, 2001, SCIENCE, V294, P2141, DOI 10.1126/science.1066556; Thomas PC, 2000, NATURE, V404, P161, DOI 10.1038/35004528; Ward W. R., 1992, MARS, P298	13	1	1	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2107	2108		10.1126/science.1067542	http://dx.doi.org/10.1126/science.1067542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739939				2022-12-28	WOS:000172647700031
J	Shindell, DT; Schmidt, GA; Mann, ME; Rind, D; Waple, A				Shindell, DT; Schmidt, GA; Mann, ME; Rind, D; Waple, A			Solar forcing of regional climate change during the maunder minimum	SCIENCE			English	Article							GENERAL-CIRCULATION MODEL; THERMOHALINE CIRCULATION; ATLANTIC OSCILLATION; GREENHOUSE-GAS; ICE-AGE; OZONE; TEMPERATURE; VARIABILITY; IRRADIANCE; SIMULATION	We examine the climate response to solar irradiance changes between the late 17th-century Maunder Minimum and the late 18th century. Global average temperature changes are small (about 0.3 degrees to 0.4 degreesC) in both a climate model and empirical reconstructions. However, regional temperature changes are quite large. In the model, these occur primarily through a forced shift toward the low index state of the Arctic Oscillation/North Atlantic Oscillation as solar irradiance decreases. This leads to colder temperatures over the Northern Hemisphere continents, especially in winter (1 degrees to 2 degreesC), in agreement with historical records and proxy data for surface temperatures.	Columbia Univ, Ctr Climate Syst Res, New York, NY 10025 USA; NASA, Inst Space Studies, New York, NY 10025 USA; Univ Virginia, Dept Environm Sci, Charlottesville, VA 22902 USA; Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA	Columbia University; National Aeronautics & Space Administration (NASA); University of Virginia; University of Massachusetts System; University of Massachusetts Amherst	Shindell, DT (corresponding author), NASA, Inst Space Studies, New York, NY 10025 USA.		Shindell, Drew/D-4636-2012; Schmidt, Gavin/D-4427-2012; Mann, Michael E/B-8472-2017	Shindell, Drew/0000-0003-1552-4715; Schmidt, Gavin/0000-0002-2258-0486; Mann, Michael E/0000-0003-3067-296X				Bard E, 2000, TELLUS B, V52, P985, DOI 10.1034/j.1600-0889.2000.d01-7.x; Bergthorsson P., 1969, JOKULL, V19, P94; Broecker WS, 2000, P NATL ACAD SCI USA, V97, P1339, DOI 10.1073/pnas.97.4.1339; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Cubasch U, 1997, CLIM DYNAM, V13, P757, DOI 10.1007/s003820050196; Delworth TL, 2000, J CLIMATE, V13, P3721, DOI 10.1175/1520-0442(2000)013<3721:IOTRTI>2.0.CO;2; Free M, 1999, J GEOPHYS RES-ATMOS, V104, P19057, DOI 10.1029/1999JD900233; GILLETT N, IN PRESS J GEOPHYS R; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; Hartmann DL, 2000, P NATL ACAD SCI USA, V97, P1412, DOI 10.1073/pnas.97.4.1412; Hegerl GC, 1997, CLIM DYNAM, V13, P613, DOI 10.1007/s003820050186; Hoerling MP, 2001, SCIENCE, V292, P90, DOI 10.1126/science.1058582; Hoyt D.V., 1993, J GEOPHYS RES, V98, P895, DOI DOI 10.1029/93JA01944; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Keigwin LD, 1999, SCIENCE, V286, P520, DOI 10.1126/science.286.5439.520; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Ohhashi Y, 1999, J METEOROL SOC JPN, V77, P495, DOI 10.2151/jmsj1965.77.2_495; Pfister C., 1995, CLIMATE AD 1500, P118; Rajagopalan B, 1998, GEOPHYS RES LETT, V25, P3967, DOI 10.1029/1998GL900065; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Shindell DT, 2001, J GEOPHYS RES-ATMOS, V106, P7193, DOI 10.1029/2000JD900547; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Shindell DT, 1998, J CLIMATE, V11, P895, DOI 10.1175/1520-0442(1998)011<0895:CCATMA>2.0.CO;2; Slonosky VC, 2001, INT J CLIMATOL, V21, P285, DOI 10.1002/joc.611; STUIVER M, 1993, RADIOCARBON, V35, P137; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; Visbeck M, 1998, GEOPHYS RES LETT, V25, P4521, DOI 10.1029/1998GL900162; Wallace JM, 2000, Q J ROY METEOR SOC, V126, P791, DOI 10.1256/smsqj.56401; WAPLE AM, IN PRESS CLIM DYN; Wuebbles DJ, 1998, GEOPHYS RES LETT, V25, P523, DOI 10.1029/98GL00057	32	541	570	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2149	2152		10.1126/science.1064363	http://dx.doi.org/10.1126/science.1064363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739952	Green Submitted			2022-12-28	WOS:000172647700046
J	Crichton, WA; Mezouar, M; Grande, T; Stolen, S; Grzechnik, A				Crichton, WA; Mezouar, M; Grande, T; Stolen, S; Grzechnik, A			Breakdown of intermediate-range order in liquid GeSe2 at high pressure	NATURE			English	Article							HIGH-TEMPERATURES; TRANSFORMATIONS; WATER	Studies of liquids with tetrahedral coordination, particularly during compression or quenching, have indicated the existence of distinct phases(1-3) in the liquid state, distinguishable by density and local structure. In systems that exhibit critical phenomena in the supercooled state, anomalous behaviour of the compressibility is also anticipated above the critical point, as revealed by simulations of water(4). Liquid GeSe2 is a potentially attractive system for studying both types of phenomena, given its two-dimensional tetrahedral structure and anomalous physical properties (including a density minimum near its melting point). Here we report in situ X-ray diffraction measurements of solid and liquid GeSe2 at high temperature and high pressure, revealing that the structure of the liquid is sensitive to pressure and that anomalous compressibility is expected. During compression of liquid GeSe2, the connectivity of the liquid changes from two- to three-dimensional, leading to a breakdown of the intermediate-range order. The gradual change in structure above the melting line may develop to a first-order liquid-liquid transition in the supercooled regime.	European Synchrotron Radiat Facil, F-38043 Grenoble, France; Norwegian Univ Sci & Technol, Dept Chem, N-7034 Trondheim, Norway; Univ Oslo, Dept Chem, N-0315 Oslo, Norway; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	European Synchrotron Radiation Facility (ESRF); Norwegian University of Science & Technology (NTNU); University of Oslo; Max Planck Society	Crichton, WA (corresponding author), European Synchrotron Radiat Facil, BP 220, F-38043 Grenoble, France.		Grande, Tor/K-4125-2015	Grande, Tor/0000-0002-2709-1219; Crichton, Wilson/0000-0001-6823-5509				AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; Brazhkin VV, 1997, HIGH PRESSURE RES, V15, P267, DOI 10.1080/08957959708240477; Crichton WA, 2002, HIGH TEMP-HIGH PRESS, V34, P235, DOI 10.1068/htjr019; DITTMAR G, 1976, ACTA CRYSTALLOGR B, V32, P2726, DOI 10.1107/S0567740876008704; GLAZOV VM, 1984, INORG MATER+, V20, P1268; Grande T, 1999, J SOLID STATE CHEM, V145, P167, DOI 10.1006/jssc.1999.8235; Grzechnik A, 1998, J SOLID STATE CHEM, V141, P248, DOI 10.1006/jssc.1998.7975; Grzechnik A, 2000, J SOLID STATE CHEM, V150, P121, DOI 10.1006/jssc.1999.8557; HAMMERSLEY AP, 1995, REV SCI INSTRUM, V66, P2729, DOI [10.1063/1.1145618, 10.1063/1.1146453]; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; KROGHMOE J, 1956, ACTA CRYSTALLOGR, V9, P951, DOI 10.1107/S0365110X56002655; Lacks DJ, 2000, PHYS REV LETT, V84, P4629, DOI 10.1103/PhysRevLett.84.4629; LEGODEC Y, 2000, SCI TECHNOLOGY HIGH; Massobrio C, 2000, J PHYS-CONDENS MAT, V12, pL697, DOI 10.1088/0953-8984/12/46/102; Massobrio C, 2001, J CHEM PHYS, V114, P7976, DOI 10.1063/1.1365108; Mishima O, 2000, PHYS REV LETT, V85, P334, DOI 10.1103/PhysRevLett.85.334; NORMAN N, 1957, ACTA CRYSTALLOGR, V10, P370, DOI 10.1107/S0365110X57001085; OHare PAG, 1996, J CHEM THERMODYN, V28, P459, DOI 10.1006/jcht.1996.0045; PALINKAS G, 1973, ACTA CRYSTALLOGR A, V29, P10, DOI 10.1107/S0567739473000021; Petri I, 1999, J PHYS-CONDENS MAT, V11, P10219, DOI 10.1088/0953-8984/11/50/314; Petri I, 2000, PHYS REV LETT, V84, P2413, DOI 10.1103/PhysRevLett.84.2413; Polsky CH, 2000, PHYS REV B, V61, P5934, DOI 10.1103/PhysRevB.61.5934; POOLE P, 1996, SCIENCE, V275, P322; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; PRASAD MVN, 1993, PHYS CHEM GLASSES, V34, P199; RUSKA J, 1976, J NON-CRYST SOLIDS, V22, P277, DOI 10.1016/0022-3093(76)90059-4; SHIMADA M, 1977, INORG CHEM, V16, P2094, DOI 10.1021/ic50174a055; Stolen S, 2000, SOLID STATE COMMUN, V115, P249, DOI 10.1016/S0038-1098(00)00173-3; Stolte M, 1999, PATHOLOGE, V20, P1, DOI 10.1007/s002920050312; VANTHIEL M, 1993, PHYS REV B, V48, P3591, DOI 10.1103/PhysRevB.48.3591	30	90	92	0	32	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					622	625		10.1038/414622a	http://dx.doi.org/10.1038/414622a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740555				2022-12-28	WOS:000172535600043
J	Fenton, KA; Korovessis, C; Johnson, AM; McCadden, A; McManus, S; Wellings, K; Mercer, CH; Carder, C; Copas, AJ; Nanchahal, K; Macdowall, W; Ridgway, G; Field, J; Erens, B				Fenton, KA; Korovessis, C; Johnson, AM; McCadden, A; McManus, S; Wellings, K; Mercer, CH; Carder, C; Copas, AJ; Nanchahal, K; Macdowall, W; Ridgway, G; Field, J; Erens, B			Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection	LANCET			English	Article								Background Studies of the epidemiology of sexually transmitted infections (STI) are largely based on surveillance data. As part of a national survey of sexual attitudes and lifestyles (Natsal 2000) in Britain, we estimated the frequency of self-reported STIs, and the prevalence of urinary Chlamydia trachomatis infection. Methods We did a stratified probability sample survey of 11 161 men and women aged 16-44 years in Britain. Computer assisted self-interviews contained items on the nature and timing of previously diagnosed STIs. Half of all sexually experienced respondents aged 18-44 years were invited to provide a urine sample for ligase chain reaction testing for C trachomatis infection. Findings 10.8% of men and 12.6% of women reported ever having an STI, 3.6% of men and 4.1% of women reported ever being diagnosed with genital warts, and 1.4% of men and 3.1% of women reported previous infection with C trachomatis. 76% of men and 57% of women ever diagnosed with an STI had been to a GUM clinic. C trachomatis was found in 2.2% (95% CI 1.5-3.2) of men and 1.5% (95% CI 1.11-2.14) of women with age-specific prevalence being highest among men aged 25-34 (3.1%) and women aged 16-24 years (3.0%). Non-married status, age, and reporting partner concurrency or two or more sexual partners in the past year were independently associated with infection with C trachomatis. Interpretation We show substantial heterogeneity in distribution of reported STIs, and the demographic and behavioural determinants of prevalent genital chlamydial infection. The results have potentially wide application for proposed chlamydia screening programmes which, given the demonstrated prevalence, must now proactively seek to involve men.	Royal Free & UCL, Ctr Infect Dis Epidemiol, Dept Primary Care, London, England; Royal Free & UCL, Ctr Infect Dis Epidemiol, Dept Populat Sci, London, England; Royal Free & UCL, Dept Sexually Transmitted Dis, London, England; PHLS Communicable Dis Surveillance Ctr, HIV STI Div, London, England; Natl Ctr Social Res, London, England; UCL Hosp NHS Trust, Dept Microbiol, London, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Ctr Sexual Hlth Res, London, England	University of London; University College London; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Fenton, KA (corresponding author), Royal Free & UCL, Ctr Infect Dis Epidemiol, Dept Primary Care, London, England.	kfenton@gum.ucl.ac.uk	McManus, Sally/S-4697-2019; McManus, Sally/HGD-4860-2022	McManus, Sally/0000-0003-2711-0819; Nanchahal, Kiran/0000-0001-8812-7628; Copas, Andrew/0000-0001-8968-5963; Johnson, Anne/0000-0003-1330-7100; Macdowall, Wendy/0000-0001-5868-8336; Erens, Robert/0000-0002-3054-504X; Erens, Bob/0000-0002-4430-954X; Mercer, Catherine/0000-0002-4220-5034				BRUNHAM RC, 1990, MED CLIN N AM, V74, P1339, DOI 10.1016/S0025-7125(16)30484-9; Carder C, 1999, INT J STD AIDS, V10, P776, DOI 10.1258/0956462991913538; *CHIEF MED OFF MED, 1998, MAIN REP CMOS EXP AD; Department of Health, 2001, NAT STRAT SEX HLTH H, P1; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0	5	312	312	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1851	1854		10.1016/S0140-6736(01)06886-6	http://dx.doi.org/10.1016/S0140-6736(01)06886-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741624				2022-12-28	WOS:000172463000010
J	Abbott, A				Abbott, A			Concern raised for missing biologist	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					475	475		10.1038/35107205	http://dx.doi.org/10.1038/35107205			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734808	Bronze			2022-12-28	WOS:000172405900004
J	Smetana, GW; Shmerling, RH				Smetana, GW; Shmerling, RH			Does this patient have temporal arteritis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GIANT-CELL ARTERITIS; ERYTHROCYTE SEDIMENTATION-RATE; PERMANENT VISUAL-LOSS; POLYMYALGIA-RHEUMATICA; BIOPSY-PROVEN; CLINICAL CHARACTERISTICS; OLMSTED COUNTY; UNITED-STATES; DISEASE; PROGNOSIS	Context Clinicians must be able to confidently diagnose temporal arteritis (TA), since failure to make a correct diagnosis may lead to irreversible visual loss as well as inappropriate evaluation and treatment of headache, fatigue, and other potential presenting symptoms. The diagnostic value of particular signs and symptoms among patients with suspected TA is unknown. Objective To determine the accuracy of historical features, physical examination, and erythrocyte sedimentation rate (ESR) in diagnosis of TA. Data Sources We performed a MEDLINE search of English-language articles published between January 1966 and July 2000 and a hand search of bibliographies of retrieved articles, previous reviews, monographs, and textbooks. Study Selection Studies that provided detailed clinical information on patients who had been referred for temporal artery biopsy. Of 114 studies retrieved, 41 met our inclusion criteria; 21 included both biopsy-positive and biopsy-negative patients and formed the core of our review. Data Extraction Both authors independently reviewed each study to determine eligibility, abstracted data using a standardized instrument, and classified study quality using predetermined criteria. Data Synthesis The prevalence of TA in the general population is less than 1%. However, in our 21 core studies, 39% of patients referred for temporal artery biopsy had positive results. The only 2 historical features that substantially increased the likelihood of TA among patients referred for biopsy were jaw claudication (positive likelihood ratio [LR], 4.2; 95% confidence interval [CI], 2.8-6.2) and diplopia (positive LR, 3.4; 95% CI, 1.3-8.6). The absence of any temporal artery abnormality was the only clinical factor that modestly reduced the likelihood of disease (negative LR, 0.53; 95% CI, 0.38-0.75). Predictive physical findings included temporal artery beading (positive LR, 4.6; 95% CI, 1.1-18.4), prominence (positive LR, 4.3; 95% CI, 2.1-8.9), and tenderness (positive LR, 2.6; 95% CI, 1.9-3.7). Normal ESR values indicated much less likelihood of disease (negative LR for abnormal ESR, 0.2; 95% CI, 0.08-0.51). Conclusions A small number of clinical features are helpful in predicting the likelihood of a positive temporal artery biopsy among patients with a clinical suspicion of disease; the most useful finding is a normal ESR, which makes TA unlikely.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Smetana, GW (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.							ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALLSOP CJ, 1981, AM J SURG PATHOL, V5, P317, DOI 10.1097/00000478-198106000-00001; BALDURSSON O, 1994, ARTHRITIS RHEUM-US, V37, P1007, DOI 10.1002/art.1780370705; BANKS PM, 1983, ARTHRITIS RHEUM, V26, P1201, DOI 10.1002/art.1780261005; BENGTSSON BA, 1981, ACTA MED SCAND, V209, P337; BEVAN AT, 1968, ANN RHEUM DIS, V27, P271, DOI 10.1136/ard.27.3.271; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; Brack A, 1999, ARTHRITIS RHEUM, V42, P311, DOI 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F; BRANUM G, 1987, SOUTHERN MED J, V80, P1527, DOI 10.1097/00007611-198712000-00010; BRITTAIN GPH, 1991, BRIT J OPHTHALMOL, V75, P656, DOI 10.1136/bjo.75.11.656; CHMELEWSKI WL, 1992, ARCH INTERN MED, V152, P1690, DOI 10.1001/archinte.152.8.1690; Cid MC, 1998, ARTHRITIS RHEUM-US, V41, P26, DOI 10.1002/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0; DARE B, 1980, MED J AUSTRALIA, V1, P372, DOI 10.5694/j.1326-5377.1980.tb134927.x; DESMET GD, 1990, J INTERN MED, V227, P237, DOI 10.1111/j.1365-2796.1990.tb00151.x; DIMANT J, 1980, NEUROLOGY, V30, P1054, DOI 10.1212/WNL.30.10.1054; DIXON ASJ, 1966, ANN RHEUM DIS, V25, P203, DOI 10.1136/ard.25.3.203; Duhaut P, 1999, ANN RHEUM DIS, V58, P335, DOI 10.1136/ard.58.6.335; Eddy DM, 1992, METAANALYSIS CONFIDE; EDDY DM, 1992, FAST PRO SOFTWARE ME; FAINARU M, 1979, J RHEUMATOL, V6, P330; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; FERNANDEZHERLIHY L, 1989, J RHEUMATOL, V16, P260; FERNANDEZHERLIHY L, 1988, J RHEUMATOL, V15, P1797; Font C, 1997, BRIT J RHEUMATOL, V36, P251; GABRIEL SE, 1995, J RHEUMATOL, V22, P93; Genereau T, 1999, RHEUMATOLOGY, V38, P709, DOI 10.1093/rheumatology/38.8.709; Glutz von Blotzheim S, 1997, Eur J Ophthalmol, V7, P375; GONZALEZ EB, 1989, ARCH INTERN MED, V149, P1561, DOI 10.1001/archinte.149.7.1561; Gonzalez-Gay MA, 1998, ARTHRITIS RHEUM, V41, P1497, DOI 10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z; GonzalezGay MA, 1997, J RHEUMATOL, V24, P2171; GOUET D, 1985, J RHEUMATOL, V12, P1209; Gran JT, 1997, J RHEUMATOL, V24, P1739; Gur H, 1996, J RHEUMATOL, V23, P1927; HALL S, 1983, LANCET, V2, P1217; HAUSER WA, 1971, MAYO CLIN PROC, V46, P597; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; Hayreh SS, 1998, AM J OPHTHALMOL, V125, P509, DOI 10.1016/S0002-9394(99)80192-5; HEALEY LA, 1980, ARTHRITIS RHEUM, V23, P641, DOI 10.1002/art.1780230605; HEDGES TR, 1983, ARCH OPHTHALMOL-CHIC, V101, P1251; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; Horton BM., 1932, PROC STAFF MEET MAYO, V7, P700; Horton BT., 1937, P STAFF MEET MAYO CL, V12, P548; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Hutchinson J., 1890, ARCH SURG-CHICAGO, V1, P323; JACOBSON DM, 1987, ARCH OPHTHALMOL-CHIC, V105, P965; Jennings GH, 1938, LANCET, V1, P424; JONASSON F, 1979, SCOT MED J, V24, P111, DOI 10.1177/003693307902400203; KENT RB, 1990, AM SURGEON, V56, P16; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; LOVE DC, 1986, ANN INTERN MED, V105, P387, DOI 10.7326/0003-4819-105-3-387; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MAMBO NC, 1979, HISTOPATHOLOGY, V3, P209, DOI 10.1111/j.1365-2559.1979.tb02998.x; Matteson EL, 1996, AM J MED, V100, P193, DOI 10.1016/S0002-9343(97)89458-2; MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P518; MILLER A, 1983, BRIT MED J, V286, P266, DOI 10.1136/bmj.286.6361.266; Myklebust G, 1996, BRIT J RHEUMATOL, V35, P1161; MYLES AB, 1991, BAILLIERE CLIN RHEUM, V5, P493, DOI 10.1016/S0950-3579(05)80068-8; OSTBERG G, 1971, ANN RHEUM DIS, V30, P224, DOI 10.1136/ard.30.3.224; Petursdottir V, 1999, RHEUMATOLOGY, V38, P1208, DOI 10.1093/rheumatology/38.12.1208; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; ROTH AM, 1984, ARCH OPHTHALMOL-CHIC, V102, P901; Salvarani C, 1997, ANN INTERN MED, V127, P27, DOI 10.7326/0003-4819-127-1-199707010-00005; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; Skaug TR, 1995, ACTA OPHTHALMOL SCAN, V73, P567; SOLOMON S, 1987, J AM GERIATR SOC, V35, P163, DOI 10.1111/j.1532-5415.1987.tb01348.x; STUART RA, 1989, NEW ZEAL MED J, V102, P431; VILASECA J, 1987, ANN RHEUM DIS, V46, P282, DOI 10.1136/ard.46.4.282; WADMAN B, 1972, ACTA MED SCAND, V192, P377; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105; WHITFIELD A G, 1963, Br J Ophthalmol, V47, P555, DOI 10.1136/bjo.47.9.555	73	265	270	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					92	101		10.1001/jama.287.1.92	http://dx.doi.org/10.1001/jama.287.1.92			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754714				2022-12-28	WOS:000172978500031
J	Baden, LR; Horowitz, G; Jacoby, H; Eliopoulos, GM				Baden, LR; Horowitz, G; Jacoby, H; Eliopoulos, GM			Quinolones and false-positive urine screening for opiates by immunoassay technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPPY SEED INGESTION; ANTIBACTERIAL ACTIVITY; PHARMACOKINETICS; TUBERCULOSIS; OFLOXACIN; MORPHINE; CODEINE; LEVOFLOXACIN; PENETRATION; PEFLOXACIN	Context Millions of assays are performed each year to monitor for substance abuse in various settings. When common medications cross-react with frequently used testing assays, false-positive results can lead to invalid conclusions. Objective To evaluate cross-reactivity of quinolone antimicrobials in common opiate screening assays and to assess the in vivo implications of this phenomenon. Design, Setting, and Participants The reactivity of 13 quinolones (levofloxacin, ofloxacin, pefloxacin, enoxacin, moxifloxacin, gatifloxacin, trovafloxacin, sparfloxacin, lomefloxacin, ciprofloxacin, clinafloxacin, norfloxacin, and nalidixic acid) was tested in 5 commercial opiate screening assays from September 1998 to March 1999. In 6 healthy volunteers, we confirmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening assays. Main Outcome Measure Opiate assay activity (threshold for positive result, 300 ng/mL of morphine). Results Nine of the quinolones caused assay results above the threshold for a positive result in at least 1 of the assays. Four of the assay systems caused false-positive results for at least 1 quinolone. Eleven of the 13 compounds caused some opiate activity by at least 1 assay system. At least 1 compound caused opiate assay activity in all 5 assay systems. Levofloxacin, oflaxacin, and perfloxacin were most likely to lead to a false-positive opiate result. Positive results were obtained in urine from all 6 volunteers. Conclusion Greater attention to the cross-reactivity of quinolones with immunoassays for opiates is needed to minimize the potential for invalid test interpretation.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Baden, LR (corresponding author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB-A400, Boston, MA 02115 USA.	lbaden@partners.org						ANDRIOLE V, 1998, QUINOLONES; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAILEY GS, 1996, ENV HLTH PERSPECT, V1, P5; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; BORNER K, 1993, DRUGS, V45, P303; Bron NJ, 1996, J ANTIMICROB CHEMOTH, V38, P1023, DOI 10.1093/jac/38.6.1023; Catrou PG, 1996, AM J CLIN PATHOL, V105, P527; Chien SC, 1997, ANTIMICROB AGENTS CH, V41, P1562, DOI 10.1128/AAC.41.7.1562; de Paula M, 1998, CLIN CHEM LAB MED, V36, P241, DOI 10.1515/CCLM.1998.041; ELSOHLY HN, 1988, J FORENSIC SCI, V33, P347; File TM, 1997, ANTIMICROB AGENTS CH, V41, P1965, DOI 10.1128/AAC.41.9.1965; GJERDE H, 1990, FORENSIC SCI INT, V44, P179, DOI 10.1016/0379-0738(90)90248-W; GUIBERT J, 1989, PATHOL BIOL, V37, P406; HAYES LW, 1987, CLIN CHEM, V33, P806; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P3110; HOFFKEN G, 1985, ANTIMICROB AGENTS CH, V27, P375, DOI 10.1128/AAC.27.3.375; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; KARABALUT N, 2000, QUINOLONE ANTIMICROB, P202; KOHNO S, 1992, CHEST, V102, P1815, DOI 10.1378/chest.102.6.1815; Meatherall R, 1997, THER DRUG MONIT, V19, P98, DOI 10.1097/00007691-199702000-00019; MONK JP, 1987, DRUGS, V33, P346, DOI 10.2165/00003495-198733040-00003; MONTAY G, 1984, ANTIMICROB AGENTS CH, V25, P463, DOI 10.1128/AAC.25.4.463; NAKASHIMA M, 1995, ANTIMICROB AGENTS CH, V39, P2635, DOI 10.1128/AAC.39.12.2635; *NAT COMM CLIN LAB, 1997, M100S7 NAT COMM CLIN; Paul BD, 1999, CLIN CHEM, V45, P510; PAUL BD, 1985, J ANAL TOXICOL, V9, P222, DOI 10.1093/jat/9.5.222; PETTITT BC, 1987, CLIN CHEM, V33, P1251; SALERNO C, 1990, THER DRUG MONIT, V12, P210; SELAVKA CM, 1991, J FORENSIC SCI, V36, P685; SLOOP G, 1995, J ANAL TOXICOL, V19, P554, DOI 10.1093/jat/19.7.554; Small PM, 2001, NEW ENGL J MED, V345, P189, DOI 10.1056/NEJM200107193450307; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; TREVILLA PH, 1995, J ANAL TOXICOL, V19, P200, DOI 10.1093/jat/19.3.200; Wise R, 1999, ANTIMICROB AGENTS CH, V43, P1508, DOI 10.1128/AAC.43.6.1508; WISE R, 1984, ANTIMICROB AGENTS CH, V26, P17, DOI 10.1128/AAC.26.1.17; YEW WW, 1990, J ANTIMICROB CHEMOTH, V26, P227, DOI 10.1093/jac/26.2.227; 2001, MED LETT DRUGS THER, V43, P87; 1998, MED LETT DRUGS THER, V40, P33; 1997, FED REG, V62, P51118; 1995, FED REG, V60, P57587; 1988, FED REG, V53, P11979	41	44	48	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3115	3119		10.1001/jama.286.24.3115	http://dx.doi.org/10.1001/jama.286.24.3115			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754677	Bronze			2022-12-28	WOS:000172927100029
J	Jin, QL; He, SY				Jin, QL; He, SY			Role of the Hrp pilus in type III protein secretion in Pseudomonas syringae	SCIENCE			English	Article							AVR PROTEINS; EXPRESSION; PROMOTER; VECTORS; CLONING; TOMATO; COLI	Bacterial surface appendages called pili and needle-like filaments are associated with protein and/or DNA transfer to recipient plant, human, or bacterial cells during pathogenesis or conjugation. Although it has long been suspected that pili function as a conduit for protein or DNA transfer, direct evidence has been lacking. The Hrp pilus of Pseudomonas syringae is assembled by the type III secretion system. We used an in situ immunogold labeling procedure to visualize the extrusion of an effector protein, AvrPto, from the tip of the Hrp pilus, providing direct evidence that a bacterial pilus can function as a conduit for protein delivery.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	He, SY (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.	hes@msu.edu		He, Sheng Yang/0000-0003-1308-498X				BRINTON CC, 1964, P NATL ACAD SCI USA, V52, P776, DOI 10.1073/pnas.52.3.776; Brown IR, 2001, MOL PLANT MICROBE IN, V14, P394, DOI 10.1094/MPMI.2001.14.3.394; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Ham JH, 1998, P NATL ACAD SCI USA, V95, P10206, DOI 10.1073/pnas.95.17.10206; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; INNES RW, 1993, J BACTERIOL, V175, P4859, DOI 10.1128/JB.175.15.4859-4869.1993; Jin QL, 2001, MOL MICROBIOL, V40, P1129, DOI 10.1046/j.1365-2958.2001.02455.x; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Koebnik R, 2001, TRENDS MICROBIOL, V9, P586, DOI 10.1016/S0966-842X(01)02255-7; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SHEN H, 1993, J BACTERIOL, V175, P5916, DOI 10.1128/JB.175.18.5916-5924.1993; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Van Gijsegem F, 2000, MOL MICROBIOL, V36, P249, DOI 10.1046/j.1365-2958.2000.01851.x; Wei WS, 2000, P NATL ACAD SCI USA, V97, P2247, DOI 10.1073/pnas.040570097; XIAO YX, 1994, J BACTERIOL, V176, P3089, DOI 10.1128/JB.176.10.3089-3091.1994; YEN KM, 1991, J BACTERIOL, V173, P5328, DOI 10.1128/jb.173.17.5328-5335.1991	22	151	160	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2556	2558		10.1126/science.1066397	http://dx.doi.org/10.1126/science.1066397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752577				2022-12-28	WOS:000172927700061
J	Meier, DE; Back, AL; Morrison, RS				Meier, DE; Back, AL; Morrison, RS			The inner life of physicians and care of the seriously ill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOCTOR-PATIENT COMMUNICATION; ASSISTED SUICIDE; MEDICAL-STUDENTS; PALLIATIVE CARE; PERSONAL GROWTH; NATIONAL SURVEY; SEXUAL CONTACT; STRESS; DEATH; COUNTERTRANSFERENCE	Seriously ill persons are emotionally vulnerable during the typically protracted course of an illness. Physicians respond to such patients' needs and emotions with emotions of their own, which may reflect a need to rescue the patient, a sense of failure and frustration when the patient's illness progresses, feelings of powerlessness against illness and its associated losses, grief, fear of becoming ill oneself, or a desire to separate from and avoid patients to escape these feelings. These emotions can affect both the quality of medical care and the physician's own sense of well-being, since unexamined emotions may also lead to physician distress, disengagement, burnout, and poor judgment. In this article, which is intended for the practicing, nonpsychiatric clinician, we describe a model for increasing physician self-awareness, which includes identifying and working with emotions that may affect patient care. Our approach is based on the standard medical model of risk factors, signs and symptoms, differential diagnosis, and intervention. Although it is normal to have feelings arising from the care of patients, physicians should take an active role in identifying and controlling those emotions.	CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Hertzberg Palliat Care Inst, New York, NY 10029 USA; Univ Washington, Sch Med, Dept Med Hist & Eth, Dept Med,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Meier, DE (corresponding author), CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Hertzberg Palliat Care Inst, Box 1070, New York, NY 10029 USA.							BALINT M, 1972, DOCTOR HIST PATIENT; BECKMAN H, 1990, J GEN INTERN MED, V5, P42, DOI 10.1007/BF02602308; BENOLIEL JQ, 1987, OMEGA-J DEATH DYING, V18, P341, DOI 10.2190/4Y6G-XQAP-0XYN-LRW9; Billings C V, 1992, Am Nurse, V24, P2; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN, P309; BLACKSHAW SL, 1994, AM J PSYCHIAT, V151, P293; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block S, 1998, ACAD MED, V73, P763, DOI 10.1097/00001888-199807000-00012; BLOCK S, 2001, MANAGING DEATH ICU T, P183; Block SD, 1996, ACAD PSYCHIATR, V20, P65, DOI 10.1007/BF03341552; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; BRADSHAW S, 1976, B MENNINGER CLIN, V40, P665; Breen CM, 2001, J GEN INTERN MED, V16, P283, DOI 10.1046/j.1525-1497.2001.00419.x; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; Buckman R., 1992, BREAK BAD NEWS GUIDE; BUTLER RN, 1975, AM J PSYCHIAT, V132, P893; CAINE ED, 1993, JAMA-J AM MED ASSOC, V270, P875, DOI 10.1001/jama.270.7.875; Casarett D, 2001, ANN INTERN MED, V134, P208, DOI 10.7326/0003-4819-134-3-200102060-00012; Charon R, 2000, ANN INTERN MED, V132, P63, DOI 10.7326/0003-4819-132-1-200001040-00011; Charon R, 2001, ANN INTERN MED, V134, P83, DOI 10.7326/0003-4819-134-1-200101020-00024; CLARKE PJ, 1981, AM J ORTHOPSYCHIAT, V51, P71, DOI 10.1111/j.1939-0025.1981.tb01349.x; Crouch M, 1986, Fam Med, V18, P93; DEBBIE, 1988, JAMA-J AM MED ASSOC, V259, P272; Dozor R B, 1992, Fam Med, V24, P538; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Epstein RM, 1998, ANN INTERN MED, V128, P435, DOI 10.7326/0003-4819-128-6-199803150-00003; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; Farber NJ, 1997, ARCH INTERN MED, V157, P2291, DOI 10.1001/archinte.157.20.2291; FREEBORN DK, 2000, PERMANENTE J, V2, P22; Friedman E, 1990, Healthc Forum J, V33, P9; GABBARD GO, 1995, JAMA-J AM MED ASSOC, V273, P1445, DOI 10.1001/jama.273.18.1445; GARTRELL N, 1986, AM J PSYCHIAT, V143, P1126; GARTRELL NK, 1992, WESTERN J MED, V157, P139; Goold SD, 2000, JAMA-J AM MED ASSOC, V283, P909, DOI 10.1001/jama.283.7.909; GORDON GH, 1986, J GEN INTERN MED, V1, P228, DOI 10.1007/BF02596188; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; Gorlin R, 2001, CAMB Q HEALTHC ETHIC, V10, P7, DOI 10.1017/S0963180101001037; Gundersen L, 2001, ANN INTERN MED, V135, P145, DOI 10.7326/0003-4819-135-2-200107170-00023; Hendin H, 2000, AM J PSYCHIAT, V157, P2022, DOI 10.1176/appi.ajp.157.12.2022; HENDIN H, 1981, AM J PSYCHOTHER, V35, P469, DOI 10.1176/appi.psychotherapy.1981.35.4.469; HOWELLS K, 1982, SOC SCI MED, V16, P1421, DOI 10.1016/0277-9536(82)90137-X; Hurwitz B, 2000, LANCET, V356, P2086, DOI 10.1016/S0140-6736(00)03412-7; JECKER NS, 1995, WESTERN J MED, V163, P287; Liossi C, 1997, PALLIATIVE MED, V11, P455, DOI 10.1177/026921639701100605; Lubitz R M, 1996, JAMA, V275, P414, DOI 10.1001/jama.275.5.414; MALTSBERGER JT, 1974, ARCH GEN PSYCHIAT, V30, P625; Manian FA, 2001, ARCH INTERN MED, V161, P801, DOI 10.1001/archinte.161.6.801; MARSHALL AA, 1995, AM J GASTROENTEROL, V90, P4; MARTIN AR, 1986, J GEN INTERN MED, V1, P252, DOI 10.1007/BF02596195; Martin C A, 1987, Hosp J, V3, P121, DOI 10.1300/J011v03n02_07; MARTIN MJ, 1981, MAYO CLIN PROC, V56, P35; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MCCUE JD, 1985, NEW ENGL J MED, V312, P449, DOI 10.1056/NEJM198502143120725; MCCUE JD, 1991, ARCH INTERN MED, V151, P2273, DOI 10.1001/archinte.151.11.2273; MEIER D, 2000, ETHNICAL DILEMMAS, P180; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Mengel MB, 1987, FAM SYST MED, V5, P176; MILES SH, 1995, HASTINGS CENT REP, V25, P17, DOI 10.2307/3562108; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MODESTIN J, 1987, BRIT J MED PSYCHOL, V60, P379, DOI 10.1111/j.2044-8341.1987.tb02757.x; Muskin PR, 1998, JAMA-J AM MED ASSOC, V279, P323, DOI 10.1001/jama.279.4.323; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Novack DH, 1999, ACAD MED, V74, P516, DOI 10.1097/00001888-199905000-00017; NOVACK DH, 1997, MED ENCOUNTER, V13, P2; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; PICK IB, 1985, INT J PSYCHOANAL, V66, P157; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; Prendergast T J, 1997, New Horiz, V5, P62; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; PUCINSKI J, 1985, BR J HOSP PSYCHIAT, V33, P90; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Rabow MW, 2001, WESTERN J MED, V174, P66, DOI 10.1136/ewjm.174.1.66; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; Schon D.A., 1987, ED REFLECTIVE PRACTI; SMITH JW, 1986, JAMA-J AM MED ASSOC, V255, P1155, DOI 10.1001/jama.255.9.1155; SMITH RC, 1988, PSYCHOSOMATICS, V29, P392, DOI 10.1016/S0033-3182(88)72339-7; SNIBBE JR, 1989, PSYCHOL REP, V65, P775, DOI 10.2466/pr0.1989.65.3.775; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STRASBURGER LH, 1992, AM J PSYCHOTHER, V46, P544, DOI 10.1176/appi.psychotherapy.1992.46.4.544; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; VALIANT GE, 1972, NEW ENGL J MED, V287, P372; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; Weiner EL, 2001, WESTERN J MED, V174, P19, DOI 10.1136/ewjm.174.1.19; WEISMAN AD, 1974, REALIZATION DEATH; WHIPPEN DA, 1991, J CLIN ONCOL, V9, P1916, DOI 10.1200/JCO.1991.9.10.1916; YARNEY G, 2001, BRIT MED J, V322, P252; ZINN WM, 1988, JAMA-J AM MED ASSOC, V259, P3296, DOI 10.1001/jama.259.22.3296	95	406	415	2	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					3007	3014		10.1001/jama.286.23.3007	http://dx.doi.org/10.1001/jama.286.23.3007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	502VY	11743845				2022-12-28	WOS:000172764500036
J	Kojouri, K; Vesely, SK; George, JN				Kojouri, K; Vesely, SK; George, JN			Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							INDUCED IMMUNE THROMBOCYTOPENIA; HYPERSENSITIVITY	Background: Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is thought to be uncommon and to have a good prognosis. Objective: To describe the frequency, clinical features, and longterm outcomes of quinine-associated TTP-HUS. Design: Case series. Setting: Hospitals in central-western Oklahoma. Patients: 225 consecutive patients with TTP-HUS, 1989-2000. Measurements: Presenting features and clinical outcomes. Results: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was associated with quinine in 17 patients. Four patients died, and 7 survivors currently have chronic renal failure. Since 1 July 1995, 132 patients with clinically suspected TTP-HUS were explicitly asked about drug exposure. Fourteen (11%) had taken quinine, and 7 had taken other drugs associated with TTP-HUS. Neurologic abnormalities were as severe in patients with quinine-associated TTP-HUS as in the 118 patients who had not taken quinine. Conclusions: Quinine is a common cause of drug-associated TTP-HUS and can cause death and chronic renal failure. When the disorder is described as TTP-HUS rather than only as HUS, the severity of neurologic abnormalities and the occasional absence of renal failure are emphasized. if recurrent disease is to be prevented, clinicians must recognize quinine as a possible cause.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Box 26901, Oklahoma City, OK 73190 USA.	Jim-George@OUHSC.edu		Vesely, Sara/0000-0003-3448-0156				BARR E, 1990, BRIT MED J, V301, P323, DOI 10.1136/bmj.301.6747.323; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; Cohen JA, 1998, J CLIN APHERESIS, V13, P16, DOI 10.1002/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0.CO;2-C; Crum NF, 2000, SOUTHERN MED J, V93, P726; Farver DK, 1999, ANN PHARMACOTHER, V33, P32, DOI 10.1345/aph.18172; George JN, 2000, BLOOD, V96, P1223, DOI 10.1182/blood.V96.4.1223.h8001223_1223_1229; GOTTSCHALL JL, 1994, AM J HEMATOL, V47, P283, DOI 10.1002/ajh.2830470407; GOTTSCHALL JL, 1991, BLOOD, V77, P306; Kedia RK, 1999, POSTGRAD MED J, V75, P429, DOI 10.1136/pgmj.75.885.429; Kojouri K, 2000, J Okla State Med Assoc, V93, P519; Medina PJ, 2001, CURR OPIN HEMATOL, V8, P286, DOI 10.1097/00062752-200109000-00004; Moake JL, 1998, THROMBOSIS HEMORRHAG, P583; NAYLOR JR, 1994, AGE AGEING, V23, P418, DOI 10.1093/ageing/23.5.418; Rock GA, 2000, BRIT J HAEMATOL, V109, P496, DOI 10.1046/j.1365-2141.2000.01941.x; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Schattner A, 1998, AM J MED, V104, P488, DOI 10.1016/S0002-9343(98)00082-5; STRONCEK DF, 1992, BLOOD, V80, P241; 1994, FED REG, V59, P43234	18	87	93	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1047	1051		10.7326/0003-4819-135-12-200112180-00008	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747383				2022-12-28	WOS:000172759700004
J	Ren, DJ; Navarro, B; Xu, HX; Yue, LX; Shi, Q; Clapham, DE				Ren, DJ; Navarro, B; Xu, HX; Yue, LX; Shi, Q; Clapham, DE			A prokaryotic voltage-gated sodium channel	SCIENCE			English	Article							FLAGELLAR MOTORS; CA2+ CHANNELS; ION CHANNELS; SELECTIVITY; TETRODOTOXIN; PERMEATION; MUTATIONS; DRIVEN; LOCUS; SITE	The pore-forming subunits of canonical voltage-gated sodium and calcium channels are encoded by four repeated domains of six-transmembrane (6TM) segments. We expressed and characterized a bacterial ion channel (NaChBac) from Bacillus halodurans that is encoded by one 6TM segment. The sequence, especially in the pore region, is similar to that of voltage-gated calcium channels. The expressed channel was activated by voltage and was blocked by calcium channel blockers. However, the channel was selective for sodium. The identification of NaChBac as a functionally expressed bacterial voltage-sensitive ion-selective channel provides insight into both voltage-dependent activation and divalent cation selectivity.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Ctr Int Fis, Lab Biofis, Bogota, Colombia	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Clapham, DE (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; ATSUMI T, 1992, NATURE, V355, P182, DOI 10.1038/355182a0; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.ph.58.030196.002025; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2001, BIOCHEM BIOPH RES CO, V281, P741, DOI 10.1006/bbrc.2001.4408; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hilber K, 2001, J BIOL CHEM, V276, P27831, DOI 10.1074/jbc.M101933200; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; Krulwich TA, 2001, BBA-BIOENERGETICS, V1505, P158, DOI 10.1016/S0005-2728(00)00285-1; NAVARRO B, UNPUB; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Sivilotti L, 1997, FEBS LETT, V409, P49, DOI 10.1016/S0014-5793(97)00479-1; SKRYMA R, 1994, AM J PHYSIOL, V267, pC544, DOI 10.1152/ajpcell.1994.267.2.C544; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Sun YM, 1997, J GEN PHYSIOL, V110, P693, DOI 10.1085/jgp.110.6.693; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; Triggle DJ, 1999, EUR J PHARMACOL, V375, P311, DOI 10.1016/S0014-2999(99)00329-5; Wappl E, 2001, J BIOL CHEM, V276, P12730, DOI 10.1074/jbc.M010164200; Yamaguchi S, 2000, J BIOL CHEM, V275, P41504, DOI 10.1074/jbc.M007165200; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yorimitsu T, 2001, BBA-BIOENERGETICS, V1505, P82, DOI 10.1016/S0005-2728(00)00279-6	32	363	375	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2372	2375		10.1126/science.1065635	http://dx.doi.org/10.1126/science.1065635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743207				2022-12-28	WOS:000172817200052
J	Bell, GI; Polonsky, KS				Bell, GI; Polonsky, KS			Diabetes mellitus and genetically programmed defects in beta-cell function	NATURE			English	Review							IMPAIRED INSULIN-SECRETION; TISSUE-SPECIFIC KNOCKOUT; FREE FATTY-ACIDS; PPAR-GAMMA; PRO12ALA POLYMORPHISM; TRANSCRIPTION FACTORS; GENE; ONSET; MUTATIONS; RESISTANCE	The pathways that control insulin secretion and regulate pancreatic beta -cell mass are crucial in the development of diabetes mellitus. Maturity-onset diabetes of the young comprises a number of single-gene disorders affecting pancreatic beta -cell function, and the consequences of mutations in these genes are so serious that diabetes develops in childhood or adolescence. A genetic basis for the more common form of type 2 diabetes, which affects 10-20% of adults in many developed countries, is less clear cut. It is also characterized by abnormal beta -cell function, but other tissues are involved as well. However, in both forms identification of causative and susceptibility genes are providing new insight into the control of insulin action and secretion, as well as suggesting new treatments for diabetes.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med & Human Genet, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; Washington University (WUSTL); Washington University (WUSTL)	Bell, GI (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.	g-bell@uchicago.edu; polonsky@im.wustl.edu						Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; *AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS5; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bray GA, 1999, DIABETES CARE, V22, P623; Carpentier A, 2000, DIABETES, V49, P399, DOI 10.2337/diabetes.49.3.399; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; Cavaghan MK, 2000, J CLIN INVEST, V106, P329, DOI 10.1172/JCI10761; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chu K, 2001, RECENT PROG HORM RES, V56, P23, DOI 10.1210/rp.56.1.23; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; Dubois M, 2000, DIABETOLOGIA, V43, P1165, DOI 10.1007/s001250051508; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Flier SN, 2001, P NATL ACAD SCI USA, V98, P7475, DOI 10.1073/pnas.131192998; Garcia-Ocana A, 2001, J CLIN ENDOCR METAB, V86, P984, DOI 10.1210/jc.86.3.984; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Luan J, 2001, DIABETES, V50, P686, DOI 10.2337/diabetes.50.3.686; Ludwig DS, 2001, JAMA-J AM MED ASSOC, V286, P1427, DOI 10.1001/jama.286.12.1427; Maassen JA, 1996, DIABETOLOGIA, V39, P375; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matschinsky F.M., 2001, HDB PHYSL 7, P125; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Moore A, 2001, DIABETES, V50, P2231, DOI 10.2337/diabetes.50.10.2231; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Okita K, 1999, BIOCHEM BIOPH RES CO, V263, P566, DOI 10.1006/bbrc.1999.1412; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Owen K, 2001, BEST PRACT RES CL EN, V15, P309, DOI 10.1053/beem.2001.0148; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; POLONSKY KS, 2001, ENDOCRINOLOGY, P697; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shimomura H, 2000, DIABETES, V49, P1597, DOI 10.2337/diabetes.49.9.1597; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; Stefan N, 2001, DIABETES, V50, P1143, DOI 10.2337/diabetes.50.5.1143; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Taylor SI, 1999, J CLIN ENDOCR METAB, V84, P4390, DOI 10.1210/jc.84.12.4390; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; Wiltshire S, 2001, AM J HUM GENET, V69, P553, DOI 10.1086/323249; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	58	368	398	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					788	791		10.1038/414788a	http://dx.doi.org/10.1038/414788a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742410				2022-12-28	WOS:000172676200058
J	Gani, R; Leach, S				Gani, R; Leach, S			Transmission potential of smallpox in contemporary populations	NATURE			English	Article							IMPACT	Despite eradication(1), smallpox still presents a risk to public health whilst laboratory stocks of virus remain(2,3). One factor crucial to any assessment of this risk is R-0, the average number of secondary cases infected by each primary case. However, recently applied estimates have varied too widely (R-0 from 1.5 to >20) to be of practical use, and often appear to disregard contingent factors such as socio-economic conditions and herd immunity(4-8). Here we use epidemic modelling(9) to show a more consistent derivation of R0. In isolated pre-twentieth century populations(10-12) with negligible herd immunity, the numbers of cases initially rose exponentially, with an R-0 between 3.5 and 6. Before outbreak controls were applied, smallpox also demonstrated similar levels of transmission in 30 sporadic outbreaks in twentieth century Europe(1), taking into account pre-existing vaccination levels(13,14) (about 50%) and the role of hospitals in doubling early transmission. Should smallpox recur, such estimates of transmission potential (R-0 from 3.5 to 6) predict a reasonably rapid epidemic rise before the implementation of public health interventions, because little residual herd immunity exists now that vaccination has ceased.	Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England		Leach, S (corresponding author), Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England.	steve.leach@camr.org.uk						ANDERSON R M, 1991; ARITA I, 1986, J HYG-CAMBRIDGE, V96, P459, DOI 10.1017/S0022172400066249; Creighton C., 1891, HIST EPIDEMICS BRITA, V2; Dietz K, 2000, NATURE, V408, P513, DOI 10.1038/35046270; DIXON C.W, 1962, SMALLPOX; Duncan CJ, 1996, J THEOR BIOL, V183, P447, DOI 10.1006/jtbi.1996.0234; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; GELFAND HM, 1971, AM J EPIDEMIOL, V93, P234, DOI 10.1093/oxfordjournals.aje.a121251; Henderson DA, 1998, EMERG INFECT DIS, V4, P488, DOI 10.3201/eid0403.980340; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HENDERSON DA, 1994, VACCINES, P13; Jezek Z, 1988, HUMAN MONKEYPOX; KOPLAN JP, 1978, TROP GEOGR MED, V30, P355; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J EPIDEMIOL, V95, P157, DOI 10.1093/oxfordjournals.aje.a121380; MELTZER MI, IN PRESS EMERG INFEC, V7; MOODY J, 1980, 1 BURF BURF SCH TOLS; OTOOLE T, 1999, EMERG INFECT DIS, V4, P488; *REG GEN, 1870, ANN REP REG GEN 1869; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; *WHO, 1999, FUT RES SMALLP VIR R; World Health Organization, 1970, HLTH ASP CHEM BIOL W; 1999, NATURE, V399, P628	24	193	196	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					748	751		10.1038/414748a	http://dx.doi.org/10.1038/414748a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742399				2022-12-28	WOS:000172676200047
J	Kuhn, G; Hijri, M; Sanders, IR				Kuhn, G; Hijri, M; Sanders, IR			Evidence for the evolution of multiple genomes in arbuscular mycorrhizal fungi	NATURE			English	Article							INTERNAL TRANSCRIBED SPACERS; SCUTELLOSPORA-CASTANEA; GIGASPORA-MARGARITA; SEXUAL REPRODUCTION; GENETIC DIVERSITY; GLOMUS-MOSSEAE; RIBOSOMAL DNA; SEQUENCES; GLOMALES; SPORES	Ancient asexuals directly contradict the evolutionary theories that explain why organisms should evolve a sexual life history(1,2). The mutualistic, arbuscular mycorrhizal fungi are thought to have been asexual for approximately 400 million years(3,4). In the absence of sex, highly divergent descendants of formerly allelic nucleotide sequences are thought to evolve in a genome(2). In mycorrhizal fungi, where individual offspring receive hundreds of nuclei from the parent, it has been hypothesized that a population of genetically different nuclei should evolve within one individual(5,6). Here we use DNA-DNA fluorescent in situ hybridization to show that genetically different nuclei co-exist in individual arbuscular mycorrhizal fungi. We also show that the population genetics techniques(4) used in other organisms are unsuitable for detecting recombination because the assumptions and underlying processes do not rt the fungal genomic structure shown here. Instead we used a phylogenetic approach to show that the within-individual genetic variation that occurs in arbuscular mycorrhizal fungi probably evolved through accumulation of mutations in an essentially clonal genome, with some infrequent recombination events. We conclude that mycorrhizal fungi have evolved to be multi-genomic.	Univ Lausanne, Inst Ecol, CH-1015 Lausanne, Switzerland	University of Lausanne	Sanders, IR (corresponding author), Univ Lausanne, Inst Ecol, Biol Bldg, CH-1015 Lausanne, Switzerland.		Sanders, Ian R/T-9988-2017; Hijri, Mohamed/AAL-5737-2021; Hijri, Mohamed/ABC-5969-2021	Sanders, Ian R/0000-0002-9591-8214; Hijri, Mohamed/0000-0001-6112-8372				Antoniolli ZI, 2000, MYCOL RES, V104, P708, DOI 10.1017/S0953756299001860; Clapp JP, 2001, NEW PHYTOL, V149, P539, DOI 10.1046/j.1469-8137.2001.00060.x; Giovannetti M, 2001, NEW PHYTOL, V151, P717, DOI 10.1046/j.0028-646x.2001.00216.x; Giovannetti M, 1999, APPL ENVIRON MICROB, V65, P5571; Hijri M, 1999, FUNGAL GENET BIOL, V26, P141, DOI 10.1006/fgbi.1998.1112; HOELZEL AR, 1991, MOL GENETIC ECOLOGY, P1; Judson Olivia P., 1996, Trends in Ecology and Evolution, V11, P41, DOI 10.1016/0169-5347(96)81040-8; Lanfranco L, 1999, MOL ECOL, V8, P37, DOI 10.1046/j.1365-294X.1999.00535.x; LloydMacgilp SA, 1996, NEW PHYTOL, V133, P103, DOI 10.1111/j.1469-8137.1996.tb04346.x; MAYNARDSMITH J, 1986, NATURE, V324, P300; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; Mes THM, 1998, MOL ECOL, V7, P1719, DOI 10.1046/j.1365-294x.1998.00508.x; Moran NA, 2000, TRENDS ECOL EVOL, V15, P321, DOI 10.1016/S0169-5347(00)01902-9; Redecker D, 1999, FUNGAL GENET BIOL, V28, P238, DOI 10.1006/fgbi.1999.1173; Redecker D, 1997, APPL ENVIRON MICROB, V63, P1756, DOI 10.1128/AEM.63.5.1756-1761.1997; Rosendahl S, 1997, MOL ECOL, V6, P821, DOI 10.1046/j.1365-294X.1997.d01-213.x; SANDERS IR, 1995, NEW PHYTOL, V130, P419, DOI 10.1111/j.1469-8137.1995.tb01836.x; Sanders IR, 1996, NEW PHYTOL, V133, P123, DOI 10.1111/j.1469-8137.1996.tb04348.x; Sanders IR, 1999, NATURE, V399, P737, DOI 10.1038/21544; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; vanGemeren IA, 1997, GENE, V198, P43, DOI 10.1016/S0378-1119(97)00290-4; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211; White T.J., 1990, PCR PROTOCOLS GUIDE, P315	24	211	226	0	74	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					745	748		10.1038/414745a	http://dx.doi.org/10.1038/414745a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742398	Green Published			2022-12-28	WOS:000172676200046
J	Alcock, C; Allsman, RA; Alves, DR; Axelrod, TS; Becker, AC; Bennett, DP; Cook, KH; Drake, AJ; Freeman, KC; Geha, M; Griest, K; Keller, SC; Lehner, MJ; Marshall, SL; Minniti, D; Nelson, CA; Peterson, BA; Popowski, P; Pratt, MR; Quinn, PJ; Stubbs, CW; Sutherland, W; Tomaney, AB; Vandehel, T; Welch, D				Alcock, C; Allsman, RA; Alves, DR; Axelrod, TS; Becker, AC; Bennett, DP; Cook, KH; Drake, AJ; Freeman, KC; Geha, M; Griest, K; Keller, SC; Lehner, MJ; Marshall, SL; Minniti, D; Nelson, CA; Peterson, BA; Popowski, P; Pratt, MR; Quinn, PJ; Stubbs, CW; Sutherland, W; Tomaney, AB; Vandehel, T; Welch, D			Direct detection of a microlens in the Milky Way	NATURE			English	Article							TELESCOPE STAR COUNTS; MACHO PROJECT; M-DWARFS	The nature of dark matter remains mysterious, with luminous material accounting for at most similar to 25 per cent of the baryons in the Universe(1,2). We accordingly undertook a survey looking for the microlensing of stars in the Large Magellanic Cloud (LMC) to determine the fraction of Galactic dark matter contained in massive compact halo objects (MACHOs). The presence of the dark matter would be revealed by gravitational lensing of the light from an LMC star as the foreground dark matter moves across the line of sight. The duration of the lensing event is the key observable parameter, but gives non-unique solutions when attempting to estimate the mass, distance and transverse velocity of the lens. The survey results to date indicate that between 8 and 50 per cent of the baryonic mass of the Galactic halo is in the form of MACHOs (ref. 3), but removing the degeneracy by identifying a lensing object would tighten the constraints on the mass in MACHOs. Here we report a direct image of a microlens, revealing it to be a nearby low-mass star in the disk of the Milky Way. This is consistent with the expected frequency of nearby stars acting as lenses, and demonstrates a direct determination of a lens mass from a microlensing event. Complete solutions such as this for halo microlensing events will probe directly the nature of the MACHOs.	Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Calif Berkeley, Ctr Particle Astrophys, Berkeley, CA 94720 USA; Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Australian Natl Univ, Supercomp Facil, Canberra, ACT 0200, Australia; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Mt Stromlo & Siding Spring Observ, Res Sch Anat, Weston, ACT 2611, Australia; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; Univ Calif San Diego, Dept Phys, San Diego, CA 92039 USA; Pontificia Univ Catolica Chile, Dept Astron, Santiago 22, Chile; Univ Washington, Dept Phys & Astron, Seattle, WA 98195 USA; European So Observ, D-85748 Munich, Germany; Univ Oxford, Dept Phys, Oxford OX1 3RH, England; McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Berkeley; University of Pennsylvania; Australian National University; Space Telescope Science Institute; Australian National University; Alcatel-Lucent; Lucent Technologies; AT&T; University of Notre Dame; University of California System; University of California Santa Cruz; University of California System; University of California San Diego; Pontificia Universidad Catolica de Chile; University of Washington; University of Washington Seattle; European Southern Observatory; University of Oxford; McMaster University	Nelson, CA (corresponding author), Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.	cnelson@igpp.ucllnl.org	Lehner, Matthew/ABA-3818-2020; Stubbs, Christopher W/C-2829-2012; Minniti, Dante/AAD-7251-2021	Lehner, Matthew/0000-0003-4077-0985; Stubbs, Christopher W/0000-0003-0347-1724; Sutherland, William/0000-0002-6498-0437; Welch, Doug/0000-0002-2350-0898; Minniti, Dante/0000-0002-7064-099X				Alcock C, 2000, ASTROPHYS J, V542, P281, DOI 10.1086/309512; ALCOCK C, 1995, ASTROPHYS J, V454, pL125, DOI 10.1086/309783; Alcock C, 2001, ASTROPHYS J, V552, P582, DOI 10.1086/320554; Alcock C, 1997, ASTROPHYS J, V486, P697, DOI 10.1086/304535; BESSELL MS, 1991, ASTRON J, V101, P662, DOI 10.1086/115714; Cassisi S, 2000, MON NOT R ASTRON SOC, V315, P679, DOI 10.1046/j.1365-8711.2000.03457.x; Gould A, 1997, ASTROPHYS J, V482, P913, DOI 10.1086/304194; GOULD A, 1992, ASTROPHYS J, V392, P442, DOI 10.1086/171443; Hogan CJ, 1999, ASTROPHYS J, V527, P42, DOI 10.1086/308085; HOLTZMAN JA, 1995, PUBL ASTRON SOC PAC, V107, P1065, DOI 10.1086/133664; REID N, 1991, ASTRON J, V102, P1428, DOI 10.1086/115970; Tytler D, 2000, PHYS REP, V333, P409, DOI 10.1016/S0370-1573(00)00032-6; Zheng Z, 2001, ASTROPHYS J, V555, P393, DOI 10.1086/321485	13	118	118	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					617	619		10.1038/414617a	http://dx.doi.org/10.1038/414617a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740553				2022-12-28	WOS:000172535600041
J	Steiner, G; Salvini-Plawen, L				Steiner, G; Salvini-Plawen, L			Invertebrate evolution - Acaenoplax - polychaete or mollusc?	NATURE			English	Article									Univ Vienna, Inst Zool, A-1090 Vienna, Austria	University of Vienna	Steiner, G (corresponding author), Univ Vienna, Inst Zool, Althanstr 14, A-1090 Vienna, Austria.			Steiner, Gerhard/0000-0001-9845-1026				BANSE K, 1983, FAUNA FLORA MITTELME, P391; Cherns L, 1998, PALAEONTOLOGY, V41, P939; Fauchald K, 1997, ZOOL SCR, V26, P71, DOI 10.1111/j.1463-6409.1997.tb00411.x; HARTLEY P, 1994, EUR EAT DISORD REV, V2, P1; Rouse GW, 1997, ZOOL SCR, V26, P139, DOI 10.1111/j.1463-6409.1997.tb00412.x; RUNNEGAR B., 1985, MOLLUSCA, V10, DOI DOI 10.1016/B978-0-12-751408-6.50008-4; SALVINI-PLAWEN L V, 1990, Iberus, V9, P1; SALVINIPLAWEN LV, 1980, MALACOLOGIA, V19, P249; Sutton MD, 2001, NATURE, V410, P461, DOI 10.1038/35068549	9	20	22	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					601	602		10.1038/414601a	http://dx.doi.org/10.1038/414601a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740549				2022-12-28	WOS:000172535600037
J	Feduccia, A				Feduccia, A			Palaeoecology - Fossils and avian evolution	NATURE			English	Article							EARLY TERTIARY ORIGIN; ORDERS; BIRDS		Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Feduccia, A (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.							Bleiweiss R, 1998, GEOLOGY, V26, P323, DOI 10.1130/0091-7613(1998)026<0323:FGASET>2.3.CO;2; Dyke GJ, 1999, NATURE, V399, P317, DOI 10.1038/20583; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; Feduccia A., 1999, ORIGIN EVOLUTION BIR, V2; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; KAROCHKIN EN, 2000, CRETACEOUS STRATIGRA, P533; Marshall CR, 1999, GEOLOGY, V27, P95, DOI 10.1130/0091-7613(1999)027<0095:FGASET>2.3.CO;2; Norell MA, 2001, NATURE, V409, P181, DOI 10.1038/35051563; SHUVALOV VF, 2000, CREATACEOUS STRATIGR, P256	9	2	2	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					507	508		10.1038/35107144	http://dx.doi.org/10.1038/35107144			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734842				2022-12-28	WOS:000172405900035
J	Keely, PJ				Keely, PJ			Rho GTPases as early markers for tumour progression	LANCET			English	Editorial Material							CELL MOTILITY; FAMILY; INVASION; RAC1		Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Keely, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA.							Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; BEARER EL, 1993, AM J RESP CELL MOL, V8, P582, DOI 10.1165/ajrcmb/8.6.582; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOSCOW JA, 1994, ONCOGENE, V9, P189; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	18	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1744	1745		10.1016/S0140-6736(01)06840-4	http://dx.doi.org/10.1016/S0140-6736(01)06840-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734226				2022-12-28	WOS:000172385100004
J	Auerbach, DJ				Auerbach, DJ			Surface science - Hitting the surface - Softly	SCIENCE			English	Editorial Material							DIRECT INELASTIC-SCATTERING; DYNAMICS; PT(111)		IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	International Business Machines (IBM)	Auerbach, DJ (corresponding author), IBM Corp, Almaden Res Ctr, 650 Harry Rd, San Jose, CA 95120 USA.		Auerbach, Daniel J/J-7109-2014	Auerbach, Daniel J/0000-0001-9494-3066				ARUMAINAYAGAM CR, 1991, PROG SURF SCI, V38, P1, DOI 10.1016/0079-6816(91)90006-P; Barker JA, 1984, SURF SCI REP, V4, P1, DOI 10.1016/0167-5729(84)90005-0; Gergen B, 2001, SCIENCE, V294, P2521, DOI 10.1126/science.1066134; Greber T, 1997, SURF SCI REP, V28, P3; Huang YH, 2000, SCIENCE, V290, P111, DOI 10.1126/science.290.5489.111; HURST JE, 1979, PHYS REV LETT, V43, P1175, DOI 10.1103/PhysRevLett.43.1175; HURST JE, 1983, J CHEM PHYS, V78, P1559, DOI 10.1063/1.444847; Thomson JJ, 1905, PHILOS MAG, V10, P584, DOI 10.1080/14786440509463405; TULLY JC, 1980, ANNU REV PHYS CHEM, V31, P319, DOI 10.1146/annurev.pc.31.100180.001535; Tully JC, 2000, ANNU REV PHYS CHEM, V51, P153, DOI 10.1146/annurev.physchem.51.1.153	10	6	11	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2488	2489		10.1126/science.1067543	http://dx.doi.org/10.1126/science.1067543			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752560				2022-12-28	WOS:000172927700036
J	Nishioka, K; Reinberg, D				Nishioka, K; Reinberg, D			Transcription - Switching partners in a regulatory tango	SCIENCE			English	Editorial Material							BINDING		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Nishioka, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016				Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	11	9	9	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2497	2498		10.1126/science.1067622	http://dx.doi.org/10.1126/science.1067622			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752565				2022-12-28	WOS:000172927700042
J	Seo, HC; Kube, M; Edvardsen, RB; Jensen, MF; Beck, A; Spriet, E; Gorsky, G; Thompson, EM; Lehrach, H; Reinhardt, R; Chourrout, D				Seo, HC; Kube, M; Edvardsen, RB; Jensen, MF; Beck, A; Spriet, E; Gorsky, G; Thompson, EM; Lehrach, H; Reinhardt, R; Chourrout, D			Miniature genome in the marine chordate Oikopleura dioica	SCIENCE			English	Article									Sara Ctr Marine Mol Biol, N-5020 Bergen, Norway; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Observ Oceanol, LOV, UPMC, CNRS,INSU, F-06234 Villefranche, France	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite	Chourrout, D (corresponding author), Sara Ctr Marine Mol Biol, Thormohlensgt 55, N-5020 Bergen, Norway.			Reinhardt, Richard/0000-0001-9376-2132; Edvardsen, Rolf/0000-0001-8430-8042				Bassham S, 2000, DEV BIOL, V220, P322, DOI 10.1006/dbio.2000.9647; Fraser CM, 1997, ELECTROPHORESIS, V18, P1207, DOI 10.1002/elps.1150180803; Monaghan P, 2000, TRENDS GENET, V16, P331, DOI 10.1016/S0168-9525(00)02051-5; Nishino A, 2001, GENESIS, V29, P36, DOI 10.1002/1526-968X(200101)29:1<36::AID-GENE1003>3.0.CO;2-J; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437	5	135	140	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2506	2506		10.1126/science.294.5551.2506	http://dx.doi.org/10.1126/science.294.5551.2506			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752568				2022-12-28	WOS:000172927700045
J	Hetherington, AM				Hetherington, AM			Guard cell signaling	CELL			English	Review								The plant hormone abscisic acid (ABA) regulates the aperture of the stomata[ pore. The recent identification of new intermediates involved in ABA signaling suggests that this complex pathway is organized as a module-based network.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England	University of Oxford; Lancaster University	Hetherington, AM (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.			Hetherington, Alistair/0000-0001-6060-9203				Blatt MR, 2000, ANNU REV CELL DEV BI, V16, P221, DOI 10.1146/annurev.cellbio.16.1.221; Gray JE, 2000, NATURE, V408, P713, DOI 10.1038/35047071; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hugouvieux V, 2001, CELL, V106, P477, DOI 10.1016/S0092-8674(01)00460-3; Hwang JU, 2001, PLANT PHYSIOL, V125, P2120, DOI 10.1104/pp.125.4.2120; Lemichez E, 2001, GENE DEV, V15, P1808, DOI 10.1101/gad.900401; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Schroeder JI, 2001, ANNU REV PLANT PHYS, V52, P627, DOI 10.1146/annurev.arplant.52.1.627; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046	13	209	240	2	37	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 14	2001	107	6					711	714		10.1016/S0092-8674(01)00606-7	http://dx.doi.org/10.1016/S0092-8674(01)00606-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747807	Bronze			2022-12-28	WOS:000172771800004
J	Bhoo, SH; Davis, SJ; Walker, J; Karniol, B; Vierstra, RD				Bhoo, SH; Davis, SJ; Walker, J; Karniol, B; Vierstra, RD			Bacteriophytochromes are photochromic histidine kinases using a biliverdin chromophore	NATURE			English	Article							EUKARYOTIC PHYTOCHROMES; BIOSYNTHESIS; PROTEIN; GENE; SIMILARITY	Phytochromes comprise a principal family of red/far-red light sensors in plants(1). Although phytochromes were thought originally to be confined to photosynthetic organisms(2,3), we have recently detected phytochrome-like proteins in two heterotrophic eubacteria, Deinococcus radiodurans and Pseudomonas aeruginosa(4). Here we show that these form part of a widespread family of bacteriophytochromes (BphPs) with homology to two-component sensor histidine kinases. Whereas plant phytochromes use phytochromobilin as the chromophore, BphPs assemble with biliverdin, an immediate breakdown product of haem, to generate photochromic kinases that are modulated by red and far-red light. In some cases, a unique haem oxygenase responsible for the synthesis of biliverdin is part of the BphP operon. Co-expression of this oxygenase with a BphP apoprotein and a haem source is sufficient to assemble holo-BphP in vivo. Both their presence in many diverse bacteria and their simplified assembly with biliverdin suggest that BphPs are the progenitors of phytochrome-type photoreceptors.	Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vierstra, RD (corresponding author), Univ Wisconsin, Mol & Cellular Biol Program, 1575 Linden Dr, Madison, WI 53706 USA.							BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; Bhaya D, 2001, P NATL ACAD SCI USA, V98, P7540, DOI 10.1073/pnas.131201098; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; ELICH TD, 1989, J BIOL CHEM, V264, P12902; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Herdman M, 2000, J MOL EVOL, V51, P205, DOI 10.1007/s002390010082; Hughes O, 1999, PLANT PHYSIOL, V121, P1059; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Vierstra RD, 2000, SEMIN CELL DEV BIOL, V11, P511, DOI 10.1006/scdb.2000.0206; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	19	232	253	1	58	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					776	779		10.1038/414776a	http://dx.doi.org/10.1038/414776a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742406				2022-12-28	WOS:000172676200054
J	Krystal, JH; Cramer, JA; Krol, WF; Kirk, GF; Rosenheck, RA				Krystal, JH; Cramer, JA; Krol, WF; Kirk, GF; Rosenheck, RA		Vet Affairs Naltrexone Cooperative	Naltrexone in the treatment of alcohol dependence.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; DISULFIRAM TREATMENT; THERAPY; DRINKING	Background: Although naltrexone, an opiate-receptor antagonist, has been approved by the Food and Drug Administration for the treatment of alcohol dependence, its efficacy is uncertain. Methods: We conducted a multicenter, double-blind, placebo-controlled evaluation of naltrexone as an adjunct to standardized psychosocial treatment. We randomly assigned 627 veterans (almost all men) with chronic, severe alcohol dependence to 12 months of naltrexone (50 mg once daily), 3 months of naltrexone followed by 9 months of placebo, or 12 months of placebo. All patients were offered individual counseling and programs to improve their compliance with study medication and were encouraged to attend Alcoholics Anonymous meetings. Results: There were 209 patients in each group; all had been sober for at least five days before randomization. At 13 weeks, we found no significant difference in the number of days to relapse between patients in the two naltrexone groups (mean, 72.3 days) and the placebo group (mean, 62.4 days; 95 percent confidence interval for the difference between groups, -3.0 to 22.8). At 52 weeks, there were no significant differences among the three groups in the percentage of days on which drinking occurred and the number of drinks per drinking day. Conclusions: Our findings do not support the use of naltrexone for the treatment of men with chronic, severe alcohol dependence. (N Engl J Med 2001;345:1734-9.) Copyright (C) 2001 Massachusetts Medical Society.	Dept Vet Affairs Connecticut Healthcare Syst, Alcohol Res Ctr, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; Dept Vet Affairs Cooperat Studies Program Coordin, Perry Point, MD USA; Dept Vet Affairs Connecticut Healthcare Syst, NE Program Evaluat Ctr, West Haven, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Krystal, JH (corresponding author), Dept Vet Affairs Connecticut Healthcare Syst, Alcohol Res Ctr, 950 Campbell Ave, West Haven, CT 06516 USA.							[Anonymous], 1994, DIAGN STAT MAN MENT, V4; ANTON RF, 1995, ALCOHOL CLIN EXP RES, V19, P92, DOI 10.1111/j.1530-0277.1995.tb01475.x; Anton RF, 1999, AM J PSYCHIAT, V156, P1758; Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P587, DOI 10.1093/alcalc/35.6.587; COLLINS JF, 1991, PATIENT COMPLIANCE M, P335; Cramer JA, 1999, J NERV MENT DIS, V187, P53, DOI 10.1097/00005053-199901000-00009; Cramer JA, 1998, DRUG AGING, V12, P7, DOI 10.2165/00002512-199812010-00002; CROOP RS, 1996, ALCOHOL CLIN EXP RES, V20, pA216; DiClemente C C, 1990, J Subst Abuse, V2, P217, DOI 10.1016/S0899-3289(05)80057-4; FAWCETT J, 1987, ARCH GEN PSYCHIAT, V44, P248; FULLER R, 1983, J CHRON DIS, V36, P161, DOI 10.1016/0021-9681(83)90090-5; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; Gianoulakis C, 1996, ALCOHOL ALCOHOLISM, V31, P33; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kranzler HR, 2000, NEUROPSYCHOPHARMACOL, V22, P493, DOI 10.1016/S0893-133X(99)00135-9; MATTSON ME, 1993, ALCOHOL CLIN EXP RES, V17, P1130; Monti PM, 1999, ALCOHOL CLIN EXP RES, V23, P1386, DOI 10.1111/j.1530-0277.1999.tb04361.x; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; OMalley SS, 1996, AM J PSYCHIAT, V153, P281; OMALLEY SS, 1995, PSYCHIAT ANN, V25, P681, DOI 10.3928/0048-5713-19951101-11; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037/0021-843X.91.3.199; SOBELL LC, 1988, BRIT J ADDICT, V83, P393; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; Swift RM, 1999, ALCOHOL RES HEALTH, V23, P207; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613	30	421	435	0	37	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1734	1739		10.1056/NEJMoa011127	http://dx.doi.org/10.1056/NEJMoa011127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742047				2022-12-28	WOS:000172656100003
J	Treisman, GJ; Angelino, AF; Hutton, HE				Treisman, GJ; Angelino, AF; Hutton, HE			Psychiatric issues in the management of patients with HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOOD DISORDERS; RISK; PREVALENCE; THERAPY; CARE; MEN	Approximately 1 million persons are now infected with human immunodeficiency virus (HIV) in the United States. Evidence exists that psychiatric disorders are common in patients with HIV and that these patients may not receive optimal care because their psychiatric disorders are a barrier to medical care, communication with clinicians, and adherence to medical recommendations. We describe herein a complex case seen at The Johns Hopkins Hospital with several psychiatric conditions that are common in our HIV clinic population. We describe the collaborative treatment of the patient by a multidisciplinary team including both medical and mental health practitioners. We briefly describe a coherent diagnostic and treatment approach to patients in HIV clinics and the supporting rationale from the literature. We discuss the need for comprehensive evaluation, a multidisciplinary treatment team, and therapeutic optimism.	Johns Hopkins Univ Hosp, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Treisman, GJ (corresponding author), Johns Hopkins Univ Hosp, Dept Psychiat & Behav Sci, 600 N Wolfe St, Baltimore, MD 21287 USA.		Angelino, Andrew/ABA-6611-2020					AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P645; Angelino AF, 2001, CLIN INFECT DIS, V33, P847, DOI 10.1086/322679; ATKINSON JH, 1988, ARCH GEN PSYCHIAT, V45, P859; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; BURACK JH, 1993, JAMA-J AM MED ASSOC, V270, P2568, DOI 10.1001/jama.270.21.2568; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; DeSilva KE, 2001, AIDS, V15, P1281, DOI 10.1097/00002030-200107060-00010; Fishman M, 1996, INT REV PSYCHIATR, V8, P267, DOI 10.3109/09540269609046311; FISHMAN M, 1998, NEUROLOGY AIDS, P524; Goodkin K, 1996, INT REV PSYCHIATR, V8, P201, DOI 10.3109/09540269609046304; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Hocqueloux L, 2001, ARCH INTERN MED, V161, P2260, DOI 10.1001/archinte.161.18.2260; Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466; Lindemann E, 1944, AM J PSYCHIAT, V101, P141, DOI 10.1176/ajp.101.2.141; LYKETSOS CG, 1994, INT J PSYCHIAT MED, V24, P103, DOI 10.2190/URTC-AQVJ-N9KG-0RL4; LYKETSOS CG, 1995, CNS DRUGS, V4, P195, DOI 10.2165/00023210-199504030-00004; Lyketsos CG, 1997, PSYCHOSOMATICS, V38, P423, DOI 10.1016/S0033-3182(97)71419-1; MCDERMOTT BE, 1994, HOSP COMMUNITY PSYCH, V45, P580; McGuire D, 2000, J PSYCHOPHARMACOL, V14, P251, DOI 10.1177/026988110001400310; McHugh PR, 1998, PERSPECTIVES PSYCHIA; Ouellet D, 1998, ANTIMICROB AGENTS CH, V42, P3107, DOI 10.1128/AAC.42.12.3107; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; PATIENCE DA, 1995, BRIT J PSYCHIAT, V167, P324, DOI 10.1192/bjp.167.3.324; PERKINS DO, 1994, AM J PSYCHIAT, V151, P233; PERRY S, 1990, JAMA-J AM MED ASSOC, V263, P679, DOI 10.1001/jama.263.5.679; PICKENS R, 1968, J PHARMACOL EXP THER, V161, P122; Ratey J J, 1992, J Child Adolesc Psychopharmacol, V2, P267, DOI 10.1089/cap.1992.2.267; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; REICH JH, 1991, J NERV MENT DIS, V179, P74, DOI 10.1097/00005053-199102000-00003; ROBINS LN, 1974, AM J EPIDEMIOL, V99, P235, DOI 10.1093/oxfordjournals.aje.a121608; ROBINS LN, 1974, AM J PUBLIC HEALTH, V64, P38, DOI 10.2105/AJPH.64.12_Suppl.38; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; TREISMAN G, 1994, RES P ARNMD, V72, P239; Tseng AL, 1999, ANN PHARMACOTHER, V33, P461, DOI 10.1345/aph.18240; Wilens TE, 1996, AM J PSYCHIAT, V153, P1147	36	63	68	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2857	2864		10.1001/jama.286.22.2857	http://dx.doi.org/10.1001/jama.286.22.2857			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500YC	11735762				2022-12-28	WOS:000172655400035
J	Penninger, JM; Woodgett, J				Penninger, JM; Woodgett, J			Stem cells - PTEN - Coupling tumor suppression to stem cells?	SCIENCE			English	Editorial Material							CANCER; GENE; BREAST; MICE		Univ Toronto, Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Penninger, JM (corresponding author), Univ Toronto, Amgen Res Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013; Woodgett, Jim/F-1087-2010	Penninger, Josef M/0000-0002-8194-3777; Woodgett, Jim/0000-0003-3731-5797				BACKMAN SA, 2001, NATURE GENET    1119; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; KWON CH, 2001, NATURE GENET    1119; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tonks NK, 1999, SCIENCE, V286, P2096, DOI 10.1126/science.286.5447.2096; Vantomme N, 2001, SURG NEUROL, V56, P201, DOI 10.1016/S0090-3019(01)00552-3	23	13	18	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2116	2118		10.1126/science.1067931	http://dx.doi.org/10.1126/science.1067931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739945				2022-12-28	WOS:000172647700037
J	Ahlund, M; Andersson, M				Ahlund, M; Andersson, M			Brood parasitism - Female ducks can double their reproduction	NATURE			English	Article							PATERNITY		Univ Gothenburg, Dept Zool, S-40530 Gothenburg, Sweden	University of Gothenburg	Ahlund, M (corresponding author), Univ Gothenburg, Dept Zool, Box 463, S-40530 Gothenburg, Sweden.							Andersson M, 2000, P NATL ACAD SCI USA, V97, P13188, DOI 10.1073/pnas.220137897; Andersson M, 2001, ECOLOGY, V82, P1433, DOI 10.1890/0012-9658(2001)082[1433:PFANTR]2.0.CO;2; Brown CR, 1998, BEHAV ECOL, V9, P158, DOI 10.1093/beheco/9.2.158; Eadie J.M., 1989, THESIS U BRIT COLUMB; EADIE JM, 1988, CAN J ZOOL, V66, P1709, DOI 10.1139/z88-247; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; LYON BE, 1993, ANIM BEHAV, V46, P911, DOI 10.1006/anbe.1993.1273; McRae SB, 1998, BEHAV ECOL, V9, P93, DOI 10.1093/beheco/9.1.93; Sheldon BC, 1999, ANIM BEHAV, V57, P285, DOI 10.1006/anbe.1998.0968; SORENSON MD, 1991, ANIM BEHAV, V42, P771, DOI 10.1016/S0003-3472(05)80122-8	10	75	77	0	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					600	601		10.1038/414600b	http://dx.doi.org/10.1038/414600b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740548				2022-12-28	WOS:000172535600036
J	Cywes, C; Wessels, MR				Cywes, C; Wessels, MR			Group A Streptococcus tissue invasion by CD44-mediated cell signalling	NATURE			English	Article							HYALURONIC-ACID CAPSULE; CD44 INTERACTION; M PROTEIN; KERATINOCYTES; RECEPTOR; BINDING; RAC1; SKIN	Streptococcus pyogenes (also known as group A Streptococcus, GAS), the agent of streptococcal sore throat and invasive soft-tissue infections, attaches to human pharyngeal or skin epithelial cells through specific recognition of its hyaluronic acid capsular polysaccharide by the hyaluronic-acid-binding protein CD44 (refs 1, 2). Because ligation of CD44 by hyaluronic acid can induce epithelial cell movement on extracellular matrix(3-5), we investigated whether molecular mimicry by the GAS hyaluronic acid capsule might induce similar cellular responses. Here we show that CD44-dependent GAS binding to polarized monolayers of human keratinocytes induced marked cytoskeletal rearrangements manifested by membrane ruffling and disruption of intercellular junctions. Transduction of the signal induced by GAS binding to CD44 on the keratinocyte surface involved Rac1 and the cytoskeleton linker protein ezrin, as well as tyrosine phosphorylation of cellular proteins. Studies of bacterial translocation in two models of human skin indicated that cell signalling triggered by interaction of the GAS capsule with CD44 opened intercellular junctions and promoted tissue penetration by GAS through a paracellular route. These results support a model of host cytoskeleton manipulation and tissue invasion by an extracellular bacterial pathogen.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Wessels, MR (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.	mwessels@channing.harvard.edu		Cywes Bentley, Colette/0000-0002-6301-0930				Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; CLINE PR, 1983, CANCER RES, V43, P3203; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; Cywes C, 2000, J CLIN INVEST, V106, P995, DOI 10.1172/JCI10195; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MCCALLUM SJ, 2000, CELLULAR MICROBIOLOG, P171; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; Oliferenko S, 2000, J CELL BIOL, V149, P241; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PARENTEAU NL, 1992, CYTOTECHNOLOGY, V9, P163, DOI 10.1007/BF02521744; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1979, INT REV CYTOL      S, V10, P25; Sabolinski ML, 1996, BIOMATERIALS, V17, P311, DOI 10.1016/0142-9612(96)85569-4; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Tchao R., 1988, ALTERN METHODS TOXIC, V6, P271; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391	22	162	169	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					648	652		10.1038/414648a	http://dx.doi.org/10.1038/414648a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740562				2022-12-28	WOS:000172535600050
J	Huitema, HEA; Gelinck, GH; van der Putten, JBPH; Kuijk, KE; Hart, CM; Cantatore, E; Herwig, PT; van Breemen, AJJM; de Leeuw, DM				Huitema, HEA; Gelinck, GH; van der Putten, JBPH; Kuijk, KE; Hart, CM; Cantatore, E; Herwig, PT; van Breemen, AJJM; de Leeuw, DM			Plastic transistors in active-matrix displays - The handling of grey levels by these large displays paves the way for electronic paper.	NATURE			English	Article									Philips Res, NL-5656 AA Eindhoven, Netherlands; Netherlands Org Appl Sci Res, Mat Technol Div, Ind Technol Inst, NL-5600 HE Eindhoven, Netherlands	Philips; Philips Research; Netherlands Organization Applied Science Research	Huitema, HEA (corresponding author), Philips Res, Professor Holstlaan 4, NL-5656 AA Eindhoven, Netherlands.	edzer.huitema@philips.com	De Leeuw, Dago/AAC-4929-2020					Cornelissen H. J., 1999, Journal of the Society for Information Display, V7, P37, DOI 10.1889/1.1985268; Gelinck GH, 2000, APPL PHYS LETT, V77, P1487, DOI 10.1063/1.1290728; Kane MG, 2000, IEEE ELECTR DEVICE L, V21, P534, DOI 10.1109/55.877202; Levi BG, 2001, PHYS TODAY, V54, P20, DOI 10.1063/1.1420502; Rogers JA, 2001, P NATL ACAD SCI USA, V98, P4835, DOI 10.1073/pnas.091588098; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; TOKITO S, 1990, POLYMER, V31, P1137, DOI 10.1016/0032-3861(90)90263-X; VAZ NA, 1987, MOL CRYST LIQ CRYST, V146, P1, DOI 10.1080/00268948708071798; Voss D, 2000, NATURE, V407, P442, DOI 10.1038/35035212	9	492	529	0	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					599	599		10.1038/414599a	http://dx.doi.org/10.1038/414599a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740546	Bronze			2022-12-28	WOS:000172535600034
J	McNeil, BJ				McNeil, BJ			Shattuck lecture - Hidden barriers to improvement in the quality of care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Massachusetts-Medical-Society	MAY 12, 2001	BOSTON, MA	Massachusetts Med Soc			ACUTE MYOCARDIAL-INFARCTION; MEDICARE BENEFICIARIES; CORONARY-ANGIOGRAPHY; HEALTH-CARE; HOSPITAL VOLUME; RESOURCE UTILIZATION; RACIAL-DIFFERENCES; UNDERUSE; OUTCOMES; MORTALITY		Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	McNeil, BJ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	mcneil@hcp.med.harvard.edu						Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Alter DA, 2001, JAMA-J AM MED ASSOC, V285, P2101, DOI 10.1001/jama.285.16.2101; *AM COLL CARD, 2001, CLIN STAT GUID; *AM HEART ASS, 2001, 2001 HEART STROK STA; Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Betriu A, 1997, NEW ENGL J MED, V337, P287; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; *BLUE CROSS BLUE S, 1999, TECHN EV COMM REP, V1; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; CENICEROS R, 2001, MORE FOLLOW BLUES PL, P1; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; Cutler DM, 1998, NBER FR HLTH POL RES, V1, P77; CUTLER DM, 1996, DETERMINANTS TECHNOL; Cutler DM, 1999, FRONTIERS HLTH POLIC, P99; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; EVERY NR, 1995, J AM COLL CARDIOL, V26, P401, DOI 10.1016/0735-1097(95)80013-7; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Frances CD, 2000, HEALTH SERV RES, V35, P1093; *FROST SULL, 2001, US NUCL MED MARK A02; Garber AM, 2001, HEALTH AFFAIR, V20, P62, DOI 10.1377/hlthaff.20.5.62; GODLEE F, 2000, FREED INF C NEW YORK; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Guadagnoli E, 2000, NEW ENGL J MED, V343, P1460, DOI 10.1056/NEJM200011163432006; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; Hannan EL, 1999, NEW ENGL J MED, V340, P1677, DOI 10.1056/NEJM199905273402112; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Harris DJ, 2000, NEW ENGL J MED, V343, P475, DOI 10.1056/NEJM200008173430706; Hawker GA, 2001, MED CARE, V39, P206, DOI 10.1097/00005650-200103000-00002; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hewitt ME, 2001, INTERPRETING VOLUME; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; *HLTH CAR FIN ADM, 2001, NAT HLTH EXP 2000 20; *HLTH CAR FIN ADM, 2000, 0065 CAG FDG PET HLT, P10; *HLTH CAR FIN ADM, 2001, MED COV ISS MAN TRAN, V136, P50; Holmes DR, 1997, CATHETER CARDIO DIAG, V40, P133, DOI 10.1002/(SICI)1097-0304(199702)40:2<133::AID-CCD1>3.0.CO;2-C; Institute of Medicine, 2001, CROSSING QUALITY CHA; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kralewski JE, 2000, HEALTH SERV RES, V35, P591; Kravitz RL, 1997, JOINT COMM J QUAL IM, V23, P268, DOI 10.1016/S1070-3241(16)30317-0; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Landon B. E., 1999, JGIM, V14, P46; Landon BE, 1998, JAMA-J AM MED ASSOC, V279, P1377, DOI 10.1001/jama.279.17.1377; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; Laouri M, 1997, INT J QUAL HEALTH C, V9, P15, DOI 10.1093/intqhc/9.1.15; Lee PY, 2001, JAMA-J AM MED ASSOC, V286, P708, DOI 10.1001/jama.286.6.708; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; *MED PAYM ADV COMM, 2001, REP C MED PAYM POL, P33; *MED PAYM ADV COMM, 2000, REP C SEL MED ISS, P126; *MED TECHN REV PAN, 2000, REV ASS METH MED TRU, P31; Meinert CL, 2001, STAT MED, V20, P1153, DOI 10.1002/sim.813; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; Newhouse JP, 1993, FREE ALL LESSONS RAN; NEWHOUSE JP, IN PRESS GOVERNANCE; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; PELTZMAN S, 1973, J POLIT ECON, V30, P207; PESAVENTO P, 2001, TURN CENTURY CENSUS; PHELPS CE, 1993, COMPETITIVE APPROACH, P139; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Rochon PA, 1999, CAN MED ASSOC J, V161, P1403; SALKEVER DS, 2000, HDB HLTH EC B, V1, P1490; SCHMALENSEE R, 1990, HDB EC, V10; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SCHUTTINGA J, 2000, BIOMEDICAL R D PRICE; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; Simini B, 1998, LANCET, V351, P682, DOI 10.1016/S0140-6736(05)78475-0; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; SUNSHINE J, 2000, 128 ANN M AM ASS PUB; Tempany CMC, 2001, JAMA-J AM MED ASSOC, V285, P562, DOI 10.1001/jama.285.5.562; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1996, DARTMOUTH ATLAS HLTH, P230; WESSEL D, 2001, WALL ST J       0621, pA1; Whittle J, 1998, MED CARE, V36, P977, DOI 10.1097/00005650-199807000-00005; Yancy CW, 2001, NEW ENGL J MED, V344, P1358, DOI 10.1056/NEJM200105033441803	95	116	116	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1612	1620		10.1056/NEJMsa011810	http://dx.doi.org/10.1056/NEJMsa011810			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	496EU	11757509				2022-12-28	WOS:000172383900006
J	Connerney, I; Shapiro, PA; McLaughlin, JS; Bagiella, E; Sloan, RP				Connerney, I; Shapiro, PA; McLaughlin, JS; Bagiella, E; Sloan, RP			Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; LONG-TERM; GRAFT-SURGERY; MORTALITY; SURVIVAL; RISK; MEN; ASSOCIATION; PROGNOSIS	Background The association of depression with cardiac events has been investigated mainly in community cohorts, in patients undergoing catheterisation, or in patients who have had myocardial infarction. We have assessed the effect of depression on outcomes after coronary artery bypass graft (CABG) surgery. Methods In a prospective study, we followed up for 1 year 207 men and 102 women, who had undergone coronary artery bypass graft surgery. We assessed depression with a structured psychiatric interview (diagnostic interview schedule) and a questionnaire (Beck depression inventory) before discharge. Cardiac events included angina or heart failure that needed admission to hospital, myocardial infarction, cardiac arrest, percutaneous transluminal coronary angioplasty, repeat CABG, and cardiac mortality. Non-cardiac events consisted of all other reasons for mortality or readmission. Findings 63 patients (20%) met modified diagnostic statistical manual IV criteria for major depressive disorder. At 12 months, 17 (27%) of these patients had a cardiac event compared with 25 of 246 (10%) who were not depressed (p<0.0008). Five variables had significant univariate associations with cardiac events: sex, living alone, low ejection fraction (<0.35), length of hospital stay, and depression. In a Cox proportional-hazard model with these five and two other variables of cardiac severity, major depressive disorder (risk ratio 2.3 [95% Cl 1.17-4.56]), low ejection fraction (2.3 [1.07-5.03]), and female sex (2.4 [1.24-4.44]) were associated with adverse outcomes. Depression did not predict deaths or admissions for noncardiac events. Interpretation Depression is an important independent risk factor for cardiac events after CABG surgery.	Univ Maryland, Med Ctr, Baltimore, MD 21201 USA; Columbia Univ, MAilman Sch Publ Hlth, New York, NY USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Columbia University; Columbia University; University System of Maryland; University of Maryland Baltimore	Connerney, I (corresponding author), Univ Maryland, Med Ctr, 22 S Greene St,Box 316, Baltimore, MD 21201 USA.	iconnerney@umm.edu			NIMH NIH HHS [K02 MH01491] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001491] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; AROMAA A, 1994, ACTA PSYCHIAT SCAND, V89, P77, DOI 10.1111/j.1600-0447.1994.tb05807.x; Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; CARNEY RM, 1995, AM J CARDIOL, V76, P562, DOI 10.1016/S0002-9149(99)80155-6; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; Denollet J, 1996, LANCET, V347, P417, DOI 10.1016/S0140-6736(96)90007-0; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; Frasure-Smith N, 2000, CIRCULATION, V101, P1919, DOI 10.1161/01.CIR.101.16.1919; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; Gray RJ, 1996, ARCH INTERN MED, V156, P769, DOI 10.1001/archinte.156.7.769; HAYNES SG, 1980, AM J EPIDEMIOL, V111, P37, DOI 10.1093/oxfordjournals.aje.a112873; Horrobin DF, 1999, PROSTAG LEUKOTR ESS, V60, P217, DOI 10.1054/plef.1999.0037; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LANGELUDDECKE P, 1989, J PSYCHOSOM RES, V33, P37, DOI 10.1016/0022-3999(89)90104-9; McKhann GM, 1997, LANCET, V349, P1282, DOI 10.1016/S0140-6736(96)09466-4; Musselman DL, 1996, AM J PSYCHIAT, V153, P1313; Pirraglia PA, 1999, INT J GERIATR PSYCH, V14, P668, DOI 10.1002/(SICI)1099-1166(199908)14:8<668::AID-GPS988>3.0.CO;2-9; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Scheier MF, 1999, ARCH INTERN MED, V159, P829, DOI 10.1001/archinte.159.8.829; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SCHROLL M, 1982, DAN MED BULL, V29, P213; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818	30	347	367	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2001	358	9295					1766	1771		10.1016/S0140-6736(01)06803-9	http://dx.doi.org/10.1016/S0140-6736(01)06803-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734233				2022-12-28	WOS:000172385100011
J	Berger, A				Berger, A			How does it work? Magnetic resonance imaging	BRITISH MEDICAL JOURNAL			English	Article																			0	87	89	3	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					35	35		10.1136/bmj.324.7328.35	http://dx.doi.org/10.1136/bmj.324.7328.35			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777806	Green Published			2022-12-28	WOS:000173205700024
J	Schwetz, BA				Schwetz, BA			Breast tissue ablation device	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					33	33		10.1001/jama.287.1.33-b	http://dx.doi.org/10.1001/jama.287.1.33-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754690				2022-12-28	WOS:000172978500005
J	Dolor, RJ; Witsell, DL; Hellkamp, AS; Williams, JW; Califf, RM; Simel, DL				Dolor, RJ; Witsell, DL; Hellkamp, AS; Williams, JW; Califf, RM; Simel, DL		CAFFS Investigators	Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis - The CAFFS trial: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MAXILLARY SINUSITIS; ORAL ANTIBIOTIC-THERAPY; CULTURES; SPRAY; IRRIGATION; CHILDREN; VALIDITY; ADJUNCT	Context It is not known whether intranasal corticosteroids are beneficial to treat acute rhinosinusitis in patients with a history of chronic or recurrent sinus symptoms. Objective To assess whether the addition of an intranasal corticosteroid to antibiotic therapy affects the speed and rate of recovery of such patients with acute rhinosinusitis. Design, Setting, and Patients A double-blind, randomized, placebo-controlled multicenter trial of 95 patients (median age, 39 years) with a history of recurrent sinusitis or chronic rhinitis and evidence of acute infection by sinus radiograph or nasal endoscopy, which was conducted from October 1998 through April 2000 at 22 sites (12 primary care and 10 otolaryngology). Intervention Two puffs (total dose, 200 mug) of fluticasone propionate (n=47) or placebo nasal spray (n=48) in each nostril once daily for 21 days; all received 2 puffs of xylometazoline hydrochloride in each nostril twice daily for 3 days and 250 mg of cefuroxime axetil twice daily for 10 days. Main Outcome Measure Time to clinical success (patient reported cured or much improved) during telephone follow-up at 10, 21, and 56 days. Results A total of 88 patients (93%) completed follow-up. Patients recorded their symptoms, work assessment, and compliance during the 3-week treatment phase. Patients receiving fluticasone achieved a significantly higher rate of clinical success than patients receiving placebo (93.5% vs 73.9%; P=.009). Patients treated with fluticasone improved significantly more rapidly (median of 6.0 days to clinical success) vs patients in the placebo group (median of 9.5 days; P=.01). Conclusions The addition of fluticasone to xylometazoline and antimicrobial therapy with cefuroxime improves clinical success rates and accelerates recovery of patients with a history of chronic rhinitis or recurrent sinusitis who present for treatment of acute rhinosinusitis.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Dept Med, Durham, NC USA; Durham Vet Affairs Med Ctr, Dept Surg, Div Internal Med, Durham, NC USA; Duke Univ, Med Ctr, Div Otolaryngol, Durham, NC USA; Univ Texas, Hlth Sci Ctr, Audie L Murphy Div, S Texas Vet Affairs Hlth Care Syst, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, Div Internal Med, San Antonio, TX USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	Dolor, RJ (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.		Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558; Dolor, Rowena/0000-0001-7317-9468				AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; AXELSSON A, 1983, ANN OTO RHINOL LARYN, V92, P75, DOI 10.1177/000348948309200118; Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; Chow JM, 1993, OTOLARYNGOL HEAD NEC, V4, P86; CUENANT G, 1986, ORL J OTO-RHINO-LARY, V48, P226, DOI 10.1159/000275873; Gold SM, 1997, LARYNGOSCOPE, V107, P1586, DOI 10.1097/00005537-199712000-00002; Hadley JA, 1997, OTOLARYNG HEAD NECK, V117, pS8, DOI 10.1016/S0194-5998(97)70002-0; Haye R., 1993, Rhinology (Utrecht), V31, P169; HAYWARD MWJ, 1990, CLIN RADIOL, V41, P163, DOI 10.1016/S0009-9260(05)80959-6; Holm AF, 1998, CLIN OTOLARYNGOL, V23, P69; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; KROUSE HA, 1983, ANN ALLERGY, V50, P385; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Nadel DM, 1998, AM J RHINOL, V12, P233, DOI 10.2500/105065898781390000; OROBELLO PW, 1991, ARCH OTOLARYNGOL, V117, P980; Pakes G E, 1994, Arch Fam Med, V3, P165, DOI 10.1001/archfami.3.2.165; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; PICCIRILLO JF, 1998, 1998 ANN M AM AC OT; POOLE MD, 1992, OTOLARYNGOL HEAD NEC, V107, P272; Qvarnberg Yrjo, 1992, Rhinology (Utrecht), V30, P103; SACKETT DL, 2000, EVIDENCE BASED MED P, P111; *SIN ALL HLTH PART, 2000, OTOLARYNGOL HEAD NEC, V123, pS1; Spector S L, 1998, J Allergy Clin Immunol, V102, pS107; SYKES DA, 1986, LANCET, V2, P359; *US DEP HHS, 1999, AHCPR PUBL; Vaidya AM, 1997, AM J RHINOL, V11, P139, DOI 10.2500/105065897782537133; Vogan JC, 2000, OTOLARYNG HEAD NECK, V122, P370, DOI 10.1016/S0194-5998(00)70051-9; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447	31	110	119	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3097	3105		10.1001/jama.286.24.3097	http://dx.doi.org/10.1001/jama.286.24.3097			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754675	Bronze			2022-12-28	WOS:000172927100027
J	Somerset, M; Weiss, M; Fahey, T				Somerset, M; Weiss, M; Fahey, T			Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS	Objectives To examine the interaction between general practitioners and pharmaceutical company representatives. Design Qualitative study of 13 consecutive meetings between general practitioner and pharmaceutical representatives. A dramaturgical model was used to inform analysis of the transcribed verbal interactions. Setting Practice in south west England. Participants 13 pharmaceutical company representatives and one general practitioner. Results The encounters were acted out in six scenes. Scene 1 was initiated by the pharmaceutical representative, who acknowledged the relative status of the two players. Scene 2 provided the opportunity for the representative to check the general practitioner's knowledge about the product. Scene 3 was used to propose clinical and cost benefits associated with the product. During scene 4, the general practitioner took centre stage and challenged aspects of this information. Scene 5 involved a recovery strategy as the representative fought to regain equilibrium. In the final scene, the representative tried to ensure future contacts. Conclusion Encounters between general practitioners and pharmaceutical representatives follow a consistent format that is implicitly understood by each player. It is naive to suppose that pharmaceutical representatives are passive resources for drug information. General practitioners might benefit from someone who can provide unbiased information about prescribing in a manner that is supportive and sympathetic to the demands of practice.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England	University of Bristol	Somerset, M (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783				AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Cialdini RB, 1988, INFLUENCE SCI PRACTI; COOK J, 2001, PHARM MARKETING, V12, P14; Goffman E, 1964, STIGMA NOTES MANAGEM; Goffman E., 1961, ASYLUMS; GOFFMAN F, 1959, PRESENTATION SELF EV; McGettigan P, 2001, BRIT J CLIN PHARMACO, V51, P184; Roughead EE, 1998, AUST NZ J MED, V28, P306, DOI 10.1111/j.1445-5994.1998.tb01953.x; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	9	13	13	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1481	1484		10.1136/bmj.323.7327.1481	http://dx.doi.org/10.1136/bmj.323.7327.1481			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751364	Green Published			2022-12-28	WOS:000172979900024
J	Leveille, SG; Ling, S; Hochberg, MC; Resnick, HE; Bandeen-Roche, KJ; Won, A; Guralnik, JM				Leveille, SG; Ling, S; Hochberg, MC; Resnick, HE; Bandeen-Roche, KJ; Won, A; Guralnik, JM			Widespread musculoskeletal pain and the progression of disability in older disabled women	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL-POPULATION; OSTEO-ARTHRITIS; UNITED-STATES; OSTEOARTHRITIS; KNEE; PREVALENCE; HEALTH; HIP; FIBROMYALGIA; ASSOCIATION	Background: Widespread musculoskeletal pain is a poorly understood but common problem in older adults. Little is known about the progression of disability related to this condition. Objective: To determine whether widespread musculoskeletal pain increases the risk for worsening disability in older women with disabilities. Design: Prospective cohort study. Setting: The Women's Health and Aging Study. Participants: 1002 community-dwelling women 65 years of age or older with disability. Measurements: Widespread musculoskeletal pain was defined as pain in the upper and lower extremities and axial pain with moderate or severe pain in at least one of the three regions. Worsening disability was defined as progression from no or mild difficulty to severe difficulty or inability to perform activities of daily living (ADLs), walk one-quarter mile, or lift 10 lbs. Results: At baseline, 24% of participants had widespread pain and 25% had no pain or only mild pain in a single site. Women with widespread pain were 2.5 to 3.5 times more likely to have severe difficulty with ADLs, walking, or lifting at baseline compared with women who had no or mild pain. In women without severe difficulty initially, widespread pain nearly doubled the risk for progression to severe difficulty in each of the tasks, after adjustment for age, body mass index, comorbid illness, and other confounders. Conclusion: Widespread musculoskeletal pain is frequent among community-dwelling older women with disability and appears to predict the progression of disability. Efforts to better understand the cause of this pain and its treatment might reduce the overall burden of disability.	Hebrew Rehabil Ctr Aged, Res & Training Inst, Boston, MA 02131 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; Univ Maryland, Baltimore, MD 21201 USA; Maryland Vet Affairs Hlth Care Syst, Baltimore, MD USA; NIA, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Leveille, SG (corresponding author), Hebrew Rehabil Ctr Aged, Res & Training Inst, 1200 Ctr St, Boston, MA 02131 USA.	leveille@mall.hrca.harvard.edu	Leveille, Suzanne G/ACS-6588-2022	Leveille, Suzanne G/0000-0003-0427-1580	NIA NIH HHS [N01-AG12112] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG012112] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bennett Robert, 1998, Current Opinion in Rheumatology, V10, P95, DOI 10.1097/00002281-199803000-00002; Brattberg G, 1996, PAIN, V67, P29, DOI 10.1016/0304-3959(96)03047-3; Cooper C, 1996, J RHEUMATOL, V23, P1938; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; CROFT P, 1993, J RHEUMATOL, V20, P710; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; FELSON DT, 1995, J RHEUMATOL, V22, P7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIED LP, 2000, WOMENS HLTH AGING ST; GURALNIK JM, 2001, WOMENS HLTH AGING ST; Hirsch R, 1996, ANN RHEUM DIS, V55, P25, DOI 10.1136/ard.55.1.25; HOCHBERG MC, 1989, SEMIN ARTHRITIS RHEU, V18, P4, DOI 10.1016/0049-0172(89)90008-5; HOCHBERG MC, 1995, J RHEUMATOL, V22, P2291; Kasper JD, 1999, ANN EPIDEMIOL, V9, P498, DOI 10.1016/S1047-2797(99)00026-5; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; LAWLESS JF, 1982, STAT MODELS METHODS, P376; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Leveille SG, 1999, J GERONTOL A-BIOL, V54, pM487, DOI 10.1093/gerona/54.10.M487; Lichtenstein MJ, 1998, J GERONTOL A-BIOL, V53, pM361; MAKELA M, 1991, BRIT MED J, V303, P216, DOI 10.1136/bmj.303.6796.216; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; *NAT CTR HLTH STAT, 1999, HLTH AG CHARTB; NORRIS JT, 1987, J AM GERIATR SOC, V35, P989, DOI 10.1111/j.1532-5415.1987.tb04001.x; Odding E, 1998, ANN RHEUM DIS, V57, P203, DOI 10.1136/ard.57.4.203; Oliveria SA, 1999, EPIDEMIOLOGY, V10, P161, DOI 10.1097/00001648-199903000-00013; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Rantanen T, 1999, ARCH PHYS MED REHAB, V80, P130, DOI 10.1016/S0003-9993(99)90109-0; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Scudds RJ, 2000, J GERONTOL A-BIOL, V55, pM393, DOI 10.1093/gerona/55.7.M393; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x	34	142	144	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1038	1046		10.7326/0003-4819-135-12-200112180-00007	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747382				2022-12-28	WOS:000172759700003
J	Knaus, WA; Scheid, WM				Knaus, WA; Scheid, WM			Antibiotics for severe chronic obstructive pulmonary disease	LANCET			English	Editorial Material									Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia	Knaus, WA (corresponding author), Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA.		Knaus, William/AAX-2138-2020					NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Zimmerman JE, 1998, CRIT CARE MED, V26, P1317, DOI 10.1097/00003246-199808000-00012	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2013	2013		10.1016/S0140-6736(01)07136-7	http://dx.doi.org/10.1016/S0140-6736(01)07136-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755603				2022-12-28	WOS:000172722800005
J	Tokita, K; Terasaki, P; Maruya, E; Saji, H				Tokita, K; Terasaki, P; Maruya, E; Saji, H			Tumour regression following stem cell infusion from daughter to microchimeric mother	LANCET			English	Article								Fetal cells are known to persist in mothers for many years. We report a patient with poorly differentiated epithelial thymic carcinoma who had a large anterior mediastinal tumour, pericardial mass, left upper and right middle lobe tumour masses, and right liver mass. She received a single infusion of 10(10) stem cells from her 32-year-old daughter. Before the transfusion, she had had persistent chimeric cells from her daughter. The tumour regressed after stem cell infusion and has remained in regression for over I year. The daughter's cells were present at 330 days post infusion.	Ctr Canc, Irvine, CA 92618 USA; Terasaki Fdn Lab, Los Angeles, CA USA; NPO HLA Lab, Kyoto, Japan	Paul I Terasaki Foundation Laboratory	Tokita, K (corresponding author), Ctr Canc, Irvine, CA 92618 USA.	medicimed@hotmail.com						Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Boasberg PD, 1996, BLOOD, V87, P3522, DOI 10.1182/blood.V87.8.3522.bloodjournal8783522; Champlin Richard, 1999, Current Opinion in Oncology, V11, P87; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; TAKASUGI M, 1973, CANCER RES, V33, P2898	5	27	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2047	2048		10.1016/S0140-6736(01)07140-9	http://dx.doi.org/10.1016/S0140-6736(01)07140-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755614				2022-12-28	WOS:000172722800015
J	Marklund, GT; Ivchenko, N; Karlsson, T; Fazakerley, A; Dunlop, M; Lindqvist, PA; Buchert, S; Owen, C; Taylor, M; Vaivalds, A; Carter, P; Andre, M; Balogh, A				Marklund, GT; Ivchenko, N; Karlsson, T; Fazakerley, A; Dunlop, M; Lindqvist, PA; Buchert, S; Owen, C; Taylor, M; Vaivalds, A; Carter, P; Andre, M; Balogh, A			Temporal evolution of the electric field accelerating electrons away from the auroral ionosphere	NATURE			English	Article							ELECTROSTATIC POTENTIALS; CURRENT REGION; BLACK AURORA; PLASMA SHEET; ALTITUDE; POLAR	The bright night-time aurorae that are visible to the unaided eye are caused by electrons accelerated towards Earth by an upward-pointing electric field(1-3). On adjacent geomagnetic field lines the reverse process occurs: a downward-pointing electric field accelerates electrons away from Earth(4-11). Such magnetic-field-aligned electric fields in the collisionless plasma above the auroral ionosphere have been predicted(12), but how they could be maintained is still a matter for debate(13). The spatial and temporal behaviour of the electric fields-a knowledge of which is crucial to an understanding of their nature-cannot be resolved uniquely by single satellite measurements. Here we report on the first observations by a formation of identically instrumented satellites crossing a beam of upward-accelerated electrons. The structure of the electric potential accelerating the beam grew in magnitude and width for about 200 s, accompanied by a widening of the downward-current sheet, with the total current remaining constant. The 200-s timescale suggests that the evacuation of the electrons from the ionosphere contributes to the formation of the downward-pointing magnetic-field-aligned electric fields. This evolution implies a growing load in the downward leg of the current circuit, which may affect the visible discrete aurorae.	Royal Inst Technol, KTH, Alfven Lab, Div Plasma Phys, SE-10044 Stockholm, Sweden; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Space & Atmospher Phys Grp, London SW7 2BW, England; Swedish Inst Space Phys, Angstromlab, SE-75121 Uppsala, Sweden	Royal Institute of Technology; University of London; University College London; Imperial College London	Marklund, GT (corresponding author), Royal Inst Technol, KTH, Alfven Lab, Div Plasma Phys, SE-10044 Stockholm, Sweden.	marklund@plasma.kth.se	Lindqvist, Per-Arne/G-1221-2016; Ivchenko, Nickolay/W-4656-2017; dunlop, malcolm w/F-1347-2010; Owen, Christopher/C-2999-2008	Lindqvist, Per-Arne/0000-0001-5617-9765; Ivchenko, Nickolay/0000-0003-2422-5426; dunlop, malcolm w/0000-0002-8195-5137; Owen, Christopher/0000-0002-5982-4667; Buchert, Stephan/0000-0003-2158-6074				ALFVEN H, 1958, TELLUS, V10, P104, DOI 10.1111/j.2153-3490.1958.tb01991.x; [Anonymous], 1998, PHYS SPACE PLASMAS; BLOCK LP, 1990, J GEOPHYS RES-SPACE, V95, P5877, DOI 10.1029/JA095iA05p05877; BOROVSKY JE, 1993, J GEOPHYS RES-SPACE, V98, P6101, DOI 10.1029/92JA02242; BOSTROM R, 1998, PHYS PLASMAS, V15, P37; CARLQVIST P, 1970, J GEOPHYS RES, V75, P7140, DOI 10.1029/JA075i034p07140; Carlson CW, 1998, GEOPHYS RES LETT, V25, P2017, DOI 10.1029/98GL00851; CHIU YT, 1981, J GEOPHYS RES-SPACE, V86, P29, DOI 10.1029/JA086iA12p10029; Ergun RE, 1998, GEOPHYS RES LETT, V25, P2025, DOI 10.1029/98GL00635; Escoubet CP, 1997, SPACE SCI REV, V79, P1; GORNEY DJ, 1985, J GEOPHYS RES-SPACE, V90, P4205, DOI 10.1029/JA090iA05p04205; Keiling A, 2001, J GEOPHYS RES-SPACE, V106, P5779, DOI 10.1029/2000JA900130; KLUMPAR DM, 1982, GEOPHYS RES LETT, V9, P873, DOI 10.1029/GL009i008p00873; LYSAK RL, 1990, SPACE SCI REV, V52, P33, DOI 10.1007/BF00704239; MARKLUND G, 1994, GEOPHYS RES LETT, V21, P1859, DOI 10.1029/94GL00194; Marklund G, 1997, J GEOPHYS RES-SPACE, V102, P17509, DOI 10.1029/97JA00334; MARKLUND G, 1995, ANN GEOPHYS, V13, P704, DOI 10.1007/s00585-995-0704-9; McFadden JP, 1999, J GEOPHYS RES-SPACE, V104, P14453, DOI 10.1029/1998JA900167; REIFF PH, 1988, J GEOPHYS RES, V93, P7441, DOI 10.1029/JA093iA07p07441; Ronnmark K, 1999, GEOPHYS RES LETT, V26, P983, DOI 10.1029/1999GL900133; Temerin M, 1998, GEOPHYS RES LETT, V25, P2365, DOI 10.1029/98GL01865; Vasyliunas V.M., 1969, PARTICLES FIELDS MAG, P60; Wygant JR, 2000, J GEOPHYS RES-SPACE, V105, P18675, DOI 10.1029/1999JA900500; 2001, ANN GEOPHYS, V19	24	122	122	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					724	727		10.1038/414724a	http://dx.doi.org/10.1038/414724a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742392				2022-12-28	WOS:000172676200040
J	Buchanan, A; Leese, M				Buchanan, A; Leese, M			Detention of people with dangerous severe personality disorders: a systematic review	LANCET			English	Article							VIOLENT RECIDIVISM; FOLLOW-UP; PSYCHOPATHY; OFFENDERS; ACCURACY; RISK; PREDICTIONS; BEHAVIOR; TREAT; SCALE	Background UK government proposals to reduce the risks posed by people with "dangerous" severe personality disorders (DSPD) include a new legal framework for indeterminate detention. We aimed to establish the degree to which those operating the framework will be able to predict which people will act violently in the future. Methods We reviewed published reports in which the accuracy of a clinical judgment or a statistically derived rating of dangerousness was validated by its use to predict the violent behaviour of adults in the community. We calculated the sensitivity and specificity of the procedures used by every study. We then applied these sensitivities and specificities to the purported base rates of violence in people with DSPD. Findings 23 studies fulfilled the criteria, and for 21 of these the sensitivity and specificity of the procedures used by the investigators could be calculated. Using the average positive predictive power of these procedures, six people would have to be detained to prevent one violent act. Making predictions over shorter periods did not improve their accuracy. Interpretation In practice, the number of people that need to be detained is likely to be higher than we reported. Differences between populations in respect of which predictions are being made and the population on which an instrument was validated will reduce the accuracy of that instrument, Not all of the necessary information will always be available.	Inst Psychiat, Dept Forens Psychiat, London SE5 8AF, England; Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Buchanan, A (corresponding author), Inst Psychiat, Dept Forens Psychiat, De Crespigny Pk, London SE5 8AF, England.		Leese, Morven N/E-4195-2010					Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Bonta J, 1996, CAN J CRIMINOL, V38, P61, DOI 10.3138/cjcrim.38.1.61; Buchanan A, 1999, PSYCHOL MED, V29, P465, DOI 10.1017/S0033291798008101; COCOZZA JJ, 1976, RUTGERS LAW REV, V29, P1084; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COPAS J, 1994, HOME OFFICE RES STAT, V36, P30; COPAS JB, 1976, BRIT J PSYCHIAT, V129, P388, DOI 10.1192/bjp.129.4.388; Douglas KS, 1999, J CONSULT CLIN PSYCH, V67, P917, DOI 10.1037/0022-006X.67.6.917; Dunn G., 1989, DESIGN ANAL RELIABIL; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Fleminger S, 1997, BRIT J PSYCHIAT, V171, P287, DOI 10.1192/bjp.171.3.287a; Grann M, 1999, LAW HUMAN BEHAV, V23, P205, DOI 10.1023/A:1022372902241; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HEDLUND JL, 1973, J CLIN PSYCHOL, V29, P443, DOI 10.1002/1097-4679(197310)29:4<443::AID-JCLP2270290413>3.0.CO;2-H; HOFFMAN PB, 1985, CRIM JUSTICE BEHAV, V12, P501, DOI 10.1177/0093854885012004007; Home Office and Department of Health, 1999, MAN DANG PEOPL SEV P; KANDEL E, 1989, ACTA PSYCHIAT SCAND, V79, P103, DOI 10.1111/j.1600-0447.1989.tb09241.x; KLASSEN D, 1989, PSYCHOL ASSESSMENT, V1, P75; KOZOL HL, 1972, CRIME DELINQUENCY, V18, P371; LEVINSON RM, 1979, J HEALTH SOC BEHAV, V20, P178, DOI 10.2307/2136438; LIDZ CW, 1993, JAMA-J AM MED ASSOC, V269, P1007, DOI 10.1001/jama.269.8.1007; MOSSMAN D, 1994, J CONSULT CLIN PSYCH, V62, P783, DOI 10.1037/0022-006X.62.4.783; MULLEN JM, 1982, J PSYCHIAT LAW, V10, P223, DOI 10.1177/009318538201000207; RICE ME, 1995, INT J LAW PSYCHIAT, V18, P333, DOI 10.1016/0160-2527(95)00015-A; RICE ME, 1995, J CONSULT CLIN PSYCH, V63, P737, DOI 10.1037/0022-006X.63.5.737; Sepejak D, 1983, Bull Am Acad Psychiatry Law, V11, P171; SERIN RC, 1995, INT J LAW PSYCHIAT, V18, P231, DOI 10.1016/0160-2527(95)00008-6; Serin RC, 1996, LAW HUMAN BEHAV, V20, P207, DOI 10.1007/BF01499355; Steadman H J, 1977, Bull Am Acad Psychiatry Law, V5, P200; STEADMAN HJ, 1982, SOC FORCES, V61, P475; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P600; Ward A, 1999, CRIM JUSTICE BEHAV, V26, P125, DOI 10.1177/0093854899026001007; Webster C D, 1984, Bull Am Acad Psychiatry Law, V12, P41; WILLIAMS P, 1982, PSYCHOL MED, V12, P431, DOI 10.1017/S003329170004678X	35	80	83	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1955	1959		10.1016/S0140-6736(01)06962-8	http://dx.doi.org/10.1016/S0140-6736(01)06962-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500HZ	11747920				2022-12-28	WOS:000172622200013
J	Burris, S; Lazzarini, Z; Loff, B				Burris, S; Lazzarini, Z; Loff, B			Are human rights good for your health?	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia	Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503; Burris, Scott/0000-0002-6013-5842				ROYLANCE FD, 2001, BALTIMORE SUN   1101, pA3	1	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1901	1901						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741653				2022-12-28	WOS:000172463000037
J	White, HD; Simes, RJ; Aylward, PEG; Armstrong, PW; Califf, RM; French, JK; Granger, CB; Marschner, IC; Topol, EJ; Van de Werf, FJ; Wilcox, RG				White, HD; Simes, RJ; Aylward, PEG; Armstrong, PW; Califf, RM; French, JK; Granger, CB; Marschner, IC; Topol, EJ; Van de Werf, FJ; Wilcox, RG		Hirulog Early Reperfusion Occlusi	Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial	LANCET			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; GUSTO-I; CLINICAL-OUTCOMES; STREPTOKINASE; INHIBITION; PREDICTORS; MORTALITY; ASPIRIN; HIRULOG	Background The combination of fibrinolytic therapy and heparin for acute myocardial infarction fails to achieve reperfusion in 40-70% of patients, and early reocclusion occurs in a substantial number. We did a randomised, open-label trial to compare the thrombin-specific anticoagulant, bivalirudin, with heparin in patients undergoing fibrinolysis with streptokinase for acute myocardial infarction. Methods 17 073 patients with acute ST-elevation myocardial infarction were randomly assigned an intravenous bolus and 48-h infusion of either bivalirudin (n=8516) or heparin (n=8557), together with a standard 1.5 million unit dose of streptokinase given directly after the antithrombotic bolus. The primary endpoint was 30-day mortality. Secondary endpoints included reinfarction within 96 h and bleeding. Strokes and reinfarctions were adjudicated by independent committees who were unaware of treatment allocation. Analysis was by intention to treat. Findings By 30 days, 919 patients (10.8%) in the bivalirudin group and 931 (10.9%) in the heparin group had died (odds ratio 0.99 [95% CI 0.90-1.09], p=0.85). The mortality rates adjusted for baseline risk factors were 10.5% for bivalirudin and 10.9% for heparin (0.96 [0.86-1.07], p=0.46). There were significantly fewer reinfarctions within 96 h in the bivalirudin group than in the heparin group (0.70 [0.56-0.87], p=0.001). Severe bleeding occurred in 58 patients (0.7%) in the bivalirudin group versus 40 patients (0.5%) in the heparin group (p=0.07), and intracerebral bleeding occurred fn 47 (0.6%) versus 32 (0.4%), respectively (p=0.09). The rates of moderate and mild bleeding were significantly higher in the bivalirudin group than the heparin group (1.32 [1.00-1.74], p=0.05; and 1.47 [1.34-1.62], p<0.0001; respectively. Transfusions were given to 118 patients (1.4%) in the bivalirudin group versus 95 patients (1.1%) in the heparin group (1.25 [0.95-1.64], p=0.11). Interpretation Bivalirudin did not reduce mortality compared with unfractionated heparin, but did reduce the rate of adjudicated reinfarction within 96 h by 30%. Small absolute increases were seen in mild and moderate bleeding fn patients given bivalirudin. Bivalirudin is a new anticoagulant treatment option in patients with acute myocardial infarction treated with streptokinase.	Green Lane Hosp, Dept Cardiol, Auckland 1030, New Zealand		White, HD (corresponding author), Green Lane Hosp, Dept Cardiol, Private Bag 92 189, Auckland 1030, New Zealand.	harveyw@adhb.govt.nz	Manolis, Antonis/F-5003-2014; Granger, Christopher B/D-3458-2014; Strahan, Thomas/F-9283-2011; Simes, Robert John/P-1497-2014	Manolis, Antonis/0000-0002-0336-4745; Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Marschner, Ian/0000-0002-6225-1572; Armstrong, Paul/0000-0002-0460-3445; Aylward, Philip/0000-0002-5358-8552				Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; BITTL JA, IN PRESS AM HEART J; Braunwald E, 2000, EUR HEART J, V21, P2005; Califf RM, 1997, AM HEART J, V133, P630, DOI 10.1016/S0002-8703(97)70164-9; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; GALVANI M, 1994, J AM COLL CARDIOL, V24, P1445, DOI 10.1016/0735-1097(94)90138-4; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Granger CB, 1998, J AM COLL CARDIOL, V31, P497, DOI 10.1016/S0735-1097(97)00539-1; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hudson MP, 2001, CIRCULATION, V104, P1229, DOI 10.1161/hc3601.095717; *INT JOINT EFF COM, 1995, LANCET, V346, P329; Kong DF, 1999, CIRCULATION, V100, P2049, DOI 10.1161/01.CIR.100.20.2049; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Ronner E, 2000, EUR HEART J, V21, P1530, DOI 10.1053/euhj.1999.2035; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, IN PRESS EUR HEART J; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; van Domburg R T, 2001, Neth Heart J, V9, P166; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; White HD, 1997, CIRCULATION, V96, P2155; White HD, 1998, AM J CARDIOL, V82, p57P, DOI 10.1016/S0002-9149(98)00663-8; White HD, 1998, J AM COLL CARDIOL, V31, P494	30	258	274	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1855	1863						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741625				2022-12-28	WOS:000172463000011
J	Makino, Y; Cao, RH; Svensson, K; Bertilsson, GR; Asman, M; Tanaka, H; Cao, YH; Berkenstam, A; Poellinger, L				Makino, Y; Cao, RH; Svensson, K; Bertilsson, GR; Asman, M; Tanaka, H; Cao, YH; Berkenstam, A; Poellinger, L			Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression	NATURE			English	Article							TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA; ANGIOGENESIS; FACTOR-1; GROWTH; ALPHA; PROTEOLYSIS; INDUCTION	Alteration of gene expression is a crucial component of adaptive responses to hypoxia. These responses are mediated by hypoxia-inducible transcription factors (HIFs)(1,2). Here we describe an inhibitory PAS (Per/Arnt/Sim) domain protein, IPAS, which is a basic helix-loop-helix (bHLH)/PAS protein structurally related to HIFs. IPAS contains no endogenous transactivation function but demonstrates dominant negative regulation of HIF-mediated control of gene expression. Ectopic expression of IPAS in hepatoma cells selectively impairs induction of genes involved in adaptation to a hypoxic environment, notably the vascular endothelial growth factor (VEGF) gene, and results in retarded tumour growth and tumour vascular density in vivo. In mice, IPAS was predominantly expressed in Purkinje cells of the cerebellum and in corneal epithelium of the eye. Expression of IPAS in the cornea correlates with low levels of expression of the VEGF gene under hypoxic conditions. Application of an IPAS antisense oligonucleotide to the mouse cornea induced angiogenesis under normal oxygen conditions, and demonstrated hypoxia-dependent induction of VEGF gene expression in hypoxic corneal cells. These results indicate a previously unknown mechanism for negative regulation of angiogenesis and maintenance of an avascular phenotype.	Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Pharmacia Corp, S-12287 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; University of Tokyo; Pfizer; Pharmacia Corporation	Poellinger, L (corresponding author), Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.	lorenz.poellinger@cmb.ki.se	Berkenstam, Anders/E-7136-2012					Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Eddy S R, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P114; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ravi R, 2000, GENE DEV, V14, P34; Sack RA, 1999, CURR EYE RES, V18, P186, DOI 10.1076/ceyr.18.3.186.5367; Semenza GL, 2000, GENE DEV, V14, P1983; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thakur A, 1998, J CLIN IMMUNOL, V18, P61, DOI 10.1023/A:1023291921695; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; WIESENDANGER R, 1992, SCANNING TUNNELING M, V1, P1; Zundel W, 2000, GENE DEV, V14, P391; [No title captured]	24	491	522	1	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					550	554		10.1038/35107085	http://dx.doi.org/10.1038/35107085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734856				2022-12-28	WOS:000172405900049
J	Dakik, HA; Salti, I; Haidar, R; Uthman, IW				Dakik, HA; Salti, I; Haidar, R; Uthman, IW			Ticlopidine associated with acute arthritis	BRITISH MEDICAL JOURNAL			English	Article							CLOPIDOGREL											Garg A, 2000, BRIT MED J, V320, P483; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					27	27		10.1136/bmj.324.7328.27	http://dx.doi.org/10.1136/bmj.324.7328.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777802	Bronze, Green Published			2022-12-28	WOS:000173205700021
J	Montgomery, SM; Ekbom, A				Montgomery, SM; Ekbom, A			Smoking during pregnancy and diabetes mellitus in a British longitudinal birth cohort	BRITISH MEDICAL JOURNAL			English	Article									Karolinska Sjukuset, Klin Epidemiol, SE-17176 Stockholm, Sweden		Montgomery, SM (corresponding author), Karolinska Sjukuset, Klin Epidemiol, SE-17176 Stockholm, Sweden.		Montgomery, Scott/AAN-2546-2020	Montgomery, Scott/0000-0001-6328-5494				BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; EKINSMYTH C, 1992, INTEGRATED APPROACH; FERRI E, 1993, LIFE 33 5 FOLLOW UP; ORAHILLY S, 1987, BRIT MED J, V294, P923, DOI 10.1136/bmj.294.6577.923; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	5	159	165	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					26	27		10.1136/bmj.324.7328.26	http://dx.doi.org/10.1136/bmj.324.7328.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777801	Green Published, Bronze			2022-12-28	WOS:000173205700020
J	Blumenthal, SJ; Kagen, J				Blumenthal, SJ; Kagen, J			The effects of socioeconomic status on health in rural and urban America	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US Dept HHS, Washington, DC 20201 USA		Blumenthal, SJ (corresponding author), US Dept HHS, Washington, DC 20201 USA.							Eberhardt MS, 2001, URBAN RURAL HLTH CHA; Pamuk E., 1998, SOCIOECONOMIC STATUS; *POP DIV US CENS B, 2001, POP EST PROGR; Prewitt E, 1997, ANN INTERN MED, V126, P485, DOI 10.7326/0003-4819-126-6-199703150-00012; *RUR INF CTR HLTH, 2001, RUR HLTH STAT	5	49	49	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					109	109		10.1001/jama.287.1.109	http://dx.doi.org/10.1001/jama.287.1.109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754719	hybrid			2022-12-28	WOS:000172978500035
J	Kalb, PE; Koehler, KG				Kalb, PE; Koehler, KG			Legal issues in scientific research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS-OF-INTEREST; PHARMACEUTICAL-INDUSTRY; BIOMEDICAL-RESEARCH; POLICIES; INVESTIGATORS	In recent years, regulatory and law enforcement authorities responsible for combating fraud and abuse have focused greater attention on the scientific research process, in particular, the process of seeking reimbursement for research costs, the process of performing clinical research, and the potential improper remuneration of researchers or research subjects. This article describes how the federal False Claims Act, which allows the government to recover treble damages plus substantial penalties from persons who knowingly submit false claims or make false statements to the government, has been used to achieve a number of multimillion-dollar settlements with research institutions. The article also discusses instances of temporary suspension of research activities at a number of prominent institutions and the investigation of illegal "inducements" or "kickbacks" provided by manufacturers to researchers and by research institutions to patients.	Sidley Austin Brown & Wood, Washington, DC USA		Kalb, PE (corresponding author), 1501 K St NW, Washington, DC 20005 USA.	pkalb@sidley.com						Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; [Anonymous], 1991, FED REG, V56, P28012; [Anonymous], 1995, FED REG, V60, P35815; [Anonymous], 1999, FED REGISTER; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; BRAINARD J, 2000, CHRONICLE HIGHE 0204, pA29; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; CIMONS M, 2000, LOS ANGELES TIM 0122, pA10; DeAngelis CD, 2000, JAMA-J AM MED ASSOC, V284, P2237, DOI 10.1001/jama.284.17.2237; *DEP HHS OFF INSP, 2000, DEP HLTH HUM SERV OF; *DEP HLTH HUM SERV, 2000, SECR SHAL BOLST PROT; *DEP HLTH HUM SERV, 2001, HUM SUBJ COMPL OV SI; *DEP HLTH HUM SERV, 1994, 272 PMS DEP HLTH HUM; *DEP HLTH HUM SERV, 2000, SPEC FRAUD AL; *DEP HLTH HUM SERV, 2000, NAT EMPH TREATM TRIA; *DEP HLTH HUM SERV, 2000, DEP HLTH HUM SERV GE; *DEP HLTH HUM SERV, 1998, DEP HLTH HUM SERV OF; *DEP HLTH HUM SERV, 2001, OIG WORK PLAN FISC Y; FABRIKANT R, 1996, HLTH CARE FRAUD ENFO; HALLAM K, 1998, MODERN HEALTHCARE, V28, P8; HILTS PJ, 1994, NY TIMES        0723, pA3; Kalb PE, 1999, JAMA-J AM MED ASSOC, V282, P1163, DOI 10.1001/jama.282.12.1163; KELLY D, 2000, RICHMOND TIMES  0109, pA1; Korn D, 2000, JAMA-J AM MED ASSOC, V284, P2234, DOI 10.1001/jama.284.17.2234; Lo B, 2000, NEW ENGL J MED, V343, P1616, DOI 10.1056/NEJM200011303432206; Martin JB, 2000, NEW ENGL J MED, V343, P1646, DOI 10.1056/NEJM200011303432213; McCrary SV, 2000, NEW ENGL J MED, V343, P1621, DOI 10.1056/NEJM200011303432207; National Bioethics Advisory Commission, 2001, ETH POL ISS RES INV; *NIH, 1997, 269 NIH; *NIH, 2001, FY 2001 BUDG; *NIH OFF EXTR RES, 2001, PROACT COMPL SIT VIS; *OFF MAN BUDG, 2000, A21 OFF MAN BUDG; ROBERTS L, 1999, US NEWS WORLD REP, V127, P14; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; SPERA A, 2000, CENTERWATCH, V7, pA181; U.S. Department of Health and Human Services, 1989, FED REGISTER, V54, P32449; *US GEN ACC OFF, 1992, HLTH INS VULN PAY LO; *US GEN ACC OFF, 2000, DEP HLTH HUM SERV GE; WALDMAN A, 1999, NY TIMES        0219, pB3; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; WEISS R, 1999, WASHINGTON POST 0512, pAO1; 1981, FED REG, V46, P8975; 1997, BNA HLTH CARE FRAUD, V1, P218; 2000, MODERN HEALTHCARE, V30, P16; 1999, BNA HLTH CARE FRAUD, V3, P356; 1997, BNA HLTH CARE FRAUD, V1, P701; 1999, FED REG, V64, P63525; 1998, BNA HLTH CARE FRAUD, V2, P936; 1992, FED REG, V57, P3330; 1980, FED REG, V45, P3751; 1998, FED REG, V63, P5250; 1980, FED REG, V45, P36390	53	19	20	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					85	91		10.1001/jama.287.1.85	http://dx.doi.org/10.1001/jama.287.1.85			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754713				2022-12-28	WOS:000172978500030
J	Ely, EW; Wheeler, AP; Thompson, BT; Ancukiewicz, M; Steinberg, KP; Bernard, GR				Ely, EW; Wheeler, AP; Thompson, BT; Ancukiewicz, M; Steinberg, KP; Bernard, GR		Acute Respiratory Distress Syndrom	Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	International Conference of the American-Lung-Association and the American-Thoracic-Society	MAY 05-10, 2000	TORONTO, CANADA	Amer Lung Assoc, Amer Thorac Soc			CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; ELDERLY MEDICAL PATIENTS; ACTIVATED PROTEIN-C; MECHANICAL VENTILATION; HOSPITALIZED ADULTS; SERIOUSLY ILL; INFORMANT QUESTIONNAIRE; COGNITIVE DECLINE	Background: The incidence of acute respiratory failure requiring mechanical ventilation increases 10-fold from the ages of 55 to 85 years, yet the rate of recovery and outcomes in older persons who develop acute lung injury are poorly defined. Objective: To examine age as an independent risk factor in recovery and intensive care unit discharge after acute lung injury. Design: Prospective cohort study. Setting: 10 U.S. university-based medical centers. Patients: 902 mechanically ventilated patients enrolled in randomized, controlled trials for the treatment of acute lung injury. Ail patients were managed according to a standardized protocol for ventilator management and weaning. Measurements: Frequency and time to achieve well-defined recovery landmarks, duration of ventilation and intensive care unit stay, and survival. Results: Median duration of mechanical ventilation was 19 days (interquartile range, 7 to >28 days) for patients 70 years of age or older (n = 173) compared with 10 days (interquartile range, 5 to 26 days) for patients younger than 70 years of age (n = 729) (P < 0.001). The duration of intensive care unit stay was 21 days for the older group (interquartile range, 11 to >28 days) and 16 days for the younger group (8 to >28 days) (P = 0.004). Survival rates decreased across increasing decades of age (P < 0.001): Patients younger than 70 years of age had a greater 28-day survival rate than patients 70 years of age or older (74.6% vs. 50.3%; P < 0.001). The proportion of survivors achieving physiologic recovery landmarks did not differ between the older and younger age groups, and the median time to pass a 2-hour spontaneous breathing trial was similar between both the older and younger patients (4 days vs. 5 days; P > 0.2). After passing a spontaneous breathing trial, however, older patients required 1 more day than younger patients to achieve unassisted breathing (P = 0.002) and 3 more days to leave the intensive care unit (P = 0.005). In a multivariable Cox proportional hazards analysis, age of 70 years or older was a strong predictor of in-hospital death (hazard ratio, 2.5 [95% Cl, 2.0 to 3.2]; P < 0.001). Conclusions: Although the survival rate among patients 70 years of age or older was high, these patients were twice as likely to die of acute lung injury compared with their younger counterparts, even after adjustment for covariates. Older survivors recovered from respiratory failure and achieved spontaneous breathing at the same rate as younger patients but had greater difficulty achieving liberation from the ventilator and being discharged from the intensive care unit.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Sch Med, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Res & Edu, Nashville, TN USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harborview Medical Center; University of Washington; University of Washington Seattle	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Sch Med, 6th Floor,6109 Med Ctr E, Nashville, TN 37232 USA.	wes.ely@mcmail.vanderbilt.edu	Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	NHLBI NIH HHS [N01-HR 46054-46064] Funding Source: Medline; NIA NIH HHS [AG01023-01A1] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046054] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agresti A, 1999, STAT MED, V18, P2191, DOI 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2191::AID-SIM249>3.0.CO;2-M; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; [Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925; Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Behrendt CE, 2000, CHEST, V118, P1100, DOI 10.1378/chest.118.4.1100; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; Bernard GR, 1997, SEPSIS, V1, P43, DOI DOI 10.1023/A:1009711301483; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chatila W, 1996, CHEST, V109, P1577, DOI 10.1378/chest.109.6.1577; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; COX DR, 1972, J R STAT SOC B, V34, P187; Dardaine V, 2001, J AM GERIATR SOC, V49, P564, DOI 10.1046/j.1532-5415.2001.49114.x; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 1999, INTENS CARE MED, V25, P581, DOI 10.1007/s001340050906; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Ely EW, 1999, AM J RESP CRIT CARE, V159, P439, DOI 10.1164/ajrccm.159.2.9805120; ELY EW, 2001, IN PRESS CHEST, P120; ELY EW, 2001, IN PRESS INTENSIVE C; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; FISHER L, 1993, BIOSTATISTICS METHOD, P542; FISHER L, 1993, BIOSTATISTICS METHOD, P815; FISHER L, 1993, BIOSTATISTICS METHOD, P311; FISHER LD, 1993, BIOSTATISTICS METHOD, P185; FISHER LD, 1993, BIOSTATISTICS METHOD, P385; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GEE MH, 1990, J APPL PHYSIOL, V69, P822, DOI 10.1152/jappl.1990.69.3.822; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; Hamel MB, 2000, J AM GERIATR SOC, V48, pS176, DOI 10.1111/j.1532-5415.2000.tb03129.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HOBBS F, 1996, 65 PLUS US, P1; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jakob SM, 1997, INTENS CARE MED, V23, P1165, DOI 10.1007/s001340050474; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P11; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Krieger BP, 1997, CHEST, V112, P1029, DOI 10.1378/chest.112.4.1029; LANDAHL S, 1980, ACTA MED SCAND, V207, P225; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; *SAS I, 1990, SAS STAT US GUID, P1030; Seely AJE, 2000, CRIT CARE MED, V28, P2193, DOI 10.1097/00003246-200007000-00003; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Srivastava S, 1999, CRIT CARE MED, V27, P2109, DOI 10.1097/00003246-199910000-00005; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Suchyta MR, 1997, CHEST, V111, P1334, DOI 10.1378/chest.111.5.1334; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	85	167	173	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					25	36		10.7326/0003-4819-136-1-200201010-00007	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	510BF	11777361				2022-12-28	WOS:000173188300003
J	Bhalla, P; Pippa, S; Williams, G				Bhalla, P; Pippa, S; Williams, G			An inexpensive and edible aid for the diagnosis of puberty in the male: multispecies evaluation of an alternative orchidometer	BRITISH MEDICAL JOURNAL			English	Article									Univ Hosp Aintree, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AE, Merseyside, England	University of Liverpool	Williams, G (corresponding author), Univ Hosp Aintree, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AE, Merseyside, England.							Chen M, 2000, BRIT MED J, V321, P1565, DOI 10.1136/bmj.321.7276.1565; Chipkevitch E, 1996, J UROLOGY, V156, P2050, DOI 10.1016/S0022-5347(01)65433-8; Prader A, 1966, Triangle, V7, P240; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Williams TM, 1995, BRIT MED J, V311, P1700, DOI 10.1136/bmj.311.7021.1700	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1486	1486		10.1136/bmj.323.7327.1486	http://dx.doi.org/10.1136/bmj.323.7327.1486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751366	Green Published			2022-12-28	WOS:000172979900027
J	Konotey-Ahulu, FID				Konotey-Ahulu, FID			The suprascientific in clinical medicine: a challenge for Professor Know-All	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Cromwell Hosp, London SW5 0TU, England		Konotey-Ahulu, FID (corresponding author), Cromwell Hosp, London SW5 0TU, England.	konotey-ahulu@cromwell-hospital.co.uk						CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Konotey-Ahulu FID, 1999, POLIT LIFE SCI, V18, P317; KONOTEYAHULU FID, 1969, BRIT MED J, V2, P48; Medawar PB, 1985, LIMITS SCI; PASCAL B, 1966, PENSEES 1657; HOLY BIBLE, V11, P33	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2001	323	7327					1452	1453		10.1136/bmj.323.7327.1452	http://dx.doi.org/10.1136/bmj.323.7327.1452			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751350	Green Published			2022-12-28	WOS:000172979900009
J	Treves, F				Treves, F			The twenty-krone piece	BRITISH MEDICAL JOURNAL			English	Article																		Treves Sir Frederick, 1923, ELEPHANT MAN OTHER R	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1474	1475		10.1136/bmj.323.7327.1474	http://dx.doi.org/10.1136/bmj.323.7327.1474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751361	Green Published			2022-12-28	WOS:000172979900021
J	Field, CB				Field, CB			Global change - Sharing the garden	SCIENCE			English	Editorial Material									Carnegie Inst Washington, Stanford, CA 94305 USA	Carnegie Institution for Science	Field, CB (corresponding author), Carnegie Inst Washington, Stanford, CA 94305 USA.							Daily GC., 1997, ISSUES ECOL, V2, P1; DeFries RS, 1999, GLOBAL BIOGEOCHEM CY, V13, P803, DOI 10.1029/1999GB900037; Rojstaczer S, 2001, SCIENCE, V294, P2549, DOI 10.1126/science.1064375; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; VITOUSEK PM, 1986, BIOSCIENCE, V36, P368, DOI 10.2307/1310258	6	50	58	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2490	2491		10.1126/science.1066317	http://dx.doi.org/10.1126/science.1066317			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752562				2022-12-28	WOS:000172927700038
J	Vollmer, WM; Sacks, FM; Ard, J; Appel, LJ; Bray, GA; Simons-Aaorton, DG; Conlin, PR; Svetkey, LP; Erlinger, TP; Moore, TJ; Karanja, N				Vollmer, WM; Sacks, FM; Ard, J; Appel, LJ; Bray, GA; Simons-Aaorton, DG; Conlin, PR; Svetkey, LP; Erlinger, TP; Moore, TJ; Karanja, N		DASH Sodium Trial Collaborative Re	Effects of diet and sodium intake on blood pressure: Subgroup analysis of the DASH-Sodium Trial	ANNALS OF INTERNAL MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; SALT SENSITIVITY; NATIONAL-HEALTH; URINARY SODIUM; HYPERTENSION; REDUCTION; PATTERNS; RISK; ASSOCIATION; POPULATION	Background: initial findings from the Dietary Approaches to Stop Hypertension (DASH)-Sodium Trial demonstrated that reduction of sodium intake in two different diets decreased blood pressure in participants with and without hypertension. Objective: To determine effects on blood pressure of reduced sodium intake and the DASH diet in additional subgroups. Design: Randomized feeding study. Setting: Four clinical centers and a coordinating center. Participants: 412 adults with untreated systolic blood pressure of 120 to 160 mm Hg and diastolic blood pressure of 80 to 95 mm Hg. Intervention: Participants followed the DASH diet or a control (typical U.S.) diet for three consecutive 30-day feeding periods, during which sodium intake (50, 100, and 150 mmol/d at 2100 kcal) varied according to a randomly assigned sequence. Body weight was maintained. Measurements: Systolic and diastolic blood pressure. Results: In all subgroups, the DASH diet and reduced sodium intake were each associated with significant decreases in blood pressure; these two factors combined produced the greatest reductions. Among nonhypertensive participants who received the control diet, lower (vs. higher) sodium intake decreased blood pressure by 7.0/3.8 mm Hg in those older than 45 years of age (P < 0.001) and by 3.7/1.5 mm Hg in those 45 years of age or younger (P < 0.05). Conclusion: The DASH diet plus reduced sodium intake is recommended to control blood pressure in diverse subgroups.	Ctr Hlth Res, Portland, OR 97227 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Boston Univ, Med Ctr, Boston, MA USA; Duke Univ, Med Ctr, Durham, NC USA; Johns Hopkins Univ, Baltimore, MD USA; NHLBI, NIH, Bethesda, MD 20892 USA; Pennington Biomed Res Ctr, Baton Rouge, LA USA	Harvard University; Brigham & Women's Hospital; Boston University; Duke University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Vollmer, WM (corresponding author), Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.	william.vollmer@kpchr.org	Appel, Larry/GLT-2608-2022	Moore, Thomas/0000-0002-5289-2018; Ard, Jamy/0000-0002-1643-6795	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635, M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL057190, U01HL057156, U01HL057173, U01HL057139, U01HL057114] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00722, M01-RR02635] Funding Source: Medline; NHLBI NIH HHS [U01-HL57114, U01-HL57156, HL03857-01, U01-HL57190, U01-HL 57173, U01-HL57139] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; de Wardener HE, 1999, J HUM HYPERTENS, V13, P1, DOI 10.1038/sj.jhh.1000759; Egan Brent M., 1997, American Journal of Clinical Nutrition, V65, p671S, DOI 10.1093/ajcn/65.2.671S; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; EPSTEIN FREDERICK H., 1967, P155; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; ISHIBASHI K, 1994, CLIN NEPHROL, V42, P376; Karanja NM, 1999, J AM DIET ASSOC, V99, pS19, DOI 10.1016/S0002-8223(99)00412-5; KOJIMA S, 1992, AM J HYPERTENS, V5, P1; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; Kumanyika SK, 1997, J AM COLL NUTR, V16, P192, DOI 10.1080/07315724.1997.10718674; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACGREGOR GA, 1982, LANCET, V1, P351, DOI 10.1016/S0140-6736(82)91389-7; McCarron DA, 2000, AM J CLIN NUTR, V71, P1013; McCarron David A., 1997, American Journal of Clinical Nutrition, V65, p712S, DOI 10.1093/ajcn/65.2.712S; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; Morris RC, 1999, HYPERTENSION, V33, P18, DOI 10.1161/01.HYP.33.1.18; *NAT HEART LUNG BL, 1991, HYPERTENSION, V17, P1; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stamler J, 1997, AM J CLIN NUTR, V65, P626, DOI 10.1093/ajcn/65.2.626S; *STAT CORP, 1997, STAT STAT SOFTW REL; Svetkey LP, 1999, ARCH INTERN MED, V159, P285, DOI 10.1001/archinte.159.3.285; Svetkey LP, 1999, J AM DIET ASSOC, V99, pS96, DOI 10.1016/S0002-8223(99)00423-X; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; WEINBERGER MH, 1991, HYPERTENSION, V18, P67, DOI 10.1161/01.HYP.18.1.67; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; Weinberger MH, 1996, HYPERTENSION, V27, P481, DOI 10.1161/01.HYP.27.3.481	36	373	389	1	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1019	1028		10.7326/0003-4819-135-12-200112180-00005	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747380				2022-12-28	WOS:000172759700001
J	Nelson, JL				Nelson, JL			Microchimerism: expanding new horizon in human health or incidental remnant of pregnancy?	LANCET			English	Editorial Material							FETAL MICROCHIMERISM		Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Nelson, JL (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.							Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Davies TF, 1999, THYROID, V9, P675, DOI 10.1089/thy.1999.9.675; Jones DEJ, 2000, J HEPATOL, V33, P834, DOI 10.1016/S0168-8278(00)80317-7; Klintschar M, 2001, J CLIN ENDOCR METAB, V86, P2494, DOI 10.1210/jc.86.6.2494; Lambert NC, 2000, J IMMUNOL, V164, P5545, DOI 10.4049/jimmunol.164.11.5545; Lo YMD, 2000, CLIN CHEM, V46, P1301; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8	8	24	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2011	2012		10.1016/S0140-6736(01)07134-3	http://dx.doi.org/10.1016/S0140-6736(01)07134-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755601				2022-12-28	WOS:000172722800003
J	Cooper, JA; Wear, MA; Weaver, AM				Cooper, JA; Wear, MA; Weaver, AM			Arp2/3 complex: Advances on the inner workings of a molecular machine	CELL			English	Review							BINDING-ACTIVITY; PROTEIN; NUCLEATION; ACTIVATION; BRANCHES	Several new papers report progress on the structure and function of Arp2/3 complex. A crystal structure, a cryo-EM structure, and a reconstitution of the complex from subunits have been reported. New results also address the nucleation mechanism and the role of bound nucleotide.	Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63130 USA.	jcooper@cellbio.wustl.edu	Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038542, R01GM047337] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038542-13, R01 GM047337-10, R01 GM038542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Dayel MJ, 2001, P NATL ACAD SCI USA, V98, P14871, DOI 10.1073/pnas.261419298; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; ICHETOVKIN I, 2001, IN PRESS CURR BIOL; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; LECLAINCHE C, 2001, J BIOL CHEM     1011; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025	18	28	32	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					703	705		10.1016/S0092-8674(01)00605-5	http://dx.doi.org/10.1016/S0092-8674(01)00605-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747805	Bronze			2022-12-28	WOS:000172771800002
J	Amato, AA; Sanelli, PC; Anderson, MP; Jeyapalan, S				Amato, AA; Sanelli, PC; Anderson, MP; Jeyapalan, S			A 51-year-old woman with lung cancer and neuropsychiatric abnormalities. Lymphocytic meningitis and lymphocytic encephalomyelitis with sensory neuronopathy and ganglionitis. Small-cell carcinoma of the lung (treated).	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANTI-HU ANTIBODY; ANTINEURONAL NUCLEAR AUTOANTIBODIES; PARANEOPLASTIC ENCEPHALOMYELITIS; NERVOUS-SYSTEM; TUMOR; NEUROPATHY; SERUM		Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Neuromuscular Div, Boston, MA 02115 USA; Massachusetts Gen Hosp, Neuromuscular Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Amato, AA (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.							ALTERMATT HJ, 1991, LAB INVEST, V65, P412; Amato AA, 1998, SEMIN NEUROL, V18, P125, DOI 10.1055/s-2008-1040868; Barohn RJ, 1998, SEMIN NEUROL, V18, P7, DOI 10.1055/s-2008-1040857; BATSON OA, 1992, CANCER, V69, P1291; Benyahia B, 1999, ANN NEUROL, V45, P162, DOI 10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R; CROFT PB, 1967, BRAIN, V90, P31, DOI 10.1093/brain/90.1.31; CROFT PB, 1969, BRAIN, V92, P1, DOI 10.1093/brain/92.1.1; Dalmau J, 1999, BRAIN, V122, P27, DOI 10.1093/brain/122.1.27; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; Dalmau J, 1999, BRAIN PATHOL, V9, P275; DALMAU J, 1992, AM J PATHOL, V141, P881; DENNYBROWN D, 1948, J NEUROL NEUROSUR PS, V11, P73, DOI 10.1136/jnnp.11.2.73; GRAUS F, 1992, NEUROLOGY, V42, P536, DOI 10.1212/WNL.42.3.536; Graus F, 2001, BRAIN, V124, P1138, DOI 10.1093/brain/124.6.1138; GRAUS F, 1987, ACTA NEUROL SCAND, V75, P249, DOI 10.1111/j.1600-0404.1987.tb07928.x; GRAUS F, 1986, AM J MED, V80, P45, DOI 10.1016/0002-9343(86)90047-1; HENSON RA, 1965, BRAIN, V88, P449, DOI 10.1093/brain/88.3.449; JEAN WC, 1994, NEUROLOGY, V44, P140, DOI 10.1212/WNL.44.1.140; Keime-Guibert F, 1999, NEUROLOGY, V53, P1719, DOI 10.1212/WNL.53.8.1719; LENNON VA, 1991, GASTROENTEROLOGY, V100, P137, DOI 10.1016/0016-5085(91)90593-A; Lucchinetti CF, 1998, NEUROLOGY, V50, P652, DOI 10.1212/WNL.50.3.652; Molinuevo JL, 1998, ANN NEUROL, V44, P976, DOI 10.1002/ana.410440620; PANEGYRES PK, 1993, J NEUROL, V240, P93, DOI 10.1007/BF00858724; ROSENBLUM MK, 1993, BRAIN PATHOL, V3, P199, DOI 10.1111/j.1750-3639.1993.tb00747.x; Saperstein DS, 2001, MUSCLE NERVE, V24, P311, DOI 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.3.CO;2-1; SMITT PAES, 1995, NEUROLOGY, V45, P1873; VEGA F, 1994, NEUROLOGY, V44, P2145, DOI 10.1212/WNL.44.11.2145; Voltz R, 1998, NEUROLOGY, V51, P1146, DOI 10.1212/WNL.51.4.1146; Voltz RD, 1997, J NEUROL NEUROSUR PS, V63, P133, DOI 10.1136/jnnp.63.2.133; Wanschitz J, 1997, NEUROLOGY, V49, P1156, DOI 10.1212/WNL.49.4.1156; WILKINSO.PC, 1965, BRAIN, V88, P529, DOI 10.1093/brain/88.3.529	33	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1758	1765		10.1056/NEJMcpc402001	http://dx.doi.org/10.1056/NEJMcpc402001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742051				2022-12-28	WOS:000172656100007
J	Goodwin, PJ; Leszcz, M; Ennis, M; Koopmans, J; Vincent, L; Guther, H; Drysdale, E; Hundleby, M; Chochinov, HM; Navarro, M; Speca, M; Hunter, J				Goodwin, PJ; Leszcz, M; Ennis, M; Koopmans, J; Vincent, L; Guther, H; Drysdale, E; Hundleby, M; Chochinov, HM; Navarro, M; Speca, M; Hunter, J			The effect of group psychosocial support on survival in metastatic breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; CLINICAL-TRIALS; GROUP-THERAPY; INTERVENTION; CARCINOMA; WOMEN	Background: Supportive-expressive group therapy has been reported to prolong survival among women with metastatic breast cancer. However, in recent studies, various psychosocial interventions have not prolonged survival. Methods: In a multicenter trial, we randomly assigned 235 women with metastatic breast cancer who were expected to survive at least three months in a 2:1 ratio to an intervention group that participated in weekly supportive-expressive group therapy (158 women) or to a control group that received no such intervention (77 women). All the women received educational materials and any medical or psychosocial care that was deemed necessary. The primary outcome was survival; psychosocial function was assessed by self-reported questionnaires. Results: Women assigned to supportive-expressive therapy had greater improvement in psychological symptoms and reported less pain (P=0.04) than women in the control group. A significant interaction of treatment-group assignment with base-line psychological score was found (P less than or equal to0.003 for the comparison of mood variables; P=0.04 for the comparison of pain); women who were more distressed benefited, whereas those who were less distressed did not. The psychological intervention did not prolong survival (median survival, 17.9 months in the intervention group and 17.6 months in the control group; hazard ratio for death according to the univariate analysis, 1.06 [95 percent confidence interval, 0.78 to 1.45]; hazard ratio according to the multivariate analysis, 1.23 [95 percent confidence interval, 0.88 to 1.72]). Conclusions: Supportive-expressive group therapy does not prolong survival in women with metastatic breast cancer. It improves mood and the perception of pain, particularly in women who are initially more distressed. (N Engl J Med 2001;345:1719-26.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Psychiat, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Nursing, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Div Clin Epidemiol, Toronto, ON M5G 1X5, Canada; Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, Calgary, AB, Canada; Hamilton Reg Canc Ctr, Dept Support Care, Hamilton, ON L8V 1C3, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; British Columbia Canc Agcy, Dept Patient & Family Counseling, Vancouver, BC V5Z 4E6, Canada; Univ Alberta, Dept Psychol, Edmonton, AB, Canada; Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; Canc Care Manitoba, Winnipeg, MB, Canada; Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada; Univ Toronto, Mt Sinai Hosp, Dept Oncol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Tom Baker Cancer Clinic; University of Calgary; McMaster University; University of British Columbia; British Columbia Cancer Agency; University of Alberta; University of Alberta; University of Manitoba; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Goodwin, PJ (corresponding author), Univ Toronto, Mt Sinai Hosp, Dept Med, 1284-600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Goodwin, Pamela/K-1477-2013; Leszcz, Molyn/N-9043-2016	Goodwin, Pamela/0000-0003-2637-6906; hunter, jonathan/0000-0001-5684-0867; Chochinov, Harvey/0000-0003-2656-4704				Classen C, 2001, ARCH GEN PSYCHIAT, V58, P494, DOI 10.1001/archpsyc.58.5.494; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; Edelman S, 1999, PSYCHO-ONCOL, V8, P474, DOI 10.1002/(SICI)1099-1611(199911/12)8:6<474::AID-PON427>3.0.CO;2-A; Edelman S, 1999, PSYCHO-ONCOL, V8, P295, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<295::AID-PON386>3.3.CO;2-P; Edmonds CVI, 1999, PSYCHO-ONCOL, V8, P74, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<74::AID-PON339>3.0.CO;2-K; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FRIEDMAN MA, 1990, CANCER, V65, P2376, DOI 10.1002/1097-0142(19900515)65:10+<2376::AID-CNCR2820651504>3.0.CO;2-A; Fukui S, 2000, CANCER, V89, P1026, DOI 10.1002/1097-0142(20000901)89:5<1026::AID-CNCR12>3.0.CO;2-5; Goodwin PJ, 2000, J CLIN EPIDEMIOL, V53, P47, DOI 10.1016/S0895-4356(99)00148-1; Kuchler T, 1999, HEPATO-GASTROENTEROL, V46, P322; Leszcz M, 1998, INT J GROUP PSYCHOTH, V48, P245, DOI 10.1080/00207284.1998.11491538; LINN MW, 1982, CANCER, V49, P1048, DOI 10.1002/1097-0142(19820301)49:5<1048::AID-CNCR2820490534>3.0.CO;2-G; McNair DM., 1992, EDITS MANUAL PROFILE; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; Spiegel D., 1991, SUPPORTIVE EXPRESSIV; TATE HC, 1979, LANCET, V2, P623, DOI 10.1016/S0140-6736(79)91676-3; Twelves CJ, 1998, EUR J CANCER, V34, P1004, DOI 10.1016/S0959-8049(97)10126-5; Weinerman, 1994, ANNU ROYAL COLL PHYS, V27, P93	20	552	565	1	41	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1719	1726		10.1056/NEJMoa011871	http://dx.doi.org/10.1056/NEJMoa011871			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500YK	11742045				2022-12-28	WOS:000172656100001
J	Maechler, P; Wollheim, CB				Maechler, P; Wollheim, CB			Mitochondrial function in normal and diabetic beta-cells	NATURE			English	Review							STIMULATED INSULIN-SECRETION; METABOLIC COUPLING FACTORS; TRNA(LEU(UUR)) MUTATION; GUANINE-NUCLEOTIDES; GENE-TRANSCRIPTION; PANCREATIC-ISLETS; GLUCOSE; DNA; EXOCYTOSIS; MELLITUS	The aetiology of type 2, or non-insulin-dependent, diabetes mellitus has been characterized in only a limited number of cases. Among these, mitochondrial diabetes, a rare subform of the disease, is the consequence of pancreatic beta -cell dysfunction caused by mutations in mitochondrial DNA, which is distinct from the nuclear genome. The impact of such mutations on beta -cell function reflects the importance of mitochondria in the control of insulin secretion. The beta -cell mitochondria serve as fuel sensors, generating factors that couple nutrient metabolism to the exocytosis of insulin-containing vesicles. The latter process requires an increase in cytosolic Ca2+, which depends on ATP synthesized by the mitochondria. This organelle also generates other factors, of which glutamate has been proposed as a potential intracellular messenger.	Univ Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Maechler, P (corresponding author), Univ Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.			Maechler, Pierre/0000-0002-2005-1433				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; COORDT MC, 1995, P SOC EXP BIOL MED, V209, P213; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91; Garcia-Martinez JA, 2000, INT J MOL MED, V6, P319; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Grimberg A, 2001, DIABETES, V50, P322, DOI 10.2337/diabetes.50.2.322; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Huypens P, 2000, DIABETOLOGIA, V43, P1012, DOI 10.1007/s001250051484; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; JONES PM, 1986, FEBS LETT, V205, P205, DOI 10.1016/0014-5793(86)80898-5; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Maassen JA, 2001, EXP CLIN ENDOCR DIAB, V109, P127, DOI 10.1055/s-2001-14834; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 2000, J PHYSIOL-LONDON, V529, P49, DOI 10.1111/j.1469-7793.2000.00049.x; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nissim I, 1999, AM J PHYSIOL-RENAL, V277, pF493, DOI 10.1152/ajprenal.1999.277.4.F493; Otabe S, 1999, BIOCHEM BIOPH RES CO, V259, P149, DOI 10.1006/bbrc.1999.0650; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Proks P, 1996, J PHYSIOL-LONDON, V496, P255, DOI 10.1113/jphysiol.1996.sp021682; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Rubi B, 2001, J BIOL CHEM, V276, P36391, DOI 10.1074/jbc.M104999200; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; SENER A, 1994, AM J PHYSIOL-ENDOC M, V267, pE573, DOI 10.1152/ajpendo.1994.267.4.E573; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950; Suzuki Y, 1997, METABOLISM, V46, P1019, DOI 10.1016/S0026-0495(97)90272-9; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; VALLAR L, 1987, J BIOL CHEM, V262, P5049; van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	82	400	408	0	35	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					807	812		10.1038/414807a	http://dx.doi.org/10.1038/414807a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742413	Green Published			2022-12-28	WOS:000172676200061
J	Ramanathan, V; Crutzen, PJ; Kiehl, JT; Rosenfeld, D				Ramanathan, V; Crutzen, PJ; Kiehl, JT; Rosenfeld, D			Atmosphere - Aerosols, climate, and the hydrological cycle	SCIENCE			English	Review							INDIAN-OCEAN EXPERIMENT; TROPOSPHERIC AEROSOLS; SHORTWAVE IRRADIANCE; STRATOCUMULUS CLOUDS; SULFATE AEROSOLS; AIR-POLLUTION; SURFACE; ALBEDO; WIDESPREAD; CHEMISTRY	Human activities are releasing tiny particles (aerosols) into the atmosphere. These human-made aerosols enhance scattering and absorption of solar radiation. They also produce brighter clouds that are less efficient at releasing precipitation. These in turn lead to Large reductions in the amount of solar irradiance reaching Earth's surface, a corresponding increase in solar heating of the atmosphere, changes in the atmospheric temperature structure, suppression of rainfall, and less efficient removal of pollutants. These aerosol effects can lead to a weaker hydrological cycle, which connects directly to availability and quality of fresh water, a major environmental issue of the 21st century.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Natl Ctr Atmospher Res, Boulder, CO 80305 USA; Max Planck Inst Chem, D-55128 Mainz, Germany; Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel	University of California System; University of California San Diego; Scripps Institution of Oceanography; National Center Atmospheric Research (NCAR) - USA; Max Planck Society; Hebrew University of Jerusalem	Ramanathan, V (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	ram@fiji.ucsd.edu	Crutzen, Paul J/F-6044-2012; Rosenfeld, Daniel/AAJ-4617-2021; Rosenfeld, Daniel/F-6077-2016	Rosenfeld, Daniel/0000-0002-0784-7656; Rosenfeld, Daniel/0000-0002-0784-7656				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; CHARLSON RJ, 1991, TELLUS A, V43, P152, DOI 10.1034/j.1600-0889.1991.t01-1-00013.x; Charlson RJ, 2001, SCIENCE, V292, P2025, DOI 10.1126/science.1060096; CLARKE AD, 1985, SCIENCE, V229, P263, DOI 10.1126/science.229.4710.263; COAKLEY JA, 1987, SCIENCE, V237, P1020, DOI 10.1126/science.237.4818.1020; Collins WD, 2001, J GEOPHYS RES-ATMOS, V106, P7313, DOI 10.1029/2000JD900507; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; CRUTZEN PJ, 1982, AMBIO, V11, P114; Eck TF, 1998, J GEOPHYS RES-ATMOS, V103, P31865, DOI 10.1029/98JD00399; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Gilgen H, 1998, J CLIMATE, V11, P2042, DOI 10.1175/1520-0442-11.8.2042; GUILTEPE I, 1996, J CLIMATOL, V9, P345; Hansen J, 2000, P NATL ACAD SCI USA, V97, P9875, DOI 10.1073/pnas.170278997; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; Haywood J, 2000, REV GEOPHYS, V38, P513, DOI 10.1029/1999RG000078; Jacobson MZ, 2001, J GEOPHYS RES-ATMOS, V106, P1551, DOI 10.1029/2000JD900514; Jayaraman A, 1998, J GEOPHYS RES-ATMOS, V103, P13827, DOI 10.1029/98JD00559; Kaufman YJ, 1997, SCIENCE, V277, P1636, DOI 10.1126/science.277.5332.1636; Kaufman YJ, 1997, J GEOPHYS RES-ATMOS, V102, P17051, DOI 10.1029/96JD03988; Kiehl JT, 1997, B AM METEOROL SOC, V78, P197, DOI 10.1175/1520-0477(1997)078<0197:EAGMEB>2.0.CO;2; King MD, 1999, B AM METEOROL SOC, V80, P2229, DOI 10.1175/1520-0477(1999)080<2229:RSOTAF>2.0.CO;2; Konzelmann T, 1996, J GEOPHYS RES-ATMOS, V101, P22833, DOI 10.1029/96JD01556; Lelieveld J, 2001, SCIENCE, V291, P1031, DOI 10.1126/science.1057103; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; MARTIN GM, 1994, J ATMOS SCI, V51, P1823, DOI 10.1175/1520-0469(1994)051<1823:TMAPOE>2.0.CO;2; MCFARQUHAR GA, IN PRESS J GEOPHYS R; Meehl GA, 1996, GEOPHYS RES LETT, V23, P3755, DOI 10.1029/96GL03478; MICHELL JFB, 1997, J CLIMATE, V10, P245; Nakajima T, 2001, GEOPHYS RES LETT, V28, P1171, DOI 10.1029/2000GL012186; NOVAKOV T, 1993, NATURE, V365, P823, DOI 10.1038/365823a0; OGREN JA, 1983, TELLUS B, V35, P241, DOI 10.1111/j.1600-0889.1983.tb00027.x; Pawlowska H, 2000, TELLUS B, V52, P868, DOI 10.1034/j.1600-0889.2000.00076.x; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289; Raes F, 2000, TELLUS B, V52, P111, DOI 10.1034/j.1600-0889.2000.00124.x; Rajeev K, 2000, J GEOPHYS RES-ATMOS, V105, P2029, DOI 10.1029/1999JD900414; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; Ramaswamy V, 1997, GEOPHYS RES LETT, V24, P567, DOI 10.1029/97GL00248; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Robertson A, 2001, J GEOPHYS RES-ATMOS, V106, P14783, DOI 10.1029/2000JD900469; Roeckner E, 1999, J CLIMATE, V12, P3004, DOI 10.1175/1520-0442(1999)012<3004:TCCSWA>2.0.CO;2; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rosenfeld D, 2001, P NATL ACAD SCI USA, V98, P5975, DOI 10.1073/pnas.101122798; Russell PB, 1999, J GEOPHYS RES-ATMOS, V104, P2289, DOI 10.1029/1998JD200025; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; Stanhill G, 2001, AGR FOREST METEOROL, V107, P255, DOI 10.1016/S0168-1923(00)00241-0; TAYLOR JP, 1994, J ATMOS SCI, V51, P1298, DOI 10.1175/1520-0469(1994)051<1298:MOCS>2.0.CO;2; TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3; Warner J., 1968, J APPL METEOROL, V7, P247, DOI [DOI 10.1175/1520-0450(1968)007<0247:ARIRAW>2.0.CO;2, 10.1175/1520-0450(1968)0070247:ARIRAW2.0.CO;2]; [No title captured]	50	2731	2939	52	1630	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2119	2124		10.1126/science.1064034	http://dx.doi.org/10.1126/science.1064034			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739947				2022-12-28	WOS:000172647700039
J	[Anonymous]				[Anonymous]			Welcome SciDev.Net	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					567	567						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740509				2022-12-28	WOS:000172535600002
J	Raz, I; Elias, D; Avron, A; Tamir, M; Metzger, M; Cohen, IR				Raz, I; Elias, D; Avron, A; Tamir, M; Metzger, M; Cohen, IR			beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial	LANCET			English	Article							INSULIN; MELLITUS; CHILDREN; MOUSE; CYCLOSPORINE; THERAPY; AUTOIMMUNITY; AUTOANTIGENS; PREDNISONE; RESPONSES	Background Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic beta cells. The 60 kDa heat-shock protein (hsp60) is one of the known target self antigens. An immunomodulatory peptide from hsp60, p277, arrested beta -cell destruction and maintained insulin production in newly diabetic NOD mice. We did a randomised, double-blind, phase II study of peptide treatment in patients with newly diagnosed (<6 months) type 1 diabetes. Methods 35 patients with type 1 diabetes and basal C-peptide concentrations above 0.1 nmol/L were assigned subcutaneous injections of 1 mg p277 and 40 mg mannitol in vegetable oil (DiaPep277; n=18) at entry, 1 month, and 6 months, or three placebo injections (mannitol in vehicle; placebo; n=17). The primary endpoint was glucagon-stimulated C-peptide production. Secondary endpoints were metabolic control and T-cell autoimmunity to hsp60 and to p277 (assayed by cytokine secretion). 31 patients completed 10 months of follow-up and were included in the intention-to-treat analysis. Findings At 10 months, mean C-peptide concentrations had fallen in the placebo group (n=16) but were maintained in the DiaPep277 group (n=15; 0.26 [SD 0.11] vs 0.93 [0.35] nmol/L; p=0.039). Need for exogenous insulin was higher in the placebo than in the DiaPep277 group (0.67 [0.33] vs 0.43 [0.17] U/kg; p=0.042). Haemoglobin Alo concentrations were low (around 7%) in both groups. T-cell reactivity to hsp60 and p277 in the DiaPep277 group showed an enhanced T-helper-2 cytokine phenotype. No adverse effects were noted, Interpretation Although this study was small, treatment of newly diagnosed type 1 diabetes with DiaPep277 seems to preserve endogenous insulin production, perhaps through induction of a shift from T-helper-1 to T-helper-2 cytokines produced by the autoimmune T cells.	Weizmann Inst Sci, Dept Immunol, IL-76326 Rehovot, Israel; Hadassah Hebrew Univ, Sch Med, Dept Internal Med, Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center	Elias, D (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76326 Rehovot, Israel.		Cohen, Irun R/B-3542-2009					Ablamunits V, 1998, J AUTOIMMUN, V11, P73, DOI 10.1006/jaut.1997.0177; Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Berger B, 2000, SCAND J CLIN LAB INV, V60, P687, DOI 10.1080/00365510050216411; BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; BODEN G, 1980, ANN INTERN MED, V92, P357, DOI 10.7326/0003-4819-92-3-357; BOUGNERES PF, 1988, NEW ENGL J MED, V318, P663, DOI 10.1056/NEJM198803173181103; BOUGNERES PF, 1990, DIABETES, V39, P1264, DOI 10.2337/diabetes.39.10.1264; Chaillous L, 2000, LANCET, V356, P545, DOI 10.1016/S0140-6736(00)02579-4; Cohen I. R., 2000, TENDING ADAMS GARDEN; DUPRE J, 1988, DIABETES, V37, P1574; EISENBARTH GS, 1985, DIABETES RES CLIN EX, V2, P271; ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; ELLIOTT RB, 1981, LANCET, V2, P1; Gomes MB, 2000, BRAZ J MED BIOL RES, V33, P211, DOI 10.1590/S0100-879X2000000200008; Graves PM, 1999, DIABETES CARE, V22, P1694, DOI 10.2337/diacare.22.10.1694; LUDVIGSSON J, 1983, BRIT MED J, V286, P176, DOI 10.1136/bmj.286.6360.176; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; SILVERSTEIN J, 1988, NEW ENGL J MED, V319, P599, DOI 10.1056/NEJM198809083191002; Verge CF, 1998, DIABETES, V47, P1857, DOI 10.2337/diabetes.47.12.1857; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	27	413	452	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1749	1753		10.1016/S0140-6736(01)06801-5	http://dx.doi.org/10.1016/S0140-6736(01)06801-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734230				2022-12-28	WOS:000172385100008
J	Tattersall, MHN				Tattersall, MHN			Examining informed consent to cancer clinical trials	LANCET			English	Editorial Material							ETHICS		Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia	University of Sydney	Tattersall, MHN (corresponding author), Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia.							Albrecht TL, 1999, J CLIN ONCOL, V17, P3324, DOI 10.1200/JCO.1999.17.10.3324; Butow PN, 2000, NEW ENGL J MED, V342, P978; Edwards SJL, 1998, BRIT MED J, V317, P1209, DOI 10.1136/bmj.317.7167.1209; GROSSMAN SA, 1994, J CLIN ONCOL, V12, P2211, DOI 10.1200/JCO.1994.12.10.2211; Hall A, 2001, INFORMED CONSENT MED, P290; Jenkins VA, 1999, EUR J CANCER, V35, P1187, DOI 10.1016/S0959-8049(99)00116-1; Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139; Titus SL, 1996, J CLIN ETHIC, V7, P60	8	9	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1742	1743		10.1016/S0140-6736(01)06838-6	http://dx.doi.org/10.1016/S0140-6736(01)06838-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734224				2022-12-28	WOS:000172385100002
J	Peile, EB; Easton, GP; Olney, S				Peile, EB; Easton, GP; Olney, S			The Renaissance School of General Medicine	BRITISH MEDICAL JOURNAL			English	Article							EDUCATION		BBC Radio Sci Unit, Dept Sci, London, England; The Surgery, London SW13 0DR, England									Bourner T, 2000, INNOV EDUC TRAIN INT, V37, P2, DOI 10.1080/135580000362025; *DIPEX, 2001, DAT IND PAT EXP; ERASMUS R, 1977, MED EDUC, V31, P435; Finucane PM, 1998, MED J AUSTRALIA, V168, P445, DOI 10.5694/j.1326-5377.1998.tb139025.x; Greenhalgh T, 1999, BRIT MED J, V318, P48; Harden RM, 1998, MED TEACH, V20, P402, DOI 10.1080/01421599880472; Headrick LA, 1998, BRIT MED J, V316, P771, DOI 10.1136/bmj.316.7133.771; Horder J P, 1977, J R Coll Gen Pract, V27, P391; KNOWLES S, 1998, ADULT LEARNER DEFINI; Leathard A., 1994, GOING INTERPROFESSIO; Lilford RJ, 2001, J ROY SOC MED, V94, P559, DOI 10.1177/014107680109401102; McMahon Tim, 1999, ED ACTION RES, V7, P163, DOI DOI 10.1080/09650799900200080; Spencer JA, 1999, BRIT MED J, V318, P1280; *STAND COMM POSTGR, 1994, CONT PROF DEV DOCT D; Turnberg L, 2000, BRIT MED J, V320, P438	15	2	2	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1454	1455		10.1136/bmj.323.7327.1454	http://dx.doi.org/10.1136/bmj.323.7327.1454			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751351	Green Published			2022-12-28	WOS:000172979900010
J	Roberts, I; Hosford, T; Edwards, P				Roberts, I; Hosford, T; Edwards, P			The World Health Organization and the prevention of road injuries: phone book analysis	BRITISH MEDICAL JOURNAL			English	Article									London Sch Hyg & Trop Med, Publ Hlth Intervent Res Unit, London WC1B 3DP, England	University of London; London School of Hygiene & Tropical Medicine	Roberts, I (corresponding author), London Sch Hyg & Trop Med, Publ Hlth Intervent Res Unit, London WC1B 3DP, England.			Edwards, Phil/0000-0003-4431-8822				AD HOC... Ad Hoc Committee on Health Research Relating to Future Interventions Options, 1996, REL FUT INT OPT INV; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1485	1485		10.1136/bmj.323.7327.1485	http://dx.doi.org/10.1136/bmj.323.7327.1485			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751365	Green Published, Green Accepted			2022-12-28	WOS:000172979900026
J	Smith, O				Smith, O			Development - A SAC of crumbs and stardust	SCIENCE			English	Article																		Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a	2	0	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2498	2498		10.1126/science.294.5551.2498	http://dx.doi.org/10.1126/science.294.5551.2498			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752566				2022-12-28	WOS:000172927700043
J	Tanis, BC; van den Bosch, MAAJ; Kemmeren, JM; Cats, VM; Helmerhorst, FM; Algra, A; van der Graaf, Y; Rosendaal, FR				Tanis, BC; van den Bosch, MAAJ; Kemmeren, JM; Cats, VM; Helmerhorst, FM; Algra, A; van der Graaf, Y; Rosendaal, FR			Oral contraceptives and the risk of myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL CASE-CONTROL; ACTIVATED PROTEIN-C; V LEIDEN MUTATION; YOUNG-WOMEN; VENOUS THROMBOSIS; CARDIOVASCULAR-DISEASE; PROGESTAGEN; RESISTANCE; INCREASES	Background: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies. We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations. Methods: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence. Subjects supplied information on oral-contraceptive use and major cardiovascular risk factors. An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls. Results: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8). The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives. Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation. Conclusions: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives. The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives. The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation. (N Engl J Med 2001;345:1787-93.) Copyright (C) 2001 Massachusetts Medical Society.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Hematol, Ctr Hemostasis & Thrombosis Res, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Obstet Gynecol & Reprod Med, Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, Utrecht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University	Rosendaal, FR (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, Bldg 1,C9-P,POB 9600, NL-2300 RC Leiden, Netherlands.							BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BOYCE J, 1963, LANCET, V1, P111, DOI 10.1016/S0140-6736(63)91117-6; *CENTR BUR STAT, 1998, STAT JB 1998, P491; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; FARLEY TMM, 1995, LANCET, V346, P1582; FOTHERBY K, 1994, CONTRACEPTION, V49, P1, DOI 10.1016/0010-7824(94)90106-6; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; Herings RMC, 1999, LANCET, V354, P1478; Hunter DJ, 1997, CONTRACEPTION, V56, P373, DOI 10.1016/S0010-7824(97)00172-8; Jick H, 1996, LANCET, V347, P627, DOI 10.1016/S0140-6736(96)91334-3; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1978, JAMA-J AM MED ASSOC, V240, P2548, DOI 10.1001/jama.240.23.2548; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1996, BRIT MED J, V312, P88; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; SARTWELL PE, 1982, EPIDEMIOL REV, V4, P95, DOI 10.1093/oxfordjournals.epirev.a036253; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; Spitzer WO, 1996, BRIT MED J, V312, P83; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; THOROGOOD M, 1990, AM J OBSTET GYNECOL, V163, P274, DOI 10.1016/0002-9378(90)90567-Q; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	30	262	267	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1787	1793		10.1056/NEJMoa003216	http://dx.doi.org/10.1056/NEJMoa003216			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752354	Green Published			2022-12-28	WOS:000172794800001
J	Smits, LJM; Essed, GGM				Smits, LJM; Essed, GGM			Short interpregnancy intervals and unfavourable pregnancy outcome: role of folate depletion	LANCET			English	Article							LOW-BIRTH-WEIGHT; FOLIC-ACID SUPPLEMENTATION; PRETERM DELIVERY; IRON-DEFICIENCY; RISK; LACTATION; REDUCTION; DEFECTS; ANEMIA; WOMEN	There is no generally accepted explanation for the excess risk of adverse pregnancy outcome after short interpregnancy intervals. In this paper, we present a hypothesis that is both biologically plausible, empirically testable, and able to explain many observations. Maternal serum and erythrocyte concentrations of folate decrease from the fifth month of pregnancy onwards and remain low for a fairly long time after delivery. Women who become pregnant before folate restoration is complete have a raised risk of folate insufficiency at the time of conception and during pregnancy. As a consequence, their offspring have higher risks of neural tube defects, intrauterine growth retardation, and preterm birth. We make several predictions based on our hypothesis and suggest ways of testing them empirically. The proposed mechanism implies, among other things, that postpartum supplementation with folic acid might prevent excess risk of unfavourable pregnancy outcome in women with short interpregnancy intervals.	Univ Maastricht, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Obstet & Gynaecol, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University	Smits, LJM (corresponding author), Univ Maastricht, Dept Epidemiol, POB 616, NL-6200 MD Maastricht, Netherlands.	Luc.Smits@epid.unimaas.nl	Smits, Luc/C-5331-2008					ACKURT F, 1995, EUR J CLIN NUTR, V49, P613; Allen LH, 2000, AM J CLIN NUTR, V71, p1280S, DOI 10.1093/ajcn/71.5.1280s; Basso O, 1998, AM J OBSTET GYNECOL, V178, P259, DOI 10.1016/S0002-9378(98)80010-0; BATES CJ, 1986, HUM NUTR-CLIN NUTR, V40C, P3; BAUMSLAG N, 1970, BMJ-BRIT MED J, V1, P16, DOI 10.1136/bmj.1.5687.16; BRUINSE HW, 1995, EUR J OBSTET GYN R B, V61, P31, DOI 10.1016/0028-2243(95)02150-Q; Czeizel AE, 1996, AM J MED GENET, V62, P179, DOI 10.1002/(SICI)1096-8628(19960315)62:2<179::AID-AJMG12>3.0.CO;2-L; DOSTALOVA L, 1984, ANN NUTR METAB, V28, P385, DOI 10.1159/000176851; ERICKSON JD, 1979, LANCET, V1, P52; FEDRICK J, 1973, BMJ-BRIT MED J, V4, P753, DOI 10.1136/bmj.4.5895.753; FERRAZ EM, 1988, AM J EPIDEMIOL, V128, P1111; Ford ES, 1999, AM J CLIN NUTR, V69, P476; Fuentes-Afflick E, 2000, OBSTET GYNECOL, V95, P383, DOI 10.1016/S0029-7844(99)00583-9; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; JONGBLOET PH, 1975, AGING GAMETES, P300; KALLAN JE, 1992, SOC BIOL, V39, P231; Kallan JE, 1997, SOC BIOL, V44, P205; Khoshnood B, 1998, AM J EPIDEMIOL, V148, P798; KLEBANOFF MA, 1988, AM J PUBLIC HEALTH, V78, P667, DOI 10.2105/AJPH.78.6.667; Klebanoff MA, 1999, NEW ENGL J MED, V340, P643, DOI 10.1056/NEJM199902253400809; LUMLEY J, 2001, COCHRANE LIB; MAHOMED K, 2001, COCHRANE LIB; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; MERCHANT K, 1990, AM J CLIN NUTR, V52, P280, DOI 10.1093/ajcn/52.2.280; QVIST I, 1986, ACTA OBSTET GYN SCAN, V65, P15, DOI 10.3109/00016348609158223; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; Scholl TO, 2000, AM J CLIN NUTR, V71, p1295S, DOI 10.1093/ajcn/71.5.1295s; Shults RA, 1999, EPIDEMIOLOGY, V10, P250, DOI 10.1097/00001648-199905000-00010; SMITH AM, 1983, J PEDIATR GASTR NUTR, V2, P622, DOI 10.1097/00005176-198311000-00009; Smits LJ, 1997, EPIDEMIOLOGY, V8, P524, DOI 10.1097/00001648-199709000-00009; Tamura T, 2000, AM J CLIN NUTR, V71, P109; Todoroff K, 2000, AM J EPIDEMIOL, V151, P505, DOI 10.1093/oxfordjournals.aje.a010236; WINKVIST A, 1992, AM J PUBLIC HEALTH, V82, P691, DOI 10.2105/AJPH.82.5.691; Wohlfahrt J, 2000, EPIDEMIOLOGY, V11, P92, DOI 10.1097/00001648-200001000-00021; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820; Zhu BP, 1999, NEW ENGL J MED, V340, P589, DOI 10.1056/NEJM199902253400801	38	166	168	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2074	2077		10.1016/S0140-6736(01)07105-7	http://dx.doi.org/10.1016/S0140-6736(01)07105-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755634				2022-12-28	WOS:000172722800034
J	Catterall, MA				Catterall, MA			Physiology - A one-domain voltage-gated sodium channel in bacteria	SCIENCE			English	Editorial Material							SHAKER POTASSIUM CHANNEL; STRUCTURAL REARRANGEMENT; MOLECULAR MECHANISMS; INACTIVATION GATE; SLOW INACTIVATION; MOVEMENT; PEPTIDE; NA+; K+; SELECTIVITY		Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, MA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	wcatt@u.washington.edu						ANDERSON PAV, 1993, P NATL ACAD SCI USA, V90, P7419, DOI 10.1073/pnas.90.15.7419; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; Ogielska EM, 1995, BIOPHYS J, V69, P2449, DOI 10.1016/S0006-3495(95)80114-1; Ong BH, 2000, J GEN PHYSIOL, V116, P653, DOI 10.1085/jgp.116.5.653; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Rohl CA, 1999, BIOCHEMISTRY-US, V38, P855, DOI 10.1021/bi9823380; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	28	16	16	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2306	2308		10.1126/science.1067417	http://dx.doi.org/10.1126/science.1067417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743190				2022-12-28	WOS:000172817200034
J	Saltiel, AR; Kahn, CR				Saltiel, AR; Kahn, CR			Insulin signalling and the regulation of glucose and lipid metabolism	NATURE			English	Review							GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR SUBSTRATE 1; PROTEIN-KINASE; MICE LACKING; PHOSPHATIDYLINOSITOL 3-KINASE; TARGETED DISRUPTION; PHOSPHOINOSITIDE 3-KINASE; DIABETES-MELLITUS; TYROSINE PHOSPHORYLATION; HEPATIC GLUCONEOGENESIS	The epidemic of type 2 diabetes and impaired glucose tolerance is one of the main causes of morbidity and mortality worldwide. In both disorders, tissues such as muscle, fat and liver become less responsive or resistant to insulin. This state is also linked to other common health problems, such as obesity, polycystic ovarian disease, hyperlipidaemia, hypertension and atherosclerosis. The pathophysiology of insulin resistance involves a complex network of signalling pathways, activated by the insulin receptor, which regulates intermediary metabolism and its organization in cells. But recent studies have shown that numerous other hormones and signalling events attenuate insulin action, and are important in type 2 diabetes.	Univ Michigan, Sch Med, Dept Med, Inst Life Sci, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Saltiel, AR (corresponding author), Univ Michigan, Sch Med, Dept Med, Inst Life Sci, Ann Arbor, MI 48109 USA.	saltiel@umich.edu; c.ronald.kahn@joslin.harvard.edu	Saltiel, Alan/L-3632-2019; Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Saltiel, Alan/0000-0002-9726-9828				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Accili D, 1999, J PEDIATR ENDOCR MET, V12, P475; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Butler AA, 2001, ENDOCRINOLOGY, V142, P1685, DOI 10.1210/en.142.5.1685; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Craparo A, 1997, J BIOL CHEM, V272, P11663; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hwang JH, 2001, J APPL PHYSIOL, V90, P1267, DOI 10.1152/jappl.2001.90.4.1267; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kessler A, 2001, AM J PHYSIOL-ENDOC M, V280, pE65, DOI 10.1152/ajpendo.2001.280.1.E65; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PONS S, 1995, MOL CELL BIOL, V15, P4453; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Skorokhod A, 1999, BIOL BULL-US, V197, P198, DOI 10.2307/1542615; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Stern MP, 2000, J CLIN INVEST, V106, P323, DOI 10.1172/JCI10725; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Taylor Simeon I., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P419; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Wada T, 1999, ENDOCRINOLOGY, V140, P4585, DOI 10.1210/en.140.10.4585; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; ZIEGLER SF, 1993, ONCOGENE, V8, P663; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	100	3587	3784	48	1417	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					799	806		10.1038/414799a	http://dx.doi.org/10.1038/414799a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742412	Green Published			2022-12-28	WOS:000172676200060
J	Bradley, J; Reuter, D; Frings, S				Bradley, J; Reuter, D; Frings, S			Facilitation of calmodulin-mediated odor adaptation by cAMP-gated channel subunits	SCIENCE			English	Article							CGMP; SENSITIVITY; MODULATION; ACTIVATION; NEURONS; TRANSDUCTION; MECHANISM; RODS	Calcium (Ca(2+)) influx through Ca(2+)-permeable ion channels plays a pivotal role in a variety of neuronal signaling processes, and negative-feed back control of this influx by Ca(2+) itself is often equally important for modulation of such signaling. Negative modulation by Ca(2+) through calmodulin (CaM) on cyclic nucleotide-gated (CNG) channels underlies the adaptation of olfactory receptor neurons to odorants. We show that this feedback requires two additional subunits of the native olfactory channel, CNGA4 and CNGB1b, even though the machinery for CaM binding and modulation is present in the principal subunit CNGA2. This provides a rationale for the presence of three distinct subunits in the native olfactory channel and underscores the subtle link between the molecular make-up of an ion channel and the physiological function it subserves.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Ecole Normale Super, Neurobiol Lab, F-75230 Paris, France	Helmholtz Association; Research Center Julich; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Frings, S (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	s.frings@fz-juelich.de		Bradley, Jonathan/0000-0002-6933-1153				Bonigk W, 1999, J NEUROSCI, V19, P5332; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; Dzeja C, 1999, EMBO J, V18, P131, DOI 10.1093/emboj/18.1.131; Frings S, 2001, CELL MOL LIFE SCI, V58, P510, DOI 10.1007/PL00000876; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; Gordon SE, 2000, METHOD ENZYMOL, V315, P772; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; Hagen V, 1996, BIOCHEMISTRY-US, V35, P7762, DOI 10.1021/bi952895b; Hagen V, 2001, ANGEW CHEM INT EDIT, V40, P1046; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; Muller F, 1998, J NEUROSCI, V18, P164; Munger SD, 2001, SCIENCE, V294, P2172, DOI 10.1126/science.1063224; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; Zufall F, 2000, CHEM SENSES, V25, P473, DOI 10.1093/chemse/25.4.473	20	81	83	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2176	2178		10.1126/science.1063415	http://dx.doi.org/10.1126/science.1063415			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739960				2022-12-28	WOS:000172647700054
J	Munger, SD; Lane, AP; Zhong, HN; Leinders-Zufall, T; Yau, KW; Zufall, F; Reed, RR				Munger, SD; Lane, AP; Zhong, HN; Leinders-Zufall, T; Yau, KW; Zufall, F; Reed, RR			Central role of the CNGA4 channel subunit in Ca2+-calmodulin-dependent odor adaptation	SCIENCE			English	Article							NUCLEOTIDE-GATED CHANNEL; OLFACTORY RECEPTOR CELL; CALCIUM-CALMODULIN; ACTIVATED CHANNEL; CATION CHANNEL; BETA-SUBUNIT; NEURONS; SENSITIVITY; RAT; TRANSDUCTION	Heteromultimeric cyclic nucleotide-gated (CNG) channels play a central role in the transduction of odorant signals and subsequent adaptation. The contributions of individual subunits to native channel function in olfactory receptor neurons remain unclear. Here, we show that the targeted deletion of the mouse CNGA4 gene, which encodes a modulatory CNG subunit, results in a defect in odorant-dependent adaptation. Channels in excised membrane patches from the CNGA4 null mouse exhibited slower Ca2+-calmodulin-mediated channel desensitization. Thus, the CNGA4 subunit accelerates the Ca2+-mediated negative feedback in olfactory signaling and allows rapid adaptation in this sensory system.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Reed, RR (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Leinders-Zufall, Trese/B-4103-2009; Leinders-Zufall, Trese/S-3664-2019; Zufall, Frank/AAE-5290-2021	Leinders-Zufall, Trese/0000-0002-0678-362X; Leinders-Zufall, Trese/0000-0002-0678-362X; Zufall, Frank/0000-0002-4383-8618	NATIONAL EYE INSTITUTE [R37EY006837] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY006837, R37 EY006837-13, R37 EY006837-14] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baker H, 1999, J NEUROSCI, V19, P9313; BAKER H, 1983, J NEUROSCI, V3, P69; Bonigk W, 1999, J NEUROSCI, V19, P5332; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Bradley J, 2001, SCIENCE, V294, P2176, DOI 10.1126/science.1063415; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Dzeja C, 1999, EMBO J, V18, P131, DOI 10.1093/emboj/18.1.131; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; Leinders-Zufall T, 1998, J NEUROSCI, V18, P5630; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; Menini A, 1999, CURR OPIN NEUROBIOL, V9, P419, DOI 10.1016/S0959-4388(99)80063-4; MUNGER SD, UNPUB; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X; Zufall F, 2000, CHEM SENSES, V25, P473, DOI 10.1093/chemse/25.4.473	23	94	99	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2172	2175		10.1126/science.1063224	http://dx.doi.org/10.1126/science.1063224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739959	Green Accepted			2022-12-28	WOS:000172647700053
J	Siegert, MJ; Ellis-Evans, JC; Tranter, M; Mayer, C; Petit, JR; Salamatin, A; Priscu, JC				Siegert, MJ; Ellis-Evans, JC; Tranter, M; Mayer, C; Petit, JR; Salamatin, A; Priscu, JC			Physical, chemical and biological processes in Lake Vostok and other Antarctic subglacial lakes	NATURE			English	Review							WATER EXCHANGE; ICE-CORE; BENEATH; CONSTRAINTS; STATION; MODEL	Over 70 lakes have now been identified beneath the Antarctic ice sheet. Although water from none of the lakes has been sampled directly, analysis of lake ice frozen (accreted) to the underside of the ice sheet above Lake Vostok, the largest of these lakes, has allowed inferences to be made on lake water chemistry and has revealed small quantities of microbes. These findings suggest that Lake Vostok is an extreme, yet viable, environment for life. All subglacial lakes are subject to high pressure (similar to 350 atmospheres), low temperatures (about -3 degreesC) and permanent darkness. Any microbes present must therefore use chemical sources to power biological processes. Importantly, dissolved oxygen is available at least at the lake surface, from equilibration with air hydrates released from melting basal glacier ice. Microbes found in Lake Vostok's accreted ice are relatively modern, but the probability of ancient lake-floor sediments leads to a possibility of a very old biota at the base of subglacial lakes.	Univ Bristol, Sch Geog Sci, Bristol Glaciol Ctr, Bristol BS8 1SS, Avon, England; British Antarctic Survey, Biosci Div, Freshwater Ecol Grp, Cambridge CB3 0ET, England; Univ Innsbruck, Inst Meteorol & Geophys, A-6020 Innsbruck, Austria; CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France; Kazan VI Lenin State Univ, Dept Appl Math, Kazan 420008, Russia; Montana State Univ, Bozeman, MT 59717 USA	University of Bristol; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); Kazan Federal University; Montana State University System; Montana State University Bozeman	Siegert, MJ (corresponding author), Univ Bristol, Sch Geog Sci, Bristol Glaciol Ctr, Bristol BS8 1SS, Avon, England.	m.j.siegert@bristol.ac.uk	Salamatin, Andrey/A-9831-2016; Siegert, Martin/M-9939-2019; Tranter, Martyn/E-3722-2010; Siegert, Martin J/A-3826-2008	Salamatin, Andrey/0000-0002-5988-6024; Siegert, Martin/0000-0002-0090-4806; Tranter, Martyn/0000-0003-2071-3094; Siegert, Martin J/0000-0002-0090-4806				Abyzov SS, 1998, MICROBIOLOGY+, V67, P451; BARKOV NI, 2001, IN PRESS ARKTIKA ANT; Barrett P.J, 1996, TERRA ANTARCTICA, V3, P103; BELL RE, UNPUB NATURE; BOTTRELL SH, IN PRESS HYDROL PROC; CHRISTNER BC, IN PRESS APPL ENV MI; Dowdeswell JA, 1999, GEOL SOC AM BULL, V111, P254, DOI 10.1130/0016-7606(1999)111<0254:TDATSO>2.3.CO;2; EllisEvans JC, 1996, BIODIVERS CONSERV, V5, P1395, DOI 10.1007/BF00051985; Fang JS, 2000, DEEP-SEA RES PT I, V47, P1173, DOI 10.1016/S0967-0637(99)00080-1; Gaidos EJ, 1999, SCIENCE, V284, P1631, DOI 10.1126/science.284.5420.1631; Gorman MR, 1999, J GEOPHYS RES-SOL EA, V104, P29311, DOI 10.1029/1999JB900271; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Jean-Baptiste P, 2001, NATURE, V411, P460, DOI 10.1038/35078045; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; KENNICUTT MC, 2001, SUBGLACIAL LAKE EXPL; Killawee JA, 1998, GEOCHIM COSMOCHIM AC, V62, P3637, DOI 10.1016/S0016-7037(98)00268-3; Kuhs W.F., 2000, PHYSICS ICE CORE REC, P373; Kwok R, 2000, J GLACIOL, V46, P689, DOI 10.3189/172756500781832710; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Lee SY, 2000, ANN NY ACAD SCI, V912, P614; Lipenkov V., 2000, PHYS ICE CORE RECORD, P327; LIPENKOV VY, 2001, IN PRESS MAT ISSLED, V91; Lipenkov VYa, 2000, PROBL ARKT ANTARKT, V72, P197; Lukin V V, 2000, PROBLEMY ARKTIKI ANT, V72, P237; Mayer C, 2000, J GLACIOL, V46, P197, DOI 10.3189/172756500781832981; MAYER C, UNPUB EARTH PLANET S; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Prentice AP, 1998, GSA TODAY, V8, P1; Priscu JC, 1999, BIOSCIENCE, V49, P997, DOI 10.2307/1313733; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; ROCHSCHILD LJ, 2001, NATURE, V409, P1092; Salamatin A. N., 1998, MAT GLYATSIOL ISSLED, V85, P233; Salamatin A. N., 2000, PHYS ICE CORE RECORD, P243; Siegert MJ, 2000, EARTH PLANET SC LETT, V179, P227, DOI 10.1016/S0012-821X(00)00121-7; Siegert MJ, 2000, EARTH-SCI REV, V50, P29, DOI 10.1016/S0012-8252(99)00068-9; Siegert MJ, 2000, NATURE, V403, P643, DOI 10.1038/35001049; Siegert MJ, 1998, J GEOPHYS RES-SOL EA, V103, P10195, DOI 10.1029/98JB00390; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; Souchez R, 2000, EARTH PLANET SC LETT, V181, P529, DOI 10.1016/S0012-821X(00)00228-4; TABACCO IE, UNPUB J GLACIOL; TRANTER M, IN PRESS HYDROL PROC; UCHIDA T, 1994, J GLACIOL, V40, P79, DOI 10.3189/S0022143000003828; Williams MJM, 2001, GEOPHYS RES LETT, V28, P531, DOI 10.1029/2000GL012107; Wuest A, 2000, OCEAN MODEL, V2, P29, DOI 10.1016/S1463-5003(00)00007-X	47	146	156	6	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					603	609		10.1038/414603a	http://dx.doi.org/10.1038/414603a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740551				2022-12-28	WOS:000172535600039
J	Estevez, R; Bottger, T; Stein, V; Birkenhager, R; Otto, E; Hildebrandt, F; Jentsch, TJ				Estevez, R; Bottger, T; Stein, V; Birkenhager, R; Otto, E; Hildebrandt, F; Jentsch, TJ			Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion	NATURE			English	Article							CHLORIDE CHANNEL; RAT-KIDNEY; MUTATIONS; GENE; COTRANSPORTER; DEAFNESS; DISEASE; JERVELL; CIC-K1; FAMILY	Renal salt loss in Bartter's syndrome is caused by impaired transepithelial transport in the loop of Henle. Sodium chloride is taken up apically by the combined activity of NKCC2 (Na+-K--2Cl(-) cotransporters) and ROMK potassium channels. Chloride ions exit from the cell through basolateral ClC-Kb chloride channels. Mutations in the three corresponding genes have been identired(1-3) that correspond to Bartter's syndrome types(1-3). The gene(4) encoding the integral membrane protein barttin is mutated in a form of Bartter's syndrome that is associated with congenital deafness and renal failure. Here we show that barttin acts as an essential beta -subunit for ClC-Ka and ClC-Kb chloride channels, with which it colocalizes in basolateral membranes of renal tubules and of potassium-secreting epithelia of the inner ear. Disease-causing mutations in either ClC-Kb or barttin compromise currents through heteromeric channels. Currents can be stimulated further by mutating a proline-tyrosine (PY) motif on barttin. This work describes the first known beta -subunit for CLC chloride channels and reveals that heteromers formed by ClC-K and barttin are crucial for renal salt reabsorption and potassium recycling in the inner ear(5).	Univ Hamburg, Zentrum Mol Neurobiol ZMNH, D-20246 Hamburg, Germany; Univ Freiburg, Kinderklin, D-79106 Freiburg, Germany	University of Hamburg; University of Freiburg	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol ZMNH, Falkenried 94, D-20246 Hamburg, Germany.		Estevez, Raul/D-8610-2015; Boettger, Thomas/E-3406-2012	Estevez, Raul/0000-0003-1579-650X; Boettger, Thomas/0000-0003-4280-8449; Otto, Edgar/0000-0002-2387-9973; Stein, Valentin/0000-0003-1222-4928; Jentsch, Thomas/0000-0002-3509-2553				ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; Ando M, 2000, NEUROSCI LETT, V284, P171, DOI 10.1016/S0304-3940(00)01021-1; Baloh RW, 1998, LANCET, V352, P1841, DOI 10.1016/S0140-6736(98)05430-0; Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Dixon MJ, 1999, HUM MOL GENET, V8, P1579, DOI 10.1093/hmg/8.8.1579; Jeck N, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e5; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kobayashi K, 2001, J AM SOC NEPHROL, V12, P1327, DOI 10.1681/ASN.V1271327; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; Vandewalle A, 1997, AM J PHYSIOL-RENAL, V272, pF678, DOI 10.1152/ajprenal.1997.272.5.F678; Waldegger S, 2000, J BIOL CHEM, V275, P24527, DOI 10.1074/jbc.M001987200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	29	421	446	1	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					558	561		10.1038/35107099	http://dx.doi.org/10.1038/35107099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734858				2022-12-28	WOS:000172405900051
J	Schnyder, G; Roffi, M; Pin, R; Flammer, Y; Lange, H; Eberli, FR; Meier, B; Turi, ZG; Hess, OM				Schnyder, G; Roffi, M; Pin, R; Flammer, Y; Lange, H; Eberli, FR; Meier, B; Turi, ZG; Hess, OM			Decreased rate of coronary restenosis after lowering of plasma homocysteine levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASCULAR-DISEASE; BALLOON ANGIOPLASTY; RISK-FACTOR; ARTERY; HYPERHOMOCYST(E)INEMIA; HYPERHOMOCYSTEINEMIA; DETERMINANTS; RADIOTHERAPY; ACTIVATION; COLLAGEN	Background: We have previously demonstrated an association between elevated total plasma homocysteine levels and restenosis after percutaneous coronary angioplasty. We designed this study to evaluate the effect of lowering plasma homocysteine levels on restenosis after coronary angioplasty. Methods: A combination of folic acid (1 mg), vitamin B(sub 12) (400 microg), and pyridoxine (10 mg) - referred to as folate treatment - or placebo was administered to 205 patients (mean [+/-SD] age, 61+/-11 years) for six months after successful coronary angioplasty in a prospective, double-blind, randomized trial. The primary end point was restenosis within six months as assessed by quantitative coronary angiography. The secondary end point was a composite of major adverse cardiac events. Results: Base-line characteristics and initial angiographic results after coronary angioplasty were similar in the two study groups. Folate treatment significantly lowered plasma homocysteine levels from 11.1+/-4.3 to 7.2+/-2.4 micromol per liter (P<0.001). At follow-up, the minimal luminal diameter was significantly larger in the group assigned to folate treatment (1.72+/-0.76 vs. 1.45+/-0.88 mm, P=0.02), and the degree of stenosis was less severe (39.9+/-20.3 percent vs. 48.2+/-28.3 percent, P=0.01). The rate of restenosis was significantly lower in patients assigned to folate treatment (19.6 percent vs. 37.6 percent, P=0.01), as was the need for revascularization of the target lesion (10.8 percent vs. 22.3 percent, P=0.047). Conclusions: Treatment with a combination of folic acid, vitamin B(sub 12), and pyridoxine significantly reduces homocysteine levels and decreases the rate of restenosis and the need for revascularization of the target lesion after coronary angioplasty. This inexpensive treatment, which has minimal side effects, should be considered as adjunctive therapy for patients undergoing coronary angioplasty. (N Engl J Med 2001;345:1593-600.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif San Diego, San Diego Med Ctr, Div Cardiol, San Diego, CA 92103 USA; Univ Hosp Bern, Swiss Cardiovasc Ctr Bern, Div Cardiol, CH-3010 Bern, Switzerland; Kardiol Praxis, Bremen, Germany	University of California System; University of California San Diego; University of Bern; University Hospital of Bern	Schnyder, G (corresponding author), Univ Calif San Diego, San Diego Med Ctr, Div Cardiol, 200 W Arbor Dr, San Diego, CA 92103 USA.	g.schnyder@lycos.com						BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Briguori C, 2000, CATHETER CARDIO INTE, V50, P390, DOI 10.1002/1522-726X(200008)50:4<390::AID-CCD4>3.0.CO;2-S; Chao CL, 1999, ATHEROSCLEROSIS, V147, P379, DOI 10.1016/S0021-9150(99)00208-7; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; ELLIS SG, 1991, CIRCULATION, V83, P1905, DOI 10.1161/01.CIR.83.6.1905; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; Kiesz RS, 2001, CIRCULATION, V103, P26; KRISHNAMURTHI S, 1985, THROMB HAEMOSTASIS, V53, P337; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; Raizner AE, 2000, CIRCULATION, V102, P951, DOI 10.1161/01.CIR.102.9.951; Robinson, 1999, CIRCULATION, V99, P983; Robinson K, 1998, CIRCULATION, V97, P437; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; SCHNYDER G, IN PRESS EUR HEART J; Schynder G, 2001, AM J CARDIOL, V88, P1027, DOI 10.1016/S0002-9149(01)01983-X; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Seshadri N, 2000, MED CLIN N AM, V84, P215, DOI 10.1016/S0025-7125(05)70215-7; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Tang LL, 1998, ATHEROSCLEROSIS, V136, P169, DOI 10.1016/S0021-9150(97)00208-6; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Tawakol A, 1997, CIRCULATION, V95, P1119; TAWAKOL A, 2000, CIRCULATION, V101, pE116; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Tsuchikane E, 1999, CIRCULATION, V100, P21, DOI 10.1161/01.CIR.100.1.21; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Wang XL, 1999, ATHEROSCLEROSIS, V146, P133, DOI 10.1016/S0021-9150(99)00111-2	37	404	418	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1593	1600		10.1056/NEJMoa011364	http://dx.doi.org/10.1056/NEJMoa011364			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11757505				2022-12-28	WOS:000172383900002
J	Bennett, T				Bennett, T			Reproductive health care in the rural United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ N Carolina, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Bennett, T (corresponding author), Univ N Carolina, Chapel Hill, NC 27514 USA.							BELLANDI D, 1998, MODERN HEALTHCARE, V28, P26; Bennett T, 1997, FAM PLANN PERSPECT, V29, P256, DOI 10.2307/2953413; Bushy A, 1998, J Am Med Womens Assoc (1972), V53, P53; Dobie SA, 1998, FAM PLANN PERSPECT, V30, P139, DOI 10.2307/2991629; Heaphy PE, 2000, J RURAL HEALTH, V16, P139, DOI 10.1111/j.1748-0361.2000.tb00447.x; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P263, DOI 10.2307/2991501; Hughes D, 1989, J Rural Health, V5, P299, DOI 10.1111/j.1748-0361.1989.tb00992.x; Miller MK, 1996, J RURAL HEALTH, V12, P6, DOI 10.1111/j.1748-0361.1996.tb00768.x; ROSENBLATT RA, 1995, AM J PUBLIC HEALTH, V85, P1423, DOI 10.2105/AJPH.85.10.1423; Schwartz R M, 2000, Matern Child Health J, V4, P7, DOI 10.1023/A:1009537817450; Smugar SS, 2000, AM J PUBLIC HEALTH, V90, P1372, DOI 10.2105/AJPH.90.9.1372; White KA, 1999, STANFORD LAW REV, V51, P1703, DOI 10.2307/1229534	12	17	17	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					112	112		10.1001/jama.287.1.112	http://dx.doi.org/10.1001/jama.287.1.112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506NK	11754722	hybrid			2022-12-28	WOS:000172978500038
J	Feskanich, D; Singh, V; Willett, WC; Colditz, GA				Feskanich, D; Singh, V; Willett, WC; Colditz, GA			Vitamin A intake and hip fractures among postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINOIC ACID; HYPERVITAMINOSIS-A; CAROTENOID DATABASE; PROSPECTIVE COHORT; DIETARY-INTAKE; BETA-CAROTENE; BONE; SUPPLEMENTATION; VEGETABLES; RESORPTION	Context Ingestion of toxic amounts of vitamin A affects bone remodeling and can have adverse skeletal effects in animals. The possibility has been raised that long-term high vitamin A intake could contribute to fracture risk in humans. Objective To assess the relationship between high vitamin A intake from foods and supplements and risk of hip fracture among postmenopausal women. Design Prospective analysis begun in 1980 with 18 years of follow-up within the Nurses' Health Study. Setting General community of registered nurses within 11 US states. Participants A total of 72337 postmenopausal women aged 34 to 77 years. Main Outcome Measures Incident hip fractures resulting from low or moderate trauma, analyzed by quintiles of vitamin A intake and by use of multivitamins and vitamin A supplements, assessed at baseline and updated during follow-up. Results From 1980 to 1998, 603 incident hip fractures resulting from low or moderate trauma were identified. After controlling for confounding factors, women in the highest quintile of total vitamin A intake (greater than or equal to 3000 mug/d of retinol equivalents [RE]) had a significantly elevated relative risk (RR) of hip fracture (RR, 1.48; 95% confidence interval [CI], 1.05-2.07; P for trend =.003) compared with women in the lowest quintile of intake (<1250 <mu>g/d of RE). This increased risk was attributable primarily to retinol (RR, 1.89; 95% CI, 1.33-2.68; P for trend <.001 comparing <greater than or equal to>2000 mug/d vs <500 <mu>g/d). The association of high retinol intake with hip fracture was attenuated among women using postmenopausal estrogens. Beta carotene did not contribute significantly to fracture risk (RR, 1.22; 95% CI, 0.90-1.66; P for trend=.10 comparing greater than or equal to 6300 mug/d vs <2550 <mu>g/d). Women currently taking a specific vitamin A supplement had a nonsignificant 40% increased risk of hip fracture (RR, 1.40; 95% CI, 0.99-1.99) compared with those not taking that supplement, and, among women not taking supplemental vitamin A, retinol from food was significantly associated with fracture risk (RR, 1.69; 95% CI, 1.05-2.74; P for trend =.05 comparing greater than or equal to 1000 mug/d vs <400 <mu>g/d). Conclusions Long-term intake of a diet high in retinol may promote the development of osteoporotic hip fractures in women. The amounts of retinol in fortified foods and vitamin supplements may need to be reassessed.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Roche Vitamins Inc, Human Nutr Res, Parsippany, NJ USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Roche Holding	Feskanich, D (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	diane.feskanich@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA87969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Hijleh G, 1997, EUR J MORPHOL, V35, P327, DOI 10.1076/ejom.35.5.327.13088; [Anonymous], 1999, NUTR REV, V57, P192; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; Binkley N, 2000, NUTR REV, V58, P138, DOI 10.1111/j.1753-4887.2000.tb01848.x; CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9; CLARK L, 1971, J COMP PATHOL, V81, P365, DOI 10.1016/0021-9975(71)90024-7; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; DIGIOVANNA JJ, 1995, ARCH DERMATOL, V131, P1263, DOI 10.1001/archderm.131.11.1263; *FOOD NUTR BOARD I, IN PRESS DIET REF IN; FORSYTH KS, 1989, LIFE SCI, V45, P2149, DOI 10.1016/0024-3205(89)90081-7; FRAME B, 1974, ANN INTERN MED, V80, P44, DOI 10.7326/0003-4819-80-1-44; FREUDENHEIM JL, 1986, AM J CLIN NUTR, V44, P863, DOI 10.1093/ajcn/44.6.863; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; HEYWOOD R, 1985, TOXICOLOGY, V36, P91, DOI 10.1016/0300-483X(85)90043-5; HOUGH S, 1988, ENDOCRINOLOGY, V122, P2933, DOI 10.1210/endo-122-6-2933; Johansson S, 2001, J BONE MINER RES, V16, P1899, DOI 10.1359/jbmr.2001.16.10.1899; Kindmark A, 1998, ACTA DERM-VENEREOL, V78, P266; KOCHHAR DM, 1984, TERATOGEN CARCIN MUT, V4, P377, DOI 10.1002/tcm.1770040407; MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3; MCGUIRE J, 1987, Dermatologica (Basel), V175, P169; Melhus H, 1998, ANN INTERN MED, V129, P770, DOI 10.7326/0003-4819-129-10-199811150-00003; METZ AL, 1985, J NUTR, V115, P929, DOI 10.1093/jn/115.7.929; Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283; MOORE T, 1945, BIOCHEM J, V39, P222, DOI 10.1042/bj0390222; MOORE T, 1979, INT J VITAM NUTR RES, V49, P14; Nierenberg DW, 1997, AM J CLIN NUTR, V66, P315, DOI 10.1093/ajcn/66.2.315; Okada Natsuko, 1994, Journal of Dermatology (Tokyo), V21, P308; OREFFO ROC, 1988, J BONE MINER RES, V3, P203; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P259; Rohde CM, 1999, J NUTR, V129, P2246, DOI 10.1093/jn/129.12.2246; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; SCHEVEN BAA, 1990, BONE, V11, P53, DOI 10.1016/8756-3282(90)90072-7; SHARMAN IM, 1985, BMJ-BRIT MED J, V290, P95, DOI 10.1136/bmj.290.6462.95; SOWERS MR, 1990, J CLIN EPIDEMIOL, V43, P693, DOI 10.1016/0895-4356(90)90040-V; TOGARI A, 1991, GEN PHARMACOL, V22, P287, DOI 10.1016/0306-3623(91)90450-K; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT W, 1998, NUTR EPIDEMIOLOGY, P125; WOLBACH SB, 1947, J BONE JOINT SURG, V29, P171; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632	41	273	290	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					47	54		10.1001/jama.287.1.47	http://dx.doi.org/10.1001/jama.287.1.47			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754708	Bronze			2022-12-28	WOS:000172978500025
J	Chien, YC; Chen, JY; Liu, MY; Yang, HI; Hsu, MM; Chen, CJ; Yang, CS				Chien, YC; Chen, JY; Liu, MY; Yang, HI; Hsu, MM; Chen, CJ; Yang, CS			Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY-POSITIVE PERSONS; WUZHOU-CITY; CHINA; DNASE	Background It is probable but unproven that Epstein-Barr virus (EBV) has a role in nasopharyngeal carcinoma. We determined whether antibodies against EBV are present before the development of nasopharyngeal carcinoma. Methods A total of 9699 men were enrolled between 1984 and 1986. Blood samples were examined for IgA antibodies against EBV capsid antigen and neutralizing antibodies against EBV-specific DNase. During 131,981 person-years of follow-up, 22 pathologically confirmed new cases of nasopharyngeal carcinoma that were diagnosed more than one year after recruitment were ascertained through linkage with the National Cancer Registry of Taiwan. Results The cumulative risk of nasopharyngeal carcinoma per 100,000 person-years was 11.2 for subjects who tested positive for neither serologic marker, 45.0 for those who had one marker, and 371.0 for those who had both markers. After adjustment for age and the presence or absence of a family history of nasopharyngeal carcinoma, the relative risk of nasopharyngeal carcinoma was 32.8 for subjects with both markers (95 percent confidence interval, 7.3 to 147.2; P<0.001) and 4.0 for subjects with one marker (95 percent confidence interval, 1.6 to 10.2; P=0.003), as compared with subjects with neither marker. The longer the duration of follow-up, the greater the difference in the cumulative incidence of nasopharyngeal carcinoma between seropositive and seronegative subjects. Conclusions IgA antibodies against EBV capsid antigen and neutralizing antibodies against EBV DNase are predictive of nasopharyngeal carcinoma. (N Engl J Med 2001;345:1877-82.) Copyright (C) 2001 Massachusetts Medical Society.	Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Otolaryngol, Taipei 100, Taiwan; Natl Taipei Coll Nursing, Dept Gen Educ, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Chien, YC (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, 1 Jen Ai Rd,Sec 1, Taipei 100, Taiwan.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019; Yang, Hwai-I/A-9470-2008; Chen, Jen-Yang/D-2085-2010	Yang, Hwai-I/0000-0002-3433-942X; 				[Anonymous], 1997, IARC MONOGRAPHS EVAL, V70, P47; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHEN JY, 1987, J MED VIROL, V23, P11, DOI 10.1002/jmv.1890230103; CHEN KP, 1979, COLOR ATLAS CANC MOR; CHENG SZD, 1991, MACROMOLECULES, V24, P150, DOI 10.1021/ma00001a024; DETHE G, 1975, INT J CANCER, V16, P713, DOI 10.1002/ijc.2910160503; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1970, J NATL CANCER I, V44, P225; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; JEANNEL D, 1999, INFECT HUMAN CANC, P125; Lin Y-H, 1997, CHINESE J PUBLIC HLT, V16, P466; Liu MY, 1997, J MED VIROL, V52, P262, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;262::AID-JMV5&gt;3.0.CO;2-0; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; WARA WM, 1975, CANCER, V35, P1313, DOI 10.1002/1097-0142(197505)35:5<1313::AID-CNCR2820350510>3.0.CO;2-B; YU MC, 1996, CANC EPIDEMIOLOGY PR, P603; ZENG Y, 1985, INT J CANCER, V36, P545, DOI 10.1002/ijc.2910360505; ZENG Y, 1983, INTERVIROLOGY, V20, P190, DOI 10.1159/000149391; ZENG Y, 1982, INT J CANCER, V29, P139, DOI 10.1002/ijc.2910290204; ZONG YS, 1992, CANCER, V69, P3, DOI 10.1002/1097-0142(19920101)69:1&lt;3::AID-CNCR2820690104&gt;3.0.CO;2-7	19	322	332	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1877	1882		10.1056/NEJMoa011610	http://dx.doi.org/10.1056/NEJMoa011610			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756578				2022-12-28	WOS:000172932700003
J	Chabriere, E; Vernede, C; Guigliarelli, B; Charon, MH; Hatchikian, EC; Fontecilla-Camps, JC				Chabriere, E; Vernede, C; Guigliarelli, B; Charon, MH; Hatchikian, EC; Fontecilla-Camps, JC			Crystal structure of the free radical intermediate of pyruvate : ferredoxin oxidoreductase	SCIENCE			English	Article							PYRUVATEFERREDOXIN OXIDOREDUCTASE; PYROCOCCUS-FURIOSUS; THIAMINE ACTION; MECHANISM; ARCHAEON; CRYSTALLOGRAPHY; DIPHOSPHATE; BACTERIUM; BONDS	In anaerobic organisms, the decarboxylation of pyruvate, a crucial component of intermediary metabolism, is catalyzed by the metalloenzyme pyruvate: ferredoxin oxidoreductase (PFOR) resulting in the generation of tow potential electrons and the subsequent acetylation of coenzyme A (CoA). PFOR is the only enzyme for which a stable acetyl thiamine diphosphate (ThDP)-based free radical reaction intermediate has been identified. The 1.87 Angstrom -resolution structure of the radical form of PFOR from Desulfovibrio africanus shows that, despite currently accepted ideas, the thiazole ring of the ThDP cofactor is markedly bent, indicating a drastic reduction of its aromaticity. In addition, the bond connecting the acetyl group to ThDP is unusually tong, probably of the one-electron type already described for several cation radicals but not yet found in a biological system. Taken together, our data, along with evidence from the literature, suggest that acetyl-CoA synthesis by PFOR proceeds via a condensation mechanism involving acetyl (PFOR-based) and thiyl (CoA-based) radicals.	Univ Grenoble 1, CNRS, CEA,Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; CNRS, Inst Biol Struct & Microbiol, Unite Bioenerget & Ingn Prot, F-13402 Marseille, France; Univ Henri Poincare, Lab Cristallog & Modelisat Mat Mineraux & Biol, CNRS, Unite Mixte Rech 7036, F-54506 Vandoeuvre Les Nancy, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Fontecilla-Camps, JC (corresponding author), Univ Grenoble 1, CNRS, CEA,Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	juan@lccp.ibs.fr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLETTA G, 1990, J AM CHEM SOC, V112, P8144, DOI 10.1021/ja00178a044; BELLVILE DJ, 1985, J AM CHEM SOC, V107, P4978, DOI 10.1021/ja00303a025; BENNETT JE, 1971, T FARADAY SOC, V67, P1587, DOI 10.1039/tf9716701587; Bock AK, 1996, EUR J BIOCHEM, V237, P35, DOI 10.1111/j.1432-1033.1996.0035n.x; Bock AK, 1997, FEBS LETT, V414, P209, DOI 10.1016/S0014-5793(97)00998-8; Bouchev VF, 1999, J AM CHEM SOC, V121, P3724, DOI 10.1021/ja984057l; BRESLOW R, 1958, J AM CHEM SOC, V80, P3719, DOI 10.1021/ja01547a064; BRESLOW R, 1962, ANN NY ACAD SCI, V98, P445, DOI 10.1111/j.1749-6632.1962.tb30565.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton RD, 1996, J AM CHEM SOC, V118, P5655, DOI 10.1021/ja960378q; CAMMACK R, 1980, FEBS LETT, V118, P271, DOI 10.1016/0014-5793(80)80236-5; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; Cody GD, 2000, SCIENCE, V289, P1337, DOI 10.1126/science.289.5483.1337; DOCAMPO R, 1987, J BIOL CHEM, V262, P12417; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maslak P, 1995, J AM CHEM SOC, V117, P12380, DOI 10.1021/ja00155a002; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PIEULLE L, 1995, BBA-PROTEIN STRUCT M, V1250, P49, DOI 10.1016/0167-4838(95)00029-T; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Schneider G, 1998, BBA-PROTEIN STRUCT M, V1385, P387, DOI 10.1016/S0167-4838(98)00082-X; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; Vernede X, 1999, J APPL CRYSTALLOGR, V32, P505, DOI 10.1107/S0021889899002678; Wachtershauser G, 2000, SCIENCE, V289, P1307, DOI 10.1126/science.289.5483.1307; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	37	117	121	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2559	2563		10.1126/science.1066198	http://dx.doi.org/10.1126/science.1066198			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752578				2022-12-28	WOS:000172927700062
J	McCarl, BA; Schneider, UA				McCarl, BA; Schneider, UA			Climate change - Greenhouse gas mitigation in US agriculture and forestry	SCIENCE			English	Editorial Material									Texas A&M Univ, Dept Agr Econ, College Stn, TX 77843 USA; Iowa State Univ, Ctr Agr & Rural Dev, Ames, IA 50011 USA	Texas A&M University System; Texas A&M University College Station; Iowa State University	Schneider, UA (corresponding author), Texas A&M Univ, Dept Agr Econ, College Stn, TX 77843 USA.		McCarl, Bruce A/E-9445-2011; Schneider, Uwe A/M-7342-2016	Schneider, Uwe A/0000-0002-6833-9292				CHANG CC, 1992, AM J AGR ECON, V74, P38, DOI 10.2307/1242988; *INT PAN CLIM CHAN, 1991, CLIM CHANG IPCC SCI; Lal R., 1998, POTENTIAL US CROPLAN, P128; McCarl B. A., 2000, REV AGR ECON, V22, P134, DOI 10.1111/1058-195.t01-1-00011; Reilly J, 1999, NATURE, V401, P549, DOI 10.1038/44069; SCHNEIDER U, 2000, THESIS TEXAS A M U; Weyant JP, 1999, ENERG J, pVII	7	206	219	6	303	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2481	2482		10.1126/science.1064193	http://dx.doi.org/10.1126/science.1064193			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752558				2022-12-28	WOS:000172927700031
J	Wasserman, SA; DiNardo, S				Wasserman, SA; DiNardo, S			Development - Staying a boy forever	SCIENCE			English	Editorial Material							DROSOPHILA SPERMATOGENESIS; STEM-CELLS; PROLIFERATION; DIVISION; ENCODES; PROTEIN; KINASE; STATS; OVARY; GENE		Univ Calif San Diego, Ctr Mol Genet, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Penn, Med Ctr, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of Pennsylvania	Wasserman, SA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.			DiNardo, Stephen/0000-0003-4131-5511				BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; FULLER MT, 1993, DEV DROSOPHILA MELAN, V1, P71; Gonczy P, 1996, DEVELOPMENT, V122, P2437; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; LINDSLEY DL, 1980, SPERMATOGENESIS; Nicola NA, 2000, EXP HEMATOL, V28, P1105, DOI 10.1016/S0301-472X(00)00525-7; ROOSENRUNGE EC, 1977, PROCESS SPERMATOGENE, P78; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; Zick K, 1911, Z WISS ZOOL ABT A, V98, P430	22	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2495	2497		10.1126/science.1067914	http://dx.doi.org/10.1126/science.1067914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752564				2022-12-28	WOS:000172927700041
J	Lori, F; Lisziewicz, J				Lori, F; Lisziewicz, J			Structured treatment interruptions for the management of HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL RESPONSES; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR; IMMUNE-RESPONSES; VIRUS; DISCONTINUATION; SUPPRESSION; DYNAMICS; AIDS; CD4	Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term use, and an increasing number of patients interrupt the prescribed continuous drug therapy for short or long periods. Some patients appear to benefit from structured treatment interruptions (STI), involving monitored repetition of on-and-off cycles of drugs; however, it is unclear whether patients and/or physicians should consider STI as a treatment option. This review is intended to provide a comprehensive update on the use of STI in clinical settings, and to carefully evaluate the advantages and potential risks for patients infected with HIV. We used a MEDLINE search to find all English-language articles published January 1999 to August 2001 regarding patients treated with highly active antiretroviral therapy for whom treatment interruption was investigated. Priority was assigned to peer-reviewed sources, when available. Otherwise, abstracts from authoritative international conferences were selected through the AIDSLINE database. Results from various studies with respect to type of drug treatment, baseline patient status, number of treatment interruptions, duration of treatment and interruption, changes in viral load, and immune system parameters were analyzed. Patients could be categorized into 3 distinct clinical scenarios: acute infection, chronic drug-suppressed infection and virological drug failure. The STI approach may offer more benefit during acute infection when the patient's immune system remains nearly intact. It is yet to be determined whether STI will facilitate the long-term management of chronic infection by decreasing drug-associated toxicity and improving quality of life without jeopardizing the efficacy of the treatment. Results from randomized controlled trials and more definitive means of gauging the status of the patient's immune system must be available before this treatment method is extended beyond the research setting. Ultimately, a safer approach using therapeutic immunization or vaccination would be preferable for stimulating vigorous T-cell-mediated immune responses and control of HIV during treatment interruption.	Res Inst Genet & Human Therapy, Washington, DC 20007 USA; Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo	Lori, F (corresponding author), Res Inst Genet & Human Therapy, 2233 Wisconsin Ave NW,Suite 503, Washington, DC 20007 USA.	rightpv@fin.it		Lisziewicz, Julianna/0000-0002-3349-4495				Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Carcelain G, 2001, J VIROL, V75, P234, DOI 10.1128/JVI.75.1.234-241.2001; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1997, SCIENCE, V277, P1927, DOI 10.1126/science.277.5334.1927; Daar ES, 1998, ANN INTERN MED, V128, P827, DOI 10.7326/0003-4819-128-10-199805150-00005; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; De Boer RJ, 1998, AIDS, V12, P1567, DOI 10.1097/00002030-199813000-00002; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; DYBUL M, 2001, 8 C RETR OPP INF FEB; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAGARD C, 2001, 8 C RETR OPP INF FEB; FAUCI AS, 2001, 1 INT AIDS SOC C PAT; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JACOBSON E, 1999, 39 ANN INT C ANT AG; Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001; LISZIEWICZ J, 2001, 2 INT C VACC DEV IMM; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Lori F, 1999, J INFECT DIS, V180, P1827, DOI 10.1086/315113; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; Margolis D, 1999, J ACQ IMMUN DEF SYND, V21, P362; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; *PAN CLIN PRACT TR, 2001, GUID US ANT AG HIV I; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Papasavvas E, 2000, J INFECT DIS, V182, P766, DOI 10.1086/315748; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; PLANA M, 2001, 8 C RETR OPP INF FEB; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Soudeyns H, 1993, Semin Immunol, V5, P175, DOI 10.1006/smim.1993.1021; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	44	80	82	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2981	2987		10.1001/jama.286.23.2981	http://dx.doi.org/10.1001/jama.286.23.2981			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743839				2022-12-28	WOS:000172764500030
J	Maisel, WH; Rawn, JD; Stevenson, WG				Maisel, WH; Rawn, JD; Stevenson, WG			Atrial fibrillation after cardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Review							ARTERY-BYPASS-SURGERY; SUPRAVENTRICULAR TACHYARRHYTHMIAS; DOUBLE-BLIND; INTRAVENOUS AMIODARONE; DRUG-THERAPY; MYOCARDIAL REVASCULARIZATION; ORAL VERAPAMIL; DOSE SOTALOL; CORONARY; PREVENTION	Purpose: To review the epidemiology, mechanisms, complications, predictors, prevention, and treatment of atrial fibrillation following cardiac surgery. Data Sources: MEDLINE search of English-language reports published between 1966 and 2000 and a search of references of relevant papers. Study Selection: Clinical and basic research studies on atrial fibrillation after cardiac surgery. Data Extraction: Relevant clinical information was extracted from selected articles. Data Synthesis: Atrial fibrillation occurs in 10% to 65% of patients after cardiac surgery, usually on the second or third postoperative day. Postoperative atrial fibrillation is associated with increased morbidity and mortality and longer, more expensive hospital stays. Prophylactic use of beta -adrenergic blockers reduces the incidence of postoperative atrial fibrillation and should be administered before and after cardiac surgery to all patients without contraindication. Prophylactic amiodarone and atrial overdrive pacing should be considered in patients at high risk for postoperative atrial fibrillation (for example, patients with previous atrial fibrillation or mitral valve surgery). For patients who develop atrial fibrillation after cardiac surgery, a strategy of rhythm management or rate management should be selected. For patients who are hemodynamically unstable or highly symptomatic or who have a contraindication to anticoagulation, rhythm management with electrical cardioversion, amiodarone, or both is preferred. Treatment of the remaining patients should focus on rate control because most will spontaneously revert to sinus rhythm within 6 weeks after discharge. All patients with atrial fibrillation persisting for more than 24 to 48 hours and without contraindication should receive anticoagulation. Conclusions: Atrial fibrillation frequently complicates cardiac surgery. Many cases can be prevented with appropriate prophylactic therapy. A strategy of rhythm management for symptomatic patients and rate management for all other patients usually results in reversion to sinus rhythm within 6 weeks of discharge.	Brigham & Womens Hosp, Div Cardiovasc, Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Maisel, WH (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.	wmaisel@partners.org						Almassi GH, 1997, ANN SURG, V226, P501, DOI 10.1097/00000658-199710000-00011; ANDREWS TC, 1991, CIRCULATION, V84, P236; [Anonymous], 1989, NEW ENGL J MED, V321, P406; Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; Blommaert D, 2000, J AM COLL CARDIOL, V35, P1411, DOI 10.1016/S0735-1097(00)00608-2; BUTLER J, 1993, BRIT HEART J, V70, P56; CAMPBELL TJ, 1985, BRIT HEART J, V54, P86; CAMPBELL TJ, 1980, AUST NZ J MED, V10, P644, DOI 10.1111/j.1445-5994.1980.tb04246.x; CARETTA Q, 1991, EUR HEART J, V12, P1107, DOI 10.1093/oxfordjournals.eurheartj.a059845; CHEN XZ, 1988, ANN THORAC SURG, V46, P406, DOI 10.1016/S0003-4975(10)64653-X; Chung MK, 2000, ANN THORAC SURG, V69, P1057, DOI 10.1016/S0003-4975(99)01338-7; COCHRANE AD, 1994, EUR J CARDIO-THORAC, V8, P194, DOI 10.1016/1010-7940(94)90114-7; CONNOLLY SJ, 1987, J AM COLL CARDIOL, V10, P1145, DOI 10.1016/S0735-1097(87)80359-5; COX JL, 1993, ANN THORAC SURG, V56, P405, DOI 10.1016/0003-4975(93)90871-E; CRESWELL LL, 1993, ANN THORAC SURG, V56, P539, DOI 10.1016/0003-4975(93)90894-N; CROSBY LH, 1990, AM J CARDIOL, V66, P1520, DOI 10.1016/0002-9149(90)90550-K; Daoud EG, 1997, NEW ENGL J MED, V337, P1785, DOI 10.1056/NEJM199712183372501; Daubert JC, 2000, J AM COLL CARDIOL, V35, P1423, DOI 10.1016/S0735-1097(00)00620-3; DAVIES MJ, 1972, BRIT HEART J, V34, P520; DAVISON R, 1985, ANN THORAC SURG, V39, P336, DOI 10.1016/S0003-4975(10)62626-4; Delfaut P, 1998, J AM COLL CARDIOL, V32, P1900, DOI 10.1016/S0735-1097(98)00489-6; FANNING WJ, 1991, ANN THORAC SURG, V52, P529, DOI 10.1016/0003-4975(91)90918-G; FERRARIS VA, 1987, ANN THORAC SURG, V43, P530, DOI 10.1016/S0003-4975(10)60202-0; FORCE T, 1990, CIRCULATION, V82, P903, DOI 10.1161/01.CIR.82.3.903; Friedman PL, 1998, AM J CARDIOL, V82, p50N, DOI 10.1016/S0002-9149(98)00586-4; Frost L, 1997, INT J CARDIOL, V58, P135, DOI 10.1016/S0167-5273(96)02856-2; FROST L, 1995, J ELECTROCARDIOL, V28, P297, DOI 10.1016/S0022-0736(05)80047-0; FROST L, 1995, INT J CARDIOL, V50, P153, DOI 10.1016/0167-5273(95)93684-K; FULLER JA, 1989, J THORAC CARDIOV SUR, V97, P821; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GAVAGHAN TP, 1985, AUST NZ J MED, V15, P27, DOI 10.1111/j.1445-5994.1985.tb02726.x; GAVAGHAN TP, 1988, BRIT HEART J, V60, P497; Geelen P, 1999, AM J CARDIOL, V84, P345, DOI 10.1016/S0002-9149(99)00292-1; GENTILI C, 1992, AM HEART J, V123, P1225, DOI 10.1016/0002-8703(92)91026-W; Gerstenfeld EP, 1999, J AM COLL CARDIOL, V33, P1981, DOI 10.1016/S0735-1097(99)00115-1; GOHLKE H, 1981, CIRCULATION, V64, P22; Gold MR, 1996, AM J CARDIOL, V78, P975, DOI 10.1016/S0002-9149(96)00519-X; Gomes JA, 1999, J AM COLL CARDIOL, V34, P334, DOI 10.1016/S0735-1097(99)00213-2; Greenberg MD, 2000, J AM COLL CARDIOL, V35, P1416, DOI 10.1016/S0735-1097(00)00610-0; Guarnieri T, 1999, J AM COLL CARDIOL, V34, P343, DOI 10.1016/S0735-1097(99)00212-0; Guarnieri T, 1999, AM J CARDIOL, V84, p152R; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HANNES W, 1993, EUR J CARDIO-THORAC, V7, P239, DOI 10.1016/1010-7940(93)90211-S; HASHIMOTO K, 1991, J THORAC CARDIOV SUR, V101, P56; Hogue CW, 2000, ANN THORAC SURG, V69, P300, DOI 10.1016/S0003-4975(99)01267-9; HOHNLOSER SH, 1991, AM HEART J, V121, P89, DOI 10.1016/0002-8703(91)90960-P; INSTALLE E, 1981, J THORAC CARDIOV SUR, V81, P302; IVEY MF, 1983, J THORAC CARDIOV SUR, V85, P214; JANSSEN J, 1986, ANGIOLOGY, V37, P601, DOI 10.1177/000331978603700807; Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0; Klemperer JD, 1996, ANN THORAC SURG, V61, P1323, DOI 10.1016/0003-4975(96)00102-6; KOWEY PR, 1992, AM J CARDIOL, V69, P963, DOI 10.1016/0002-9149(92)90802-6; Kurz DJ, 1999, PACE, V22, P721, DOI 10.1111/j.1540-8159.1999.tb00535.x; LAMB RK, 1988, EUR HEART J, V9, P32; LANDYMORE RW, 1991, EUR J CARDIO-THORAC, V5, P436, DOI 10.1016/1010-7940(91)90191-L; LAUB GW, 1993, CRIT CARE MED, V21, P1474, DOI 10.1097/00003246-199310000-00014; LEITCH JW, 1990, J THORAC CARDIOV SUR, V100, P338; Maisel WH, 1997, ANN INTERN MED, V127, P281, DOI 10.7326/0003-4819-127-4-199708150-00004; MALOUF JF, 1993, EUR HEART J, V14, P1451, DOI 10.1093/eurheartj/14.11.1451; MASON JW, 1987, NEW ENGL J MED, V316, P455; Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300; MCALISTER HF, 1990, J THORAC CARDIOV SUR, V99, P911; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MENDES LA, 1995, J AM COLL CARDIOL, V25, P198, DOI 10.1016/0735-1097(94)00329-O; MERRICK AF, 1995, EUR J CARDIO-THORAC, V9, P146, DOI 10.1016/S1010-7940(05)80062-4; MULLEN JC, 1987, J THORAC CARDIOV SUR, V94, P558; Naccarelli GV, 2000, AM J CARDIOL, V85, p36D; NYSTROM U, 1993, THORAC CARDIOV SURG, V41, P34, DOI 10.1055/s-2007-1013817; Ommen SR, 1997, NEW ENGL J MED, V336, P1429, DOI 10.1056/NEJM199705153362006; Oral H, 1999, NEW ENGL J MED, V340, P1849, DOI 10.1056/NEJM199906173402401; ORLANDO JR, 1979, CHEST, V76, P521, DOI 10.1378/chest.76.5.521; Pfisterer ME, 1997, ANN THORAC SURG, V64, P1113, DOI 10.1016/S0003-4975(97)00804-7; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Redle JD, 1999, AM HEART J, V138, P144, DOI 10.1016/S0002-8703(99)70260-7; REED GL, 1988, NEW ENGL J MED, V319, P1246, DOI 10.1056/NEJM198811103191903; Reimold SC, 1998, AM J CARDIOL, V82, p66N, DOI 10.1016/S0002-9149(98)00587-6; ROFFMAN JA, 1981, ANN THORAC SURG, V31, P496, DOI 10.1016/S0003-4975(10)61337-9; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROUSOU JA, 1985, CIRCULATION, V72, P259; RUBIN DA, 1987, J THORAC CARDIOV SUR, V94, P331; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; SATO S, 1992, J THORAC CARDIOV SUR, V104, P297; SEITELBERGER R, 1994, J THORAC CARDIOV SUR, V107, P811; SMITH PK, 1983, J THORAC CARDIOV SUR, V85, P105; STEPHENSON LW, 1980, ANN THORAC SURG, V29, P113, DOI 10.1016/S0003-4975(10)61647-5; SUTTORP MJ, 1990, J THORAC CARDIOV SUR, V100, P921; SUTTORP MJ, 1991, AM J CARDIOL, V68, P1163, DOI 10.1016/0002-9149(91)90188-Q; TAYLOR GJ, 1987, AM J CARDIOL, V60, P905, DOI 10.1016/0002-9149(87)91045-9; TCHERVENKOV CI, 1983, ANN THORAC SURG, V36, P314, DOI 10.1016/S0003-4975(10)60134-8; TCHERVENKOV CI, 1983, ANN THORAC SURG, V36, P437, DOI 10.1016/S0003-4975(10)60484-5; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; TYRAS DH, 1979, J THORAC CARDIOV SUR, V77, P310; VanderLugt JT, 1999, CIRCULATION, V100, P369, DOI 10.1161/01.CIR.100.4.369; VECHT RJ, 1986, INT J CARDIOL, V13, P125, DOI 10.1016/0167-5273(86)90137-3; WAFA SS, 1989, AM J CARDIOL, V63, P1058, DOI 10.1016/0002-9149(89)90078-7; WEBER MAJ, 1990, AM J CARDIOL, V66, P1464, DOI 10.1016/0002-9149(90)90535-9; Weber UK, 1998, EUR HEART J, V19, P794; WHITE HD, 1984, CIRCULATION, V70, P479, DOI 10.1161/01.CIR.70.3.479; WILLIAMS DB, 1985, J THORAC CARDIOV SUR, V90, P592; WISTBACKA JOM, 1995, J CARDIOTHOR VASC AN, V9, P140, DOI 10.1016/S1053-0770(05)80184-3; Yilmaz AT, 1996, J CARDIAC SURG, V11, P61, DOI 10.1111/j.1540-8191.1996.tb00010.x; YOUSIF H, 1990, INT J CARDIOL, V26, P313, DOI 10.1016/0167-5273(90)90087-L; Zaman AG, 2000, CIRCULATION, V101, P1403, DOI 10.1161/01.CIR.101.12.1403	104	498	523	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1061	1073		10.7326/0003-4819-135-12-200112180-00010	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747385				2022-12-28	WOS:000172759700006
J	Lester, H				Lester, H			10-minute consultation - First episode psychosis	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Sch Med, Dept Primary Care, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lester, H (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care, Birmingham B15 2TT, W Midlands, England.								0	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1408	1408		10.1136/bmj.323.7326.1408	http://dx.doi.org/10.1136/bmj.323.7326.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744566	Bronze, Green Published			2022-12-28	WOS:000172900400019
J	Talley, NJ				Talley, NJ			Serotoninergic neuroenteric modulators	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; 5-HT3 RECEPTOR ANTAGONIST; FUNCTIONAL GASTROINTESTINAL DISORDERS; HUMAN SMALL-INTESTINE; QUALITY-OF-LIFE; HEALTHY-VOLUNTEERS; RECTAL SENSITIVITY; COLONIC TRANSIT; LONGITUDINAL MUSCLE; VISCERAL PERCEPTION	Irritable bowel syndrome (IBS) is common and can be disabling. Several drugs that modulate serotonin (5HT) and other neurotransmitters In the gut (neuroenteric modulators) have either become available or are in development, but progress has been slowed by toxicity. Blockade of 5HT(3) receptors slows colonic transit, Increases fluid absorption and Increases left colon compliance. Alosetron, a potent 5HT(3) receptor antagonist, has, in women but not in men, a clinically significant but modest therapeutic gain over placebo in the relief of abdominal pain and discomfort and bowel-habit disturbance (but not bloating) in diarrhoea-predominant IBS. However, the drug unexpectedly was associated with Ischaemic colitis and, very rarely, severe constipation-induced complications, and alosetron has been withdrawn. Cilansetron may have similar efficacy in men and women. 5HT(4) receptor stimulation results In accelerated colonic transit, and tegaserod, a partial 5HT(4) receptor agonist, has modest but clinically significant advantage over placebo in constipation-predominant IBS; the benefit seems to be confined to females. Long-term published data are lacking and safety concerns have been raised. Prucalopride, a full 5HT(4) agonist that has been promising in idiopathic chronic constipation, may also be limited by toxicity. Other 5HT receptor antagonists and agonists are under development for IBS. However, for modulators of single receptors to achieve a substantial therapeutic gain, and to do so safely, drug targets based on the pathophysiology of IBS need to be better defined.	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia	Nepean Hospital; University of Sydney	Talley, NJ (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, POB 63, Penrith, NSW 2751, Australia.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				Akehurst R, 2001, GUT, V48, P272, DOI 10.1136/gut.48.2.272; Appel S, 1997, CLIN PHARMACOL THER, V62, P546, DOI 10.1016/S0009-9236(97)90050-3; Appel-Dingemanse S, 1999, BRIT J CLIN PHARMACO, V47, P483, DOI 10.1046/j.1365-2125.1999.00936.x; Appel-Dingemanse S, 2001, EUR J CLIN PHARMACOL, V56, P889, DOI 10.1007/s002280000239; Balfour JAB, 2000, DRUGS, V59, P511; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BASSOTTI G, 1988, GUT, V29, P1173, DOI 10.1136/gut.29.9.1173; Bearcroft CP, 1998, GUT, V42, P42, DOI 10.1136/gut.42.1.42; Bearcroft CP, 1997, ALIMENT PHARM THERAP, V11, P1109, DOI 10.1046/j.1365-2036.1997.d01-1389.x; Berman S, 2000, EUR J PAIN-LONDON, V4, P157, DOI 10.1053/eujp.2000.0167; Bharucha AE, 2000, GUT, V47, P667, DOI 10.1136/gut.47.5.667; Borman RA, 1996, EUR J PHARMACOL, V309, P271, DOI 10.1016/0014-2999(96)00466-9; BORMAN RA, 1995, BRIT J PHARMACOL, V114, P1525, DOI 10.1111/j.1476-5381.1995.tb14935.x; BORMAN RA, 1993, BRIT J PHARMACOL, V110, P927, DOI 10.1111/j.1476-5381.1993.tb13901.x; BORMAN RA, 1997, ANN NY ACAD SCI, V812, P327; Bouras EP, 2001, GASTROENTEROLOGY, V120, P354, DOI 10.1053/gast.2001.21166; BRADETTE M, 1994, DIGEST DIS SCI, V39, P1171, DOI 10.1007/BF02093780; Camilleri M, 2000, LANCET, V355, P1035, DOI 10.1016/S0140-6736(00)02033-X; Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149; Camilleri M, 2001, ALIMENT PHARM THER, V15, P277, DOI 10.1046/j.1365-2036.2001.00925.x; CANN PA, 1984, DIGEST DIS SCI, V29, P239, DOI 10.1007/BF01296258; CARAS S, 2001, IN PRESS GASTROENTER; Chan J, 2000, GASTROENTEROLOGY, V118, pA184, DOI 10.1016/S0016-5085(00)82812-7; Coleman N, 2001, GUT, V48, pA44; COSTALL B, 1992, PHARMACOL TOXICOL, V70, P157, DOI 10.1111/j.1600-0773.1992.tb00448.x; D'Amato M, 1999, GASTROENTEROLOGY, V116, pA981; DAPOIGNY M, 1995, DIGEST DIS SCI, V40, P2244, DOI 10.1007/BF02209014; de Bruijn K M, 1992, Drugs, V43 Suppl 3, P11; Delvaux M, 1998, ALIMENT PHARM THER, V12, P849, DOI 10.1046/j.1365-2036.1998.00375.x; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; DROSSMAN DA, 2000, ROME, V2; Emmanuel AV, 1998, GUT, V42, P511, DOI 10.1136/gut.42.4.511; Farup PG, 1998, SCAND J GASTROENTERO, V33, P128; Friedel D, 2001, GASTROENTEROLOGY, V120, P557, DOI 10.1053/gast.2001.21177; Furness JB, 1999, AM J PHYSIOL-GASTR L, V277, pG922, DOI 10.1152/ajpgi.1999.277.5.G922; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; GORARD DA, 1994, ALIMENT PHARM THER, V8, P159; Gralnek IM, 2000, GASTROENTEROLOGY, V119, P654, DOI 10.1053/gast.2000.16484; Grider JR, 1998, GASTROENTEROLOGY, V115, P370, DOI 10.1016/S0016-5085(98)70203-3; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; Gwee KA, 1999, GUT, V44, P400, DOI 10.1136/gut.44.3.400; Hahn B, 1998, DIGEST DIS SCI, V43, P2715, DOI 10.1023/A:1026663613695; Hamm LR, 1999, AM J GASTROENTEROL, V94, P1279, DOI 10.1016/S0002-9270(99)00133-1; HAMMER J, 1993, ALIMENT PHARM THERAP, V7, P543; Hillier K., 1994, British Journal of Pharmacology, V112, p102P; Horton R, 2001, LANCET, V357, P1544, DOI 10.1016/S0140-6736(00)04776-0; Houghton LA, 2000, ALIMENT PHARM THER, V14, P775; Humphrey PPA, 1999, ALIMENT PHARM THER, V13, P31; ISGAR B, 1983, GUT, V24, P190, DOI 10.1136/gut.24.3.190; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; Jailwala J, 2000, ANN INTERN MED, V133, P136, DOI 10.7326/0003-4819-133-2-200007180-00013; Johanson JF, 2000, GASTROENTEROLOGY, V118, pA175, DOI 10.1016/S0016-5085(00)82777-8; Jones RH, 1999, ALIMENT PHARM THER, V13, P1419; Kamo I, 2000, EUR J PHARMACOL, V401, P235, DOI 10.1016/S0014-2999(00)00468-4; Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5; Koloski NA, 2000, AM J GASTROENTEROL, V95, P67; Kozlowski CM, 2000, GUT, V46, P474, DOI 10.1136/gut.46.4.474; Lecci A, 2000, NEUROPEPTIDES, V34, P303, DOI 10.1054/npep.2000.0825; LEFKOWITZ M, IN PRESS GASTROENTER; Locke GR, 2000, AM J GASTROENTEROL, V95, P157, DOI 10.1111/j.1572-0241.2000.01678.x; Malcolm A, 2000, ALIMENT PHARM THERAP, V14, P783; Mayer EA, 2001, GUT, V48, P585, DOI 10.1136/gut.48.5.585; Mertz H, 2000, GASTROENTEROLOGY, V118, P842, DOI 10.1016/S0016-5085(00)70170-3; Morris-Yates A, 1998, AM J GASTROENTEROL, V93, P1311; Muller-Lissner SA, 2001, ALIMENT PHARM THER, V15, P1655, DOI 10.1046/j.1365-2036.2001.01094.x; Munakata J, 1997, GASTROENTEROLOGY, V112, P55, DOI 10.1016/S0016-5085(97)70219-1; OWENS DM, 1995, ANN INTERN MED, V122, P107, DOI 10.7326/0003-4819-122-2-199501150-00005; Poen AC, 1999, ALIMENT PHARM THER, V13, P1493; Poynard T, 2001, ALIMENT PHARM THER, V15, P355, DOI 10.1046/j.1365-2036.2001.00937.x; Prather CM, 2000, GASTROENTEROLOGY, V118, P463, DOI 10.1016/S0016-5085(00)70251-4; Prins NH, 1999, BRIT J PHARMACOL, V128, P849, DOI 10.1038/sj.bjp.0702762; Prins NH, 2000, BRIT J PHARMACOL, V131, P927, DOI 10.1038/sj.bjp.0703615; PRIOR A, 1993, ALIMENT PHARM THERAP, V7, P175; PRIOR A, 1988, Alimentary Pharmacology and Therapeutics, V2, P535; Roarty TP, 1997, ALIMENT PHARM THER, V11, P1059, DOI 10.1046/j.1365-2036.1997.00237.x; Ruth M, 1998, ALIMENT PHARM THERAP, V12, P35; Scarpignato C, 1999, Can J Gastroenterol, V13 Suppl A, p50A; Schikowski A, 1999, GASTROENTEROLOGY, V116, pA643; Scott LJ, 1999, DRUGS, V58, P491, DOI 10.2165/00003495-199958030-00013; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; STEADMAN CJ, 1992, MAYO CLIN PROC, V67, P732, DOI 10.1016/S0025-6196(12)60797-6; Stevens JA, 1997, BEHAV RES THER, V35, P319, DOI 10.1016/S0005-7967(96)00104-0; TALLEY NJ, 1992, ALIMENT PHARM THER, V6, P273; TALLEY NJ, 1995, GASTROENTEROLOGY, V109, P1736, DOI 10.1016/0016-5085(95)90738-6; Talley NJ, 2001, ALIMENT PHARM THER, V15, P525, DOI 10.1046/j.1365-2036.2001.00941.x; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; TALLEY NJ, 1990, DIGEST DIS SCI, V35, P477, DOI 10.1007/BF01536922; TALLEY NJ, 1989, DIGEST DIS SCI, V34, P1511, DOI 10.1007/BF01537102; Talley NJ, 1996, AM J GASTROENTEROL, V91, P1675; TAM FSF, 1994, BRIT J PHARMACOL, V113, P143, DOI 10.1111/j.1476-5381.1994.tb16186.x; Thumshirn M, 2000, ALIMENT PHARM THERAP, V14, P869; TOMBLON H, 2000, GASTROENTEROLOGY, V118, pA140; Toulouse M, 2000, BRIT J PHARMACOL, V129, P193, DOI 10.1038/sj.bjp.0703040; Tuladhar BR, 1996, BRIT J PHARMACOL, V117, P1679, DOI 10.1111/j.1476-5381.1996.tb15339.x; Watson ME, 2001, AM J GASTROENTEROL, V96, P455; WESTON AP, 1993, DIGEST DIS SCI, V381, P159; ZIGHELBOIM J, 1995, DIGEST DIS SCI, V40, P819, DOI 10.1007/BF02064986	97	112	138	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2061	2068		10.1016/S0140-6736(01)07103-3	http://dx.doi.org/10.1016/S0140-6736(01)07103-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755632				2022-12-28	WOS:000172722800032
J	[Anonymous]				[Anonymous]			What are the effects of the fifth revision of the Declaration of Helsinki?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material														Tollman, Stephen/0000-0003-0744-7588					0	26	28	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 15	2001	323	7326					1417	1417						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744569				2022-12-28	WOS:000172900400022
J	Fahnestock, M; Abdalati, W; Joughin, I; Brozena, J; Gogineni, P				Fahnestock, M; Abdalati, W; Joughin, I; Brozena, J; Gogineni, P			High geothermal heat row, basal melt, and the origin of rapid ice how in central Greenland	SCIENCE			English	Article							SHEET; ELEVATION; STREAM; GISP2; MODEL; CORE; FLOW	Age-depth relations from internal layering reveal a large region of rapid basal melting in Greenland. Melt is localized at the onset of rapid ice flow in the large ice stream that drains north off the summit dome and other areas in the northeast quadrant of the ice sheet. Locally, high melt rates indicate geothermal fluxes 15 to 30 times continental background. The southern limit of melt coincides with magnetic anomalies and topography that suggest a volcanic origin.	Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20742 USA; NASA, Washington, DC 20546 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; USN, Res Lab, Washington, DC 20375 USA; Univ Kansas, Remote Sensing Lab, Lawrence, KS 66045 USA	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of Defense; United States Navy; Naval Research Laboratory; University of Kansas	Fahnestock, M (corresponding author), Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20742 USA.		Joughin, Ian R/A-2998-2008; Fahnestock, Mark/N-2678-2013; Joughin, Ian/AAR-7778-2021	Joughin, Ian R/0000-0001-6229-679X; Joughin, Ian/0000-0001-6229-679X				Alley RB, 1997, J GEOPHYS RES-OCEANS, V102, P26367, DOI 10.1029/96JC03837; BLANKENSHIP DD, 1993, NATURE, V361, P526, DOI 10.1038/361526a0; BROZENA JM, 1991, IAG S SERIES, V110, P203; BROZENA JM, 1996, THESIS U CAMBRIDGE; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; DAHLJENSEN D, 1993, NATO ASI SER, V1, P517; Dansgaard W., 1969, J GLACIOL, V8, P215, DOI [10.3189/S0022143000031208, DOI 10.3189/S0022143000031208, 10.3189/s0022143000031208]; Davis CH, 1998, SCIENCE, V279, P2086, DOI 10.1126/science.279.5359.2086; Engelhardt H, 1997, J GLACIOL, V43, P207, DOI 10.3189/S0022143000003166; FAHNESTOCK M, IN PRESS J GEOPHYS R; FOWLER AC, 1995, J GLACIOL, V41, P554, DOI 10.3189/S002214300003478X; Gogineni S, 1998, J GLACIOL, V44, P659, DOI 10.3189/S0022143000002161; Hempel L, 2000, J GLACIOL, V46, P369, DOI 10.3189/172756500781833070; Hulbe CL, 1999, J GEOPHYS RES-SOL EA, V104, P25349, DOI 10.1029/1999JB900264; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; JACOBEL RW, 1995, GEOPHYS RES LETT, V22, P587, DOI 10.1029/95GL00110; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; Joughin IR, 2000, ANN GLACIOL, V31, P141, DOI 10.3189/172756400781820002; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; NYE JF, 1957, PROC R SOC LON SER-A, V239, P113, DOI 10.1098/rspa.1957.0026; PATERSON WSB, 1994, PHYSICS GLACIERS, P215; Raymond CF, 2000, J GLACIOL, V46, P665, DOI 10.3189/172756500781832701; Scambos TA, 1998, J GLACIOL, V44, P97, DOI 10.3189/S0022143000002392; SCLATER JG, 1980, REV GEOPHYS, V18, P269, DOI 10.1029/RG018i001p00269; SMITH RB, 1994, J VOLCANOL GEOTH RES, V61, P121, DOI 10.1016/0377-0273(94)90002-7; TAYLOR KC, 1993, NATURE, V366, P549, DOI 10.1038/366549a0; Tulaczyk S, 2000, J GEOPHYS RES-SOL EA, V105, P483, DOI 10.1029/1999JB900328; Zwally HJ, 2000, ANN GLACIOL-SER, V31, P126, DOI 10.3189/172756400781820318; [No title captured]	30	196	199	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2338	2342		10.1126/science.1065370	http://dx.doi.org/10.1126/science.1065370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743197				2022-12-28	WOS:000172817200042
J	Nasmyth, K				Nasmyth, K			A prize for proliferation	CELL			English	Article							CELL-DIVISION CYCLE; MATURATION-PROMOTING FACTOR; SISTER-CHROMATID SEPARATION; GENETIC-CONTROL; FISSION YEAST; DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-BASIS; RE-REPLICATION		Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at		Nasmyth, Kim/0000-0001-7030-4403				Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BENEDEN EV, 1883, ARCH BIOL PARIS, V4, P265; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Boveri T., 1902, Verb Ges Wurzburg, Vxxxv, P67; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Chen KC, 2000, MOL BIOL CELL, V11, P369, DOI 10.1091/mbc.11.1.369; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FARMER JB, 1905, J MICROSC SCI, V48, P489; FLEMMING W, 1880, ARCH MIKROSK ANAT, V18, P151, DOI DOI 10.1007/BF02952594; FLEMMING W, 1887, ARCH MIKROSK ANAT EN, V29, P389; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hiraga S, 2000, ANNU REV GENET, V34, P21, DOI 10.1146/annurev.genet.34.1.21; IMIGER S, 1995, CELL, V81, P269; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jacob F., 1965, NOBEL LECT; JANSSENS FA, 1909, CELLULE, V25, P387; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; JOHNSON RT, 1971, BIOL REV, V46, P97, DOI 10.1111/j.1469-185X.1971.tb01180.x; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; LEE P D K, 1987, Journal of Pediatric Endocrinology, V2, P31; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan TH, 1911, J EXP ZOOL, V11, P365, DOI 10.1002/jez.1400110404; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Nigg E A, 1992, Semin Cell Biol, V3, P245, DOI 10.1016/1043-4682(92)90026-R; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; NUSSLEINVOLHARD C, 1995, NOBEL LECT; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Popper K. R., 1963, CONJECTURES REFUTAT; RAMAK R, 1850, UNTERSUCHUNGEN ENTWI; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; ROUX W, 1883, BEDEUTUNG KEMTHEILUN; RUSCH HP, 1966, J CELL BIOL, V31, P204, DOI 10.1083/jcb.31.1.204; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHLEIDEN MJ, 1838, BEITRAEGE PHYTOGENES; Schwann T., 1839, MIKROSCOPISCHE UNTER; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sutton WS, 1903, BIOL BULL-US, V4, P231, DOI 10.2307/1535741; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THURIAUX P, 1978, MOL GEN GENET, V161, P215, DOI 10.1007/BF00274190; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WALKER PMB, 1952, PROC R SOC SER B-BIO, V140, P274, DOI 10.1098/rspb.1952.0062; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEISMANN A, 1883, UEBER DIE VERERBUNG; WEISMANN A, 1887, ZAHL RICHTUNGSKOERPE; WIESCHAUS EF, 1995, NOBEL LECT; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	99	68	70	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					689	701		10.1016/S0092-8674(01)00604-3	http://dx.doi.org/10.1016/S0092-8674(01)00604-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747804	Bronze			2022-12-28	WOS:000172771800001
J	Hasbun, R; Abrahams, J; Jekel, J; Quagliarello, VJ				Hasbun, R; Abrahams, J; Jekel, J; Quagliarello, VJ			Computed tomography of the head before lumbar puncture in adults with suspected meningitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NIH STROKE SCALE; BACTERIAL-MENINGITIS; RELIABILITY; EPISODES	Background: In adults with suspected meningitis clinicians routinely order computed tomography (CT) of the head before performing a lumbar puncture. Methods: We prospectively studied 301 adults with suspected meningitis to determine whether clinical characteristics that were present before CT of the head was performed could be used to identify patients who were unlikely to have abnormalities on CT. The Modified National Institutes of Health Stroke Scale was used to identify neurologic abnormalities. Results: Of the 301 patients with suspected meningitis, 235 (78 percent) underwent CT of the head before undergoing lumbar puncture. In 56 of the 235 patients (24 percent), the results of CT were abnormal; 11 patients (5 percent) had evidence of a mass effect. The clinical features at base line that were associated with an abnormal finding on CT of the head were an age of at least 60 years, immunocompromise, a history of central nervous system disease, and a history of seizure within one week before presentation, as well as the following neurologic abnormalities: an abnormal level of consciousness, an inability to answer two consecutive questions correctly or to follow two consecutive commands, gaze palsy, abnormal visual fields, facial palsy, arm drift, leg drift, and abnormal language (e.g., aphasia). None of these features were present at base line in 96 of the 235 patients who underwent CT scanning of the head (41 percent). The CT scan was normal in 93 of these 96 patients, yielding a negative predictive value of 97 percent. Of the three misclassified patients, only one had a mild mass effect on CT, and all three subsequently underwent lumbar puncture, with no evidence of brain herniation one week later. Conclusions: In adults with suspected meningitis, clinical features can be used to identify those who are unlikely to have abnormal findings on CT of the head. (N Engl J Med 2001;345:1727-33.) Copyright (C) 2001 Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Quagliarello, VJ (corresponding author), Yale Univ, Sch Med, Dept Internal Med, LCI 800, New Haven, CT 06520 USA.							ARCHER BD, 1993, CAN MED ASSOC J, V148, P961; Aronin SI, 1998, ANN INTERN MED, V129, P862, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00004; Attia J, 1999, JAMA-J AM MED ASSOC, V282, P175, DOI 10.1001/jama.282.2.175; Baker Nancy D., 1994, Journal of Emergency Medicine, V12, P597, DOI 10.1016/0736-4679(94)90409-X; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DAUBE JR, 1993, NEUROLOGY, V43, P625; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Elmore JG, 1996, AM J MED, V100, P78, DOI 10.1016/S0002-9343(96)90015-7; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Gopal AK, 1999, ARCH INTERN MED, V159, P2681, DOI 10.1001/archinte.159.22.2681; GOWER DJ, 1987, J NEUROL NEUROSUR PS, V50, P1071, DOI 10.1136/jnnp.50.8.1071; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; TUNKEL AR, 2000, MANDELL DOUGLAS BENN, V1, P959; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; WITYK RJ, 1994, STROKE, V25, P1300	19	235	243	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1727	1733		10.1056/NEJMoa010399	http://dx.doi.org/10.1056/NEJMoa010399			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742046				2022-12-28	WOS:000172656100002
J	Laerum, H; Ellingsen, G; Faxvaag, A				Laerum, H; Ellingsen, G; Faxvaag, A			Doctors' use of electronic medical records systems in hospitals: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION-SYSTEM; PHYSICIANS; ATTITUDES; CHALLENGES	Objectives To compare the use of three electronic medical records systems by doctors in Norwegian hospitals for general clinical tasks. Design Cross sectional questionnaire survey. Semistructured telephone interviews with key staff in information technology in each hospital for details of local implementation of the systems. Setting 32 hospital units in 19 Norwegian hospitals with electronic medical records systems. Setting 32 hospital units in 19 Norwegian hospitals with electronic medical records systems. Participants 227 (72%) of 314 hospital doctors responded, equally distributed between the three electronic medical records systems. Main outcome measures Proportion of respondents who used the electronic system, calculated for each of 23 tasks; difference in proportions of users of different systems when functionality of systems was similar. Results Most tasks listed in the questionnaire (15/23) were generally covered with implemented functions in the electronic medical records systems. However, the systems were used for only 2-7 of the tasks, mainly associated with reading patient data. Respondents showed significant differences in frequency of use of the different systems for four tasks for which the systems offered equivalent functionality. The respondents scored highly in computer literacy (72.2/100), and computer use showed no correlation with respondents' age, sex, or work position. User satisfaction scores were generally positive (67.2/100), with some difference between the systems. Conclusions Doctors used electronic medical records systems for far fewer tasks than the systems supported.	NTNU, Fac Med, Dept Physiol & Biomed Engn, Kvalis Project, Trondheim, Norway; NTNU, Fac Phys Informat & Math, Dept Comp & Informat Sci, Kvalis Project, Trondheim, Norway; NTNU, Fac Med, Dept Bone & Joint Disorders, Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Laerum, H (corresponding author), Reg Hosp Trondheim, 5 Et Kreftbygget, N-7006 Trondheim, Norway.	hallvard.larum@medisin.ntnu.no	Lærum, Hallvard/AAJ-7358-2020	Lærum, Hallvard/0000-0001-7029-249X				AYDIN CE, 1991, INFORM MANAGE, V20, P119, DOI 10.1016/0378-7206(91)90049-8; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BROWN SH, 1994, J AM MED INFORM ASSN, V1, P381, DOI 10.1136/jamia.1994.95153426; CHIN HL, 1995, P ANN S COMPUT APPL, V7, P717; Cork RD, 1998, J AM MED INFORM ASSN, V5, P164, DOI 10.1136/jamia.1998.0050164; Dick R, 1995, Healthc Inform, V12, P114; DICK R, 1995, HEALTHC INFORM, V12, P114; DICK R, 1995, HEALTHC INFORM, V12, P112; DOLL WJ, 1991, MIS QUART, V15, P5, DOI 10.2307/249429; Friedman CP, 1997, EVALUATION METHODS M, P1; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; Grimson J, 1998, IEEE Trans Inf Technol Biomed, V2, P124, DOI 10.1109/4233.735777; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; HEEKS R, 1999, 9 I DEV POL MAN INF; Mitchell E, 2001, BMJ-BRIT MED J, V322, P279, DOI 10.1136/bmj.322.7281.279; Sittig DF, 1999, J AM MED INFORM ASSN, P400	16	132	132	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2001	323	7325					1344	1348						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	501ZC	11739222				2022-12-28	WOS:000172716900018
J	Merelle, ME; Griffioen, RW; Dankert-Roelse, JE				Merelle, ME; Griffioen, RW; Dankert-Roelse, JE			Cystic fibrosis presenting with intracerebral haemorrhage	LANCET			English	Editorial Material							VITAMIN-K		Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Paediat, Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Griffioen, RW (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	R.W.Griffioen@amc.uva.nl						Beker LT, 1997, J PEDIATR GASTR NUTR, V24, P512, DOI 10.1097/00005176-199705000-00003; DURIE PR, 1994, CAN MED ASSOC J, V151, P933; Greer FR, 1999, ACTA PAEDIATR, V88, P95, DOI 10.1080/080352599750029817; Uitentuis J, 1990, Ned Tijdschr Geneeskd, V134, P1642	4	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1960	1960		10.1016/S0140-6736(01)06963-X	http://dx.doi.org/10.1016/S0140-6736(01)06963-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747921				2022-12-28	WOS:000172622200014
J	Matsuda, T; Kamimura, O; Kasai, H; Harada, K; Yoshida, T; Akashi, T; Tonomura, A; Nakayama, Y; Shimoyama, J; Kishio, K; Hanaguri, T; Kitazawa, K				Matsuda, T; Kamimura, O; Kasai, H; Harada, K; Yoshida, T; Akashi, T; Tonomura, A; Nakayama, Y; Shimoyama, J; Kishio, K; Hanaguri, T; Kitazawa, K			Oscillating rows of vortices in superconductors	SCIENCE			English	Article							VORTEX LATTICES; CHAINS; LINE	Superconductors can be used as dissipation-free electrical conductors as long as vortices are pinned. Vortices in high-temperature superconductors, however, behave anomalously, reflecting the anisotropic layered structure, and can move readily, thus preventing their practical use. Specifically, in a magnetic field tilted toward the layer plane, a special vortex arrangement (chain-lattice state) is formed. Real-time observation of vortices using high-resolution Lorentz microscopy revealed that the images of chain vortices begin to disappear at a much lower temperature, T-d, than the superconducting transition temperature, T-c.. We attribute this image disappearance to the longitudinal oscillation of vortices along the chains.	Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Hitachi Instruments Serv Co Ltd, Shinjuku Ku, Tokyo 1600004, Japan; Univ Tokyo, Dept Appl Chem, Tokyo 1138656, Japan; Univ Tokyo, Sch Frontier Sci, Dept Adv Mat Sci, Tokyo 1130033, Japan	Hitachi Limited; University of Tokyo; University of Tokyo	Tonomura, A (corresponding author), Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan.	tonomura@harl.hitachi.co.jp	Kishio, Kohji/AAL-2904-2020; Hanaguri, Tetsuo/I-6710-2012	Hanaguri, Tetsuo/0000-0003-2896-0081; Kishio, Kohji/0000-0002-2759-8618; Nakayama, Yuri/0000-0003-1705-5078				ABRIKOSOV AA, 1957, SOV PHYS JETP-USSR, V5, P1174; BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BOLLE CA, 1991, PHYS REV LETT, V66, P112, DOI 10.1103/PhysRevLett.66.112; BUZDIN AI, 1990, JETP LETT+, V51, P191; CLEM JR, 1991, PHYS REV B, V43, P7837, DOI 10.1103/PhysRevB.43.7837; Floria LM, 1996, ADV PHYS, V45, P505, DOI 10.1080/00018739600101557; GRIGORIEVA IV, 1994, PHYSICA C, V235, P2705, DOI 10.1016/0921-4534(94)92573-9; HARADA K, 1992, NATURE, V360, P51, DOI 10.1038/360051a0; Kawasaki T, 2000, APPL PHYS LETT, V76, P1342, DOI 10.1063/1.126028; Koshelev AE, 1999, PHYS REV LETT, V83, P187, DOI 10.1103/PhysRevLett.83.187; Oral A, 1998, PHYS REV LETT, V80, P3610, DOI 10.1103/PhysRevLett.80.3610; Reichhardt C, 1998, PHYS REV B, V58, P6534, DOI 10.1103/PhysRevB.58.6534; Tonomura A, 2001, NATURE, V412, P620, DOI 10.1038/35088021	13	73	74	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2136	2138		10.1126/science.1065968	http://dx.doi.org/10.1126/science.1065968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739950				2022-12-28	WOS:000172647700042
J	Cross, HF; Haarbrink, M; Egerton, G; Yazdanbakhsh, M; Taylor, MJ				Cross, HF; Haarbrink, M; Egerton, G; Yazdanbakhsh, M; Taylor, MJ			Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood	LANCET			English	Article							ADVERSE REACTIONS; ONCHOCERCIASIS; INTERLEUKIN-6; BACTERIA	Wolbachia bacteria seem to have evolved as essential endosymbionts of their filarial nematode hosts. Studies in mice have suggested that these bacteria are associated with systemic inflammatory reactions to filarial chemotherapy. We took blood samples from 15 Indonesian patients before and after treatment with diethylcarbamazine far Brugia malayi infection, and recorded the severity of any post-treatment inflammatory reactions. Blood from all three patients with severe adverse reactions and from one of six with moderate reactions was positive for Wolbachia DNA 4-48 h after diethylcarbamazine treatment. We suggest that these severe inflammatory reactions are associated with the release of endosymbionts into the blood after treatment for filariasis.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands	Liverpool School of Tropical Medicine; University of Liverpool; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Taylor, MJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.		Yazdanbakhsh, Maria/AAI-3996-2020	Yazdanbakhsh, Maria/0000-0002-7666-1441; Taylor, Mark/0000-0003-3396-9275				Gardon J, 1997, LANCET, V350, P18, DOI 10.1016/S0140-6736(96)11094-1; Haarbrink M, 2000, J INFECT DIS, V182, P564, DOI 10.1086/315735; Hoerauf A, 2000, LANCET, V355, P1242, DOI 10.1016/S0140-6736(00)02095-X; Taylor MJ, 2000, J EXP MED, V191, P1429, DOI 10.1084/jem.191.8.1429; TURNER PF, 1994, J INFECT DIS, V169, P1071, DOI 10.1093/infdis/169.5.1071	5	94	99	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1873	1875		10.1016/S0140-6736(01)06899-4	http://dx.doi.org/10.1016/S0140-6736(01)06899-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741630				2022-12-28	WOS:000172463000016
J	Greiner, J; Cuby, JG; McCaughrean, MJ				Greiner, J; Cuby, JG; McCaughrean, MJ			An unusually massive stellar black hole in the Galaxy	NATURE			English	Article							X-RAY BINARIES; QUASI-PERIODIC OSCILLATIONS; MICROQUASAR GRO J1655-40; CANDIDATE GRS-1915+105; RXTE OBSERVATIONS; OUTBURST; CURVE; STAR	The X-ray source known as GRS1915+105 belongs to a group dubbed 'microquasars'(1,2). These objects are binary systems which sporadically eject matter at speeds that appear superluminal, as is the case for some quasars. GRS1915+105 is also one of only two known binary sources thought to contain a maximally spinning black hole(3). Determining the basic parameters of GRS195+105, such as the masses of the components, will help us to understand jet formation in this system, as well as providing links to other objects which exhibit jets. Using X-ray data, indirect methods(4,5) have previously been used to infer a variety of masses for the accreting compact object in the range 10-30 solar masses (M-circle dot). Here we report a direct measurement of the orbital period and mass function of GRS1915+105, which allow us to deduce a mass of 14 +/-4 M-circle dot for the black hole. Black holes with masses >5-7M(circle dot) challenge the conventional picture of black-hole formation in binary systems(6-9). Based on the mass estimate, we interpret the distinct X-ray variability of GRS1915+105 as arising from instabilities in an accretion disk that is dominated by radiation pressure, and radiating near the Eddington limit (the point where radiation pressure supports matter against gravity). Also, the mass estimate constrains most models which relate observable X-ray properties to the spin of black holes in microquasars.	European So Observ, Santiago 19, Chile; Astrophys Inst Potsdam, D-14482 Potsdam, Germany	European Southern Observatory	Greiner, J (corresponding author), Astrophys Inst Potsdam, D-14482 Potsdam, Germany.			Greiner, Jochen/0000-0002-9875-426X; McCaughrean, Mark/0000-0002-1452-5268				Brown GE, 1999, NEW ASTRON, V4, P313, DOI 10.1016/S1384-1076(99)00023-8; Brown GE, 2001, NEW ASTRON, V6, P457, DOI 10.1016/S1384-1076(01)00077-X; CUI W, 1998, APJ, V492, P53; DEVILLARD N, 2000, ECLIPSE USERS GUIDE; EGGLETON PP, 1986, MON NOT R ASTRON SOC, V220, pP13, DOI 10.1093/mnras/220.1.13P; Fender RP, 1999, MON NOT R ASTRON SOC, V304, P865, DOI 10.1046/j.1365-8711.1999.02364.x; FICH M, 1989, ASTROPHYS J, V342, P272, DOI 10.1086/167591; Greiner J, 2001, ASTRON ASTROPHYS, V373, pL37, DOI 10.1051/0004-6361:20010771; Greiner J., 1998, New Astronomy Reviews, V42, P597, DOI 10.1016/S1387-6473(98)00079-7; Greiner J, 2000, AIP CONF PROC, V522, P307, DOI 10.1063/1.1291729; GREINER J, 1996, APJ, V473, P107; Kalogera V, 1999, ASTROPHYS J, V521, P723, DOI 10.1086/307562; KALOGERA V, IN PRESS ASP C SER; McClintock JE, 2001, ASTROPHYS J, V551, pL147, DOI 10.1086/320030; Merloni A, 2000, MON NOT R ASTRON SOC, V313, P193, DOI 10.1046/j.1365-8711.2000.03226.x; Mirabel IF, 1998, NATURE, V392, P673, DOI 10.1038/33603; MIRABEL IF, 1994, NATURE, V371, P46, DOI 10.1038/371046a0; Morgan EH, 1997, ASTROPHYS J, V482, P993, DOI 10.1086/304191; Nowak MA, 1997, ASTROPHYS J, V477, pL91, DOI 10.1086/310534; Phillips SN, 1999, MON NOT R ASTRON SOC, V304, P839, DOI 10.1046/j.1365-8711.1999.02357.x; Shahbaz T, 1996, MON NOT R ASTRON SOC, V282, P977, DOI 10.1093/mnras/282.3.977; Sobczak GJ, 1999, ASTROPHYS J, V520, P776, DOI 10.1086/307474; Titarchuk L, 1998, ASTROPHYS J, V499, P315, DOI 10.1086/305642; Warmels R. H., 1991, PASP C SER, V25, P115; Watarai K, 2000, PUBL ASTRON SOC JPN, V52, P133, DOI 10.1093/pasj/52.1.133; Wellstein S, 1999, ASTRON ASTROPHYS, V350, P148; [No title captured]	29	251	254	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					522	525		10.1038/35107019	http://dx.doi.org/10.1038/35107019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734847	Green Submitted			2022-12-28	WOS:000172405900040
J	Polis, MA; Sidorov, IA; Yoder, C; Jankelevich, S; Metcalf, J; Mueller, BU; Dimitrov, MA; Pizzo, P; Yarchoan, R; Dimitrov, DS				Polis, MA; Sidorov, IA; Yoder, C; Jankelevich, S; Metcalf, J; Mueller, BU; Dimitrov, MA; Pizzo, P; Yarchoan, R; Dimitrov, DS			Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy	LANCET			English	Article							LYMPHOCYTE COUNTS; PHASE I/II; THERAPY; INFECTION; SUPPRESSION; DURATION; CHILDREN; VIRUS	Background Early assessment of antiretroviral drug efficacy is important for prevention of the emergence of drug-resistant virus and unnecessary exposure to ineffective drug regimens. Current US guidelines for changing therapy are based on measurements of plasma HIV-1 RNA concentrations 4 or 8 weeks after the start of treatment with cut-off points of 0.75 or 1.00 log, respectively. We investigated the possibility of assessing drug efficacy from measurements of plasma HIV-1 concentrations made during the first week on therapy. Methods The kinetics of virus decay in plasma during the first 12 weeks of treatment was analysed for 124 HIV-1-infected patients being treated for the first time with a protease inhibitor. Patients with a continuous decline of HIV-1 concentrations and in whom HIV-1 was either undetectable or declined by more than 1.5 log at 12 weeks were defined as good responders; the rest were poor responders. Findings The individual virus decay rate constants (k) at day 6 correlated significantly (r>0.66, p<0.0001) with changes in HIV-1 concentrations at 4, 8, and 12 weeks, and correctly predicted 84% of the responses with a cut-off value of k=0.21 per day (in log scale). Reduction in plasma HIV-1 of less than 0.72 log by day 6 after initiation of therapy predicted poor long-term responses in more than 99% of patients. Interpretation These results suggest that changes in HIV-1 concentration at day 6 after treatment initiation are major correlates of longer-term virological responses. They offer a very early measure of individual long-term responses, suggesting that treatment could be optimised after only a few days of therapy.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21701 USA; NIH, Warren Grant Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Hematol Serv, Houston, TX 77030 USA; NIH, Ctr Sci Review, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; National Institutes of Health (NIH) - USA; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Polis, MA (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10,Room 11C103, Bethesda, MD 20892 USA.			Polis, Michael/0000-0002-9151-2268; Sidorov, Igor/0000-0001-6519-4983	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000390, ZIAAI000390] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Grossman Z, 1998, IMMUNOL TODAY, V19, P528, DOI 10.1016/S0167-5699(98)01353-X; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Hoetelmans RMW, 1998, AIDS, V12, pF111, DOI 10.1097/00002030-199811000-00002; Huang W, 2001, J INFECT DIS, V183, P1455, DOI 10.1086/320192; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Lepri AC, 2001, AIDS, V15, P47, DOI 10.1097/00002030-200101050-00008; Maggiolo F, 2000, J ACQ IMMUN DEF SYND, V25, P36, DOI 10.1097/00126334-200009010-00005; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MILLER RG, 1974, BIOMETRIKA, V61, P1; Mittler J, 2001, ANTIMICROB AGENTS CH, V45, P1438, DOI 10.1128/AAC.45.5.1438-1443.2001; Mueller BU, 1998, PEDIATRICS, V102, P101, DOI 10.1542/peds.102.1.101; Mueller BU, 1998, AIDS, V12, pF191, DOI 10.1097/00002030-199815000-00004; Mueller BU, 1998, PEDIATRICS, V101, P335, DOI 10.1542/peds.101.3.335; Nelson PW, 2000, MATH BIOSCI, V163, P201, DOI 10.1016/S0025-5564(99)00055-3; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; *US HLTH HUM SERV, 2001, GUID US ANT AG HIV I; Wein LM, 1998, J THEOR BIOL, V192, P81, DOI 10.1006/jtbi.1997.0622; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; Wu H, 1999, AIDS, V13, P429, DOI 10.1097/00002030-199902250-00022; Wu HL, 1999, J INFECT DIS, V179, P799, DOI 10.1086/314670	25	85	86	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1760	1765		10.1016/S0140-6736(01)06802-7	http://dx.doi.org/10.1016/S0140-6736(01)06802-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734232				2022-12-28	WOS:000172385100010
J	Tong, AHY; Drees, B; Nardelli, G; Bader, GD; Brannetti, B; Castagnoli, L; Evangelista, M; Ferracuti, S; Nelson, B; Paoluzi, S; Quondam, M; Zucconi, A; Hogue, CWV; Fields, S; Boone, C; Cesareni, G				Tong, AHY; Drees, B; Nardelli, G; Bader, GD; Brannetti, B; Castagnoli, L; Evangelista, M; Ferracuti, S; Nelson, B; Paoluzi, S; Quondam, M; Zucconi, A; Hogue, CWV; Fields, S; Boone, C; Cesareni, G			A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules	SCIENCE			English	Article							DOMAINS; BINDING; SPECIFICITY; ACTIVATION; BEE1P	Peptide recognition modules mediate many protein-protein interactions critical for the assembly of macromolecular complexes. Complete genome sequences have revealed thousands of these domains, requiring improved methods for identifying their physiologically relevant binding partners. We have developed a strategy combining computational prediction of interactions from phage-display ligand consensus sequences with large-scale two-hybrid physical interaction tests. Application to yeast SH3 domains generated a phage-display network containing 394 interactions among 206 proteins and a two-hybrid network containing 233 interactions among 145 proteins. Graph theoretic analysis identified 59 highly likely interactions common to both networks, Las17 (Bee1), a member of the Wiskott-Aldrich Syndrome protein (WASP) family of actin-assembly proteins, showed multiple SH3 interactions, many of which were confirmed in vivo by coimmunoprecipitation.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; University of Toronto; University of Rome Tor Vergata; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Queens University - Canada; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Fields, S (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.	fields@u.washington.edu; charlie.boone@utoronto.ca; giovanni.cesareni@uniroma2.it	Hogue, Christopher W V/AAZ-3934-2020; Bader, Gary/C-1176-2009; Hogue, Christopher/B-6726-2008; Cesareni, Gianni/AAW-1382-2020	Hogue, Christopher W V/0000-0002-3107-5246; Bader, Gary/0000-0003-0185-8861; Castagnoli, Luisa/0000-0001-5283-8671; , Barbara/0000-0001-9436-0362	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR11823] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Colwill K, 1999, GENETICS, V152, P881; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Mayer BJ, 2001, J CELL SCI, V114, P1253; MOCHIDA J, COMMUNICATION; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	21	532	556	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 11	2002	295	5553					321	324		10.1126/science.1064987	http://dx.doi.org/10.1126/science.1064987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11743162				2022-12-28	WOS:000173278600048
J	Oxman, AD; Chalmers, I; Sackett, DL				Oxman, AD; Chalmers, I; Sackett, DL			A practical guide to informed consent to treatment	BRITISH MEDICAL JOURNAL			English	Article									Natl Publ Hlth Inst, Hlth Serv Res Unit, N-0403 Oslo, Norway; UK Cochrane Ctr, Oxford OX2 6HE, England; Trout Res & Educ Ctr Irish Lake, Markdale, ON N0C 1H0, Canada	Cochrane Centre	Oxman, AD (corresponding author), Natl Publ Hlth Inst, Hlth Serv Res Unit, Postboks 4404, N-0403 Oslo, Norway.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				DOYAL L, 2000, INFORMED CONSENT MED; *TROUT RES ED CTR, 2001, DO OUTC PAT TREAT RA	2	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1464	1466		10.1136/bmj.323.7327.1464	http://dx.doi.org/10.1136/bmj.323.7327.1464			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751357	Green Published			2022-12-28	WOS:000172979900017
J	Saxton, WM				Saxton, WM			Microtubules, motors, and mRNA localization mechanisms: Watching fluorescent messages move	CELL			English	Review							MESSENGER-RNA LOCALIZATION; DROSOPHILA OOCYTES; PROTEIN; TRANSPORT; COMPLEX	Proper spatial and temporal localization of specific mRNAs is pivotal in the early stages of development. To dissect the mechanisms of localization, several groups are employing advanced fluorescence microscopy to track RNA movements in live oocytes and embryos.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Saxton, WM (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.				NIGMS NIH HHS [R01 GM046295-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; Bullock SL, 2001, NATURE, V414, P611, DOI 10.1038/414611a; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; Gross SP, 2000, J CELL BIOL, V148, P945, DOI 10.1083/jcb.148.5.945; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Pankratz Michael J., 1993, P467; Riechmann V, 2001, CURR OPIN GENET DEV, V11, P374, DOI 10.1016/S0959-437X(00)00207-0; SERANO T, 1995, DEVELOPMENT, V121, P3809; Simmonds AJ, 2001, CELL, V105, P197, DOI 10.1016/S0092-8674(01)00311-7; Swan A, 1996, DEVELOPMENT, V122, P3577; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427; Wilkie GS, 2001, CELL, V105, P209, DOI 10.1016/S0092-8674(01)00312-9	17	22	22	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 14	2001	107	6					707	710		10.1016/S0092-8674(01)00602-X	http://dx.doi.org/10.1016/S0092-8674(01)00602-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747806	Bronze			2022-12-28	WOS:000172771800003
J	Beaumont, C; Jamieson, RA; Nguyen, MH; Lee, B				Beaumont, C; Jamieson, RA; Nguyen, MH; Lee, B			Himalayan tectonics explained by extrusion of a low-viscosity crustal channel coupled to focused surface denudation	NATURE			English	Article							SOUTHERN TIBET; LANGTANG VALLEY; EVOLUTION; DEFORMATION; CRYSTALLINE; SEQUENCE; BELT	Recent interpretations of Himalayan-Tibetan tectonics have proposed that channel flow in the middle to lower crust can explain outward growth of the Tibetan plateau(1-3), and that ductile extrusion of high-grade metamorphic rocks between coeval normal- and thrust-sense shear zones can explain exhumation of the Greater Himalayan sequence(4-7). Here we use coupled thermal-mechanical numerical models to show that these two processes-channel flow and ductile extrusion-may be dynamically linked through the effects of surface denudation focused at the edge of a plateau that is underlain by low-viscosity material. Our models provide an internally self-consistent explanation for many observed features of the Himalayan-Tibetan system(8-10).	Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada; Dalhousie Univ, Dept Earth Sci, Halifax, NS B3H 3J5, Canada	Dalhousie University; Dalhousie University	Beaumont, C (corresponding author), Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada.	Chris.Beaumont@Dal.Ca						BEAUMONT C, SLAV NO CORD LITH EV, P112; Burchfiel B. C., 1992, SPEC PAP GEOL SOC AM, V269; Clark MK, 2000, GEOLOGY, V28, P703, DOI 10.1130/0091-7613(2000)28<703:TOBTEM>2.0.CO;2; DeCelles PG, 2000, SCIENCE, V288, P497, DOI 10.1126/science.288.5465.497; DeCelles PG, 2001, TECTONICS, V20, P487, DOI 10.1029/2000TC001226; FRANCELANORD C, 1993, GEOL SOC SP, V74, P603, DOI 10.1144/GSL.SP.1993.074.01.40; Fraser G, 2000, J METAMORPH GEOL, V18, P665, DOI 10.1046/j.1525-1314.2000.00283.x; GLEASON GC, 1995, TECTONOPHYSICS, V247, P1, DOI 10.1016/0040-1951(95)00011-B; Grujic D, 1996, TECTONOPHYSICS, V260, P21, DOI 10.1016/0040-1951(96)00074-1; GRUJIC D, IN PRESS EARTH PLANE; Harrison TM, 1997, EARTH PLANET SC LETT, V146, pE1, DOI 10.1016/S0012-821X(96)00215-4; Hauck ML, 1998, TECTONICS, V17, P481, DOI 10.1029/98TC01314; Hodges KV, 1996, TECTONICS, V15, P1264, DOI 10.1029/96TC01791; Hodges KV, 2000, GEOL SOC AM BULL, V112, P324, DOI 10.1130/0016-7606(2000)112<324:TOTHAS>2.0.CO;2; INGER S, 1992, J METAMORPH GEOL, V10, P439, DOI 10.1111/j.1525-1314.1992.tb00095.x; Jamieson RA, 2002, J METAMORPH GEOL, V20, P9, DOI 10.1046/j.0263-4929.2001.00357.x; Lee J, 2000, TECTONICS, V19, P872, DOI 10.1029/1999TC001147; MACFARLANE AM, 1995, J METAMORPH GEOL, V13, P595, DOI 10.1111/j.1525-1314.1995.tb00245.x; Mackwell SJ, 1998, J GEOPHYS RES-SOL EA, V103, P975, DOI 10.1029/97JB02671; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Parrish RR, 1996, GEOL SOC AM BULL, V108, P904, DOI 10.1130/0016-7606(1996)108<0904:ICOTAA>2.3.CO;2; Royden L, 1996, J GEOPHYS RES-SOL EA, V101, P17679, DOI 10.1029/96JB00951; Searle MP, 1997, J GEOL, V105, P295, DOI 10.1086/515924; Shen F, 2001, J GEOPHYS RES-SOL EA, V106, P6793, DOI 10.1029/2000JB900389; Vannay JC, 2001, GEOL MAG, V138, P253, DOI 10.1017/S0016756801005313; WHITE NM, IN PRESS EARTH PLANE; WILLETT S, 1993, GEOLOGY, V21, P371, DOI 10.1130/0091-7613(1993)021<0371:MMFTTO>2.3.CO;2; Wu CD, 1998, TECTONICS, V17, P28, DOI 10.1029/97TC03386; Zeitler PK, 2001, TECTONICS, V20, P712, DOI 10.1029/2000TC001243	30	1261	1386	16	305	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					738	742		10.1038/414738a	http://dx.doi.org/10.1038/414738a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742396				2022-12-28	WOS:000172676200044
J	Wiersma, DS; Cavalieri, S				Wiersma, DS; Cavalieri, S			Light emission - A temperature-tunable random laser	NATURE			English	Article							SCATTERING MEDIUM; GENERATION; MEDIA		Univ Florence, European Lab Nonlinear Spect, Dipartimento Fis, I-50125 Florence, Italy; Ist Nazl Fis Mat, I-50125 Florence, Italy	University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Wiersma, DS (corresponding author), Univ Florence, European Lab Nonlinear Spect, Dipartimento Fis, Largo E Fermi 2, I-50125 Florence, Italy.	wiersma@lens.unifi.it	wiersma, diederik/ABG-6454-2021	wiersma, diederik/0000-0001-8150-7425				Beenakker CWJ, 1998, PHYS REV LETT, V81, P1829, DOI 10.1103/PhysRevLett.81.1829; Berger GA, 1997, PHYS REV E, V56, P6118, DOI 10.1103/PhysRevE.56.6118; Cao H, 1999, PHYS REV LETT, V82, P2278, DOI 10.1103/PhysRevLett.82.2278; Drzaic P. S., 1995, LIQUID CRYSTAL DISPE, DOI 10.1142/2337; GOUEDARD C, 1993, J OPT SOC AM B, V10, P2358, DOI 10.1364/JOSAB.10.002358; John S, 1996, PHYS REV A, V54, P3642, DOI 10.1103/PhysRevA.54.3642; LAWANDY NM, 1994, NATURE, V368, P436, DOI 10.1038/368436a0; LETOKHOV VS, 1968, SOV PHYS JETP-USSR, V26, P835; Sheng P., 1995, INTRO WAVE SCATTERIN, Vsecond; Wiersma DS, 1996, PHYS REV E, V54, P4256, DOI 10.1103/PhysRevE.54.4256; Wiersma DS, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.144208; XUNYA J, 2000, PHYS REV LETT, V85, P70; ZYUZIN AY, 1995, PHYS REV E, V51, P5274, DOI 10.1103/PhysRevE.51.5274	13	301	305	3	124	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					708	709		10.1038/414708a	http://dx.doi.org/10.1038/414708a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742383				2022-12-28	WOS:000172676200031
J	Cattaneo, A; Buzzetti, R				Cattaneo, A; Buzzetti, R		Breastfeeding Res Training Working	Quality improvement report - Effect on rates of breast feeding of training for the Baby Friendly Hospital Initiative	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEER COUNSELORS; KNOWLEDGE; ATTITUDES; PROMOTION; DURATION; INTERVENTION; PREVALENCE; INCREASE	Problem Breastfeeding rates and related hospital practices need improvement in Italy and elsewhere. Training of staff is necessary, but its effectiveness needs assessment. Context Eight hospitals in different regions of Italy. Design Controlled, non-randomised study. Data collected in three phases. Training after the first phase ill group 1 hospitals and after the second phase in group 2. Strategies for change Training of trainers and Subsequent training Of health workers with a slightly adapted version of the 18 hour Unicef Course Oil breastfeeding management and promotion. Key measures for improvement Hospital practices, knowledge of 571 health workers, and breastfeeding rates at discharge, three, and six months in 2669 mother and baby pairs. Effects of change After training hospitals improved their compliance with the "ten steps to successful breast feeding," from an average of 2.4 steps at phase one to 7.7 at phase three. Knowledge scores of health professionals increased from 0.41 to 0.72 in group 1 (training after phase one) and from 0.53 to 0.75 in group 2 (after phase two). The rate of exclusive breast feeding at discharge increased significantly after training: 41% to 77% in group 1 mid 23% to 73% in group 2, as did the rates of full (exclusive plus predominant) breast feeding at three months (37% to 50% in group 1 v 40% to 59% in group 2) and any breast feeding at six months (43% to 62% in group 1 v 41% to 64% in group 2 ). Lessons learnt Training for at least three days with a course including practical sessions and counselling skills is effective in changing hospital practices, knowledge of health workers, and breastfeeding rates.	Ist Infanzia, Unit Hlth Serv Res & Int Cooperat, I-34137 Trieste, Italy; CEVEAS, Modena, Italy		Cattaneo, A (corresponding author), Ist Infanzia, Unit Hlth Serv Res & Int Cooperat, Via Istria 65-1, I-34137 Trieste, Italy.	cattanco@burlo.trieste.it	Cattaneo, Adriano/G-6685-2011; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				Aarts C, 2000, INT J EPIDEMIOL, V29, P1041, DOI 10.1093/ije/29.6.1041; Armitage P., 2001, STAT METHODS MED RES; Becker G E, 1992, J Hum Lact, V8, P137, DOI 10.1177/089033449200800318; BRADLEY JE, 1992, J TROP PEDIATRICS, V38, P228, DOI 10.1093/tropej/38.5.228; Cattaneo A, 2000, ACTA PAEDIATR, V89, P88, DOI 10.1080/080352500750029130; DELSANTO M, 1998, QUADERNI ASS CULTURA, V4, P10; Division of Diarrhoeal and Acute Respiratory Disease Control, 1991, IND ASS BREASTF PRAC; FREED GL, 1995, JAMA-J AM MED ASSOC, V273, P472, DOI 10.1001/jama.273.6.472; FREED GL, 1995, PEDIATRICS, V96, P490; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; Henderson L, 2000, BRIT MED J, V321, P1196, DOI 10.1136/bmj.321.7270.1196; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; NHS Center for Reviews and Dissemination, 2000, EFFECTIVE HLTH CARE, V6, P1; PRASAD B, 1995, BRIT MED J, V310, P621, DOI 10.1136/bmj.310.6980.621; Radford A, 2001, BRIT MED J, V322, P555, DOI 10.1136/bmj.322.7285.555; Rea MF, 1999, B WORLD HEALTH ORGAN, V77, P492; Schafer E, 1998, BIRTH-ISS PERINAT C, V25, P101, DOI 10.1046/j.1523-536x.1998.00101.x; Schanler RJ, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e35; SIKORSKI J, 2000, COCHRANE DATABASE SY; Taylor A, 1998, BMJ-BRIT MED J, V316, P1117, DOI 10.1136/bmj.316.7138.1117; *UNICEF, 1999, BAB FRIENDL HOSP INT; UNICEF, 1993, BREASTF MAN PROM BAB; Valdes V, 1995, J Hum Lact, V11, P185, DOI 10.1177/089033449501100318; WESTPHAL MF, 1995, B WORLD HEALTH ORGAN, V73, P461; WHO: Global Data Bank on Breastfeeding, 1996, GLOB DAT BANK BREAST; *WHO UNICEF, 1993, IND ASS HLTH FAC PRA; WHO & UNICEF (World Health Organization & UNICEF), 1993, BREASTF COUNS TRAIN; WILLIAMS EL, 1995, AM J PREV MED, V11, P26, DOI 10.1016/S0749-3797(18)30497-5; World Health Organization, 1998, COMPL FEED YOUNG CHI; Wright A, 1996, PEDIATRICS, V97, P669	32	135	141	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2001	323	7325					1358	1362		10.1136/bmj.323.7325.1358	http://dx.doi.org/10.1136/bmj.323.7325.1358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739226	Green Published			2022-12-28	WOS:000172716900022
J	Spence, D				Spence, D			Uses of error: Knowledge gaps	LANCET			English	Editorial Material									Siebens Drake Roberts Res Inst, London, ON N6G 2V2, Canada		Spence, D (corresponding author), Siebens Drake Roberts Res Inst, London, ON N6G 2V2, Canada.		Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098					0	1	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1934	1934		10.1016/S0140-6736(01)06958-6	http://dx.doi.org/10.1016/S0140-6736(01)06958-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747916				2022-12-28	WOS:000172622200009
J	Bond, G; Kromer, B; Beer, J; Muscheler, R; Evans, MN; Showers, W; Hoffmann, S; Lotti-Bond, R; Hajdas, I; Bonani, G				Bond, G; Kromer, B; Beer, J; Muscheler, R; Evans, MN; Showers, W; Hoffmann, S; Lotti-Bond, R; Hajdas, I; Bonani, G			Persistent solar influence on north Atlantic climate during the Holocene	SCIENCE			English	Article							YOUNGER DRYAS; ICE CORE; ATMOSPHERIC C-14; DIFFUSION-MODEL; BERYLLIUM 10; OCEAN; GREENLAND; VARIABILITY; TEMPERATURE; CIRCULATION	Surface winds and surface ocean hydrography in the subpolar North Atlantic appear to have been influenced by variations in solar output through the entire Holocene. The evidence comes from a close correlation between inferred changes in production rates of the cosmogenic nuclides carbon-14 and beryllium-10 and centennial to millennial. time scale changes in proxies of drift ice measured in deep-sea sediment cores. A solar forcing mechanism therefore may underlie at least the Holocene segment of the North Atlantic's "1500-year" cycle. The surface hydrographic changes may have affected production of North Atlantic Deep Water, potentially providing an additional mechanism for amplifying the solar signals and transmitting them globally.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Heidelberg Acad Sci, Inst Environm Phys, INF 229, D-69120 Heidelberg, Germany; Eidgenoss Anstalt Wasserversorgung Abwasswerreini, CH-8600 Dubendorf, Switzerland; Univ Arizona, Lab Tree Ring Res, Tucson, AZ 85721 USA; N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27695 USA; ITP ETH Honggerberg, Accelerator Mass Spectrometry Lab 14C, CH-8093 Zurich, Switzerland	Columbia University; Ruprecht Karls University Heidelberg; University of Arizona; University of North Carolina; North Carolina State University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bond, G (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Route 9W, Palisades, NY 10964 USA.	gcb@ldeo.columbia.edu	Hajdas, Irka/C-6696-2011	Hajdas, Irka/0000-0003-2373-2725; Muscheler, Raimund/0000-0003-2772-3631				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; Bianchi GG, 1999, NATURE, V397, P515, DOI 10.1038/17362; BJORCK S, IN PRESS GEOLOGY; Black DE, 1999, SCIENCE, V286, P1709, DOI 10.1126/science.286.5445.1709; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Bond GC, 1999, GEOPH MONOG SERIES, V112, P35; Broecker WS, 1999, SCIENCE, V286, P1132, DOI 10.1126/science.286.5442.1132; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; Chapman MR, 1999, GEOLOGY, V27, P795, DOI 10.1130/0091-7613(1999)027<0795:GIVFNA>2.3.CO;2; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; DENTON G H, 1973, Quaternary Research (Orlando), V3, P155, DOI 10.1016/0033-5894(73)90040-9; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; DUPLESSY JC, 1992, NATO SERIES, V1, P201; EPSTEIN S, 1953, GEOL SOC AM BULL, V64, P1315, DOI 10.1130/0016-7606(1953)64[1315:RCITS]2.0.CO;2; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Fischer H, 1998, GEOPHYS RES LETT, V25, P1749, DOI 10.1029/98GL01177; FRIEDRICH M, 1999, QUAT INT, V61; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Holland MM, 2001, J CLIMATE, V14, P656, DOI 10.1175/1520-0442(2001)014<0656:TROIOI>2.0.CO;2; Hurrell JW, 2001, SCIENCE, V291, P603, DOI 10.1126/science.1058761; Isarin RFB, 1999, QUATERNARY RES, V51, P158, DOI 10.1006/qres.1998.2023; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; KEIGWIN LD, 1991, J GEOPHYS RES-OCEANS, V96, P16811, DOI 10.1029/91JC01624; Keigwin LD, 1999, SCIENCE, V286, P520, DOI 10.1126/science.286.5439.520; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; Krahmann G, 2001, J PHYS OCEANOGR, V31, P1287, DOI 10.1175/1520-0485(2001)031<1287:FAPOTA>2.0.CO;2; Kukla G, 1997, QUATERNARY SCI REV, V16, P605, DOI 10.1016/S0277-3791(96)00114-X; KUSHNIR Y, 1994, J CLIMATE, V7, P141, DOI 10.1175/1520-0442(1994)007<0141:IVINAS>2.0.CO;2; Kwok R, 1999, J GEOPHYS RES-OCEANS, V104, P5177, DOI 10.1029/1998JC900103; Labeyrie L, 1999, GEOPH MONOG SERIES, V112, P77; Lamb H.H., 1995, CLIMATE HIST MODERN, P211; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Lean J, 1999, J ATMOS SOL-TERR PHY, V61, P25, DOI 10.1016/S1364-6826(98)00113-8; LEVITUS S, 1992, 18 NAT OC DAT CTR; Marchal O, 2001, EARTH PLANET SC LETT, V185, P383, DOI 10.1016/S0012-821X(00)00383-6; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; Mayewski PA, 1997, J GEOPHYS RES-OCEANS, V102, P26345, DOI 10.1029/96JC03365; MCMANUS J, IN PRESS QUAT RES; MCMANUS JF, 1994, NATURE, V371, P326, DOI 10.1038/371326a0; Muscheler R, 2000, NATURE, V408, P567, DOI 10.1038/35046041; Neff U, 2001, NATURE, V411, P290, DOI 10.1038/35077048; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; OESCHGER H, 1975, TELLUS, V27, P168, DOI 10.1111/j.2153-3490.1975.tb01671.x; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; PFLAUMANN U, UNPUB PALEOCEANOGRAP; Raisbeck G. M., 1998, MINERAL MAG A, V62A, P1228; Rind D., 1998, J GEOPHYS RES, V103, P5493; RUDELS B, 1995, PHILOS T R SOC A, V352, P287, DOI 10.1098/rsta.1995.0071; Schmidt G. A., 1999, GLOBAL SEAWATER OXYG; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; SIEGENTHALER U, 1983, J GEOPHYS RES-OCEANS, V88, P3599, DOI 10.1029/JC088iC06p03599; STUIVER M, 1961, J GEOPHYS RES, V66, P273, DOI 10.1029/JZ066i001p00273; STUIVER M, 1980, SCIENCE, V207, P11, DOI 10.1126/science.207.4426.11; STUIVER M, 1989, NATURE, V338, P405, DOI [10.1038/338405a0, 10.1038/286868a0]; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; VanGeel B, 1996, J QUATERNARY SCI, V11, P451, DOI 10.1002/(SICI)1099-1417(199611/12)11:6<451::AID-JQS275>3.0.CO;2-9; VAUTARD R, 1992, PHYSICA D, V58, P95, DOI 10.1016/0167-2789(92)90103-T; Verschuren D, 2000, NATURE, V403, P410, DOI 10.1038/35000179; Visbeck M, 1998, GEOPHYS RES LETT, V25, P4521, DOI 10.1029/1998GL900162; Waelbroeck C, 1998, PALEOCEANOGRAPHY, V13, P272, DOI 10.1029/98PA00071; WEINELT M, COMMUNICATION; WEINELT M, 1995, YOUNGER DRYAS, P109; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265	69	2249	2455	13	500	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2130	2136		10.1126/science.1065680	http://dx.doi.org/10.1126/science.1065680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739949				2022-12-28	WOS:000172647700041
J	Cohn, JN; Tognoni, G				Cohn, JN; Tognoni, G		Valsartan Heart Failure Trial Inve	A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; MORTALITY; MORBIDITY; DYSFUNCTION; RATIONALE; ENALAPRIL; AT1	Background: Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure. Methods: A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours. Results: Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure: 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs. Conclusions: Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination. (N Engl J Med 2001;345:1667-75.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA; Mario Negri Inst Pharmacol Res, Grp Italiano Studio Sopravvivenza Infarto Miocard, I-20157 Milan, Italy	University of Minnesota System; University of Minnesota Twin Cities; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Cohn, JN (corresponding author), Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Mayo Mail Code 508,420 Delaware St SE, Minneapolis, MN 55455 USA.		Prozesky, Hans Walter/ABE-6956-2020	Prozesky, Hans Walter/0000-0001-9715-3449				Baruch L, 1999, CIRCULATION, V99, P2658, DOI 10.1161/01.CIR.99.20.2658; CINTRON G, 1993, CIRCULATION, V87, P17; COHN J N, 1973, Circulation, V48, P5; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cohn JN, 1999, J CARD FAIL, V5, P155, DOI 10.1016/S1071-9164(99)90038-6; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Cohn JN, 2000, EUR J HEART FAIL, V2, P439, DOI 10.1016/S1388-9842(00)00130-6; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; DZAU VJ, 1993, ARCH INTERN MED, V153, P937, DOI 10.1001/archinte.153.8.937; FRANCIS GS, 1990, FASEB J, V4, P3068, DOI 10.1096/fasebj.4.13.2210153; Harrap SB, 1996, CIRCULATION, V93, P1148, DOI 10.1161/01.CIR.93.6.1148; Hjalmarson A, 1999, LANCET, V353, P2001; Jacobi J, 1999, AM J HYPERTENS, V12, P418; Jilma B, 1997, LIFE SCI, V60, P1859, DOI 10.1016/S0024-3205(97)00146-X; JONES CG, 1999, EUR J HEART FAIL, V1, P425, DOI DOI 10.1016/S1388-9842(99)00059-8; Jorde UP, 2000, CIRCULATION, V101, P844, DOI 10.1161/01.CIR.101.8.844; KAWAMURA M, 1992, CLIN EXP PHARMACOL P, V19, P547, DOI 10.1111/j.1440-1681.1992.tb00503.x; Lechat P, 1999, LANCET, V353, P9; Leri A, 2000, AM J PATHOL, V156, P1663, DOI 10.1016/S0002-9440(10)65037-7; Louis A, 2001, EUR J HEART FAIL, V3, P381, DOI 10.1016/S1388-9842(01)00149-0; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Patten RD, 1998, CURR OPIN CARDIOL, V13, P162; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; POPOVIC JR, 1998, VITAL HLTH STAT SERI, V148; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WONG M, 1993, CIRCULATION, V87, P65; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	30	2143	2245	2	73	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1667	1675		10.1056/NEJMoa010713	http://dx.doi.org/10.1056/NEJMoa010713			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759645				2022-12-28	WOS:000172517200003
J	Dickson, D				Dickson, D			Weaving a social web - The Internet promises to revolutionize public engagement with science and technology.	NATURE			English	Editorial Material																			0	13	14	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					587	587		10.1038/414587a	http://dx.doi.org/10.1038/414587a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740537	Bronze			2022-12-28	WOS:000172535600027
J	Kessler, AT; Kourtis, AP				Kessler, AT; Kourtis, AP			Liver abscess due to eikenella corrodens from a fishbone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Emory Univ, Sch Med, Atlanta, GA 30303 USA	Emory University	Kessler, AT (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30303 USA.			Kourtis, Athena/0000-0003-1585-1310					0	17	17	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					E5	E5		10.1056/ENEJMicm010433	http://dx.doi.org/10.1056/ENEJMicm010433			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759661				2022-12-28	WOS:000172517200005
J	Hargreaves, S				Hargreaves, S			Rising tensions: Sharia law in Nigeria	LANCET			English	Editorial Material														Hargreaves, Sally/0000-0003-2974-4348					0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1900	1901		10.1016/S0140-6736(01)06895-7	http://dx.doi.org/10.1016/S0140-6736(01)06895-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741652				2022-12-28	WOS:000172463000036
J	Reneman, L; Booij, J; de Bruin, K; Reitsma, JB; de Wolff, FA; Gunning, WB; den Heeten, GL; van den Brink, W				Reneman, L; Booij, J; de Bruin, K; Reitsma, JB; de Wolff, FA; Gunning, WB; den Heeten, GL; van den Brink, W			Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons	LANCET			English	Article							POSITRON-EMISSION-TOMOGRAPHY; BETA-CIT BINDING; IN-VIVO; DOPAMINE TRANSPORTERS; NONHUMAN-PRIMATES; PARTIAL RECOVERY; 52-WEEK PERIOD; NEUROTOXICITY; METHYLENEDIOXYMETHAMPHETAMINE; HUMANS	Background 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is a popular recreational drug that has been shown to damage brain serotonin neurons in high doses. However, effects of moderate MDMA use on serotonin neurons have not been studied, and sex differences and the longterm effects of MDMA use on serotonin neurons have not been identified. We investigated the effects of moderate and heavy MDMA use, sex differences, and long-term effects of MDMA use on serotonin neurons in different brain regions. Methods By means of flyers posted in "rave" venues in Amsterdam, the Netherlands, we recruited 15 moderate MDMA users, 23 heavy MDMA users, 16 ex-MDMA users who had stopped using MDMA for more than 1 year, and 15 controls who claimed never to have used MDMA. We studied the effects of MDMA on brain serotonin neurons using (123)iodine-2 beta -carbomethoxy-3 beta-(4-iodophenyl) tropane ([I-123][beta -CIT)-a radioligand that binds with high affinity to serotonin transporters. Density of binding (expressed as a ratio of region-of-interest binding over binding in the cerebellum) was calculated by single-photon-emission computed tomography (SPELT). Findings We saw significant effects of group and group by sex (p=0.041 and p=0.022, respectively) on overall [I-123])beta -CIT binding ratios. In heavy MDMA users, significant decreases in overall binding ratios were seen in women (p<0.01) but not men (p=0.587). In female ex-MDMA users, overall densities of serotonin transporters were significantly higher than in heavy MDMA users (p=0.004), but not higher than in controls (p=0.524). Interpretation Our results indicate that heavy use of MDMA is associated with neurotoxic effects on serotonin neurons, that women might be more susceptible than men, and that MDMA-induced neurotoxic changes in several brain regions of female ex-MDMA users are reversible.	Univ Amsterdam, Acad Med Ctr, Dept Nucl Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Toxicol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Child & Adolescent Psychiat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Med Ctr, Toxicol Lab, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Reneman, L (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Nucl Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Booij, Jan/AAD-7159-2019	Reneman, Liesbeth/0000-0002-5912-9971				*ADD RES I US, 1998, ECST DUTCH RAV SCEN; Booij J, 1999, EUR J NUCL MED, V26, P171, DOI 10.1007/s002590050374; Boot BP, 2000, LANCET, V355, P1818, DOI 10.1016/S0140-6736(00)02276-5; Chang L, 1999, AM J PSYCHIAT, V156, P716; COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338; FARDE L, 1994, SYNAPSE, V16, P93, DOI 10.1002/syn.890160203; Gerra G, 2000, BIOL PSYCHIAT, V47, P127, DOI 10.1016/S0006-3223(99)00180-8; Hatzidimitriou G, 1999, J NEUROSCI, V19, P5096; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; Hommer DW, 2001, AM J PSYCHIAT, V158, P198, DOI 10.1176/appi.ajp.158.2.198; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; LARUELLE M, 1994, J CEREBR BLOOD F MET, V14, P982, DOI 10.1038/jcbfm.1994.131; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lew R, 1996, J PHARMACOL EXP THER, V276, P855; Liechti ME, 2001, PSYCHOPHARMACOLOGY, V154, P161, DOI 10.1007/s002130000648; Malison RT, 1998, BIOL PSYCHIAT, V44, P1090, DOI 10.1016/S0006-3223(98)00272-8; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; NELSON HE, 1991, REV NATL ADULT READI; Pirker W, 2000, J NUCL MED, V41, P36; PIRKER W, 1995, J NEURAL TRANSM-GEN, V100, P247, DOI 10.1007/BF01276462; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; RICAURTE GA, 1992, J PHARMACOL EXP THER, V261, P616; Sabol KE, 1996, J PHARMACOL EXP THER, V276, P846; Scheffel U, 1998, SYNAPSE, V29, P183, DOI 10.1002/(SICI)1098-2396(199806)29:2<183::AID-SYN9>3.0.CO;2-3; SCHIFANO F, 1994, BIOL PSYCHIAT, V36, P763, DOI 10.1016/0006-3223(94)90088-4; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; Semple DM, 1999, BRIT J PSYCHIAT, V175, P63, DOI 10.1192/bjp.175.1.63; SWAAB DF, 1985, SCIENCE, V228, P1112, DOI 10.1126/science.3992248	30	173	173	0	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1864	1869		10.1016/S0140-6736(01)06888-X	http://dx.doi.org/10.1016/S0140-6736(01)06888-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741626				2022-12-28	WOS:000172463000012
J	Cantalupo, C; Hopkins, WD				Cantalupo, C; Hopkins, WD			Asymmetric Broca's area in great apes - A region of the ape brain is uncannily similar to one linked with speech in humans.	NATURE			English	Article							PLANUM TEMPORALE; LANGUAGE; MRI		Emory Univ, Yerkes Reg Primate Res Ctr, Div Psychobiol, Atlanta, GA 30322 USA; Emory Univ, Yerkes Reg Primate Res Ctr, Living Links Ctr, Atlanta, GA 30322 USA; Georgia State Univ, Language Res Ctr, Atlanta, GA 30303 USA; Berry Coll, Dept Psychol, Mt Berry, GA 30149 USA	Emory University; Emory University; University System of Georgia; Georgia State University	Cantalupo, C (corresponding author), Emory Univ, Yerkes Reg Primate Res Ctr, Div Psychobiol, Atlanta, GA 30322 USA.				NICHD NIH HHS [P01 HD038051, P01 HD038051-050005] Funding Source: Medline; NINDS NIH HHS [R01 NS036605, R01 NS036605-08, R01 NS042867-05, R01 NS042867] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD038051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036605, R01NS042867] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Bailey P, 1950, ISOCORTEX CHIMPANZEE; BROCA P, 1861, B SOC ANAT, V2, P330; CORBALLIS MC, 1992, COGNITION, V44, P197, DOI 10.1016/0010-0277(92)90001-X; Foundas AL, 1998, BRAIN LANG, V64, P282, DOI 10.1006/brln.1998.1974; GALABURDA AM, 1984, CEREBRAL DOMINANCE B, P11; Gannon PJ, 1998, SCIENCE, V279, P220, DOI 10.1126/science.279.5348.220; Hopkins WD, 1998, J COMP PSYCHOL, V112, P95, DOI 10.1037/0735-7036.112.1.95; Hopkins WD, 1998, NEUROREPORT, V9, P2913, DOI 10.1097/00001756-199808240-00043; HOSTETTER AB, IN PRESS J COMP PSYC; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; von Bonin G, 1949, PRECENTRAL MOTOR COR, P7; Zolfonoun Ehsan, 2015, CLIN CHEM LAB MED, V103, P835, DOI [10.1515/ract-2015-2466, DOI 10.1515/CCLM-2022-0965]	13	243	243	2	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					505	505		10.1038/35107134	http://dx.doi.org/10.1038/35107134			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734839	Green Accepted			2022-12-28	WOS:000172405900032
J	Joffe, S; Cook, EF; Cleary, PD; Clark, JW; Weeks, JC				Joffe, S; Cook, EF; Cleary, PD; Clark, JW; Weeks, JC			Quality of informed consent in cancer clinical trials: a cross-sectional survey	LANCET			English	Article							INFORMATION; PERCEPTIONS	Background Investigators have to obtain informed consent before enrolling participants in clinical trials. We wanted to measure the quality of understanding among participants in clinical trials of cancer therapies, to identify correlates of increased understanding, and to assess providers' beliefs about clinical research. We also sought evidence of therapeutic misconceptions in participants and providers. Methods We sent a standard questionnaire to 287 adult patients with cancer who had recently enrolled in a clinical trial at one of three affiliated institutions, and surveyed the provider who obtained each patient's consent. Findings 207 of 287 (72%) patients responded. 90% (186) of these respondents were satisfied with the informed consent process and most considered themselves to be well informed. Nevertheless, many did not recognise nonstandard treatment (74%), the potential for incremental risk from participation (63%), the unproven nature of the treatment (70%), the uncertainty of benefits to self (29%), or that trials are done mainly to benefit future patients (25%). In multivariate analysis, increased knowledge was associated with college education, speaking only English at home, use of the US National Cancer Institute consent form template, not signing the consent form at initial discussion, presence of a nurse, and careful reading of the consent form. Only 28 of 61 providers (46%) recognised that the main reason for clinical trials is benefit to future patients. Interpretation Misconceptions about cancer clinical trials are frequent among trial participants, and physician/investigators might share some of these misconceptions. Efforts to educate providers and participants about the underlying goals of clinical trials are needed.	Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Paediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA; Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Weeks, JC (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Paediat Oncol, 454 BRK Suite 21,44 Binney St, Boston, MA 02115 USA.		Cleary, Paul/AAF-7048-2019; Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER; AHRQ HHS [T32 HS00063] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Aaronson NK, 1996, J CLIN ONCOL, V14, P984, DOI 10.1200/JCO.1996.14.3.984; Advisory Committee on Human Radiation Experiments, 1996, FIN REP; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Bjorn E, 1999, J MED ETHICS, V25, P263, DOI 10.1136/jme.25.3.263; *COMPR WORK GROUP, 2001, REC DEV INF CONS DOC; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; FREEDMAN B, 1992, CLIN RES, V40, P653; HOWARD JM, 1981, CONTROL CLIN TRIALS, V2, P287, DOI 10.1016/0197-2456(81)90019-2; Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139; LEVINE RJ, 1986, ETHICS REGULATION CL; McCarthy CR, 1998, CONSENT SEEKING JUST, P11; MEISEL A, 1977, AM J PSYCHIAT, V134, P285; Miller CK, 1996, PHARMACOTHERAPY, V16, P872; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; Moreno J, 1998, JAMA-J AM MED ASSOC, V280, P1951, DOI 10.1001/jama.280.22.1951; MORROW G, 1978, CANCER, V42, P793, DOI 10.1002/1097-0142(197808)42:2<793::AID-CNCR2820420252>3.0.CO;2-C; *NAT COMM PROT HUM, 1998, ETH RES HUM SUBJ SEL, P19; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; RIECKEN HW, 1982, JAMA-J AM MED ASSOC, V248, P344, DOI 10.1001/jama.248.3.344; Schaeffer MH, 1996, AM J MED, V100, P261, DOI 10.1016/S0002-9343(97)89483-1; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; SKRUTKOWSKI M, 1998, IRB, P1; SUGARMAN J, 1998, ETHICS RES HUMAN SUB, P12; TAUB HA, 1986, J AM GERIATR SOC, V34, P601, DOI 10.1111/j.1532-5415.1986.tb05766.x; United States Department of Health and Human Services, 1991, FED REGISTER, V56, P28012; *WORLD MED ASS DEC, 1998, ETH RES HUM SUBJ SEL, P14	31	444	460	3	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1772	1777		10.1016/S0140-6736(01)06805-2	http://dx.doi.org/10.1016/S0140-6736(01)06805-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	496FG	11734235				2022-12-28	WOS:000172385100013
J	van der Lely, AJ; Hutson, RK; Trainer, PJ; Besser, GM; Barkan, AL; Katznelson, L; Klibanski, A; Herman-Bonert, V; Melmed, S; Vance, ML; Freda, PU; Stewart, PM; Friend, KE; Clemmons, DR; Johannsson, G; Stavrou, S; Cook, DM; Phillips, LS; Strasburger, CJ; Hacker, S; Zib, KA; Davis, RJ; Scarlett, JA; Thorner, M				van der Lely, AJ; Hutson, RK; Trainer, PJ; Besser, GM; Barkan, AL; Katznelson, L; Klibanski, A; Herman-Bonert, V; Melmed, S; Vance, ML; Freda, PU; Stewart, PM; Friend, KE; Clemmons, DR; Johannsson, G; Stavrou, S; Cook, DM; Phillips, LS; Strasburger, CJ; Hacker, S; Zib, KA; Davis, RJ; Scarlett, JA; Thorner, M			Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist	LANCET			English	Article							TRANSSPHENOIDAL SURGERY; GH ANTAGONIST; OCTREOTIDE; THERAPY	Background Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulinlike growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings Mean serum IGF-1 concentrations fell by at least 50%: 467 mug/L (SE 24), 526 mug/L (29), and 523 mug/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 <mu>g/L (2.1), 12.5 mug/L (3.0), and 14.2 mug/L (5.7) (p<0.001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8.0 <mu>g/L (2.5) at baseline, rose to 15.2 mug/L (2.4) on drug, and fell back within 30 days of withdrawal to 8.3 mug/L (2.7). Antibodies to growth hormone were detected in 27 (16.9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p<0.05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11.46 months (0.70) decreased by 0.033 cm(3) (0.057; p=0.353). Interpretation Pegvisomant is an effective medical treatment for acromegaly.	Erasmus MC, NL-3015 GD Rotterdam, Netherlands; Univ Tennessee, Knoxville, TN USA; Christie Hosp, Manchester, Lancs, England; St Bartholomews Hosp, London, England; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; NYU, Med Ctr, New York, NY 10016 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Munich, Klinikum Innenstadt, D-8000 Munich, Germany; StatWorks Inc, Chapel Hill, NC USA; Sensus Drug Dev Corp, Austin, TX USA	Erasmus University Rotterdam; Erasmus MC; University of Tennessee System; University of Tennessee Knoxville; Christie NHS Foundation Trust; Christie Hospital; University of London; Queen Mary University London; University of Michigan System; University of Michigan; Harvard University; Massachusetts General Hospital; Cedars Sinai Medical Center; University of Virginia; Columbia University; University of Birmingham; University of Texas System; UTMD Anderson Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Sahlgrenska University Hospital; New York University; Oregon Health & Science University; Emory University; University of Munich	van der Lely, AJ (corresponding author), Erasmus MC, 40 Dr Molewaterpl, NL-3015 GD Rotterdam, Netherlands.	vanderlely@inw3.azr.nl	Davis, Roger/GWR-3631-2022	Davis, Roger/0000-0002-4926-3413; Katznelson, Laurence/0000-0001-8115-5714; Trainer, Peter/0000-0003-0146-3835; Johannsson, Gudmundur/0000-0003-3484-8440				Abs R, 1998, J CLIN ENDOCR METAB, V83, P374, DOI 10.1210/jc.83.2.374; Barkan AL, 1997, J CLIN ENDOCR METAB, V82, P3187, DOI 10.1210/jc.82.10.3187; Chanson P, 2000, Pituitary, V2, P269, DOI 10.1023/A:1009961116472; Chen NY, 1996, ENDOCRINOLOGY, V137, P5163, DOI 10.1210/en.137.11.5163; CHEN NY, 1995, ENDOCRINOLOGY, V136, P660, DOI 10.1210/en.136.2.660; Esposito C, 1996, KIDNEY INT, V50, P506, DOI 10.1038/ki.1996.342; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Freda PU, 1998, J NEUROSURG, V89, P353, DOI 10.3171/jns.1998.89.3.0353; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; HANSEN I, 1986, AM J PHYSIOL, V250, pE269, DOI 10.1152/ajpendo.1986.250.3.E269; Herman-Bonert VS, 2000, J CLIN ENDOCR METAB, V85, P2958, DOI 10.1210/jc.85.8.2958; JAFFE CA, 1992, ENDOCRIN METAB CLIN, V21, P713, DOI 10.1016/S0889-8529(18)30210-X; Jaquet P, 2000, J CLIN ENDOCR METAB, V85, P781, DOI 10.1210/jc.85.2.781; Lancranjan I, 1999, Pituitary, V1, P105; LUNDIN P, 1992, J COMPUT ASSIST TOMO, V16, P519, DOI 10.1097/00004728-199207000-00004; NEWMAN CB, 1995, J CLIN ENDOCR METAB, V80, P2768, DOI 10.1210/jc.80.9.2768; Powell JS, 2000, J CLIN ENDOCR METAB, V85, P2068, DOI 10.1210/jc.85.5.2068; REUBI JC, 1989, J CLIN ENDOCR METAB, V68, P844, DOI 10.1210/jcem-68-4-844; SONKSEN PH, 1993, HORM RES, V40, P68, DOI 10.1159/000183770; Swearingen B, 1998, J CLIN ENDOCR METAB, V83, P3419, DOI 10.1210/jc.83.10.3419; Thirone ACP, 1997, MOL CELL ENDOCRINOL, V130, P33, DOI 10.1016/S0303-7207(97)00071-3; Trainer PJ, 2000, NEW ENGL J MED, V342, P1171, DOI 10.1056/NEJM200004203421604; Utiger RD, 2000, NEW ENGL J MED, V342, P1210, DOI 10.1056/NEJM200004203421611; van der Lely AJ, 2001, J CLIN ENDOCR METAB, V86, P478, DOI 10.1210/jc.86.2.478; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; vanderLely AJ, 1997, J CLIN ENDOCR METAB, V82, P3185, DOI 10.1210/jc.82.10.3185	27	429	451	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2001	358	9295					1754	1759		10.1016/S0140-6736(01)06844-1	http://dx.doi.org/10.1016/S0140-6736(01)06844-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734231	Green Submitted			2022-12-28	WOS:000172385100009
J	Megerian, CA; Hadlock, TA; Curtin, HD; Kruskal, MO				Megerian, CA; Hadlock, TA; Curtin, HD; Kruskal, MO			An eight-year-old boy with fever, headache, and vertigo two days after aural trauma - Traumatic perilymphatic fistula through the round window of the ear, with bacterial labyrinthitis and communication of the labyrinth with the cerebrospinal fluid compartment at an undetermined site. Meningitis due to Streptococcus pneumoniae.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TEMPORAL BONE-FRACTURES; DIAGNOSIS		Univ Massachusetts, Med Ctr, Dept Otolaryngol Head & Neck Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Megerian, CA (corresponding author), Univ Massachusetts, Med Ctr, Dept Otolaryngol Head & Neck Surg, Worcester, MA 01605 USA.							BASSIOUNI M, 1991, OTOLARYNGOLOGY, P1601; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Dagi T F, 1983, Am J Emerg Med, V1, P295, DOI 10.1016/0735-6757(83)90109-2; Dahiya R, 1999, J TRAUMA, V47, P1079, DOI 10.1097/00005373-199912000-00014; Dichgans M, 1999, NEUROLOGY, V52, P1003, DOI 10.1212/WNL.52.5.1003; FEE GA, 1968, ARCH OTOLARYNGOL, V88, P477; FOYT D, 1998, PEDIAT OTOLOGY NEURO, P163; GLARNER H, 1994, J TRAUMA, V36, P198, DOI 10.1097/00005373-199402000-00009; GOODHILL V, 1981, ANN OTO RHINOL LARYN, V90, P99, DOI 10.1177/000348948109000201; GURDJIAN ES, 1946, SURG GYNECOL OBSTET, V83, P219; HOUGH JVD, 1969, ANN OTO RHINOL LARYN, V78, P210, DOI 10.1177/000348946907800202; JACKLER RK, 1993, OTOLARYNG HEAD NECK, V109, P14, DOI 10.1177/019459989310900104; Kahn JB, 2000, AM J OTOL, V21, P743; KAUFMAN B, 1969, ACTA RADIOL DIAGN, V9, P83; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; NEELY JG, 1982, LARYNGOSCOPE, V92, P609; ROCKETT FX, 1964, AMER J ROENTGENOL RA, V91, P640; Schuknecht H, 1974, PATHOLOGY EAR; Schuknecht H F, 1988, Adv Otorhinolaryngol, V39, P1; SINGLETON GT, 1986, OTOLARYNG HEAD NECK, V94, P426, DOI 10.1177/019459988609400403; Swartz JD, 1996, HEAD NECK IMAGING, P1425	21	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1901	1907		10.1056/NEJMcpc010040	http://dx.doi.org/10.1056/NEJMcpc010040			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756582				2022-12-28	WOS:000172932700007
J	Seufert, J; Ebert, K; Muller, J; Eulert, J; Hendrich, C; Werner, E; Schutze, N; Schulz, G; Kenn, W; Richtmann, H; Palitzsch, KD; Jakob, F				Seufert, J; Ebert, K; Muller, J; Eulert, J; Hendrich, C; Werner, E; Schutze, N; Schulz, G; Kenn, W; Richtmann, H; Palitzsch, KD; Jakob, F			Octreotide therapy for tumor-induced osteomalacia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOGENIC OSTEOMALACIA; PHOSPHATE; METABOLISM; DISORDERS; HORMONE		Univ Wurzburg, Med Poliklin, Div Endocrinol Metab & Mol Med, D-97070 Wurzburg, Germany; Univ Wurzburg, Dept Pathol, D-97070 Wurzburg, Germany; Univ Wurzburg, Dept Orthoped Surg, D-97070 Wurzburg, Germany; Univ Wurzburg, Dept Nucl Med, D-97070 Wurzburg, Germany; Univ Wurzburg, Dept Radiol, D-97070 Wurzburg, Germany; Univ Regensburg, Dept Internal Med 1, Div Endocrinol, D-8400 Regensburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Regensburg	Jakob, F (corresponding author), Univ Wurzburg, Med Poliklin, Div Endocrinol Metab & Mol Med, Klin Str 6-8, D-97070 Wurzburg, Germany.		Jakob, Franz/F-9894-2015; Jakob, Franz/D-8526-2015					Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; CAI Q, 1994, NEW ENGL J MED, V330, P1645, DOI 10.1056/NEJM199406093302304; DiMeglio LA, 2000, ENDOCRIN METAB CLIN, V29, P591, DOI 10.1016/S0889-8529(05)70152-3; ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Kumar R, 1997, NEPHROL DIAL TRANSPL, V12, P11, DOI 10.1093/ndt/12.1.11; Kumar R, 2000, BONE, V27, P333, DOI 10.1016/S8756-3282(00)00334-3; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Legovini P, 1997, J ENDOCRINOL INVEST, V20, P434, DOI 10.1007/BF03347998; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Marx SJ, 2001, NEW ENGL J MED, V344, P696; Murer H, 2001, CURR OPIN NEPHROL HY, V10, P555, DOI 10.1097/00041552-200109000-00002; Nguyen BD, 1999, CLIN NUCL MED, V24, P130; Park Yong-Koo, 1994, Journal of Korean Medical Science, V9, P289; Rhee Y, 2001, CLIN ENDOCRINOL, V54, P551, DOI 10.1046/j.1365-2265.2001.01056.x; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Terek RM, 2001, NEW ENGL J MED, V345, P903, DOI 10.1056/NEJMcpc010029; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664	21	155	164	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1883	1888		10.1056/NEJMoa010839	http://dx.doi.org/10.1056/NEJMoa010839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756579				2022-12-28	WOS:000172932700004
J	Gilewski, T				Gilewski, T			The subtle power of compassion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BAUBY J, 1997, DIVING BELL BUTTERFL, P29; CAMPBELL J, 1988, POWER MYTH, P201	2	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3052	3053		10.1001/jama.286.24.3052	http://dx.doi.org/10.1001/jama.286.24.3052			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754649				2022-12-28	WOS:000172927100001
J	Manning, SW; Kromer, B; Kuniholm, PI; Newton, MW				Manning, SW; Kromer, B; Kuniholm, PI; Newton, MW			Anatolian tree rings and a new chronology for the east Mediterranean bronze-iron ages	SCIENCE			English	Article							ICE CORE; BC; C-14; CALIBRATION; TELECONNECTIONS; TERRESTRIAL; SANTORINI; MINOAN; GREECE; BP	We report an extensive program of high-precision radiocarbon dating to establish the best date for a floating 1599-year Anatolian tree ring chronology that spans the later third millennium B.C. through the earlier first millennium B.C. This chronology is directly associated with a number of key sites and ancient personages. A previously suggested dating is withdrawn and is replaced by a robust new date fix 22 (+ 4 or -7) years earlier. These new radiocarbon wiggle-matched dates offer a unique independent resource for establishing the precise chronology of the ancient Near East and Aegean and help resolve, among others, a tong-standing debate in favor of the so-called Middle Mesopotamian chronology.	Univ Reading, Dept Archaeol, Reading RG6 6AA, Berks, England; Heidelberger Akad Wissensch, D-69120 Heidelberg, Germany; Cornell Univ, Malcolm & Carolyn Wiener Lab Aegean & Near Easter, Ithaca, NY 14853 USA	University of Reading; Ruprecht Karls University Heidelberg; Cornell University	Manning, SW (corresponding author), Univ Reading, Dept Archaeol, POB 218 Whiteknights, Reading RG6 6AA, Berks, England.							BRAZIUNAS TF, 1995, GLOBAL BIOGEOCHEM CY, V9, P565, DOI 10.1029/95GB01725; BRONKRAMSEY C, 1995, RADIOCARBON, V37, P425; CHARPIN D, 1985, ANN RECH INTERDISCIP, V4, P293; CILINGIROGLU A., 2001, AYANIS 1 10 YEARS EX; Clausen HB, 1997, J GEOPHYS RES-OCEANS, V102, P26707, DOI 10.1029/97JC00587; Cole-Dai JH, 2000, J GEOPHYS RES-ATMOS, V105, P24431, DOI 10.1029/2000JD900254; Gasche H., 1998, DATING FALL BABYLON; HAAS V., 1986, REICH URARTU ALTORIE; HAMMER CU, 1987, NATURE, V328, P517, DOI 10.1038/328517a0; HAMMER CU, 2000, SYNCHRONISATION CIVI, P35; HAMMER CU, 2001, SCIEM2000EUR HAIND L; KROMER B, 1993, RADIOCARBON, V35, P125, DOI 10.1017/S0033822200013862; KROMER B, 1992, RADIOCARBON AFTER FOUR DECADES, P184; Kromer B, 2001, SCIENCE, V294, P2529, DOI 10.1126/science.1066114; Kuniholm P. I., 1992, SYRIA, V69, P379; Kuniholm P.I., 1993, STUDIES HONOR N OZGU, P371; Kuniholm P. I., 1977, THESIS U PENNSYLVANI; Kuniholm PI, 1996, NATURE, V381, P780, DOI 10.1038/381780a0; KUNIHOLM PI, 1993, TILLE HOYUK, V4, P179; Manning S. W., 1999, TEST TIME VOLCANO TH; McCormac FG, 1995, RADIOCARBON, V37, P395, DOI 10.1017/S0033822200030873; Michaud V, 2000, J VOLCANOL GEOTH RES, V99, P195, DOI 10.1016/S0377-0273(00)00173-6; MICHEL C., 1997, JEOL, V35-36, P111; NEWTON M, IN PRESS KAMAN KALEH; Nimet Ozguc, 2001, KULTEPE KANIS SEALED; ozguc N., 1980, ANCIENT ART SEALS, P61; PEARSON GW, 1986, RADIOCARBON, V28, P911, DOI 10.1017/S0033822200060197; PEARSON GW, 1993, RADIOCARBON, V35, P105, DOI 10.1017/S0033822200013850; Prag AJNW, 1989, ANATOLIAN STUDIES, V39, P159; SPARKS RJ, COMMUNICATION; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; Stuiver M, 1998, GEOPHYS RES LETT, V25, P329, DOI 10.1029/97GL03694; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; TUNCA O, 1989, ANATOLIA ANCIENT NEA, P481; Van Geel B, 1998, RADIOCARBON, V40, P535, DOI 10.1017/S0033822200018403; VanGeel B, 1996, J QUATERNARY SCI, V11, P451, DOI 10.1002/(SICI)1099-1417(199611/12)11:6<451::AID-JQS275>3.0.CO;2-9; VEENHOF KR, 2000, AKKADICA, V119, P137; VOIGT MJA, COMMUNICATION; Whiting R. M. J., 1990, TALL AL HAMIDIYA, P167; Young R. S., 1981, 3 GREAT EARLY TUMULI	40	80	83	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2532	2535		10.1126/science.1066112	http://dx.doi.org/10.1126/science.1066112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11743159				2022-12-28	WOS:000172927700054
J	Willett, WC; Stampfer, MJ				Willett, WC; Stampfer, MJ			What vitamins should I be taking, doctor?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; SUPPLEMENT USE; COLON-CANCER; MICRONUTRIENT DEFICIENCIES; CONTROLLED-TRIAL; DIETARY-FOLATE; UNITED-STATES; MAJOR CAUSE; RISK; PREVENTION		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Willett, WC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA.							Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM CANC SOC, 2001, REC; *AM HEART ASS, 2001, VIT MIN SUPPL; Ames BN, 1999, P NATL ACAD SCI USA, V96, P12216, DOI 10.1073/pnas.96.22.12216; Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7; Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; Ascherio A, 1999, ANN INTERN MED, V130, P963, DOI 10.7326/0003-4819-130-12-199906150-00003; Balluz LS, 2000, ARCH FAM MED, V9, P258, DOI 10.1001/archfami.9.3.258; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; BOSTICK RM, 1993, CANCER RES, V53, P4230; Chan JM, 1999, CANCER EPIDEM BIOMAR, V8, P893; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; *GISSI PREV INV, 2001, LANCET, V357, P642; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Holick MF, 1996, J NUTR, V126, pS1159, DOI 10.1093/jn/126.suppl_4.1159S; Hunt J, 2001, J AM DIET ASSOC, V101, P115, DOI 10.1016/S0002-8223(01)00026-8; Institute of Medicine, 2000, DIET REF INT VIT C V, P529; Jacobs EJ, 2001, CANCER EPIDEM BIOMAR, V10, P17; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Krebs-Smith SM, 1998, CANCER-AM CANCER SOC, V83, P1425, DOI 10.1002/(SICI)1097-0142(19981001)83:7&lt;1425::AID-CNCR21&gt;3.0.CO;2-5; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; Mark SD, 1996, AM J EPIDEMIOL, V143, P658, DOI 10.1093/oxfordjournals.aje.a008798; Melhus H, 1998, ANN INTERN MED, V129, P770, DOI 10.7326/0003-4819-129-10-199811150-00003; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; *PREV SERV TASK FO, 2002, GUID CLIN PREV SERV, V1996, P467; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 2000, MED CLIN N AM, V84, P239, DOI 10.1016/S0025-7125(05)70216-9; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Salonen JT, 2000, J INTERN MED, V248, P377, DOI 10.1046/j.1365-2796.2000.00752.x; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; USDA, NUTR YOUR HLTH DIET; Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; White E, 1997, CANCER EPIDEM BIOMAR, V6, P769; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Wu KN, 1999, CANCER EPIDEM BIOMAR, V8, P209; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632	57	84	88	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1819	1824		10.1056/NEJMcp010710	http://dx.doi.org/10.1056/NEJMcp010710			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752359				2022-12-28	WOS:000172794800006
J	Cobelens, F; Borgdorff, M				Cobelens, F; Borgdorff, M			Boosting, BCG, and time of reading in tuberculin skin testing	LANCET			English	Editorial Material									Royal Netherlands TB Assoc KNCV, NL-2501 CC The Hague, Netherlands	KNCV Tuberculosis Foundation	Cobelens, F (corresponding author), Royal Netherlands TB Assoc KNCV, NL-2501 CC The Hague, Netherlands.			Cobelens, Frank/0000-0002-4367-1133				BASS JB, 1981, AM REV RESPIR DIS, V123, P394; COMSTOCK G W, 1960, Bull World Health Organ, V23, P683; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; Menzies D, 2000, CLIN INFECT DIS, V31, pS71, DOI 10.1086/314075; Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120; Singh D, 2001, AM J RESP CRIT CARE, V164, P962, DOI 10.1164/ajrccm.164.6.2102076; *WHO TUB RES OFF, 1955, B WORLD HEALTH ORGAN, V12, P189; *WHO TUB RES OFF, 1955, B WORLD HEALTH ORGAN, V12, P197	8	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2014	2014		10.1016/S0140-6736(01)07137-9	http://dx.doi.org/10.1016/S0140-6736(01)07137-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755604				2022-12-28	WOS:000172722800006
J	Welburn, SC; Picozzi, K; Fevre, EM; Coleman, PG; Odiit, M; Carrington, M; Maudlin, I				Welburn, SC; Picozzi, K; Fevre, EM; Coleman, PG; Odiit, M; Carrington, M; Maudlin, I			Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene	LANCET			English	Article							BRUCEI-RHODESIENSE; EXPRESSION; GAMBIENSE; PCR	Background The expansion of sleeping sickness caused by Trypanosoma brucei rhodesiense beyond its traditional focus in southeast Uganda has been linked with large-scale livestock restocking. To assess the risk presented to the human population by domestic livestock, human-infective T b rhodesiense must be distinguished from non-human-infective T brucei brucei, since both parasites can be present in cattle. We investigated the use of a simple genetic marker to characterise parasites collected from cattle in villages within the new sleeping sickness focus in Soroti District, Uganda. Methods 70 T brucei sl samples of known human infectivity status collected from human beings and cattle in Tororo District, Uganda, from 1989 to 1991 were screened for the presence of the human-serum-resistance-associated (SRA) gene by conventional PCR. In 2000-01, blood samples from 200 randomly selected cattle in six villages and two markets in Soroti District were screened for T brucei sl parasites (ie, both T b brucei and T b rhodesiense) by PCR; positive samples were screened for the presence of the SRA gene. Findings The SRA gene was present in all 29 samples from patients with sleeping sickness in Tororo District. Of the 41 samples collected from cattle at the same time, the SRA gene was present in the eight samples that tested resistant to human serum in vitro, whereas it was absent from all 33 isolates that were sensitive to human serum in vitro. Of the 200 cattle sampled in Soroti District, we estimated that up to 18% (95% CI 12-23) were infected with T b rhodesiense. Interpretation Detection of the SRA gene could provide the basis for a simple diagnostic test to enable targeted control of T b rhodesiense in the domestic livestock reservoir, thereby reducing the public-health burden of sleeping sickness in east Africa.	Univ Edinburgh, Ctr Trop Vet Med, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Livestock Hlth Res Inst, Torono, Uganda; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge	Welburn, SC (corresponding author), Univ Edinburgh, Ctr Trop Vet Med, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland.		Carrington, Mark/N-4892-2018; Carrington, Mark/N-3653-2019	Carrington, Mark/0000-0002-6435-7266; Carrington, Mark/0000-0002-6435-7266; Welburn, Susan/0000-0002-9903-7086; Fevre, Eric/0000-0001-8931-4986				ARTAMA WT, 1992, PARASITOLOGY, V104, P67, DOI 10.1017/S0031182000060819; Barrett MP, 2001, LANCET, V358, P603, DOI 10.1016/S0140-6736(01)05817-2; BRUN R, 1987, Z PARASITENKD, V73, P218; de Almeida PP, 1998, ACTA TROP, V70, P269, DOI 10.1016/S0001-706X(98)00031-X; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; Fevre EM, 2001, LANCET, V358, P625, DOI 10.1016/S0140-6736(01)05778-6; Geerts S, 2001, TRENDS PARASITOL, V17, P25, DOI 10.1016/S1471-4922(00)01827-4; Hide G, 1998, EXP PARASITOL, V89, P21, DOI 10.1006/expr.1998.4265; HIDE G, 1991, EXPERIENTIA, V47, P128, DOI 10.1007/BF01945413; HIDE G, 1990, MOL BIOCHEM PARASIT, V39, P213, DOI 10.1016/0166-6851(90)90060-Y; HIDE G, 1994, PARASITOLOGY, V109, P95, DOI 10.1017/S0031182000077805; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; KOERNER T, 1995, PARASITOL TODAY, V11, P303, DOI 10.1016/0169-4758(95)80046-8; MacLeod A, 2000, P NATL ACAD SCI USA, V97, P13442, DOI 10.1073/pnas.230434097; Milner JD, 1999, MOL BIOCHEM PARASIT, V104, P271, DOI 10.1016/S0166-6851(99)00151-6; Odiit M, 1997, E AFR MED J, V74, P792; Smith DH, 1998, BRIT MED BULL, V54, P341, DOI 10.1093/oxfordjournals.bmb.a011692; VANNIEUWENHOVE S, 1999, PROGR HUMAN AFRICAN, P235; Welburn SC, 2001, TRENDS PARASITOL, V17, P19, DOI 10.1016/S1471-4922(00)01839-0; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	20	165	168	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2017	2019		10.1016/S0140-6736(01)07096-9	http://dx.doi.org/10.1016/S0140-6736(01)07096-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755607				2022-12-28	WOS:000172722800009
J	Trumpp, A; Refaeli, Y; Oskarsson, T; Gasser, S; Murphy, M; Martin, GR; Bishop, JM				Trumpp, A; Refaeli, Y; Oskarsson, T; Gasser, S; Murphy, M; Martin, GR; Bishop, JM			c-Myc regulates mammalian body size by controlling cell number but not cell size	NATURE			English	Article							DROSOPHILA MYC; MICE; GENE; INACTIVATION; EXPRESSION; GROWTH	Overexpression of the proto-oncogene c-myc has been implicated in the genesis of diverse human tumours. c-Myc seems to regulate diverse biological processes, but its role in tumorigenesis and normal physiology remains enigmatic(1). Here we report the generation of an allelic series of mice in which c-myc expression is incrementally reduced to zero. Fibroblasts from these mice show reduced proliferation and after complete loss of c-Myc function they exit the cell cycle. We show that Myc activity is not needed for cellular growth but does determine the percentage of activated T cells that re-enter the cell cycle. In vivo, reduction of c-Myc levels results in reduced body mass owing to multiorgan hypoplasia, in contrast to Drosophila dmyc mutants, which are smaller as a result of hypotrophy(2). We rnd that dmyc substitutes for c-myc in fibroblasts, indicating they have similar biological activities. This suggests there may be fundamental differences in the mechanisms by which mammals and insects control body size. We propose that in mammals c-Myc controls the decision to divide or not to divide and thereby functions as a crucial mediator of signals that determine organ and body size.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA	Swiss Institute Experimental Cancer Research; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Trumpp, A (corresponding author), Swiss Inst Expt Canc Res, Ch des Boveresses 155, CH-1066 Epalinges, Switzerland.		Trumpp, Andreas/Z-2141-2019; gasser, stephan/A-2309-2013; Oskarsson, Thordur/HBP-9601-2022	Trumpp, Andreas/0000-0002-6212-3466; Oskarsson, Thordur/0000-0002-0983-6969; Gasser, Stephan/0000-0002-5616-0914				Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HOLZEL M, 2001, 21 EMBO; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STEVENSON RD, 1995, P ROY SOC B-BIOL SCI, V259, P105, DOI 10.1098/rspb.1995.0016; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x	27	356	378	1	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					768	773		10.1038/414768a	http://dx.doi.org/10.1038/414768a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742404				2022-12-28	WOS:000172676200052
J	Hauser, J				Hauser, J			The consultation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2781	2782		10.1001/jama.286.22.2781	http://dx.doi.org/10.1001/jama.286.22.2781			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735730				2022-12-28	WOS:000172655400001
J	Haigh, JD				Haigh, JD			Climate - Climate variability and the influence of the Sun	SCIENCE			English	Editorial Material							11-YEAR SOLAR-CYCLE; NORTHERN-HEMISPHERE		Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BW, England	Imperial College London	Haigh, JD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BW, England.		Haigh, Joanna D/F-6847-2014	Haigh, Joanna D/0000-0001-5504-4754				Baldwin MP, 2001, SCIENCE, V294, P581, DOI 10.1126/science.1063315; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Haigh JD, 1999, Q J ROY METEOR SOC, V125, P871, DOI 10.1002/qj.49712555506; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; KODERA K, 1995, J GEOPHYS RES-ATMOS, V100, P14077, DOI 10.1029/95JD01172; Larkin A, 2000, SPACE SCI REV, V94, P199, DOI 10.1023/A:1026771307057; Luterbacher J, 1999, GEOPHYS RES LETT, V26, P2745, DOI 10.1029/1999GL900576; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Osborn TJ, 1999, CLIM DYNAM, V15, P685, DOI 10.1007/s003820050310; Robock A, 2001, B AM METEOROL SOC, V82, P2189, DOI 10.1175/1520-0477(2001)082<2189:SFNFDS>2.3.CO;2; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; van Loon H, 1999, GEOPHYS RES LETT, V26, P2893, DOI 10.1029/1999GL900596	13	71	82	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2109	2111		10.1126/science.1067013	http://dx.doi.org/10.1126/science.1067013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739941				2022-12-28	WOS:000172647700033
J	Heun, P; Laroche, T; Shimada, K; Furrer, P; Gasser, SM				Heun, P; Laroche, T; Shimada, K; Furrer, P; Gasser, SM			Chromosome dynamics in the yeast interphase nucleus	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; LIVING CELLS; IN-VIVO; SCALE; ORC; VISUALIZATION; TERRITORIES; DROSOPHILA	Little is known about the dynamics of chromosomes in interphase nuclei. By tagging four chromosomal regions with a green fluorescent protein fusion to lac repressor, we monitored the movement and subnuclear position of specific sites in the yeast genome, sampling at short time intervals. We found that early and late origins of replication are highly mobile in G(1) phase, frequently moving at or faster than 0.5 micrometers/10 seconds, in an energy-dependent fashion. The rapid diffusive movement of chromatin detected in G(1) becomes constrained in S phase through a mechanism dependent on active DNA replication. In contrast, telomeres and centromeres provide replication-independent constraint on chromatin movement in both G(1) and S phases.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland	University of Geneva	Gasser, SM (corresponding author), Univ Geneva, Dept Mol Biol, Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland.		Heun, Patrick/F-3883-2011; Heun, Patrick/AAH-7390-2020	Heun, Patrick/0000-0001-8400-1892; Gasser, Susan/0000-0003-3610-9123				Belgareh N, 1997, J CELL BIOL, V136, P747, DOI 10.1083/jcb.136.4.747; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Blaszczyk M., UNPUB; Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2; Buchenau P, 1997, J CELL BIOL, V137, P291, DOI 10.1083/jcb.137.2.291; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; Csink AK, 1998, J CELL BIOL, V143, P13, DOI 10.1083/jcb.143.1.13; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Heun P, 2001, J CELL BIOL, V152, P385, DOI 10.1083/jcb.152.2.385; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; Kim S, 1997, YEAST, V13, P735, DOI 10.1002/(SICI)1097-0061(19970630)13:8<735::AID-YEA136>3.0.CO;2-V; LAROCHE T, UNPUB; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MAHY NL, 2000, CHROMATIN STRUCTURE; Manders EMM, 1999, J CELL BIOL, V144, P813, DOI 10.1083/jcb.144.5.813; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Rubbi L, 1997, BIOCHEM J, V328, P401, DOI 10.1042/bj3280401; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	34	347	349	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2181	2186		10.1126/science.1065366	http://dx.doi.org/10.1126/science.1065366			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739961				2022-12-28	WOS:000172647700056
J	Masuzaki, H; Paterson, J; Shinyama, H; Morton, NM; Mullins, JJ; Seckl, JR; Flier, JS				Masuzaki, H; Paterson, J; Shinyama, H; Morton, NM; Mullins, JJ; Seckl, JR; Flier, JS			A transgenic model of visceral obesity and the metabolic syndrome	SCIENCE			English	Article							ADIPOSE-TISSUE; FAT DISTRIBUTION; MICE; EXPRESSION; LEPTIN; BODY; GLUCOCORTICOIDS; TROGLITAZONE; ADIPOCYTES; SYSTEM	The adverse metabolic consequences of obesity are best predicted by the quantity of visceral fat. Excess glucocorticoids produce visceral, obesity and diabetes, but circulating glucocorticoid levels are normal in typical obesity. Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11 beta hydroxysteroid dehydrogenase type 1 (11 beta HSD-1). We created transgenic mice overexpressing 11 beta HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans. These mice had increased adipose levels of corticosterone and developed visceral obesity that was exaggerated by a high-fat diet. The mice also exhibited pronounced insulin-resistant diabetes, hyperlipidemia, and, surprisingly, hyperphagia despite hyperleptinemia. Increased adipocyte 11 beta HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Edinburgh, Mol Med Ctr, Endocrinol Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Edinburgh; University of Edinburgh	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, 330 Brookline Ave, Boston, MA 02215 USA.		Morton, NICHOLAS/ABF-3774-2020; Seckl, Jonathan R/C-3555-2013; Flier, jeffrey/AAG-6223-2019					Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Aubert J, 1997, BIOCHEM J, V328, P701, DOI 10.1042/bj3280701; Berger J, 2001, J BIOL CHEM, V276, P12629, DOI 10.1074/jbc.M003592200; Bjorntorp P, 2000, NUTRITION, V16, P924, DOI 10.1016/S0899-9007(00)00422-6; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Kawai T, 1999, METABOLISM, V48, P1102, DOI 10.1016/S0026-0495(99)90122-1; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; Kobayashi J, 1999, BRIT J CLIN PHARMACO, V47, P433, DOI 10.1046/j.1365-2125.1999.00920.x; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; RAHIMY MH, 1989, J STEROID BIOCHEM, V33, P179, DOI 10.1016/0022-4731(89)90292-6; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Rooman R, 1999, J ENDOCRINOL, V163, P543, DOI 10.1677/joe.0.1630543; ROSMOND R, 1998, J CLIN ENDOCR METAB, V83, P1806; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR183, DOI 10.1152/ajpregu.1995.268.1.R183; Szymczak J, 1998, STEROIDS, V63, P319, DOI 10.1016/S0039-128X(98)00019-1; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	34	1420	1550	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2166	2170		10.1126/science.1066285	http://dx.doi.org/10.1126/science.1066285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739957				2022-12-28	WOS:000172647700051
J	Hunsaker, RP; Stone, JR				Hunsaker, RP; Stone, JR			Renal-cell carcinoma extending into the vena cava and right side of the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Hunsaker, RP (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1676	1676		10.1056/NEJMicm980108	http://dx.doi.org/10.1056/NEJMicm980108			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759646				2022-12-28	WOS:000172517200004
J	Kamal, A; Almenar-Queralt, A; LeBlanc, JF; Roberts, EA; Goldstein, LSB				Kamal, A; Almenar-Queralt, A; LeBlanc, JF; Roberts, EA; Goldstein, LSB			Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; SUBCELLULAR-LOCALIZATION; MICE LACKING; CLEAVAGE; DEFICITS; RELEASE; POOL	Proteolytic processing of amyloid precursor protein (APP) generates amyloid-beta peptide and has been implicated in the pathogenesis of Alzheimer's disease(1). However, the normal function of APP, whether this function is related to the proteolytic processing of APP, and where this processing takes place in neurons in vivo remain unknown. We have previously shown that the axonal transport of APP in neurons is mediated by the direct binding of APP to the kinesin light chain subunit of kinesin-I, a microtubule motor protein(2). Here we identify an axonal membrane compartment that contains APP, beta -secretase and presenilin-1. The fast anterograde axonal transport of this compartment is mediated by APP and kinesin-I. Proteolytic processing of APP can occur in the compartment in vitro and in vivo in axons. This proteolysis generates amyloid-beta and a carboxy-terminal fragment of APP, and liberates kinesin-I from the membrane. These results suggest that APP functions as a kinesin-I membrane receptor, mediating the axonal transport of beta -secretase and presenilin-1, and that processing of APP to amyloid-beta by secretases can occur in an axonal membrane compartment transported by kinesin-I.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Ciphergen Biosyst Inc, Fremont, CA 94555 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Goldstein, LSB (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.	lgoldstein@ucsd.edu						Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; KOO EH, 1994, J BIOL CHEM, V269, P17386; Magara F, 1999, P NATL ACAD SCI USA, V96, P4656, DOI 10.1073/pnas.96.8.4656; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; POTEMPSKA A, 1991, J BIOL CHEM, V266, P8464; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Seabrook GR, 1999, NEUROPHARMACOLOGY, V38, P349, DOI 10.1016/S0028-3908(98)00204-4; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	30	473	499	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					643	648		10.1038/414643a	http://dx.doi.org/10.1038/414643a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740561				2022-12-28	WOS:000172535600049
J	Voznesenskaya, EV; Franceschi, VR; Kiirats, O; Freitag, H; Edwards, GE				Voznesenskaya, EV; Franceschi, VR; Kiirats, O; Freitag, H; Edwards, GE			Kranz anatomy is not essential for terrestrial C-4 plant photosynthesis	NATURE			English	Article							MALIC ENZYME; CHENOPODIACEAE; COTYLEDONS; EXPANSION; LEAVES; GENUS; CO2	An important adaptation to CO2-limited photosynthesis in cyanobacteria, algae and some plants was development of CO2-concentrating mechanisms (CCM)(1). Evolution of a CCM occurred many times in flowering plants, beginning at least 15-20 million years ago, in response to atmospheric CO2 reduction, climate change, geological trends, and evolutionary diversification of species(2). In plants, this is achieved through a biochemical inorganic carbon pump called C-4 photosynthesis, discovered 35 years ago(3). C4 photosynthesis is advantageous when limitations on carbon acquisition are imposed by high temperature, drought and saline conditions. It has been thought that a specialized leaf anatomy, composed of two, distinctive photosynthetic cell types (Kranz anatomy), is required for C-4 photosynthesis(4). We provide evidence that C-4 photosynthesis can function within a single photosynthetic cell in terrestrial plants. Borszczowia aralocaspica (Chenopodiaceae) has the photosynthetic features of C-4 plants, yet lacks Kranz anatomy. This species accomplishes C-4 photosynthesis through spatial compartmentation of photosynthetic enzymes, and by separation of two types of chloroplasts and other organelles in distinct positions within the chlorenchyma cell cytoplasm.	Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Russian Acad Sci, VL Komarov Bot Inst, Lab Anat & Morphol, St Petersburg 197376, Russia; Univ Gesamthsch Kassel, D-34109 Kassel, Germany	Washington State University; Russian Academy of Sciences; Komarov Botanical Institute, Russian Academy of Sciences	Edwards, GE (corresponding author), Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.	edwardsg@wsu.edu	Voznesenskaya, Elena/H-9098-2013	Voznesenskaya, Elena/0000-0002-5919-3340				Akhani H, 1997, PLANT SYST EVOL, V206, P187, DOI 10.1007/BF00987948; Badger Murray R., 2000, Advances in Photosynthesis, V9, P369; CAROLIN RC, 1973, BOT J LINN SOC, V66, P259, DOI 10.1111/j.1095-8339.1973.tb02174.x; CERLING TE, 1994, NATURE, V371, P112, DOI 10.1038/371112a0; Dai ZY, 1996, PLANTA, V198, P563, DOI 10.1007/BF00262643; Edwards G., 1983, C3 C4 MECH CELLULAR; Edwards GE, 2001, PLANT PHYSIOL, V125, P46, DOI 10.1104/pp.125.1.46; FARQUHAR GD, 1983, AUST J PLANT PHYSIOL, V10, P205, DOI 10.1071/PP9830205; Freitag H, 2000, PLANT BIOLOGY, V2, P154, DOI 10.1055/s-2000-9462; HATCH M. D., 1971, Photosynthesis and photorespiration, P139; Kanai R., 1999, C4 PLANT BIOL, P49, DOI [10.5860/choice.36-6275, DOI 10.5860/CHOICE.36-6275, DOI 10.1016/B978-012614440-6/50004-5]; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LONG JJ, 1994, J BIOL CHEM, V269, P2827; Maroco JP, 2000, PLANT CELL ENVIRON, V23, P115, DOI 10.1046/j.1365-3040.2000.00531.x; Matsuoka M, 2001, ANNU REV PLANT PHYS, V52, P297, DOI 10.1146/annurev.arplant.52.1.297; Maurino VG, 1996, BIOCHEM MOL BIOL INT, V38, P239; Pagani M, 1999, SCIENCE, V285, P876, DOI 10.1126/science.285.5429.876; Pyankov VI, 1999, PLANT CELL PHYSIOL, V40, P125, DOI 10.1093/oxfordjournals.pcp.a029519; Pyankov VI, 2000, PHOTOSYNTH RES, V63, P69, DOI 10.1023/A:1006377708156; Sage RF, 2001, PLANT BIOLOGY, V3, P202, DOI 10.1055/s-2001-15206; Sage RF, 1999, C4 PLANT BIOL; Sheehy J.E., 2000, CROP SCI, DOI DOI 10.2135/CROPSCI2002.2227; VOZNESENSKAYA E V, 1986, Botanicheskii Zhurnal (St. Petersburg), V71, P1291; Voznesenskaya EV, 1999, J EXP BOT, V50, P1779, DOI 10.1093/jexbot/50.341.1779; Voznesenskaya EV, 2001, ANN BOT-LONDON, V88, P337, DOI 10.1006/anbo.2001.1457; Winter K, 1996, CRASSULACEAN ACID ME	26	216	248	6	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	2001	414	6863					543	546		10.1038/35107073	http://dx.doi.org/10.1038/35107073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734854				2022-12-28	WOS:000172405900047
J	Rabinowitz, HK; Paynter, NP				Rabinowitz, HK; Paynter, NP			The rural vs urban practice decision	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University	Rabinowitz, HK (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA.							*AM AC FAM PHYS, 2001, 2001 MATH INF SHEET; Council on Graduate Medical Education, 1998, PHYS DISTR HLTH CAR; JOLLY P., 1998, AAMC DATA BOOK STAT; PHILLIPS DM, 1998, PHYSICIAN RECRUITMEN; Rabinowitz HK, 2001, JAMA-J AM MED ASSOC, V286, P1041, DOI 10.1001/jama.286.9.1041; Rosenthal T C, 1998, Fam Med, V30, P90; Starfield B., 1992, PRIMARY CARE CONCEPT; WRIGHT GE, 2001, TXB RURAL MED	8	42	42	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					113	113		10.1001/jama.287.1.113	http://dx.doi.org/10.1001/jama.287.1.113			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754723	hybrid			2022-12-28	WOS:000172978500039
J	Lam, CLK				Lam, CLK			Confucius School of Medicine: the way to great learning	BRITISH MEDICAL JOURNAL			English	Article									Univ Hong Kong, Ap Lei Chau Clin, Dept Med, Family Med Unit, Ap Lei Chau, Hong Kong, Peoples R China	University of Hong Kong	Lam, CLK (corresponding author), Univ Hong Kong, Ap Lei Chau Clin, Dept Med, Family Med Unit, 3rd Floor,161 Main St, Ap Lei Chau, Hong Kong, Peoples R China.		Lam, Cindy Lo Kuen/C-4314-2009					FULGHUM R, 1999, CHICKEN SOUP SOUL, P127; LEGGE J, 1994, CHINESE CLASSICS, V1, P355; Regehr G, 1996, ACAD MED, V71, P988, DOI 10.1097/00001888-199609000-00015	3	2	2	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1458	1459		10.1136/bmj.323.7327.1458	http://dx.doi.org/10.1136/bmj.323.7327.1458			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751353	Green Submitted, Green Published			2022-12-28	WOS:000172979900013
J	Moine, H; Mandel, JL				Moine, H; Mandel, JL			Biomedicine - Do G quartets orchestrate fragile X pathology?	SCIENCE			English	Editorial Material									CNRS, UPR 9002, F-67084 Strasbourg, France; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moine, H (corresponding author), CNRS, UPR 9002, F-67084 Strasbourg, France.		Moine, Herve/Q-2328-2016; Mandel, Jean Louis/Q-2668-2016	Moine, Herve/0000-0002-6250-7902; Mandel, Jean Louis/0000-0002-0535-6589				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Bardoni B, 2000, AM J MED GENET, V97, P153, DOI 10.1002/1096-8628(200022)97:2<153::AID-AJMG7>3.0.CO;2-M; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Crawford DC, 2001, GENET MED, V3, P359, DOI 10.1097/00125817-200109000-00006; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deng JP, 2001, P NATL ACAD SCI USA, V98, P13665, DOI 10.1073/pnas.241374798; Greenough WT, 2001, P NATL ACAD SCI USA, V98, P7101, DOI 10.1073/pnas.141145998; Kooy RF, 2000, MOL MED TODAY, V6, P193, DOI 10.1016/S1357-4310(00)01674-9; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Nimchinsky EA, 2001, J NEUROSCI, V21, P5139, DOI 10.1523/JNEUROSCI.21-14-05139.2001; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	13	13	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2487	2488		10.1126/science.1068352	http://dx.doi.org/10.1126/science.1068352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752559				2022-12-28	WOS:000172927700035
J	Richmond, B				Richmond, B			Neuroscience - Information coding	SCIENCE			English	Editorial Material							CORTEX; DISCHARGE; NEURONS; SIGNALS		NIMH, Neuropsychol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Richmond, B (corresponding author), NIMH, Neuropsychol Lab, Bldg 9, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002032, ZIAMH002619, Z01MH002032, Z01MH002619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Jacobs GA, 2000, J NEUROSCI, V20, P2934; Lee D, 1998, J NEUROSCI, V18, P1161; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; Oram MW, 1998, TRENDS NEUROSCI, V21, P259, DOI 10.1016/S0166-2236(97)01216-2; Petersen RS, 2001, NEURON, V32, P503, DOI 10.1016/S0896-6273(01)00481-0; Reich DS, 2001, SCIENCE, V294, P2566, DOI 10.1126/science.1065839; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; Wiener MC, 2001, J NEUROSCI, V21, P8210, DOI 10.1523/JNEUROSCI.21-20-08210.2001; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	11	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2493	2494		10.1126/science.1067928	http://dx.doi.org/10.1126/science.1067928			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752563				2022-12-28	WOS:000172927700039
J	Averhoff, F; Shapiro, CN; Bell, BP; Hyams, I; Burd, L; Deladisma, A; Simard, EP; Nalin, D; Kuter, B; Ward, C; Lundberg, M; Smith, N; Margolis, HS				Averhoff, F; Shapiro, CN; Bell, BP; Hyams, I; Burd, L; Deladisma, A; Simard, EP; Nalin, D; Kuter, B; Ward, C; Lundberg, M; Smith, N; Margolis, HS			Control of hepatitis A through routine vaccination of children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-WIDE OUTBREAK; TRANSMISSION; INFECTION	Context The impact of routine hepatitis A vaccination of children living in large communities with elevated disease rates has not been evaluated. Objective To determine the effect of routine vaccination of children on disease incidence in a community with recurrent hepatitis A epidemics. Design, Setting, and Participants Community-based demonstration project conducted from January 12, 1995, through December 31, 2000, in Butte County, California, among children aged 2 to 17 years. Intervention In 1995, vaccination was offered to children aged 2 to 12 years during vaccination clinics conducted on 2 occasions 6 to 12 months apart at most schools in the county. In 1996-2000, vaccine was distributed to community health care clinicians, who vaccinated eligible children without charge. Vaccine was also available at health department clinics, selected child care centers, and other sites. Main Outcome Measures Hepatitis A vaccination coverage, hepatitis A incidence, and vaccine effectiveness. Results During the study period, 29789 (66.2%) of an estimated 44982 eligible children received at least 1 vaccine dose; 17681 (89.3%) received a second dose. The number of hepatitis A cases among the entire county population declined 93.5% during the study period, from 57 cases in 1995 to 4 in 2000, the lowest number of cases reported in the county since hepatitis A surveillance began in 1966. The 2000 incidence rate of 1.9 per 100000 population was the lowest of any county in the state. Of the 245 cases reported during the 6-year period, 40 (16.3%) occurred among children 17 years of age or younger, of which 16 (40%) occurred in 1995 and only 1 in 2000. One of the 27 case patients eligible for vaccination had been vaccinated, having received the first dose 3 days before symptom onset. The estimated protective vaccine efficacy was 98% (95% confidence interval, 86%-100%). Conclusions In this population, hepatitis A vaccine was highly effective in preventing disease among recipients. Childhood vaccination appears to have decreased hepatitis A incidence among children and adults and controlled the disease in a community with recurrent epidemics.	Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Butte Cty Dept Publ Hlth, Oroville, CA USA; Calif Dept Hlth Serv, Immunizat Branch, Berkeley, CA 94704 USA; Merck Vaccine Div, West Point, PA USA; Merck Res Labs, West Point, PA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Health Care Services; Merck & Company; Merck & Company	Bell, BP (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr Infect Dis, Mailstop G-37,1600 Clifton Rd, Atlanta, GA 30333 USA.		Simard, Edgar/G-4552-2010	Simard, Edgar/0000-0001-8093-2067				*AL DEP HLTH SOC S, 1993, STAT AL EP B, V18; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Bell BP, 1998, J INFECT DIS, V178, P1579, DOI 10.1086/314518; *CDCP, 1996, HEP SURV, P16; *CDCP, 1987, HEPATITIS SURVEILLAN, V51, P6; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P600; Craig AS, 1998, CLIN INFECT DIS, V27, P531, DOI 10.1086/514700; GILDON B, 1992, SOUTHERN MED J, V85, P9, DOI 10.1097/00007611-199201000-00004; GRECO D, 1986, INT J EPIDEMIOL, V15, P108, DOI 10.1093/ije/15.1.108; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; MAJEED FA, 1992, EPIDEMIOL INFECT, V109, P167; MANN JM, 1982, PUBLIC HEALTH REP, V97, P516; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; NALIN DR, 1993, J HEPATOL, V18, pS51, DOI 10.1016/S0168-8278(05)80379-4; PAVIA AT, 1990, AM J EPIDEMIOL, V131, P1085, DOI 10.1093/oxfordjournals.aje.a115601; SAGLIOCCA L, 1988, EUR J EPIDEMIOL, V4, P470, DOI 10.1007/BF00146400; SHAW FE, 1986, AM J EPIDEMIOL, V123, P1057, DOI 10.1093/oxfordjournals.aje.a114334; SHAW FE, 1990, AM J PUBLIC HEALTH, V80, P1091, DOI 10.2105/AJPH.80.9.1091; Staes CJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.4.e54; VANBENEDEN C, 1998, INT C EM INF DIS M M; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; YANG NY, 1988, AM J EPIDEMIOL, V127, P599	25	97	101	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2968	2973		10.1001/jama.286.23.2968	http://dx.doi.org/10.1001/jama.286.23.2968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743837	Bronze			2022-12-28	WOS:000172764500028
J	van Lommel, P; van Wees, R; Meyers, V; Elfferich, I				van Lommel, P; van Wees, R; Meyers, V; Elfferich, I			Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands	LANCET			English	Article							SYNCOPE	Background Some people report a near-death experience (NDE) after a life-threatening crisis. We aimed to establish the cause of this experience and assess factors that affected its frequency, depth, and content. Methods In a prospective study, we included 344 consecutive cardiac patients who were successfully resuscitated after cardiac arrest in ten Dutch hospitals. We compared demographic, medical, pharmacological, and psychological data between patients who reported NDE and patients who did not (controls) after resuscitation. In a longitudinal study of life changes after NDE, we compared the groups 2 and 8 years later. Findings 62 patients (18%) reported NDE, of whom 41 (12%) described a core experience. Occurrence of the experience was not associated with duration of cardiac arrest or unconsciousness, medication, or fear of death before cardiac arrest. Frequency of NDE was affected by how we defined NDE, the prospective nature of the research in older cardiac patients, age, surviving cardiac arrest in first myocardial infarction, more than one cardiopulmonary resuscitation (CPR) during stay in hospital, previous NDE, and memory problems after prolonged CPR. Depth of the experience was affected by sex, surviving CPR outside hospital, and fear before cardiac arrest. Significantly more patients who had an NDE, especially a deep experience, died within 30 days of CPR (p<0.0001). The process of transformation after NDE took several years, and differed from those of patients who survived cardiac arrest without NDE. Interpretation We do not know why so few cardiac patients report NDE after CPR, although age plays a part. With a purely physiological explanation such as cerebral anoxia for the experience, most patients who have been clinically dead should report one.	Hosp Rijnstate, Div Cardiol, NL-6800 TA Arnhem, Netherlands; Capelle AD, Ijssel, Netherlands	Rijnstate Hospital	van Lommel, P (corresponding author), Hosp Rijnstate, Div Cardiol, POB 9555, NL-6800 TA Arnhem, Netherlands.							AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; [Anonymous], 1998, MED PSYCHIAT, V1, P92; Appelby L., 1989, BMJ-BRIT MED J, V298, P976; Atwater P.M.H., 1988, COMING BACK LIFE AFT; Blackmore S., 1993, DYING LIVE SCI NEAR; CLUTE HL, 1990, ANESTHESIOLOGY, V73, P821, DOI 10.1097/00000542-199011000-00004; DICKEY W, 1992, BRIT HEART J, V67, P334; Greyson B, 2000, LANCET, V355, P460; GREYSON B, 1993, PSYCHIATRY, V56, P390; Greyson B, 1998, PERSPECT BIOL MED, V42, P14; GREYSON B, 1983, J NERV MENT DIS, V171, P369, DOI 10.1097/00005053-198306000-00007; Grof S., 1977, HUMAN ENCOUNTER DEAT; Groth-Marnat G, 1998, J HUMANIST PSYCHOL, V38, P110, DOI 10.1177/00221678980383005; Jansen K. L. R, 1996, NEAR DEATH EXPERIENC, P265; LEMPERT T, 1994, LANCET, V344, P829, DOI 10.1016/S0140-6736(94)92389-2; MEDUNA LJ, 1950, CARBON DIOXIDE THERA; Morse M., 1996, NEAR DEATH EXPERIENC, P299; MORSE M, 1990, TRANSFORMED LIGHT; OWENS JE, 1990, LANCET, V336, P1175, DOI 10.1016/0140-6736(90)92780-L; Parnia S, 2001, RESUSCITATION, V48, P149, DOI 10.1016/S0300-9572(00)00328-2; Penfield W., 1958, EXCITABLE CORTEX CON; Ring K., 1984, HEADING OMEGA SEARCH; Ring K, 1980, LIFE DEATH SCI INVES; Ring K., 1999, MINDSIGHT NEAR DEATH; ROBERTS G, 1988, BRIT J PSYCHIAT, V153, P607, DOI 10.1192/bjp.153.5.607; SABOM MB, 1988, LIGHT DEATH 1 DOCTOR, P37; SABORN M, 1982, RECOLLECTIONS DEATH; Schmied I, 1999, TODESNAHE INTERDISZI, P217; SCHOENBECK SB, 1991, J NEAR DEATH STUDIES, V9, P211; SCHROTERKUNHARD.M, 1999, TODESNAHE INTERDISZI, P65; WHINNERY JE, 1990, ARCH NEUROL-CHICAGO, V47, P764, DOI 10.1001/archneur.1990.00530070058012	31	268	282	4	123	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2039	2045		10.1016/S0140-6736(01)07100-8	http://dx.doi.org/10.1016/S0140-6736(01)07100-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755611				2022-12-28	WOS:000172722800013
J	Balter, M				Balter, M			Archaeology - Did plaster hold neolithic society together?	SCIENCE			English	News Item																		ROBERTS N, 1998, SCIENCE         1120, P1442	1	3	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2278	+		10.1126/science.294.5550.2278	http://dx.doi.org/10.1126/science.294.5550.2278			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	503TT	11743181				2022-12-28	WOS:000172817200017
J	Bouchard, MJ; Wang, LH; Schneider, RJ				Bouchard, MJ; Wang, LH; Schneider, RJ			Calcium signaling by HBx protein in hepatitis B virus DNA replication	SCIENCE			English	Article							X-PROTEIN; TYROSINE PHOSPHORYLATION; ION-CHANNEL; MITOCHONDRIA; ACTIVATION; KINASE; CELLS; PYK2; SRC; INFECTION	Hepatitis B virus (HBV) infects more than 300 million people and is a leading cause of liver cancer and disease. The HBV HBx: protein is essential for infection; HBx activation of Src is important for HBV DNA replication. In our study, HBx activated cytosolic calcium-dependent proline-rich tyrosine kinase-2 (Pyk2), a Src kinase activator. HBx activation of HBV DNA replication was blocked by inhibiting Pyk2 or calcium signaling mediated by mitochondrial calcium channels, which suggests that HBx targets mitochondrial calcium regulation. Reagents that increased cytosolic calcium substituted for HBx protein in HBV DNA replication. Thus, alteration of cytosolic calcium was a fundamental requirement for HBV replication and was mediated by HBx protein.	NYU, Dept Microbiol, New York, NY 10016 USA	New York University	Schneider, RJ (corresponding author), NYU, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.			Schneider, Robert/0000-0001-5807-5564	NCI NIH HHS [F32CA-4476, R0ICA-565633] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Baron KT, 1997, EUR J PHARMACOL, V340, P295, DOI 10.1016/S0014-2999(97)01433-7; Beatch MD, 2000, J VIROL, V74, P5569, DOI 10.1128/JVI.74.12.5569-5576.2000; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Brunet JP, 2000, J VIROL, V74, P2323, DOI 10.1128/JVI.74.5.2323-2332.2000; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ganem D, 2001, HEPADNAVIRIDAE VIRUS, P2923; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; NATOLI G, 1994, ONCOGENE, V9, P2837; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Ren ST, 2001, J VIROL, V75, P1104, DOI 10.1128/JVI.75.3.1104-1116.2001; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Zhao JH, 2000, J CELL SCI, V113, P3063; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	29	305	330	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2376	2378		10.1126/science.294.5550.2376	http://dx.doi.org/10.1126/science.294.5550.2376			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743208				2022-12-28	WOS:000172817200053
J	Tong, AHY; Evangelista, M; Parsons, AB; Xu, H; Bader, GD; Page, N; Robinson, M; Raghibizadeh, S; Hogue, CWV; Bussey, H; Andrews, B; Tyers, M; Boone, C				Tong, AHY; Evangelista, M; Parsons, AB; Xu, H; Bader, GD; Page, N; Robinson, M; Raghibizadeh, S; Hogue, CWV; Bussey, H; Andrews, B; Tyers, M; Boone, C			Systematic genetic analysis with ordered arrays of yeast deletion mutants	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; SYNTHETIC LETHAL; BUDDING YEAST; MORPHOGENESIS; MUTATIONS; SCREEN	In Saccharomyces cerevisiae, more than 80% of the similar to 6200 predicted genes are nonessential, implying that the genome is buffered from the phenotypic consequences of genetic perturbation. To evaluate function, we developed a method for systematic construction of double mutants, termed synthetic genetic array (SGA) analysis, in which a query mutation is crossed to an array of similar to 4700 deletion mutants. Inviable double-mutant meiotic progeny identify functional relationships between genes. SGA analysis of genes with roles in cytoskeletal organization (BNI1, ARP2, ARC40, BIM1), DNA synthesis and repair (SGS1, RAD27), or uncharacterized functions (BBC1, NBP2) generated a network of 291 interactions among 204 genes. Systematic application of this approach should produce a global map of gene function.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Virtek Engn Sci Inc, Toronto, ON M5R 2J7, Canada	University of Toronto; University of Toronto; Queens University - Canada; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University	Andrews, B (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.		Hogue, Christopher/B-6726-2008; Tyers, Michael/ABE-3194-2021; Hogue, Christopher W V/AAZ-3934-2020; Robinson, Mark D./O-2254-2019; Bader, Gary/C-1176-2009; Robinson, Mark D/A-6432-2015	Hogue, Christopher W V/0000-0002-3107-5246; Robinson, Mark D./0000-0002-3048-5518; Bader, Gary/0000-0003-0185-8861; Robinson, Mark D/0000-0002-3048-5518				Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Barstead R, 2001, CURR OPIN CHEM BIOL, V5, P63, DOI 10.1016/S1367-5931(00)00173-3; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bloom K, 2000, NAT CELL BIOL, V2, pE96, DOI 10.1038/35014089; Chen CY, 1998, GENETICS, V150, P577; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; EVANGELISTA M, IN PRESS NATURE CELL; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; Kroll ES, 1996, GENETICS, V143, P95; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; MAIOLATESI M, COMMUNICATION; MOCHIDA J, COMMUNICATION; Mullen JR, 2001, GENETICS, V157, P103; NOVICK P, 1989, GENETICS, V121, P659; OOI SL, COMMUNICATION; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; TONG AJ, UNPUB; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Wang TT, 1997, GENETICS, V147, P1595; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	29	1554	1588	5	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2364	2368		10.1126/science.1065810	http://dx.doi.org/10.1126/science.1065810			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743205				2022-12-28	WOS:000172817200050
J	Arlettaz, R; Jones, G; Racey, PA				Arlettaz, R; Jones, G; Racey, PA			Effect of acoustic clutter on prey detection by bats	NATURE			English	Article							SPECIES MYOTIS-MYOTIS; LONG-EARED BATS; ECHOLOCATION SIGNALS; FEEDING-BEHAVIOR; GLEANING BAT; DISCRIMINATION; MOTHS; STRATEGY	Bats that capture animal prey from substrates often emit characteristic echolocation calls that are short-duration, frequency-modulated (FM) and broadband(1). Such calls seem to be suited to locating prey in uncluttered habitats, including flying prey, but may be less effective for finding prey among cluttered backgrounds because echoes reflecting from the substrate mask the acoustic signature of prey(2-4). Perhaps these call designs serve primarily for spatial orientation(5-7). Furthermore, it has been unclear whether the acoustic image conveyed by FM echoes enables fine texture discrimination(3,8,9), or whether gleaning bats that forage in echo-cluttering environments must locate prey by using other cues, such as prey-generated sounds(5-7,10-13). Here we show that two species of insectivorous gleaning bats perform badly when compelled to detect silent and immobile prey in clutter, but are very efficient at capturing noisy prey items among highly cluttered backgrounds, and both dead or live prey in uncluttered habitats. These findings suggest that the short, broadband FM echolocation calls associated with gleaning bats are not adapted to detecting prey in clutter.	Univ Bern, Inst Zool, Div Conservat Biol, CH-3012 Bern, Switzerland; Univ Lausanne, Inst Ecol, CH-1015 Lausanne, Switzerland; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England; Univ Aberdeen, Dept Zool, Aberdeen AB24 2TZ, Scotland	University of Bern; University of Lausanne; University of Bristol; University of Aberdeen	Arlettaz, R (corresponding author), Univ Bern, Inst Zool, Div Conservat Biol, Baltzerstr 6, CH-3012 Bern, Switzerland.	raphael.arlettaz@nat.unibe.ch	Arlettaz, Raphaël/O-2182-2016	Arlettaz, Raphaël/0000-0001-6360-5339; Jones, Gareth/0000-0002-1904-3735				ANDERSON ME, 1993, ANIM BEHAV, V46, P1151, DOI 10.1006/anbe.1993.1304; ANDERSON ME, 1991, ANIM BEHAV, V42, P489, DOI 10.1016/S0003-3472(05)80048-X; Arlettaz R, 1999, J ANIM ECOL, V68, P460, DOI 10.1046/j.1365-2656.1999.00293.x; Arlettaz R, 1997, J ANIM ECOL, V66, P897, DOI 10.2307/6005; Arlettaz R, 1996, ANIM BEHAV, V51, P1, DOI 10.1006/anbe.1996.0001; BARCLAY RMR, 1994, ANIM BEHAV, V48, P1013, DOI 10.1006/anbe.1994.1334; BELL GP, 1982, BEHAV ECOL SOCIOBIOL, V10, P217, DOI 10.1007/BF00299688; BRIGHAM RM, 1995, ECOSCIENCE, V2, P276, DOI 10.1080/11956860.1995.11682294; FAURE PA, 1990, J COMP PHYSIOL A, V166, P843; FAURE PA, 1994, J COMP PHYSIOL A, V174, P651; FAURE PA, 1992, ANIM BEHAV, V44, P31, DOI 10.1016/S0003-3472(05)80751-1; FUZESSERY ZM, 1993, J COMP PHYSIOL A, V171, P767, DOI 10.1007/BF00213073; HABERSETZER J, 1983, J COMP PHYSIOL, V152, P275, DOI 10.1007/BF00611192; Jensen ME, 2001, J EXP BIOL, V204, P199; Johnston DS, 2001, J MAMMAL, V82, P362, DOI 10.1644/1545-1542(2001)082<0362:IAPLVI>2.0.CO;2; NEUWEILER G, 1989, TRENDS ECOL EVOL, V4, P160, DOI 10.1016/0169-5347(89)90120-1; NEUWEILER G, 1990, PHYSIOL REV, V70, P615, DOI 10.1152/physrev.1990.70.3.615; Norman AP, 1999, ANIM BEHAV, V57, P829, DOI 10.1006/anbe.1998.1028; Schmidt S, 2000, J COMP PHYSIOL A, V186, P975, DOI 10.1007/s003590000151; SCHMIDT S, 1988, NATURE, V331, P617, DOI 10.1038/331617a0; Schnitzler HU, 2001, BIOSCIENCE, V51, P557, DOI 10.1641/0006-3568(2001)051[0557:EBIEB]2.0.CO;2; SCHUMM A, 1991, BEHAV ECOL SOCIOBIOL, V28, P255; Siemers BM, 2000, BEHAV ECOL SOCIOBIOL, V47, P400, DOI 10.1007/s002650050683; SIMMONS JA, 1988, J ACOUST SOC AM, V84, P551, DOI 10.1121/1.396832; SIMMONS JA, 1980, J COMP PHYSIOL, V135, P61, DOI 10.1007/BF00660182; WEIBEL ER, 1998, PRINCIPLES ANIMAL DE	26	152	158	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					742	745		10.1038/414742a	http://dx.doi.org/10.1038/414742a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742397				2022-12-28	WOS:000172676200045
J	Michel, T; Reichhart, JM; Hoffmann, JA; Royet, J				Michel, T; Reichhart, JM; Hoffmann, JA; Royet, J			Drosophila Toll is activated by Gram-positive bacteria through a circulating peptidoglycan recognition protein	NATURE			English	Article							HOST-DEFENSE; INNATE IMMUNITY; ANTIFUNGAL; INFECTION; RECEPTORS; GENE; TLR4	Microbial infection activates two distinct intracellular signalling cascades in the immune-responsive fat body of Drosophila(1,2). Gram-positive bacteria and fungi predominantly induce the Toll signalling pathway, whereas Gram-negative bacteria activate the Imd pathway(3,4). Loss-of-function mutants in either pathway reduce the resistance to corresponding infections(4,5). Genetic screens have identified a range of genes involved in these intracellular signalling cascades(6-12), but how they are activated by microbial infection is largely unknown. Activation of the transmembrane receptor Toll requires a proteolytically cleaved form of an extracellular cytokine-like polypeptide, Spatzle(13), suggesting that Toll does not itself function as a bona fide recognition receptor of microbial patterns. This is in apparent contrast with the mammalian Toll-like receptors(14) and raises the question of which host molecules actually recognize microbial patterns to activate Toll through Spatzle. Here we present a mutation that blocks Toll activation by Gram-positive bacteria and significantly decreases resistance to this type of infection. The mutation semmelweis (seml) inactivates the gene encoding a peptidoglycan recognition protein (PGRP-SA). Interestingly, seml does not affect Toll activation by fungal infection, indicating the existence of a distinct recognition system for fungi to activate the Toll pathway.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Royet, J (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.			Michel, Tatiana/0000-0002-0146-9236				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CELINE LF, 1999, SEMMELWEIS IMAGINAIR; Franc NC, 2000, MICROBES INFECT, V2, P243, DOI 10.1016/S1286-4579(00)00304-X; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Turner M W, 2000, Rev Immunogenet, V2, P305; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	30	584	617	1	69	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					756	759		10.1038/414756a	http://dx.doi.org/10.1038/414756a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742401				2022-12-28	WOS:000172676200049
J	White, PD; Thomas, JM; Kangro, HO; Bruce-Jones, WDA; Amess, J; Crawford, DH; Grover, SA; Clare, AW				White, PD; Thomas, JM; Kangro, HO; Bruce-Jones, WDA; Amess, J; Crawford, DH; Grover, SA; Clare, AW			Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis	LANCET			English	Article							EPSTEIN-BARR-VIRUS; GLANDULAR FEVER; PSYCHIATRIC-DISORDERS; RISK-FACTORS; LIFE-EVENTS; SYMPTOMS; PERSONALITY; PERSISTENCE; RELIABILITY; DEPRESSION	Background Certain infections can trigger chronic fatigue syndromes (CFS) in a minority of people infected, but the reason is unknown. We describe some factors that predict or are associated with prolonged fatigue after infectious mononucleosis and contrast these factors with those that predicted mood disorders after the same infection. Methods We prospectively studied a cohort of 250 primary-care patients with infectious mononucleosis or ordinary upper-respiratory-tract infections until 6 months after clinical onset. We sought predictors of both acute and chronic fatigue syndromes and mood disorders from clinical, laboratory, and psychosocial measures. Findings An empirically defined fatigue syndrome 6 months after onset, which excluded comorbid psychiatric disorders, was most reliably predicted by a positive Monospot test at onset (odds ratio 2.1 [95% CI 1.4-3.3]) and lower physical fitness (0.35 [0.15-0.8]). Cervical lymphadenopathy and initial bed rest were associated with, or predicted, a fatigue syndrome up to 2 months after onset. By contrast, mood disorders were predicted by a premorbid psychiatric history (2.3 [1.4-3.9]), an emotional personality score (1.21 [1.11-1.35]), and social adversity (1.7 [1.0-2.9]). Definitions of CFS that included comorbid mood disorders were predicted by a mixture of those factors that predicted either the empirically defined fatigue syndrome or mood disorders. Interpretation The predictors of a prolonged fatigue syndrome after an infection differ with both definition and time, depending particularly on the presence or absence of comorbid mood disorders. The particular infection and its consequent immune reaction may have an early role, but physical deconditioning may also be important. By contrast, mood disorders are predicted by factors that predict mood disorders in general.	St Bartholomews & Royal London Sch Med & Dent, Dept Psychol Med, London, England; St Bartholomews & Royal London Sch Med & Dent, Dept Comp Sci, London, England; St Bartholomews & Royal London Sch Med & Dent, Dept Virol, London, England; St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, London, England; Univ London St Georges Hosp, Sch Med, Dept Virol, London SW17 0RE, England; Univ Edinburgh, Dept Med Microbiol, Edinburgh, Midlothian, Scotland	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; St Georges University London; University of Edinburgh	White, PD (corresponding author), St Bartholomews Hosp, St Bartholomews & Royal London Sch Med, Dept Psychol Med, London EC1A 7BE, England.			White, Peter/0000-0002-8193-5355				Ayres JG, 1998, QJM-MON J ASSOC PHYS, V91, P105, DOI 10.1093/qjmed/91.2.105; BERELOWITZ GJ, 1995, J VIRAL HEPATITIS, V2, P133, DOI 10.1111/j.1365-2893.1995.tb00018.x; Brown GW, 1989, LIFE EVENTS ILLNESS; BRUCEJONES WDA, 1994, PSYCHOL MED, V24, P651, DOI 10.1017/S003329170002780X; Buchwald DS, 2000, AM J MED, V109, P531, DOI 10.1016/S0002-9343(00)00560-X; Buckley L, 1999, J PSYCHOSOM RES, V46, P395, DOI 10.1016/S0022-3999(98)00120-2; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CLARK MR, 1995, AM J MED, V98, P187, DOI 10.1016/S0002-9343(99)80403-3; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; DALRYMPLE W, 1964, Postgrad Med, V35, P345; Dantzer R, 1998, ANN NY ACAD SCI, V856, P132, DOI 10.1111/j.1749-6632.1998.tb08321.x; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Eysenck H.J., 1975, MANUAL EYSENCK PERSO; FLEISHER GR, 1983, J CLIN MICROBIOL, V17, P619, DOI 10.1128/JCM.17.4.619-624.1983; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fulcher KY, 2000, J NEUROL NEUROSUR PS, V69, P302, DOI 10.1136/jnnp.69.3.302; Harvey V P, 1970, J Sports Med Phys Fitness, V10, P185; HENLE W, 1974, HUM PATHOL, V5, P551, DOI 10.1016/S0046-8177(74)80006-7; HOTOPF M, 1996, J NEUROL NEUROSUR PS, V60, P495; Katon W, 1999, GEN HOSP PSYCHIAT, V21, P21, DOI 10.1016/S0163-8343(98)00068-1; KENDELL RE, 1968, BRIT J PSYCHIAT, V114, P767, DOI 10.1192/bjp.114.511.767; LAMBORE S, 1991, J FAM PRACTICE, V33, P33; LEE CL, 1968, AM J CLIN PATHOL, V49, P12; Lloyd Andrew R., 1998, American Journal of Medicine, V105, p7S, DOI 10.1016/S0002-9343(98)00157-0; *OFF POP CONS SURV, 1980, CLASS OCC COD IND; PERKINS DO, 1994, AM J PSYCHIAT, V151, P233; Ray C, 1995, BRIT J MED PSYCHOL, V68, P323, DOI 10.1111/j.2044-8341.1995.tb01839.x; RILEY MS, 1990, BRIT MED J, V301, P953, DOI 10.1136/bmj.301.6758.953; *ROYAL COLL, 1996, CHRON FAT SYNDR REP, P1; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; SVEDMYR E, 1975, P NATL ACAD SCI USA, V72, P1622, DOI 10.1073/pnas.72.4.1622; Theorell T, 1999, PSYCHOSOM MED, V61, P304, DOI 10.1097/00006842-199905000-00009; THOMPSON DS, 1969, J AMER COLL HEALTH A, V17, P453; van der Werf SP, 2000, J PSYCHOSOM RES, V49, P373, DOI 10.1016/S0022-3999(00)00197-5; van Os J, 2001, BRIT J PSYCHIAT, V178, pS72, DOI 10.1192/bjp.178.40.s72; Vercoulen JHMM, 1998, J PSYCHOSOM RES, V45, P507, DOI 10.1016/S0022-3999(98)00023-3; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Wessely S, 1998, CHRONIC FATIGUE ITS; WHITE PD, 1995, PSYCHOL MED, V25, P917, DOI 10.1017/S0033291700037405; White PD, 1998, BRIT J PSYCHIAT, V173, P475, DOI 10.1192/bjp.173.6.475; WHITE PD, 1994, PERS INDIV DIFFER, V16, P801, DOI 10.1016/0191-8869(94)90223-2; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	113	114	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1946	1954		10.1016/S0140-6736(01)06961-6	http://dx.doi.org/10.1016/S0140-6736(01)06961-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	500HZ	11747919				2022-12-28	WOS:000172622200012
J	Feinberg, H; Mitchell, DA; Drickamer, K; Weis, WI				Feinberg, H; Mitchell, DA; Drickamer, K; Weis, WI			Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR	SCIENCE			English	Article							MANNOSE-BINDING PROTEIN; CELLS	Dendritic cell specific intracellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin (DC-SIGN), a C-type lectin present on the surface of dendritic cells, mediates the initial interaction of dendritic cells with T cells by binding to ICAM-3. DC-SIGN and DC-SIGNR, a related receptor found on the endothelium of Liver sinusoids, placental capillaries, and Lymph nodes, bind to oligosaccharides that are present on the envelope of human immunodeficiency virus (HIV), an interaction that strongly promotes viral infection of T cells. Crystal structures of carbohydrate-recognition domains of DC-SIGN and of DC-SIGNR bound to oligosaccharide, in combination with binding studies, reveal that these receptors selectively recognize endogenous high-mannose oligosaccharides and may represent a new avenue for developing HIV prophylactics.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.		Mitchell, Daniel A/A-6580-2009; Weis, William I/G-1437-2011	Mitchell, Daniel A/0000-0003-0936-6212; Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x	19	539	579	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2163	2166		10.1126/science.1066371	http://dx.doi.org/10.1126/science.1066371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739956				2022-12-28	WOS:000172647700050
J	Caffarelli, C; Petroccione, T				Caffarelli, C; Petroccione, T			False-negative food challenges in children with suspected food allergy	LANCET			English	Article							HYPERSENSITIVITY	Food allergy can be diagnosed from an immediate-onset reaction after oral food challenge. We administered 370 challenges fn 242 children; five (3%) of the 193 children tolerating foods on challenges developed immediate symptoms when the same preparation of foods was ingested openly at home the next day. We confirmed the food allergy by subsequent double-blind challenges. All children had positive skin-prick test reactions and all, but one, specific IgE antibodies to the offending foods. Our findings suggest that open feedings under observation, the day after negative challenges, are useful to eliminate false-negative challenge results.	Univ Parma, Dept Paediat, I-43100 Parma, Italy	University of Parma	Caffarelli, C (corresponding author), Univ Parma, Dept Paediat, I-43100 Parma, Italy.		Caffarelli, Carlo/AAC-2488-2022					BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Caffarelli C, 1998, PEDIATR RES, V44, P485, DOI 10.1203/00006450-199810000-00004; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; vanHalteren HK, 1996, J ALLERGY CLIN IMMUN, V97, P1058, DOI 10.1016/S0091-6749(96)70258-0; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X	5	56	57	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1871	1872		10.1016/S0140-6736(01)06897-0	http://dx.doi.org/10.1016/S0140-6736(01)06897-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741628				2022-12-28	WOS:000172463000014
J	Moret, Y; Schmid-Hempel, P				Moret, Y; Schmid-Hempel, P			Entomology - Immune defence in bumble-bee offspring	NATURE			English	Article							IMMUNIZATION; HEMOLYMPH; SYSTEM; INSECT		ETH Zurich, ETH Zentrum NW, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Moret, Y (corresponding author), ETH Zurich, ETH Zentrum NW, CH-8092 Zurich, Switzerland.		Moret, Yannick/I-9282-2012					Barnes AI, 2000, P ROY SOC B-BIOL SCI, V267, P177, DOI 10.1098/rspb.2000.0984; Coste A, 2000, J VIROL, V74, P8966, DOI 10.1128/JVI.74.19.8966-8971.2000; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P539, DOI 10.1016/0965-1748(94)90089-2; Moret Y, 2000, SCIENCE, V290, P1166, DOI 10.1126/science.290.5494.1166; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; Nigam Y, 1997, J INVERTEBR PATHOL, V69, P279, DOI 10.1006/jipa.1996.4652; Rollier C, 2000, VACCINE, V18, P3091, DOI 10.1016/S0264-410X(00)00130-4; SCHIMDHEMPEL P, 1998, PARASITES SOCIAL INS; Schmid-Hempel R, 1998, FUNCT ECOL, V12, P22, DOI 10.1046/j.1365-2435.1998.00153.x; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; TORNQVIST PO, 1996, DIS ASIAN AQUACULTUR, V3, P203	13	173	177	3	93	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					506	506		10.1038/35107138	http://dx.doi.org/10.1038/35107138			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734840				2022-12-28	WOS:000172405900033
J	Geba, GP; Weaver, AL; Polis, AB; Dixon, ME; Schnitzer, TJ				Geba, GP; Weaver, AL; Polis, AB; Dixon, ME; Schnitzer, TJ		VACT Grp	Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; GASTROINTESTINAL TOXICITY; OSTEO-ARTHRITIS; CYCLOOXYGENASE-2; EXPRESSION; CLASSIFICATION; MANAGEMENT; INHIBITION; PREFERENCE	Context Osteoarthritis (OA) is often treated with nonsteroidal ant-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2). Objective To assess the relative therapeutic efficacy of rofecoxib, celecoxib, and acetaminophen in adults with OA. Design and Setting Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United States. Patients Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen. Interventions Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n=96); rofecoxib 25 mg/d (n=95); celecoxib, 200 mg/d (n=97); or acetaminophen, 4000 mg/d (n=94) for 6 weeks. Main Outcome Measures Assessments over days 1 to 6 and over 6 weeks included pain on walking, night pain, pain at rest, and morning stiffness as measured on a Western Ontario McMaster Universities Osteoarthritis Index (100-mm visual analog scale [VAS]) and global response to therapy compared among 4 treatment groups. Results 79% of patients completed the study, More patients treated with acetaminophen discontinued early due to lack of efficacy than patients treated with COX-2 inhibitors (31% vs 18%-19%). Efficacy assessed in the first 6 days of therapy showed greatest response to rofecoxib, 25 mg/d, followed by rofecoxib, 12.5 mg/d, celecoxib, and acetaminophen, respectively, in terms of relief of pain on walking (-32.2, -29.0, -26.4, and -20.6 mm change on the VAS; P less than or equal to .04 for all others vs acetaminophen; P=.05 for 25-mg rofecoxib vs celecoxib), rest pain (-21.8, -18.6, -15.5, and -12.5 mm; P less than or equal to .02 for either dose of rofecoxib vs acetaminophen and P=.02 for rofecoxib, 25 mg/d, vs celecoxib), night pain (-25.2, -22.0, -18.7, and -18.8 mm; P=.04 for rofecoxib, 25 mg/d, vs both acetaminophen and celecoxib), and morning stiffness (-30.4,-28.4,-25.7, and -20.9 mm; P less than or equal to .02 for either dose of rofecoxib vs acetaminophen). Over 6 weeks, rofecoxib, 25 mg/d, provided greatest response for night pain (P<.002 vs celecoxib and P=.006 vs acetaminophen and P=.02 vs rofecoxib, 12.5 mg/d), composite pain subscale (P<less than or equal to>.03 vs all other treatments), stiff ness subscale (P less than or equal to .04 vs celecoxib and acetaminophen), and physical function subscale (P=.001 vs acetaminophen). Global responses over 6 weeks showed a similar pattern (good or excellent response at week 6: 60%, 56%, 46%, and 39%, respectively; P less than or equal to .03 for rofecoxib, 25 mg/d, vs celecoxib and acetaminophen; P=.02 for rofecoxib, 12.5 mg/d, vs acetaminophen). All treatments were generally safe and well tolerated. Conclusion Rofecoxib, 25 mg/d, provided efficacy advantages over acetaminophen, 4000 mg/d, celecoxib, 200 mg/d, and rofecoxib, 12.5 mg, for symptomatic knee OA.	Merck & Co Inc, US Human Hlth, W Point, PA 19486 USA; Arthrit Ctr Nebraska, Lincoln, NE USA; Northwestern Univ, Chicago, IL 60611 USA	Merck & Company; Northwestern University	Geba, GP (corresponding author), Merck & Co Inc, US Human Hlth, POB 4, W Point, PA 19486 USA.	gregory_geba@merck.com						Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; *AM SOC HLTH SYST, 1894, AHFS DRUG INF 2000; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; Creamer P, 1998, CLIN GERIATR MED, V14, P435; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Ehrich EW, 1999, J RHEUMATOL, V26, P2438; FELSON DT, 1993, RHEUM DIS CLIN N AM, V19, P607; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; Langman MJ, 1999, JAMA-J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929; LEE SH, 1992, J BIOL CHEM, V267, P25934; LYONSGIORDANO B, 1993, EXP CELL RES, V206, P58, DOI 10.1006/excr.1993.1120; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Pincus T, 2000, J RHEUMATOL, V27, P1020; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; Scheiman JM, 1996, GASTROENTEROL CLIN N, V25, P279, DOI 10.1016/S0889-8553(05)70247-8; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Williams GW, 2001, CLIN THER, V23, P213, DOI 10.1016/S0149-2918(01)80004-7; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; Wolfe F, 2000, ARTHRITIS RHEUM-US, V43, P378, DOI 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2; Yelin E, 1998, OSTEOARTHRITIS, P23	30	185	191	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					64	71		10.1001/jama.287.1.64	http://dx.doi.org/10.1001/jama.287.1.64			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754710	Bronze			2022-12-28	WOS:000172978500027
J	Heady, HR				Heady, HR			A delicate balance: The economics of rural health care delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA	West Virginia University	Heady, HR (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.							EDERHARDT MS, 2001, URBAN RURAL HLTH CHA; HART GL, 2001, TXB RURAL MED, P74; MOHR P, 2001, ESTABLISHING FAIR ME; WELLEVER A, 2001, AREA WAGE INDEX MEDI	4	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					110	110		10.1001/jama.287.1.110	http://dx.doi.org/10.1001/jama.287.1.110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506NK	11754720	hybrid			2022-12-28	WOS:000172978500036
J	Altschuler, EL				Altschuler, EL			One of the oldest cases of schizophrenia in Gogol's Diary of a Madman	BRITISH MEDICAL JOURNAL			English	Article									Univ Calif San Diego, Brain & Percept Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Altschuler, EL (corresponding author), Univ Calif San Diego, Brain & Percept Lab, 9500 Gilman Dr,0109, La Jolla, CA 92093 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NJC, 1976, JAMA-J AM MED ASSOC, V235, P1868, DOI 10.1001/jama.235.17.1868; BARK NM, 1985, BRIT J PSYCHIAT, V146, P436, DOI 10.1192/bjp.146.4.436; FANGER D, 1979, CREATION  N GOGOL, P115; FEDIO P, 1986, PSYCHIAT CLIN N AM, V9, P267; Gogol Nikolai, 1972, DIARY MADMAN OTHER S; HARE E, 1988, BRIT J PSYCHIAT, V153, P521, DOI 10.1192/bjp.153.4.521; Haslam J, 1809, OBSERVATIONS MELANCH; Kohl F, 1999, PSYCHIAT PRAX, V26, P105; MOSKOVITZ RA, 1978, LANCET, V1, P664; Pinel P, 1809, TRAITE MED PHILOS AL; Schultz SK, 1999, LANCET, V353, P1425, DOI 10.1016/S0140-6736(98)07549-7	12	6	7	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1475	1477		10.1136/bmj.323.7327.1475	http://dx.doi.org/10.1136/bmj.323.7327.1475			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506PA	11751362	Green Published			2022-12-28	WOS:000172979900022
J	Mason, J; Freemantle, N; Nazareth, I; Eccles, M; Haines, A; Drummond, M				Mason, J; Freemantle, N; Nazareth, I; Eccles, M; Haines, A; Drummond, M			When is it cost-effective to change the behavior of health professionals?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONVERTING-ENZYME-INHIBITORS; PRIMARY-CARE; DEVELOPMENT PROJECT; HEART-FAILURE; GUIDELINE; NORTH	Because of the workings of health care systems, new, important, and cost-effective treatments sometimes do not become routine care while well-marketed products of equivocal value achieve widespread adoption. Should policymakers attempt to influence clinical behavior and correct for these inefficiencies? Implementation methods achieve a certain level of behavioral change but cost money to enact. These factors can be combined with the cost-effectiveness of treatments to estimate an overall policy cost-effectiveness. In general, policy cost-effectiveness is always less attractive than treatment cost-effectiveness. Consequently trying to improve the uptake of underused cost-effective care or reduce the overuse of new and expensive treatments may not always make economic sense. in this article, we present a method for calculating policy cost-effectiveness and illustrate it with examples from a recent trial, conducted during 1997 and 1998, of educational outreach by community pharmacists to influence physician prescribing in England.	Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Birmingham, Dept Primary Care & Gen Practice, Edgbaston, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England; London Sch Hyg & Trop Med, London WC1, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	Newcastle University - UK; University of Birmingham; University of London; University College London; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine; University of York - UK	Mason, J (corresponding author), Newcastle Univ, Ctr Hlth Serv Res, 21 Claremont Pl, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	james.mason@ncl.ac.uk	Eccles, Martin P/AAD-4029-2020; Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; Haines, Andy/0000-0002-8053-4605; Freemantle, Nick/0000-0001-5807-5740; Nazareth, Irwin/0000-0003-2146-9628				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BIRMINGHAM R, 2000, GEN PERSONAL MED STA; Durieux P, 2000, JAMA-J AM MED ASSOC, V283, P2816, DOI 10.1001/jama.283.21.2816; Eccles M, 1999, FAM PRACT, V16, P103, DOI 10.1093/fampra/16.2.103; Eccles M, 1998, BMJ-BRIT MED J, V316, P1369, DOI 10.1136/bmj.316.7141.1369; *EFF HLTH CAR, 1994, U LEEDS B, V8; Freemantle N, 1999, CONTROL CLIN TRIALS, V20, P479, DOI 10.1016/S0197-2456(99)00023-9; Freemantle N, 2000, PHARMACOECONOMICS, V17, P319, DOI 10.2165/00019053-200017040-00001; FREEMANTLE N, 1996, COCHRANE DATABASE SY, V3; FREEMANTLE N, IN PRESS BR J GEN PR; Mason J, 1999, J Health Serv Res Policy, V4, P106; Mason J, 2000, BRIT MED J, V321, P1113, DOI 10.1136/bmj.321.7269.1113; *NAT EL LIB HLTH, 2001, CLIN GUID DAT N ENGL; *OPCS, 1995, OPCS MON MORB STAT G	14	141	143	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2988	2992		10.1001/jama.286.23.2988	http://dx.doi.org/10.1001/jama.286.23.2988			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743840	Green Accepted			2022-12-28	WOS:000172764500031
J	French, CC				French, CC			Dying to know the truth: visions of a dying brain, or false memories?	LANCET			English	Editorial Material							IMAGINATION INFLATION		Univ London Goldsmiths Coll, Anomalist Psychol Res Unit, London SE14 6NW, England	University of London; Goldsmiths University London	French, CC (corresponding author), Univ London Goldsmiths Coll, Anomalist Psychol Res Unit, London SE14 6NW, England.	c.french@gold.ac.uk						BLACKMORE S, 1996, ENCY PARANORMAL, P480; Blackmore S., 1993, DYING LIVE SCI NEAR; Garry M, 1996, PSYCHON B REV, V3, P208, DOI 10.3758/BF03212420; Goff LM, 1998, MEM COGNITION, V26, P20, DOI 10.3758/BF03211367; Heaps C, 1999, PSYCHON B REV, V6, P313, DOI 10.3758/BF03214120; Hyman IE, 1998, MEMORY, V6, P1, DOI 10.1080/741941598; Loftus EF, 2001, PSYCHOLOGIST, V14, P584; Parnia S, 2001, RESUSCITATION, V48, P149, DOI 10.1016/S0300-9572(00)00328-2; PARNIA S, IN PRESS RESUSCITATI	9	29	31	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2010	2011		10.1016/S0140-6736(01)07133-1	http://dx.doi.org/10.1016/S0140-6736(01)07133-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	502BB	11755600				2022-12-28	WOS:000172722800002
J	Srivatsa, B; Srivatsa, S; Johnson, KL; Samura, O; Lee, SL; Bianchi, DW				Srivatsa, B; Srivatsa, S; Johnson, KL; Samura, O; Lee, SL; Bianchi, DW			Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study	LANCET			English	Article							BONE-MARROW; CELLS; IMMUNOLOGY; PREGNANCY; DNA	Background Some so-called autoimmune diseases in women might be alloimmune and represent a chronic graft-versus-host response attributable to transplacentally acquired fetal cells. Thyroid disease is more common in women than men, and post partum exacerbation of thyroiditis is common. Our aim was to investigate whether there is an association between fetal cell microchimerism and thyroid disease in women. Methods Surgical specimens were obtained from 29 women who underwent thyroidectomy for various thyroid disorders. Control specimens were taken from clinically and histologically normal thyroids obtained at necropsy from eight women who died from unrelated conditions. Medical records and pregnancy histories were reviewed. Fluorescence in-situ hybridisation analysis was done with probes specific for X and Y chromosomes. Slides were examined with a fluorescence microscope to detect the presence of male cells-with one X and one Y signal in the nucleus-among maternal cells containing two X signals. Findings Male cells were seen in thyroid sections from 16 patients but not in those from controls (p=0.01). Male cells (1-165 per slide) were seen individually or in clusters in all thyroid diseases and were not restricted to inflammatory thyroid diseases. In one patient with a progressively enlarging goitre, we noted fully differentiated male thyroid follicles closely attached to and indistinguishable from the rest of the thyroid. Interpretation Our findings suggest a relation between fetal cell microchimerism and thyroid disease. Furthermore, fetal stem cells might be capable of differentiation into mature thyroid follicles in their mothers with favourable environmental and developmental factors.	Tufts Univ, New England Med Ctr,Sch Med, Dept Paediat,Div Genet, Floating Hosp Children, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr,Sch Med, Div Endocrinol Diabet Metab & Mol Med, Dept Med, Boston, MA 02111 USA	Floating Hospital For Children; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Bianchi, DW (corresponding author), Tufts Univ, New England Med Ctr,Sch Med, Dept Paediat,Div Genet, Floating Hosp Children, Box 394,750 Washington St, Boston, MA 02111 USA.	DBianchi@Lifespan.org	Samura, Osamu/AAD-1079-2020	Samura, Osamu/0000-0002-7249-1537	NICHD NIH HHS [HD07492, HD43204] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDO T, 2001, 83 ANN M END SOC JUN; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Bianchi DW, 2000, AM J MED GENET, V91, P22, DOI 10.1002/(SICI)1096-8628(20000306)91:1<22::AID-AJMG4>3.0.CO;2-3; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Davies TF, 1999, THYROID, V9, P675, DOI 10.1089/thy.1999.9.675; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; DEMOOR G, 1988, ACTA CLIN BELG, V43, P231; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HUTCHINSON DL, 1967, AM J OBSTET GYNECOL, V99, P702, DOI 10.1016/0002-9378(67)90418-8; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; Johnson TC, 2000, AMBIO, V29, P2, DOI 10.1639/0044-7447(2000)029[0002:THHOLV]2.0.CO;2; Klintschar M, 2001, J CLIN ENDOCR METAB, V86, P2494, DOI 10.1210/jc.86.6.2494; Nath J, 1998, BIOTECH HISTOCHEM, V73, P6, DOI 10.3109/10520299809140502; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Schmorl G, 1893, PATHOLOGISCHE ANATOM; SCHRODER J, 1974, TRANSPLANTATION, V17, P346, DOI 10.1097/00007890-197404000-00003; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Tyndall A, 1998, NAT MED, V4, P386, DOI 10.1038/nm0498-386; Vietor HE, 2000, BLOOD, V95, P2709; ZHENG YL, 1995, PRENATAL DIAG, V15, P897, DOI 10.1002/pd.1970151004	23	200	205	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2001	358	9298					2034	2038		10.1016/S0140-6736(01)07099-4	http://dx.doi.org/10.1016/S0140-6736(01)07099-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755610				2022-12-28	WOS:000172722800012
J	Randall, VA				Randall, VA			Is alopecia areata an autoimmune disease?	LANCET			English	Editorial Material							GENE-RELATED PEPTIDE; HAIR-GROWTH; SUBSTANCE-P; HUMAN SKIN; EXPRESSION; INNERVATION; FOLLICLES; NERVES; MICE		Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England	University of Bradford	Randall, VA (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	v.a.randall@bradford.ac.uk						Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; Colombe BW, 1999, J INVEST DERM SYMP P, V4, P216, DOI 10.1038/sj.jidsp.5640214; Daly TJ, 1998, ARCH DERMATOL, V134, P1164, DOI 10.1001/archderm.134.9.1164; Duvic M, 2001, CLIN DERMATOL, V19, P135, DOI 10.1016/S0738-081X(00)00124-3; Freyschmidt-Paul P, 2000, J INVEST DERMATOL, V115, P653, DOI 10.1046/j.1523-1747.2000.00113.x; Gilhar A, 1999, J INVEST DERM SYMP P, V4, P207, DOI 10.1038/sj.jidsp.5640212; Hordinsky M, 1996, INT CONGR SER, V1111, P197; Hordinsky M, 1999, J INVEST DERM SYMP P, V4, P316, DOI 10.1038/sj.jidsp.5640237; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Madani S, 2000, J AM ACAD DERMATOL, V42, P549, DOI 10.1016/S0190-9622(00)90164-6; McElwee KJ, 1996, BRIT J DERMATOL, V135, P211, DOI 10.1111/j.1365-2133.1996.tb01149.x; McElwee KJ, 1999, EXP DERMATOL, V8, P371, DOI 10.1111/j.1600-0625.1999.tb00385.x; Messenger AG, 2000, HAIR AND ITS DISORDERS: BIOLOGY, PATHOLOGY AND MANAGEMENT, P177; Nutbrown M, 1996, BRIT J DERMATOL, V135, P204, DOI 10.1046/j.1365-2133.1996.d01-976.x; Olerud JE, 1999, J INVEST DERMATOL, V112, P873, DOI 10.1046/j.1523-1747.1999.00596.x; Olsen E, 1999, J AM ACAD DERMATOL, V40, P242, DOI 10.1016/S0190-9622(99)70195-7; PAUS R, 1994, LAB INVEST, V71, P134; Peters EMJ, 2001, J INVEST DERMATOL, V116, P236, DOI 10.1046/j.1523-1747.2001.01232.x; Philpott MP, 2000, HAIR AND ITS DISORDERS: BIOLOGY, PATHOLOGY AND MANAGEMENT, P103; Picardi A, 2001, PSYCHOTHER PSYCHOSOM, V70, P118, DOI 10.1159/000056237; Rossi R, 1997, NEUROREPORT, V8, P1135, DOI 10.1097/00001756-199703240-00015; SKINNER RB, 1995, JAMA-J AM MED ASSOC, V273, P1419, DOI 10.1001/jama.273.18.1419; TOBIN DJ, 1994, J INVEST DERMATOL, V102, P721, DOI 10.1111/1523-1747.ep12375477; Toyoda M, 2001, BRIT J DERMATOL, V144, P46, DOI 10.1046/j.1365-2133.2001.03951.x	24	42	46	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1922	1924		10.1016/S0140-6736(01)06943-4	http://dx.doi.org/10.1016/S0140-6736(01)06943-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747911				2022-12-28	WOS:000172622200004
J	Zou, ZG; Ye, JH; Sayama, K; Arakawa, H				Zou, ZG; Ye, JH; Sayama, K; Arakawa, H			Direct splitting of water under visible light irradiation with an oxide semiconductor photocatalyst	NATURE			English	Article							PARTICLES; EVOLUTION; H-2; O-2	The photocatalytic splitting of water into hydrogen and oxygen using solar energy is a potentially clean and renewable source for hydrogen fuel. The first photocatalysts suitable for water splitting(1), or for activating hydrogen production from carbohydrate compounds made by plants from water and carbon dioxide(2), were developed several decades ago. But these catalysts operate with ultraviolet light, which accounts for only 4% of the incoming solar energy and thus renders the overall process impractical. For this reason, considerable efforts have been invested in developing photocatalysts capable of using the less energetic but more abundant visible light(3-7), which accounts for about 43% of the incoming solar energy. However, systems that are sufficiently stable and efficient for practical use have not yet been realized. Here we show that doping of indium-tantalum-oxide with nickel yields a series of photocatalysts, In1-xNixTaO4 (x = 0-0.2), which induces direct splitting of water into stoichiometric amounts of oxygen and hydrogen under visible light irradiation with a quantum yield of about 0.66%. Our findings suggest that the use of solar energy for photocatalytic water splitting might provide a viable source for 'clean' hydrogen fuel, once the catalytic efficiency of the semiconductor system has been improved by increasing its surface area and suitable modifications of the surface sites.	Natl Inst Adv Ind Sci & Technol, PCRC, Tsukuba, Ibaraki 3058565, Japan; NIMS, MEL, Tsukuba, Ibaraki 3050047, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute for Materials Science	Zou, ZG (corresponding author), Natl Inst Adv Ind Sci & Technol, PCRC, 1-1-1 Higashi, Tsukuba, Ibaraki 3058565, Japan.		Sayama, Kazuhiro/L-6577-2018; tang, jing/HHR-9815-2022; YE, Jinhua/H-2755-2011	Sayama, Kazuhiro/0000-0003-1847-5242; YE, Jinhua/0000-0002-8105-8903				DAREEDWARDS MP, 1981, J CHEM SOC FARAD T 2, V77, P643, DOI 10.1039/f29817700643; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; GEOFFREY BS, 1997, J PHYS CHEM B, V101, P2508; IZUMI F, 1985, J CRYSTALLOGR SOC JA, V27, P23; KAWAI T, 1980, NATURE, V286, P474, DOI 10.1038/286474a0; Kim HG, 1999, CHEM COMMUN, P1077, DOI 10.1039/a902892g; KIM YI, 1993, J PHYS CHEM-US, V97, P11802, DOI 10.1021/j100147a038; KIM YI, 1991, J AM CHEM SOC, V113, P9561, DOI 10.1021/ja00025a021; KUDO A, 1989, J CATAL, V120, P337, DOI 10.1016/0021-9517(89)90274-1; Kudo A, 1998, CHEM LETT, P1027, DOI 10.1246/cl.1998.1027; LINSEBIGLER AL, 1995, CHEM REV, V95, P735, DOI 10.1021/cr00035a013; Machida M, 2000, CHEM MATER, V12, P812, DOI 10.1021/cm990577j; YOSHIMURA J, 1993, J PHYS CHEM-US, V97, P1970, DOI 10.1021/j100111a039; Zou ZG, 2000, CHEM PHYS LETT, V332, P271, DOI 10.1016/S0009-2614(00)01265-3; Zou ZG, 2001, CHEM MATER, V13, P1765, DOI 10.1021/cm000687m	15	2876	2989	46	2990	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					625	627		10.1038/414625a	http://dx.doi.org/10.1038/414625a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740556				2022-12-28	WOS:000172535600044
J	Beroukas, T; Hiscock, J; Jonsson, R; Waterman, SA; Gordon, TP				Beroukas, T; Hiscock, J; Jonsson, R; Waterman, SA; Gordon, TP			Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome	LANCET			English	Article								Secretions from salivary and lacrimal glands are reduced in patients with primary Sjogren's syndrome (PSS). Since aquaporin 5 is involved in transport of water and is present in salivary and lacrimal glands, this protein was thought to have a major role in the pathogenesis of PSS. We used indirect immunofluorescence and an immunoperoxidase technique to assess expression and subcellular localisation of aquaporin 5 in patients and controls. Our results suggest that the distribution and density of aquaporin 5 in salivary glands does not differ between patients with PSS and those without. Thus, the role of aquaporin 5 in the pathogenesis of PSS needs to be reassessed and alternative pathogenetic mechanisms investigated.	Flinders Med Ctr, Dept Immunol Allergy & Arthritis, Bedford Pk, SA 5042, Australia; Univ Bergen, Broegelmann Res Lab, Bergen, Norway	Flinders Medical Centre; University of Bergen	Gordon, TP (corresponding author), Flinders Med Ctr, Dept Immunol Allergy & Arthritis, Bedford Pk, SA 5042, Australia.	imtg@flinders.edu.au		Waterman, Sally/0000-0003-2579-3636; Gordon, Thomas/0000-0003-3232-8249				Gresz V, 2001, AM J PHYSIOL-GASTR L, V281, pG247, DOI 10.1152/ajpgi.2001.281.1.G247; Jonsson R., 2001, ARTHRITIS ALLIED CON, Vp, P1736; NIELSEN S, 1997, AM J PHYSIOL, V42, pC1549; Steinfeld S, 2001, LAB INVEST, V81, P143, DOI 10.1038/labinvest.3780221; Tsubota K, 2001, LANCET, V357, P688, DOI 10.1016/S0140-6736(00)04140-4	5	75	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1875	1876		10.1016/S0140-6736(01)06900-8	http://dx.doi.org/10.1016/S0140-6736(01)06900-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741631				2022-12-28	WOS:000172463000017
J	Shorvon, S				Shorvon, S			Pyrrolidone derivatives	LANCET			English	Article							LEVETIRACETAM UCB L059; AMPA RECEPTOR MODULATORS; ADD-ON THERAPY; DOUBLE-BLIND; LONG-TERM; ANTICONVULSANT DRUG; ALZHEIMERS-DISEASE; ANTIEPILEPTIC DRUG; PYRAMIDAL NEURONS; PARTIAL SEIZURES	The pyrrolidone (2-oxopyrrolidine) family of chemicals has been the subject of research for mare than three decades. Experimental and clinical work first focused on their so-called nootropic effects; later name the possibilities for neuroprotection after stroke and use as antiepileptic agents. Piracetam, the first of the class, was developed by pioneering research by C Giurgea in the late 1960s, and it was he who coined the term "nootropic", to mean enhancement of learning and memory. The term is sometimes extended to include other actions such as neuroprotection. These properties, together with the lack of other generally adverse psychopharmacological actions (eg, sedation, analgesia, or motor or behavioural changes), distinguish the pyrrolidones from other psychoactive drug classes. The mechanisms of action of these drugs are still not fully established; indeed, different compounds in this class may have different modes of action. Interest in this drug class has recently been reawakened by the licensing of levetiracetam as a potentially major new antiepileptic drug and of piracetam for its antimyoclonic action and effects after stroke and in mild cognitive impairment. Other drugs in this class are currently at an advanced stage of development, and the renewal of interest in this therapeutic area is likely to mean not only that more pyrrolidones will enter clinical practice in the next few years but also that the clinical indications of drugs already licensed will widen.	Natl Neurol Inst, Singapore 308433, Singapore; UCL, Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Clin Neurol, London WC1, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Shorvon, S (corresponding author), Natl Neurol Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	s.shorvon@ion.ucl.ac.uk	Shorvon, Simon D/A-2019-2009					Bartolini L, 1996, PHARMACOL BIOCHEM BE, V53, P277, DOI 10.1016/0091-3057(95)02021-7; Ben-Menachem E, 2000, EPILEPSIA, V41, P1276, DOI 10.1111/j.1528-1157.2000.tb04605.x; Betts T, 2000, SEIZURE-EUR J EPILEP, V9, P80, DOI 10.1053/seiz.2000.0380; Birnstiel S, 1997, N-S ARCH PHARMACOL, V356, P611, DOI 10.1007/PL00005097; Black MD, 2000, EUR J PHARMACOL, V394, P85, DOI 10.1016/S0014-2999(00)00120-5; BROWN P, 1993, MOVEMENT DISORD, V8, P63, DOI 10.1002/mds.870080112; Browne TR, 2000, J CLIN PHARMACOL, V40, P590, DOI 10.1177/00912700022009369; BRYANT RC, 1973, PSYCHOPHARMACOLOGIA, V29, P121, DOI 10.1007/BF00422644; Cereghino JJ, 2000, NEUROLOGY, V55, P236, DOI 10.1212/WNL.55.2.236; CORASANITI MT, 1995, FUNCT NEUROL, V10, P151; CROISILE B, 1993, NEUROLOGY, V43, P301, DOI 10.1212/WNL.43.2.301; DeDeyn PP, 1997, STROKE, V28, P2347, DOI 10.1161/01.STR.28.12.2347; ENDERBY P, 1994, CLIN NEUROPHARMACOL, V17, P320, DOI 10.1097/00002826-199408000-00003; Endo H, 1997, BEHAV BRAIN RES, V83, P243, DOI 10.1016/S0166-4328(97)86079-2; FALLARINO F, 1995, J NEUROCHEM, V65, P912; FLICKER L, 1999, COCHRANE LIB, V1, P1; FORDYCE DE, 1995, BRAIN RES, V672, P170, DOI 10.1016/0006-8993(94)01389-Y; FUJIMAKI Y, 1995, ARZNEIMITTELFORSCH, V45, P748; Genton P, 1999, PHARMACOPSYCHIATRY, V32, P49; Genton P, 2000, EPILEPTIC DISORD, V2, P99; GIURGEA C, 1977, PROG NEURO-PSYCHOPHA, V1, P235, DOI 10.1016/0364-7722(77)90046-7; GOULIAEV AH, 1994, BRAIN RES REV, V19, P180, DOI 10.1016/0165-0173(94)90011-6; GOWER AJ, 1992, EUR J PHARMACOL, V222, P193, DOI 10.1016/0014-2999(92)90855-X; Gower AJ, 1995, EPILEPSY RES, V22, P207, DOI 10.1016/0920-1211(95)00077-1; Grant R, 2000, EPILEPSY RES, V42, P89, DOI 10.1016/S0920-1211(00)00158-3; Harada Shigeo, 1995, Journal of Toxicological Sciences, V20, P309; Hashizume K, 2000, EPILEPSY RES, V39, P221, DOI 10.1016/S0920-1211(00)00099-1; HERRSCHAFT H, 1998, CNS DRUGS S1, V9, P1; Hiramatsu M, 1997, BEHAV BRAIN RES, V83, P107, DOI 10.1016/S0166-4328(97)86053-6; Hitzenberger G, 1998, CNS DRUGS, V9, P19, DOI 10.2165/00023210-199809001-00003; Huber W, 1997, ARCH PHYS MED REHAB, V78, P245, DOI 10.1016/S0003-9993(97)90028-9; Imran MB, 1998, CLIN NUCL MED, V23, P601, DOI 10.1097/00003072-199809000-00008; Kashida Y, 1996, TOXICOL PATHOL, V24, P549, DOI 10.1177/019262339602400503; KATAOKA Y, 1995, JPN J PHARMACOL, V67, P87, DOI 10.1254/jjp.67.87; Katsunuma H, 1998, PSYCHIAT CLIN NEUROS, V52, P198, DOI 10.1111/j.1440-1819.1998.tb01028.x; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Kolta A, 1998, BRAIN RES, V788, P269, DOI 10.1016/S0006-8993(97)01444-3; Koskiniemi M, 1998, J NEUROL NEUROSUR PS, V64, P344, DOI 10.1136/jnnp.64.3.344; Krakow K, 2001, NEUROLOGY, V56, P1772, DOI 10.1212/WNL.56.12.1772; LEE CR, 1994, DRUG AGING, V4, P257, DOI 10.2165/00002512-199404030-00007; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Loscher W, 2000, EPILEPSY RES, V40, P63, DOI 10.1016/S0920-1211(00)00108-X; LOSCHER W, 1993, EUR J PHARMACOL, V232, P147, DOI 10.1016/0014-2999(93)90768-D; Lu Y, 1997, BRAIN RES, V768, P197, DOI 10.1016/S0006-8993(97)00644-6; Ma YX, 1998, ANN NY ACAD SCI, V854, P508; Margineanu DG, 2000, PHARMACOL RES, V42, P281; MARGINEANU DG, 1995, EUR J PHARMACOL, V286, P321, DOI 10.1016/0014-2999(95)00597-8; MARTIN JR, 1993, DRUG INVEST, V5, P4, DOI 10.1007/BF03258426; Muller WE, 1997, BIOCHEM PHARMACOL, V53, P135, DOI 10.1016/S0006-2952(96)00463-7; Nakamura K, 1999, EUR J PHARMACOL, V380, P81, DOI 10.1016/S0014-2999(99)00534-8; Nakamura K, 2000, BRAIN RES, V862, P266, DOI 10.1016/S0006-8993(00)02160-0; Nicolas JM, 1999, DRUG METAB DISPOS, V27, P250; Niespodziany I, 2001, NEUROSCI LETT, V306, P5, DOI 10.1016/S0304-3940(01)01884-5; Nishizaki T, 1999, BRAIN RES, V826, P281, DOI 10.1016/S0006-8993(99)01312-8; NOYER M, 1995, EUR J PHARMACOL, V286, P137, DOI 10.1016/0014-2999(95)00436-O; O'Gorman DA, 1998, ANESTHESIOLOGY, V89, P699, DOI 10.1097/00000542-199809000-00021; Odumeru O, 1997, BEHAV BRAIN RES, V83, P173; Ogasawara T, 1999, PHARMACOL BIOCHEM BE, V64, P41, DOI 10.1016/S0091-3057(99)00108-2; Ogiso T, 2000, BIOL PHARM BULL, V23, P482; Ogiso T, 1998, J PHARM SCI, V87, P594, DOI 10.1021/js970355p; OHJIMI H, 1994, J PHARMACOL EXP THER, V268, P396; Orgogozo JM, 1998, CNS DRUGS, V9, P41, DOI 10.2165/00023210-199809001-00005; Oyaizu M, 1999, BRAIN RES, V822, P72, DOI 10.1016/S0006-8993(99)01077-X; PARNETTI L, 1995, CLIN PHARMACOKINET, V29, P110, DOI 10.2165/00003088-199529020-00005; Patsalos PN, 2000, PHARMACOL THERAPEUT, V85, P77, DOI 10.1016/S0163-7258(99)00052-2; PEUVOT J, 1995, BIOCHEM PHARMACOL, V50, P1129, DOI 10.1016/0006-2952(95)00225-O; POSCHEL BPH, 1993, DRUGS EXPT CLIN RES, V12, P853; Rigo J. M., 2000, Epilepsia, V41, P35; RONCARI G, 1993, DRUG INVEST, V5, P68, DOI 10.1007/BF03258428; Sakurai T, 1998, NEUROSCI LETT, V246, P69, DOI 10.1016/S0304-3940(98)00244-4; SARA SJ, 1972, PSYCHOPHARMACOLOGIA, V25, P32, DOI 10.1007/BF00422614; SENIN U, 1993, DRUG INVEST, V5, P96, DOI 10.1007/BF03258430; Sharief MK, 1996, J EPILEPSY, V9, P106, DOI 10.1016/0896-6974(96)00010-2; Shiotani T, 2000, BRAIN RES, V859, P255, DOI 10.1016/S0006-8993(00)01971-5; Shirane M, 2000, NEUROPHARMACOLOGY, V39, P866, DOI 10.1016/S0028-3908(99)00271-3; Shorvon SD, 2000, EPILEPSIA, V41, P1179, DOI 10.1111/j.1528-1157.2000.tb00323.x; Smith L, 2000, EPILEPSIA, V41, pS48; Takayanagi I, 1997, JPN J PHARMACOL, V73, P1, DOI 10.1254/jjp.73.1; Takeo S, 1996, ARCH INT PHARMACOD T, V331, P232; Takeo S, 1997, BIOL PHARM BULL, V20, P360; Takeo S, 1997, BRIT J PHARMACOL, V121, P477, DOI 10.1038/sj.bjp.0701161; TERWINGHE G, 1978, ACTA NEUROL BELG, V78, P30; Trenite DGAKN, 1996, EPILEPSY RES, V25, P225, DOI 10.1016/S0920-1211(96)00031-9; VanVleymen B, 1996, ACTA NEUROL BELG, V96, P270; VERLOES R, 1988, PSYCHOPHARMACOLOGY, V95, P226; VILLARDITA C, 1992, NEUROPSYCHOBIOLOGY, V25, P24, DOI 10.1159/000118805; WATANABE T, 1994, ARZNEIMITTEL-FORSCH, V44-1, P239; WOLTHUIS OL, 1971, EUR J PHARMACOL, V16, P283, DOI 10.1016/0014-2999(71)90029-X; WoodruffPak DS, 1997, PSYCHOPHARMACOLOGY, V131, P130, DOI 10.1007/s002130050275; WoodruffPak DS, 1997, BEHAV BRAIN RES, V83, P179, DOI 10.1016/S0166-4328(97)86065-2; XUE CD, 1994, CAN J PHYSL PHARM S1, V72, P405; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Yoshii M, 1998, Nihon Yakurigaku Zasshi, V112 Suppl 1, p41P	93	115	134	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1885	1892		10.1016/S0140-6736(01)06890-8	http://dx.doi.org/10.1016/S0140-6736(01)06890-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741647				2022-12-28	WOS:000172463000031
J	Fujiwara, M; Caswell, H				Fujiwara, M; Caswell, H			Demography of the endangered North Atlantic right whale	NATURE			English	Article							EUBALAENA-GLACIALIS; SURVIVAL	Northern right whales (Eubalaena glacialis) were formerly abundant in the northwestern Atlantic, but by 1900 they had been hunted to near extinction. After the end of commercial whaling the population was thought to be recovering slowly; however, evidence indicates that it has been declining since about 1990 (ref. 1). There are now fewer than 300 individuals, and the species may already be functionally extinct(2,3) owing to demographic stochasticity or the difficulty of females locating mates in the vast Atlantic Ocean (Allee effect(4)). Using a data set containing over 10,000 sightings of photographically identified individuals we estimated trends in right whale demographic parameters since 1980. Here we construct, using these estimates, matrix population models allowing us to analyse the causes of right whale imperilment. Mortality has increased, especially among mother whales, causing declines in population growth rate, life expectancy and the mean lifetime number of reproductive events between the period 1980-1995. Increased mortality of mother whales can explain the declining population size, suggesting that the population is not doomed to extinction as a result of the Allee effect. An analysis of extinction time shows that demographic stochasticity has only a small effect, but preventing the deaths of only two female right whales per year would increase the population growth rate to replacement level.	Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Fujiwara, M (corresponding author), Woods Hole Oceanog Inst, Dept Biol, MS34, Woods Hole, MA 02543 USA.	mfujiwara@whoi.edu	Fujiwara, Masami/C-3115-2012	Fujiwara, Masami/0000-0002-9255-6043; Caswell, Hal/0000-0003-4394-6894				Akaike H, 1973, INT S INFORMATION TH, P267; Allee W.C, 1931, ANIMAL AGGREGATION S; BRAULT S, 1993, ECOLOGY, V74, P1444, DOI 10.2307/1940073; Burnham KP., 2004, MODEL SELECTION MULT, V2, DOI 10.1007/b97636; Caswell, 2000, MATRIX POPULATION MO; Caswell H, 1999, P NATL ACAD SCI USA, V96, P3308, DOI 10.1073/pnas.96.6.3308; Caswell H, 1989, MATRIX POPULATION MO; CRONE MJ, 1990, RIGHT WHALE EUBALAEN; FUJIWARA M, IN PRESS ECOLOGY; Gerber LR, 2000, AM SCI, V88, P316, DOI 10.1511/2000.29.773; HOLDEN C, 2001, SCIENCE, V291, P429; HOSMER DW, 1989, APPL LOGISTIC REGRES; KNOWLTON AR, 1994, CAN J ZOOL, V72, P1297, DOI 10.1139/z94-173; KNOWLTON AR, 1997, NEW ENGLAND AQUARIUM, V973, P31; KRAUS SD, 1990, MAR MAMMAL SCI, V6, P278, DOI 10.1111/j.1748-7692.1990.tb00358.x; Krause S. J., 1986, Rapid Thermal Processing, P145; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; NICHOLS JD, 1992, ECOLOGY, V73, P306, DOI 10.2307/1938741; OLESIUK PF, 1990, INDIVIDUAL RECOGNITI, P209; Planque B, 1998, J MAR BIOL ASSOC UK, V78, P1015, DOI 10.1017/S0025315400044969; Tuljapurkar S., 1997, STRUCTURED POPULATIO; WARING GT, 1999, NMFSNE153 NOAA	22	219	240	1	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	2001	414	6863					537	541		10.1038/35107054	http://dx.doi.org/10.1038/35107054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734852				2022-12-28	WOS:000172405900045
J	Hentschel, M; Kienberger, R; Spielmann, C; Reider, GA; Milosevic, N; Brabec, T; Corkum, P; Heinzmann, U; Drescher, M; Krausz, F				Hentschel, M; Kienberger, R; Spielmann, C; Reider, GA; Milosevic, N; Brabec, T; Corkum, P; Heinzmann, U; Drescher, M; Krausz, F			Attosecond metrology	NATURE			English	Article							ORDER HARMONIC-GENERATION; NONLINEAR OPTICS; LASER FIELDS; PULSES; FRONTIERS	The generation of ultrashort pulses is a key to exploring the dynamic behaviour of matter on ever-shorter timescales. Recent developments have pushed the duration of laser pulses close to its natural limit-the wave cycle, which lasts somewhat longer than one femtosecond (1 fs = 10(-15) s) in the visible spectral range. Time-resolved measurements with these pulses are able to trace dynamics of molecular structure, but fail to capture electronic processes occurring on an attosecond (1 as = 10(-18) s) timescale. Here we trace electronic dynamics with a time resolution of less than or equal to 150 as by using a subfemtosecond soft-X-ray pulse and a few-cycle visible light pulse. Our measurement indicates an attosecond response of the atomic system, a soft-X-ray pulse duration of 650 +/- 150 as and an attosecond synchronism of the soft-X-ray pulse with the light field. The demonstrated experimental tools and techniques open the door to attosecond spectroscopy of bound electrons.	Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria; Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Univ Bielefeld, Fak Phys, D-33615 Bielefeld, Germany	Technische Universitat Wien; National Research Council Canada; University of Bielefeld	Krausz, F (corresponding author), Vienna Tech Univ, Inst Photon, Gusshausstr 27, A-1040 Vienna, Austria.		Spielmann, Christian/G-9476-2013; Heinzmann, Ulrich/A-6248-2012; Hädrich, Steffen/B-4331-2008	Spielmann, Christian/0000-0002-5223-4170; Reider, Georg A/0000-0003-4029-4659; Corkum, Paul/0000-0003-3394-5572; Kienberger, Reinhard/0000-0001-8781-3685				BECKER U, 1996, VUV SOFT XRAY PHOTOI, P152; Bhattacharjee Y, 2001, NATURE, V412, P474, DOI 10.1038/35087741; Brabec T, 2000, REV MOD PHYS, V72, P545, DOI 10.1103/RevModPhys.72.545; Christov IP, 1997, PHYS REV LETT, V78, P1251, DOI 10.1103/PhysRevLett.78.1251; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; ITATANI J, UNPUB PHYS REV LETT; IVANOV M, 1995, PHYS REV LETT, V74, P2933, DOI 10.1103/PhysRevLett.74.2933; KITZLER M, UNPUB PHYS REV LETT; Krausz F, 2001, PHYS WORLD, V14, P41; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; LHUILLIER A, 1993, PHYS REV LETT, V70, P774, DOI 10.1103/PhysRevLett.70.774; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; MILOSEVIC N, UNPUB PHYS REV LETT; Papadogiannis NA, 1999, PHYS REV LETT, V83, P4289, DOI 10.1103/PhysRevLett.83.4289; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; Paulus GG, 2001, NATURE, V414, P182, DOI 10.1038/35102520; Poppe A, 2001, APPL PHYS B-LASERS O, V72, P373, DOI 10.1007/s003400000526; Spielmann C, 1997, SCIENCE, V278, P661, DOI 10.1126/science.278.5338.661; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Zewail AH, 2000, J PHYS CHEM A, V104, P5660, DOI 10.1021/jp001460h	20	2300	2371	19	539	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					509	513		10.1038/35107000	http://dx.doi.org/10.1038/35107000			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734845				2022-12-28	WOS:000172405900038
J	Margolin, A; Kleber, HD; Avants, SK; Konefal, J; Gawin, F; Stark, E; Sorensen, J; Midkiff, E; Wells, E; Jackson, TR; Bullock, M; Culliton, PD; Boles, S; Vaughan, R				Margolin, A; Kleber, HD; Avants, SK; Konefal, J; Gawin, F; Stark, E; Sorensen, J; Midkiff, E; Wells, E; Jackson, TR; Bullock, M; Culliton, PD; Boles, S; Vaughan, R			Acupuncture for the treatment of cocaine addiction - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSTANCE-ABUSE TREATMENT; AURICULAR ACUPUNCTURE; TREATMENT SERVICES; DEPENDENCE; THERAPIES; EFFICACY; ADJUNCT	Context Auricular acupuncture is widely used to treat cocaine addiction in the United States and Europe. However, evidence from controlled studies regarding this treatment's effectiveness has been inconsistent. Objective To investigate the effectiveness of auricular acupuncture as a treatment for cocaine addiction. Design Randomized, controlled, single-blind clinical trial conducted from November 1996 to April 1999. Setting Six community-based clinics in the United States: 3 hospital-affiliated clinics and 3 methadone maintenance programs. Patients Six hundred twenty cocaine-dependent adult patients (mean age, 38.8 years; 69.2% men); 412 used cocaine only and 208 used both opiates and cocaine and were receiving methadone maintenance. Intervention Patients were randomly assigned to receive auricular acupuncture (n=222), a needle-insertion control condition (n=203), or a relaxation control condition (n=195). Treatments were offered 5 times weekly for 8 weeks. Concurrent drug counseling was also offered to patients in all conditions. Main Outcome Measures Cocaine use during treatment and at the 3- and 6-month postrandomization follow-up based on urine toxicology screens; retention in treatment. Results Intent-to-treat analysis of urine samples showed a significant overall reduction in cocaine use (odds ratio, 1.40; 95% confidence interval, 1.11-1.74; P=.002) but no differences by treatment condition (P=.90 for acupuncture vs both control conditions). There were also no differences between the conditions in treatment retention (44%-46% for the full 8 weeks). Counseling sessions in all 3 conditions were poorly attended. Conclusions Within the clinical context of this study, acupuncture was not more effective than a needle insertion or relaxation control in reducing cocaine use. Our study does not support the use of acupuncture as a stand-alone treatment for cocaine addiction or in contexts in which patients receive only minimal concurrent psychosocial treatment. Research will be needed to examine acupuncture's contribution to addiction treatment when provided in an ancillary role.	Yale Univ, Sch Med, Subst Abuse Ctr, New Haven, CT 06519 USA; Columbia Univ, Natl Ctr Addict & Subst Abuse, New York, NY USA; Columbia Univ, Sch Med, New York, NY USA; Univ Miami, Sch Med, Miami, FL USA; Univ Calif Los Angeles, Lab Study Addict, Los Angeles, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Evergreen Treatment Serv, Seattle, WA USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA	Yale University; Columbia University; Columbia University; University of Miami; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Hennepin County Medical Center	Margolin, A (corresponding author), Yale Univ, Sch Med, Subst Abuse Ctr, 34 Pk St, New Haven, CT 06519 USA.	arthur.margolin@yale.edu			NIDA NIH HHS [R01-DAO8513, R01-DA00277] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008513] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agosti V, 1996, AM J DRUG ALCOHOL AB, V22, P29, DOI 10.3109/00952999609001643; AVANTS SK, 1995, J SUBST ABUSE TREAT, V12, P195; Avants SK, 2000, ARCH INTERN MED, V160, P2305, DOI 10.1001/archinte.160.15.2305; BRUMBAUGH AG, 1995, TRANSFORMATION RECOV; BULLOCK ML, 1989, LANCET, V1, P1435; Bullock ML, 1999, J SUBST ABUSE TREAT, V16, P31, DOI 10.1016/S0740-5472(98)00002-6; Crits-Christoph P, 1999, ARCH GEN PSYCHIAT, V56, P493, DOI 10.1001/archpsyc.56.6.493; First M.B., 2014, STRUCTURED CLIN INTE; Gurevich MI, 1996, J SUBST ABUSE TREAT, V13, P165, DOI 10.1016/0740-5472(96)00028-1; HIGGINS ST, 1993, AM J PSYCHIAT, V150, P763; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; KONEFAL J, 1994, J ADDICT DIS, V13, P71; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIPTON DS, 1994, J SUBST ABUSE TREAT, V11, P205, DOI 10.1016/0740-5472(94)90077-9; Margolin A, 1998, JAMA-J AM MED ASSOC, V280, P1626, DOI 10.1001/jama.280.18.1626; Margolin A, 1995, DRUG ALCOHOL DEPEN, V40, P125, DOI 10.1016/0376-8716(95)01198-6; Margolin A, 1998, J ALTERN COMPLEM MED, V4, P405, DOI 10.1089/acm.1998.4.405; Margolin A, 1996, J SUBST ABUSE TREAT, V13, P471, DOI 10.1016/S0740-5472(96)00065-7; MARGOLIN A, 1995, AM J CHINESE MED, V23, P105, DOI 10.1142/S0192415X95000146; MARGOLIN A, IN PRESS J ALTERN CO; MCLELLAN AT, 1992, J NERV MENT DIS, V180, P101, DOI 10.1097/00005053-199202000-00007; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller WR, 1996, PSYCHOL ADDICT BEHAV, V10, P81, DOI 10.1037/0893-164X.10.2.81; *NADA, 1999, REG TRAIN RES MAN; Office of National Drug Control Policy, 2000, NAT DRUG CONTR STRAT; POKLIS A, 1987, J ANAL TOXICOL, V11, P228, DOI 10.1093/jat/11.5.228; Richard AJ, 1995, J SUBST ABUSE TREAT, V12, P401, DOI 10.1016/0740-5472(95)02013-6; SMITH MO, 1997, SUBSTANCE ABUJSE COM, P484; *SUBST AB MENT HLT, 2000, PUBL SMA; ULETT GA, 1992, BEYOND YIN YANG; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; WELLS EA, 1995, AM J ADDICTION, V4, P198, DOI 10.3109/10550499509038105; WOODY G, ADDICTION COUNSELING	33	92	102	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					55	63		10.1001/jama.287.1.55	http://dx.doi.org/10.1001/jama.287.1.55			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506NK	11754709				2022-12-28	WOS:000172978500026
J	Kiger, AA; Jones, DL; Schulz, C; Rogers, MB; Fuller, MT				Kiger, AA; Jones, DL; Schulz, C; Rogers, MB; Fuller, MT			Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue	SCIENCE			English	Article							DROSOPHILA SPERMATOGENESIS; PROTEIN; KINASE; PROLIFERATION; MELANOGASTER; EXPRESSION; ENCODES; OVARY; FATE; EYE	Stem cells generate many differentiated, short-lived cell types, such as blood, skin, and sperm, throughout adult life. Stem cells maintain a tong-term capacity to divide, producing daughter cells that either self-renew or initiate differentiation. Although the surrounding microenvironment or "niche" influences stem cell fate decisions, few signals that emanate from the niche to specify stem cell self-renewal have been identified. Here we demonstrate that the apical hub cells in the Drosophila testis act as a cellular niche that supports stem cell self-renewal. Hub cells express the ligand Unpaired (Upd), which activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in adjacent germ cells to specify self-renewal and continual maintenance of the germ line stem cell population.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Fuller, MT (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, 279 Campus Dr, Stanford, CA 94305 USA.			Fuller, Margaret T/0000-0002-3804-4987	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078176, T32GM007790] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07493] Funding Source: Medline; NIDDK NIH HHS [P01-DK53074] Funding Source: Medline; NIGMS NIH HHS [GM07790-22, R01 GM078176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; Casso D, 1999, MECH DEVELOP, V88, P229, DOI 10.1016/S0925-4773(99)00174-4; Gonczy P, 1996, DEVELOPMENT, V122, P2437; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jones D. B., UNPUB; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; KIGER AA, UNPUB; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li M., UNPUB; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1999, DEV BIOL, V213, P432, DOI 10.1006/dbio.1999.9390; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; LUSCHNIG S, UNPUB; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Van Doren M, 1998, CURR BIOL, V8, P243; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; XU T, 1993, DEVELOPMENT, V117, P1223; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	25	507	533	4	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2542	2545		10.1126/science.1066707	http://dx.doi.org/10.1126/science.1066707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752574				2022-12-28	WOS:000172927700057
J	Wald, NJ; Law, MR; Morris, JK; Wald, DS				Wald, NJ; Law, MR; Morris, JK; Wald, DS			Quantifying the effect of folic acid	LANCET			English	Article							NEURAL-TUBE DEFECTS; PLASMA HOMOCYSTEINE CONCENTRATIONS; YOUNG-WOMEN; VITAMIN SUPPLEMENTATION; FOOD FORTIFICATION; RANDOMIZED TRIAL; FOLATE STATUS; SERUM FOLATE; PREVENTION; DISEASE	Background Folic acid is known to prevent neural-tube defects (NTDs) but the size of the effect for a given dose is unclear. We aimed to quantify such an effect. Methods We used published data from 13 studies of folic acid supplementation on serum folate concentrations and results from a large cohort study of the risk of NTDs according to serum folate, to measure the preventive effect of specified increases in intake of folic acid. Findings Serum folate concentrations increase by 0.94 ng/mL (95% Cl 0.77-1.10) for every 0.1 mg/day increase in folic acid intake in women aged 20-35 years, and about double that in people aged 40-65. Every doubling of serum folate concentration roughly halves the risk of an NTD. These two effects can be combined to predict the reduction in risk according to intake of extra folic acid and background serum folate concentration. Such results predict that the preventive effect is greater in women with low serum folate than in those with higher concentrations. The results have also been used to predict direct observations from large randomised trials and the effect of food fortification. From a typical western background serum folate of 5 ng/mL, about 0.2 mg/day (the US level of folic acid fortification) would be expected to reduce NTDs by about 20%; a similar effect can be expected from the current British recommendation (0.24 mg/day). An increase of 0.4 mg/day would reduce risk by about 36%, of 1 mg/day by 57%, and taking a 5-mg tablet daily would reduce risk by about 85%. Interpretation Folic acid fortification levels should be increased. Additionally women planning a pregnancy should take 5 mg folic acid tablets daily, instead of the 0.4 mg dose presently recommended.	Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London, England; St Marys Hosp, Dept Cardiol, Portsmouth PO3 6AQ, Hants, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, Charterhouse Sq, London, England.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; BOWER C, 1995, EUR J CLIN NUTR, V49, P787; Bronstrup A, 1998, AM J CLIN NUTR, V68, P1104; Brouwer IA, 1999, AM J CLIN NUTR, V69, P99; *CDC, 2000, MMWR-MORBID MORTAL W, V49, P962; Committee on Medical Aspects of Food and Nutrition Policy, 2000, FOL AC PREV DIS; Coppen A, 2000, J AFFECT DISORDERS, V60, P121, DOI 10.1016/S0165-0327(00)00153-1; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; Cuskelly GJ, 1999, AM J CLIN NUTR, V70, P234; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DICKENSON J, 1995, Q J MED, V88, P357; Dierkes J, 1998, INT J VITAM NUTR RES, V68, P98; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; Gregory J., 1990, DIETARY NUTR SURVEY; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; HESEKER H, 1987, J NUTR SCI VITAMINOL, V33, P163, DOI 10.3177/jnsv.33.163; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; KIRKE PN, 1993, Q J MED, V86, P703; LAURENCE KM, 1980, BRIT MED J, V281, P1592, DOI 10.1136/bmj.281.6255.1592; Lawrence JM, 1999, LANCET, V354, P915, DOI 10.1016/S0140-6736(99)03227-4; Lobo A, 1999, AM J CARDIOL, V83, P821, DOI 10.1016/S0002-9149(98)01041-8; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Morris JK, 1999, J MED SCREEN, V6, P182, DOI 10.1136/jms.6.4.182; Rader JI, 1999, FOOD TESTING ANAL, V5, P14; Riddell LJ, 2000, AM J CLIN NUTR, V71, P1448; Schorah CJ, 1998, EUR J CLIN NUTR, V52, P407, DOI 10.1038/sj.ejcn.1600576; SMITHELLS RW, 1983, LANCET, V1, P1027; Speizer, 1976, NATURAL HIST CHRONIC, P218; Truswell AS, 1997, EUR J CLIN NUTR, V51, P839, DOI 10.1038/sj.ejcn.1600493; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; van der Griend R, 1999, ATHEROSCLEROSIS, V143, P177, DOI 10.1016/S0021-9150(98)00273-1; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; WALD N, 1993, ANN NY ACAD SCI, V678, P112; WALD N, 1991, LANCET, V338, P132; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; WALD NJ, 1994, LANCET, V343, P307, DOI 10.1016/S0140-6736(94)91156-8; Ward M, 1997, QJM-MON J ASSOC PHYS, V90, P519, DOI 10.1093/qjmed/90.8.519	42	249	265	1	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2069	2073		10.1016/S0140-6736(01)07104-5	http://dx.doi.org/10.1016/S0140-6736(01)07104-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755633				2022-12-28	WOS:000172722800033
J	Broecker, WS; Hemming, S				Broecker, WS; Hemming, S			Paleoclimate - Climate swings come into focus	SCIENCE			English	Editorial Material							ATLANTICS HEINRICH EVENTS; NORTH-ATLANTIC; ICE-SHEET; OSCILLATIONS; PROVENANCE; SEDIMENTS; ISOTOPES; RECORD; SEA		Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Broecker, WS (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Hemming, Sidney/0000-0001-8117-2303				ANDREWS JT, 1992, GEOLOGY, V20, P1087, DOI 10.1130/0091-7613(1992)020<1087:DCRSNL>2.3.CO;2; Arz HW, 1998, QUATERNARY RES, V50, P157, DOI 10.1006/qres.1998.1992; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Bond GC, 1999, GEOPH MONOG SERIES, V112, P35; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; GROUSSET FE, 1993, PALEOCEANOGRAPHY, V8, P175, DOI 10.1029/92PA02923; Gwiazda RH, 1996, PALEOCEANOGRAPHY, V11, P77, DOI 10.1029/95PA03135; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Hemming SR, 1998, EARTH PLANET SC LETT, V164, P317, DOI 10.1016/S0012-821X(98)00224-6; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; PORTER SC, 1995, NATURE, V375, P305, DOI 10.1038/375305a0; ROOTH C, 1982, PROG OCEANOGR, V11, P139; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750	17	55	58	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2308	2309		10.1126/science.1068389	http://dx.doi.org/10.1126/science.1068389			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743191				2022-12-28	WOS:000172817200035
J	Cao, YX; Bonizzi, G; Seagroves, TN; Greten, FR; Johnson, R; Schmidt, EV; Karin, M				Cao, YX; Bonizzi, G; Seagroves, TN; Greten, FR; Johnson, R; Schmidt, EV; Karin, M			IKK alpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development	CELL			English	Article							NF-KAPPA-B; MICE LACKING; LIVER DEGENERATION; BREAST-CANCER; KINASE-ALPHA; BETA SUBUNIT; CELL-GROWTH; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION	To identify functions of the IKK alpha subunit of I kappaB kinase that require catalytic activity, we generated an Ikk alpha (AA) knockin allele containing alanines instead of serines in the activation loop. Ikk alpha (AA/AA) mice are healthy and fertile, but females display a severe lactation defect due to impaired proliferation of mammary epithelia[ cells. IKK alpha. activity is required for NF-kappaB activation in mammary epithelial cells during pregnancy and in response to RANK ligand but not TNF alpha. IKK alpha and NF-kappaB activation are also required for optimal cyclin Dl induction. Defective RANK signaling or cyclin D1 expression results in the same phenotypic effect as the Ikk alpha (AA) mutation, which is completely suppressed by a mammary specific cyclin D1 transgene. Thus, IKK alpha is a critical intermediate in a pathway that controls mammary epithelial proliferation in response to RANK signaling via cyclin D1.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, Mol Biol Sect, La Jolla, CA 92093 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Childrens Serv, Charlestown, MA 02129 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Bonizzi, Giuseppina/AAD-9042-2022; Johnson, Randall/AAM-1189-2021; Seagroves, Tiffany/AAE-3278-2019; Greten, Florian R/AAF-5196-2020	Johnson, Randall/0000-0002-4084-6639; Seagroves, Tiffany/0000-0002-6937-943X; Greten, Florian R/0000-0002-3928-6080				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Delhase M, 1999, COLD SPRING HARB SYM, V64, P491, DOI 10.1101/sqb.1999.64.491; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1999, DNA ALTERATIONS CANC; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nishimura T, 2000, AM J REPROD IMMUNOL, V43, P351, DOI 10.1111/j.8755-8920.2000.430604.x; PULLAN SE, 1997, EPITHELIAL CELL CULT, P97; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	50	391	411	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					763	775		10.1016/S0092-8674(01)00599-2	http://dx.doi.org/10.1016/S0092-8674(01)00599-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747812	Bronze			2022-12-28	WOS:000172771800009
J	Spiller, RC				Spiller, RC			ABC of the upper gastrointestinal tract - Anorexia, nausea, vomiting, and pain	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Nottingham NG7 2RD, England	University of Nottingham	Spiller, RC (corresponding author), Univ Nottingham, Nottingham NG7 2RD, England.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1354	1357		10.1136/bmj.323.7325.1354	http://dx.doi.org/10.1136/bmj.323.7325.1354			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739225	Green Published			2022-12-28	WOS:000172716900021
J	Archer, D; Martin, P				Archer, D; Martin, P			Ocean circulation - Thin walls tell the tele	SCIENCE			English	Editorial Material							CALCIFICATION; FORAMINIFERA		Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Archer, D (corresponding author), Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA.		Archer, David/K-7371-2012; Martin, Pamela A/C-3678-2012	Archer, David/0000-0002-4523-7912; 				BERGER WH, 1967, SCIENCE, V156, P383, DOI 10.1126/science.156.3773.383; Broecker W, 2001, PALEOCEANOGRAPHY, V16, P531, DOI 10.1029/2000PA000600; Broecker WS, 1999, PALEOCEANOGRAPHY, V14, P596, DOI 10.1029/1999PA900016; Broecker WS, 2001, SCIENCE, V294, P2152, DOI 10.1126/science.1064171; BROECKER WS, UNPUB; BROECKER WS, IN PRESS PALEOCEANOG; LOHMANN GP, 1995, PALEOCEANOGRAPHY, V10, P445, DOI 10.1029/95PA00059; PETERSON LC, 1985, AM GEOPHYS UNION GEO, V32, P251; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0	10	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2108	2109		10.1126/science.1067168	http://dx.doi.org/10.1126/science.1067168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739940				2022-12-28	WOS:000172647700032
J	Theissen, G				Theissen, G			Genetics of identity	NATURE			English	Editorial Material									Univ Jena, Inst Genet, D-07743 Jena, Germany	Friedrich Schiller University of Jena	Theissen, G (corresponding author), Univ Jena, Inst Genet, Philosophenweg 12, D-07743 Jena, Germany.							Goto K, 2001, CURR OPIN GENET DEV, V11, P449, DOI 10.1016/S0959-437X(00)00216-1; Gutierrez-Cortines ME, 2000, TRENDS PLANT SCI, V5, P471, DOI 10.1016/S1360-1385(00)01761-1; Jack T, 2001, TRENDS PLANT SCI, V6, P310, DOI 10.1016/S1360-1385(01)01987-2; Theissen G, 2001, NATURE, V409, P469, DOI 10.1038/35054172	4	15	15	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					491	491		10.1038/35107163	http://dx.doi.org/10.1038/35107163			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734829				2022-12-28	WOS:000172405900024
J	Prasad, V; Smith, A				Prasad, V; Smith, A			Preoperative assessment: from tribalism to cooperation	LANCET			English	Editorial Material									Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England		Smith, A (corresponding author), Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England.							Abenstein JP, 1996, ANESTH ANALG, V82, P1273, DOI 10.1097/00000539-199606000-00030; *AM SOC AN, 1987, BAS STAND PREAN CAR; *ASS AN, 1998, AN GREAT BRIT IR PHY; FLETCHER R, 1998, TODAYS ANAESTHETIST, V13, P54; *GEN MED COUNC, 1995, NEW DOCT; Kinley H, 2001, Health Technol Assess, V5, P1; MCGRORY M, 1998, J ONE DAY SURG, V7, P18; Munro J, 1997, HEALTH TECHNOL ASSES, V1, P1; *NHS MAN EX, 1991, JUN DOCT NEW DEAL; Rolly G, 1996, EUR J ANAESTH, V13, P325, DOI 10.1046/j.1365-2346.1996.00963.x	10	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1747	1748		10.1016/S0140-6736(01)06843-X	http://dx.doi.org/10.1016/S0140-6736(01)06843-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734229				2022-12-28	WOS:000172385100007
J	Osler, M; Prescott, E; Gronbaek, M; Christensen, U; Due, P; Engholm, G				Osler, M; Prescott, E; Gronbaek, M; Christensen, U; Due, P; Engholm, G			Income inequality, individual income, and mortality in Danish adults: analysis of pooled data from two cohort studies	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; MULTILEVEL ANALYSIS	Objective To analyse the association between area income inequality and mortality after adjustment for individual income and other established risk factors. Design Analysis of pooled data front two cohort studies. The relation between income inequality in small areas of residence (parishes) and individual mortality was examined with Cox proportional hazard analyses. Setting Two population studies conducted in Copenhagen, Denmark. Participants 13 710 women and 12 018 men followed for a mean of 12.8 years. Main outcome measure All cause mortality. Results Age standardised mortality was highest in the parishes with the least equal income distribution. After adjustment for individual risk factors, parish income inequality was not associated with mortality, whereas individual household income was. Thus, individuals in the highest income quarter had lower mortality than those in the lowest quarter (adjusted hazard ratio for men 0.51 (95% confidence interval 0.45 to 0.59) and for women 0.60 (0.54 to 0.68)). Conclusion Area income inequality is not in itself associated with all cause mortality in this Danish population. Adjustment for individual risk factors makes the apparent effect disappear, This may be the result of Denmark's welfare system, based on a Nordic model.	Univ Copenhagen, Inst Publ Hlth, Copenhagen Ctr Prospect Studies, Dept Social Med, DK-2200 Copenhagen N, Denmark; Copenhagen Univ Hosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-1399 Copenhagen, Denmark; Ctr Res Hlth & Social Stat, DK-2100 Copenhagen, Denmark	University of Copenhagen; Aarhus University; University of Copenhagen	Osler, M (corresponding author), Univ Copenhagen, Inst Publ Hlth, Copenhagen Ctr Prospect Studies, Dept Social Med, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Prescott, Eva/AAJ-7441-2020; Osler, Merete/AAF-7885-2019	Gronbaek, Morten Klocker/0000-0002-8473-6474; Prescott, Eva/0000-0002-4134-0349; Christensen, Ulla/0000-0001-7797-6640; Osler, Merete/0000-0002-6921-220X				Appleyard M., 1989, SCAND J SOC MED, V41, P1; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Diez-Roux AV, 2000, SOC SCI MED, V50, P673, DOI 10.1016/S0277-9536(99)00320-2; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; HAGERUP L, 1981, SCAND J SOC MED S20, V9, P5; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Kawachi I., 2000, SOCIAL EPIDEMIOLOGY; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; Lochner K, 2001, AM J PUBLIC HEALTH, V91, P385, DOI 10.2105/AJPH.91.3.385; Lynch J W, 1997, J Health Psychol, V2, P297, DOI 10.1177/135910539700200303; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; LYNCH JW, 2000, BRIT MED J, V320, P1002; POULSEN ME, 1995, STAT PERSONS DENMARK; Ross NA, 2000, BRIT MED J, V320, P898, DOI 10.1136/bmj.320.7239.898; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; *UN, 1977, STAT PAP 7, V61; Waitzman NJ, 1998, MILBANK Q, V76, P341, DOI 10.1111/1468-0009.00095; WILKINSON R, 1996, UNHEALTHY SOC AFFICT; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953	21	120	122	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					13	16		10.1136/bmj.324.7328.13	http://dx.doi.org/10.1136/bmj.324.7328.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	510JV	11777797	Green Published, Bronze			2022-12-28	WOS:000173205700016
J	Gelijns, AC; Thier, SO				Gelijns, AC; Thier, SO			Medical innovation and institutional interdependence - Rethinking university-industry connections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICT-OF-INTEREST; CLINICAL-TRIALS; BIOTECHNOLOGY	University-industry research collaborations have been key to a continued high degree of technological innovation in medicine. Recently, however, critical questions have been posed about the potential negative aspects of highly productive means of encouraging Innovation. Concerns center on blurring roles between academic research and the commercial world and the implications of universities' new found readiness to benefit financially from their intellectual property. The roles of both parties are often inadequately captured by considering members of university faculties as single-mindedly devoted to the advancement of fundamental knowledge and industrial firms as mere developers of university research. Rather, medical innovation depends on extensive interactions between universities and industry, with knowledge and technology transfer flowing in both directions. These interactions have had important public health and economic benefits. Yet, there is a risk to the university-industry relationship if the cultural and ethical principles of one partner overwhelm those of the other. Therefore, universities and industry need to maximize the upsides of collaboration and minimize the down-sides by means of internal organizational change as well as formation of new models of collaboration, such as intellectual partnerships or virtual research organizations. This article reviews the numerous institutional patterns of innovation and draws implications for organizational and public policies.	Columbia Univ Coll Phys & Surg, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10032 USA; Partners Hlth Care Syst, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Columbia University; Columbia University; Partners Healthcare System; Harvard University; Harvard Medical School	Gelijns, AC (corresponding author), Columbia Univ Coll Phys & Surg, Int Ctr Hlth Outcomes & Innovat Res, 600 W 168th St,7th Floor, New York, NY 10032 USA.	acp10@columbia.edu						Agnew B, 2000, SCIENCE, V289, P1266, DOI 10.1126/science.289.5483.1266; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; ATKINSON SH, 1994, HEALTH AFFAIR, V13, P159, DOI 10.1377/hlthaff.13.3.159; Audretsch DB, 1996, AM ECON REV, V86, P641; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; BLUMENTHAL D, 1994, HEALTH AFFAIR, V13, P176, DOI 10.1377/hlthaff.13.3.176; Cockburn I, 1996, P NATL ACAD SCI USA, V93, P12725, DOI 10.1073/pnas.93.23.12725; DeAngelis CD, 2000, JAMA-J AM MED ASSOC, V284, P2237, DOI 10.1001/jama.284.17.2237; FELDMAN B, 2000, NOBLE PRIZE HIST GEN; Gelijns AC, 1998, NEW ENGL J MED, V339, P693, DOI 10.1056/NEJM199809033391010; Henderson R., 1999, SOURCES IND LEADERSH, P267, DOI DOI 10.1023/A:1011124621952; Kassirer JP, 2000, JAMA-J AM MED ASSOC, V284, P2156, DOI 10.1001/jama.284.17.2156; Lo B, 2000, NEW ENGL J MED, V343, P1616, DOI 10.1056/NEJM200011303432206; Mansfield E, 1998, RES POLICY, V26, P773, DOI 10.1016/S0048-7333(97)00043-7; MASSING DE, 1999, AUTM LICENSING SURVE; MOSKOWITZ AJ, 1998, NAT AC ENG NOV 2 WAS; MOSKOWITZ AJ, 1997, TXB SURG BIOL BASIS, P36; Mowery DC, 2001, RES POLICY, V30, P99, DOI 10.1016/S0048-7333(99)00100-6; National Science Board, 2000, SCI ENG IND; PARRISH J, 1998, NAT AC ENG NOV 2 WAS; *PHS, 2001, FIN REL CLIN RES ISS; Rettig RA, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.2.129; ROSENBERG N, 1994, RES POLICY, V23, P323, DOI 10.1016/0048-7333(94)90042-6; ROSENBERG N, 1996, MOSAIC EC GROWTH, P335; SPETZ J, 1995, MED INN CR, V5, P41; Zucker LG, 1998, AM ECON REV, V88, P290; Zucker LG, 1996, P NATL ACAD SCI USA, V93, P12709, DOI 10.1073/pnas.93.23.12709; 2000, ATLANTIC MONTHLY, V285, P39	29	84	85	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					72	77		10.1001/jama.287.1.72	http://dx.doi.org/10.1001/jama.287.1.72			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506NK	11754711				2022-12-28	WOS:000172978500028
J	Ong, JP; Achkar, EA				Ong, JP; Achkar, EA			A retained pharmacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ong, JP (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2001	345	26					1889	1889		10.1056/NEJMicm980909	http://dx.doi.org/10.1056/NEJMicm980909			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TY	11756580				2022-12-28	WOS:000172932700005
J	Leibovici, L				Leibovici, L			Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-CARE UNIT	Objective To determine whether remote, retroactive intercessory prayer, said for a group of patients with a bloodstream infection. has an effect on outcomes. Design Double blind, parallel group, randomised controlled trial of a retroactive intervention. Setting University hospital. Subjects All 3393 adult patients whose bloodstream infection was detected at the hospital in 1990-6. Intervention In July 2000 patients were randomised to a control group and an intervention group. A remote, retroactive intercessory prayer was said for the well being and full recovery of the intervention group. Main outcome measures Mortality in hospital, length of stay in hospital, and duration of fever. Results Mortality was 28.1% (475/1691) in the intervention group and 30.2% (514/1702) in the control group (P for difference = 0.4). Length of stay in hospital and duration of fever were significantly shorter in the intervention group than in the control group (P = 0.01 and P = 0.04, respectively). Conclusions Remote. retroactive intercessory prayer said for a group is associated with a shorter stay in hospital and shorter duration of fever in patients with a bloodstream infection and should be considered for use in clinical practice.	Rabin Med Ctr, Dept Med, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Med, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							Astin JA, 2000, ANN INTERN MED, V132, P903, DOI 10.7326/0003-4819-132-11-200006060-00009; BORGES JL, 1970, LABYRINTHS; BYRD RC, 1988, SOUTHERN MED J, V81, P826, DOI 10.1097/00007611-198807000-00005; Harris WS, 1999, ARCH INTERN MED, V159, P2273, DOI 10.1001/archinte.159.19.2273; Landsberg PT, 2000, NATURE, V403, P609, DOI 10.1038/35001182	5	101	102	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1450	1451		10.1136/bmj.323.7327.1450	http://dx.doi.org/10.1136/bmj.323.7327.1450			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751349	Green Published, Bronze			2022-12-28	WOS:000172979900008
J	Brown, R; Chaloner, E; Mannion, S; Cheatle, T				Brown, R; Chaloner, E; Mannion, S; Cheatle, T			10-year experience of injuries sustained during clearance of anti-personnel mines	LANCET			English	Article								Clearance of anti-personnel mines and unexploded ordnance In countries recovering from war usually continues long after conflict has ceased. We prospectively recorded 92 traumatic injuries sustained by 73 mineclearers working In seven countries over a period of 10 years. 15% of Injuries were fatal, with an incidence of 116 injuries per 100 000 workers per year. Limb Injury occurred in 59% of cases, with an overall amputation rate of 30%. 44% of Injuries were sustained by workers handling a mine, resulting In severe upper limb and facial Injuries. The Incidence of facial Injuries fell after the Introduction of visors.	Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England; Univ Coll Hosp NHS Trust, London, England; Lilongwe Cent Hosp, Lilingwe, Malawi; Malawi Polio, Lilingwe, Malawi	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; University of London; University College London	Brown, R (corresponding author), Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England.							ASCERIO A, 1995, LANCET, V346, P721; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; *UN MIN ACT SERV, 1997, INT STAND HUM MIN CL	3	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2048	2049		10.1016/S0140-6736(01)07141-0	http://dx.doi.org/10.1016/S0140-6736(01)07141-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755615				2022-12-28	WOS:000172722800016
J	Pawliuk, R; Westerman, KA; Fabry, ME; Payen, E; Tighe, R; Bouhassira, EE; Acharya, SA; Ellis, J; London, IM; Eaves, CJ; Humphries, RK; Beuzard, Y; Nagel, RL; Leboulch, P				Pawliuk, R; Westerman, KA; Fabry, ME; Payen, E; Tighe, R; Bouhassira, EE; Acharya, SA; Ellis, J; London, IM; Eaves, CJ; Humphries, RK; Beuzard, Y; Nagel, RL; Leboulch, P			Correction of sickle cell disease in transgenic mouse models by gene therapy	SCIENCE			English	Article							HUMAN BETA-GLOBIN; LOCUS-CONTROL REGION; ERYTHROID-CELLS; RETROVIRUS VECTORS; MESSENGER-RNA; KNOCKOUT MICE; HEMOGLOBIN-S; EXPRESSION; ELEMENTS; ANEMIA	Sickle Cell disease (SCD) is caused by a single point mutation in the human beta (A) globin gene that results in the formation of an abnormal hemoglobin [HbS (alpha (2)beta (S)(2))]. We designed a beta (A) globin gene variant that prevents HbS polymerization and introduced it into a lentiviral vector we optimized for transfer to hematopoietic stem cells and gene expression in the adult red blood cell lineage. Long-term expression (up to 10 months) was achieved, without preselection, in all transplanted mice with erythroid-specific accumulation of the antisickling protein in up to 52% of total hemoglobin and 99% of circulating red blood cells. In two mouse SCD models, Berkeley and SAD, inhibition of red blood cell dehydration and sickling was achieved with correction of hematological parameters, splenomegaly, and prevention of the characteristic urine concentration defect.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; Yeshiva Univ Albert Einstein Coll Med, Div Hematol, Bronx, NY 10461 USA; Hop St Louis, INSERM, EMI 0111, F-75010 Paris, France; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ British Columbia, Terry Fox Lab, Vancouver, BC V5Z 3L6, Canada; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Yeshiva University; Albert Einstein College of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Massachusetts Institute of Technology (MIT); University of British Columbia; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Leboulch, P (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.		Payen, Emmanuel/S-5357-2018; Ellis, James/F-4789-2011; Bouhassira, Eric/AAZ-4184-2021	Payen, Emmanuel/0000-0002-1329-2327; Ellis, James/0000-0002-4400-0091; Humphries, Richard/0000-0003-0540-7005	NHLBI NIH HHS [HL554352] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alami R, 1999, BLOOD CELL MOL DIS, V25, P110, DOI 10.1006/bcmd.1999.0235; ALKAN O, 2000, 3 AM SOC GEN THER DE; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Blouin MJ, 2000, NAT MED, V6, P177, DOI 10.1038/72279; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; BUNN HF, 1994, MOL BASIS BLOOD DIS, P207; Chang JC, 1998, P NATL ACAD SCI USA, V95, P14886, DOI 10.1073/pnas.95.25.14886; CHANG JC, 1992, P NATL ACAD SCI USA, V89, P3107, DOI 10.1073/pnas.89.7.3107; Emery DW, 1999, HUM GENE THER, V10, P877, DOI 10.1089/10430349950018283; Fabry ME, 2001, BLOOD, V97, P410, DOI 10.1182/blood.V97.2.410; GELINAS R, 1992, BONE MARROW TRANSPL, V9, P157; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; Kalberer CP, 2000, P NATL ACAD SCI USA, V97, P5411, DOI 10.1073/pnas.100082597; LEBOULCH P, 1994, EMBO J, V13, P3065, DOI 10.1002/j.1460-2075.1994.tb06605.x; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; MCCUNE SL, 1994, P NATL ACAD SCI USA, V91, P9852, DOI 10.1073/pnas.91.21.9852; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; Nagel RL, 2001, BRIT J HAEMATOL, V112, P19, DOI 10.1046/j.1365-2141.2001.02286.x; Nagel RL, 2001, DISORDERS HEMOGLOBIN, P711; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; PLAVEC I, 1993, BLOOD, V81, P1384; Raftopoulos H, 1997, BLOOD, V90, P3414, DOI 10.1182/blood.V90.9.3414; Rubin JE, 2000, BLOOD, V95, P3242; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; Sabatino DE, 2000, P NATL ACAD SCI USA, V97, P13294, DOI 10.1073/pnas.230453097; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; TAKEKOSHI KJ, 1995, P NATL ACAD SCI USA, V92, P3014, DOI 10.1073/pnas.92.7.3014; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	33	424	454	6	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2368	2371		10.1126/science.1065806	http://dx.doi.org/10.1126/science.1065806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743206				2022-12-28	WOS:000172817200051
J	Frank, RG; Goldman, HH; McGuire, TG				Frank, RG; Goldman, HH; McGuire, TG			Will parity in coverage result in better mental health care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED CARE		Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; University System of Maryland; University of Maryland Baltimore	Frank, RG (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NIMH NIH HHS [P01MH-59876, R01MH-43703, R01MH-59245] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH059876] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Burnam MA, 1999, HEALTH AFFAIR, V18, P22, DOI 10.1377/hlthaff.18.5.22; DELANEY T, 2000, MENTAL HLTH PARITY; Department of Health and Human Services, 1999, MENT HLTH REP SURG G; *EMPL BEN RES I, 1999, EBRI HLTH BEN DAT BO; FEIN R, 1958, EC MENTAL ILLNESS RE; Frank RG, 2000, J HEALTH ECON, V19, P829, DOI 10.1016/S0167-6296(00)00059-X; Frank RG, 2000, HDB HLTH EC, P894; FRONSTIN P, 2000, SOURCES HLTH INSURAN; Gitterman D, 2000, 10 NIMH BIENN RES C; Gitterman DP, 2001, ADM POLICY MENT HLTH, V28, P353, DOI 10.1023/A:1011113932599; Goldman W, 1998, HEALTH AFFAIR, V17, P40, DOI 10.1377/hlthaff.17.2.40; Hennessy KD, 2001, HEALTH AFFAIR, V20, P58, DOI 10.1377/hlthaff.20.4.58; HUSTEAD E, 1985, AM J PSYCHIAT, V142, P181; Ma CA, 1998, HEALTH AFFAIR, V17, P53, DOI 10.1377/hlthaff.17.2.53; MCGUIRE T, 1981, FINANCING PSYCHOTHER; Newhouse JP., 1993, INSURANCE EXPT GROUP; Pacula RL, 2000, HEALTH SERV RES, V35, P263; Pescosolido BA, 2000, AM VIEWS MENTAL HLTH; Sturm Roland, 1998, J Ment Health Policy Econ, V1, P129, DOI 10.1002/(SICI)1099-176X(1998100)1:3<129::AID-MHP16>3.0.CO;2-U; Zuvekas SH, 2001, HEALTH AFFAIR, V20, P214, DOI 10.1377/hlthaff.20.2.214	20	43	43	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1701	1704		10.1056/NEJM200112063452311	http://dx.doi.org/10.1056/NEJM200112063452311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498NH	11759651				2022-12-28	WOS:000172517200010
J	Petersen, S; Casellas, R; Reina-San-Martin, B; Chen, HT; Difilippantonio, MJ; Wilson, PC; Hanitsch, L; Celeste, A; Muramatsu, M; Pilch, DR; Redon, C; Ried, T; Bonner, WM; Honjo, T; Nussenzweig, MC; Nussenzweig, A				Petersen, S; Casellas, R; Reina-San-Martin, B; Chen, HT; Difilippantonio, MJ; Wilson, PC; Hanitsch, L; Celeste, A; Muramatsu, M; Pilch, DR; Redon, C; Ried, T; Bonner, WM; Honjo, T; Nussenzweig, MC; Nussenzweig, A			AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching	NATURE			English	Article							DOUBLE-STRAND BREAKS; CYTIDINE DEAMINASE AID; HEAVY-CHAIN SWITCH; SOMATIC HYPERMUTATION; B-CELLS; IMMUNOGLOBULIN GENES; DNA-DAMAGE; RECOMBINATION; REPAIR; SEQUENCES	Class switch recombination (CSR) is a region-specific DNA recombination reaction that replaces one immunoglobulin heavy-chain constant region (CH) gene with another. This enables a single variable (V) region gene to be used in conjunction with different downstream CH genes, each having a unique biological activity. The molecular mechanisms that mediate CSR have not been defined, but activation-induced cytidine deaminase (AID), a putative RNA-editing enzyme, is required for this reaction(1). Here we report that the Nijmegen breakage syndrome protein (Nbs1) and phosphorylated H2A histone family member X (gamma -H2AX, also known as gamma -H2afx), which facilitate DNA double-strand break (DSB) repair(2-4), form nuclear foci at the CH region in the G1 phase of the cell cycle in cells undergoing CSR, and that switching is impaired in H2AX(-/-) mice. Localization of Nbs1 and gamma -H2AX to the IgH locus during CSR is dependent on AID. In addition, AID is required for induction of switch region (S mu)-specific DNA lesions that precede CSR. These results place AID function upstream of the DNA modifications that initiate CSR.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Kyoto Univ, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University; Howard Hughes Medical Institute; Kyoto University	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.		Reina-San-Martin, Bernardo/I-9484-2016; Wilson, Patrick/HGC-3157-2022; Muramatsu, Masamichi/C-4339-2015; Difilippantonio, Michael/AAF-2839-2021; Honjo, Tasuku/N-4470-2016; Nussenzweig, Michel/AAE-7292-2019	Reina-San-Martin, Bernardo/0000-0003-2083-6166; Muramatsu, Masamichi/0000-0002-0153-3533; Difilippantonio, Michael/0000-0002-4676-7034; Hanitsch, Leif G./0000-0002-8181-0093	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010298] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bemark M, 2000, J EXP MED, V192, P1509, DOI 10.1084/jem.192.10.1509; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	30	407	418	1	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					660	665		10.1038/414660a	http://dx.doi.org/10.1038/414660a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740565	Green Accepted			2022-12-28	WOS:000172535600053
J	Ye, YH; Meyer, HH; Rapoport, TA				Ye, YH; Meyer, HH; Rapoport, TA			The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; MEDIATED PROTEOLYSIS; UBIQUITIN; DEGRADATION; PROTEASOME; PATHWAY; P97; MECHANISM	In eukaryotic cells, incorrectly folded proteins in the endoplasmic reticulum (ER) are exported into the cytosol and degraded by the proteasome(1). This pathway is co-opted by some viruses. For example, the US11 protein of the human cytomegalovirus targets the major histocompatibility complex class I heavy chain for cytosolic degradation(2). How proteins are extracted from the ER membrane is unknown. In bacteria and mitochondria, members of the AAA ATPase family are involved in extracting and degrading membrane proteins(3,4). Here we demonstrate that another member of this family, Cdc48 in yeast and p97 in mammals, is required for the export of ER proteins into the cytosol. Whereas Cdc48/p97 was previously known to function in a complex with the cofactor p47 (ref. 5) in membrane fusion(6-8), we demonstrate that its role in ER protein export requires the interacting partners Ufd1 and Npl4. The AAA ATPase interacts with substrates at the ER membrane and is needed to release them as polyubiquitinated species into the cytosol. We propose that the Cdc48/p97-Ufd1-Npl4 complex extracts proteins from the ER membrane for cytosolic degradation.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Yale University	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.		Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; DeHoratius C, 1996, MOL BIOL CELL, V7, P1835, DOI 10.1091/mbc.7.11.1835; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	30	860	879	3	61	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					652	656		10.1038/414652a	http://dx.doi.org/10.1038/414652a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740563				2022-12-28	WOS:000172535600051
J	Poser, CM; Brinar, VV				Poser, CM; Brinar, VV			Problems with diagnostic criteria for multiple sclerosis	LANCET			English	Editorial Material							PREDICT CONVERSION; MRI		Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Zagreb, Fac Med, Dept Neurol, Zagreb 41000, Croatia	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Zagreb	Poser, CM (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.	oposer@caregroup.harvard.edu						Barkhof F, 1997, BRAIN, V120, P2059, DOI 10.1093/brain/120.11.2059; FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Tintore M, 2000, AM J NEURORADIOL, V21, P702; VINUELA FV, 1982, AM J NEURORADIOL, V3, P277	8	17	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2001	358	9295					1746	1747		10.1016/S0140-6736(01)06842-8	http://dx.doi.org/10.1016/S0140-6736(01)06842-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734228				2022-12-28	WOS:000172385100006
J	Nasrin, D; Collignon, PJ; Roberts, L; Wilson, EJ; Pilotto, LS; Douglas, RM				Nasrin, D; Collignon, PJ; Roberts, L; Wilson, EJ; Pilotto, LS; Douglas, RM			Effect of beta lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; CARRIAGE	Objective To examine the relation between use of antibiotics in a cohort of preschool children and nasal carriage of resistant strains of pneumococcus. Design and participants Prospective cohort study over two years of 461 children aged under 4 years living in Canberra, Australia. Main outcome measures Use of drugs, respiratory symptoms, and visits to doctors were documented in a daily diary by parents of the children during 25 months of observation. Isolates of pneumococci, which were cultured from nasal swabs collected approximately six monthly, were tested for antibiotic resistance. Results From the four swab collections 631 positive pneumococcal isolates from 461 children were found, of which 13.6% were resistant to penicillin. Presence of penicillin resistant pneumococci was significantly associated with children's use of a beta lactam antibiotic in the two months before each swab collection (odds ratio 2.03 (95% confidence interval 1.15 to 3.56, P = 0.01)). The odds ratio of the association remained >1 (though did not reach significance at the 0.05 level) for use in the six months before swab collection. The association was seen in children who received only penicillin or only cephalosporin antibiotics in that period. The odds ratio was 4.67 (1.29 to 17.09, P = 0.02) in children who had received both types of beta lactam in the two months before their nasal swab. The modelled odds of carrying penicillin resistant pneumococcus was 4% higher for each additional day 0 of use of beta lactam antibiotics in die six months before swab collection. Conclusions Reduction in beta lactam use could quickly reduce the carriage rates of penicillin resistant pneumococci in early childhood. In view of the propensity of these organisms to be spread among children in the community, the prevalence of penicillin resistant organisms may fall as a consequence.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Canberra Hosp, Infect Dis Unit, Canberra, ACT, Australia; Canberra Hosp, Dept Microbiol, Canberra, ACT, Australia; Flinders Univ S Australia, Dept Gen Practice, Adelaide, SA 5001, Australia	Australian National University; Australian National University; Canberra Hospital; Australian National University; Canberra Hospital; Flinders University South Australia	Nasrin, D (corresponding author), 9C-A Impiana Condo,1 Tasik Ampang, Ampang 68000, Selangor, Malaysia.		Collignon, Peter/U-4846-2019	Collignon, Peter/0000-0001-8648-9203				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; DELMAR CB, 2000, COCHRANE DATABASE SY; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Hennekens C.H., 1987, EPIDEMIOLOGY MED; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; Low DE, 1998, JAMA-J AM MED ASSOC, V279, P394, DOI 10.1001/jama.279.5.394; NASRIN D, 2000, THESIS AUSTR NATL U; *NAT COMM CLIN LAB, 1994, M100S5 NCCLS; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; Turnidge JD, 1999, MED J AUSTRALIA, V170, P152, DOI 10.5694/j.1326-5377.1999.tb127710.x; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; [No title captured]	16	101	101	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2002	324	7328					28	30A		10.1136/bmj.324.7328.28	http://dx.doi.org/10.1136/bmj.324.7328.28			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777803	Green Published, Bronze			2022-12-28	WOS:000173205700022
J	Yuan, ZL; Kardynal, BE; Stevenson, RM; Shields, AJ; Lobo, CJ; Cooper, K; Beattie, NS; Ritchie, DA; Pepper, M				Yuan, ZL; Kardynal, BE; Stevenson, RM; Shields, AJ; Lobo, CJ; Cooper, K; Beattie, NS; Ritchie, DA; Pepper, M			Electrically driven single-photon source	SCIENCE			English	Article							QUANTUM DOTS; MOLECULE; FLUORESCENCE	Electroluminescence from a single quantum dot within the intrinsic region of a p-i-n junction is shown to act as an electrically driven single-photon source. At low injection currents, the dot electroluminescence spectrum reveals a single sharp line due to exciton recombination, white another tine due to the biexciton emerges at higher currents. The second-order correlation function of the diode displays anti-bunching under a continuous drive current. Single-photon emission is stimulated by subnanosecond voltage pulses. These results suggest that semiconductor technology can be used to mass-produce a single-photon source for applications in quantum information technology.	Toshiba Res Europe Ltd, Cambridge Res Lab, Cambridge CB4 0WE, England; Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	Toshiba Corporation; University of Cambridge; University of Cambridge	Shields, AJ (corresponding author), Toshiba Res Europe Ltd, Cambridge Res Lab, 260 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WE, England.	andrew.shields@crl.toshiba.co.uk	Lobo, Charlene/B-3977-2013; Kardynal, Beata/K-3625-2013; Ritchie, David/K-2206-2014; Yuan, Zhiliang/AAY-7430-2021; Lobo, Charlene/G-5003-2011; Yuan, Zhiliang/HHZ-6646-2022; Yuan, Zhiliang/C-9609-2010	Lobo, Charlene/0000-0002-2746-1363; Kardynal, Beata/0000-0001-7425-727X; Ritchie, David/0000-0002-9844-8350; Yuan, Zhiliang/0000-0001-5276-9151; Lobo, Charlene/0000-0002-2746-1363; Yuan, Zhiliang/0000-0001-5276-9151; Yuan, Zhiliang/0000-0001-5276-9151; Beattie, Neil/0000-0002-0098-4420				[Anonymous], 1999, QUANTUM DOT HETEROST; BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; Brassard G, 2000, PHYS REV LETT, V85, P1330, DOI 10.1103/PhysRevLett.85.1330; Brouri R, 2000, OPT LETT, V25, P1294, DOI 10.1364/OL.25.001294; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; Brunel C, 1999, PHYS REV LETT, V83, P2722, DOI 10.1103/PhysRevLett.83.2722; De Martini F, 1996, PHYS REV LETT, V76, P900, DOI 10.1103/PhysRevLett.76.900; Fleury L, 2000, PHYS REV LETT, V84, P1148, DOI 10.1103/PhysRevLett.84.1148; Foden CL, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.011803; IMAMOGLU A, 1994, PHYS REV LETT, V72, P210, DOI 10.1103/PhysRevLett.72.210; Kim J, 1999, NATURE, V397, P500, DOI 10.1038/17295; KNILL E, 2001, NATURE, V46, P409; Kurtsiefer C, 2000, PHYS REV LETT, V85, P290, DOI 10.1103/PhysRevLett.85.290; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; Michler P, 2000, NATURE, V406, P968, DOI 10.1038/35023100; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; MURRAY R, 1999, JPN J APPL PHYS, V38, P2022; Santori C, 2001, PHYS REV LETT, V86, P1502, DOI 10.1103/PhysRevLett.86.1502; Thompson RM, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201302; Walls D. F., 1994, QUANTUM OPT; Zwiller V, 2001, APPL PHYS LETT, V78, P2476, DOI 10.1063/1.1366367	23	995	1019	10	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	2002	295	5552					102	105		10.1126/science.1066790	http://dx.doi.org/10.1126/science.1066790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	509HV	11743163				2022-12-28	WOS:000173143100041
J	Quaini, F; Urbanek, K; Beltrami, AP; Finato, N; Beltrami, CA; Nadal-Ginard, B; Kajstura, J; Leri, A; Anversa, P				Quaini, F; Urbanek, K; Beltrami, AP; Finato, N; Beltrami, CA; Nadal-Ginard, B; Kajstura, J; Leri, A; Anversa, P			Chimerism of the transplanted heart (Publication with Expression of Concern. See vol. 379, pg. 1870, 2018)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Publication with Expression of Concern							IN-SITU HYBRIDIZATION; STEM-CELLS; P-GLYCOPROTEIN; VENTRICULAR MYOCYTES; ENDOTHELIAL-CELLS; MUSCLE; ORIGIN; CHROMOSOME; MECHANISMS; EXPRESSION	Background: Cases in which a male patient receives a heart from a female donor provide an unusual opportunity to test whether primitive cells translocate from the recipient to the graft and whether cells with the phenotypic characteristics of those of the recipient ultimately reside in the donor heart. The Y chromosome can be used to detect migrated undifferentiated cells expressing stem-cell antigens and to discriminate between primitive cells derived from the recipient and those derived from the donor. Methods: We examined samples from the atria of the recipient and the atria and ventricles of the graft by fluorescence in situ hybridization to determine whether Y chromosomes were present in eight hearts from female donors implanted into male patients. Primitive cells bearing Y chromosomes that expressed c-kit, MDR1, and Sca-1 were also investigated. Results: Myocytes, coronary arterioles, and capillaries that had a Y chromosome made up 7 to 10 percent of those in the donor hearts and were highly proliferative. As compared with the ventricles of control hearts, the ventricles of the transplanted hearts had markedly increased numbers of cells that were positive for c-kit, MDR1, or Sca-1. The number of primitive cells was higher in the atria of the hosts and the atria of the donor hearts than in the ventricles of the donor hearts, and 12 to 16 percent of these cells contained a Y chromosome. Undifferentiated cells were negative for markers of bone marrow origin. Progenitor cells expressing MEF2, GATA-4, and nestin (which identify the cells as myocytes) and Flk1 (which identifies the cells as endothelial cells) were identified. Conclusions: Our results show a high level of cardiac chimerism caused by the migration of primitive cells from the recipient to the grafted heart. Putative stem cells and progenitor cells were identified in control myocardium and in increased numbers in transplanted hearts. (N Engl J Med 2002;346:5-15.) Copyright (C) 2002 Massachusetts Medical Society.	New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Univ Udine, Dept Pathol, I-33100 Udine, Italy	New York Medical College; University of Udine	Anversa, P (corresponding author), New York Med Coll, Dept Med, Vosburgh Pavil, Valhalla, NY 10595 USA.	piero_anversa@nymc.edu	Finato, Nicoletta/A-7351-2010; beltrami, carlo a/A-8026-2008; Beltrami, Antonio/C-5291-2008; Mordwinkin, Nicholas M/A-4347-2010	Beltrami, Antonio/0000-0002-0679-2710; Quaini, Federico/0000-0003-2377-4810	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038132, R01HL065577, R01HL066923, R01HL065573, R01HL039902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015756, R01AG017042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66923, HL-65577, HL-38132, HL-39902, HL-65573] Funding Source: Medline; NIA NIH HHS [AG-17042, AG-15756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anversa P, 1998, CIRC RES, V83, P1, DOI 10.1161/01.RES.83.1.1; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami CA, 1997, J MOL CELL CARDIOL, V29, P2789, DOI 10.1006/jmcc.1997.0514; Bunting Kevin D., 2000, Blood, V96, P902; Byrne JG, 2000, J HEART LUNG TRANSPL, V19, P786, DOI 10.1016/S1053-2498(00)00130-3; Demetris A J, 1997, Ann Transplant, V2, P27; Demeule M, 2001, BIOCHEM BIOPH RES CO, V281, P827, DOI 10.1006/bbrc.2001.4312; Frede S E, 1996, Transpl Immunol, V4, P227, DOI 10.1016/S0966-3274(96)80022-0; Fyfe B, 1996, CIRCULATION, V93, P1133, DOI 10.1161/01.CIR.93.6.1133; Gaetano C, 2001, CIRC RES, V88, pE38; Hafizi S, 1997, CURR OPIN CARDIOL, V12, P495, DOI 10.1097/00001573-199711000-00001; Hancock WW, 2000, CURR OPIN IMMUNOL, V12, P511, DOI 10.1016/S0952-7915(00)00130-8; Hessel H, 1996, HISTOCHEM CELL BIOL, V106, P481, DOI 10.1007/BF02473310; Hillebrands JL, 2001, J CLIN INVEST, V107, P1411, DOI 10.1172/JCI10233; HRUBAN RH, 1993, AM J PATHOL, V142, P975; Ichikawa N, 2000, LIVER TRANSPLANT, V6, P686, DOI 10.1053/jlts.2000.19029; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang XL, 2000, EMBO J, V19, P3192, DOI 10.1093/emboj/19.13.3192; Johnson KL, 2000, BIOTECHNIQUES, V29, P1220, DOI 10.2144/00296st01; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; KENNEDY LJ, 1971, NEW ENGL J MED, V285, P884, DOI 10.1056/NEJM197110142851603; Kitagawa-Sakakida S, 2000, J HEART LUNG TRANSPL, V19, P584, DOI 10.1016/S1053-2498(00)00105-4; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Miles C, 1997, DEVELOPMENT, V124, P537; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pauly RR, 1997, METHOD CELL BIOL, V52, P133, DOI 10.1016/S0091-679X(08)60377-5; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Triulzi DJ, 2001, TRANSFUSION, V41, P419, DOI 10.1046/j.1537-2995.2001.41030419.x; Wagoner LE, 1996, CIRCULATION, V93, P111, DOI 10.1161/01.CIR.93.1.111; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Wollensak G, 1999, EXP EYE RES, V68, P341, DOI 10.1006/exer.1998.0611; Wu M, 2000, GENE DEV, V14, P301; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568	39	945	1054	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					5	15		10.1056/NEJMoa012081	http://dx.doi.org/10.1056/NEJMoa012081			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11777997	Bronze			2022-12-28	WOS:000173033600002
J	Parker, RA				Parker, RA			Caring for patients at the end of life: Reflections after 12 years of practice	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Physicians have the privilege and authority to assist patients and their families at the end of life. Regardless of diagnosis, commonalities occur in the dying process, and palliative care benefits patients and families. This perspective chronicles my experience over 12 years caring for 95 patients at the end of life, illustrated in part with six vignettes. I describe interactions with families, discuss logistic issues around dying, examine the do-not-resuscitate issue, and highlight experiences with home visits. I also touch on how I communicate with the family after a death. I hope to express the significance of what I have learned while assisting patients and families at this critical juncture.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Healthcare Associates, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Parker, RA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Healthcare Associates, 1 Autumn St, Boston, MA 02215 USA.	raparker@caregroup.harvard.edu							0	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					72	75		10.7326/0003-4819-136-1-200201010-00012	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777365				2022-12-28	WOS:000173188300007
J	Keith, CR				Keith, CR			Adolescent suicide - Perspectives on a clinical quandary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CSF		Duke Univ, Med Ctr, Div Child & Adolescent Psychiat, Durham, NC 27516 USA	Duke University	Keith, CR (corresponding author), Duke Univ, Med Ctr, Div Child & Adolescent Psychiat, 2131 Marions Ford, Durham, NC 27516 USA.							Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; KRUESI MJP, 1988, BIOL PSYCHIAT, V24, P507, DOI 10.1016/0006-3223(88)90161-8; NORDSTROM P, 1994, SUICIDE LIFE-THREAT, V24, P1; Zametkin AJ, 2001, JAMA-J AM MED ASSOC, V286, P3120, DOI 10.1001/jama.286.24.3120; 2001, J AM ACAD CHILD ADOL, V40, P24	5	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3126	3127		10.1001/jama.286.24.3126	http://dx.doi.org/10.1001/jama.286.24.3126			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505QM	11754679				2022-12-28	WOS:000172927100031
J	Dashe, JS; Cunningham, FG				Dashe, JS; Cunningham, FG			Subclinical hypothyroidism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							PREGNANCY; DISEASE		Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Dashe, JS (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BURROW GN, 1994, NEW ENGL J MED, V331, P1072; *COMM OBST PRACT, 2000, SCREEN HYP; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; Davies TF, 2000, THYROID, V10, P107, DOI 10.1089/thy.2000.10.107; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801	5	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1855	1855						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752369				2022-12-28	WOS:000172794800029
J	Leggett, J; Convery, R				Leggett, J; Convery, R			Scurvy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Craigavon Area Hosp, Portadown BT63 5QQ, North Ireland		Leggett, J (corresponding author), Craigavon Area Hosp, Portadown BT63 5QQ, North Ireland.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1818	1818		10.1056/NEJMicm010202	http://dx.doi.org/10.1056/NEJMicm010202			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752358				2022-12-28	WOS:000172794800005
J	McPhee, S; Markowitz, AJ				McPhee, S; Markowitz, AJ			Psychological considerations, growth, and transcendence at the end of life - The art of the possible	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Hall D, 1998, WITHOUT POEMS; Kenyon Jane, 1996, OTHERWISE NEW SELECT; Nouwen H. J. M., 1994, OUR GREATEST GIFT ME	4	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					3002	3002		10.1001/jama.286.23.3002	http://dx.doi.org/10.1001/jama.286.23.3002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743842				2022-12-28	WOS:000172764500033
J	Goodner, B; Hinkle, G; Gattung, S; Miller, N; Blanchard, M; Qurollo, B; Goldman, BS; Cao, YW; Askenazi, M; Halling, C; Mullin, L; Houmiel, K; Gordon, J; Vaudin, M; Iartchouk, O; Epp, A; Liu, F; Wollam, C; Allinger, M; Doughty, D; Scott, C; Lappas, C; Markelz, B; Flanagan, C; Crowell, C; Gurson, J; Lomo, C; Sear, C; Strub, G; Cielo, C; Slater, S				Goodner, B; Hinkle, G; Gattung, S; Miller, N; Blanchard, M; Qurollo, B; Goldman, BS; Cao, YW; Askenazi, M; Halling, C; Mullin, L; Houmiel, K; Gordon, J; Vaudin, M; Iartchouk, O; Epp, A; Liu, F; Wollam, C; Allinger, M; Doughty, D; Scott, C; Lappas, C; Markelz, B; Flanagan, C; Crowell, C; Gurson, J; Lomo, C; Sear, C; Strub, G; Cielo, C; Slater, S			Genome sequence of the plant pathogen and biotechnology agent Agrobacterium tumefaciens C58	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ALPHA-PROTEOBACTERIA; ESCHERICHIA-COLI; DNA; PLASMID; TUMOR; TRANSFORMATION; EVOLUTION; SYMBIONT; EXPORT	Agrobacterium tumefaciens is a plant pathogen capable of transferring a defined segment of DNA to a host plant, generating a gall tumor. Replacing the transferred tumor-inducing genes with exogenous DNA allows the introduction of any desired gene into the plant. Thus, A. tumefaciens has been critical for the development of modern plant genetics and agricultural biotechnology. Here we describe the genome of A. tumefaciens strain C58, which has an unusual structure consisting of one circular and one linear chromosome. We discuss genome architecture and evolution and additional genes potentially involved in virulence and metabolic parasitism of host plants.	Cereon Genom LLC, Cambridge, MA 02139 USA; Univ Richmond, Dept Biol, Richmond, VA 23173 USA; Hiram Coll, Dept Biol, Hiram, OH 44234 USA; Monsanto Co, St Louis, MO 63167 USA	University of Richmond; Hiram College; Monsanto	Slater, S (corresponding author), Cereon Genom LLC, 45 Sidney St, Cambridge, MA 02139 USA.	steven.c.slater@cereon.com		Qurollo, Barbara/0000-0002-9849-2511; Askenazi, Manor/0000-0003-1646-833X; Miller, Nora/0000-0003-0764-8881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM061690] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15 GM61690-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARDETSERVENT A, 1993, J BACTERIOL, V175, P7869, DOI 10.1128/JB.175.24.7869-7874.1993; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Barnett MJ, 2001, P NATL ACAD SCI USA, V98, P9883, DOI 10.1073/pnas.161294798; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bhat TK, 1998, BIODEGRADATION, V9, P343, DOI 10.1023/A:1008397506963; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; Boschiroli ML, 2001, CURR OPIN MICROBIOL, V4, P58, DOI 10.1016/S1369-5274(00)00165-X; Brassinga AKC, 2001, J BACTERIOL, V183, P1824, DOI 10.1128/JB.183.5.1824-1829.2001; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; Casjens S, 1997, MOL MICROBIOL, V26, P581, DOI 10.1046/j.1365-2958.1997.6051963.x; CHILTON MD, 1977, CELL, V11, P263, DOI 10.1016/0092-8674(77)90043-5; Deneke J, 2000, P NATL ACAD SCI USA, V97, P7721, DOI 10.1073/pnas.97.14.7721; Dessaux Y., 1998, RHIZOBIACEAE MOL BIO, P173, DOI DOI 10.1007/978-94-011-5060-6_9; Domian IJ, 1999, P NATL ACAD SCI USA, V96, P6648, DOI 10.1073/pnas.96.12.6648; Finan TM, 2001, P NATL ACAD SCI USA, V98, P9889, DOI 10.1073/pnas.161294698; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Goodner BW, 1999, J BACTERIOL, V181, P5160, DOI 10.1128/JB.181.17.5160-5166.1999; HAMILTON RH, 1971, EXPERIENTIA, V27, P229, DOI 10.1007/BF02145913; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Jumas-Bilak E, 1998, J BACTERIOL, V180, P2749, DOI 10.1128/JB.180.10.2749-2755.1998; Kahng LS, 2001, J BACTERIOL, V183, P3065, DOI 10.1128/JB.183.10.3065-3075.2001; Kaneko T, 2000, DNA RES, V7, P381, DOI 10.1093/dnares/7.6.381; Karem KL, 2000, MICROBES INFECT, V2, P1193, DOI 10.1016/S1286-4579(00)01273-9; Karlin S, 2001, TRENDS MICROBIOL, V9, P335, DOI 10.1016/S0966-842X(01)02079-0; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KRISHNAN M, 1991, J BACTERIOL, V173, P903, DOI 10.1128/jb.173.2.903-905.1991; Lai EM, 2000, J BACTERIOL, V182, P3705, DOI 10.1128/JB.182.13.3705-3716.2000; LAPOINTE G, 1992, J BACTERIOL, V174, P2631, DOI 10.1128/jb.174.8.2631-2639.1992; LeVier K, 2000, SCIENCE, V287, P2492, DOI 10.1126/science.287.5462.2492; Li PL, 2000, J BACTERIOL, V182, P179, DOI 10.1128/JB.182.1.179-188.2000; Lyi SM, 1999, MOL MICROBIOL, V31, P339, DOI 10.1046/j.1365-2958.1999.01178.x; Moreno E, 1998, FEMS MICROBIOL REV, V22, P255, DOI 10.1111/j.1574-6976.1998.tb00370.x; Newell CA, 2000, MOL BIOTECHNOL, V16, P53, DOI 10.1385/MB:16:1:53; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; Ogata H, 2001, SCIENCE, V293, P2093, DOI 10.1126/science.1061471; Oke V, 1999, CURR OPIN MICROBIOL, V2, P641, DOI 10.1016/S1369-5274(99)00035-1; OTTEN L, 1992, MOL PLANT MICROBE IN, V5, P279, DOI 10.1094/MPMI-5-279; PARKE D, 1995, J BACTERIOL, V177, P3808, DOI 10.1128/jb.177.13.3808-3817.1995; Penyalver R, 2001, APPL ENVIRON MICROB, V67, P654, DOI 10.1128/AEM.67.2.654-664.2001; Plano GV, 2001, MOL MICROBIOL, V40, P284, DOI 10.1046/j.1365-2958.2001.02354.x; Purcell M, 1998, INFECT IMMUN, V66, P2245, DOI 10.1128/IAI.66.5.2245-2255.1998; ROSENBERG C, 1984, MOL GEN GENET, V196, P533, DOI 10.1007/BF00436205; SCHLUTER A, 1995, MOL GEN GENET, V247, P206, DOI 10.1007/BF00705651; Schuerman PL, 1997, APPL MICROBIOL BIOT, V47, P560, DOI 10.1007/s002530050973; SHAW CH, 1991, BIOESSAYS, V13, P25, DOI 10.1002/bies.950130105; SKARSTAD K, COMMUNICATION; Subramaniyan S, 2000, FEMS MICROBIOL LETT, V183, P1, DOI 10.1111/j.1574-6968.2000.tb08925.x; Suzuki K, 2000, GENE, V242, P331, DOI 10.1016/S0378-1119(99)00502-8; Suzuki K, 2001, DNA RES, V8, P141, DOI 10.1093/dnares/8.4.141; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Topping J F, 1995, Methods Mol Biol, V49, P63; Van Montagu M., 1979, DEV GENETICS, P71; Vierstra RD, 2000, SEMIN CELL DEV BIOL, V11, P511, DOI 10.1006/scdb.2000.0206; WILLEMS A, 1993, INT J SYST BACTERIOL, V43, P305, DOI 10.1099/00207713-43-2-305; Willis LB, 1999, J BACTERIOL, V181, P4176, DOI 10.1128/JB.181.14.4176-4184.1999; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456; Young JM, 2001, INT J SYST EVOL MICR, V51, P89, DOI 10.1099/00207713-51-1-89; Zhu J, 2000, J BACTERIOL, V182, P3885, DOI 10.1128/JB.182.14.3885-3895.2000; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x	62	492	1177	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2323	2328		10.1126/science.1066803	http://dx.doi.org/10.1126/science.1066803			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743194				2022-12-28	WOS:000172817200038
J	Brownlee, M				Brownlee, M			Biochemistry and molecular cell biology of diabetic complications	NATURE			English	Review							PROTEIN-KINASE-C; GLYCATION END-PRODUCTS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ENDOTHELIUM-DEPENDENT VASODILATION; ALDOSE REDUCTASE INHIBITION; GLUCOSE-MODIFIED PROTEINS; GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; NITRIC-OXIDE; NERVE-CONDUCTION	Diabetes-specific microvascular disease is a leading cause of blindness, renal failure and nerve damage, and diabetes-accelerated atherosclerosis leads to increased risk of myocardial infarction, stroke and limb amputation. Four main molecular mechanisms have been implicated in glucose-mediated vascular damage. All seem to reflect a single hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain. This integrating paradigm provides a new conceptual framework for future research and drug discovery.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Brownlee, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	brownlee@aecom.yu.edu						Abordo EA, 1996, IMMUNOL LETT, V53, P7, DOI 10.1016/0165-2478(96)02601-6; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Coppey LJ, 2001, BRIT J PHARMACOL, V134, P21, DOI 10.1038/sj.bjp.0704216; CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961; Craven PA, 1997, DIABETES, V46, P671, DOI 10.2337/diabetes.46.4.671; Craven PA, 2001, DIABETES, V50, P2114, DOI 10.2337/diabetes.50.9.2114; CRAVEN RP, IN PRESS METABOLISM; Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DU XD, IN PRESS J CLIN INVE; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283; ENGERMAN RL, 1994, DIABETOLOGIA, V37, P141, DOI 10.1007/s001250050084; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FEDEROFF HJ, 1993, DIABETES, V42, P509, DOI 10.2337/diabetes.42.4.509; Feener EP, 1996, CONTRIB NEPHROL, V118, P180; Ganz MB, 2000, AM J PHYSIOL-ENDOC M, V278, pE146, DOI 10.1152/ajpendo.2000.278.1.E146; Gerstein HC, 2000, LANCET, V355, P253; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Glogowski EA, 1999, KIDNEY INT, V55, P486, DOI 10.1046/j.1523-1755.1999.00284.x; Goldberg HJ, 2000, DIABETES, V49, P863, DOI 10.2337/diabetes.49.5.863; Greene DA, 1999, NEUROLOGY, V53, P580, DOI 10.1212/WNL.53.3.580; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; HENNEKENS, 1990, ARCH OPHTHALMOL-CHIC, V108, P1234; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Hsueh Willa A., 1998, American Journal of Medicine, V105, p4S, DOI 10.1016/S0002-9343(98)00205-8; HUIJBERTS MSP, 1993, J CLIN INVEST, V92, P1407, DOI 10.1172/JCI116716; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Phillips SL, 1999, DIABETES, V48, P2083, DOI 10.2337/diabetes.48.10.2083; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667; Quinn M, 1996, DIABETOLOGIA, V39, P940; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; SCHMIDT RF, 1996, ESPRIT CACID, V1, P1; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Stitt AW, 1997, AM J PATHOL, V150, P523; STUDER RK, 1993, DIABETES, V42, P118, DOI 10.2337/diabetes.42.1.118; Suzuki K, 1998, J BIOCHEM-TOKYO, V123, P353; TANAKA S, 1988, J MOL BIOL, V203, P495, DOI 10.1016/0022-2836(88)90015-0; Temelkova-Kurktschiev TS, 2000, DIABETES CARE, V23, P1830, DOI 10.2337/diacare.23.12.1830; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; Tsuji H, 1998, BIOCHEM BIOPH RES CO, V245, P583, DOI 10.1006/bbrc.1998.8489; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; Wagenknecht LE, 2001, DIABETES, V50, P861, DOI 10.2337/diabetes.50.4.861; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WILSON DC, 1992, ACTA PAEDIATR, V81, P84, DOI 10.1111/j.1651-2227.1992.tb12087.x; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 2001, DIABETES, V50, P1491, DOI 10.2337/diabetes.50.6.1491; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855	99	6299	6819	37	1242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					813	820		10.1038/414813a	http://dx.doi.org/10.1038/414813a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742414				2022-12-28	WOS:000172676200062
J	Drenth, JPH; van der Meer, JWM				Drenth, JPH; van der Meer, JWM			Medical progress: Hereditary periodic fever.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL MEDITERRANEAN-FEVER; ENCODING MEVALONATE KINASE; HYPERIMMUNOGLOBULINEMIA-D; HYPER-IGD; CUTANEOUS MANIFESTATIONS; CLINICAL SPECTRUM; HIBERNIAN FEVER; AA AMYLOIDOSIS; GENE; MUTATIONS		Radboud Univ Nijmegen Med Ctr, Div Gastroenterol & Hepatol, Dept Med, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Div Gen Internal Med, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Drenth, JPH (corresponding author), Radboud Univ Nijmegen Med Ctr, Div Gastroenterol & Hepatol, Dept Med, POB 9101, NL-6500 HB Nijmegen, Netherlands.	joostphdrenth@cs.com	Drenth, J.P.H./H-8025-2014; Drenth, Joost/V-7436-2019; van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690				Aksentijevich I, 1999, AM J HUM GENET, V64, P949, DOI 10.1086/302327; Aksentijevich I, 1997, CELL, V90, P797; Alt HL, 1930, J AMER MED ASSOC, V94, P1457, DOI 10.1001/jama.1930.02710450001001; AYESH SK, 1993, BLOOD, V81, P1424; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Ben-Chetrit E, 1998, LANCET, V351, P659, DOI 10.1016/S0140-6736(97)09408-7; Ben-Chetrit E, 2000, HUM MUTAT, V15, P385, DOI 10.1002/(SICI)1098-1004(200004)15:4<385::AID-HUMU22>3.0.CO;2-A; Bernot A, 1997, NAT GENET, V17, P25; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; Cazeneuve C, 2000, AM J HUM GENET, V67, P1136, DOI 10.1016/S0002-9297(07)62944-9; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Chen XG, 1998, HUM MUTAT, V11, P456, DOI 10.1002/(SICI)1098-1004(1998)11:6<456::AID-HUMU6>3.0.CO;2-G; Cuisset L, 1999, AM J HUM GENET, V65, P1054, DOI 10.1086/302589; Cuisset L, 2001, EUR J HUM GENET, V9, P260, DOI 10.1038/sj.ejhg.5200614; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; de Kleijn EMH, 1997, MEDICINE, V76, P392, DOI 10.1097/00005792-199711000-00002; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; Dode C, 2000, ARTHRITIS RHEUM-US, V43, P1535, DOI 10.1002/1529-0131(200007)43:7<1535::AID-ANR18>3.0.CO;2-C; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Drenth JPH, 2001, J PHARMACOL EXP THER, V298, P1221; DRENTH JPH, 1995, BLOOD, V85, P3586, DOI 10.1182/blood.V85.12.3586.bloodjournal85123586; DRENTH JPH, 1995, EUR J CLIN INVEST, V25, P683, DOI 10.1111/j.1365-2362.1995.tb01986.x; DRENTH JPH, 1994, ARCH DERMATOL, V130, P59, DOI 10.1001/archderm.130.1.59; DRENTH JPH, 1994, HUM GENET, V94, P616, DOI 10.1007/BF00206953; Drewe E, 2000, NEW ENGL J MED, V343, P1044, DOI 10.1056/NEJM200010053431412; DRIESSEN O, 1968, ACTA ENDOCRINOL-COP, V57, P177, DOI 10.1530/acta.0.0570177; ESHEL G, 1994, BRIT J SURG, V81, P894, DOI 10.1002/bjs.1800810633; GAFNI J, 1968, ISRAEL J MED SCI, V4, P995; Galon J, 2000, CURR OPIN IMMUNOL, V12, P479, DOI 10.1016/S0952-7915(00)00124-2; Gang N, 1999, J RHEUMATOL, V26, P890; GENY B, 1974, BIOMEDICINE, V20, P125; Gershoni-Baruch R, 1999, Hum Mutat, V14, P91, DOI 10.1002/(SICI)1098-1004(1999)14:1<91::AID-HUMU22>3.0.CO;2-8; GERTZ MA, 1987, MAYO CLIN PROC, V62, P1095, DOI 10.1016/S0025-6196(12)62502-6; Grateau G, 2000, CURR OPIN RHEUMATOL, V12, P61, DOI 10.1097/00002281-200001000-00010; HARALDSSON A, 1992, J CLIN IMMUNOL, V12, P424, DOI 10.1007/BF00918854; HELLER H, 1958, ARCH INTERN MED, V102, P50, DOI 10.1001/archinte.1958.00260190052007; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; Hoffman HM, 2000, AM J HUM GENET, V66, P1693, DOI 10.1086/302874; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Houten SM, 1999, HUM MOL GENET, V8, P1523, DOI 10.1093/hmg/8.8.1523; Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691; Houten SM, 2000, BBA-MOL CELL BIOL L, V1529, P19, DOI 10.1016/S1388-1981(00)00135-9; KARENKO L, 1993, J INTERN MED, V233, P101; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; Kataoka H, 1998, ANN INTERN MED, V129, P424, DOI 10.7326/0003-4819-129-5-199809010-00022; Kees S, 1997, QJM-MON J ASSOC PHYS, V90, P643; Klasen IS, 2001, CLIN DIAGN LAB IMMUN, V8, P58, DOI 10.1128/CDLI.8.1.58-61.2001; Livneh A, 2000, BEST PRACT RES CL RH, V14, P477, DOI 10.1053/berh.2000.0089; LIVNEH A, 1994, ARTHRITIS RHEUM-US, V37, P1804, DOI 10.1002/art.1780371215; Livneh A, 1999, AMYLOID, V6, P1, DOI 10.3109/13506129908993281; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; MAJEED HA, 1990, Q J MED, V75, P607; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; McDermott M F, 1999, Rev Rhum Engl Ed, V66, P484; McDermott MF, 1998, AM J HUM GENET, V62, P1446, DOI 10.1086/301886; McDermott MF, 2000, ARTHRITIS RHEUM-US, V43, P2034, DOI 10.1002/1529-0131(200009)43:9<2034::AID-ANR14>3.0.CO;2-J; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Mulley J, 1998, AM J HUM GENET, V62, P884, DOI 10.1086/301793; Padeh S, 1999, J PEDIATR-US, V135, P98, DOI 10.1016/S0022-3476(99)70335-5; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; PRIEUR AM, 1984, SEM HOP PARIS, V60, P163; Rios SE, 2001, BBA-MOL CELL BIOL L, V1531, P165, DOI 10.1016/S1388-1981(01)00105-6; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; Shohat M, 1999, EUR J HUM GENET, V7, P287, DOI 10.1038/sj.ejhg.5200303; SIEGAL S, 1945, ANN INTERN MED, V23, P1, DOI 10.7326/0003-4819-23-1-1; Simon A, 2001, AM J MED, V110, P313, DOI 10.1016/S0002-9343(00)00716-6; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; Thomas KT, 1999, J PEDIATR-US, V135, P15, DOI 10.1016/S0022-3476(99)70321-5; Toro JR, 2000, ARCH DERMATOL, V136, P1487, DOI 10.1001/archderm.136.12.1487; Touitou I, 2001, ARTHRITIS RHEUM, V44, P163, DOI 10.1002/1529-0131(200101)44:1<163::AID-ANR20>3.0.CO;2-Z; Tunca M, 1997, BRIT J RHEUMATOL, V36, P1005; TUNCA M, 2000, CLIN EXP RHEUMATOL, V18, P302; VANDERMEER JWM, 1984, LANCET, V1, P1087; Watkins JB, 1999, NEW ENGL J MED, V341, P593, DOI 10.1056/NEJM199908193410808; WILLIAMSON LM, 1982, Q J MED, V51, P469; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803; Zweers E J, 1993, Ned Tijdschr Geneeskd, V137, P1570	79	304	329	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1748	1757		10.1056/NEJMra010200	http://dx.doi.org/10.1056/NEJMra010200			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742050				2022-12-28	WOS:000172656100006
J	Hunt, GR; Corballis, MC; Gray, RD				Hunt, GR; Corballis, MC; Gray, RD			Laterality in tool manufacture by crows - Neural processing and not ecological factors may influence 'handedness' in these birds.	NATURE			English	Article							MANUAL LATERALITY; CALEDONIAN CROWS; HAND; SPECIALIZATION; PAN		Univ Auckland, Dept Psychol, Auckland 92019, New Zealand	University of Auckland	Hunt, GR (corresponding author), Univ Auckland, Dept Psychol, Auckland 92019, New Zealand.		Gray, Russell/H-2078-2015	Gray, Russell/0000-0002-9858-0191; Corballis, Michael/0000-0002-3126-6114				Bradshaw JL., 1993, EVOLUTION LATERAL AS; BYRNE RW, 1991, CORTEX, V27, P521, DOI 10.1016/S0010-9452(13)80003-2; Corballis M.C., 1991, LOPSIDED APE EVOLUTI; FAGOT J, 1991, PSYCHOL BULL, V109, P76, DOI 10.1037/0033-2909.109.1.76; HARRIS LJ, 1989, CAN J PSYCHOL, V43, P369, DOI 10.1037/h0084228; Hopkins WD, 1996, PSYCHON B REV, V3, P449, DOI 10.3758/BF03214548; Hopkins WD, 1998, J COMP PSYCHOL, V112, P95, DOI 10.1037/0735-7036.112.1.95; Hunt GR, 2000, P ROY SOC B-BIOL SCI, V267, P403, DOI 10.1098/rspb.2000.1015; Hunt GR, 1996, NATURE, V379, P249, DOI 10.1038/379249a0; McGrew WC, 1997, INT J PRIMATOL, V18, P787, DOI 10.1023/A:1026347913888; McGrew WC, 2001, BEHAVIOUR, V138, P329, DOI 10.1163/15685390152032497; Vallortigara G, 1999, BRAIN RES REV, V30, P164, DOI 10.1016/S0165-0173(99)00012-0	12	62	64	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					707	707		10.1038/414707a	http://dx.doi.org/10.1038/414707a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	501GD	11742382	Bronze			2022-12-28	WOS:000172676200030
J	Moller, DE				Moller, DE			New drug targets for type 2 diabetes and the metabolic syndrome	NATURE			English	Review							ACTIVATED PROTEIN-KINASE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; INDUCED INSULIN-RESISTANCE; FATTY-ACID OXIDATION; PPAR-GAMMA; MICE LACKING; GLUCOSE-TOLERANCE; GENE-EXPRESSION; RECEPTOR-ALPHA; GLUCAGON	An insidious increase in features of the 'metabolic syndrome' - obesity, insulin resistance and dyslipidaemia - has conspired to produce a worldwide epidemic of type 2 insulin-resistant diabetes mellitus. Most current therapies for this disease were developed in the absence of defined molecular targets or an understanding of disease pathogenesis. Emerging knowledge of key pathogenic mechanisms, such as the impairment of glucose-stimulated insulin secretion and the role of 'lipotoxicity' as a probable cause of hepatic and muscle resistance to insulin's effects on glucose metabolism, has led to a host of new molecular drug targets. Several have been validated through genetic engineering in mice or the preliminary use of lead compounds and therapeutic agents in animals and humans.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Moller, DE (corresponding author), Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA.							Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Ahren B, 2001, DIABETES, V50, pA104; Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger J, 2001, J BIOL CHEM, V276, P12629, DOI 10.1074/jbc.M003592200; BERGER J, IN PRESS ANN REV MED; BRAND CL, 1994, DIABETOLOGIA, V37, P985, DOI 10.1007/BF00400461; Bush EN, 2001, DIABETES, V50, pA81; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; COHEN N, 1995, J CLIN INVEST, V95, P2501, DOI 10.1172/JCI117951; Combatsiaris TP, 2001, DIABETES, V50, pA271; Connell RD, 1999, EXPERT OPIN THER PAT, V9, P701, DOI 10.1517/13543776.9.6.701; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Demuth HU, 2000, DIABETES, V49, pA102; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Edwards CMB, 1999, DIABETES, V48, P86, DOI 10.2337/diabetes.48.1.86; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gerhold D, 2000, DIABETES, V49, pA212; Goldstein BJ, 1998, VITAM HORM, V54, P67, DOI 10.1016/S0083-6729(08)60922-X; Goodyear L J, 2000, Exerc Sport Sci Rev, V28, P113; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Henriksen EJ, 2001, DIABETES, V50, pA279; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Kopelman PG, 1998, LANCET, V352, P5; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Moller DE, 2001, ADV PROTEIN CHEM, V56, P181; MOLLER DE, 2000, HDB EXPT PHARM OBESI, P404; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; OAKES ND, 1994, DIABETES, V43, P1203, DOI 10.2337/diabetes.43.10.1203; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Parker JC, 1998, DIABETES, V47, P1630, DOI 10.2337/diabetes.47.10.1630; Petersen KF, 1999, DIABETOLOGIA, V42, pA42; PICKUP J, 1997, TXB DIABETES, V1; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Roden M, 1996, J CLIN INVEST, V97, P642, DOI 10.1172/JCI118460; Rubins HB, 2000, AM J CARDIOL, V86, P543, DOI 10.1016/S0002-9149(00)01010-9; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Shah P, 2000, J CLIN ENDOCR METAB, V85, P4053, DOI 10.1210/jc.85.11.4053; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; SOHDA T, 1982, CHEM PHARM BULL, V30, P3580; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Treadway JL, 2001, EXPERT OPIN INV DRUG, V10, P439, DOI 10.1517/13543784.10.3.439; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UNGER RH, 1971, NEW ENGL J MED, V285, P443; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; Wagner JA, 2001, DIABETES, V50, pA134; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974; Zhang BB, 2000, CURR OPIN CHEM BIOL, V4, P461, DOI 10.1016/S1367-5931(00)00103-4; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	77	795	892	2	99	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					821	827		10.1038/414821a	http://dx.doi.org/10.1038/414821a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742415				2022-12-28	WOS:000172676200063
J	Pisetsky, DS; St Clair, EW				Pisetsky, DS; St Clair, EW			Progress in the treatment of rheumatoid arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOUBLE-BLIND; COMBINATION THERAPY; GASTROINTESTINAL TOXICITY; METHOTREXATE; LEFLUNOMIDE; PLACEBO; SULFASALAZINE; CYCLOSPORINE; IMPROVEMENT		Duke Univ, Med Ctr, Div Rheumatol Allergy & Clin Immunol, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Durham, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Pisetsky, DS (corresponding author), Duke Univ, Med Ctr, Div Rheumatol Allergy & Clin Immunol, 1516 Durham Vet Affairs Med Ctr,Box 151G, Durham, NC 27710 USA.	dpiset@acpub.duke.edu						ALARCON GS, 1995, RHEUM DIS CLIN N AM, V21, P589; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Dougados M, 1999, ANN RHEUM DIS, V58, P220, DOI 10.1136/ard.58.4.220; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Kremer JM, 2000, ARTHRITIS RHEUM, V43, pS224; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; ODell JR, 1997, RHEUM DIS CLIN N AM, V23, P779, DOI 10.1016/S0889-857X(05)70360-4; Proudman SM, 2000, ARTHRITIS RHEUM, V43, P1809, DOI 10.1002/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D; Sharp JT, 2000, ARTHRITIS RHEUM-US, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Sokka T, 2000, ARTHRITIS RHEUM, V43, P386, DOI 10.1002/1529-0131(200002)43:2<386::AID-ANR19>3.0.CO;2-Z; Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542; Tugwell P, 2000, ARTHRITIS RHEUM, V43, P506, DOI 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Wolfe F, 2000, ARTHRITIS RHEUM-US, V43, P2751, DOI 10.1002/1529-0131(200012)43:12<2751::AID-ANR15>3.0.CO;2-6	27	66	67	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2787	2790		10.1001/jama.286.22.2787	http://dx.doi.org/10.1001/jama.286.22.2787			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735734				2022-12-28	WOS:000172655400002
J	Deb, SK; Wilding, M; Somayazulu, M; McMillan, PF				Deb, SK; Wilding, M; Somayazulu, M; McMillan, PF			Pressure-induced amorphization and an amorphous-amorphous transition in densified porous silicon	NATURE			English	Article							PHASE-TRANSITION; TEMPERATURE; LIQUID; SI; CRYSTALLIZATION; RELAXATION; SURFACE	Crystalline and amorphous forms of silicon are the principal materials used for solid-state electronics and photovoltaics technologies. Silicon is therefore a well-studied material, although new structures and properties are still being discovered(1-4). Compression of bulk silicon, which is tetrahedrally coordinated at atmospheric pressure, results in a transition to octahedrally coordinated metallic phases(5). In compressed nanocrystalline Si particles, the initial diamond structure persists to higher pressure than for bulk material, before transforming to high-density crystals(6). Here we report compression experiments on films of porous Si, which contains nanometre-sized domains of diamond-structured material(7-9). At pressures larger than 10 GPa we observed pressure-induced amorphization(10,11). Furthermore, we rnd from Raman spectroscopy measurements that the high-density amorphous form obtained by this process transforms to low-density amorphous silicon upon decompression. This amorphous-amorphous transition is remarkably similar to that reported previously for water(12,13), which suggests an underlying transition between a high-density and a low-density liquid phase in supercooled Si (refs 10, 14, 15). The Si melting temperature decreases with increasing pressure, and the crystalline semiconductor melts to a metallic liquid with average coordination similar to5 (ref. 16).	UCL, Christopher Ingold Labs, Dept Chem, London WC1H 0AJ, England; Royal Inst Great Britain, Davy Faraday Res Lab, London W1X 4BS, England; Argonne Natl Lab, Adv Photon Source, HPCAT, Argonne, IL 60439 USA; Univ Calif Davis, Thermochem Facil, Davis, CA 95616 USA; Bhabha Atom Res Ctr, Div Solid State Phys, Mumbai 400085, India	University of London; University College London; United States Department of Energy (DOE); Argonne National Laboratory; University of California System; University of California Davis; Bhabha Atomic Research Center (BARC)	McMillan, PF (corresponding author), UCL, Christopher Ingold Labs, Dept Chem, 20 Gordon St, London WC1H 0AJ, England.	paulm@ri.ac.uk	McMillan, Paul/AAI-9067-2020	Wilding, Martin/0000-0002-0802-0423				ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; Angell CA, 1996, J NON-CRYST SOLIDS, V207, P463, DOI 10.1016/S0022-3093(96)00261-X; Angell CA, 2000, J NON-CRYST SOLIDS, V274, P319, DOI 10.1016/S0022-3093(00)00222-2; Ansell S, 1998, J PHYS-CONDENS MAT, V10, pL73, DOI 10.1088/0953-8984/10/3/005; Bellet D, 1996, THIN SOLID FILMS, V276, P1, DOI 10.1016/0040-6090(95)08035-X; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; BRODSKY MH, 1974, PHYS REV B, V9, P1646, DOI 10.1103/PhysRevB.9.1646; COLLINS RT, 1997, PHYS TODAY      0124; DEB SK, 1997, ADV HIGH PRESSURE SC, P147; DONOVAN EP, 1985, J APPL PHYS, V57, P1795, DOI 10.1063/1.334406; Gaal-Nagy K, 1999, PHYS STATUS SOLIDI B, V211, P275, DOI 10.1002/(SICI)1521-3951(199901)211:1<275::AID-PSSB275>3.0.CO;2-O; GOLDSTEIN AN, 1992, SCIENCE, V256, P1425, DOI 10.1126/science.256.5062.1425; Kamalakaran R, 2000, J PHYS-CONDENS MAT, V12, P2681, DOI 10.1088/0953-8984/12/12/309; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; Lai SL, 1996, PHYS REV LETT, V77, P99, DOI 10.1103/PhysRevLett.77.99; LIU LG, 1987, ELEMENTS OXIDES SILI, P37; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; Moynihan CT, 2000, J NON-CRYST SOLIDS, V274, P131, DOI 10.1016/S0022-3093(00)00198-8; Papadimitriou D, 1998, PHYS REV B, V58, P14089, DOI 10.1103/PhysRevB.58.14089; PILTZ RO, 1995, PHYS REV B, V52, P4072, DOI 10.1103/PhysRevB.52.4072; PONYATOVSKY EG, 1992, MATER SCI REP, V8, P147, DOI 10.1016/0920-2307(92)90007-N; Poole PH, 1997, SCIENCE, V275, P322, DOI 10.1126/science.275.5298.322; Ramachandran GK, 2000, J PHYS-CONDENS MAT, V12, P4013, DOI 10.1088/0953-8984/12/17/308; Rhim WK, 2000, J CRYST GROWTH, V208, P313, DOI 10.1016/S0022-0248(99)00437-6; Sharma SM, 1996, PROG MATER SCI, V40, P1, DOI 10.1016/0079-6425(95)00006-2; THOMPSON MO, 1984, PHYS REV LETT, V52, P2360, DOI 10.1103/PhysRevLett.52.2360; Tolbert SH, 1996, PHYS REV LETT, V76, P4384, DOI 10.1103/PhysRevLett.76.4384; XIE YH, 1994, PHYS REV B, V49, P5386, DOI 10.1103/PhysRevB.49.5386	30	326	331	4	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	2001	414	6863					528	530		10.1038/35107036	http://dx.doi.org/10.1038/35107036			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734849				2022-12-28	WOS:000172405900042
J	Darzi, A; Mackay, S				Darzi, A; Mackay, S			Recent advances in minimal access surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LAPAROSCOPIC ADRENALECTOMY; SPLENECTOMY; PHEOCHROMOCYTOMA; CHOLECYSTECTOMY; HERNIOPLASTY; EXPERIENCE; CANCER		Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Acad Surg Unit, London W2 1NY, England	Imperial College London	Darzi, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Acad Surg Unit, London W2 1NY, England.	a.darzi@ic.ac.uk						Baba S, 1999, WORLD J UROL, V17, P54, DOI 10.1007/s003450050105; Bowrey D J, 1999, Semin Laparosc Surg, V6, P194; Cocks JR, 1998, AUST NZ J SURG, V68, P506, DOI 10.1111/j.1445-2197.1998.tb04812.x; Cuschieri A, 1999, J ROY COLL SURG EDIN, V44, P187; DARZI A, 1995, SURG ENDOSC-ULTRAS, V9, P414; Darzi A, 1993, Endosc Surg Allied Technol, V1, P13; DARZI A, 1995, SURG ENDOSC-ULTRAS, V9, P301; DARZI A, 1993, BRIT J SURG, V80, P1552, DOI 10.1002/bjs.1800801221; Duh QY, 1996, SURGERY, V120, P1079; Gagner M, 1996, SURGERY, V120, P1076, DOI 10.1016/S0039-6060(96)80058-4; GAGNER M, 1992, NEW ENGL J MED, V327, P1033; Gagner M, 1997, ANN SURG, V226, P238, DOI 10.1097/00000658-199709000-00003; GAGNER M, 1994, SURG ENDOSC-ULTRAS, V8, P135, DOI 10.1007/BF00316627; Glasgow RE, 1999, WORLD J SURG, V23, P384, DOI 10.1007/PL00012313; GRACE P, 1991, IRISH MED J, V84, P12; Klingler PJ, 1999, SURG LAPAROSC ENDOSC, V9, P1, DOI 10.1097/00019509-199901000-00001; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; LICHTENSTEIN IL, 1993, SURG CLIN N AM, V73, P529; Miccoli P, 1997, J LAPAROENDOSC ADV A, V7, P167, DOI 10.1089/lap.1997.7.167; MONSON JRT, 1994, SURG LAPAROSC ENDOSC, V4, P6; Nduka CC, 1998, SURG ENDOSC-ULTRAS, V12, P1031, DOI 10.1007/s004649900774; NDUKA CC, 1994, BRIT J SURG, V81, P648, DOI 10.1002/bjs.1800810506; Rutherford JC, 1996, WORLD J SURG, V20, P758, DOI 10.1007/s002689900115; Scott HJ, 1997, BRIT J SURG, V84, P1005, DOI 10.1002/bjs.1800840729; Taffinder N, 1999, SURG ENDOSC-ULTRAS, V13, P1087, DOI 10.1007/s004649901179; Terrosu G, 1999, SURGERY, V125, P154; Terrosu G, 1998, SURGERY, V124, P839, DOI 10.1016/S0039-6060(98)70006-6; Tsangaris TN, 1999, SURG ENDOSC, V13, P43, DOI 10.1007/s004649900895; Veronesi U, 1999, JNCI-J NATL CANCER I, V91, P368, DOI 10.1093/jnci/91.4.368	29	83	87	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	2002	324	7328					31	34		10.1136/bmj.324.7328.31	http://dx.doi.org/10.1136/bmj.324.7328.31			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510JV	11777804	Green Published			2022-12-28	WOS:000173205700023
J	Al-Shahi, R; Will, RG; Warlow, CP				Al-Shahi, R; Will, RG; Warlow, CP			Amount of research interest in rare and common neurological conditions: bibliometric study	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Warlow, CP (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.			Al-Shahi Salman, Rustam/0000-0002-2108-9222				Frankel S, 1989, Health Trends, V21, P56; Global Forum for Health Research, 2000, 10 90 REP HLTH RES; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Tallon D, 2000, LANCET, V355, P2037, DOI 10.1016/S0140-6736(00)02351-5; WARLOW CP, 2001, BRAINS DIS NERVOUS S	5	18	18	4	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1461	1462		10.1136/bmj.323.7327.1461	http://dx.doi.org/10.1136/bmj.323.7327.1461			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751355	Green Submitted, Green Published			2022-12-28	WOS:000172979900015
J	Hoffenberg, R				Hoffenberg, R			Christiaan Barnard: his first transplants and their impact on concepts of death	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRAIN-DEATH				Hoffenberg, R (corresponding author), 304 57A Newstead Terrace, Brisbane, Qld 5006, Australia.							[Anonymous], 1968, JAMA, V205, P337; Capron AM, 2001, NEW ENGL J MED, V344, P1244, DOI 10.1056/NEJM200104193441611; Capron AM, 1999, DEFINITION OF DEATH, P117; Fost N, 1999, DEFINITION OF DEATH, P161; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MOHANDAS A, 1971, J NEUROSURG, V35, P211, DOI 10.3171/jns.1971.35.2.0211; PALLIS C, 1987, MED LEG J, V2, P84; *ROYAL COLL FAC UK, 1976, BMJ-BRIT MED J, V2, P1187; Shewmon DA, 1998, NEUROLOGY, V51, P1538, DOI 10.1212/WNL.51.6.1538; Truog RD, 1997, HASTINGS CENT REP, V27, P29, DOI 10.2307/3528024; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; 1967, S AFR MED J, V41, P1257	12	35	38	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2001	323	7327					1478	1480		10.1136/bmj.323.7327.1478	http://dx.doi.org/10.1136/bmj.323.7327.1478			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751363	Green Published			2022-12-28	WOS:000172979900023
J	Garcia, LR; Mehta, P; Sternberg, PW				Garcia, LR; Mehta, P; Sternberg, PW			Regulation of distinct muscle behaviors controls the C. elegans male's copulatory spicules during mating	CELL			English	Article							LEVAMISOLE RESISTANCE; SYNAPTIC-TRANSMISSION; GENE-TRANSFER; MUTANTS; MUTATIONS; G(Q)ALPHA; ENCODES; CELLS; INTERACTS	We demonstrate through cell ablation, molecular genetic, and pharmacological approaches that during C. elegans male mating behavior, the male inserts his copulatory spicules into the hermaphrodite by regulating periodic and prolonged spicule muscle contractions. Distinct cholinergic neurons use different ACh receptors and calcium channels in the spicule muscles to mediate these contractile behaviors. The PCB and PCC sensory neurons facilitate periodic contraction through muscle-encoded UNC-68 ryanodine receptor calcium channels. The SPC motor neurons trigger prolonged contraction through EGL-19 L-type voltage-gated calcium channels. The male gonad then lengthens the duration of EGL-19-mediated prolonged muscle contraction. This regulation of muscle contraction provides a paradigm to explain how animals initiate, monitor, and maintain a behavioral motor program.	CALTECH, Div Biol, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Sternberg, PW (corresponding author), CALTECH, Div Biol, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	pws@caltech.edu						ALFONSO A, 1994, J NEUROSCI, V14, P2290; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; BRENNER S, 1974, GENETICS, V77, P71; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; FINNEY D J, 1971, P333; Fleming JT, 1997, J NEUROSCI, V17, P5843; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1983, GENETICS, V103, P43; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; LEWIS JA, 1980, GENETICS, V95, P905; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; Maryon EB, 1998, J CELL SCI, V111, P2885; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Miller LM, 1996, GENETICS, V143, P1181; Moerman Donald G., 1997, Cold Spring Harbor Monograph Series, V33, P417; Ogawa H, 1998, J BIOL CHEM, V273, P2192, DOI 10.1074/jbc.273.4.2192; RAND JB, 1985, PSYCHOPHARMACOL BULL, V21, P623; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Riddle Donald L., 1997, Cold Spring Harbor Monograph Series, V33, P739; Robatzek M, 2001, CURR BIOL, V11, P288, DOI 10.1016/S0960-9822(01)00074-4; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; TRIBUT F, 1994, J EXP BIOL, V186, P325; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475	43	81	82	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					777	788		10.1016/S0092-8674(01)00600-6	http://dx.doi.org/10.1016/S0092-8674(01)00600-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747813	Bronze			2022-12-28	WOS:000172771800010
J	Lopes, WA; Jaeger, HM				Lopes, WA; Jaeger, HM			Hierarchical self-assembly of metal nanostructures on diblock copolymer scaffolds	NATURE			English	Article							THIN-FILMS; DENSITY; ARRAYS; SIZE	Self-assembly is emerging as an elegant, 'bottom-up' method for fabricating nanostructured materials(1-8). This approach becomes particularly powerful when the ease and control offered by the self-assembly of organic components is combined with the electronic, magnetic or photonic properties of inorganic components(2,5,9). Here we demonstrate a versatile hierarchical approach for the assembly of organic-inorganic, copolymer- metal nanostructures in which one level of self-assembly guides the next. In a first step, ultrathin diblock copolymer films form a regular scaffold of highly anisotropic, stripe-like domains(10-12). During a second assembly step, differential wetting guides diffusing metal atoms to aggregate selectively along the scaffold, producing highly organized metal nanostructures. We rnd that, in contrast to the usual requirement of near-equilibrium conditions for ordering(2,3,13), the metal arranged on the copolymer scaffold produces the most highly ordered configurations when the system is far from equilibrium. We delineate two distinct assembly modes of the metal component-chains of separate nanoparticles and continuous wires-each characterized by different ordering kinetics and strikingly different current-voltage characteristics. These results therefore demonstrate the possibility of guided, large-scale assembly of laterally nanostructured systems.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Jaeger, HM (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	h-jaeger@uchicago.edu						Balazs AC, 1999, CURR OPIN COLLOID IN, V4, P443, DOI 10.1016/S1359-0294(00)00021-2; Black CT, 2000, SCIENCE, V290, P1131, DOI 10.1126/science.290.5494.1131; Boal AK, 2000, NATURE, V404, P746, DOI 10.1038/35008037; Cole DH, 1997, PHYS REV LETT, V78, P5006, DOI 10.1103/PhysRevLett.78.5006; Cordan AS, 2000, J APPL PHYS, V87, P345, DOI 10.1063/1.371867; Fasolka MJ, 2001, ANN REV MATER RES, V31, P323, DOI 10.1146/annurev.matsci.31.1.323; Ford EM, 1999, APPL PHYS LETT, V75, P421, DOI 10.1063/1.124395; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; GERENSER LJ, 1992, METALLIZED PLASTICS, V3, P163; GUICO RS, IN PRESS POLYM MAT S, V85; Harrison C, 2000, SCIENCE, V290, P1558, DOI 10.1126/science.290.5496.1558; Higgins AM, 2000, NATURE, V404, P476, DOI 10.1038/35006597; Lin BH, 1999, J APPL PHYS, V85, P3180, DOI 10.1063/1.369658; LOPES W, UNPUB PHYS REV E; Morkved TL, 1998, POLYMER, V39, P3871, DOI 10.1016/S0032-3861(97)10218-X; Morkved TL, 1997, EUROPHYS LETT, V40, P643, DOI 10.1209/epl/i1997-00517-6; MORKVED TL, 1994, APPL PHYS LETT, V64, P422, DOI 10.1063/1.111118; Morkved TL, 1996, SCIENCE, V273, P931, DOI 10.1126/science.273.5277.931; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; PIUZ F, 1972, PHYS STATUS SOLIDI A, V14, P129, DOI 10.1002/pssa.2210140114; Sanchez C, 2001, MRS BULL, V26, P377, DOI 10.1557/mrs2001.91; Spatz JP, 2000, LANGMUIR, V16, P407, DOI 10.1021/1a990070n; Tang WH, 1998, MACROMOLECULES, V31, P3130, DOI 10.1021/ma971524v; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Wu S., 1982, POLYM INTERFACES ADH	26	791	845	7	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					735	738		10.1038/414735a	http://dx.doi.org/10.1038/414735a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742395				2022-12-28	WOS:000172676200043
J	Christopoulos, S; Minuk, J; Assimakopoulos, P; Kahn, SR				Christopoulos, S; Minuk, J; Assimakopoulos, P; Kahn, SR			Clinical picture: Epidural lipomatosis	LANCET			English	Editorial Material									Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Dept Neurol, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University	Christopoulos, S (corresponding author), Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1982	1982		10.1016/S0140-6736(01)06965-3	http://dx.doi.org/10.1016/S0140-6736(01)06965-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747940	Bronze			2022-12-28	WOS:000172622200033
J	Heldin, CH; Ericsson, J				Heldin, CH; Ericsson, J			Signal transduction - RIPping tyrosine kinase receptors apart	SCIENCE			English	Editorial Material							INTRAMEMBRANE PROTEOLYSIS		Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Heldin, CH (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, SE-75124 Uppsala, Sweden.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574				Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065	8	31	32	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2111	+		10.1126/science.1067628	http://dx.doi.org/10.1126/science.1067628			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739942				2022-12-28	WOS:000172647700034
J	Feldman, KA; Enscore, RE; Lathrop, SL; Matyas, BT; McGuill, M; Schriefer, ME; Stiles-Enos, D; Dennis, DT; Petersen, LR; Hayes, EB				Feldman, KA; Enscore, RE; Lathrop, SL; Matyas, BT; McGuill, M; Schriefer, ME; Stiles-Enos, D; Dennis, DT; Petersen, LR; Hayes, EB			An outbreak of primary pneumonic tularemia on martha's vineyard	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background: In the summer of 2000, an outbreak of primary pneumonic tularemia occurred on Martha's Vineyard, Massachusetts. The only previously reported outbreak of pneumonic tularemia in the United States also occurred on the island in 1978. Methods: We conducted a case-control study of adults with pneumonic tularemia and investigated the environment to identify risk factors for primary pneumonic tularemia. Patients with confirmed cases were residents of or visitors to Martha's Vineyard who had symptoms suggestive of primary pneumonic tularemia, were ill between May 15 and October 31, 2000, and had a positive laboratory test for tularemia. Controls were adults who had spent at least 15 days on Martha's Vineyard between May 15 and September 28, 2000. Results: We identified 15 patients with tularemia; 11 of these cases were primary pneumonic tularemia. Francisella tularensis type A was isolated from blood and lung tissue of the one man who died. Patients were more likely than controls to have used a lawn mower or brush cutter in the two weeks before the illness (odds ratio, 9.2; 95 percent confidence interval, 1.6 to 68.0) and during the summer (odds ratio, undefined; 95 percent confidence interval, 1.8 to (infinity)). Lawn mowing and brush cutting remained significant risk factors after adjustment for other potentially confounding variables. Only one patient reported being exposed to a rabbit while cutting brush. Of 40 trapped animals, 1 striped skunk and 1 Norway rat were seropositive for antibodies against F. tularensis. Conclusions: Study of this outbreak of primary pneumonic tularemia implicates lawn mowing and brush cutting as risk factors for this infection. (N Engl J Med 2001;345:1601-6.) Copyright (C) 2001 Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Ft Collins, CO 80522 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA; Massachusetts Dept Publ Hlth, Boston, MA USA; Marthas Vineyard Hosp, Oak Bluffs, MA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Massachusetts Department of Public Health	Feldman, KA (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, POB 2087,Rampart Rd, Ft Collins, CO 80522 USA.			Enscore, Russell/0000-0002-1290-1100				[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; AYRES JC, 1948, NEW ENGL J MED, V238, P187, DOI 10.1056/NEJM194802052380606; Belding DL, 1941, NEW ENGL J MED, V224, P1085, DOI 10.1056/NEJM194106262242602; BELL J F, 1975, Journal of Wildlife Diseases, V11, P421; BELL JF, 1979, CRC HDB SERIES ZOO A, V2, P161; BROWN SL, 1980, J CLIN MICROBIOL, V11, P146, DOI 10.1128/JCM.11.2.146-148.1980; DAHLSTRAND S, 1971, Scandinavian Journal of Infectious Diseases, V3, P7; DEAN A, 1995, EPI INFO VERSION 6 W; DENNIS DT, 1999, INFECT DIS; DENNIS DT, 1998, MAXCY ROSENAU LAST P, P354; HALSTED CC, 1978, PEDIATRICS, V61, P660; Hopla CE, 1994, HDB ZOONOSES, P113; Hornick R. B., 1998, BACTERIAL INFECT HUM, P823; Jellison W.L., 1974, TULAREMIA N AM 1930; LENHART SW, 1997, DHHS PUBLICATION; MARTONE WJ, 1979, JAMA-J AM MED ASSOC, V242, P2315, DOI 10.1001/jama.242.21.2315; MCCARTHY VP, 1990, PEDIATR INFECT DIS J, V9, P298, DOI 10.1097/00006454-199004000-00018; MCDOWELL JW, 1964, TULAREMIA; MEHTA C, 1992, STATXACT VERSION 4 0; Murin S, 2000, CLIN CHEST MED, V21, P121, DOI 10.1016/S0272-5231(05)70012-5; PARKER RR, 1951, NATL I HLTH B, V193, P1; PENN RL, 1995, MANDELL DOUGLAS BENN, V2, P2060; PITTMAN B, 1977, J CLIN MICROBIOL, V5, P621; POMANSKAIA L. A., 1957, Journal of Microbiology, Epidemiology and Immunobiology, V28, P597; *SAS I, 1996, SAS VERS 6 12; SMITH CN, 1946, BIOL CONTROL AM DOG; TEUTSCH SM, 1979, NEW ENGL J MED, V301, P826, DOI 10.1056/NEJM197910113011507; Williams J, 1998, LANCET, V351, P1697, DOI 10.1016/S0140-6736(97)10444-5; 1993, MMWR MORB MORTAL WKL, V42, P1	29	198	205	0	16	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1601	1606		10.1056/NEJMoa011374	http://dx.doi.org/10.1056/NEJMoa011374			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11757506				2022-12-28	WOS:000172383900003
J	Pearson, H				Pearson, H			China caught out as model shows net fall in fish	NATURE			English	News Item																			0	1	1	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					477	477		10.1038/35107216	http://dx.doi.org/10.1038/35107216			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734811	Bronze			2022-12-28	WOS:000172405900008
J	Sur, B; Rogge, RB; Hammond, RP; Anghel, VNP; Katsaras, J				Sur, B; Rogge, RB; Hammond, RP; Anghel, VNP; Katsaras, J			Atomic structure holography using thermal neutrons	NATURE			English	Article							X-RAY HOLOGRAPHY; ELECTRON HOLOGRAPHY; RESOLUTION; MICROSCOPY; IMAGES	The idea of atomic-resolution holography has its roots in the X-ray work of Bragg(1) and in Gabor's electron interference microscope(2). Gabor's lensless microscope was not realized in his time, but over the past twelve years there has been a steady increase in the number of reports on atomic-resolution holography. All of this work involves the use of electrons(3-6) or hard X-rays(7-11) to produce the hologram. Neutrons are often unique among scattering probes in their interaction with materials: for example, the relative visibility of hydrogen and its isotopes is a great advantage in the study of polymers and biologically relevant materials. Recent work(12) proposed that atomic-resolution holography could be achieved with thermal neutrons. Here we use monochromatic thermal neutrons, adopting the inside-source concept of Szoke(13), to image planes of oxygen atoms located above and below a single hydrogen atom in the oxide mineral simpsonite(14).	Atom Energy Canada Ltd, Chalk River Labs, Chalk River, ON K0J 1J0, Canada; CNR, Steacie Inst Mol Sci, Chalk River, ON K0J 1J0, Canada; McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada	Atomic Energy of Canada Limited; National Research Council Canada; McMaster University	Rogge, RB (corresponding author), Atom Energy Canada Ltd, Chalk River Labs, Chalk River, ON K0J 1J0, Canada.		Katsaras, John/K-4525-2018	Anghel, Vinicius Nicolae Petre/0000-0003-0604-4701; Katsaras, John/0000-0002-8937-4177				BARTON JJ, 1991, PHYS REV LETT, V67, P3106, DOI 10.1103/PhysRevLett.67.3106; Bompadre SG, 1999, PHYS REV LETT, V83, P2741, DOI 10.1103/PhysRevLett.83.2741; BOWLEY H, 1939, J R SOC W AUST, V25, P89; Bragg WL, 1942, NATURE, V149, P470, DOI 10.1038/149470a0; Cser L, 2001, EUROPHYS LETT, V54, P747, DOI 10.1209/epl/i2001-00316-7; ECRIT TS, 1992, CAN MINERAL, V30, P663; Faigel G, 1999, REP PROG PHYS, V62, P355, DOI 10.1088/0034-4885/62/3/002; GABOR D, 1948, NATURE, V161, P777, DOI 10.1038/161777a0; Gog T, 1996, PHYS REV LETT, V76, P3132, DOI 10.1103/PhysRevLett.76.3132; HARP GR, 1990, PHYS REV LETT, V65, P1012, DOI 10.1103/PhysRevLett.65.1012; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; ORCHOWSKI A, 1995, PHYS REV LETT, V74, P399, DOI 10.1103/PhysRevLett.74.399; Sears V.F., 1992, NEUTRON NEWS, V3, P26, DOI [10.1080/10448639208218770, DOI 10.1080/10448639208218770]; SIEGER MT, 1994, PHYS REV LETT, V73, P3117, DOI 10.1103/PhysRevLett.73.3117; Spence J, 2001, NATURE, V410, P1037, DOI 10.1038/35074228; Szoke A., 1986, AIP Conference Proceedings, P361, DOI 10.1063/1.35963; TAYLOR LER, 1939, J R SOC W AUST, V25, P93; TEGZE M, 1991, EUROPHYS LETT, V16, P41, DOI 10.1209/0295-5075/16/1/008; Tegze M, 1999, PHYS REV LETT, V82, P4847, DOI 10.1103/PhysRevLett.82.4847; Tegze M, 1996, NATURE, V380, P49, DOI 10.1038/380049a0; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; ZHARNIKOV M, 1994, PHYS REV LETT, V73, P3548, DOI 10.1103/PhysRevLett.73.3548	22	54	58	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					525	527		10.1038/35107026	http://dx.doi.org/10.1038/35107026			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734848				2022-12-28	WOS:000172405900041
J	Wildermuth, MC; Dewdney, J; Wu, G; Ausubel, FM				Wildermuth, MC; Dewdney, J; Wu, G; Ausubel, FM			Isochorismate synthase is required to synthesize salicylic acid for plant defence	NATURE			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DISEASE RESISTANCE; ARABIDOPSIS; TOBACCO; BIOSYNTHESIS; INDUCTION; MUTANT; PROTEIN	Salicylic acid (SA) mediates plant defences against pathogens, accumulating in both infected and distal leaves in response to pathogen attack(1-5). Pathogenesis-related gene expression and the synthesis of defensive compounds associated with both local and systemic acquired resistance (LAR and SAR) in plants require SA. In Arabidopsis, exogenous application of SA suffices to establish SAR, resulting in enhanced resistance to a variety of pathogens. However, despite its importance in plant defence against pathogens, SA biosynthesis is not well defined. Previous work has suggested that plants synthesize SA from phenylalanine(6-10); however, SA could still be produced when this pathway was inhibited(6,8), and the specirc activity of radiolabelled SA in feeding experiments was often lower than expected(7,8). Some bacteria such as Pseudomonas aeruginosa synthesize SA using isochorismate synthase (ICS) and pyruvate lyase(11). Here we show, by cloning and characterizing an Arabidopsis defence-related gene (SID2) defined by mutation, that SA is synthesized from chorismate by means of ICS, and that SA made by this pathway is required for LAR and SAR responses.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Brandeis Univ, Michtom Sch Comp Sci, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Brandeis University; Harvard University; Harvard Medical School	Ausubel, FM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							Bender J, 1998, P NATL ACAD SCI USA, V95, P5655, DOI 10.1073/pnas.95.10.5655; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Clarke JD, 1998, PLANT CELL, V10, P557, DOI 10.1105/tpc.10.4.557; Coquoz JL, 1998, PLANT PHYSIOL, V117, P1095, DOI 10.1104/pp.117.3.1095; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dempsey DA, 1999, CRIT REV PLANT SCI, V18, P547, DOI 10.1080/07352689991309397; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; Dewdney J, 2000, PLANT J, V24, P205, DOI 10.1046/j.1365-313x.2000.00870.x; Dorey S, 1997, MOL PLANT MICROBE IN, V10, P646, DOI 10.1094/MPMI.1997.10.5.646; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; LEON J, 1995, P NATL ACAD SCI USA, V92, P10413, DOI 10.1073/pnas.92.22.10413; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; MauchMani B, 1996, PLANT CELL, V8, P203, DOI 10.1105/tpc.8.2.203; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; Reuber TL, 1998, PLANT J, V16, P473, DOI 10.1046/j.1365-313x.1998.00319.x; Ribnicky DM, 1998, PLANT PHYSIOL, V118, P565, DOI 10.1104/pp.118.2.565; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; van Tegelen LJP, 1999, PLANT PHYSIOL, V119, P705, DOI 10.1104/pp.119.2.705; YALPANI N, 1993, PLANT PHYSIOL, V103, P315, DOI 10.1104/pp.103.2.315; Yang YO, 1996, P NATL ACAD SCI USA, V93, P14972, DOI 10.1073/pnas.93.25.14972	30	1513	1591	7	254	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					562	565		10.1038/35107108	http://dx.doi.org/10.1038/35107108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734859				2022-12-28	WOS:000172405900052
J	Anderson, J				Anderson, J			The Francois Rabelais School of Medicine	BRITISH MEDICAL JOURNAL			English	Article							PHARMACEUTICAL-INDUSTRY		Monash Univ, Hlth Serv Res, Monash Inst, Ctr Clin Effectiveness, Clayton, Vic 3168, Australia	Monash University	Anderson, J (corresponding author), Monash Univ, Hlth Serv Res, Monash Inst, Ctr Clin Effectiveness, Clayton, Vic 3168, Australia.							Angell M, 2000, NEW ENGL J MED, V342, P1902, DOI 10.1056/NEJM200006223422509; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Freud S., 1885, UBER COCA; Hogan DB, 1999, CAN MED ASSOC J, V161, P842; Isaacs D, 1999, BRIT MED J, V319, P1618, DOI 10.1136/bmj.319.7225.1618; OSMOND H, 1957, ANN NY ACAD SCI, V66, P418, DOI 10.1111/j.1749-6632.1957.tb40738.x; Rabelais Francois, 1955, GARGANTUA PANTAGRUEL; Rutkow IM, 2000, ARCH SURG-CHICAGO, V135, P1478, DOI 10.1001/archsurg.135.12.1478; Sackett D. L., 1998, EVIDENCE BASED MED P; Smith R, 1995, BRIT MED J, V311, P1655, DOI 10.1136/bmj.311.7021.1655; 2001, NO FREE LUNCH REQUIR	11	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1456	1457		10.1136/bmj.323.7327.1456	http://dx.doi.org/10.1136/bmj.323.7327.1456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751352	Green Published			2022-12-28	WOS:000172979900012
J	Petersdorf, EW; Hansen, JA; Martin, PJ; Woolfrey, A; Malkki, M; Gooley, T; Storer, B; Mickelson, E; Smith, A; Anasetti, C				Petersdorf, EW; Hansen, JA; Martin, PJ; Woolfrey, A; Malkki, M; Gooley, T; Storer, B; Mickelson, E; Smith, A; Anasetti, C			Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DONOR MARROW TRANSPLANTATION; UNRELATED DONORS; HLA-C; LYMPHOCYTES-T; MOLECULES; LEUKEMIA; COMPATIBILITY; ENGRAFTMENT; ASSOCIATION; EXPERIENCE	Background: Successful engraftment of hematopoietic stem cells from unrelated donors is influenced by disparities between the donor and recipient for HLA-A, B, and C alleles. Disparities between HLA sequence polymorphisms that are serologically detectable are termed antigen mismatches, whereas those that can be identified only by DNA-based typing methods are termed allele mismatches. Whether both kinds of polymorphisms are important in transplantation is not known. We tested the hypothesis that allele mismatches that are detectable only at the DNA level are less immunogenic than those that are serologically detectable and thereby are associated with a lower risk of graft failure after hematopoietic-cell transplantation. Methods: We used DNA sequencing to define the HLA-A, B, and C alleles in 471 patients who received bone marrow from unrelated donors for the treatment of chronic myeloid leukemia after myeloablative conditioning therapy. The odds ratios for graft failure were determined for recipients of transplants from donors with a single class I allele mismatch, a single class I antigen mismatch, or two or more class I mismatches, as compared with those with no mismatch. Results: A single HLA allele mismatch did not increase the risk of graft failure, whereas a single antigen mismatch significantly increased the risk. The risk was also increased if the recipient was HLA homozygous at the mismatched class I locus or if the donor had two or more class I mismatches. Conclusions: HLA class I antigen mismatches that are serologically detectable confer an enhanced risk of graft failure after hematopoietic-cell transplantation. Transplants from donors with a single class I allele mismatch that is not serologically detectable may be used without an increased risk of graft failure. (N Engl J Med 2001;345:1794-800.) Copyright (C) 2001 Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Med, Seattle, WA USA; Seattle Canc Care Alliance, Seattle, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance	Petersdorf, EW (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [R29CA072978, P30CA015704, P01CA018029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033484] Funding Source: NIH RePORTER; NCI NIH HHS [CA15704, CA72978, CA18029] Funding Source: Medline; NIAID NIH HHS [AI33484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; ANASETTI C, 1994, TRANSFUS SCI, V15, P221, DOI 10.1016/0955-3886(94)90134-1; Anasetti C., 1999, HEMATOPOIETIC CELL T, P904; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BUNCE M, 1997, GENETIC DIVERSITY HL, V1, P83; DAUSSET J, 1954, C R SOC BIOL, V146, P1539; Davies SM, 2000, BLOOD, V96, P4096; DUPONT B, 1980, HISTOCOMPATIBILITY T, P229; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1987, TRANSPLANTATION, V43, P842, DOI 10.1097/00007890-198743060-00014; Klein J, 2000, NEW ENGL J MED, V343, P1504; Marsh S. G. E., 2001, Tissue Antigens, V57, P236; McGlave PB, 2000, BLOOD, V95, P2219, DOI 10.1182/blood.V95.7.2219.007k27_2219_2225; Neisig A, 1998, J IMMUNOL, V160, P171; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; Petersdorf EW, 1998, BLOOD, V92, P3515, DOI 10.1182/blood.V92.10.3515.422k49_3515_3520; Petersdorf EW, 1996, P NATL ACAD SCI USA, V93, P15358, DOI 10.1073/pnas.93.26.15358; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; Petersdorf EW, 2001, BRIT J HAEMATOL, V112, P988, DOI 10.1046/j.1365-2141.2001.02655.x; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Schreuder GMT, 1999, HUM IMMUNOL, V60, P1157, DOI 10.1016/S0198-8859(99)00111-1; Takemoto SK, 2000, NEW ENGL J MED, V343, P1078, DOI 10.1056/NEJM200010123431504; Valiante N M, 1997, Biol Blood Marrow Transplant, V3, P229; VANROOD JJ, 1963, J CLIN INVEST, V42, P1382	33	221	230	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1794	U4		10.1056/NEJMoa011826	http://dx.doi.org/10.1056/NEJMoa011826			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752355	Bronze			2022-12-28	WOS:000172794800002
J	Day, INM; Wilson, DI				Day, INM; Wilson, DI			Science, medicine, and the future - Genetics and cardiovascular risk	BRITISH MEDICAL JOURNAL			English	Review							HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR GENE; HEART-DISEASE; MUTATIONS; SPECTRUM		Southampton Univ Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England	University of Southampton	Day, INM (corresponding author), Southampton Univ Hosp, Div Human Genet, Duthie Bldg Mp808, Southampton SO16 6YD, Hants, England.		Wilson, David/A-6264-2010	Wilson, David/0000-0001-8779-2060				Bhatnagar D, 2000, BRIT MED J, V321, P1497, DOI 10.1136/bmj.321.7275.1497; BOUGHMAN JA, 1987, AM J MED GENET, V26, P839, DOI 10.1002/ajmg.1320260411; Burn J, 1998, LANCET, V351, P311, DOI 10.1016/S0140-6736(97)06486-6; Day INM, 1997, HUM MUTAT, V10, P116; Gould AL, 1998, CIRCULATION, V97, P946; GROSSMAN M, 1995, NAT MED, V1, P1148, DOI 10.1038/nm1195-1148; Gu DF, 2000, ANN HUM GENET, V64, P383, DOI 10.1046/j.1469-1809.2000.6450383.x; Haddad L, 1999, J LIPID RES, V40, P1113; HILL JS, 1991, ARTERIOSCLER THROMB, V11, P290, DOI 10.1161/01.ATV.11.2.290; Indolfi C, 1999, Cardiol Rev, V7, P324, DOI 10.1097/00045415-199911000-00010; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; MISEREZ AR, 1995, ARTERIOSCL THROM VAS, V15, P1719, DOI 10.1161/01.ATV.15.10.1719; *MVRIAD GEN, 2001, CARDIARISK; *NAT CTR BIOT INF, 2001, OMIM ONL MEND INH MA; Pimstone SN, 1998, ARTERIOSCL THROM VAS, V18, P309, DOI 10.1161/01.ATV.18.2.309; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Tassabehji M, 1997, HUM MOL GENET, V6, P1029, DOI 10.1093/hmg/6.7.1029; Tybjaerg-Hansen A, 1998, NEW ENGL J MED, V338, P1577, DOI 10.1056/NEJM199805283382203	20	16	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1409	1412		10.1136/bmj.323.7326.1409	http://dx.doi.org/10.1136/bmj.323.7326.1409			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744567	Green Published			2022-12-28	WOS:000172900400020
J	Mulvany, F; O'Callaghan, E; Takei, N; Byrne, M; Fearon, P; Larkin, C				Mulvany, F; O'Callaghan, E; Takei, N; Byrne, M; Fearon, P; Larkin, C			Effect of social class at birth on risk and presentation of schizophrenia: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNTREATED PSYCHOSIS; PRENATAL EXPOSURE; EARLY-ONSET; DURATION; COHORT; MOBILITY; DISORDER	Objectives To examine if low parental social class increases children's risk of subsequently developing schizophrenia or modifies the presentation. Design Case-control study with historical controls. Setting Geographically defined region in south Dublin. Participants 352 patients with first presentation of schizophrenia matched with the next registered same sex birth from the same birth registration district. Main outcome measures Social class at birth. Age at presentation to psychiatric services, admission to hospital, and diagnosis of schizophrenia. Results Risk of schizophrenia was not increased in people from lower social classes. There was a slight excess risk among people in highest social classes (odds ratio 0.59, 95% confidence interval 0.40 to 0.85). However, the mean age at presentation was 24.8 years for patients whose parents were in the highest social class compared with 33.1 years for those in the lowest social class at birth. Conclusions Although social class of origin does not seem to be an important risk factor for schizophrenia. it partially determines the age at which patients receive treatment. The relation between low social class at birth and poor outcome may be at least partially mediated through treatment delay.	Cluain Mhuire Family Ctr, Hosp Order St John God, Dept Adult Psychiat, Stanley Fdn Res Unit, Blackrock, Dublin, Ireland; Univ Coll Dublin, Dept Psychiat, Dublin 2, Ireland; Hamamatsu Univ Sch Med, Dept Psychiat & Neurol, Hamamatsu, Shizuoka 4313192, Japan; Inst Psychiat, Div Psychol Med, London SE5 8AF, England	University College Dublin; Hamamatsu University School of Medicine; University of London; King's College London	O'Callaghan, E (corresponding author), Cluain Mhuire Family Ctr, Hosp Order St John God, Dept Adult Psychiat, Stanley Fdn Res Unit, Blackrock, Dublin, Ireland.	eadbhard@indigo.ie	Takei, Nori/GWZ-7464-2022; Takei, Nori/AAC-8578-2019					[Anonymous], 1987, NEW DIR MENT HLTH SE; Argyle M., 1994, PSYCHOL SOCIAL CLASS; ARO S, 1995, BRIT J PSYCHIAT, V166, P759, DOI 10.1192/bjp.166.6.759; BIRTCHNELL J, 1971, PSYCHOL MED, V1, P209, DOI 10.1017/S0033291700041830; Bosma H, 1999, BRIT MED J, V319, P1469, DOI 10.1136/bmj.319.7223.1469; Carbone S, 1999, ACTA PSYCHIAT SCAND, V100, P96, DOI 10.1111/j.1600-0447.1999.tb10830.x; Central Statistics Office, 1986, CENS POP 1986 CLASS; Clarke M, 1999, SCHIZOPHR RES, V36, P38; COOPER B, 1961, BRIT J PREV SOC MED, V15, P17; Croudace TJ, 2000, PSYCHOL MED, V30, P177, DOI 10.1017/S0033291799001464; *DEP HLTH SOC SEC, 1980, INEQ HLTH REP RES WO; DOHRENWEND BP, 1992, SCIENCE, V255, P946, DOI 10.1126/science.1546291; Geddes JR, 1995, BRIT J PSYCHIAT, V167, P786, DOI 10.1192/bjp.167.6.786; GOLDBERG EM, 1963, BRIT J PSYCHIAT, V109, P785, DOI 10.1192/bjp.109.463.785; HARE EH, 1972, BRIT J PSYCHIAT, V121, P515, DOI 10.1192/bjp.121.5.515; Hultman CM, 1999, BRIT MED J, V318, P421, DOI 10.1136/bmj.318.7181.421; JONES PB, 1993, BRIT J PSYCHIAT, V162, P65, DOI 10.1192/bjp.162.1.65; LOEBEL AD, 1992, AM J PSYCHIAT, V149, P1183; Makikyro T, 1997, SCHIZOPHR RES, V23, P245, DOI 10.1016/S0920-9964(96)00119-3; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; Roberts K., 1980, LINKING HOME SCH NEW; SAUGSTAD LF, 1989, SCHIZOPHRENIA BULL, V15, P9, DOI 10.1093/schbul/15.1.9; Saxena S, 1999, BRIT MED J, V318, P642, DOI 10.1136/bmj.318.7184.642; Schwartz JE, 2000, ARCH GEN PSYCHIAT, V57, P593, DOI 10.1001/archpsyc.57.6.593; SHAM PC, 1992, BRIT J PSYCHIAT, V160, P461, DOI 10.1192/bjp.160.4.461; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; TURNER RJ, 1967, AM SOCIOL REV, V32, P104, DOI 10.2307/2091723; Warner R.G.G., 1995, SCHIZOPHRENIA; WIERSMA D, 1983, PSYCHOL MED, V13, P141, DOI 10.1017/S0033291700050145; Wynn S. W., 1994, Nutrition and Health (Bicester), V9, P303	30	44	47	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 15	2001	323	7326					1398	1401		10.1136/bmj.323.7326.1398	http://dx.doi.org/10.1136/bmj.323.7326.1398			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505EX	11744563	Bronze, Green Published			2022-12-28	WOS:000172900400016
J	Liu, Y; Zadorozhny, Y; Rosario, MM; Rock, BY; Carrigan, PT; Wang, H				Liu, Y; Zadorozhny, Y; Rosario, MM; Rock, BY; Carrigan, PT; Wang, H			Destruction of the global phase coherence in ultrathin, doubly connected superconducting cylinders	SCIENCE			English	Article							TRANSITIONS	In doubly connected superconductors, such as hollow cylinders, the fluxoid is known to be quantized, allowing the superfluid velocity to be controlled by an applied magnetic flux and the sample size. The sample-size-induced increase in superfluid velocity has been predicted to lead to the destruction of superconductivity around half-integer flux quanta. We report transport measurements in ultrathin Al and Au0.7In0.3 cylinders verifying the presence of this destructive regime characterized by the loss of the global phase coherence and reveal a phase diagram featuring disconnected phase coherent regions, as opposed to the single region seen in larger superconducting cylinders studied previously.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Liu, Y (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.		Wang, Haohua/G-8875-2011	Wang, Haohua/0000-0001-5380-4297				ANDERSON PW, 1959, J PHYS CHEM SOLIDS, V11, P26, DOI 10.1016/0022-3697(59)90036-8; DEAVER BS, 1961, PHYS REV LETT, V7, P43, DOI 10.1103/PhysRevLett.7.43; DEGENNES PG, 1981, CR ACAD SCI II, V292, P279; DEGENNES PG, 1966, SUPERCONDUCTIVITY ME, P185; Deo PS, 1997, PHYS REV LETT, V79, P4653, DOI 10.1103/PhysRevLett.79.4653; DOLL R, 1961, PHYS REV LETT, V7, P51, DOI 10.1103/PhysRevLett.7.51; Geim AK, 1998, NATURE, V396, P144, DOI 10.1038/24110; Geim AK, 1997, NATURE, V390, P259, DOI 10.1038/36797; GIORDANO N, 1988, PHYS REV LETT, V61, P2137, DOI 10.1103/PhysRevLett.61.2137; Goldman AM, 1998, PHYS TODAY, V51, P39, DOI 10.1063/1.882069; Kapitulnik A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125322; KITTEL C, 1996, INTRO SOLID STATE PH, P253; LITTLE WA, 1962, PHYS REV LETT, V9, P9, DOI 10.1103/PhysRevLett.9.9; MOSHCHALKOV VV, 1995, NATURE, V373, P319, DOI 10.1038/373319a0; Sobnack MB, 2001, PHYS REV LETT, V86, P716, DOI 10.1103/PhysRevLett.86.716; STRALEY JP, 1982, PHYS REV B, V26, P4922, DOI 10.1103/PhysRevB.26.4922; Tang ZK, 2001, SCIENCE, V292, P2462, DOI 10.1126/science.1060470; Tinkham M, 1996, CZECH J PHYS, V46, P3139, DOI 10.1007/BF02548121; Tinkham M, 1996, INTRO SUPERCONDUCTIV, P119; YANG CN, 1962, REV MOD PHYS, V34, P694, DOI 10.1103/RevModPhys.34.694; Zadorozhny Y, 2001, EUROPHYS LETT, V55, P712, DOI 10.1209/epl/i2001-00472-2; Zadorozhny Y, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.144521	22	85	88	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2332	2334		10.1126/science.1066144	http://dx.doi.org/10.1126/science.1066144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743195	Green Submitted			2022-12-28	WOS:000172817200040
J	Stillman, B				Stillman, B			DNA replication - Genomic views of genome duplication	SCIENCE			English	Editorial Material							S-PHASE; COMPLEX; CDC45P		Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	10	13	14	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2301	+		10.1126/science.1067929	http://dx.doi.org/10.1126/science.1067929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743187				2022-12-28	WOS:000172817200031
J	Bojang, KA; Milligan, PJM; Pinder, M; Vigneron, L; Alloueche, A; Kester, KE; Ballou, WR; Conway, DJ; Reece, WHH; Gothard, P; Yamuah, L; Delchambre, M; Voss, G; Greenwood, BM; Hill, A; McAdam, KPWJ; Tornieporth, N; Cohen, JD; Doherty, T				Bojang, KA; Milligan, PJM; Pinder, M; Vigneron, L; Alloueche, A; Kester, KE; Ballou, WR; Conway, DJ; Reece, WHH; Gothard, P; Yamuah, L; Delchambre, M; Voss, G; Greenwood, BM; Hill, A; McAdam, KPWJ; Tornieporth, N; Cohen, JD; Doherty, T		RTS,S Malaria Vaccine Trial Team	Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial	LANCET			English	Article							CIRCUMSPOROZOITE-PROTEIN; SPF66 VACCINE; T-CELL; SAFETY; IMMUNOGENICITY; RESPONSES; HETEROGENEITY; IMMUNIZATION; RTS,S/SBAS2; CHILDREN	Background RTS,S/AS02 is a pre-erythrocytic malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum fused to HBsAg, incorporating a new adjuvant (AS02). We did a randomised trial of the efficacy of RTS,S/AS02 against natural P falciparum infection in semi-immune adult men in The Gambia. Methods 306 men aged 18-45 years were randomly assigned three doses of either RTS,S/AS02 or rabies vaccine (control). Volunteers were given sulfadoxine/pyrimethamine 2 weeks before dose 3, and kept under surveillance throughout the malaria transmission season. Blood smears were collected once a week and whenever a volunteer developed symptoms compatible with malaria. The primary endpoint was time to first infection with P falciparum. Analysis was per protocol. Findings 250 men (131 in the RTS,S/AS02 group and 119 in the control group) received three doses of vaccine and were followed up for 15 weeks. RTS,S/AS02 was safe and well tolerated. P falciparum infections occurred significantly earlier in the control group than the RTS,S/AS02 group (Wilcoxon's test p=0.018). Vaccine efficacy, adjusted for confounders, was 34% (95% CI 8.0-53, p=0.014). Protection seemed to wane: estimated efficacy during the first 9 weeks of follow-up was 71% (46-85), but decreased to 0% (-52 to 34) in the last 6 weeks. Vaccination induced strong antibody responses to circumsporozoite protein and strong T-cell responses. Protection was not limited to the NF54 parasite genotype from which the vaccine was derived. 158 men received a fourth dose the next year and were followed up for 9 weeks; during this time, vaccine efficacy was 47% (4-71, p=0.037). Interpretation RTS,S/AS02 is safe, immunogenic, and is the first pre-erythrocytic vaccine to show significant protection against natural P falciparum infection.	MRC Labs, Banjul, Gambia; London Sch Hyg & Trop Med, London WC1, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; GlaxoSmithKline Biol, Rixensart, Belgium	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; GlaxoSmithKline	Bojang, KA (corresponding author), MRC Labs, POB 273, Banjul, Gambia.	kbojang@mrc.gm	HILL, Adrian V>S>/C-1306-2008; Kester, Kent/A-2114-2011; Kester, Kent/AAF-8235-2020; Milligan, Paul/D-8985-2017	Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395; Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037				AALEN OO, 1988, STAT MED, V7, P1121, DOI 10.1002/sim.4780071105; Acosta CJ, 1999, TROP MED INT HEALTH, V4, P368, DOI 10.1046/j.1365-3156.1999.00406.x; Alloueche A, 2000, MOL BIOCHEM PARASIT, V106, P273, DOI 10.1016/S0166-6851(99)00221-2; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; BALLOU WR, 1987, LANCET, V1, P1277; BROWN AE, 1988, J CLIN IMMUNOL, V8, P342, DOI 10.1007/BF00917149; Collet D, 1994, MODELING SURVIVAL DA; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Doherty JF, 1999, AM J TROP MED HYG, V61, P865, DOI 10.4269/ajtmh.1999.61.865; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Durham LK, 1999, J ROY STAT SOC C-APP, V48, P395, DOI 10.1111/1467-9876.00160; ETLINGER HM, 1988, J IMMUNOL, V140, P626; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMANN SL, 1990, MALARIA VACCINE DEV; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; LENGELOR C, 1998, COCHRANE LIB; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; NOYA O, 1994, J INFECT DIS, V170, P396, DOI 10.1093/infdis/170.2.396; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; SCHUMACHER M, 1987, STAT MED, V6, P773, DOI 10.1002/sim.4780060708; SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Therneau TM., 2000, MODELING SURVIVAL DA; THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WEBSTER HK, 1988, J CLIN MICROBIOL, V26, P923, DOI 10.1128/JCM.26.5.923-927.1988	32	413	438	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2001	358	9297					1927	1934		10.1016/S0140-6736(01)06957-4	http://dx.doi.org/10.1016/S0140-6736(01)06957-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747915				2022-12-28	WOS:000172622200008
J	Bosch, X				Bosch, X			European Parliament debate on human cloning collapses	LANCET			English	News Item																		2001, LANCET, V358, P1785	1	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1974	1974		10.1016/S0140-6736(01)07011-8	http://dx.doi.org/10.1016/S0140-6736(01)07011-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747937				2022-12-28	WOS:000172622200031
J	McCarter, J; Boge, G; Darlow, G				McCarter, J; Boge, G; Darlow, G			Safeguarding the world's natural treasures	SCIENCE			English	Editorial Material									Field Museum, 1400 Lake Shore Dr, Chicago, IL 60605 USA	Field Museum of Natural History (Chicago)	McCarter, J (corresponding author), Field Museum, 1400 Lake Shore Dr, Chicago, IL 60605 USA.							MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; RAVEN PH, 1992, SCIENCE, V258, P1099, DOI 10.1126/science.258.5085.1099; WILSON E O, 1992	3	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 7	2001	294	5549					2099	2101		10.1126/science.1067223	http://dx.doi.org/10.1126/science.1067223			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739937				2022-12-28	WOS:000172647700026
J	Brown, BG; Zhao, XQ; Chait, A; Fisher, LD; Cheung, MC; Morse, JS; Dowdy, AA; Marino, EK; Bolson, EL; Alaupovic, P; Frohlich, J; Albers, JJ; Serafini, L; Huss-Frechette, E; Wang, S; DeAngelis, D; Dodek, A				Brown, BG; Zhao, XQ; Chait, A; Fisher, LD; Cheung, MC; Morse, JS; Dowdy, AA; Marino, EK; Bolson, EL; Alaupovic, P; Frohlich, J; Albers, JJ; Serafini, L; Huss-Frechette, E; Wang, S; DeAngelis, D; Dodek, A			Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; ARTERY-DISEASE; HEPATIC LIPASE; HEART-DISEASE; CHOLESTEROL; REGRESSION; THERAPY; PLASMA; ATHEROSCLEROSIS; PROGRESSION	Background: Both lipid-modifying therapy and antioxidant vitamins are thought to have benefit in patients with coronary disease. We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary disease and low plasma levels of high-density lipoprotein (HDL) cholesterol. Methods: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels, and normal low-density lipoprotein (LDL) cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, antioxidants, simvastatin-niacin plus antioxidants, or placebos. The end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). Results: The mean levels of LDL and HDL cholesterol were unaltered in the antioxidant group and the placebo group; these levels changed substantially (by -42 percent and +26 percent, respectively) in the simvastatin-niacin group. The protective increase in HDL2 with simvastatin plus niacin was attenuated by concurrent therapy with antioxidants. The average stenosis progressed by 3.9 percent with placebos, 1.8 percent with antioxidants (P=0.16 for the comparison with the placebo group), and 0.7 percent with simvastatin-niacin plus antioxidants (P=0.004) and regressed by 0.4 percent with simvastatin-niacin alone (P<0.001). The frequency of the clinical end point was 24 percent with placebos, 3 percent with simvastatin-niacin alone, 21 percent in the antioxidant-therapy group, and 14 percent in the group given simvastatin-niacin plus antioxidants. Conclusions: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned. (N Engl J Med 2001;345:1583-92.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Washington, Sch Med, Dept Med, Div Cardiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oklahoma Medical Research Foundation; University of British Columbia	Brown, BG (corresponding author), Univ Washington, Sch Med, Dept Med, Div Cardiol, Box 356422,Hlth Sci Bldg,Rm A509,1959 NE Pacific, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49546] Funding Source: Medline; NIDDK NIH HHS [DK 17047, DK 35816] Funding Source: Medline; PHS HHS [MO1 00037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Assmann G, 1998, EUR HEART J, V19, pA2; BROWN BG, 1993, CIRCULATION, V87, P66; BROWN BG, 1986, PROG CARDIOVASC DIS, V28, P403; Brown BG, 1998, CAN J CARDIOL, V14, p6A; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CHEUNG MC, 1991, J LIPID RES, V32, P383; Cheung MC, 2001, ARTERIOSCL THROM VAS, V21, P1320, DOI 10.1161/hq0801.095151; Cohen JC, 1999, CURR OPIN LIPIDOL, V10, P259, DOI 10.1097/00041433-199906000-00008; CURRY MD, 1980, BIOCHIM BIOPHYS ACTA, V617, P503, DOI 10.1016/0005-2760(80)90016-8; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FISHER LD, 1993, BIOSTATISTICS METHOD, P973; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENEST J, 1993, ARTERIOSCLER THROMB, V13, P1728, DOI 10.1161/01.ATV.13.12.1728; *GISSI PREV INV, 2001, LANCET, V357, P642; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1999, CLIN TRIALS CARDIOVA, P206; JACOBS SM, 1999, MINIMUM DOSE CRYSTAL; JOHANSSON J, 1995, ARTERIOSCL THROM VAS, V15, P1049, DOI 10.1161/01.ATV.15.8.1049; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; Mahley RW, 2000, J LIPID RES, V41, P1290; Meade T, 1999, EUR HEART J, V20, P725; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PHILLIPS NR, 1993, CIRCULATION, V88, P2762, DOI 10.1161/01.CIR.88.6.2762; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steingberg FM, 1999, AM J CLIN NUTR, V69, P1293; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; WILSON, 1991, AM J MED, V90, P537; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WILSON PWF, 1991, AM J MED, V90, P11, DOI 10.1016/0002-9343(91)90500-W; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zambon A, 1999, CIRCULATION, V99, P1959, DOI 10.1161/01.CIR.99.15.1959; Zhao XQ, 2001, J AM COLL CARDIOL, V37, p268A	39	1473	1572	0	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2001	345	22					1583	1592		10.1056/NEJMoa011090	http://dx.doi.org/10.1056/NEJMoa011090			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496EU	11757504	Bronze			2022-12-28	WOS:000172383900001
J	Skjaerven, R; Wilcox, AJ; Lie, RT				Skjaerven, R; Wilcox, AJ; Lie, RT			The interval between pregnancies and the risk of preeclampsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; PRE-ECLAMPSIA; PRETERM DELIVERY; PATERNITY; WOMEN; ABORTION; SMOKING; DONOR	Background: The risk of preeclampsia is generally lower in second pregnancies than in first pregnancies, but not if the mother has a new partner for the second pregnancy. One explanation is that the risk is reduced with repeated maternal exposure and adaptation to specific antigens from the same partner. However, the difference in risk might instead be explained by the interval between births. A longer interbirth interval may be associated with both a change of partner and a higher risk of preeclampsia. Methods: We used data from the Medical Birth Registry of Norway, a population-based registry that includes births that occurred between 1967 and 1998. We studied 551,478 women who had two or more singleton deliveries and 209,423 women who had three or more singleton deliveries. Results: Preeclampsia occurred during 3.9 percent of first pregnancies, 1.7 percent of second pregnancies, and 1.8 percent of third pregnancies when the woman had the same partner. The risk in a second or third pregnancy was directly related to the time that had elapsed since the preceding delivery, and when the interbirth interval was 10 years or more, the risk approximated that among nulliparous women. After adjustment for the presence or absence of a change of partner, maternal age, and year of delivery, the odds ratio for preeclampsia for each one-year increase in the interbirth interval was 1.12 (95 percent confidence interval, 1.11 to 1.13). In unadjusted analyses, a pregnancy involving a new partner was associated with higher risk of preeclampsia, but after adjustment for the interbirth interval, the risk of preeclampsia was reduced (odds ratio for preeclampsia with a change of partner, 0.73; 95 percent confidence interval, 0.66 to 0.81). Conclusions: The protective effect of previous pregnancy against preeclampsia is transient. After adjustment for the interval between births, a change of partner is not associated with an increased risk of preeclampsia. (N Engl J Med 2002;346:33-8.) Copyright (C) 2002 Massachusetts Medical Society.	Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Med Stat, N-5021 Bergen, Norway; Univ Bergen, Med Birth Registry Norway, Locus Registry Based Epidemiol, N-5021 Bergen, Norway; NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA	University of Bergen; University of Bergen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Skjaerven, R (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Med Stat, Armauer Hansens Bldg, N-5021 Bergen, Norway.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049027, ZIAES049027] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], CHESLEYS HYPERTENSIV; Basso O, 1998, INT J EPIDEMIOL, V27, P642, DOI 10.1093/ije/27.4.642; Conde-Agudelo A, 2000, BRIT MED J, V321, P1255, DOI 10.1136/bmj.321.7271.1255; Dekker G, 2001, LANCET, V357, P209, DOI 10.1016/S0140-6736(00)03599-6; Dekker G A, 1998, Obstet Gynecol Surv, V53, P377, DOI 10.1097/00006254-199806000-00023; Dekker GA, 1999, SEMIN PERINATOL, V23, P24, DOI 10.1016/S0146-0005(99)80057-3; Dekker GA, 1998, AM J OBSTET GYNECOL, V179, P1359, DOI 10.1016/S0002-9378(98)70160-7; DUFFUS GM, 1968, LANCET, V1, P994; Eras JL, 2000, EPIDEMIOLOGY, V11, P36, DOI 10.1097/00001648-200001000-00009; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; FEENEY JG, 1980, EUR J OBSTET GYN R B, V11, P35, DOI 10.1016/0028-2243(80)90051-9; Fu HS, 2000, J BIOSOC SCI, V32, P63, DOI 10.1017/S0021932000000638; Haug K, 2000, ACTA OBSTET GYN SCAN, V79, P485, DOI 10.1034/j.1600-0412.2000.079006485.x; Haug K, 1998, ACTA PAEDIATR, V87, P1023, DOI 10.1080/080352598750031310; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; Need J A, 1976, Perspect Nephrol Hypertens, V5, P169; NEED JA, 1975, BRIT MED J, V1, P548, DOI 10.1136/bmj.1.5957.548; NEED JA, 1983, J REPROD IMMUNOL, V5, P329, DOI 10.1016/0165-0378(83)90242-5; Pipkin FB, 2001, NEW ENGL J MED, V344, P925, DOI 10.1056/NEJM200103223441209; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; ROBILLARD PY, 1993, J REPROD IMMUNOL, V24, P1, DOI 10.1016/0165-0378(93)90032-D; Robillard PY, 1999, EUR J OBSTET GYN R B, V84, P37, DOI 10.1016/S0301-2115(98)00250-4; Sibai BM, 1997, AM J OBSTET GYNECOL, V177, P1003, DOI 10.1016/S0002-9378(97)70004-8; Smith GN, 1997, AM J OBSTET GYNECOL, V177, P455, DOI 10.1016/S0002-9378(97)70215-1; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; Tubbergen P, 1999, J REPROD IMMUNOL, V45, P81, DOI 10.1016/S0165-0378(99)00040-6; Zhu BP, 1999, NEW ENGL J MED, V340, P589, DOI 10.1056/NEJM199902253400801	28	270	282	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					33	38		10.1056/NEJMoa011379	http://dx.doi.org/10.1056/NEJMoa011379			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11778000	Bronze			2022-12-28	WOS:000173033600005
J	Morin, K; Rakatansky, H; Riddick, FA; Morse, LJ; O'Bannon, JM; Goldrich, NS; Ray, P; Weiss, M; Sade, RA; Spillman, MA				Morin, K; Rakatansky, H; Riddick, FA; Morse, LJ; O'Bannon, JM; Goldrich, NS; Ray, P; Weiss, M; Sade, RA; Spillman, MA			Managing conflicts of interest in the conduct of clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	The interaction between medical research and for-profit corporations is not new, but it has expanded considerably in recent years. Some of the recent trends may accelerate the research process, particularly when large clinical trials are required. However, a renewed commitment to the application of high ethical standards is essential to ensure that societal trust in research is not eroded, subjects enrolled in trials do not become merely a means to an end, and medical research is efficiently translated into clinical advances that will benefit future patients. This article focuses on the analysis of conflicts of interest in the conduct of clinical trials in both academic and community-based settings. Specifically, it discusses how the roles of research scientists and clinical practitioners differ and the importance of ensuring that participants' consent to enroll in clinical trials is not the result of confusion about the goals of an experimental treatment that may resemble clinical care. The article also discusses the potential conflicts of interest that can arise when clinicians stand to gain from enrolling their own patients as subjects in clinical trials and examines various instances in which disclosure of information regarding funding and compensation may serve to minimize such conflicts. This article emphasizes that to preserve the integrity of research and to protect the welfare of human subjects who enroll in trials, physicians should have adequate training in the conduct of research and be familiar with the ethics of research, When a physician has treated or continues to treat a patient who is eligible to enroll as a subject in a clinical trial conducted by the same physician, someone other than the treating physician should obtain the participant's informed consent. Finally, the article addresses disclosure of financial incentives and related funding issues.	Amer Med Assoc, Council Eth & Judicial Affairs, Eth Stand Grp, Chicago, IL 60610 USA	American Medical Association	Morin, K (corresponding author), Amer Med Assoc, Council Eth & Judicial Affairs, Eth Stand Grp, 515 N State St, Chicago, IL 60610 USA.	Karine_Morin@ama-assn.org						AARON HJ, 2000, EXT MED REIMB CLIN T; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; [Anonymous], 1990, BLACKS LAW DICT, V6th; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; BARNES M, 1999, BNA HLTH LAW REP, V8, P1344; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P441; BLUMENSTYK G, 1998, CHRONICLE HIGHE 0320, pA39; BLUMGART HL, 1970, EXPT HUMAN SUBJECTS, P39; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; BRAINARD J, 2000, CHRONICLE HIGHE 0204, pA2; Buchanan L, 1995, ANN ONCOL, V6, P867, DOI 10.1093/oxfordjournals.annonc.a059352; *COUNC ETH JUD AFF, 2000, COD MED ETH CURR OP, P59; CYS J, 2000, AM MED NEWS, V43, P7; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Eichenwald Kurt, 1999, N Y Times Web, pA16; FISHER B, 1994, NEW ENGL J MED, V330, P1458; Foy R, 1998, BRIT MED J, V317, P1168, DOI 10.1136/bmj.317.7167.1168; HUBLER E, 1999, DENVER POST     0924, pA1; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; KATZ J, 1996, CONFLICTS INTEREST C, P286; Katz Jay, 1993, St Louis Univ Law J, V38, P7; Kaufman Marc, 2000, WASH POST       0822, pA2; KNOX RA, 2000, BOSTON GLOBE    0526, pA1; Larkin M, 1999, LANCET, V354, P1534, DOI 10.1016/S0140-6736(05)76572-7; Lemmens T, 2000, MILBANK Q, V78, P547, DOI 10.1111/1468-0009.00185; LEVINE RJ, 1988, ETHICS REGULATION CL, P95; LIGHTFOOT GD, 1999, ACPR MONITOR     FAL, P17; Lind S. E, 1996, ETHICS RES INVOLVING, P185; MANIER J, 1999, CHICAGO TRIBUNE 0828, pA1; MILLER A, 1999, AM MED NEWS     0927, P21; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; MONMANEY T, 1999, LOS ANGELES TIM 0928, pA1; NELSON D, 2000, WASHINGTON POST 0208, pA2; *NIH, 2001, REQ ED PROT HUM RES; *OFF INSP GEN DEP, 2000, PUBL OFF INSP GEN DE; *OFF INSP GEN DEP, 1998, PUBL OFF INSP GEN DE; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; *PRIC, 2001, PHARM IND REV R D; Rettig RA, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.2.129; Rodwin M. A., 1993, MED MONEY MORALS PHY; RODWIN MA, 1995, AM J LAW MED, V21, P241; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; Searight H R, 1996, J Am Board Fam Pract, V9, P14; Seto B, 2001, KENNEDY INST ETHIC J, V11, P87, DOI 10.1353/ken.2001.0007; SHAMP J, 1999, HERALD SUN      0512, pA1; Shimm D.S., 1996, CONFLICTS INTEREST C, P321; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; *US DEP HHS OFF HU, 2001, FIN REL CLIN RES	48	141	142	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2002	287	1					78	84		10.1001/jama.287.1.78	http://dx.doi.org/10.1001/jama.287.1.78			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506NK	11754712				2022-12-28	WOS:000172978500029
J	Keely, JL; Herald, MT; Harris, JP; Bernene, JL; Blumenthal, D; Francis, CK; Hamilton, CR; Hickey, ME; Hood, GA; Riley, WJ; Rodilosso, PT; Seibel, JA; Toman, LA; Wellikson, LD; Whitcomb, WF; Gullen, DJ; Fryhofer, SA				Keely, JL; Herald, MT; Harris, JP; Bernene, JL; Blumenthal, D; Francis, CK; Hamilton, CR; Hickey, ME; Hood, GA; Riley, WJ; Rodilosso, PT; Seibel, JA; Toman, LA; Wellikson, LD; Whitcomb, WF; Gullen, DJ; Fryhofer, SA		Amer Coll Physicians; Amer Soc Internal Med	Pharmacist scope of practice	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; EVENTS	This paper explores the increased scope of practice of U.S. pharmacists. It presents background information on the pharmacy profession and outlines how the medical profession can work with pharmacists to enhance patient safety and quality of care. The paper calls for further research on the effects of pharmacy automation and the move to the Doctor of Pharmacy degree on pharmacy practice. Other positions Include support for patient education and hospital rounds, opposition to independent pharmacist prescriptive privileges and initiation of drug therapy, increased use of the pharmacist as immunizer (as allowed by state law), and continued support for the American College of Physicians-American Society of Internal Medicine 1990 therapeutic substitution position.	Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Keely, JL (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AM COLL CLIN PHAR, 2000, BILL CLIN PHARM SERV, P35; *AM PHARM ASS, 2000, FACTS PHARM PHARM; *AM PHARM ASS, 2000, PHARM ED; *AM PHARM ASS, 2000, PHARM LIC PHARM LAWS; BARKER KN, 1998, CONSULT PHARM, V13, P261; Berringer R, 1999, J Am Pharm Assoc (Wash), V39, P791; Carmichael JM, 1997, PHARMACOTHERAPY, V17, P1050; DAVIDSON TG, 1993, PHARMACOTHERAPY, V13, P252; *DSM, 2000, CRED PHARM NAT I STA; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; McMullin ST, 1999, ARCH INTERN MED, V159, P2306, DOI 10.1001/archinte.159.19.2306; MEINHARDT RA, 1999, DRUG BENEFIT TRENDS, V11, P32; NORRIS S, 2000, ISSUE BRIEF SCOPE PR; WHITE LJ, 1990, ANN INTERN MED, V113, P160	15	108	114	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					79	85		10.7326/0003-4819-136-1-200201010-00014	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00014			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777367				2022-12-28	WOS:000173188300009
J	Sadeghi-Nejad, A; Insoft, RM; Graeme-Cook, FM; Boepple, PA				Sadeghi-Nejad, A; Insoft, RM; Graeme-Cook, FM; Boepple, PA			A newborn girl with seizures and persistent hypoglycemia. Diffuse beta-cell hyperplasia (nesidioblastosis) of the pancreas.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FOCAL ADENOMATOUS HYPERPLASIA; HYPERINSULINEMIC HYPOGLYCEMIA; FAMILIAL HYPERINSULINISM; INSULIN-RESPONSE; HUMAN-FETAL; GENE; MUTATION; INFANCY; PANCREATECTOMY; INHERITANCE		Tufts Univ New England Med Ctr, Floating Hosp Children, Div Pediat Endocrinol & Metab, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Floating Hospital For Children; Tufts Medical Center; Tufts University	Sadeghi-Nejad, A (corresponding author), Tufts Univ New England Med Ctr, Floating Hosp Children, Div Pediat Endocrinol & Metab, 750 Washington St, Boston, MA 02111 USA.							BRUINING G J, 1990, Current Opinion in Pediatrics, V2, P758, DOI 10.1097/00008480-199008000-00024; de Lonlay-Debeney P, 1999, NEW ENGL J MED, V340, P1169, DOI 10.1056/NEJM199904153401505; deLonlay P, 1997, J CLIN INVEST, V100, P802, DOI 10.1172/JCI119594; DODEK AB, 1992, PEDIATRICS, V90, P636; DUBOIS J, 1995, PEDIATR RADIOL, V25, P512, DOI 10.1007/BF02015782; Glaser B, 1999, DIABETES, V48, P1652, DOI 10.2337/diabetes.48.8.1652; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; GLASER B, 1993, J PEDIATR-US, V123, P644, DOI 10.1016/S0022-3476(05)80970-9; King AD, 1998, BRIT J RADIOL, V71, P20, DOI 10.1259/bjr.71.841.9534694; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; Lindley KJ, 1996, ARCH DIS CHILD, V74, P373, DOI 10.1136/adc.74.5.373; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nestorowicz A, 1998, HUM MOL GENET, V7, P1527; OBENSHAIN SS, 1970, NEW ENGL J MED, V283, P566, DOI 10.1056/NEJM197009102831104; OTONKOSKI T, 1988, DIABETES, V37, P286, DOI 10.2337/diabetes.37.3.286; Senior B, 1989, Acta Paediatr Scand Suppl, V352, P1; SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749; Sokoloff L., 1972, BASIC NEUROCHEMISTRY, P299; Stanley CA, 1999, NEW ENGL J MED, V340, P1200, DOI 10.1056/NEJM199904153401510; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THORNTON PS, 1991, J PEDIATR-US, V119, P721, DOI 10.1016/S0022-3476(05)80286-0; Thornton PS, 1998, J PEDIATR-US, V132, P9, DOI 10.1016/S0022-3476(98)70477-9; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495	26	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1833	1839		10.1056/NEJMcpc392001	http://dx.doi.org/10.1056/NEJMcpc392001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752361				2022-12-28	WOS:000172794800008
J	Rathore, SS				Rathore, SS			Welcome to the process	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2913	2914		10.1001/jama.286.23.2913	http://dx.doi.org/10.1001/jama.286.23.2913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743811				2022-12-28	WOS:000172764500001
J	Kane, B				Kane, B			Cancer chemotherapy: Teaching old drugs new tricks	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1107	1110		10.7326/0003-4819-135-12-200112180-00035	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747409				2022-12-28	WOS:000172759700027
J	Hamilton, JW				Hamilton, JW			Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis	LANCET			English	Editorial Material							CONDUCTANCE REGULATOR CFTR; MUTATIONS; CHANNELS		Dartmouth Coll, Sch Med, Environm Hlth Sci Ctr, Dartmouth Tox Met Res Program, Hanover, NH 03755 USA	Dartmouth College	Hamilton, JW (corresponding author), Dartmouth Coll, Sch Med, Environm Hlth Sci Ctr, Dartmouth Tox Met Res Program, Hanover, NH 03755 USA.							ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; Clancy JP, 2001, AM J RESP CRIT CARE, V163, P1683, DOI 10.1164/ajrccm.163.7.2004001; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; GUAYBRODER C, 1995, BIOCHEMISTRY-US, V34, P9079, DOI 10.1021/bi00028a017; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; Maitra R, 2001, AM J PHYSIOL-CELL PH, V280, pC1031, DOI 10.1152/ajpcell.2001.280.5.C1031; Robinson LJ, 1996, BIOCHEM PHARMACOL, V52, P1081, DOI 10.1016/0006-2952(96)81736-9; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sheppard DN, 1996, MOL MED TODAY, V2, P290, DOI 10.1016/1357-4310(96)10028-9; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Wieczorek SJ, 2001, CLIN CHIM ACTA, V308, P1, DOI 10.1016/S0009-8981(01)00419-3; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	17	10	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2014	2016		10.1016/S0140-6736(01)07138-0	http://dx.doi.org/10.1016/S0140-6736(01)07138-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755605				2022-12-28	WOS:000172722800007
J	Berendsen, HJC				Berendsen, HJC			Bioinformatics - Reality simulation - Observe while it happens	SCIENCE			English	Editorial Material							DYNAMICS		Univ Groningen, Groningen Biomol Sci & Biotechnol Inst GBB, NL-9747 AG Groningen, Netherlands	University of Groningen	Berendsen, HJC (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst GBB, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.							Berendsen HJC, 1998, SCIENCE, V282, P642, DOI 10.1126/science.282.5389.642; Berendsen HJC, 1996, SCIENCE, V271, P954, DOI 10.1126/science.271.5251.954; BERENDSEN HJC, 1976, MODELS PROTEINS; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; de Groot BL, 2001, FEBS LETT, V504, P206, DOI 10.1016/S0014-5793(01)02743-0; Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535; Jensen MO, 2001, STRUCTURE, V9, P1083, DOI 10.1016/S0969-2126(01)00668-2; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MARRINK SJ, 1994, J PHYS CHEM-US, V98, P4155, DOI 10.1021/j100066a040; MARRINK SJ, 1996, J PHYS CHEM-US, V100, P16279; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0	11	13	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2304	2305		10.1126/science.1067546	http://dx.doi.org/10.1126/science.1067546			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743188				2022-12-28	WOS:000172817200032
J	Saba, M; Ciuti, C; Bloch, J; Thierry-Mieg, V; Andre, R; Dang, LS; Kundermann, S; Mura, A; Bongiovanni, G; Staehli, JL; Deveaud, B				Saba, M; Ciuti, C; Bloch, J; Thierry-Mieg, V; Andre, R; Dang, LS; Kundermann, S; Mura, A; Bongiovanni, G; Staehli, JL; Deveaud, B			High-temperature ultrafast polariton parametric amplification in semiconductor microcavities	NATURE			English	Article							STIMULATED SCATTERING; AMPLIFIER; EMISSION; COHERENT; EXCITONS; DEVICES; GAIN	Cavity polaritons, the elementary optical excitations of semiconductor microcavities, may be understood as a superposition of excitons and cavity photons(1). Owing to their composite nature, these bosonic particles have a distinct optical response, at the same time very fast and highly nonlinear. Very efficient light amplification due to polariton-polariton parametric scattering has recently been reported in semiconductor microcavities at liquid-helium temperatures(2-11). Here we demonstrate polariton parametric amplification up to 120 K in GaAlAs-based microcavities and up to 220 K in CdTe-based microcavities. We show that the cut-off temperature for the amplification is ultimately determined by the binding energy of the exciton. A 5-mum-thick planar microcavity can amplify a weak light pulse more than 5,000 times. The effective gain coefficient of an equivalent homogeneous medium would be 10(7) cm(-1). The subpicosecond duration and high efficiency of the amplification could be exploited for high-repetition all-optical microscopic switches and amplifiers. 10(5) polaritons occupy the same quantum state during the amplification, realizing a dynamical condensate of strongly interacting bosons which can be studied at high temperature.	Swiss Fed Inst Technol Lausanne, PH Ecublens, Dept Phys, CH-1015 Lausanne EPFL, Switzerland; CNRS, L2M, F-92225 Bagneux, France; Univ Grenoble 1, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Univ Cagliari, Dipartimento Fis, I-09042 Monserrato, Italy; Univ Cagliari, Ist Nazl Fis Mat, I-09042 Monserrato, Italy	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Cagliari; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Cagliari	Saba, M (corresponding author), Swiss Fed Inst Technol Lausanne, PH Ecublens, Dept Phys, CH-1015 Lausanne EPFL, Switzerland.	Michele.Saba@epfl.ch	Bloch, Jacqueline/S-2062-2017; mura, andrea/G-4775-2013; Deveaud, Benoit/A-4782-2013; Ciuti, Cristiano/K-7248-2012; Deveaud, Benoit/N-1947-2014; André, Régis/M-4629-2014; Mura, Alessandro/AAG-1885-2020; Ciuti, Cristiano/GYR-1378-2022; Saba, Michele/M-4239-2013; Ciuti, Cristiano/GYR-1331-2022	Bloch, Jacqueline/0000-0001-7823-8420; Deveaud, Benoit/0000-0002-9776-6314; Ciuti, Cristiano/0000-0002-1134-7013; Deveaud, Benoit/0000-0002-9776-6314; André, Régis/0000-0003-3035-4291; Ciuti, Cristiano/0000-0002-1134-7013; Saba, Michele/0000-0001-6416-3122; 				Baumberg JJ, 2000, PHYS REV B, V62, P16247, DOI 10.1103/PhysRevB.62.R16247; Bloch J, 1998, APPL PHYS LETT, V73, P1694, DOI 10.1063/1.122248; Ciuti C, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.041303; Ciuti C, 2000, PHYS REV B, V62, pR4825, DOI 10.1103/PhysRevB.62.R4825; Dang LS, 1998, PHYS REV LETT, V81, P3920, DOI 10.1103/PhysRevLett.81.3920; Dasbach G, 2000, PHYS REV B, V62, P13076, DOI 10.1103/PhysRevB.62.13076; EHRENSTEIN D, 2000, PHYS REV FOCUS, V5; Houdre R, 2000, PHYS REV LETT, V85, P2793, DOI 10.1103/PhysRevLett.85.2793; Huang R, 2000, PHYS REV B, V61, pR7854, DOI 10.1103/PhysRevB.61.R7854; Imamoglu A, 1996, PHYS REV A, V53, P4250, DOI 10.1103/PhysRevA.53.4250; Kelkar PV, 1997, PHYS REV B, V56, P7564, DOI 10.1103/PhysRevB.56.7564; Lidzey DG, 1998, NATURE, V395, P53, DOI 10.1038/25692; Lidzey DG, 2000, SCIENCE, V288, P1620, DOI 10.1126/science.288.5471.1620; Pearton SJ, 1999, J APPL PHYS, V86, P1, DOI 10.1063/1.371145; Ponce FA, 1997, NATURE, V386, P351, DOI 10.1038/386351a0; Savvidis PG, 2000, PHYS REV B, V62, P13278, DOI 10.1103/PhysRevB.62.R13278; Savvidis PG, 2000, PHYS REV LETT, V84, P1547, DOI 10.1103/PhysRevLett.84.1547; Stevenson RM, 2000, PHYS REV LETT, V85, P3680, DOI 10.1103/PhysRevLett.85.3680; WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314; Yamamoto Y, 2000, NATURE, V405, P629, DOI 10.1038/35015196	20	332	337	9	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					731	735		10.1038/414731a	http://dx.doi.org/10.1038/414731a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742394				2022-12-28	WOS:000172676200042
J	Thompson, JB; Kindt, JH; Drake, B; Hansma, HG; Morse, DE; Hansma, PK				Thompson, JB; Kindt, JH; Drake, B; Hansma, HG; Morse, DE; Hansma, PK			Bone indentation recovery time correlates with bond reforming time	NATURE			English	Article							ATOMIC-FORCE MICROSCOPY; COLLAGEN CROSS-LINKS; SCANNING ELECTRON; FIBRILS; TITIN; IMMUNOGLOBULIN; MICROCRACKING; STRENGTH; DOMAINS; CORNEA	Despite centuries of work, dating back to Galileo(1), the molecular basis of bone's toughness and strength remains largely a mystery. A great deal is known about bone microsctructure(2-5) and the microcracks(6,7) that are precursors to its fracture, but little is known about the basic mechanism for dissipating the energy of an impact to keep the bone from fracturing. Bone is a nanocomposite of hydroxyapatite crystals and an organic matrix. Because rigid crystals such as the hydroxyapatite crystals cannot dissipate much energy, the organic matrix, which is mainly collagen, must be involved. A reduction in the number of collagen cross links has been associated with reduced bone strength(8-10) and collagen is molecularly elongated ('pulled') when bovine tendon is strained(11). Using an atomic force microscope(12-16), a molecular mechanistic origin for the remarkable toughness of another biocomposite material, abalone nacre, has been found(12). Here we report that bone, like abalone nacre, contains polymers with 'sacrircial bonds' that both protect the polymer backbone and dissipate energy. The time needed for these sacrificial bonds to reform after pulling correlates with the time needed for bone to recover its toughness as measured by atomic force microscope indentation testing. We suggest that the sacrificial bonds found within or between collagen molecules may be partially responsible for the toughness of bone.	Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Thompson, JB (corresponding author), Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA.	jbthomp@physics.ucsb.edu						An Y.H., 2000, MECH TESTING BONE BO; ASCENZI A, 1993, J BIOMECH, V26, P95, DOI 10.1016/0021-9290(93)90040-L; Bigi A, 1997, BIOMATERIALS, V18, P657, DOI 10.1016/S0142-9612(96)00156-1; BURSTEIN AH, 1975, J BONE JOINT SURG AM, V57, P956, DOI 10.2106/00004623-197557070-00013; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Charras GT, 2001, ULTRAMICROSCOPY, V86, P85, DOI 10.1016/S0304-3991(00)00076-0; CHERNOFF EAG, 1992, J VAC SCI TECHNOL A, V10, P596, DOI 10.1116/1.577736; Currey JD., 1984, MECH ADAPTATIONS BON; Dufrene YF, 1999, LANGMUIR, V15, P2871, DOI 10.1021/la981066z; EINBINDER J, 1951, J BIOL CHEM, V188, P335; El Feninat F, 1998, J BIOMED MATER RES, V42, P549, DOI 10.1002/(SICI)1097-4636(19981215)42:4<549::AID-JBM10>3.3.CO;2-C; FULLWOOD NJ, 1995, CURR EYE RES, V14, P529, DOI 10.3109/02713689508998399; GREENE E.C., 1963, AM PHILOS SOC, V2, P227; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Lin H, 1999, BIOCHEMISTRY-US, V38, P9956, DOI 10.1021/bi990800q; Miyagawa A, 2000, JPN J OPHTHALMOL, V44, P591, DOI 10.1016/S0021-5155(00)00272-0; Oberhauser AF, 2001, P NATL ACAD SCI USA, V98, P468, DOI 10.1073/pnas.021321798; OXLUND H, 1995, BONE, V17, pS365, DOI 10.1016/8756-3282(95)00328-B; Paige MF, 2001, MICRON, V32, P355, DOI 10.1016/S0968-4328(00)00038-X; Reilly GC, 2000, J BIOMECH, V33, P337, DOI 10.1016/S0021-9290(99)00167-0; Reilly GC, 1999, J EXP BIOL, V202, P543; REVENKO I, 1994, BIOL CELL, V80, P67, DOI 10.1016/0248-4900(94)90019-1; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1998, BIOPHYS J, V75, P3008, DOI 10.1016/S0006-3495(98)77741-0; Sasaki N, 1996, J BIOMECH, V29, P1131, DOI 10.1016/0021-9290(96)00024-3; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107; Yamamoto S, 2000, ARCH HISTOL CYTOL, V63, P127, DOI 10.1679/aohc.63.127	30	382	398	3	118	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					773	776		10.1038/414773a	http://dx.doi.org/10.1038/414773a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742405				2022-12-28	WOS:000172676200053
J	Chertow, GM; Lee, J; Kuperman, GJ; Burdick, E; Horsky, J; Seger, DL; Lee, R; Mekala, A; Song, J; Komaroff, AL; Bates, DW				Chertow, GM; Lee, J; Kuperman, GJ; Burdick, E; Horsky, J; Seger, DL; Lee, R; Mekala, A; Song, J; Komaroff, AL; Bates, DW			Guided medication dosing for inpatients with renal insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	31st Congress of the American-Society-of-Nephrology	OCT 24-28, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			ADVERSE DRUG EVENTS; FAILURE; INTERVENTION; PREVENTION; MORTALITY	Context Usual drug-prescribing practices may not consider the effects of renal insufficiency on the disposition of certain drugs. Decision aids may help optimize prescribing behavior and reduce medical error. Objective To determine if a system application for adjusting drug close and frequency in patients with renal insufficiency, when merged with a computerized order entry system, improves drug prescribing and patient outcomes. Design, Setting, and Patients Four consecutive 2-month intervals consisting of control (usual computerized order entry) alternating with intervention (computerized order entry plus decision support system), conducted in September 1997-April 1998 with outcomes assessed among a consecutive sample of 17 828 adults admitted to an urban tertiary care teaching hospital. Intervention Real-time computerized decision support system for prescribing drugs in patients with renal insufficiency. During intervention periods, the adjusted dose list, default dose amount, and default frequency were displayed to the order-entry user and a notation was provided that adjustments had been made based on renal insufficiency. During control periods, these recommended adjustments were not revealed to the order-entry user, and the unadjusted parameters were displayed. Main Outcome Measures Rates of appropriate prescription by dose and frequency, length of stay, hospital and pharmacy costs, and changes in renal function, compared among patients with renal insufficiency who were hospitalized during the intervention vs control periods. Results A total of 7490 patients were found to have some degree of renal insufficiency. In this group, 97 151 orders were written on renally cleared or nephrotoxic medications, of which 14440 (15%) had at least 1 dosing parameter modified Ely the computer based on renal function. The fraction of prescriptions deemed appropriate during the intervention vs control periods by dose was 67% vs 54% (P<.001) and by frequency was 59% vs 35% (P<.001). Mean (SD) length of stay was 4.3 (4.5) days vs 4.5 (4.8) days in the intervention vs control periods, respectively (P=.009). There were no significant differences in estimated hospital and pharmacy costs or in the proportion of patients who experienced a decline in renal function during hospitalization. Conclusions Guided medication dosing for inpatients with renal insufficiency appears to result in improved dose and frequency choices. This intervention demonstrates a way in which computer-based decision support systems can improve care.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gen Internal Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Renal Div, Boston, MA 02115 USA; Partners Healthcare Syst, Dept Informat Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Partners Healthcare System	Chertow, GM (corresponding author), UCSF Laurel Hts, Dept Med Res, 3333 Calif St,Suite 430, San Francisco, CA 94118 USA.			Horsky, Jan/0000-0001-6326-9427; Kuperman, Gilad/0000-0002-4130-1577; Chertow, Glenn/0000-0002-7599-0534				Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; EDWARDS N, 1994, HEALTH CARE FINANC R, V16, P45; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Nolan CR, 1998, J AM SOC NEPHROL, V9, P710; Obialo CI, 2000, ARCH INTERN MED, V160, P1309, DOI 10.1001/archinte.160.9.1309; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Wang R, 1998, ARCH INTERN MED, V158, P2464, DOI 10.1001/archinte.158.22.2464	15	304	311	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2839	2844		10.1001/jama.286.22.2839	http://dx.doi.org/10.1001/jama.286.22.2839			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735759	Bronze			2022-12-28	WOS:000172655400032
J	Strauss, RS; Pollack, HA				Strauss, RS; Pollack, HA			Epidemic increase in childhood overweight, 1986-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; NATIONAL-HEALTH; OBESITY; ADOLESCENTS; INTERVENTION; PREVALENCE; CHILDREN; GROWTH	Context Overweight is the most common health problem facing US children. Data for adults suggest that overweight prevalence has increased by more than 50% in the last 10 years. Data for children also suggest that the prevalence of overweight continues to increase rapidly. Objective To investigate recent changes in the prevalence of overweight within a nationally representative sample of children, Design, Setting, and Participants The National Longitudinal Survey cf Youth, a prospective cohort study conducted from 1986 to 1998 among 8270 children aged 4 to 12 years (24 174 growth points were analyzed). Main Outcome Measures Prevalence of overweight children, defined as body mass index (BMI) greater than the 95th percentile for age and sex, and prevalence of overweight and at-risk children, defined as BMI greater than the 85th percentile for age and sex. The roles of race/ethnicity, sex, income, and region of residence were also examined. Results Between 1986 and 1998, overweight increased significantly and steadily among African American (P<.001), Hispanic (P<.001), and white (P=.03) children. By 1998, overweight prevalence increased to 21.5% among African Americans, 21.8% among Hispanics, and 12.3% among non-Hispanic whites. In addition, overweight children were heavier in 1998 compared with 1986 (P<.001). After adjusting for confounding variables, overweight increased fastest among minorities and Southerners, creating large demographic differences in the prevalence of childhood overweight by 1998. The number of children with BMI greater than the 85th percentile increased significantly from 1986 to 1998 among African American and Hispanic children (P<.001 for both) and nonsignificantly among white children (P=.77). Conclusions Childhood overweight continues to increase rapidly in the Un ted States, particularly among African Americans and Hispanics. Culturally competent treatment strategies as well as other policy interventions are required to increase physical activity and encourage healthy eating patterns among children.	UMDNJ, Robert Wood Johnson Med Sch, Div Pediat Gastroenterol & Nutr,Dept Pediat, Childhood Weight Control Program, New Brunswick, NJ 08903 USA; Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Michigan System; University of Michigan	Strauss, RS (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Div Pediat Gastroenterol & Nutr,Dept Pediat, Childhood Weight Control Program, 1 Robert Wood Johnson Pl,CN-19, New Brunswick, NJ 08903 USA.		Pollack, Harold A/A-1166-2007		PHS HHS [U48/CCU51577] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; *CTR HUM RES RES, 2000, 1998 CHILD YOUNG AD, P1; *CTR HUM RES RES, 1993, NLSY CHILD HDB, P85; Erlinger TP, 2000, J AM GERIATR SOC, V48, P1486, DOI 10.1111/jgs.2000.48.11.1486; Gauthier BM, 2000, ARCH PEDIAT ADOL MED, V154, P625, DOI 10.1001/archpedi.154.6.625; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GORTMAKER SL, 1987, AM J DIS CHILD, V141, P535, DOI 10.1001/archpedi.1987.04460050077035; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Levine JA, 2001, J MARRIAGE FAM, V63, P355, DOI 10.1111/j.1741-3737.2001.00355.x; MELNICK TA, 1998, MMWR-MORBID MORTAL W, V47, P980; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; National Center for Health Statistics, 2001, PREV OV CHILDR AD US; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; WHITAKER RC, 1994, J PEDIATR-US, V125, P535, DOI 10.1016/S0022-3476(94)70004-4; 1997, MMWR MORB MORTAL WKL, V46, P199	21	788	804	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2845	2848		10.1001/jama.286.22.2845	http://dx.doi.org/10.1001/jama.286.22.2845			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735760	Bronze			2022-12-28	WOS:000172655400033
J	Bachmann, A; Schneider, M; Theilenberg, E; Grawe, F; Knust, E				Bachmann, A; Schneider, M; Theilenberg, E; Grawe, F; Knust, E			Drosophila Stardust is a partner of Crumbs in the control of epithelial cell polarity	NATURE			English	Article							ZONULA ADHERENS FORMATION; GUANYLATE KINASE DOMAINS; INTRAMOLECULAR INTERACTION; PLASMA-MEMBRANE; BAZOOKA; PROTEIN; LOCALIZATION; ORGANIZATION; EXPRESSION; ARMADILLO	The polarized architecture of epithelial cells depends on the highly stereotypic distribution of cellular junctions and other membrane-associated protein complexes. In epithelial cells of the Drosophila embryo, three distinct domains subdivide the lateral plasma membrane. The most apical one comprises the subapical complex (SAC). It is followed by the zonula adherens (ZA) and, further basally, by the septate junction(1). A core component of the SAC is the transmembrane protein Crumbs, the cytoplasmic domain of which recruits the PDZ-protein Discs Lost into the complex(2,3). Cells lacking crumbs or the functionally related gene stardust fail to organize a continuous ZA and to maintain cell polarity(4-6). Here we show that stardust provides an essential component of the SAC. Stardust proteins colocalize with Crumbs and bind to the carboxy-terminal amino acids of its cytoplasmic tail. We introduce two different Stardust proteins here: one MAGUK protein, characterized by a PDZ domain, an SH3 domain and a guanylate kinase domain; and a second isoform comprising only the guanylate kinase domain. The Stardust proteins represent versatile candidates as structural and possibly regulatory constituents of the SAC, a crucial element in the control of epithelial cell polarity.	Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Knust, E (corresponding author), Univ Dusseldorf, Inst Genet, Univ Str 1, D-40225 Dusseldorf, Germany.	knust@uni-duesseldorf.de	Knust, Elisabeth/B-4338-2017	Grawe, Ferdi/0000-0001-6448-4989				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Grawe F, 1996, DEVELOPMENT, V122, P951; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HOVEMANN BT, 1991, NUCLEIC ACIDS RES, V19, P4909, DOI 10.1093/nar/19.18.4909; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; Lammel U, 2000, DEV GENES EVOL, V210, P525, DOI 10.1007/s004270000096; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Muller HAJ, 2000, DEV DYNAM, V218, P52; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; TOWER J, 1993, GENETICS, V133, P347; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740	30	227	231	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					638	643		10.1038/414638a	http://dx.doi.org/10.1038/414638a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740560				2022-12-28	WOS:000172535600048
J	Hong, Y; Stronach, B; Perrimon, N; Jan, LY; Jan, YN				Hong, Y; Stronach, B; Perrimon, N; Jan, LY; Jan, YN			Drosophila Stardust interacts with Crumbs to control polarity of epithelia but not neuroblasts	NATURE			English	Article							ZONULA ADHERENS FORMATION; LARVAL CUTICLE; ZYGOTIC LOCI; PLASMA-MEMBRANE; CELL POLARITY; LOCALIZATION; MUTATIONS; PROTEIN; MELANOGASTER; BAZOOKA	Establishing cellular polarity is critical for tissue organization and function. Initially discovered in the landmark genetic screen for Drosophila developmental mutants(1-4), bazooka, crumbs, shotgun and stardust mutants exhibit severe disruption in apicobasal polarity in embryonic epithelia, resulting in multilayered epithelia, tissue disintegration, and defects in cuticle formation(5). Here we report that stardust encodes single PDZ domain MAGUK (membrane-associated guanylate kinase) proteins that are expressed in all primary embryonic epithelia from the onset of gastrulation. Stardust colocalizes with Crumbs(6) at the apicolateral boundary, although their expression patterns in sensory organs differ. Stardust binds to the carboxy terminus of Crumbs in vitro, and Stardust and Crumbs are mutually dependent in their stability, localization and function in controlling the apicobasal polarity of epithelial cells. However, for the subset of ectodermal cells that delaminate and form neuroblasts, their polarity requires the function of Bazooka(7,8), but not of Stardust or Crumbs.	Univ Calif San Francisco, Dept Physiol & Biochem, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Jan, YN (corresponding author), Univ Calif San Francisco, Dept Physiol & Biochem, Howard Hughes Med Inst, San Francisco, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498; Stronach, Beth/0000-0002-1699-8683; Perrimon, Norbert/0000-0001-7542-472X				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Brenman JE, 1998, J NEUROSCI, V18, P8805; Casso David, 2000, Mechanisms of Development, V91, P451, DOI 10.1016/S0925-4773(00)00248-3; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Grawe F, 1996, DEVELOPMENT, V122, P951; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; Muller HAJ, 2000, DEV DYNAM, V218, P52; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Rashbass P, 2000, CURR BIOL, V10, pR234, DOI 10.1016/S0960-9822(00)00372-9; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5	29	197	199	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					634	638		10.1038/414634a	http://dx.doi.org/10.1038/414634a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740559				2022-12-28	WOS:000172535600047
J	Hurst, JL; Payne, CE; Nevison, CM; Marie, AD; Humphries, RE; Robertson, DHL; Cavaggioni, A; Beynon, RJ				Hurst, JL; Payne, CE; Nevison, CM; Marie, AD; Humphries, RE; Robertson, DHL; Cavaggioni, A; Beynon, RJ			Individual recognition in mice mediated by major urinary proteins	NATURE			English	Article							HOUSE MOUSE; FEMALE MICE; SYNTHETIC ANALOGS; BINDING; STIMULATION; CHEMISTRY; PHEROMONE; MARKING	The ability to recognize individuals is essential to many aspects of social behaviour, such as the maintenance of stable social groups, parent-offspring or mate recognition, inbreeding avoidance and the modulation of competitive relationships. Odours are a primary mediator of individuality signals among many mammals(1). One source of odour complexity in rodents, and possibly in humans, resides in the highly polymorphic major histocompatibility complex (MHC)(2). The olfactory acuity of mice(3) and rats(4) allows them to distinguish between the urinary odours of congenic strains differing only in single genes within the MHC, although the chemical mediators or odorants are unknown. However, rodent urine also contains a class of proteins, termed major urinary proteins (MUPs)(5), that bind and release small volatile pheromones(6,7). We have shown that the combinatorial diversity of expression of MUPs among wild mice might be as great as for MHC, and at protein concentrations a million times higher(8). Here we show in wild house mice (Mus domesticus) that urinary MUPs play an important role in the individual recognition mechanism.	Univ Liverpool, Dept Vet Clin Sci & Anim Husb, Neston CH64 7TE, England; Univ Liverpool, Dept Preclin Vet Sci, Liverpool L69 3BX, Merseyside, England; Univ Padua, Dipartimento Anat & Fisiol Umana, I-35100 Padua, Italy	University of Liverpool; University of Liverpool; University of Padua	Hurst, JL (corresponding author), Univ Liverpool, Dept Vet Clin Sci & Anim Husb, Neston CH64 7TE, England.	jane.hurst@liverpool.ac.uk	Beynon, Robert J/K-1408-2014; Mariee, Amr/AAA-4370-2022; Hurst, Jane L/G-8793-2015	Beynon, Robert J/0000-0003-0857-495X; Hurst, Jane L/0000-0002-3728-9624; Mariee, Amr/0000-0001-5786-2072				BACCHINI A, 1992, EXPERIENTIA, V48, P419, DOI 10.1007/BF01923448; Beynon RJ, 2001, CHEM SIGNAL, V9, P149; BEYNON RJ, 1999, ADV CHEM COMMUNICATI, P137; BISHOP JO, 1982, EMBO J, V1, P615, DOI 10.1002/j.1460-2075.1982.tb01217.x; Brennan PA, 1999, NEUROSCIENCE, V90, P1463, DOI 10.1016/S0306-4522(98)00556-9; Brown R. E., 1985, SOCIAL ODOURS MAMMAL, V1-2; Humphries RE, 1999, ANIM BEHAV, V58, P1177, DOI 10.1006/anbe.1999.1252; Hurst JL, 1998, ANIM BEHAV, V55, P1289, DOI 10.1006/anbe.1997.0650; Hurst JL, 2001, CHEM SIGNAL, V9, P43; HURST JL, 1990, ANIM BEHAV, V40, P209, DOI 10.1016/S0003-3472(05)80916-9; JEMIOLO B, 1986, P NATL ACAD SCI USA, V83, P4576, DOI 10.1073/pnas.83.12.4576; JEMIOLO B, 1985, ANIM BEHAV, V33, P1114, DOI 10.1016/S0003-3472(85)80170-6; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; Lucke C, 1999, EUR J BIOCHEM, V266, P1210, DOI 10.1046/j.1432-1327.1999.00984.x; Marchlewska-Koj A, 2000, J CHEM ECOL, V26, P2355, DOI 10.1023/A:1005578911652; Marie AD, 2001, PROTEIN SCI, V10, P411, DOI 10.1110/ps.31701; Mucignat-Caretta C, 1999, ANIM BEHAV, V57, P765, DOI 10.1006/anbe.1998.1023; Nevison CM, 2000, P ROY SOC B-BIOL SCI, V267, P687, DOI 10.1098/rspb.2000.1057; NOVOTNY M, 1990, EXPERIENTIA, V46, P109, DOI 10.1007/BF01955433; NOVOTNY M, 1985, P NATL ACAD SCI USA, V82, P2059, DOI 10.1073/pnas.82.7.2059; Novotny MV, 1999, P ROY SOC B-BIOL SCI, V266, P2017, DOI 10.1098/rspb.1999.0880; PAYNE CE, 2000, CHEM SIGNALS VERTEBR, P233; Pearse-Pratt R, 1998, GENETICA, V104, P223, DOI 10.1023/A:1026489524199; Robertson DHL, 1996, BIOCHEM J, V316, P265, DOI 10.1042/bj3160265; ROBERTSON DHL, 1993, J CHEM ECOL, V19, P1405, DOI 10.1007/BF00984885; Singer AG, 1997, P NATL ACAD SCI USA, V94, P2210, DOI 10.1073/pnas.94.6.2210; SINGER AG, 1993, J CHEM ECOL, V19, P569, DOI 10.1007/BF00994326; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; YAMAZAKI K, 1983, P NATL ACAD SCI-BIOL, V80, P5685, DOI 10.1073/pnas.80.18.5685; Yamazaki K, 1998, GENETICA, V104, P235, DOI 10.1023/A:1026433925744	30	467	485	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 6	2001	414	6864					631	634		10.1038/414631a	http://dx.doi.org/10.1038/414631a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740558				2022-12-28	WOS:000172535600046
J	Montaner, JSG; O'Shaughnessy, MV; Schechter, MT				Montaner, JSG; O'Shaughnessy, MV; Schechter, MT			Industry-sponsored clinical research: a double-edged sword	LANCET			English	Article							OF-INTEREST; DRUGS; QUALITY; SCIENCE; TRIALS	Drug development has accelerated exponentially since the 1950s. It is difficult to estimate the relative contributions or rates of success of industry sponsored as opposed to government supported research in any field. However, it is clear that much of the therapeutic innovation of recent decades has emerged from biotechnology and pharmaceutical industry sponsored efforts. This sponsorship is leading to new stresses in the relationship between academic institutions and industry.	Univ British Columbia, St Pauls Hosp, Canadian HIV Trials Network, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Schechter, MT (corresponding author), Univ British Columbia, St Pauls Hosp, Canadian HIV Trials Network, 620-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	martin.schechter@ubc.ca	Montaner, Julio/K-7621-2012	Schechter, Martin/0000-0001-6063-2155				Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, CONTROL CLIN TRIALS, V9, P137; [Anonymous], 1986, AM J CARDIOL, V57, P91; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; Bero LA, 1999, BRIT MED J, V319, P653, DOI 10.1136/bmj.319.7211.653; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; Cho MK, 2000, JAMA-J AM MED ASSOC, V284, P2203, DOI 10.1001/jama.284.17.2203; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Dickersin K., 1993, ONLINE J CURR CLIN T, pDoc No 50; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Garattini S, 1997, J NEPHROL, V10, P283; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; KAITIN KI, 1993, J CLIN PHARMACOL, V33, P412, DOI 10.1002/j.1552-4604.1993.tb04680.x; LAURITSEN K, 1987, LANCET, V1, P1091; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Vogel G, 1997, SCIENCE, V276, P525	23	95	95	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1893	1895		10.1016/S0140-6736(01)06891-X	http://dx.doi.org/10.1016/S0140-6736(01)06891-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741648				2022-12-28	WOS:000172463000032
J	Opie, LH				Opie, LH			Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension	LANCET			English	Editorial Material							CONVERTING ENZYME-INHIBITION; CALCIUM-CHANNEL BLOCKERS; BLOOD-PRESSURE CONTROL; RENAL-DISEASE; NEPHROPATHY; PROGRESSION; PROTEINURIA; DIET		Univ Cape Town, Dept Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Dept Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa.							Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Bakris GL, 1997, HYPERTENSION, V29, P744, DOI 10.1161/01.HYP.29.3.744; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Black HR, 1997, ARCH INTERN MED, V157, P2413; BP TRIAL, 2000, LANCET, V355, P1955; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Chrysostomou A, 2001, NEW ENGL J MED, V345, P925, DOI 10.1056/NEJM200109203451215; DiBona GF, 2000, HYPERTENSION, V36, P1083, DOI 10.1161/01.HYP.36.6.1083; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Lacourciere Y, 2000, KIDNEY INT, V58, P762, DOI 10.1046/j.1523-1755.2000.00224.x; Lazarus JM, 1997, HYPERTENSION, V29, P641, DOI 10.1161/01.HYP.29.2.641; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2096; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X	19	27	27	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1829	1831		10.1016/S0140-6736(01)06879-9	http://dx.doi.org/10.1016/S0140-6736(01)06879-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741617				2022-12-28	WOS:000172463000003
J	Poldrack, RA; Clark, J; Pare-Blagoev, EJ; Shohamy, D; Moyano, JC; Myers, C; Gluck, MA				Poldrack, RA; Clark, J; Pare-Blagoev, EJ; Shohamy, D; Moyano, JC; Myers, C; Gluck, MA			Interactive memory systems in the human brain	NATURE			English	Article							EVENT-RELATED FMRI; CAUDATE-NUCLEUS; HIPPOCAMPUS; ACQUISITION; AMNESIA; LESIONS; PLACE; RATS	Learning and memory in humans rely upon several memory systems, which appear to have dissociable brain substrates(1,2). A fundamental question concerns whether, and how, these memory systems interact. Here we show using functional magnetic resonance imaging (FMRI) that these memory systems may compete with each other during classification learning in humans. The medial temporal lobe and basal ganglia were differently engaged across subjects during classification learning depending upon whether the task emphasized declarative or nondeclarative memory, even when the to-be-learned material and the level of performance did not differ. Consistent with competition between memory systems suggested by animal studies(3,4) and neuroimaging(5), activity in these regions was negatively correlated across individuals. Further examination of classification learning using event-related FMRI showed rapid modulation of activity in these regions at the beginning of learning, suggesting that subjects relied upon the medial temporal lobe early in learning. However, this dependence rapidly declined with training, as predicted by previous computational models of associative learning(6-8).	Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02131 USA; Harvard Univ, Sch Med, Charlestown, MA 02131 USA; Harvard Univ, Grad Sch Educ, Cambridge, MA 02138 USA; Rutgers State Univ, Dept Psychol, Newark, NJ 07102 USA; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick	Poldrack, RA (corresponding author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02131 USA.		Myers, Catherine E./AAU-5804-2020	Myers, Catherine E./0000-0002-2776-4823; Shohamy, Daphna/0000-0003-4239-4960				Buchel C, 1998, NEUROIMAGE, V8, P140, DOI 10.1006/nimg.1998.0351; Dale AM, 1999, HUM BRAIN MAPP, V8, P109, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<109::AID-HBM7>3.3.CO;2-N; EICHENBAUM H, 1988, BEHAV NEUROSCI, V102, P331, DOI 10.1037/0735-7044.102.3.331; Eichenbaum HE, 2001, CONDITIONING CONSCIO; Friston KJ, 1999, NEUROIMAGE, V10, P607, DOI 10.1006/nimg.1999.0498; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Gluck M.A., 2001, GATEWAY MEMORY INTRO; GLUCK MA, 1993, HIPPOCAMPUS, V3, P491, DOI 10.1002/hipo.450030410; GLUCK MA, 1988, J EXP PSYCHOL GEN, V117, P227, DOI 10.1037/0096-3445.117.3.227; Gluck MA, 1996, LEARN MEMORY, V3, P326, DOI 10.1101/lm.3.4.326; HOPKINS R, 2001, SOC NEUR ABSTR, V27; HORWITZ B, 1995, BEHAV BRAIN RES, V66, P187, DOI 10.1016/0166-4328(94)00139-7; Kim JJ, 2001, TRENDS NEUROSCI, V24, P324, DOI 10.1016/S0166-2236(00)01818-X; Knowlton B J, 1994, Learn Mem, V1, P106; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Knowlton BJ, 1996, NEUROPSYCHOLOGY, V10, P538; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; PACKARD MG, 1989, J NEUROSCI, V9, P1465; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Packard MG, 1999, P NATL ACAD SCI USA, V96, P12881, DOI 10.1073/pnas.96.22.12881; Petri HL, 1984, NEUROPSYCHOLOGY MEMO, P287; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Reber PJ, 1996, BEHAV NEUROSCI, V110, P861, DOI 10.1037/0735-7044.110.5.861; SEARS LL, 1990, BEHAV NEUROSCI, V104, P681, DOI 10.1037/0735-7044.104.5.681; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tagamets MA, 2001, BRAIN RES BULL, V54, P267, DOI 10.1016/S0361-9230(00)00435-4; Waldvogel D, 2000, NATURE, V406, P995, DOI 10.1038/35023171; WARRINGTON EK, 1982, NEUROPSYCHOLOGIA, V20, P233, DOI 10.1016/0028-3932(82)90099-9; WINOCUR G, 1976, NEUROPSYCHOLOGIA, V14, P97, DOI 10.1016/0028-3932(76)90011-7	29	783	790	4	79	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					546	550		10.1038/35107080	http://dx.doi.org/10.1038/35107080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	496PV	11734855				2022-12-28	WOS:000172405900048
J	Matsumori, Y; Amagasa, M; Sato, S				Matsumori, Y; Amagasa, M; Sato, S			Clinical picture: Ruptured intracerebral abscess	LANCET			English	Editorial Material									Yamagata City Hosp Saiseikan, Dept Neurosurg, Yamagata 9908533, Japan		Matsumori, Y (corresponding author), Yamagata City Hosp Saiseikan, Dept Neurosurg, Yamagata 9908533, Japan.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1771	1771		10.1016/S0140-6736(01)06804-0	http://dx.doi.org/10.1016/S0140-6736(01)06804-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734234				2022-12-28	WOS:000172385100012
J	Warren, R				Warren, R			Is breast MRI mature enough to be recommended for general use?	LANCET			English	Editorial Material									Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Warren, R (corresponding author), Addenbrookes Hosp, Dept Radiol, Hills Rd, Cambridge CB2 2QQ, England.							Brown J, 2000, BREAST, V9, P78, DOI 10.1054/brst.2000.0136; Heywang S H, 1985, Rofo, V143, P207, DOI 10.1055/s-2008-1052791; HEYWANG SH, 1989, RADIOLOGY, V171, P95, DOI 10.1148/radiology.171.1.2648479; Kinkel K, 2001, J MAGN RESON IMAGING, V13, P821, DOI 10.1002/jmri.1117; PACI E, 1997, J NATL CANC I MONOGR, V22, P21; Stoutjesdijk MJ, 2001, JNCI-J NATL CANCER I, V93, P1095, DOI 10.1093/jnci/93.14.1095; The Royal College of Radiologists, 1998, MAK BEST US DEP CLIN, V4th; Warren RML, 2000, BRIT J RADIOL, V73, P123, DOI 10.1259/bjr.73.866.10884723	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 24	2001	358	9295					1745	1746		10.1016/S0140-6736(01)06841-6	http://dx.doi.org/10.1016/S0140-6736(01)06841-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734227				2022-12-28	WOS:000172385100005
J	Meyer, JM; Silliman, NP; Wang, WJ; Siepman, NY; Sugg, JE; Morris, D; Zhang, J; Bhattacharyya, H; King, EC; Hopkins, RJ				Meyer, JM; Silliman, NP; Wang, WJ; Siepman, NY; Sugg, JE; Morris, D; Zhang, J; Bhattacharyya, H; King, EC; Hopkins, RJ			Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H-pylori antimicrobial resistance partnership (SHARP) study, 1993-1999	ANNALS OF INTERNAL MEDICINE			English	Article							DOUBLE-BLIND; ANTIBIOTIC-RESISTANCE; CLARITHROMYCIN RESISTANCE; NITROIMIDAZOLE RESISTANCE; CONTROLLED-TRIALS; ULCER RECURRENCE; TRIPLE THERAPY; SUSCEPTIBILITY; METRONIDAZOLE; ERADICATION	Background: Pretreatment antimicrobial resistance has an important impact on the efficacy of many Helicobacter pylori treatment regimens. Objective: To estimate the prevalence of H. pylori resistance to antimicrobials in the United States, to characterize risk factors associated with H. pylori antimicrobial resistance, and to explore the association between drug utilization and antimicrobial resistance patterns over time. Design: Meta-analysis using patient-level data. Setting: 20 nationwide trials of H. pylori eradication. Patients: 3624 men and women, each of whom contributed one isolate. Measurements: Rates of H. pylori resistance to clarithromycin, metronidazole, and amoxicillin, according to geographic region, age, sex, study year, ethnicity, ulcer status, test method, and study. Results: Overall resistance to clarithromycin, metronidazole, and amoxicillin was 10.1% (95% CI, 9.1% to 11.1% [360 of 3571 patients]), 36.9% (CI, 35.1% to 38.7% [1063 of 2883 patients]), and 1.4% (CI, 1.0% to 1.8% [48 of 3486 patients]), respectively. In multivariable analyses, multiple risk factors were associated with resistance to individual agents. Clarithromycin resistance was significantly associated with geographic region (P = 0.050), older age (P < 0.001), female sex (P < 0.001), inactive ulcer disease (P < 0.001), and study (P = 0.010). Metronidazole resistance was significantly associated with female sex (P < 0.001), earlier year of study enrollment (P = 0.036), Asian ethnicity (P < 0.001), use of an epsilometer test (P = 0.002), and study (P < 0.001). Amoxicillin resistance was low and was not significantly associated with any risk factor. In the 1990s, when rates for use of oral macrolides and metronidazole were relatively stable, clarithromycin resistance rates were stable and metronidazole resistance rates varied. Conclusions: Clinicians should consider risk factors for antimicrobial resistance when deciding which patients should have susceptibility testing and when choosing appropriate H. pylori treatments in the empirical setting.	US FDA, Ctr Drug Evaluat & Res, Div Pharmaceut Evaluat 3 HFD880, Rockville, MD 20850 USA; AstraZeneca LP, Wayne, NJ USA; TAP Pharmaceut Prod Inc, Deerfield, IL USA; Abbott Labs, Abbott Pk, IL 60064 USA; Pfizer Cent Res, New York, NY USA; Procter & Gamble Co, Mason, OH USA	US Food & Drug Administration (FDA); AstraZeneca; Abbott Laboratories; Takeda Pharmaceutical Company Ltd; TAP Pharmaceuticals; Abbott Laboratories; Pfizer; Procter & Gamble	Meyer, JM (corresponding author), US FDA, Ctr Drug Evaluat & Res, Div Pharmaceut Evaluat 3 HFD880, 9201 Corp Blvd,Roo S-402, Rockville, MD 20850 USA.		King, Eileen/Q-1815-2015					[Anonymous], 1992, Eur J Clin Microbiol Infect Dis, V11, P777; Berger JO., 1980, STAT DECISION THEORY; De Koster E, 2000, GASTROENTEROLOGY, V118, pA495, DOI 10.1016/S0016-5085(00)84101-3; Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023/A:1005457226341; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Fennerty MB, 1998, ARCH INTERN MED, V158, P1651, DOI 10.1001/archinte.158.15.1651; Graham DY, 1998, GASTROENTEROLOGY, V115, P1272, DOI 10.1016/S0016-5085(98)70100-3; Graham DY, 1996, AM J GASTROENTEROL, V91, P1072; Greenhouse JB, 1996, STAT MED, V15, P2077, DOI 10.1002/(SICI)1097-0258(19961015)15:19<2077::AID-SIM348>3.0.CO;2-X; Harford W, 1996, Helicobacter, V1, P243, DOI 10.1111/j.1523-5378.1996.tb00046.x; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Kato M, 2000, ANTIMICROB AGENTS CH, V44, P2214, DOI 10.1128/AAC.44.8.2214-2216.2000; Laine L, 1999, GASTROENTEROLOGY, V116, pA228; Laine L, 1998, AM J GASTROENTEROL, V93, P2106; Laine L, 1998, ALIMENT PHARM THERAP, V12, P377; Laine L, 2000, AM J GASTROENTEROL, V95, P3393, DOI 10.1111/j.1572-0241.2000.03349.x; Megraud F, 1999, ANTIMICROB AGENTS CH, V43, P2747, DOI 10.1128/AAC.43.11.2747; Megraud F, 1997, ALIMENT PHARM THERAP, V11, P43, DOI 10.1046/j.1365-2036.11.s1.11.x; Osato MS, 2000, GASTROENTEROLOGY, V118, pA676, DOI 10.1016/S0016-5085(00)84844-1; Osato MS, 2000, GASTROENTEROLOGY, V118, pA500, DOI 10.1016/S0016-5085(00)84121-9; Osato MS, 1998, GASTROENTEROLOGY, V114, pA250, DOI 10.1016/S0016-5085(98)81016-0; Schwartz H, 1998, AM J GASTROENTEROL, V93, P584, DOI 10.1111/j.1572-0241.1998.169_b.x; Tanner MA, 1993, TOOLS STAT INFERENCE; Van der Wouden EJ, 2000, ALIMENT PHARM THER, V14, P7; van der Wouden EJ, 1999, AM J GASTROENTEROL, V94, P1751, DOI 10.1111/j.1572-0241.1999.01202.x; Weissfeld A, 1997, GASTROENTEROLOGY, V112, pA328	26	159	173	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	2002	136	1					13	24		10.7326/0003-4819-136-1-200201010-00008	http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510BF	11777360				2022-12-28	WOS:000173188300002
J	Bernardi, L; Sleight, P; Bandinelli, G; Cencetti, S; Fattorini, L; Wdowczyc-Szulc, J; Lagi, A				Bernardi, L; Sleight, P; Bandinelli, G; Cencetti, S; Fattorini, L; Wdowczyc-Szulc, J; Lagi, A			Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study	BRITISH MEDICAL JOURNAL			English	Article							HEART-RATE-VARIABILITY; MORTALITY; FAILURE; HUMANS	Objective To test whether rhythmic formulas such as the rosary and yoga mantras can synchronise and reinforce inherent cardiovascular rhythms and modify, baroreflex sensitivity. Design Comparison of effects of recitation of the Ave Maria (in Latin) or of a mantra, during spontaneous and metronome controlled breathing, on breathing rate and oil spontaneous oscillations in RR interval, and on blood pressure and cerebral circulation. Setting Florence and Pavia, Italy. Participants 23 healthy adults. Main outcome measures Breathing rate, regularity of breathing, baroreflex sensitivity, frequency of cardiovascular oscillations. Results Both prayer and mantra caused striking, powerful, and synchronous increases in existing cardiovascular rhythms when recited six times a minute. Baroreflex sensitivity also increased significantly, from 9.5 (SD 4.6) to 11.5 (4.9) ms/mm. Hg, P < 0.05. Conclusion Rhythm formulas that involve breathing at six breaths per minute induce favourable psychological and possibly physiological effects.	Univ Pavia, Dipartimento Med Interna, I-27100 Pavia, Italy; John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Unita Osped S Maria Nuova, Dipartimento Med Interna, I-50100 Florence, Italy; Univ Gdansk, Dept Cardiol, PL-80211 Gdansk, Poland	University of Pavia; University of Oxford; Fahrenheit Universities; University of Gdansk	Bernardi, L (corresponding author), Univ Pavia, Dipartimento Med Interna, I-27100 Pavia, Italy.							Bernardi L, 1998, LANCET, V351, P1308, DOI 10.1016/S0140-6736(97)10341-5; Bernardi L, 2000, J AM COLL CARDIOL, V35, P1462, DOI 10.1016/S0735-1097(00)00595-7; Bernardi L, 2001, J HYPERTENS, V19, P2221, DOI 10.1097/00004872-200112000-00016; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; DEBOER RW, 1987, AM J PHYSIOL, V253, pH680, DOI 10.1152/ajpheart.1987.253.3.H680; Friedman EH, 2000, INT J CARDIOL, V73, P199, DOI 10.1016/S0167-5273(00)00214-X; HEWITT J, 1983, YOGA BREATHING POSTU; La Rovere MT, 1998, LANCET, V351, P478; LEHMANN J, 1976, KREUZFAHRER; Mayer S, 1876, SITZUNGSBERICHT MATH, V74, P281; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; Piepoli M, 1997, CIRCULATION, V95, P1813; SLEIGHT P, 1995, CLIN SCI, V88, P103, DOI 10.1042/cs0880103	13	226	238	1	38	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1446	1449		10.1136/bmj.323.7327.1446	http://dx.doi.org/10.1136/bmj.323.7327.1446			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751348	Green Published			2022-12-28	WOS:000172979900007
J	Gergen, B; Nienhaus, H; Weinberg, WH; McFarland, EW				Gergen, B; Nienhaus, H; Weinberg, WH; McFarland, EW			Chemically induced electronic excitations at metal surfaces	SCIENCE			English	Article							INDUCED CHEMISTRY; ADSORPTION; DESORPTION; AG(111); SPECTROSCOPY; MOLECULES; KINETICS; AG(011); WATER; NO2	The energy released in low-energy chemisorption or physisorption of molecules on metal surfaces is usually expected to be dissipated by surface vibrations (phonons). Theoretical descriptions of competing electronic excitations are incomplete, and experimental observation of excited charge carriers has been difficult except at energies high enough to eject electrons from the surface. We observed reaction-induced electron excitations during gas interactions with polycrystalline silver for a variety of species with adsorption energies between 0.2 and 3.5 electron volts. The probability of exciting a detectable electron increases with increasing adsorption energy, and the measured time dependence of the electron current can be understood in terms of the strength and mechanism of adsorption.	Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; Gerhard Mercator Univ, Festkorperphys Lab, D-47048 Duisburg, Germany; Symyx Technol, Santa Clara, CA 95051 USA	University of California System; University of California Santa Barbara; University of Duisburg Essen	McFarland, EW (corresponding author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.		McFarland, Eric/G-1763-2014					ARVANITIS D, 1986, PHYS REV LETT, V57, P3175, DOI 10.1103/PhysRevLett.57.3175; BROWN WA, 1995, SURF SCI, V330, P41, DOI 10.1016/0039-6028(95)00397-5; CAMPBELL CT, 1985, SURF SCI, V157, P43, DOI 10.1016/0039-6028(85)90634-X; Darling GR, 1995, REP PROG PHYS, V58, P1595, DOI 10.1088/0034-4885/58/12/001; ELLIOTT GS, 1990, CHEM PHYS LETT, V175, P371, DOI 10.1016/0009-2614(90)80127-Y; Gergen B, 2001, SURF SCI, V488, P123, DOI 10.1016/S0039-6028(01)01124-4; Greber T, 1997, SURF SCI REP, V28, P3; KUIPERS EW, 1988, SURF SCI, V205, P241, DOI 10.1016/0039-6028(88)90175-6; METIU H, 1982, ISRAEL J CHEM, V22, P329; Monch W, 1996, J VAC SCI TECHNOL B, V14, P2985, DOI 10.1116/1.588947; Nienhaus H, 1999, PHYS REV LETT, V82, P446, DOI 10.1103/PhysRevLett.82.446; PawelaCrew J, 1996, J CHEM PHYS, V104, P1699, DOI 10.1063/1.470756; Peng XL, 2000, J APPL PHYS, V88, P4097, DOI 10.1063/1.1290711; Petek H, 1997, PROG SURF SCI, V56, P239, DOI 10.1016/S0079-6816(98)00002-1; RODRIGUEZSANTIAGO L, 1995, J CHEM PHYS, V103, P9738, DOI 10.1063/1.469937; SCHONHAMMER K, 1981, PHYS REV B, V24, P7084, DOI 10.1103/PhysRevB.24.7084; Schwaner AL, 1996, SURF SCI, V351, P228, DOI 10.1016/0039-6028(95)01356-3; THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X; UNGURIS J, 1981, SURF SCI, V109, P522, DOI 10.1016/0039-6028(81)90425-8; Wetterer SM, 1998, J PHYS CHEM B, V102, P9266, DOI 10.1021/jp982338+; WU KJ, 1989, J CHEM PHYS, V91, P7964, DOI 10.1063/1.457214; ZHOU XL, 1992, J PHYS CHEM-US, V96, P7703, DOI 10.1021/j100198a040	22	263	272	1	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2521	2523		10.1126/science.1066134	http://dx.doi.org/10.1126/science.1066134			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752571				2022-12-28	WOS:000172927700050
J	Reich, DS; Mechler, F; Victor, JD				Reich, DS; Mechler, F; Victor, JD			Independent and redundant information in nearby cortical neurons	SCIENCE			English	Article							VISUAL-CORTEX; SPIKE TRAINS; DISCHARGE	In the primary visual cortex (V1), nearby neurons are tuned to similar stimulus features, and, depending on the manner and time scale over which neuronal signals are analyzed, the resulting redundancy may mitigate deleterious effects of response variability. We estimated information rates in the short-time scale responses of clusters of up to six simultaneously recorded nearby neurons in monkey V1. Responses were almost independent if we kept track of which neuron fired each spike but were redundant if we summed responses over the cluster. Redundancy was independent of cluster size. Summing neuronal responses to reduce variability discards potentially useful information, and the discarded information increases with cluster size.	Rockefeller Univ, Biophys Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Rockefeller University; Cornell University	Reich, DS (corresponding author), Rockefeller Univ, Biophys Lab, 1230 York Ave, New York, NY 10021 USA.		Reich, Daniel S./E-5701-2010; Victor, Jonathan D./D-2931-2009	Reich, Daniel S./0000-0002-2628-4334; Victor, Jonathan D./0000-0002-9293-0111	NEI NIH HHS [EY07138, EY9314] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009314] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abbott LF, 1999, NEURAL COMPUT, V11, P91, DOI 10.1162/089976699300016827; Bair W, 2001, J NEUROSCI, V21, P1676, DOI 10.1523/JNEUROSCI.21-05-01676.2001; De Angelo J, 1999, Expert Opin Pharmacother, V1, P19; Fee MS, 1996, J NEUROSCI METH, V69, P175, DOI 10.1016/S0165-0270(96)00050-7; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Koch C, 2000, NAT NEUROSCI, V3, P1171, DOI 10.1038/81444; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; Machens CK, 2001, J NEUROSCI, V21, P3215, DOI 10.1523/JNEUROSCI.21-09-03215.2001; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; Nirenberg S, 2001, NATURE, V411, P698, DOI 10.1038/35079612; Panzeri S, 2001, NEURAL COMPUT, V13, P1311, DOI 10.1162/08997660152002870; Reich DS, 2001, J NEUROPHYSIOL, V85, P305, DOI 10.1152/jn.2001.85.1.305; Reich DS, 2000, J NEUROSCI, V20, P1964; REICH DS, 2001, THESIS ROCKEFELLER U; Rolls ET, 1997, EXP BRAIN RES, V114, P149, DOI 10.1007/PL00005615; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Strong SP, 1998, PHYS REV LETT, V80, P197, DOI 10.1103/PhysRevLett.80.197; Sutter E.E., 1992, NONLINEAR VISION, P171, DOI [10.1201/9781351075060-6, DOI 10.1201/9781351075060-6]; Williams SR, 2000, J NEUROSCI, V20, P8238, DOI 10.1523/JNEUROSCI.20-22-08238.2000; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	21	204	207	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2001	294	5551					2566	2568		10.1126/science.1065839	http://dx.doi.org/10.1126/science.1065839			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752580				2022-12-28	WOS:000172927700064
J	Kuo, HC; Cheng, CF; Clark, RB; Lin, JJC; Lin, JLC; Hoshijima, M; Nguyen-Tran, VTB; Gu, YS; Ikeda, Y; Chu, PH; Ross, J; Giles, WR; Chien, KR				Kuo, HC; Cheng, CF; Clark, RB; Lin, JJC; Lin, JLC; Hoshijima, M; Nguyen-Tran, VTB; Gu, YS; Ikeda, Y; Chu, PH; Ross, J; Giles, WR; Chien, KR			A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I-to and confers susceptibility to ventricular tachycardia	CELL			English	Article							TRANSIENT OUTWARD CURRENT; SUDDEN CARDIAC DEATH; K+ CHANNEL; HEART-FAILURE; MOUSE HEARTS; EXPRESSION; MYOCYTES; SUBUNIT; MICE; REPOLARIZATION	KChIP2, a gene encoding three auxiliary subunits of Kv4.2 and Kv4.3, is preferentially expressed in the adult heart, and its expression is downregulated in cardiac hypertrophy. Mice deficient for KChIP2 exhibit normal cardiac structure and function but display a prolonged elevation in the ST segment on the electrocardiogram. The KChIP2(-/-) mice are highly susceptible to the induction of cardiac arrhythmias. Single-cell analysis revealed a substrate for arrhythmogenesis, including a complete absence of transient outward potassium current, It., and a marked increase in action potential duration. These studies demonstrate that a defect in KChIP2 is sufficient to confer a marked genetic susceptibility to arrhythmias, establishing a novel genetic pathway for ventricular tachycardia via a loss of the transmural gradient of I-to.	Univ Calif San Diego, Sch Med, UCSD Salk Program Mol Med, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calgary, Fac Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	University of California System; University of California San Diego; University of Calgary; University of Iowa	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, UCSD Salk Program Mol Med, Inst Mol Med, La Jolla, CA 92093 USA.		Chu, Pao-Hsien/P-5249-2019; CHENG, Ching-Feng/AAB-8861-2019; gu, yu/GSD-4507-2022	Chu, Pao-Hsien/0000-0003-0361-6348; CHENG, Ching-Feng/0000-0003-0104-0146; Ikeda, Yasuhiro/0000-0002-2970-7304; Nguyen-Tran, Van/0000-0001-5678-1908				An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Antzelevitch C, 2001, CURR OPIN CARDIOL, V16, P1, DOI 10.1097/00001573-200101000-00001; Antzelevitch C, 2001, EUR HEART J, V22, P356, DOI 10.1053/euhj.2000.2461; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Baker LC, 2000, CIRC RES, V86, P396, DOI 10.1161/01.RES.86.4.396; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Berul CI, 1997, J CLIN INVEST, V99, P570, DOI 10.1172/JCI119197; Berul CI, 1996, CIRCULATION, V94, P2641, DOI 10.1161/01.CIR.94.10.2641; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; ELSHERIF N, 2000, CARDIAC ELECTROPHYSI, P662; Fiset C, 1997, J PHYSIOL-LONDON, V504, P557, DOI 10.1111/j.1469-7793.1997.557bd.x; Giese KP, 1998, LEARN MEMORY, V5, P257; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Kaab S, 1996, CIRC RES, V78, P262, DOI 10.1161/01.RES.78.2.262; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Nabauer M, 1996, CIRCULATION, V93, P168, DOI 10.1161/01.CIR.93.1.168; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Nguyen-Tran VTB, 2000, CELL, V102, P671, DOI 10.1016/S0092-8674(00)00089-1; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Swiderski RE, 1999, DEV DYNAM, V216, P16, DOI 10.1002/(SICI)1097-0177(199909)216:1<16::AID-DVDY4>3.0.CO;2-1; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; TOMITA F, 1994, CIRC RES, V75, P296, DOI 10.1161/01.RES.75.2.296; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wickenden AD, 1999, CIRC RES, V85, P1067; Yan GX, 1999, CIRCULATION, V100, P1660, DOI 10.1161/01.CIR.100.15.1660; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	33	358	367	0	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 14	2001	107	6					801	813		10.1016/S0092-8674(01)00588-8	http://dx.doi.org/10.1016/S0092-8674(01)00588-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747815	Bronze			2022-12-28	WOS:000172771800012
J	Norio, P; Schildkraut, CL				Norio, P; Schildkraut, CL			Visualization of DNA replication on individual Epstein-Barr virus episomes	SCIENCE			English	Article							DIHYDROFOLATE-REDUCTASE DOMAIN; HIGH-RESOLUTION; FIBER-FISH; SITES; HYBRIDIZATION; INITIATION; ORIGIN; GENOME; PAUSE; FORKS	The duplication of the mammalian genome is an organized event, but there is limited information about the precision of the duplication program at specific genetic loci. We developed an approach that allows DNA replication events to be visualized in individual DNA molecules. Studying the latent replication of Epstein-Barr virus episomes, we show that different initiation sites are used to commence DNA replication from a specific portion of the viral genome (zone), whereas termination does not seem to be genomically defined. We conclude that initiation zones and pausing sites are major organizers of the duplication program, but initiation, fork progression, and termination of replication can vary in each molecule.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Norio, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM45751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allemand JF, 1997, BIOPHYS J, V73, P2064, DOI 10.1016/S0006-3495(97)78236-5; ATEN JA, 1992, HISTOCHEM J, V24, P251, DOI 10.1007/BF01046839; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; HUBERMAN JA, 1966, P NATL ACAD SCI USA, V55, P599, DOI 10.1073/pnas.55.3.599; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kalejta RF, 1996, MOL CELL BIOL, V16, P4923; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; LITTLE RD, 1995, MOL CELL BIOL, V15, P2893; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; NORIO P, UNPUB; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; van de Rijke FM, 2000, J HISTOCHEM CYTOCHEM, V48, P743, DOI 10.1177/002215540004800602; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Yates J.L, 1996, DNA REPLICATION EUKA, P751; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	24	115	120	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2361	2364		10.1126/science.1064603	http://dx.doi.org/10.1126/science.1064603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743204				2022-12-28	WOS:000172817200049
J	Wang, ZR; Kiledjian, M				Wang, ZR; Kiledjian, M			Functional link between the mammalian exosome and mRNA decapping	CELL			English	Article							MESSENGER-RNA DEGRADATION; PROTEIN COMPLEX; ENDORIBONUCLEASE ACTIVITY; ENDONUCLEOLYTIC CLEAVAGE; SACCHAROMYCES-CEREVISIAE; CAP STRUCTURE; YEAST-CELLS; STABILITY; TURNOVER; TRANSLATION	Mechanistic understanding of mammalian mRNA turnover remains incomplete. We demonstrate that the 3' to 5' exoribonuclease decay pathway is a major contributor to mRNA decay both in cells and in cell extract. An exoribonuclease-dependent scavenger decapping activity was identified that follows decay of the mRNA and hydrolyzes the residual cap. The decapping activity is associated with a subset:Of the exosome proteins in vivo, implying a higher-order degradation complex consisting of exoribonucleases and a decapping activity, which together coordinate the decay of an mRNA. These findings indicate that following deadenylation of mammal mRNA, degradation proceeds by a coupled 3' to 5' exoribonucleolytic activity and subsequent hydrolysis of the cap structure by a scavenger decapping activity.	Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kiledjian, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	kiledjia@biology.rutgers.edu			NIDDK NIH HHS [DK51611] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051611] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bonnerot C, 2000, MOL CELL BIOL, V20, P5939, DOI 10.1128/MCB.20.16.5939-5946.2000; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brouwer R, 2001, J BIOL CHEM, V276, P6177, DOI 10.1074/jbc.M007603200; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GELPI C, 1990, CLIN EXP IMMUNOL, V81, P59; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Kiledjian M, 1999, METHODS, V17, P84, DOI 10.1006/meth.1998.0710; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NUSS DL, 1975, CELL, V6, P21, DOI 10.1016/0092-8674(75)90069-0; NUSS DL, 1977, J BIOL CHEM, V252, P2815; REIMER G, 1986, J IMMUNOL, V137, P3802; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WICKENS MP, 1983, J MOL BIOL, V163, P1, DOI 10.1016/0022-2836(83)90027-X; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200; Zhang S, 1999, MOL CELL BIOL, V19, P7568; Zhang S, 1999, METHODS, V17, P46, DOI 10.1006/meth.1998.0706	57	200	208	4	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					751	762		10.1016/S0092-8674(01)00592-X	http://dx.doi.org/10.1016/S0092-8674(01)00592-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747811	Bronze			2022-12-28	WOS:000172771800008
J	Gandon, S; Mackinnon, MJ; Nee, S; Read, AF				Gandon, S; Mackinnon, MJ; Nee, S; Read, AF			Imperfect vaccines and the evolution of pathogen virulence	NATURE			English	Article								Vaccines rarely provide full protection from disease. Nevertheless, partially effective (imperfect) vaccines may be used to protect both individuals and whole populations(1-3). We studied the potential impact of different types of imperfect vaccines on the evolution of pathogen virulence (induced host mortality) and the consequences for public health. Here we show that vaccines designed to reduce pathogen growth rate and/or toxicity diminish selection against virulent pathogens. The subsequent evolution leads to higher levels of intrinsic virulence and hence to more severe disease in unvaccinated individuals. This evolution can erode any population-wide benefits such that overall mortality rates are unaffected, or even increase, with the level of vaccination coverage. In contrast, infection-blocking vaccines induce no such effects, and can even select for lower virulence. These findings have policy implications for the development and use of vaccines that are not expected to provide full immunity, such as candidate vaccines for malaria(4).	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Gandon, S (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland.	Sylvain.Gandon@ed.ac.uk	GANDON, Sylvain/AHC-0976-2022; Mackinnon, Margaret/L-3155-2013	GANDON, Sylvain/0000-0003-2624-7856; Mackinnon, Margaret/0000-0003-1279-9625				ANDERSON R M, 1991; ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; Caswell, 2000, MATRIX POPULATION MO; *CDC, 2000, MROB MORTAL WKLY REP, V46, P1094; Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353; DIECKMANN U, 2001, VIRULENCE MANAGEMENT; Ebert D, 1998, SCIENCE, V282, P1432, DOI 10.1126/science.282.5393.1432; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Gandon S, 2000, P ROY SOC B-BIOL SCI, V267, P985, DOI 10.1098/rspb.2000.1100; Gandon S, 2001, EVOLUTION, V55, P1056, DOI 10.1554/0014-3820(2001)055[1056:HLHATE]2.0.CO;2; GUPTA S, 1997, P ROY SOC LOND B BIO, V266, P1435; HALLORAN ME, 1989, MATH BIOSCI, V94, P115, DOI 10.1016/0025-5564(89)90074-6; Hoffman SL, 1996, MALARIA VACCINE DEV; LEVIN S, 1981, AM NAT, V117, P308, DOI 10.1086/283708; Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; Mackinnon MJ, 1999, EVOLUTION, V53, P689, DOI [10.2307/2640710, 10.1111/j.1558-5646.1999.tb05364.x]; MAY RM, 1994, J THEOR BIOL, V170, P95, DOI 10.1006/jtbi.1994.1171; MCLEAN AR, 1995, P ROY SOC B-BIOL SCI, V261, P389, DOI 10.1098/rspb.1995.0164; MCLEAN SA, 1993, P ROY SOC LOND B BIO, V256, P9; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; Read AF, 2001, SCIENCE, V292, P1099, DOI 10.1126/science.1059410; Regoes RR, 2000, EVOLUTION, V54, P64, DOI 10.1111/j.0014-3820.2000.tb00008.x; Ronce O, 2001, EVOLUTION, V55, P1520, DOI 10.1111/j.0014-3820.2001.tb00672.x; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; vanBaalen M, 1995, AM NAT, V146, P881, DOI 10.1086/285830; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Witter RL, 1997, ACTA VET HUNG, V45, P251; Woolhouse MEJ, 2001, SCIENCE, V292, P1109, DOI 10.1126/science.1059026; Zuckerman AJ, 2000, LANCET, V355, P1382, DOI 10.1016/S0140-6736(00)02132-2	30	443	450	0	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 13	2001	414	6865					751	756		10.1038/414751a	http://dx.doi.org/10.1038/414751a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742400	Green Published			2022-12-28	WOS:000172676200048
J	Farnham, FR; James, DV				Farnham, FR; James, DV			"Dangerousness" and dangerous law	LANCET			English	Editorial Material									UCL Royal Free & UCL Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England	University of London; University College London	James, DV (corresponding author), UCL Royal Free & UCL Med Sch, Dept Psychiat & Behav Sci, Royal Free Campus, London NW3 2PF, England.	david.james5@ntlworld.com						[Anonymous], CULTURE CONTROL; *DEPT HLTH, 1999, FUT RRG PRIS HLTH CA; Freedman D, 2001, J AM ACAD PSYCHIATRY, V29, P89; Health Advisory Committee for the Prison Service, 1997, PROV MENT HLTH CAR P; HM Chief Inspector of Prisons (HMCIP), 1996, PAT PRIS NEW STRAT H; Hotopf M, 2000, BRIT J PSYCHIAT, V176, P479, DOI 10.1192/bjp.176.5.479; Mullen PE, 1999, BRIT MED J, V319, P1146, DOI 10.1136/bmj.319.7218.1146; Rogers R, 2000, LAW HUMAN BEHAV, V24, P595, DOI 10.1023/A:1005575113507	8	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1926	1926		10.1016/S0140-6736(01)06977-X	http://dx.doi.org/10.1016/S0140-6736(01)06977-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747914				2022-12-28	WOS:000172622200007
J	O'Neill, D				O'Neill, D			Present, rather than, advance directives	LANCET			English	Editorial Material									Adelaide & Meath Hosp, Trinity Ctr Hlth Sci, Dept Med Gerontol, Dublin 24, Ireland	Trinity College Dublin	O'Neill, D (corresponding author), Adelaide & Meath Hosp, Trinity Ctr Hlth Sci, Dept Med Gerontol, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bondeson Jan, 2001, BURIED ALIVE TERRIFY; Ebrahim S, 2000, BRIT MED J, V320, P1155, DOI 10.1136/bmj.320.7243.1155; Fagerlin A, 2001, HEALTH PSYCHOL, V20, P166, DOI 10.1037/0278-6133.20.3.166; Grimaldo DA, 2001, ANESTHESIOLOGY, V95, P43, DOI 10.1097/00000542-200107000-00012; LOEWY EH, 1992, ARCH INTERN MED, V152, P1973, DOI 10.1001/archinte.152.10.1973; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; O'Neill D, 1997, IRISH J PSYCHOL MED, V14, P121, DOI 10.1017/S079096670000330X; SOROS G, 2001, REFLECTION DEATH AM; Ulrich L., 2001, PATIENT SELF DETERMI	11	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1921	1922		10.1016/S0140-6736(01)06973-2	http://dx.doi.org/10.1016/S0140-6736(01)06973-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747910				2022-12-28	WOS:000172622200003
J	Parsons, TJ; Power, C; Manor, O				Parsons, TJ; Power, C; Manor, O			Fetal and early life growth and body mass index from birth to early adulthood in 1958 British cohort: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							CATCH-UP GROWTH; CORONARY HEART-DISEASE; WEIGHT-FOR-HEIGHT; CARDIOVASCULAR RISK; BLOOD-PRESSURE; IN-UTERO; CHILDHOOD; OBESITY; ADOLESCENCE; WOMEN	Objectives To determine the influence of birth weight on body mass index at different stages of later life; whether this relation persists after accounting for potential confounding factors; and the role of indicators of fetal growth (birth weight relative to parental size) and childhood growth. Design Longitudinal study of the 1958 British birth cohort. Setting England, Scotland, and Wales. Participants All singletons born 3-9 March 1958 (10 683 participants with data available at age 33). Main outcome measures Body mass index at ages 7, 11, 16, 23, and 33 years. Results The relation between birth weight and body mass index was positive and weak, becoming more J shaped with increasing age. When adjustments were made for maternal weight, there was no relation between birth weight and boyd mass index at age 33. Indicators of poor fetal growth based on the mother's body size were not predictive, but the risk of adult obesity was higher among participants who had grown to a greater proportion of their eventual adult height by age 7. In men only, the effect of childhood growth was strongest in those with lower birth weights and, to a lesser extend, those born to lighter mothers. Conclusions Maternal weight (or body mass index) largely explains the association between birth weight and adult body mass index, and it may be a more important risk factor for obesity in the child than birth weight. Birth weight and maternal weight seem to modify the effect of childhood linear growth on adult obesity in men. Intergenerational associations between the mother's and her offspring's body mass index seem to underlie the well documented association between birth weight and body mass index. Other measures of fetal growth are needed for a fuller understanding of the role of the intrauterine environment in the development of obesity.	Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England; Hebrew Univ Jerusalem, Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel	University of London; University College London; Hebrew University of Jerusalem	Parsons, TJ (corresponding author), Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England.							BEUNEN G, 1994, INT J OBESITY, V18, P670; Butler N.R., 1963, PERINATAL MORTALITY; *CTR LONG STUD I E, 1994, NAT CHILD DEV STUD C; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DIETZ WH, 1994, AM J CLIN NUTR, V59, P955, DOI 10.1093/ajcn/59.5.955; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Forsen T, 1999, BRIT MED J, V319, P1403, DOI 10.1136/bmj.319.7222.1403; FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; *GREAT BRIT GEN RE, 1956, CENS 1951 CLASS OCC; Hulman S, 1998, J PEDIATR-US, V132, P90, DOI 10.1016/S0022-3476(98)70491-3; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; LAKE JK, 1998, THESIS U COLL LONDON; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; Ong KKL, 2000, BRIT MED J, V320, P1244; Ong KKL, 2000, BRIT MED J, V320, P967, DOI 10.1136/bmj.320.7240.967; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; POWER C, 1988, INT J OBESITY, V12, P445; SEIDMAN DS, 1991, AM J DIS CHILD, V145, P782; vanLenthe FJ, 1996, AM J CLIN NUTR, V64, P18, DOI 10.1093/ajcn/64.1.18; Whitaker RC, 1998, J PEDIATR-US, V132, P768, DOI 10.1016/S0022-3476(98)70302-6	24	363	373	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2001	323	7325					1331	1335		10.1136/bmj.323.7325.1331	http://dx.doi.org/10.1136/bmj.323.7325.1331			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501ZC	11739217	Bronze, Green Published			2022-12-28	WOS:000172716900014
J	Flanigan, RC; Salmon, SE; Blumenstein, BA; Bearman, SI; Roy, V; McGrath, PC; Caton, JR; Munshi, N; Crawford, ED				Flanigan, RC; Salmon, SE; Blumenstein, BA; Bearman, SI; Roy, V; McGrath, PC; Caton, JR; Munshi, N; Crawford, ED			Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYTOREDUCTIVE SURGERY; PROGNOSTIC-FACTORS; CARCINOMA; INTERLEUKIN-2; IMMUNOTHERAPY; CHEMOTHERAPY; COMBINATION; SURVIVAL; THERAPY; FAILURE	Background: The value of nephrectomy in metastatic renal-cell cancer has long been debated. Several nonrandomized studies suggest a higher rate of response to systemic therapy and longer survival in patients who have undergone nephrectomy. Methods: We randomly assigned patients with metastatic renal-cell cancer who were acceptable candidates for nephrectomy to undergo radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone. The primary end point was survival, and the secondary end point was a response of the tumor to treatment. Results: The median survival of 120 eligible patients assigned to surgery followed by interferon was 11.1 months, and among the 121 eligible patients assigned to interferon alone it was 8.1 months (P=0.05). The difference in median survival between the two groups was independent of performance status, metastatic site, and the presence or absence of a measurable metastatic lesion. Conclusions: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferon therapy alone. (N Engl J Med 2001;345:1655-9.) Copyright (C) 2001 Massachusetts Medical Society.	Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA; Univ Arizona, Ctr Canc, Tucson, AZ USA; SW Oncol Grp, Ctr Stat, San Antonio, TX 78245 USA; Univ Colorado, Denver, CO 80202 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Univ Kentucky, Med Ctr, Lexington, KY USA; Brooke Army Med Ctr, Wilford Hall Med Ctr, San Antonio, TX USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Loyola University Chicago; University of Arizona; Southwest Oncology Group; University of Colorado System; University of Colorado Denver; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Kentucky; San Antonio Military Medical Center; United States Department of Defense; United States Army; University of Arkansas System; University of Arkansas Medical Sciences	Flanigan, RC (corresponding author), SW Oncol Grp SWOG 8949, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.	rflanig@luc.edu	Munshi, Nikhil/ABE-2338-2021		NCI NIH HHS [CA22433, CA63845, CA38926, CA42777, CA35090, CA27057, CA58882, CA58861, CA45450, CA46136, CA32102, CA45461, CA63850, CA74647, CA46113, CA76132, CA37981, CA35431, CA46441, CA45560, CA20319, CA16385, CA14028, CA13612, CA35281, CA35261, CA35192, CA35176, CA58686, CA12644, CA04920, CA35128, CA76447, CA76448, CA76462, CA04919, CA52654, CA35119, CA58416, CA46282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA035090, U10CA045461, U10CA058686, U10CA058882, U10CA058861, U10CA035261, U10CA046136, U10CA045560, U10CA045450, U10CA020319, U10CA035431, U10CA013612, U10CA046441, U10CA035119, U10CA046282, U10CA035192, U10CA016385, U10CA012644, U10CA014028, U10CA058416, U10CA038926, U10CA052654, U10CA037981, U10CA063850, U10CA027057, U10CA004919, U10CA046113, U10CA032102, U10CA076447, U10CA035176, U10CA042777, U10CA004920, U10CA022433, U10CA063845, U10CA035128, U10CA035281, U10CA074647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cox D. R., 1984, ANAL SURVIVAL DATA; DEKERNION JB, 1983, J UROLOGY, V130, P2, DOI 10.1016/S0022-5347(17)50926-X; Figlin RA, 1999, J CLIN ONCOL, V17, P2521, DOI 10.1200/JCO.1999.17.8.2521; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; Flanigan R C, 1996, Semin Urol Oncol, V14, P227; FLANIGAN RC, 1987, UROL CLIN N AM, V14, P757; FLANIGAN RC, 1997, UROL ANN, V11, P95; FOWLER JE, 1986, J UROLOGY, V135, P22, DOI 10.1016/S0022-5347(17)45502-9; Franklin J R, 1996, Semin Urol Oncol, V14, P230; Fujikawa K, 2000, J UROLOGY, V164, P673, DOI 10.1016/S0022-5347(05)67278-3; FUSELIER HA, 1983, J UROLOGY, V130, P445, DOI 10.1016/S0022-5347(17)51243-4; GARFIELD DH, 1972, CANCER, V30, P190, DOI 10.1002/1097-0142(197207)30:1<190::AID-CNCR2820300127>3.0.CO;2-H; GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177; JOHNSON DE, 1975, J UROLOGY, V114, P27, DOI 10.1016/S0022-5347(17)66934-9; KROWN SE, 1987, CANCER, V59, P647, DOI 10.1002/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#; MANI S, 1995, J UROLOGY, V154, P35, DOI 10.1016/S0022-5347(01)67218-5; MARSHALL ME, 1992, P AN M AM SOC CLIN, V11, P206; MIDDLETON RG, 1967, J UROLOGY, V97, P973, DOI 10.1016/S0022-5347(17)63157-4; MUSS HB, 1987, J CLIN ONCOL, V5, P286, DOI 10.1200/JCO.1987.5.2.286; NEIDHART JA, 1980, CANCER, V46, P1128, DOI 10.1002/1097-0142(19800901)46:5<1128::AID-CNCR2820460509>3.0.CO;2-3; NISHIYAMA K, 1993, CANCER, V71, P3611, DOI 10.1002/1097-0142(19930601)71:11<3611::AID-CNCR2820711124>3.0.CO;2-T; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROBERTSON CN, 1990, J UROLOGY, V144, P614, DOI 10.1016/S0022-5347(17)39537-X; Tanguay S, 1996, J UROLOGY, V156, P1586, DOI 10.1016/S0022-5347(01)65454-5; TYKKA H, 1981, SCAND J UROL NEPHROL, P1; Walther MM, 1997, J UROLOGY, V158, P1675, DOI 10.1016/S0022-5347(01)64091-6; YAGODA A, 1993, UROL CLIN N AM, V20, P303	27	1247	1287	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1655	1659		10.1056/NEJMoa003013	http://dx.doi.org/10.1056/NEJMoa003013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759643				2022-12-28	WOS:000172517200001
J	Weber, KT				Weber, KT			Mechanisms of disease - Aldosterone in congestive heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXTRACELLULAR-MATRIX TURNOVER; COLLAGEN TYPE-I; ANGIOTENSIN-II; MYOCARDIAL FIBROSIS; ENDOTHELIAL-CELLS; CARDIAC PATIENT; SODIUM; RAT; SERUM; SPIRONOLACTONE		Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Cardiovasc Dis, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Weber, KT (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Cardiovasc Dis, Rm 353 Dobbs Res Inst,951 Court Ave, Memphis, TN 38163 USA.							ANDERSON WA, 1967, AM J ANAT, V121, P217, DOI 10.1002/aja.1001210204; Anker SD, 1997, CIRCULATION, V96, P526; AUGUST JT, 1958, J CLIN INVEST, V37, P1549, DOI 10.1172/JCI103747; BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; Campbell S E, 1992, Blood Press, V1, P149, DOI 10.3109/08037059209077510; CODY RJ, 1988, KIDNEY INT, V34, P361, DOI 10.1038/ki.1988.189; CODY RJ, 1986, J CLIN INVEST, V77, P1441, DOI 10.1172/JCI112456; COHEN EL, 1967, J CLIN INVEST, V46, P418, DOI 10.1172/JCI105543; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COPPAGE WS, 1962, J CLIN INVEST, V41, P1672, DOI 10.1172/JCI104624; COPPAGE WS, 1960, ANN NY ACAD SCI, V88, P815, DOI 10.1111/j.1749-6632.1960.tb20074.x; DAVIS JAMES O., 1965, HANDBOOK PHYSIOL, V3, P2071; DICKER SE, 1973, J PHYSIOL-LONDON, V228, P193, DOI 10.1113/jphysiol.1973.sp010081; Diez J, 1996, CIRCULATION, V93, P1026, DOI 10.1161/01.CIR.93.5.1026; DIEZ J, 1995, CIRCULATION, V91, P1450, DOI 10.1161/01.CIR.91.5.1450; Dzau VJ, 1998, EUR HEART J, V19, pJ2; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Farquharson CAJ, 2000, CIRCULATION, V101, P594, DOI 10.1161/01.CIR.101.6.594; Futcher PH, 1942, AM J MED SCI, V204, P52, DOI 10.1097/00000441-194207000-00008; Greene EL, 1996, J CLIN INVEST, V98, P1063, DOI 10.1172/JCI118867; HALL CE, 1965, LAB INVEST, V14, P285; HARRIS P, 1983, CARDIOVASC RES, V17, P437, DOI 10.1093/cvr/17.8.437; HARRIS P, 1983, CARDIOVASC RES, V17, P373, DOI 10.1093/cvr/17.7.373; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; HORISBERGER JD, 1992, HYPERTENSION, V19, P221, DOI 10.1161/01.HYP.19.3.221; KAGAWA CM, 1957, SCIENCE, V126, P1015, DOI 10.1126/science.126.3281.1015; KAISSLING B, 1982, CELL TISSUE RES, V224, P469, DOI 10.1007/BF00213746; KLAPPACHER G, 1995, AM J CARDIOL, V75, P913, DOI 10.1016/S0002-9149(99)80686-9; LARAGH JH, 1962, CIRCULATION, V25, P1015, DOI 10.1161/01.CIR.25.6.1015; Laviades C, 1998, CIRCULATION, V98, P535, DOI 10.1161/01.CIR.98.6.535; LIDDLE GW, 1958, ARCH INTERN MED, V102, P998, DOI 10.1001/archinte.1958.00260230144018; Liddle GW, 1978, ALDOSTERONE ANTAGONI, P91; LUETSCHER JA, 1954, J CLIN INVEST, V33, P1441, DOI 10.1172/JCI103022; MacFadyen RJ, 1997, CARDIOVASC RES, V35, P30, DOI 10.1016/S0008-6363(97)00091-6; MERRILL AJ, 1946, J CLIN INVEST, V25, P389, DOI 10.1172/JCI101720; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Nishimura H, 1980, Adv Exp Med Biol, V130, P29; Okubo S, 1997, J CLIN INVEST, V99, P855, DOI 10.1172/JCI119249; ONEIL RG, 1985, J MEMBRANE BIOL, V85, P169, DOI 10.1007/BF01871269; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Querejeta R, 2000, CIRCULATION, V101, P1729; ROBERT V, 1994, HYPERTENSION, V24, P30, DOI 10.1161/01.HYP.24.1.30; Rocha R, 1998, HYPERTENSION, V31, P451, DOI 10.1161/01.HYP.31.1.451; ROSSIER BC, 1987, TRENDS BIOCHEM SCI, V12, P483, DOI 10.1016/0968-0004(87)90235-0; ROVNER DR, 1965, J CLIN ENDOCR METAB, V25, P53, DOI 10.1210/jcem-25-1-53; Schwartzkopff B, 1998, CARDIOVASC RES, V40, P4, DOI 10.1016/S0008-6363(98)00174-6; SEALEY JE, 1995, HYPERTENSION PATHOPH, V2, P1763; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; Seymour WB, 1942, J CLIN INVEST, V21, P229, DOI 10.1172/JCI101294; SILVA P, 1977, KIDNEY INT, V11, P466, DOI 10.1038/ki.1977.64; Silvestre JS, 1999, CIRCULATION, V99, P2694, DOI 10.1161/01.CIR.99.20.2694; Silvestre JS, 1998, J BIOL CHEM, V273, P4883, DOI 10.1074/jbc.273.9.4883; Slight SH, 1999, J MOL CELL CARDIOL, V31, P1175, DOI 10.1006/jmcc.1999.0963; Smith HW, 1964, CIRCULATION BLOOD ME, P545; SPACH MS, 1995, CARDIOVASC RES, V30, P337, DOI 10.1016/0008-6363(96)88514-2; STANTON BA, 1981, KIDNEY INT, V19, P36, DOI 10.1038/ki.1981.5; STEAD EA, 1949, AM J MED, V6, P232, DOI 10.1016/0002-9343(49)90018-2; Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1; Sun Y, 1997, CARDIOVASC RES, V35, P138, DOI 10.1016/S0008-6363(97)00097-7; Sun Y, 2000, HYPERTENSION, V35, P1078, DOI 10.1161/01.HYP.35.5.1078; Sutton MS, 1997, CIRCULATION, V96, P3294; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAIT JF, 1965, J CLIN ENDOCR METAB, V25, P219, DOI 10.1210/jcem-25-2-219; Tait SAS, 1998, STEROIDS, V63, P440, DOI 10.1016/S0039-128X(98)00050-6; Takeda Y, 1996, J CLIN ENDOCR METAB, V81, P2797, DOI 10.1210/jc.81.8.2797; TAKEDA Y, 1995, HYPERTENSION, V25, P170, DOI 10.1161/01.HYP.25.2.170; TOBIAN LOUIS, 1960, PHYSIOL REVS, V40, P280; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; VILLARREAL D, 1995, CARDIOVASC RES, V30, P27, DOI 10.1016/S0008-6363(95)90141-8; WADE JB, 1990, AM J PHYSIOL, V259, pF88, DOI 10.1152/ajprenal.1990.259.1.F88; Warren JV, 1944, ARCH INTERN MED, V73, P0138, DOI 10.1001/archinte.1944.00210140028004; WEBER KT, 1993, AM J CARDIOL, V71, pA3, DOI 10.1016/0002-9149(93)90238-8; WEBER KT, 1994, NEWS PHYSIOL SCI, V9, P123; Weber KT, 1999, REGUL PEPTIDES, V82, P1, DOI 10.1016/S0167-0115(99)00032-4; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Weber KT, 1997, CIRCULATION, V96, P4065; WEBER KT, 1993, CARDIOVASC RES, V27, P341, DOI 10.1093/cvr/27.3.341; Weber KT, 1999, INT J BIOCHEM CELL B, V31, P395, DOI 10.1016/S1357-2725(98)00125-3; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S., 1992, NEW ENGL J MED, V327, P685, DOI [DOI 10.1056/NEJM199209033271003, 10.1056/NEJM199209033271003.Erratumin]; Zannad F, 2000, CIRCULATION, V102, P2700, DOI 10.1161/01.CIR.102.22.2700; Zannad F, 2001, CIRCULATION, V103, P476; ZUCKER IH, 1995, PROG CARDIOVASC DIS, V37, P397, DOI 10.1016/S0033-0620(05)80020-9	86	528	557	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1689	1697		10.1056/NEJMra000050	http://dx.doi.org/10.1056/NEJMra000050			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759649				2022-12-28	WOS:000172517200008
J	Cornely, OA; Schirmacher, P				Cornely, OA; Schirmacher, P			Clinical picture: Bacterial translocation in neutropenic sepsis	LANCET			English	Editorial Material									Univ Cologne, Dept Hematol Oncol & Infect Dis, D-50931 Cologne, Germany; Univ Cologne, Dept Pathol, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Cornely, OA (corresponding author), Univ Cologne, Dept Hematol Oncol & Infect Dis, D-50931 Cologne, Germany.		Cornely, Oliver A./J-5095-2013	Cornely, Oliver A./0000-0001-9599-3137					0	16	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1842	1842		10.1016/S0140-6736(01)06884-2	http://dx.doi.org/10.1016/S0140-6736(01)06884-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741622	Bronze			2022-12-28	WOS:000172463000008
J	Goodlad, RA; Englyst, HN				Goodlad, RA; Englyst, HN			Redefining dietary fibre: potentially a recipe for disaster	LANCET			English	Editorial Material							RECURRENCE		Imperial Canc Res Fund, Histopathol Unit, London WC2A 3PX, England	Cancer Research UK	Goodlad, RA (corresponding author), Imperial Canc Res Fund, Histopathol Unit, 35-43 Lincolns Inn Fields, London WC2A 3PX, England.	goodlad@icrf.icnet.uk		Goodlad, Robert/0000-0002-7660-4287				Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; [Anonymous], 1998, FAO Food Nutr Pap, V66, P1; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Englyst HN, 1996, FOOD CHEM, V57, P15, DOI 10.1016/0308-8146(96)00056-8; Goodlad RA, 2001, GUT, V48, P587, DOI 10.1136/gut.48.5.587; McCullough JS, 1998, GUT, V42, P799, DOI 10.1136/gut.42.6.799; Michels KB, 2000, JNCI-J NATL CANCER I, V92, P1740, DOI 10.1093/jnci/92.21.1740; *PAN DEF DIET FIB, 2001, PROP DEF DIET FIB; PELL JD, 1995, GASTROENTEROLOGY, V108, P1745, DOI 10.1016/0016-5085(95)90136-1; SOUTHGATE DAT, 1985, DIETARY FIBRE FIBRE, P31; TROWELL H, 1985, DIETARY FIBRE FIBRE, P1; Wasan HS, 1996, LANCET, V348, P319, DOI 10.1016/S0140-6736(96)01401-8; Wasan HS, 1998, J PATHOL, V185, P246; Williamson SLH, 1999, CARCINOGENESIS, V20, P805, DOI 10.1093/carcin/20.5.805	14	24	27	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 1	2001	358	9296					1833	1834		10.1016/S0140-6736(01)06882-9	http://dx.doi.org/10.1016/S0140-6736(01)06882-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741620				2022-12-28	WOS:000172463000006
J	Lewin, S; Meyer, IH				Lewin, S; Meyer, IH			Torture, ill-treatment, and sexual identity	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; Columbia Univ, Mailman Sch Publ Hlth, Div Sociomed Sci, New York, NY USA	University of London; London School of Hygiene & Tropical Medicine; Columbia University	Lewin, S (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.		Meyer, Ilan H/A-2142-2009					ALTMAN D, 1997, HLTH HUMAN RIGHTS, V2, P15; *AM PSYCH ASS, 2001, GAY LESB BIS ISS; *AMN INT, 2001, EGYPT REL CHILD IMPR; Amnesty International, 2001, CRIM HAT CONSP SIL T; Meyer IH, 2001, AM J PUBLIC HEALTH, V91, P856, DOI 10.2105/AJPH.91.6.856	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1899	1900		10.1016/S0140-6736(01)06894-5	http://dx.doi.org/10.1016/S0140-6736(01)06894-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	497NU	11741651				2022-12-28	WOS:000172463000035
J	Chao, W; Huynh, KD; Spencer, RJ; Davidow, LS; Lee, JT				Chao, W; Huynh, KD; Spencer, RJ; Davidow, LS; Lee, JT			CTCF, a candidate trans-acting factor for X-inactivation choice	SCIENCE			English	Article							ENHANCER-BLOCKING ACTIVITY; XIST EXPRESSION; CHROMOSOME; GENE; METHYLATION; MOUSE; TSIX; INSULATOR; REGION; PARENT	In mammals, X-inactivation silences one of two female X chromosomes. Silencing depends on the noncoding gene, Xist ((i) under bar nactive (X) under bar-(s) under bar pecific (t) under bar ranscript), and is blocked by the antisense gene, Tsix. Deleting the choice/imprinting center in Tsix affects X-chromosome selection. Here, we identify the insulator and transcription factor, CTCF, as a candidate trans-acting factor for X-chromosome selection. The choice/imprinting center contains tandem CTCF binding sites that function in an enhancer-blocking assay. In vitro binding is reduced by CpG methylation and abolished by including non-CpG methylation. We postulate that Tsix and CTCF together establish a regulatable epigenetic switch for X-inactivation.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Genet, Howard Hughes Med Inst,Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Lee, JT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Genet, Howard Hughes Med Inst,Dept Mol Biol, Boston, MA 02114 USA.			Chao, Wendy/0000-0002-9418-8723				Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; Debrand E, 1999, MOL CELL BIOL, V19, P8513; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Prissette M, 2001, HUM MOL GENET, V10, P31, DOI 10.1093/hmg/10.1.31; Sado T, 2001, DEVELOPMENT, V128, P1275; SHARMAN GB, 1971, NATURE, V230, P231, DOI 10.1038/230231a0; Stavropoulos N, 2001, P NATL ACAD SCI USA, V98, P10232, DOI 10.1073/pnas.171243598; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0	27	220	239	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					345	347		10.1126/science.1065982	http://dx.doi.org/10.1126/science.1065982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511RD	11743158				2022-12-28	WOS:000173278600055
J	Silverman, WA; Chalmers, I				Silverman, WA; Chalmers, I			Casting and drawing lots: a time honoured way of dealing with uncertainty and ensuring fairness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZATION; CARE		UK Cochrane Ctr, Oxford OX2 7LG, England	Cochrane Centre	Chalmers, I (corresponding author), UK Cochrane Ctr, Oxford OX2 7LG, England.	ichalmers@cochrane.co.uk						Chalmers I, 2001, INT J EPIDEMIOL, V30, P1156, DOI 10.1093/ije/30.5.1156; CHALMERS I, 1983, BIRTH-ISS PERINAT C, V10, P151; FIENBERG SE, 1971, SCIENCE, V171, P255, DOI 10.1126/science.171.3968.255; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; MACATASNEY G, 1998, LEITRIM CROPPIES 177, P19; SILVERMAN WA, 1981, CONTROL CLIN TRIALS, V2, P161, DOI 10.1016/0197-2456(81)90006-4; SILVERMAN WA, 2001, CONTROLLED TRIALS HI; THEOBALD G. W., 1937, Lancet, P1397; Toroyan T, 2000, J MED ETHICS, V26, P319, DOI 10.1136/jme.26.5.319; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; Van Helmont J. A., 1662, ORIATRIKE PHYSICK RE, P526	11	15	15	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2001	323	7327					1467	1468		10.1136/bmj.323.7327.1467	http://dx.doi.org/10.1136/bmj.323.7327.1467			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506PA	11751358	Green Published			2022-12-28	WOS:000172979900018
J	Bateman, DN; Clark, R; Azuara-Blanco, A; Bain, M; Forrest, J				Bateman, DN; Clark, R; Azuara-Blanco, A; Bain, M; Forrest, J			The impact of new drugs on management of glaucoma in Scotland: observational study	BRITISH MEDICAL JOURNAL			English	Article							OPEN-ANGLE GLAUCOMA		Royal Edinburgh & Associated Hosp, Scottish Poisons Informat Bur, Natl Poisons Informat Serv Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland; Common Serv Agcy NHS, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland; Aberdeen Royal Infirm, Dept Ophthalmol, Aberdeen AB25 2ZN, Scotland	Royal Infirmary of Edinburgh; University of Aberdeen	Bateman, DN (corresponding author), Royal Edinburgh & Associated Hosp, Scottish Poisons Informat Bur, Natl Poisons Informat Serv Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland.			Bateman, David Nicholas/0000-0002-8971-862X; Azuara-Blanco, Augusto/0000-0002-4805-9322				Evans J., 1996, HEALTH TRENDS, V28, P5; Harley K, 1996, Health Bull (Edinb), V54, P410; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; MIGDAL C, 1994, OPHTHALMOLOGY, V101, P1651; Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83	5	37	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2001	323	7326					1401	1402		10.1136/bmj.323.7326.1401	http://dx.doi.org/10.1136/bmj.323.7326.1401			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505EX	11744564	Bronze, Green Published			2022-12-28	WOS:000172900400017
J	Ganem, D				Ganem, D			Virology - The X files - One step closer to closure	SCIENCE			English	Editorial Material							VIRUS HBX PROTEIN; KINASES; SPECIFICITY; CREB; RAS		Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ganem, D (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA.							BOUCHARD M, 1908, SCIENCE, V294, P2376; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; GANEM D, 2001, FIELDS VIROLOGY, P2923; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	9	16	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2299	2300		10.1126/science.1067850	http://dx.doi.org/10.1126/science.1067850			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743185				2022-12-28	WOS:000172817200029
J	Oh, J; Takahashi, R; Kondo, S; Mizoguchi, A; Adachi, E; Sasahara, RM; Nishimura, S; Imamura, Y; Kitayama, H; Alexander, DB; Ide, C; Horan, TP; Arakawa, T; Yoshida, H; Nishikawa, SI; Itoh, Y; Seiki, M; Itohara, S; Takahashi, C; Noda, M				Oh, J; Takahashi, R; Kondo, S; Mizoguchi, A; Adachi, E; Sasahara, RM; Nishimura, S; Imamura, Y; Kitayama, H; Alexander, DB; Ide, C; Horan, TP; Arakawa, T; Yoshida, H; Nishikawa, SI; Itoh, Y; Seiki, M; Itohara, S; Takahashi, C; Noda, M			The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis	CELL			English	Article							BLOOD-VESSEL FORMATION; TISSUE INHIBITOR; SUPPRESSOR GENE; MESSENGER-RNA; IN-VIVO; METALLOPROTEINASES; RAS; ACTIVATION; EXPRESSION; CELLS	Matrix metalloproteinases (MMPs) are essential for proper extracellular matrix remodeling. We previously found that a membrane-anchored glycoprotein, RECK, negatively regulates MMP-9 and inhibits tumor invasion and metastasis. Here we show that RECK regulates two other MMPs, MMP-2 and MT1-MMP, known to be involved in cancer progression, that mice lacking a functional RECK gene die around E10.5 with defects in collagen fibrils, the basal lamina, and vascular development, and that this phenotype is partially suppressed by MMP-2 null mutation. Also, vascular sprouting is dramatically suppressed in tumors derived from RECK,expressing fibrosarcoma cells grown in nude mice. These results support a role for RECK in the regulation of MMP-2 in vivo and implicate RECK downregulation in tumor angiogenesis.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068501, Japan; Kitasato Univ, Grad Sch Med Sci, Dept Mol Morphol, Kanagawa 2288555, Japan; RIKEN, Brain Res Inst, Wako, Saitama 3510198, Japan; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA; Univ Tokyo, Inst Med Sci, Dept Canc Res, Tokyo 1080071, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kitasato University; RIKEN; Amgen; University of Tokyo	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.		Seiki, Motoharu/K-9443-2015; Itohara, Shigeyoshi/I-8769-2012	Itohara, Shigeyoshi/0000-0002-2410-9989; Oh, Junseo/0000-0002-0754-4946; Itoh, Yoshifumi/0000-0002-2128-2823				BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DAVIES B, 1993, CANCER RES, V53, P5365; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; FAGAN JB, 1981, J BIOL CHEM, V256, P520; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; GARBISA S, 1987, CANCER RES, V47, P1523; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; HOWARD BH, 1978, J BIOL CHEM, V253, P5869; Ikeda M, 2000, CLIN CANCER RES, V6, P3290; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LOHLER J, 1984, CELL, V38, P597, DOI 10.1016/0092-8674(84)90514-2; Matsuo S, 1999, PATHOL INT, V49, P383, DOI 10.1046/j.1440-1827.1999.00887.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Nothnick WB, 1997, BIOL REPROD, V56, P1181, DOI 10.1095/biolreprod56.5.1181; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REPONEN P, 1992, J BIOL CHEM, V267, P7856; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Takahashi C, 1996, ONCOGENE, V12, P2137; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yamamoto M, 1996, CANCER RES, V56, P384; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	48	538	580	1	33	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 14	2001	107	6					789	800		10.1016/S0092-8674(01)00597-9	http://dx.doi.org/10.1016/S0092-8674(01)00597-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747814	Bronze, Green Submitted			2022-12-28	WOS:000172771800011
J	Smith, O				Smith, O			Biomedicine - In the nic of time	SCIENCE			English	Editorial Material																		Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; HU Y, 2001, DEV CELL        1130; LOPEZSCHIER H, 2001, DEV CELL        1130	3	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 7	2001	294	5549					2118	2118		10.1126/science.294.5549.2118	http://dx.doi.org/10.1126/science.294.5549.2118			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	500VQ	11739946				2022-12-28	WOS:000172647700038
J	Kumar, S; Sarr, MG; Kamath, PS				Kumar, S; Sarr, MG; Kamath, PS			Current concepts - Mesenteric venous thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VEIN-THROMBOSIS; DIAGNOSIS; CT		Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kamath, PS (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	kamath.patrick@mayo.edu	Gloviczki, Peter/H-4149-2019; Kumar, Shaji K/A-9853-2008	Kumar, Shaji K/0000-0001-5392-9284				ABDU RA, 1987, SURGERY, V101, P383; ALKARAWI MA, 1990, HEPATO-GASTROENTEROL, V37, P507; BOLEY SJ, 1992, SURG CLIN N AM, V72, P183; CLARK RA, 1984, AM J ROENTGENOL, V142, P555, DOI 10.2214/ajr.142.3.555; Condat B, 2001, GASTROENTEROLOGY, V120, P490, DOI 10.1053/gast.2001.21209; D'Cruz A J, 1995, Acta Paediatr Jpn, V37, P17; Elliot J W, 1895, Ann Surg, V21, P9, DOI 10.1097/00000658-189521060-00002; GRENDELL JH, 1982, GASTROENTEROLOGY, V82, P358; HADDAD MC, 1992, GASTROINTEST RADIOL, V17, P34, DOI 10.1007/BF01888505; HARWARD TRS, 1989, J VASC SURG, V9, P328, DOI 10.1067/mva.1989.vs0090328; INAHARA T, 1971, ANN SURG, V174, P956, DOI 10.1097/00000658-197112000-00012; JONA J, 1974, JAMA-J AM MED ASSOC, V227, P1033, DOI 10.1001/jama.227.9.1033; KALEYA RN, 1989, PROGR GASTROINTESTIN, P417; KHODADADI J, 1980, ARCH SURG-CHICAGO, V115, P315; KIDAMBI H, 1986, J CLIN ULTRASOUND, V14, P199, DOI 10.1002/jcu.1870140308; LEVY PJ, 1990, SURG GYNECOL OBSTET, V170, P287; MATHEWS JE, 1971, AM J SURG, V122, P579, DOI 10.1016/0002-9610(71)90282-0; NAITOVE A, 1965, ANN SURG, V161, P516, DOI 10.1097/00000658-196504000-00005; Norton ID, 1998, HEPATOLOGY, V28, P1154, DOI 10.1002/hep.510280434; RHEE RY, 1994, J VASC SURG, V20, P688, DOI 10.1016/S0741-5214(94)70155-5; ROBIN P, 1988, LANCET, V1, P1391; TOMCHIK FS, 1970, RADIOLOGY, V96, P249, DOI 10.1148/96.2.249; VOGELZANG RL, 1988, AM J ROENTGENOL, V150, P93, DOI 10.2214/ajr.150.1.93; Warren S, 1935, SURG GYNECOL OBSTET, V61, P102; WIERSEMA MJ, 1995, GASTROINTEST ENDOSC, V42, P19, DOI 10.1016/S0016-5107(95)70237-7	25	342	388	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2001	345	23					1683	1688		10.1056/NEJMra010076	http://dx.doi.org/10.1056/NEJMra010076			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	498NH	11759648				2022-12-28	WOS:000172517200007
J	DiClemente, RJ				DiClemente, RJ			Development of programmes for enhancing sexual health	LANCET			English	Editorial Material							CHLAMYDIA-TRACHOMATIS; TRANSMITTED INFECTIONS; ADOLESCENTS; WOMEN		Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat & Med, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health; Emory University	DiClemente, RJ (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.							DICLEMENTE RJ, 1993, JAMA-J AM MED ASSOC, V270, P760, DOI 10.1001/jama.270.6.760; DICLEMENTE RJ, 1994, CLIN PEDIATR, V32, P235; Fortenberry JD, 1999, SEX TRANSM DIS, V26, P26, DOI 10.1097/00007435-199901000-00005; HILLIS SD, 1994, AM J OBSTET GYNECOL, V170, P801, DOI 10.1016/S0002-9378(94)70286-1; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; KIRBY D, 1995, PREVENTING AIDS THEO, P117; Orr DP, 1998, JAMA-J AM MED ASSOC, V280, P564, DOI 10.1001/jama.280.6.564; Peterson JL, 2000, HDB HIV PREVENTION; Richey CM, 1999, SEX TRANSM DIS, V26, P4, DOI 10.1097/00007435-199901000-00002	9	19	19	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1828	1829		10.1016/S0140-6736(01)06878-7	http://dx.doi.org/10.1016/S0140-6736(01)06878-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741616				2022-12-28	WOS:000172463000002
J	Schwartz, RS; Curfman, GD				Schwartz, RS; Curfman, GD			Perspective: Can the heart repair itself?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	22	25	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2002	346	1					2	4		10.1056/NEJM200201033460102	http://dx.doi.org/10.1056/NEJM200201033460102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507NB	11777996				2022-12-28	WOS:000173033600001
J	Chambers, R; Boath, E; Chambers, S				Chambers, R; Boath, E; Chambers, S			The A to Z of authorship: analysis of influence of initial letter of surname on order of authorship	BRITISH MEDICAL JOURNAL			English	Article									Staffordshire Univ, Sch Hlth, Ctr Hlth Policy & Practice, Stafford ST18 0AD, England; Newcastle Under Lyme Sch, Newcastle Under Lyme ST5 1DB, England	Staffordshire University	Chambers, R (corresponding author), Staffordshire Univ, Sch Hlth, Ctr Hlth Policy & Practice, Stafford ST18 0AD, England.			Boath, Elizabeth/0000-0001-6126-362X				ADLER L, 2001, WEEK            0818, P32; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696; 2001, BMJ              AUG; 2001, LANCET           AUG	4	13	15	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2001	323	7327					1460	1461		10.1136/bmj.323.7327.1460	http://dx.doi.org/10.1136/bmj.323.7327.1460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	506PA	11751354	Green Published			2022-12-28	WOS:000172979900014
J	Yokoya, T; Kiss, T; Chainani, A; Shin, S; Nohara, M; Takagi, H				Yokoya, T; Kiss, T; Chainani, A; Shin, S; Nohara, M; Takagi, H			Fermi surface sheet-dependent superconductivity in 2H-NbSe2	SCIENCE			English	Article							DENSITY-WAVE MECHANISM; GAP ANISOTROPY; PHOTOEMISSION-SPECTROSCOPY; ENERGY	High-resolution angle-resolved photoemission spectroscopy was used to study the superconducting energy gap and changes in the spectra[ function across the superconducting transition in the quasi-two-dimensional superconductor 2H-NbSe2. The momentum dependence of the superconducting gap was determined on different Fermi surface sheets. The results indicate Fermi surface sheet-dependent superconductivity in this Low-transition temperature multiband system and provide a description consistent with thermodynamic measurements and the anomalous de Haas-van Alphen oscillations observed in the superconducting phase. The present data suggest the importance of Fermi surface sheet-dependent superconductivity in explaining exotic superconductivity in other multiband systems with complex Fermi surface topology, such as the borides and f-electron superconductors.	Univ Tokyo, Inst Solid State Phys, Chiba 2778581, Japan; Inst Plasma Res, Bhat 382428, Gandhinagar, India; Univ Tokyo, Dept Adv Mat Sci, Tokyo 1130033, Japan	University of Tokyo; Institute for Plasma Research (IPR); University of Tokyo	Yokoya, T (corresponding author), Univ Tokyo, Inst Solid State Phys, Chiba 2778581, Japan.	yokoya@issp.u-tokyo.ac.jp	SHIN, SHIK/ABH-1500-2020; Chainani, Ashish/B-3071-2011; Takagi, Hidenori/B-2935-2010; YOKOYA, Takayoshi/B-1478-2011; Chainani, Ashish/ABH-8078-2020; TAKAGI, HIDENORI/Q-1041-2019; NOHARA, Minoru/B-1476-2011	Chainani, Ashish/0000-0002-5639-5393; TAKAGI, HIDENORI/0000-0001-5700-3761; NOHARA, Minoru/0000-0003-1931-9903				Anderson P. W., 1997, THEORY SUPERCONDUCTI; BINNIG G, 1980, PHYS REV LETT, V45, P1352, DOI 10.1103/PhysRevLett.45.1352; CLAYMAN BP, 1971, SOLID STATE COMMUN, V9, P1881, DOI 10.1016/0038-1098(71)90574-6; CORCORAN R, 1994, J PHYS-CONDENS MAT, V6, P4479, DOI 10.1088/0953-8984/6/24/010; Ding H, 1996, PHYS REV B, V54, pR9678, DOI 10.1103/PhysRevB.54.R9678; GRAEBNER JE, 1976, PHYS REV LETT, V36, P422, DOI 10.1103/PhysRevLett.36.422; HESS HF, 1991, PHYSICA B, V169, P422, DOI 10.1016/0921-4526(91)90262-D; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Nohara M, 1999, J PHYS SOC JPN, V68, P1078, DOI 10.1143/JPSJ.68.1078; Norman MR, 1998, PHYS REV B, V57, pR11093, DOI 10.1103/PhysRevB.57.R11093; SAULS JA, 1994, ADV PHYS, V43, P113, DOI 10.1080/00018739400101475; Schrieffer J. R., 1983, THEORY SUPERCONDUCTI; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; SOORYAKUMAR R, 1980, PHYS REV LETT, V45, P660, DOI 10.1103/PhysRevLett.45.660; Straub T, 1999, PHYS REV LETT, V82, P4504, DOI 10.1103/PhysRevLett.82.4504; Tonjes WC, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.235101; Valla T, 2000, PHYS REV LETT, V85, P4759, DOI 10.1103/PhysRevLett.85.4759; Valla T, 1999, SCIENCE, V285, P2110, DOI 10.1126/science.285.5436.2110; Yokoya T, 2000, PHYS REV LETT, V85, P4952, DOI 10.1103/PhysRevLett.85.4952	19	299	301	10	203	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2518	2520		10.1126/science.1065068	http://dx.doi.org/10.1126/science.1065068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11752570				2022-12-28	WOS:000172927700049
J	Wells, J; Marshall, P; Crawley, B; Dickersin, K				Wells, J; Marshall, P; Crawley, B; Dickersin, K			Newspaper reporting of screening mammography	ANNALS OF INTERNAL MEDICINE			English	Article							MASS-MEDIA; NEWS MEDIA; COVERAGE; MEDICINE; QUALITY; CANCER; ASSOCIATION; GUIDELINES; ACCURACY; BENEFITS	Background: Continuing controversy surrounds screening mammography, particularly for women 40 to 49 years of age. Newspapers are potentially important sources of information on this topic, but it is not known whether they provide well-founded and objective information and recommendations. Objective: To examine how screening mammography is reported in newspapers. Design: Cross-sectional descriptive study. Setting: 6 top-circulation U.S. newspapers, 1990 to 1997 Measurements: Number of articles about screening mammography, issues covered by the articles, information sources, content and sources of quotes, recommendations cited in articles, and presentation of risks and benefits. Results: The most common theme of newspaper articles about mammography was screening for women 40 to 49 years of age. Thirty-one percent of the articles presented information without citing a source or justification. Quotes and recommendations in the articles were approximately twice as likely to support as to express reservations about mammography for women aged 40 to 49 years. Recommendations changed little over time and rarely reflected changes in recommendations of national organizations. Of the 102 articles describing the benefits of mammography, 95% expressed them in relative terms and 11% expressed them in absolute terms. Conclusions: Newspapers tended to overrepresent support for screening mammography for women aged 40 to 49 years. Reports would have been improved by identification of all sources for information cited, less reliance on relatively few sources, and discussion of benefits in absolute as well as relative terms. Medical journalism may benefit from identification of standards similar to those used for reporting medical research.	Univ Maryland, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Wells, J (corresponding author), Univ Oxford, Dept Publ Hlth & Primary Care, Hlth Serv Res Unit, Inst Hlth Sci, Old Rd, Oxford OX3 7LF, England.	jane.wells@berks-ha.nhs.uk	Dickersin, Kay/A-4576-2008					BORMAN SC, 1978, JOURNALISM QUART, V55, P345, DOI 10.1177/107769907805500220; Brown J, 1996, SOC SCI MED, V43, P1685, DOI 10.1016/0277-9536(95)00402-5; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; CAUDILL E, 1989, JOURNALISM QUART, V66, P458, DOI 10.1177/107769908906600228; DODD GD, 1993, CANCER, V72, P1429, DOI 10.1002/1097-0142(19930815)72:4+<1429::AID-CNCR2820721403>3.0.CO;2-N; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FREIMUTH VS, 1983, J COMMUN, V34, P62; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P625, DOI 10.5694/j.1326-5377.1995.tb126047.x; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; Hansen A., 1994, PUBLIC UNDERST SCI, V3, P111, DOI DOI 10.1088/0963-6625/3/2/001; HOUN F, 1995, AM J PUBLIC HEALTH, V85, P1082, DOI 10.2105/AJPH.85.8_Pt_1.1082; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Johnson T, 1998, NEW ENGL J MED, V339, P87, DOI 10.1056/NEJM199807093390206; JORDAN DL, 1993, PUBLIC OPIN QUART, V57, P191, DOI 10.1086/269365; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; Krippendorf K., 1980, CONTENT ANAL; Long M., 1995, PUBLIC UNDERST SCI, V4, P119, DOI DOI 10.1088/0963-6625/4/2/002; MCCOMBS ME, 1972, PUBLIC OPIN QUART, V36, P176, DOI 10.1086/267990; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Molitor F., 1993, HEALTH COMMUN, V5, P209, DOI DOI 10.1207/S15327027HC0503_4; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; NAPOLI M, 1997, NIH CONS DEV C BREAS, P27; Nelkin D, 1996, LANCET, V347, P1600, DOI 10.1016/S0140-6736(96)91081-8; Nelkin D, 1995, SELLING SCI PRESS CO; *NIH, 1978, JNCI-J NATL CANCER I, V60, P1519; *NIH CONS STAT, 1997, 103 NIH; OTTEN AL, 1992, HEALTH AFFAIR, V11, P111, DOI 10.1377/hlthaff.11.4.111; OXMAN AD, 1993, J CLIN EPIDEMIOL, V46, P987, DOI 10.1016/0895-4356(93)90166-X; PHILLIPS DP, 1991, NEW ENGL J MED, V325, P1180, DOI 10.1056/NEJM199110173251620; Potosky AL, 1998, MED CARE, V36, P257, DOI 10.1097/00005650-199803000-00004; Shuchman M, 1997, ANN INTERN MED, V126, P976, DOI 10.7326/0003-4819-126-12-199706150-00008; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; Tabar L, 1996, INT J CANCER, V68, P693; TANKARD JW, 1974, JOURNALISM QUART, V51, P219, DOI 10.1177/107769907405100204; *US PREV SERV TASK, 1996, GUID CLIN SERV; Weber R. P., 1990, BASIC CONTENT ANAL, V2nd; Wells J, 1998, BRIT MED J, V317, P1224, DOI 10.1136/bmj.317.7167.1224; Winsten J A, 1985, Health Aff (Millwood), V4, P5, DOI 10.1377/hlthaff.4.1.5; WRIGHT WR, 1975, J COMMUN, V25, P171, DOI 10.1111/j.1460-2466.1975.tb00621.x; 1992, J GERONTOL, V47, P5; 1996, MMWR MORB MORTAL WKL, V45, P57	46	37	38	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2001	135	12					1029	1037		10.7326/0003-4819-135-12-200112180-00006	http://dx.doi.org/10.7326/0003-4819-135-12-200112180-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502TW	11747381				2022-12-28	WOS:000172759700002
J	Srinivasan, SR; Berenson, GS				Srinivasan, SR; Berenson, GS			Apolipoproteins B and A-I as predictors of risk of coronary artery disease	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; HEART-DISEASE; CHOLESTEROL		Tulane Univ, Tulane Ctr Cardiovasc Hlth, Hlth Sci Ctr, New Orleans, LA 70112 USA; Tulane Univ, Dept Epidemiol, Hlth Sci Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University	Berenson, GS (corresponding author), Tulane Univ, Tulane Ctr Cardiovasc Hlth, Hlth Sci Ctr, New Orleans, LA 70112 USA.							AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; FREEDMAN DS, 1986, NEW ENGL J MED, V315, P721, DOI 10.1056/NEJM198609183151202; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KRAUSS RM, 1988, ARTERIOSCLEROSIS, V8, P155, DOI 10.1161/01.ATV.8.2.155; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601	8	6	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2012	2013		10.1016/S0140-6736(01)07135-5	http://dx.doi.org/10.1016/S0140-6736(01)07135-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755602				2022-12-28	WOS:000172722800004
J	Huelsenbeck, JP; Ronquist, F; Nielsen, R; Bollback, JP				Huelsenbeck, JP; Ronquist, F; Nielsen, R; Bollback, JP			Evolution - Bayesian inference of phylogeny and its impact on evolutionary biology	SCIENCE			English	Review							MAXIMUM-LIKELIHOOD-ESTIMATION; AMINO-ACID SITES; MARKOV-CHAINS; SEQUENCES; GENE; SUBSTITUTION; MODELS; RATES; SELECTION; TREES	As a discipline, phylogenetics is becoming transformed by a flood of molecular data. These data allow broad questions to be asked about the history of life, but also present difficult statistical and computational problems. Bayesian inference of phyto logeny brings a new perspective to a number of outstanding issues in evolutionary biology, including the analysis of large phylogenetic trees and complex evolutionary models and the detection of the footprint of natural selection in DNA sequences.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Uppsala Univ, Evolutionary Biol Ctr, Dept Syst Zool, SE-75236 Uppsala, Sweden; Cornell Univ, Dept Biometr, Ithaca, NY 14853 USA	University of Rochester; Uppsala University; Cornell University	Huelsenbeck, JP (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.		Huelsenbeck, John P/C-6398-2013; Ronquist, Fredrik/Q-2013-2015; Nielsen, Rasmus/D-4405-2009	Ronquist, Fredrik/0000-0002-3929-251X; Nielsen, Rasmus/0000-0003-0513-6591				Atrian S, 1998, J MOL EVOL, V47, P211, DOI 10.1007/PL00006378; Beerli P, 1999, GENETICS, V152, P763; Brower AVZ, 2000, P ROY SOC B-BIOL SCI, V267, P1201, DOI 10.1098/rspb.2000.1129; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1968, THESIS U CHIGAGO; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; GELMAN A, 1995, BAYASIAN DATA ANAL; GEYER CJ, 1991, COMPUTING SCIENCE AND STATISTICS, P156; Gilks W. R., 1996, MARKOV CHAIN MONTE C; GOLDMAN N, 1993, J MOL EVOL, V36, P182, DOI 10.1007/BF00166252; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.1093/biomet/57.1.97; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huelsenbeck JP, 2000, SCIENCE, V288, P2349, DOI 10.1126/science.288.5475.2349; Jukes T.H., 1969, MAMMALIAN PROTEIN ME; KUHNER MK, 1995, GENETICS, V140, P1421; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Losos Jonathan B., 1994, P60; Mau B, 1999, BIOMETRICS, V55, P1, DOI 10.1111/j.0006-341X.1999.00001.x; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Nielsen R, 1998, GENETICS, V148, P929; Nielsen R, 2000, GENETICS, V154, P931; NIELSEN R, IN PRESS P PAC S BIO; Nielsen R. D., UNPUB; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Rannala B, 1996, J MOL EVOL, V43, P304, DOI 10.1007/PL00006090; Sanderson MJ, 2000, SYST BIOL, V49, P671, DOI 10.1080/106351500750049761; Savolainen V, 2000, SYST BIOL, V49, P306, DOI 10.1093/sysbio/49.2.306; Soltis DE, 2000, BOT J LINN SOC, V133, P381, DOI [10.1111/j.1095-8339.2000.tb01588.x, 10.1006/bojl.2000.0380]; Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P2509, DOI 10.1073/pnas.051605998; Swanson WJ, 2001, MOL BIOL EVOL, V18, P376, DOI 10.1093/oxfordjournals.molbev.a003813; Tavare S., 1986, LECT MATH LIFE SCI, V17, P57; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; TIERNEY L, 1994, ANN STAT, V22, P1701, DOI 10.1214/aos/1176325750; Yang ZH, 2000, GENETICS, V155, P431; YANG ZH, 1993, MOL BIOL EVOL, V10, P1396; Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7; Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548	40	2103	2187	5	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2310	2314		10.1126/science.1065889	http://dx.doi.org/10.1126/science.1065889			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743192	Green Submitted			2022-12-28	WOS:000172817200036
J	Wang, YJ; Cheng, H; Edwards, RL; An, ZS; Wu, JY; Shen, CC; Dorale, JA				Wang, YJ; Cheng, H; Edwards, RL; An, ZS; Wu, JY; Shen, CC; Dorale, JA			A high-resolution absolute-dated Late Pleistocene monsoon record from Hulu Cave, China	SCIENCE			English	Article							NORTH-ATLANTIC; GREENLAND ICE; CLIMATE; PALEOCLIMATE; INSTABILITY; HISTORY; EVENTS	Oxygen isotope records of five stalagmites from Hulu Cave near Nanjing bear a remarkable resemblance to oxygen isotope records from Greenland ice cores, suggesting that East Asian Monsoon intensity changed in concert with Greenland temperature between 11,000 and 75,000 years before the present (yr. B.P.). Between 11,000 and 30,000 yr. B.P., the timing of changes in the monsoon, as established with Th-230 dates, generally agrees with the timing of temperature changes from the Greenland Ice Sheet Project Two (GISP2) core, which supports GISP2's chronology in this interval. Our record links North Atlantic climate with the meridional transport of heat and moisture from the warmest part of the ocean where the summer East Asian Monsoon originates.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Nanjing Normal Univ, Coll Geog Sci, Nanjing 210097, Peoples R China; Chinese Acad Sci, Inst Earth Environm, State Key Lab Loess & Quaternary Geol, Xian 710054, Peoples R China; Nanjing Univ, State Key Lab Mineral Deposits Res, Nanjing 210008, Peoples R China; Natl Cheng Kung Univ, Dept Earth Sci, Tainan, Taiwan; Univ Missouri, Dept Geol Sci, Columbia, MO USA	University of Minnesota System; University of Minnesota Twin Cities; Nanjing Normal University; Chinese Academy of Sciences; Institute of Earth Environment, CAS; Nanjing University; National Cheng Kung University; University of Missouri System; University of Missouri Columbia	Edwards, RL (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.	edwar001@umn.edu	CHENG, HAI/H-3413-2017; Edwards, R. Lawrence/I-3124-2014; AN, Zhisheng/F-8834-2012; lin, ke/GZM-8300-2022; Shen, Chuan-Chou/H-9642-2013	CHENG, HAI/0000-0002-5305-9458; Edwards, R. Lawrence/0000-0002-7027-5881; Shen, Chuan-Chou/0000-0003-2833-2771				An ZS, 2000, QUATERNARY SCI REV, V19, P171, DOI 10.1016/S0277-3791(99)00060-8; Bar-Matthews M, 1999, EARTH PLANET SC LETT, V166, P85, DOI 10.1016/S0012-821X(98)00275-1; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BROECKER WS, 1994, NATURE, V372, P421, DOI 10.1038/372421a0; Clemens SC, 1996, SCIENCE, V274, P943, DOI 10.1126/science.274.5289.943; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Dorale JA, 1998, SCIENCE, V282, P1871, DOI 10.1126/science.282.5395.1871; DORALE JA, 2000, THESIS U MINNESOTA; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; FRIEDMAN I, 1977, 44055 US GEOL SURV, P33; HENDY CH, 1971, GEOCHIM COSMOCHIM AC, V35, P801, DOI 10.1016/0016-7037(71)90127-X; Hendy IL, 1999, GEOLOGY, V27, P291, DOI 10.1130/0091-7613(1999)027<0291:LQNPSW>2.3.CO;2; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Kienast M, 2001, SCIENCE, V291, P2132, DOI 10.1126/science.1057131; KUKLA G, 1988, GEOLOGY, V16, P811, DOI 10.1130/0091-7613(1988)016<0811:PCICDB>2.3.CO;2; KUTZBACH JE, 1981, SCIENCE, V214, P59, DOI 10.1126/science.214.4516.59; Li B, 2000, SCI CHINA SER D, V43, P277, DOI 10.1007/BF02906823; LI WX, 1989, NATURE, V339, P534, DOI 10.1038/339534a0; Liu TS., 1985, LOESS ENV, P168; LUDWIG KR, 1992, SCIENCE, V258, P284, DOI 10.1126/science.258.5080.284; Luo XZ, 1997, INT J MASS SPECTROM, V171, P105, DOI 10.1016/S0168-1176(97)00136-5; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; PORTER SC, 1995, NATURE, V375, P305, DOI 10.1038/375305a0; ROEMMICH D, 1980, J PHYS OCEANOGR, V10, P1972, DOI 10.1175/1520-0485(1980)010<1972:EOMHFI>2.0.CO;2; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; SHEN CC, IN PRESS CHEM GEOL; Wang PX, 1999, MAR GEOL, V156, P5, DOI 10.1016/S0025-3227(98)00172-8; Zheng S H, 1983, CHINESE SCI BULL, V28, P801	30	2172	2695	41	803	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2345	2348		10.1126/science.1064618	http://dx.doi.org/10.1126/science.1064618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743199				2022-12-28	WOS:000172817200044
J	Wood, DW; Setubal, JC; Kaul, R; Monks, DE; Kitajima, JP; Okura, VK; Zhou, Y; Chen, L; Wood, GE; Almeida, NF; Woo, L; Chen, YC; Paulsen, IT; Eisen, JA; Karp, PD; Bovee, D; Chapman, P; Clendenning, J; Deatherage, G; Gillet, W; Grant, C; Kutyavin, T; Levy, R; Li, MJ; McClelland, E; Palmieri, A; Raymond, C; Rouse, G; Saenphimmachak, C; Wu, ZN; Romero, P; Gordon, D; Zhang, SP; Yoo, HY; Tao, YM; Biddle, P; Jung, M; Krespan, W; Perry, M; Gordon-Kamm, B; Liao, L; Kim, S; Hendrick, C; Zhao, ZY; Dolan, M; Chumley, F; Tingey, SV; Tomb, JF; Gordon, MP; Olson, MV; Nester, EW				Wood, DW; Setubal, JC; Kaul, R; Monks, DE; Kitajima, JP; Okura, VK; Zhou, Y; Chen, L; Wood, GE; Almeida, NF; Woo, L; Chen, YC; Paulsen, IT; Eisen, JA; Karp, PD; Bovee, D; Chapman, P; Clendenning, J; Deatherage, G; Gillet, W; Grant, C; Kutyavin, T; Levy, R; Li, MJ; McClelland, E; Palmieri, A; Raymond, C; Rouse, G; Saenphimmachak, C; Wu, ZN; Romero, P; Gordon, D; Zhang, SP; Yoo, HY; Tao, YM; Biddle, P; Jung, M; Krespan, W; Perry, M; Gordon-Kamm, B; Liao, L; Kim, S; Hendrick, C; Zhao, ZY; Dolan, M; Chumley, F; Tingey, SV; Tomb, JF; Gordon, MP; Olson, MV; Nester, EW			The genome of the natural genetic engineer Agrobacterium tumefaciens C58	SCIENCE			English	Article							BRUCELLA-ABORTUS; PROTEIN; SEQUENCE; SYSTEM; TRANSFORMATION; REPLICATION; CHROMOSOMES; DETERMINANT; RESISTANCE; SECRETION	The 5.67-megabase genome of the plant pathogen Agrobacterium tumefaciens C58 consists of a circular chromosome, a linear chromosome, and two plasmids. Extensive orthology and nucleotide colinearity between the genomes of A. tumefaciens and the plant symbiont Sinorhizobium meliloti suggest a recent evolutionary divergence. Their similarities include metabolic, transport, and regulatory systems that promote survival in the highly competitive rhizosphere; differences are apparent in their genome structure and virulence gene complement. Availability of the A. tumefaciens sequence will facilitate investigations into the molecular basis of pathogenesis and the evolutionary divergence of pathogenic and symbiotic lifestyles.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Estadual Campinas, CBMEG, BR-13083970 Campinas, SP, Brazil; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Genome Ctr, Seattle, WA 98195 USA; Univ Fed Mato Grosso, Dept Comp & Stat, BR-79070900 Campo Grande, MS, Brazil; Inst Genome Res, Rockville, MD 20850 USA; SRI Int, Bioinformat Res Grp, Menlo Pk, CA 94025 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Dupont Co Inc, Newark, DE 19714 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Bot, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Universidade Estadual de Campinas; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidade Federal de Mato Grosso; J. Craig Venter Institute; SRI International; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; DuPont; DuPont; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nester, EW (corresponding author), Univ Washington, Dept Microbiol, 1959 NE Pacific St,Box 357242, Seattle, WA 98195 USA.	gnester@u.washington.edu	Paulsen, Ian T/K-3832-2012; Setubal, Joao Carlos/C-7305-2012; Almeida, Nalvo/B-5856-2012; Romero, Pedro R/D-4110-2018; Okura, Vagner/J-9180-2016; Eisen, Jonathan A./H-2706-2019; Karp, Peter/C-3514-2012	Paulsen, Ian T/0000-0001-9015-9418; Setubal, Joao Carlos/0000-0001-9174-2816; Romero, Pedro R/0000-0002-6995-5193; Okura, Vagner/0000-0002-3591-4051; Eisen, Jonathan A./0000-0002-0159-2197; Karp, Peter/0000-0002-5876-6418; Almeida, Nalvo/0000-0001-5615-1746; Kaul, Rajinder/0000-0002-7895-9284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032618] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19642, GM32618] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARDETSERVENT A, 1993, J BACTERIOL, V175, P7869, DOI 10.1128/JB.175.24.7869-7874.1993; Bao K, 2001, GENE DEV, V15, P1518, DOI 10.1101/gad.896201; CARSIOTIS M, 1989, INFECT IMMUN, V57, P3276, DOI 10.1128/IAI.57.11.3276-3280.1989; Christie PJ, 2001, MOL MICROBIOL, V40, P294, DOI 10.1046/j.1365-2958.2001.02302.x; Coleman SA, 2001, INFECT IMMUN, V69, P4373, DOI 10.1128/IAI.69.7.4373-4381.2001; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; De Iannino NI, 1998, J BACTERIOL, V180, P4392; DECLEENE M, 1976, BOT REV, V42, P389, DOI 10.1007/BF02860827; Denoyelle S., SYNTHESIS SAR STUDY; Dessaux Y., 1998, RHIZOBIACEAE MOL BIO, P173, DOI DOI 10.1007/978-94-011-5060-6_9; Downie JA, 2001, NATURE, V412, P597, DOI 10.1038/35088167; Eisen JA, 2000, GENOME BIOL, V1; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Forward JA, 1997, J BACTERIOL, V179, P5482, DOI 10.1128/jb.179.17.5482-5493.1997; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; HAMILTON RH, 1971, EXPERIENTIA, V27, P229, DOI 10.1007/BF02145913; HARPER JR, 2001, PRINCIPLES BACTERIAL, P43; Ichige A, 1997, J BACTERIOL, V179, P209, DOI 10.1128/jb.179.1.209-216.1997; Jumas-Bilak E, 1998, J BACTERIOL, V180, P2749, DOI 10.1128/JB.180.10.2749-2755.1998; Kalogeraki VS, 1999, MOL MICROBIOL, V34, P512, DOI 10.1046/j.1365-2958.1999.01617.x; Kalogeraki VS, 1998, J BACTERIOL, V180, P5660, DOI 10.1128/JB.180.21.5660-5667.1998; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; LeVier K, 2000, SCIENCE, V287, P2492, DOI 10.1126/science.287.5462.2492; Li PL, 1999, J BACTERIOL, V181, P5033, DOI 10.1128/JB.181.16.5033-5041.1999; Luo ZQ, 1999, J BACTERIOL, V181, P618, DOI 10.1128/JB.181.2.618-626.1999; MARTINEZ E, 1987, J BACTERIOL, V169, P2828, DOI 10.1128/jb.169.6.2828-2834.1987; MATTHYSSE AG, 1998, RHIZOBIACEAE MOL BIO, P235; Miller KJ, 1996, ANNU REV MICROBIOL, V50, P101, DOI 10.1146/annurev.micro.50.1.101; Minambres B, 2000, J BIOL CHEM, V275, P39529, DOI 10.1074/jbc.M005136200; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; MOORE LW, 1981, BIOL RHIZOBIACEAE, P15; Ochman H, 2001, SCIENCE, V292, P1096, DOI 10.1126/science.1058543; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Ramirez-Romero MA, 2000, J BACTERIOL, V182, P3117, DOI 10.1128/JB.182.11.3117-3124.2000; Robertson GT, 1999, MOL MICROBIOL, V34, P690, DOI 10.1046/j.1365-2958.1999.01629.x; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Volff JN, 2000, FEMS MICROBIOL LETT, V186, P143, DOI 10.1016/S0378-1097(00)00118-X; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Young JM, 2001, INT J SYST EVOL MICR, V51, P89, DOI 10.1099/00207713-51-1-89; Zhu J, 2000, J BACTERIOL, V182, P3885, DOI 10.1128/JB.182.14.3885-3895.2000; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x	50	618	1315	1	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 14	2001	294	5550					2317	2323		10.1126/science.1066804	http://dx.doi.org/10.1126/science.1066804			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743193				2022-12-28	WOS:000172817200037
J	Siris, ES; Miller, PD; Barrett-Connor, E; Faulkner, KG; Wehren, LE; Abbott, TA; Berger, ML; Santora, AC; Sherwood, LM				Siris, ES; Miller, PD; Barrett-Connor, E; Faulkner, KG; Wehren, LE; Abbott, TA; Berger, ML; Santora, AC; Sherwood, LM			Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women - Results from the National Osteoporosis Risk Assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIP FRACTURE; ELDERLY WOMEN; PERIMENOPAUSAL WOMEN; GENETIC-DIFFERENCES; SELF-REPORTS; OLDER WOMEN; MASS; POPULATION; VALIDITY; HOSPITALIZATION	Context Large segments of the population at risk for osteoporosis and fracture have not been evaluated, and the usefulness of peripheral measurements for short-term prediction of fracture risk is uncertain. Objectives To describe the occurrence of low bone mineral density (BMD) in postmenopausal women, its risk factors, and fracture incidence during short-term follow-up. Design The National Osteoporosis Risk Assessment, a longitudinal observational study initiated September 1997 to March 1999, with approximately 12 months of subsequent follow-up. Setting and Participants A total of 200160 ambulatory postmenopausal women aged 50 years or older with no previous osteoporosis diagnosis, derived from 4236 primary care practices in 34 states. Main Outcome Measures Baseline BMD T scores, obtained from peripheral bone densitometry performed at the heel, finger, or forearm; risk factors for low BMD, derived from questionnaire responses; and clinical fracture rates at 12-month follow-up. Results Using World Health Organization criteria, 39.6% had osteopenia (T score of -1 to -2.49) and 7.2% had osteoporosis (T score less than or equal to -2.5). Age, personal or family history of fracture, Asian or Hispanic heritage, smoking, and cortisone use were associated with significantly increased likelihood of osteoporosis; higher body mass index, African American heritage, estrogen or diuretic use, exercise, and alcohol consumption significantly decreased the likelihood. Among the 163 979 participants with follow-up information, osteoporosis was associated with a fracture rate approximately 4 times that of normal BMD (rate ratio, 4.03; 95% confidence interval [CII, 3.59-4.53) and osteopenia was associated with a 1.8-fold higher rate (95% Cl, 1.49-2.18). Conclusions Almost half of this population had previously undetected low BMD, including 7% with osteoporosis. Peripheral BMD results were highly predictive of fracture risk. Given the economic and social costs of osteoporotic fractures, strategies to identify and manage osteoporosis in the primary care setting need to be established and implemented.	Columbia Univ, Coll Phys & Surg, New York, NY USA; Colorado Ctr Bone Res, Lakewood, CO USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Synarc, Portland, OR USA; Univ Maryland, Baltimore, MD 21201 USA; Merck & Co Inc, W Point, PA USA	Columbia University; Colorado Center For Bone Research; University of California System; University of California San Diego; Synarc; University System of Maryland; University of Maryland Baltimore; Merck & Company	Siris, ES (corresponding author), Columbia Presbyterian Med Ctr, Toni Stabile Osteoporosis Ctr, 180 Ft Washington Ave, New York, NY 10032 USA.							ANDERSON JJB, 1994, ADV NUTR RES, V9, P129; BAUER RL, 1988, AM J EPIDEMIOL, V127, P145, DOI 10.1093/oxfordjournals.aje.a114774; Bergmann MM, 1998, AM J EPIDEMIOL, V147, P969; BLACK DM, 1992, J BONE MINER RES, V7, P633; Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DAVIS JW, 1994, J BONE MINER RES, V9, P305; DAVIS JW, 1994, CALCIFIED TISSUE INT, V55, P249, DOI 10.1007/BF00310400; Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532-5415.2000.tb02641.x; FASANO G, 1998, BONE, V23, pS590; Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P1063, DOI 10.2106/00004623-200008000-00001; Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100; Grampp S, 1997, J BONE MINER RES, V12, P697, DOI 10.1359/jbmr.1997.12.5.697; GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532-5415.1995.tb05557.x; Hajcsar EE, 2000, CAN MED ASSOC J, V163, P819; HOLBROOK TL, 1993, BMJ-BRIT MED J, V306, P1506, DOI 10.1136/bmj.306.6891.1506; Honkanen K, 1999, AM J EPIDEMIOL, V150, P511; Ismail AA, 2000, OSTEOPOROSIS INT, V11, P248, DOI 10.1007/s001980050288; Johnell O, 1997, Am J Med, V103, p20S, DOI 10.1016/S0002-9343(97)90023-1; Kamel HK, 2000, AM J MED, V109, P326, DOI 10.1016/S0002-9343(00)00457-5; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KROGER H, 1994, CALCIFIED TISSUE INT, V55, P1, DOI 10.1007/BF00310160; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Miller P, 2001, J BONE MINER RES, V16, pS193; MILLER P, 2001, INT SOC CLIN DENS AN; Miller PD, 1998, J CLIN DENSITOM, V1, P211, DOI 10.1385/JCD:1:3:211; *NAT OST FDN, 1998, OSTEOPOROS INT S4, V8, pS1; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NGUYEN TV, 1994, J BONE MINER RES, V9, P1339; POLLITZER WS, 1989, AM J CLIN NUTR, V50, P1244, DOI 10.1093/ajcn/50.6.1244; Pothuaud L, 1998, OSTEOPOROSIS INT, V8, P618, DOI 10.1007/s001980050108; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Ross PD, 1996, CALCIFIED TISSUE INT, V59, P339, DOI 10.1007/s002239900137; ROSS PD, 1991, AM J EPIDEMIOL, V133, P801, DOI 10.1093/oxfordjournals.aje.a115959; SCHOTT AM, 1995, J BONE MINER RES, V10, P243; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SILVERMAN SL, 1988, AM J PUBLIC HEALTH, V78, P1482, DOI 10.2105/AJPH.78.11.1482; Siris E, 1998, OSTEOPOROSIS INT, V8, pS62; TURNER CH, 1995, OSTEOPOROSIS INT, V5, P130, DOI 10.1007/BF01623314; World Health Organization, 1994, ASS FRACT RISK APPL	43	894	932	2	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2001	286	22					2815	2822		10.1001/jama.286.22.2815	http://dx.doi.org/10.1001/jama.286.22.2815			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YC	11735756	Bronze			2022-12-28	WOS:000172655400029
J	Boydell, J; van Os, J; McKenzie, K; Allardyce, J; Goel, R; McCreadie, RG; Murray, RM				Boydell, J; van Os, J; McKenzie, K; Allardyce, J; Goel, R; McCreadie, RG; Murray, RM			Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOTIC ILLNESS; RELIABILITY; DENSITY; BRITAIN	Objective To determine whether the incidence of schizophrenia among people from non-white ethnic minorities is greater in neighbourhoods where they constitute a smaller proportion of the total population. Design Ecological design including retrospective study of case records to calculate the incidence of schizophrenia in the ethnic minority population across electoral wards and multi-level analysis to examine interaction between individuals and environment. Setting 15 electoral wards in Camberwell, South London. Participants All people aged 16 years and over who had contact with psychiatric services during 1988-97. Main outcome measure Incidence rates of schizophrenia according to Research Diagnostic Criteria. Results The incidence of schizophrenia in non-white ethnic minorities increased significantly as the proportion of such minorities in the local population fell. The incidence rate ratio varied in a dose-response fashion from 2.38 (95% confidence interval 1.49 to 3.79) in the third of wards where non-white ethnic minorities formed the largest proportion (28-57%) of the local population to 4.4 (2.49 to 7.75) in the third of wards where they formed the smallest proportion (8-22%). Conclusion The incidence of schizophrenia in non-white ethnic minorities in London is greater when they comprise a smaller proportion of the local population.	Inst Psychiat, Div Psychol Med, London SF5 8AF, England; Maastricht Univ, European Grad Sch Neurosci, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland	University of London; King's College London; Maastricht University	Boydell, J (corresponding author), Inst Psychiat, Div Psychol Med, Denmark Hill, London SF5 8AF, England.	j.kelly@iop.kcl.ac.uk	van Os, Jim/V-8884-2019; Murray, Robin M/F-8658-2012; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/I-9496-2012; van Os, Jim/C-2113-2014	van Os, Jim/0000-0002-7245-1586; Murray, Robin M/0000-0003-0829-0519; van Os, Jim/0000-0002-7245-1586; mckenzie, kwame/0000-0001-6419-8130; ALLARDYCE, JUDITH/0000-0003-4094-552X				Bhugra D, 1997, PSYCHOL MED, V27, P791, DOI 10.1017/S0033291797005369; CASTLE D, 1991, BRIT J PSYCHIAT, V159, P790, DOI 10.1192/bjp.159.6.790; COCHRANE R, 1988, BRIT J PSYCHIAT, V153, P363, DOI 10.1192/bjp.153.3.363; *DEP ENV, 1991, IND LOC COND; HALPERN D, 1993, SOC SCI MED, V36, P597, DOI 10.1016/0277-9536(93)90056-A; HARRISON G, 1988, PSYCHOL MED, V18, P643, DOI 10.1017/S0033291700008321; Hutchinson G, 1999, INT REV PSYCHIATR, V11, P122, DOI 10.1080/09540269974285; Hutchinson G, 1996, BRIT J PSYCHIAT, V169, P776, DOI 10.1192/bjp.169.6.776; Hutchinson G, 1997, BRIT J PSYCHIAT, V171, P145, DOI 10.1192/bjp.171.2.145; King G, 1995, SOC HLTH, P93; KING M, 1994, BMJ-BRIT MED J, V309, P1115, DOI 10.1136/bmj.309.6962.1115; *LOND RES CTR, 1997, ROUND PROJ METH; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MCKENZIE K, 1995, BMJ-BRIT MED J, V311, P1325, DOI 10.1136/bmj.311.7016.1325; MURPHY HBM, 1965, P 5 ANN C COMM MENT, P5; *OFF POP CENS SURV, 1991, 1991 CENS LOC BAS ST; RABKIN JG, 1979, AM J PSYCHIAT, V136, P1562; Sharpley M, 2001, BRIT J PSYCHIAT, V178, pS60, DOI 10.1192/bjp.178.40.s60; VanOs J, 1996, PSYCHOL MED, V26, P203, DOI 10.1017/S0033291700033845; WESSELY S, 1991, BRIT J PSYCHIAT, V159, P795, DOI 10.1192/bjp.159.6.795; Williams D R, 1996, Ethn Dis, V6, P1; Williams J, 1996, PSYCHOL MED, V26, P775, DOI 10.1017/S003329170003779X; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	23	275	278	0	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2001	323	7325					1336	1338		10.1136/bmj.323.7325.1336	http://dx.doi.org/10.1136/bmj.323.7325.1336			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	501ZC	11739218	Green Published, Bronze			2022-12-28	WOS:000172716900015
J	Kinoshita, T; Doi, M; Suetsugu, N; Kagawa, T; Wada, M; Shimazaki, K				Kinoshita, T; Doi, M; Suetsugu, N; Kagawa, T; Wada, M; Shimazaki, K			phot1 and phot2 mediate blue light regulation of stomatal opening	NATURE			English	Article							GUARD-CELL PROTOPLASTS; VICIA-FABA; SIGNAL-TRANSDUCTION; ACTION SPECTRUM; PHOSPHORYLATION; PHOTORECEPTOR; PROTEIN; BINDING; MUTANTS; PLANTS	The stomatal pores of higher plants allow for gaseous exchange into and out of leaves. Situated in the epidermis, they are surrounded by a pair of guard cells which control their opening in response to many environmental stimuli, including blue light(1,2). Opening of the pores is mediated by K+ accumulation in guard cells through a K+ channel and driven by an inside-negative electrical potential(3). Blue light causes phosphorylation and activation of the plasma membrane H+-ATPase that creates this potential(1,2,4-6). Thus far, no blue light receptor mediating stomatal opening has been identified(7), although the carotenoid, zeaxanthin, has been proposed(2,8). Arabidopsis mutants deficient in specific blue-light-mediated responses have identified(7,9-14) four blue light receptors, cryptochrome 1 (cry1), cryptochrome 2 (cry2), phot1 and phot2. Here we show that in a double mutant of phot1 and phot2 stomata do not respond to blue light although single mutants are phenotypically normal. These results demonstrate that phot1 and phot2 act redundantly as blue light receptors mediating stomatal opening.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8108560, Japan; Natl Inst Basic Biol, Div Biol Regulat & Photobiol, Okazaki, Aichi 4448585, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Tokyo 1920397, Japan; Japan Sci & Technol Corp, PRESTO, Unit Proc & Combined Circuit, Kawaguchi, Saitama 3320012, Japan	Kyushu University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Tokyo Metropolitan University; Japan Science & Technology Agency (JST)	Shimazaki, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8108560, Japan.		Kinoshita, Toshinori/C-2891-2012; Suetsugu, Noriyuki/AAB-5274-2019	Kinoshita, Toshinori/0000-0001-7621-1259; Suetsugu, Noriyuki/0000-0002-3328-3313				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; ASSMANN SM, 1985, NATURE, V318, P285, DOI 10.1038/318285a0; BALLIO A, 1964, NATURE, V203, P297, DOI 10.1038/203297a0; Baum G, 1999, P NATL ACAD SCI USA, V96, P13554, DOI 10.1073/pnas.96.23.13554; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs WR, 2001, PLANT CELL, V13, P993, DOI 10.1105/tpc.13.5.993; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Eckert M, 2000, J EXP BOT, V51, P1435, DOI 10.1093/jexbot/51.349.1435; Eisinger W, 2000, PLANT PHYSIOL, V122, P99, DOI 10.1104/pp.122.1.99; HUALA E, 1997, SCIENCE, V278, P2121; IINO M, 1985, P NATL ACAD SCI USA, V82, P8019, DOI 10.1073/pnas.82.23.8019; Jarillo JA, 2001, NATURE, V410, P952, DOI 10.1038/35073622; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; KARLSSON PE, 1986, PHYSIOL PLANTARUM, V66, P207, DOI 10.1111/j.1399-3054.1986.tb02410.x; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; KONDO N, 1978, PLANT CELL PHYSIOL, V19, P365, DOI 10.1093/oxfordjournals.pcp.a075604; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Schroeder JI, 2001, ANNU REV PLANT PHYS, V52, P627, DOI 10.1146/annurev.arplant.52.1.627; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SCHWARTZ A, 1984, PLANTA, V161, P129, DOI 10.1007/BF00395472; SHIMAZAKI K, 1986, NATURE, V319, P324, DOI 10.1038/319324a0; Shimazaki K, 1999, PHYSIOL PLANTARUM, V105, P554, DOI 10.1034/j.1399-3054.1999.105322.x; Willmer C., 1996, STOMATA, DOI DOI 10.1007/978-94-011-0579-8; Zeiger E, 1998, J EXP BOT, V49, P433, DOI 10.1093/jexbot/49.suppl_1.433	30	667	699	4	188	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 6	2001	414	6864					656	660		10.1038/414656a	http://dx.doi.org/10.1038/414656a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	498WB	11740564				2022-12-28	WOS:000172535600052
J	Auchincloss, S; Pridmore, S				Auchincloss, S; Pridmore, S			Vomiting, burns, and irrational behaviour	LANCET			English	Editorial Material							PORPHYRIA		Royal Hobart Hosp, Dept Psychol Med, Hobart, Tas 7000, Australia	Royal Hobart Hospital	Auchincloss, S (corresponding author), Royal Hobart Hosp, Dept Psychol Med, Hobart, Tas 7000, Australia.			Pridmore, Saxby/0000-0002-9170-1798				DESNICK RJ, 1998, HARRISONS PRINCIPLES; Kanaan C, 1989, Obstet Gynecol Surv, V44, P244, DOI 10.1097/00006254-198904000-00003; SANTOSH PJ, 1994, BIOL PSYCHIAT, V36, P744, DOI 10.1016/0006-3223(94)90085-X; Thadani H, 2000, BMJ-BRIT MED J, V320, P1647, DOI 10.1136/bmj.320.7250.1647	4	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1870	1870		10.1016/S0140-6736(01)06889-1	http://dx.doi.org/10.1016/S0140-6736(01)06889-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741627				2022-12-28	WOS:000172463000013
J	Sano, N; Wang, H; Chhowalla, M; Alexandrou, I; Amaratunga, GAJ				Sano, N; Wang, H; Chhowalla, M; Alexandrou, I; Amaratunga, GAJ			Nanotechnology - Synthesis of carbon 'onions' in water	NATURE			English	Article							NANOTUBES		Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England	University of Cambridge	Sano, N (corresponding author), Himeji Inst Technol, Dept Chem Engn, Himeji, Hyogo 6712201, Japan.							CABIOCH T, 1995, J MATER SCI, V30, P4787, DOI 10.1007/BF01154486; Hsin YL, 2001, ADV MATER, V13, P830, DOI 10.1002/1521-4095(200106)13:11<830::AID-ADMA830>3.0.CO;2-4; HSU WK, 1995, NATURE, V377, P687, DOI 10.1038/377687a0; Ishigami M, 2000, CHEM PHYS LETT, V319, P457, DOI 10.1016/S0009-2614(00)00151-2; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; Tenne R, 1998, CHEM MATER, V10, P3225, DOI 10.1021/cm9802189; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483	7	441	458	3	209	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2001	414	6863					506	507		10.1038/35107141	http://dx.doi.org/10.1038/35107141			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496PV	11734841				2022-12-28	WOS:000172405900034
J	Vallance, P				Vallance, P			Biotechnology and new companies arising from academia	LANCET			English	Article								20 years ago, an academic biomedical scientist or clinician who set up a company would probably have been perceived by colleagues as "on the make" and rather unacademic-"not one of us", in other words. Nowadays, academics who have started companies are commonplace, and in some universities the businessman-academic Is becoming the norm, although still far more common in the USA than in Europe. At best, the opportunity to capitalise on a discovery has the potential to motivate research workers, provide greater funding for research, and ultimately create wealth. At worst, the spawning of a company from within academia has the potential to use public employees, space, and equipment for personal gain, and divert academics from the pursuit of profound scientific questions into more immediate product-driven research or even marketing dressed up as research. Here, I discuss some of the Issues surrounding biotechnology and spin-off companies originating in academia.	UCL, Ctr Clin Pharmacol & Therapeut, London WC1E 6JJ, England	University of London; University College London	Vallance, P (corresponding author), UCL, Ctr Clin Pharmacol & Therapeut, 5 Univ St, London WC1E 6JJ, England.	rmhapav@ucl.ac.uk						LLEWELLYNSMITH C, 1999, UCL NEWSLETTER, P7; Mansour P, 1999, LANCET, V353, P1888, DOI 10.1016/S0140-6736(05)75100-X; Schull M, 2000, BRIT MED J, V321, P833; Spurgeon D, 1998, NATURE, V396, P715, DOI 10.1038/25431	4	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2001	358	9295					1804	1806		10.1016/S0140-6736(01)06798-8	http://dx.doi.org/10.1016/S0140-6736(01)06798-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	496FG	11734259				2022-12-28	WOS:000172385100035
J	Ascherio, A; Munger, KL; Lennette, ET; Spiegelman, D; Hernan, MA; Olek, MJ; Hankinson, SE; Hunter, DJ				Ascherio, A; Munger, KL; Lennette, ET; Spiegelman, D; Hernan, MA; Olek, MJ; Hankinson, SE; Hunter, DJ			Epstein-Barr virus antibodies and risk of multiple sclerosis - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CD8(+) T-CELLS; NUCLEAR ANTIGEN; INFECTION; EBV; VARIANT; HUMAN-HERPESVIRUS-6; ASSOCIATION; AUTOIMMUNE; RESPONSES; DISEASE		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Multiple Sclerosis Unit, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Virolab Inc, Berkeley, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Alberto.Ascherio@channing.harvard.edu		Olek, Michael/0000-0002-3840-2772	NCI NIH HHS [CA67262, CA49449] Funding Source: Medline; NINDS NIH HHS [NS35624] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA049449, R01CA049449, R01CA067262, U01CA067262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhyani N, 2000, J INFECT DIS, V182, P1321, DOI 10.1086/315893; Ascherio A, 2000, EPIDEMIOLOGY, V11, P220, DOI 10.1097/00001648-200003000-00023; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; COMPSTON DAS, 1986, BRAIN, V109, P325, DOI 10.1093/brain/109.2.325; CUOMO L, 1995, AIDS RES HUM RETROV, V11, P1241, DOI 10.1089/aid.1995.11.1241; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Flamand L, 1996, J VIROL, V70, P1784, DOI 10.1128/JVI.70.3.1784-1791.1996; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P00281; Haahr S, 1995, Mult Scler, V1, P73; Hafler DA, 1999, J CLIN INVEST, V104, P527, DOI 10.1172/JCI8193; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; Hernan MA, 1999, NEUROLOGY, V53, P1711, DOI 10.1212/WNL.53.8.1711; Hernan MA, 2001, EPIDEMIOLOGY, V12, P301, DOI 10.1097/00001648-200105000-00009; Hernan MA, 2001, AM J EPIDEMIOL, V154, P69, DOI 10.1093/aje/154.1.69; HILTON DA, 1994, J NEUROL NEUROSUR PS, V57, P975, DOI 10.1136/jnnp.57.8.975; Hunter SF, 2000, NEUROLOGY, V55, P164, DOI 10.1212/WNL.55.2.164; Jabs WJ, 1999, CLIN EXP IMMUNOL, V116, P468; Knox KK, 2000, CLIN INFECT DIS, V31, P894, DOI 10.1086/318141; LARSEN PD, 1985, NEUROLOGY, V35, P435, DOI 10.1212/WNL.35.3.435; LENNETTE E, 2000, IMMUNE ADHERENCE HEM; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; LINDBERG C, 1991, NEUROEPIDEMIOLOGY, V10, P62, DOI 10.1159/000110248; Marrie RA, 2000, NEUROLOGY, V54, P2307, DOI 10.1212/WNL.54.12.2307; MARTYN CN, 1993, J NEUROL NEUROSUR PS, V56, P167, DOI 10.1136/jnnp.56.2.167; MARTYN CN, 1991, MCALPINES MULTIPLE S, P2; Morre SA, 2001, NEUROLOGY, V56, P692, DOI 10.1212/WNL.56.5.692; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; Munch M, 1998, ACTA NEUROL SCAND, V97, P171; OPERSKALSKI EA, 1989, NEUROLOGY, V39, P825, DOI 10.1212/WNL.39.6.825; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; SHIRODARIA PV, 1987, ARCH NEUROL-CHICAGO, V44, P1237, DOI 10.1001/archneur.1987.00520240019006; Soldan SS, 2000, ANN NEUROL, V47, P306, DOI 10.1002/1531-8249(200003)47:3<306::AID-ANA5>3.0.CO;2-A; Tan LC, 1999, J IMMUNOL, V162, P1827; van Sechel AC, 1999, J IMMUNOL, V162, P129; VAUGHAN JH, 1995, SPRINGER SEMIN IMMUN, V17, P203; Vaughan JH, 1996, J NEUROIMMUNOL, V69, P95; Wandinger KP, 2000, NEUROLOGY, V55, P178, DOI 10.1212/WNL.55.2.178; WARNER HB, 1981, LANCET, V2, P1290; Winer S, 2001, J IMMUNOL, V166, P4751, DOI 10.4049/jimmunol.166.7.4751	45	368	383	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3083	3088		10.1001/jama.286.24.3083	http://dx.doi.org/10.1001/jama.286.24.3083			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754673	Bronze			2022-12-28	WOS:000172927100025
J	Schlecht, NF; Kulaga, S; Robitaille, J; Ferreira, S; Santos, M; Miyamura, RA; Duarte-Franco, E; Rohan, TE; Ferenczy, A; Villa, LL; Franco, EL				Schlecht, NF; Kulaga, S; Robitaille, J; Ferreira, S; Santos, M; Miyamura, RA; Duarte-Franco, E; Rohan, TE; Ferenczy, A; Villa, LL; Franco, EL			Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; WOMEN; RISK; DNA; LESIONS	Context Human papillomavirus (HPV) infection is believed to be the central cause of cervical cancer, although most of the epidemiological evidence has come from retrospective, case-control studies, which do not provide information on the dynamics of cumulative or persistent exposure to HPV infection. Objective To assess the risks of cervical neoplasia related to prior persistent HPV infections. Design and Setting Longitudinal study of the natural history of HPV infection and cervical neoplasia in women residing in the city of Sao Paulo, Brazil, which was conducted between November 1993 and March 1997 and involved repeated measurements of HPV and lesions with follow-up until June 2000. Participants A total of 1611 women with no cytological lesions at enrollment and HPV test results available from the first 2 visits. Main Outcome Measure Cervical specimens taken for Papanicolaou cytology and HPV testing every 4 months in the first year and twice yearly thereafter. Incident cervical cancer precursor lesions ascertained by expert review of all cytology smears. Results The incidence rate of squamous intraepithelial lesions (SILs) was 0.73 per 1000 women-months (95% confidence interval [CII, 0.5-0.9) among women free of HPV at the 2 initial visits and 8.68 (95% Cl, 2.3-15.1) among women with HPV type 16 or 18 infections persisting over both visits. Relative to those negative for HPV oncogenic types at both initial visits, the relative risk (RR) of incident SIL was 10.19 (95% Cl, 5.9-17.6) for persistent infections with any known oncogenic HPV types. The equivalent RR of incident high-grade SIL was 11.67 (95% Cl, 4.1-33.3). The RRs of lesions were considerably higher for persistent infections with HPV type 16 or 18. Conclusion A strong relationship exists between persistent HPV infections and SIL incidence, particularly for HPV types 16 and 18.	McGill Univ, Dept Oncol, Montreal, PQ H2W 1S6, Canada; McGill Univ, Dept Epidemiol, Montreal, PQ, Canada; McGill Univ, Dept Pathol, Montreal, PQ, Canada; Ludwig Inst Canc Res, Sao Paulo, Brazil; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA	McGill University; McGill University; McGill University; Ludwig Institute for Cancer Research; Yeshiva University; Albert Einstein College of Medicine	Franco, EL (corresponding author), McGill Univ, Dept Oncol, 546 Pine Ave W, Montreal, PQ H2W 1S6, Canada.	eduardo.franco@mcgill.ca	VILLA, LUISA/AAH-4761-2019; Franco, Eduardo/C-6445-2014	VILLA, LUISA/0000-0003-4074-2335; Franco, Eduardo/0000-0002-4409-8084; Schlecht, Nicolas/0000-0003-2482-244X	NCI NIH HHS [CA70269] Funding Source: Medline; PHS HHS [MA13647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; FRANCO EL, 1994, JNCI-J NATL CANCER I, V86, P1558, DOI 10.1093/jnci/86.20.1558; Franco EL, 1999, JNCI-J NATL CANCER I, V91, P506, DOI 10.1093/jnci/91.6.506; FRANCO EL, 1999, PAN AM J PUBLIC HLTH, V6, P223; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; *IARC, 1995, IARC MON EV CARC RIS, V64; KATAJA V, 1989, EUR J EPIDEMIOL, V5, P1, DOI 10.1007/BF00145037; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Londesborough P, 1996, INT J CANCER, V69, P364; Moscicki AB, 2001, JAMA-J AM MED ASSOC, V285, P2995, DOI 10.1001/jama.285.23.2995; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; SOLOMON D, 1989, ACTA CYTOL, V33, P567; Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; Ylitalo N, 2000, LANCET, V355, P2194, DOI 10.1016/S0140-6736(00)02402-8	22	401	439	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2001	286	24					3106	3114		10.1001/jama.286.24.3106	http://dx.doi.org/10.1001/jama.286.24.3106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505QM	11754676	Bronze			2022-12-28	WOS:000172927100028
J	Kromer, B; Manning, SW; Kuniholm, PI; Newton, MW; Spurk, M; Levin, I				Kromer, B; Manning, SW; Kuniholm, PI; Newton, MW; Spurk, M; Levin, I			Regional (CO2)-C-14 offsets in the troposphere: Magnitude, mechanisms, and consequences	SCIENCE			English	Article							RADIOCARBON TIME SCALE; PRECISION BIDECADAL CALIBRATION; ANATOLIAN TREE-RINGS; AGE CALIBRATION; SOLAR; TERRESTRIAL; CHRONOLOGY; CYCLE	Radiocarbon dating methods typically assume that there are no significant tropospheric (CO2)-C-14 gradients within the low- to mid-latitude zone of the Northern Hemisphere. Comparison of tree ring C-14 data from southern Germany and Anatolia supports this assumption in general but also documents episodes of significant short-term regional (CO2)-C-14 offsets. We suggest that the offset is caused by an enhanced seasonal (CO2)-C-14. cycle, with seasonally peaked flux of stratospheric C-14 into the troposphere during periods of low solar magnetic activity, coinciding with substantial atmospheric cooling. Short-term episodes of regional (CO2)-C-14, offsets are important to palaeoclimate studies and to high-resolution archaeological dating.	Heidelberger Akad Wissensch, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Umweltphys, D-69120 Heidelberg, Germany; Univ Reading, Dept Archaeol, Reading RG6 6AA, Berks, England; Cornell Univ, Malcolm & Carolyn Wiener Lab Aegean & Near Easter, Ithaca, NY 14853 USA; Univ Hohenheim, Inst Bot 210, D-70593 Stuttgart, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Reading; Cornell University; University Hohenheim	Kromer, B (corresponding author), Heidelberger Akad Wissensch, Neuenheimer Feld 229, D-69120 Heidelberg, Germany.	bernd.kromer@iup.uni-heidelberg.de						BALACHANDRAN NK, 1995, J CLIMATE, V8, P2058, DOI 10.1175/1520-0442(1995)008<2058:MTEOUV>2.0.CO;2; Bard E, 2000, TELLUS B, V52, P985, DOI 10.1034/j.1600-0889.2000.d01-7.x; BOND G, 2001, SCIENCE         1115; BRAZIUNAS TF, 1995, GLOBAL BIOGEOCHEM CY, V9, P565, DOI 10.1029/95GB01725; BRIFF AKR, 2001, J GEOPHYS RES, V106, P2929; Chmielewski FM, 2001, AGR FOREST METEOROL, V108, P101, DOI 10.1016/S0168-1923(01)00233-7; HESSHAIMER V, 1997, THESIS U HEIDELBERG; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; KROMER B, 1993, RADIOCARBON, V35, P125, DOI 10.1017/S0033822200013862; KROMER B, 1992, RADIOCARBON AFTER FOUR DECADES, P184; Kuniholm PI, 1996, NATURE, V381, P780, DOI 10.1038/381780a0; Lamb H.H., 1995, CLIMATE HIST MODERN, P211; Lean J, 1998, J CLIMATE, V11, P3069, DOI 10.1175/1520-0442(1998)011<3069:CFBCSR>2.0.CO;2; Levin I, 2000, RADIOCARBON, V42, P69, DOI 10.1017/S0033822200053066; Manning S. W., 1999, TEST TIME VOLCANO TH; Manning SW, 2001, SCIENCE, V294, P2532, DOI 10.1126/science.1066112; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; McCormac FG, 1995, RADIOCARBON, V37, P395, DOI 10.1017/S0033822200030873; NESMERIBES E, 1994, NATO ASI SER, V1, P71; PEARSON GW, 1993, RADIOCARBON, V35, P25, DOI 10.1017/S0033822200013795; Ramsey CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903; Shindell DT, 2001, J GEOPHYS RES-ATMOS, V106, P7193, DOI 10.1029/2000JD900547; SPURK M, 1998, RADIOCARBON, V40, P1; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; STUIVER M, 1980, SCIENCE, V207, P11, DOI 10.1126/science.207.4426.11; Stuiver M, 1998, GEOPHYS RES LETT, V25, P329, DOI 10.1029/97GL03694; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUIVER M, 1993, RADIOCARBON, V35, P35, DOI 10.1017/S0033822200013801; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Van Geel B, 1998, RADIOCARBON, V40, P535, DOI 10.1017/S0033822200018403; van Loon H, 1998, J CLIMATE, V11, P1529, DOI 10.1175/1520-0442(1998)011<1529:TGROTS>2.0.CO;2; VOGEL JC, 1993, RADIOCARBON, V35, P73, DOI 10.1017/S0033822200013825	32	62	62	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2001	294	5551					2529	2532		10.1126/science.1066114	http://dx.doi.org/10.1126/science.1066114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505QU	11743160				2022-12-28	WOS:000172927700053
J	Catella-Lawson, F; Reilly, MP; Kapoor, SC; Cucchiara, AJ; DeMarco, S; Tournier, B; Vyas, SN; FitzGerald, GA				Catella-Lawson, F; Reilly, MP; Kapoor, SC; Cucchiara, AJ; DeMarco, S; Tournier, B; Vyas, SN; FitzGerald, GA			Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN H-2 SYNTHASE; LOW-DOSE ASPIRIN; PLATELET CYCLOOXYGENASE; MYOCARDIAL-INFARCTION; HEALTHY-VOLUNTEERS; CRYSTAL-STRUCTURE; DOUBLE-BLIND; ROFECOXIB; PROSTACYCLIN	Background: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies. Methods: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily). Results: Serum thromboxane B(sub 2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(sub 2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin. Conclusions: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin. (N Engl J Med 2001;345:1809-17.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Penn, Sch Med, Ctr Expt Therapeut, EUPenn Grp Investigators, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Cardiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Gen Clin Res Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, EUPenn Grp Investigators, 153 Johnson Pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010	Reilly, Muredach/0000-0002-3035-9386	NCRR NIH HHS [M01RR00040] Funding Source: Medline; NHLBI NIH HHS [HL 5400, HL 62250] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSANDRINI P, 1985, THROMB RES, V37, P1, DOI 10.1016/0049-3848(85)90027-1; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; *ANT TRIAL GROUP, IN PRESS BMJ; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951; BRUNE K, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)90228-0; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Crofford LJ, 2000, ARTHRITIS RHEUM, V43, P1891, DOI 10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R; DIMINNO G, 1983, BLOOD, V61, P1081; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; FITZGERALD GA, 1981, J CLIN INVEST, V68, P1272, DOI 10.1172/JCI110373; FORNARO G, 1993, CIRCULATION, V87, P162, DOI 10.1161/01.CIR.87.1.162; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GREEN K, 1989, PROSTAG OTH LIPID M, V37, P311, DOI 10.1016/0090-6980(89)90001-4; Greenberg HE, 2000, J CLIN PHARMACOL, V40, P1509; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Hawkey C, 2000, ARTHRITIS RHEUM-US, V43, P370, DOI 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; LIVIO M, 1982, PROSTAGLANDINS, V23, P787, DOI 10.1016/0090-6980(82)90123-X; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P5890; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Meade TW, 1998, LANCET, V351, P233; Pathmakanthan S, 1998, IRISH MED J, V91, P58; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; Patrignani P, 1999, J PHYSIOL PHARMACOL, V50, P661; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PEDERSEN AK, 1985, CLIN PHARMACOL THER, V37, P36, DOI 10.1038/clpt.1985.8; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1587, DOI 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X; RAO GHR, 1983, ARTERIOSCLEROSIS, V3, P383, DOI 10.1161/01.ATV.3.4.383; REILLY IAG, 1987, BLOOD, V69, P180; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P570; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P382, DOI 10.1097/00001648-200007000-00004; SCIULLI MG, 2000, P 11 INT C ADV PROST, P38; Singh G, 1999, J RHEUMATOL, V26, P18; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; VESTERQVIST O, 1984, PROSTAGLANDINS, V27, P627, DOI 10.1016/0090-6980(84)90098-4	46	1020	1078	2	51	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2001	345	25					1809	1817		10.1056/NEJMoa003199	http://dx.doi.org/10.1056/NEJMoa003199			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503JF	11752357				2022-12-28	WOS:000172794800004
J	Kagawa-Singer, M; Blackhall, LJ				Kagawa-Singer, M; Blackhall, LJ			Negotiating cross-cultural issues at the end of life - "You got to go where he lives"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RACIAL-DIFFERENCES; DECISION-MAKING; HEALTH-CARE; CANCER; ATTITUDES; ETHNICITY; BLACK; PHYSICIANS; RACE; PREFERENCES	Culture fundamentally shapes how individuals make meaning out of illness, suffering, and dying. With increasing diversity in the United States, encounters between patients and physicians of different backgrounds are becoming more common. Thus the risk for cross-cultural misunderstandings surrounding care at the end of life is also increasing. Studies have shown cultural differences in attitudes toward truth telling, life-prolonging technology, and decision-making styles at the end of life. Using 2 case studies of patients, one of an African American couple in the southern United States and the other of a Chinese-American family in Hawaii, we outline some of the major issues involved in cross-cultural care and indicate how the patient, family, and clinician can navigate among differing cultural beliefs, values, and practices. Skilled use of cross-cultural understanding and communication techniques increases the likelihood that both the process and outcomes of care are satisfactory for all involved.	Univ Calif Los Angeles, Sch Publ Hlth & Asian Amer Studies, Los Angeles, CA 90095 USA; Univ Virginia, Ctr Palliat Care & Res, Charlottesville, VA USA; Univ Virginia, Ctr Biomed Eth, Charlottesville, VA USA	University of California System; University of California Los Angeles; University of Virginia; University of Virginia	Kagawa-Singer, M (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth & Asian Amer Studies, 650 Charles E Young Dr, Los Angeles, CA 90095 USA.		Wang, Zi Dan/GZH-3012-2022					ABRAHAM J, 2000, PHYSICIANS GUIDE PAI; ANNAS GJ, 1979, AM J LAW MED, V4, P367; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; BARKER JC, 1992, WESTERN J MED, V157, P248; BERLIN EA, 1983, WESTERN J MED, V139, P934; BEYENE Y, 1992, W J MED, P328; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Braun K. L, 2000, CULTURAL ISSUES END; BUCHMAN R, 1992, BREAK BAD NEWS; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Chadwick G L, 1997, J Int Assoc Physicians AIDS Care, V3, P27; Chen J, 2001, NEW ENGL J MED, V344, P1443, DOI 10.1056/NEJM200105103441906; Clinton WJ., 2000, OFF PRES FED REGIST, V65, P67249; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; *COUNC EC ADV, 1997, CHANG AM IND SOC EC, P40; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; CRAWLEY L, 2001, INNOVATIONS END LIFE; CRAWLEY L, 2001, RESPECTING CULTURAL; DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; Dana R., 1993, MULTICULTURAL ASSESS; DAVIDSON MN, 1991, TRANSPLANT P, V23, P2531; DEVORE W, 1990, SOCIAL WORK PRACTICE; EMANUEL LL, 1993, HASTINGS CENT REP, V23, P6, DOI 10.2307/3562059; Emanuel LL, 2000, ARCH FAM MED, V9, P1181, DOI 10.1001/archfami.9.10.1181; Ersek M, 1998, Oncol Nurs Forum, V25, P1683; Fadiman A., 1997, SPIRIT CATCHES YOU Y; Fang J, 1996, NEW ENGL J MED, V335, P1545, DOI 10.1056/NEJM199611213352101; Fielding R, 1996, PSYCHO-ONCOL, V5, P321, DOI 10.1002/(SICI)1099-1611(199612)5:4<321::AID-PON226>3.0.CO;2-K; Francis CK, 2001, J NATL MED ASSOC, V93, P157; FRIEDMAN L C, 1988, Journal of Psychosocial Oncology, V6, P75; Gilbert Daniel Todd, 1998, HDB SOCIAL PSYCHOL, V2; Hallowell A. Irving, 1955, CULTURE EXPERIENCE; Haynes MA, 1999, UNEQUAL BURDEN CANC, DOI 10.17226/6377; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; IRISH D, 1993, ETHNIC VARIATIONS; Ishii S., 1984, CROSS CURR, V11, P49; Kagawa-Singer M., 1994, GERONTOLOGY GERIATRI, V15, P101; KAGAWASINGER M, 1994, J COMMUNITY PSYCHOL, P192; KATON W, 1980, WESTERN J MED, V133, P9; Kim MS, 1996, COMMUN MONOGR, V63, P29, DOI 10.1080/03637759609376373; Kleinman A., 1988, ILLNESS NARRATIVES; Kleinman A., 1980, PATIENTS HEALERS CON; KOENIG BA, 1995, WESTERN J MED, V163, P244; KOENIG BA, 1993, I MED WORKSH DYING D; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lebra TS., 1976, JAPANESE PATTERNS BE, DOI [10.1515/9780824846404, DOI 10.1515/9780824846404]; LIKE RC, 2000, PATIENT CARE, P189; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Morrison RS, 1998, ARCH INTERN MED, V158, P2493, DOI 10.1001/archinte.158.22.2493; Mouton C., 2000, CULTURAL ISSUES END, P71; MULLER JH, 1992, WESTERN J MED, V157, P323; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, P250; *NAT BIOETH ADV CO, 2001, ENS VOL INF CONS PRO, P103; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; PARRY JK, 1990, SOCIAL WORK PRACTICE; Paul B., 1955, HLTH CULTURE COMMUNI; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; ROTHENBERG LS, 1996, ANN REV LAW ETHICS, V4, P335; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Stuart MR, 1993, 15 MINUTE HOUR APPL; Surbone A, 2000, ANN NY ACAD SCI, V913, P52; Takayama T, 2001, SOC SCI MED, V53, P1335, DOI 10.1016/S0277-9536(00)00413-5; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; Tong K L, 1994, J Palliat Care, V10, P26; Uba L, 1994, ASIAN AM PERSONALITY; Veatch, 2000, CROSS CULTURAL PERSP; Wellisch D, 1999, PSYCHO-ONCOL, V8, P207, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<207::AID-PON357>3.0.CO;2-B; YEO G, 2000, CULTURAL ISSUES END, P356; ZANE N, IN PRESS ASIAN AM ME	80	369	370	2	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2993	3001		10.1001/jama.286.23.2993	http://dx.doi.org/10.1001/jama.286.23.2993			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	502VY	11743841				2022-12-28	WOS:000172764500032
J	Kroenke, K; West, SL; Swindle, R; Gilsenan, A; Eckert, GJ; Dolor, R; Stang, P; Zhou, XH; Hays, R; Weinberger, M				Kroenke, K; West, SL; Swindle, R; Gilsenan, A; Eckert, GJ; Dolor, R; Stang, P; Zhou, XH; Hays, R; Weinberger, M			Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; DEPRESSION; ANTIDEPRESSANTS; DISORDERS; UTILITY; COST	Context Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. Objective To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Design Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Setting Thirty-seven clinics in 2 US primary care research networks. Patients A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Interventions Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. Main Outcome Measures The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other depression and psychological measures, multiple measures of social and work functioning, and other domains of health-related quality of life, such as physical functioning, concentration and memory, vitality, bodily pain, sleep, and sexual functioning. Results Follow-up interviews were successfully completed in 94% of patients at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and + 17.4 in the sertraline group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. Conclusions The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Eli Lilly & Co, Indianapolis, IN 46285 USA; Richard L Roudebush Vet Affairs Med Ctr, Ctr Hlth Serv Res, Indianapolis, IN 46202 USA; Indiana Univ, Dept Psychol, Bloomington, IN USA; Res Triangle Inst, Durham, NC USA; Duke Univ, Sch Med, Durham, NC USA; Duke Primary Care Res Consortium, Durham, NC USA; Primary Care Network, Philadelphia, PA USA; Galt Associates, Philadelphia, PA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, RAND Hlth Program, Los Angeles, CA 90024 USA; Univ N Carolina, Chapel Hill, NC USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University Bloomington; Research Triangle Institute; Duke University; Duke University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill	Kroenke, K (corresponding author), Regenstrief Inst Hlth Care, RG-61050 Wishard Blvd, Indianapolis, IN 46202 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X; Dolor, Rowena/0000-0001-7317-9468; Zhou, Xiaohua/0000-0001-7935-1222; Kroenke, Kurt/0000-0002-0114-4669				[Anonymous], 1990, HLTH DAILY LIVING FO; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Clark JA, 2001, MED CARE, V39, P1118, DOI 10.1097/00005650-200110000-00009; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Glaser M, 1997, DRUG TOP, V141, P45; HAYS RD, 1996, DERIVATION PHYSICAL; Heiligenstein J H, 1995, Int Psychogeriatr, V7 Suppl, P125, DOI 10.1017/S1041610295002407; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lachin JM, 1999, CONTROL CLIN TRIALS, V20, P408, DOI 10.1016/S0197-2456(99)00022-7; LERNER DA, 1998, GLAXO WELLCOME INC W; Little R. J. A., 1987, STAT ANAL MISSING DA; Mason J, 2000, BRIT J GEN PRACT, V50, P366; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; Nelson JC, 1997, J CLIN PSYCHIAT, V58, P26; Nurnberg HG, 1999, J CLIN PSYCHIAT, V60, P574, DOI 10.4088/JCP.v60n0902; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; SIMON G, 1995, J CLIN EPIDEMIOL, V48, P363, DOI 10.1016/0895-4356(94)00141-C; SIMON GE, 1993, J PSYCHIAT RES, V27, P247, DOI 10.1016/0022-3956(93)90035-Z; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Snow V, 2000, ANN INTERN MED, V132, P738, DOI 10.7326/0003-4819-132-9-200005020-00010; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stewart AL, 1992, MEASURING FUNCTIONIN; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JJ, 1993, SF 36 HLTH SURV MANU; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011; [No title captured]	31	236	243	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2001	286	23					2947	2955		10.1001/jama.286.23.2947	http://dx.doi.org/10.1001/jama.286.23.2947			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502VY	11743835	Bronze			2022-12-28	WOS:000172764500026
J	Joutel, A; Favrole, P; Labauge, P; Chabriat, H; Lescoat, C; Andreux, F; Domenga, V; Cecillon, M; Vahedi, K; Ducros, A; Cave-Riant, F; Bousser, MG; Tournier-Lasserve, E				Joutel, A; Favrole, P; Labauge, P; Chabriat, H; Lescoat, C; Andreux, F; Domenga, V; Cecillon, M; Vahedi, K; Ducros, A; Cave-Riant, F; Bousser, MG; Tournier-Lasserve, E			Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis	LANCET			English	Article								CADASIL (cerebral autosomal dominant arteriopathy with subcortical Infarcts and leucoencephalopathy) Is a small-artery disease of the brain caused by NOTCH3 mutations that lead to an abnormal accumulation of NOTCH3 within the vasculature. We aimed to establish whether immunostaining skin biopsy samples with a monoclonal antibody specific for NOTCH3 could form the basis of a reliable and easy diagnostic test. We compared the sensitivity and specificity of this method In two groups of patients suspected of having CADASIL with complete scanning of mutation-ca using exons of NOTCH3 (in a retrospective series of 39 patients) and with limited scanning of four exons that are mutation hotspots (prospective series of 42 patients). In the retrospective series skin biopsy was positive in 21 (96%) of the 22 CADASIL patients examined and negative In all others; In the prospective series, seven of the 42 patients had a positive skin biopsy whereas only four had a mutation detected by limited NOTCH3 scanning. Our Immunostaining technique Is highly sensitive (96%) and specific (100%) for diagnosis of CADASIL.	Fac Med Lariboisiere, INSERM, F-75010 Paris, France; Hop Lariboisiere, Lab Cytogenet, F-75475 Paris, France; Cent Hosp Univ Caremeau, Serv Neurol, Nimes, France; Hop Lariboisiere, Serv Neurol, F-75475 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Nimes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Joutel, A (corresponding author), Fac Med Lariboisiere, INSERM, EPI 99-21,10 Ave Verdun, F-75010 Paris, France.		Joutel, Anne/K-5601-2017; Tournier-Lasserve, Elisabeth/N-7134-2017; DUCROS, Anne/D-1899-2010; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; DUCROS, Anne/0000-0001-5560-5013; Chabriat, Hugues/0000-0001-8436-6074				BAUDRIMONT M, 1998, NEUROPATHOL APPL NEU, V24, P148; Joutel A, 2000, ANN NEUROL, V47, P388, DOI 10.1002/1531-8249(200003)47:3<388::AID-ANA19>3.3.CO;2-H; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500	5	161	180	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 15	2001	358	9298					2049	2051		10.1016/S0140-6736(01)07142-2	http://dx.doi.org/10.1016/S0140-6736(01)07142-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502BB	11755616				2022-12-28	WOS:000172722800017
J	Freeman, R; Weinstein, E; Marincola, E; Rosenbaum, J; Solomon, F				Freeman, R; Weinstein, E; Marincola, E; Rosenbaum, J; Solomon, F			Careers - Competition and careers in biosciences	SCIENCE			English	Editorial Material									Natl Bur Econ Res, Cambridge, MA 02138 USA; Harvard Univ, Cambridge, MA 02138 USA; Amer Soc Cell Biol, Bethesda, MD 20814 USA; MIT, Cambridge, MA 02139 USA	National Bureau of Economic Research; Harvard University; Massachusetts Institute of Technology (MIT)	Freeman, R (corresponding author), Natl Bur Econ Res, Cambridge, MA 02138 USA.		Rosenbaum, Janet/Y-6915-2018	Rosenbaum, Janet/0000-0001-9796-513X				DAVIS G, 1997, MATH MARKET; FREEMAN RB, 1975, AM ECON REV, V65, P27; LAZEAR EP, 1981, J POLIT ECON, V89, P841, DOI 10.1086/261010; Marincola E, 1998, SCIENCE, V281, P645, DOI 10.1126/science.281.5377.645; *NAT SCI FDN, 1997, SCI ENG STAT DAT SYS; National Research Council, 1998, TRENDS EARL CAR LIF; PRESTON A, 2000, DO DIFFERENCES RATES	7	63	62	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 14	2001	294	5550					2293	2294		10.1126/science.1067477	http://dx.doi.org/10.1126/science.1067477			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	503TT	11743184				2022-12-28	WOS:000172817200025
J	Heard, E; Rougeulle, C; Arnaud, D; Avner, P; Allis, CD; Spector, DL				Heard, E; Rougeulle, C; Arnaud, D; Avner, P; Allis, CD; Spector, DL			Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation	CELL			English	Article							XIST RNA; DOSAGE COMPENSATION; H4 ACETYLATION; GENE; CHROMATIN; HYPOACETYLATION; INITIATION; MACROH2A1; PROMOTER; COMPLEX	Coating of the X chromosome by Xist RNA is an essential trigger for X inactivation. However, little is known about the early chromatin remodeling events: that transform this signal into transcriptional silencing. Here we report that methylation of histone H3 lysine 9 on the inactive X chromosome occurs immediately after Xist RNA coating and before transcriptional inactivation of X-linked genes. X-chromosomal H3 Lys-9 methylation occurs during the same window of time as H3 Lys-9 hypoacetylation and H3 Lys-4 hypomethylation. Histone H3 modifications thus represent the earliest known chromatin changes during X inactivation. We also identify a unique "hotspot" of H3 Lys-9 methylation 5' to Xist, and we propose that this acts as a nucleation center for Xist RNA-dependent spread of inactivation along the X chromosome via H3 Lys-9 methylation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Inst Pasteur, F-75724 Paris 15, France; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Cold Spring Harbor Laboratory; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Virginia	Heard, E (corresponding author), Inst Curie, CNRS, UMR 218, 26 Rue Ulm, F-75248 Paris 05, France.	edith.heard@curie.fr	Heard, Edith/D-7197-2017	Heard, Edith/0000-0001-8052-7117; Rougeulle, Claire/0000-0003-3861-4940	NIGMS NIH HHS [GM53512, GM42694, R01 GM042694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694, R37GM053512, R01GM053512] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BOGGS BA, 2001, IN PRESS NAT GENET; Boumil RM, 2001, HUM MOL GENET, V10, P2225; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Heard E, 1999, MOL CELL BIOL, V19, P3156; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; Hogan B, 1994, MANIPULATING MOUSE E; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 2000, CURR OPIN GENET DEV, V10, P555, DOI 10.1016/S0959-437X(00)00127-1; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MCBURNEY MW, 1988, BIOESSAYS, V9, P85, DOI 10.1002/bies.950090211; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; Morey C, 2001, HUM MOL GENET, V10, P1403, DOI 10.1093/hmg/10.13.1403; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; O'Neill LP, 1999, EMBO J, V18, P2897, DOI 10.1093/emboj/18.10.2897; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Rasmussen TP, 2000, J CELL BIOL, V150, P1189, DOI 10.1083/jcb.150.5.1189; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; RIGGS AD, 1985, BIOCH BIOL DNA METHY, P211; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	46	401	412	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2001	107	6					727	738		10.1016/S0092-8674(01)00598-0	http://dx.doi.org/10.1016/S0092-8674(01)00598-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	502ZC	11747809				2022-12-28	WOS:000172771800006
J	Mas, JL; Arquizan, C; Lamy, C; Zuber, M; Cabanes, L; Derumeaux, G; Coste, J				Mas, JL; Arquizan, C; Lamy, C; Zuber, M; Cabanes, L; Derumeaux, G; Coste, J		Patent Foramen Ovale Atrial Septal	Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE ISCHEMIC-STROKE; CRYPTOGENIC STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; RISK; ABNORMALITIES; MULTICENTER; CLOSURE; SHUNT	Background: Patent foramen ovale and atrial septal aneurysm have been identified as potential risk factors for stroke, but information about their effect on the risk of recurrent stroke is limited. We studied the risks of recurrent cerebrovascular events associated with these cardiac abnormalities. Methods: A total of 581 patients (age, 18 to 55 years) who had had an ischemic stroke of unknown origin within the preceding three months were consecutively enrolled at 30 neurology departments. All patients received aspirin (300 mg per day) for secondary prevention. Results: After four years, the risk of recurrent stroke was 2.3 percent (95 percent confidence interval, 0.3 to 4.3 percent) among the patients with patent foramen ovale alone, 15.2 percent (95 percent confidence interval, 1.8 to 28.6 percent) among the patients with both patent foramen ovale and atrial septal aneurysm, and 4.2 percent (95 percent confidence interval, 1.8 to 6.6 percent) among the patients with neither of these cardiac abnormalities. There were no recurrences among the patients with an atrial septal aneurysm alone. The presence of both cardiac abnormalities was a significant predictor of an increased risk of recurrent stroke (hazard ratio for the comparison with the absence of these abnormalities, 4.17; 95 percent confidence interval, 1.47 to 11.84), whereas isolated patent foramen ovale, whether small or large, was not. Conclusions: Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered. (N Engl J Med 2001;345:1740-6.) Copyright (C) 2001 Massachusetts Medical Society.	Hop St Anne, Serv Neurol, F-75674 Paris 14, France; Univ Paris 05, Dept Cardiol, Cochin Hosp, Paris, France; Univ Paris 05, Cochin Hosp, Dept Biostat, Paris, France; Univ Rouen, Hop Charles Nicolle, Dept Cardiol, Rouen, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Rouen; Universite de Rouen Normandie	Mas, JL (corresponding author), Hop St Anne, Serv Neurol, 1 Rue Cabanis, F-75674 Paris 14, France.	mas@chsa.broca.inserm.fr	DERUMEAUX, Genevieve A/T-2489-2018	DERUMEAUX, Genevieve A/0000-0003-1471-1631				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Armitage P., 1987, STAT METHODS MED RES; Berthet K, 2000, STROKE, V31, P398, DOI 10.1161/01.STR.31.2.398; Bogousslavsky J, 1996, NEUROLOGY, V46, P1301, DOI 10.1212/WNL.46.5.1301; BRIDGES ND, 1992, CIRCULATION, V86, P1902, DOI 10.1161/01.CIR.86.6.1902; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; CABANES L, IN PRESS J AM SOC EC; Cujec B, 1999, CAN J CARDIOL, V15, P57; De Castro S, 2000, STROKE, V31, P2407, DOI 10.1161/01.STR.31.10.2407; Devuyst G, 1996, NEUROLOGY, V47, P1162, DOI 10.1212/WNL.47.5.1162; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; HANNA JP, 1994, STROKE, V25, P782, DOI 10.1161/01.STR.25.4.782; HAUSMANN D, 1995, J AM COLL CARDIOL, V26, P1030, DOI 10.1016/0735-1097(95)00288-9; HOMMA S, 1994, STROKE, V25, P582, DOI 10.1161/01.STR.25.3.582; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; MAS JL, 1995, AM HEART J, V130, P1083, DOI 10.1016/0002-8703(95)90212-0; MAS JL, 1994, EUR HEART J, V15, P446, DOI 10.1093/oxfordjournals.eurheartj.a060524; MUGGE A, 1995, CIRCULATION, V91, P2785, DOI 10.1161/01.CIR.91.11.2785; Overell JR, 2000, NEUROLOGY, V55, P1172, DOI 10.1212/WNL.55.8.1172; PEARSON AC, 1991, J AM COLL CARDIOL, V18, P1223, DOI 10.1016/0735-1097(91)90539-L; RANOUX D, 1993, STROKE, V24, P31, DOI 10.1161/01.STR.24.1.31; SCHNEIDER B, 1990, J AM COLL CARDIOL, V16, P1000, DOI 10.1016/S0735-1097(10)80354-7; Schuchlenz HW, 2000, AM J MED, V109, P456, DOI 10.1016/S0002-9343(00)00530-1; Serena J, 1998, STROKE, V29, P1322, DOI 10.1161/01.STR.29.7.1322; SILVER MD, 1978, ARCH PATHOL LAB MED, V102, P62; Steiner MM, 1998, STROKE, V29, P944, DOI 10.1161/01.STR.29.5.944; Stone DA, 1996, AM HEART J, V131, P158, DOI 10.1016/S0002-8703(96)90065-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WEBSTER MWI, 1988, LANCET, V2, P11; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; [No title captured]	31	931	969	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2001	345	24					1740	1746		10.1056/NEJMoa011503	http://dx.doi.org/10.1056/NEJMoa011503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500YK	11742048				2022-12-28	WOS:000172656100004
J	Navarro, M; Gull, K				Navarro, M; Gull, K			A pol I transcriptional body associated with VSG mono-allelic expression in Trypanosoma brucei	NATURE			English	Article							VARIANT SURFACE GLYCOPROTEIN; AMANITIN-RESISTANT TRANSCRIPTION; GENE-EXPRESSION; AFRICAN TRYPANOSOMES; RNA; SITES; DIFFERENTIATION; VISUALIZATION; LOCALIZATION; ORGANIZATION	In the mammalian host, African trypanosomes generate consecutive waves of parasitaemia by changing their antigenic coat. Because this coat consists of a single type of variant surface glycoprotein (VSG), the question arises of how a trypanosome accomplishes the transcription of only one of a multi-allelic family of VSG expression site loci to display a single VSG type on the surface at any one time(1). No major differences have been detected between the single active expression site and the cohort of inactive expression sites(2). Here we identify an extranucleolar body containing RNA polymerase I (pol I) that is transcriptionally active and present only in the bloodstream form of the parasite. Visualization of the active expression site locus by tagging with green fluorescent protein(3) shows that it is specifically located at this unique pol I transcriptional factory. The presence of this transcriptional body in postmitotic nuclei and its stability in the nucleus after DNA digestion provide evidence for a coherent structure. We propose that the recruitment of a single expression site and the concomitant exclusion of inactive loci from a discrete transcriptional body define the mechanism responsible for VSG mono-allelic expression.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Navarro, M (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Navarro, Miguel/C-3685-2009	Navarro, Miguel/0000-0003-2301-2699				Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; Borst P, 1999, TRENDS GENET, V15, P95, DOI 10.1016/S0168-9525(98)01680-1; Chaves I, 1998, P NATL ACAD SCI USA, V95, P12328, DOI 10.1073/pnas.95.21.12328; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Ersfeld K, 1997, SCIENCE, V276, P611, DOI 10.1126/science.276.5312.611; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; Laufer G, 1999, MOL CELL BIOL, V19, P5466; MATTHEWS KR, 1994, J CELL BIOL, V125, P1147, DOI 10.1083/jcb.125.5.1147; Navarro M, 1996, MOL CELL BIOL, V16, P3615; Navarro M, 1998, MOL BIOCHEM PARASIT, V94, P53, DOI 10.1016/S0166-6851(98)00049-8; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Robinson NP, 1999, MOL CELL BIOL, V19, P5839; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	30	249	248	1	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 13	2001	414	6865					759	763		10.1038/414759a	http://dx.doi.org/10.1038/414759a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501GD	11742402				2022-12-28	WOS:000172676200050
J	Cook, DJ; Guyatt, G; Rocker, G; Sjokvist, P; Weaver, B; Dodek, P; Marshall, J; Leasa, D; Levy, M; Varon, J; Fisher, M; Cook, R				Cook, DJ; Guyatt, G; Rocker, G; Sjokvist, P; Weaver, B; Dodek, P; Marshall, J; Leasa, D; Levy, M; Varon, J; Fisher, M; Cook, R		Canadian Critical Care Trials Grp	Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study	LANCET			English	Article							ADVANCE DIRECTIVES; LIFE-SUPPORT; CONTROLLED TRIAL; DECISION-MAKING; PREFERENCES; PHYSICIANS; CHOICES; PATIENT; ORDERS; ILL	Background Resuscitation directives should be a sign of patient's preference. Our objective was to ascertain prevalence, predictors, and procurement pattern of cardiopulmonary resuscitation directives within 24 h of admission to the intensive-care unit (ICU). Methods We enrolled 2916 patients aged 18 years and older from 15 ICUs in four countries, and recorded whether, when, and by whom their cardiopulmonary resuscitation directives were established. By polychotomous logistic regression we identified factors associated with a resuscitate or do-not-resuscitate directive. Findings Of 2916 patients, 318 (11%; 95% CI 9.8-12.1) had an explicit resuscitation directive. In 159 (50%; 44.4-55.6) patients, the directive was do-not-resuscitate. Directives were established by residents for 145 (46%; 40.0-51.3) patients. Age strongly predicted do-not-resuscitate directives: for 50-64, 65-74, and 75 years and older, odds ratios were 3.4 (95% CI 1.6-7.3), 4.4 (2.2-9.2), and 8.8 (4.4-17.8), respectively. APACHE II scores greater than 20 predicted resuscitate and do-not-resuscitate directives in a similar way. An explicit directive was likely for patients admitted at night (odds ratio 1.4 [1.0-1.9] and 1.6 [1.2-2.3] for resuscitate and do-not-resuscitate, respectively) and during weekends (1.9 [1.3-2.7] and 2.2 [1.5-3.2], respectively). Inability to make a decision raised the likelihood of a do-not-resuscitate (3.7 [2.6-5.4]) than a resuscitate (1.7 [1.2-2.3]) directive (p=0.0005). Within Canada and the USA, cities differed strikingly, as did centres within cities. Interpretation Cardiopulmonary resuscitation directives established within 24 h of admission to ICU are uncommon. As well as clinical factors, timing and location of admission might determine rate and nature of resuscitation directives.	Dalhousie Univ, Dept Med, Halifax, NS, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; Huddinge Univ, Dept Anaesthesia & Intens Care, Stockholm, Sweden; Brown Univ, Dept Med, Providence, RI 02912 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Sydney, Dept Anaesthesia & Med, Sydney, NSW 2006, Australia	Dalhousie University; McMaster University; McMaster University; University of British Columbia; University of Toronto; Western University (University of Western Ontario); University of Waterloo; Brown University; Baylor College of Medicine; University of Sydney	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, Hamilton, ON L8N 4A6, Canada.		Varon, Joseph/R-5198-2019; Varon, Joseph/T-9481-2019	Varon, Joseph/0000-0002-7622-9974; Cook, Richard/0000-0002-1414-4908				AGRESTI A, 1990, CATEGORICAL DATA ANA, P306; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301; CHWALOW AJ, 1992, FUNDAM CLIN PHARM, V6, P319, DOI 10.1111/j.1472-8206.1992.tb00126.x; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; Emergency Cardiac Care Committee and Subcommittees American Heart Association, 1992, JAMA-J AM MED ASSOC, V268, P2282; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hayes S, 1999, J ROY COLL PHYS LOND, V33, P348; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; JOHNSON RF, 1995, CHEST, V107, P752, DOI 10.1378/chest.107.3.752; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Johnston SC, 1998, J GEN INTERN MED, V13, P43, DOI 10.1046/j.1525-1497.1998.00008.x; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Kernerman P, 1997, J CRIT CARE, V12, P155, DOI 10.1016/S0883-9441(97)90026-5; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lyons RA, 2000, LANCET, V355, P595, DOI 10.1016/S0140-6736(00)01265-4; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V265, P1868; OSBORNE M, 1994, LANCET, V343, P778, DOI 10.1016/S0140-6736(94)91845-7; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Sjokvist P., 1998, CLIN INTENSIVE CARE, V9, P81, DOI [10.3109/tcic.9.2.81.85, DOI 10.3109/TCIC.9.2.81.85]; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; Walter SD, 1998, CRIT CARE MED, V26, P44, DOI 10.1097/00003246-199801000-00015; WENGER NS, 1994, J GEN INTERN MED, V9, P539, DOI 10.1007/BF02599276	31	91	96	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 8	2001	358	9297					1941	1945		10.1016/S0140-6736(01)06960-4	http://dx.doi.org/10.1016/S0140-6736(01)06960-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500HZ	11747918				2022-12-28	WOS:000172622200011
J	Ricaurte, GA; McCann, UD				Ricaurte, GA; McCann, UD			Assessing long-term effects of MDMA (Ecstasy)	LANCET			English	Editorial Material							(ECSTASY)-INDUCED SEROTONIN NEUROTOXICITY; ANIMALS; USERS		Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University	Ricaurte, GA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21224 USA.							Bishop Georgia A., 1993, P91; FISCHER C, 1995, J NEUROSCI, V15, P5476; Gouzoulis-Mayfrank E, 2000, J NEUROL NEUROSUR PS, V68, P719, DOI 10.1136/jnnp.68.6.719; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; Hatzidimitriou G, 1999, J NEUROSCI, V19, P5096; Heinz A, 2000, BRIT J PSYCHIAT, V176, P193, DOI 10.1192/bjp.176.2.193-a; JOHNSTON LD, 2001, 014924 NIH NAT I DRU, P156; Malison RT, 1998, BIOL PSYCHIAT, V44, P1090, DOI 10.1016/S0006-3223(98)00272-8; McCann UD, 2000, NEUROPSYCHOBIOLOGY, V42, P11, DOI 10.1159/000026665; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; Milroy CM, 1999, J ROY SOC MED, V92, P68, DOI 10.1177/014107689909200206; Parrott AC, 2000, NEUROPSYCHOBIOLOGY, V42, P17, DOI 10.1159/000026666; Reneman L, 2001, ARCH GEN PSYCHIAT, V58, P901, DOI 10.1001/archpsyc.58.10.901; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; Shulgin AT, 1978, PSYCHOPHARMACOLOGY H	15	20	20	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 1	2001	358	9296					1831	1832		10.1016/S0140-6736(01)06880-5	http://dx.doi.org/10.1016/S0140-6736(01)06880-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497NU	11741618				2022-12-28	WOS:000172463000004
